

EASLâ€™EORTC Clinical Practice Guidelines: Management

Journal of Hepatology

56, 908-943

DOI: [10.1016/j.jhep.2011.12.001](https://doi.org/10.1016/j.jhep.2011.12.001)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Assessment and triage of hepatocellular carcinoma. , 0, , 85-90.		0
2	The Production of Rotational and Vibrational Transitions in Encounters between Molecules. Advances in Atomic and Molecular Physics, 1965, 1, 149-194.	2.0	210
3	Myofibrillar Proteins of Skeletal Muscle. Advances in Food Research, 1971, 19, 279-360.	0.3	50
4	Chapter 13 Palaeogeomorphic and Unconformity Traps. Developments in Petroleum Science, 1983, 16, 279-302.	0.2	0
5	Chapter 1 Motor and Action Perspectives on Motor Behaviour. Advances in Psychology, 1988, 50, 3-44.	0.1	31
6	The Intracisternal A-Particle Gene Family: Structure and Functional Aspects. Advances in Cancer Research, 1988, 51, 183-276.	1.9	338
7	Clustering of Platinum Atoms in Zeolite EMT Supercage: Comprehensive Physicochemical Characterization. Studies in Surface Science and Catalysis, 1994, 84, 765-772.	1.5	10
8	Advances in Ultracold Collisions: Experimentation and Theory. Advances in Atomic, Molecular and Optical Physics, 1995, , 45-78.	2.3	51
9	Deep-sea microbial research and its aspect to high pressure biotechnology. Progress in Biotechnology, 1996, 13, 17-20.	0.2	1
10	S-Nitrosothiol detection. Methods in Enzymology, 1996, 268, 293-298.	0.4	37
11	3 Recent Advances in the Chemistry and Biology of Carbapenem Antibiotics. Progress in Medicinal Chemistry, 1996, 33, 99-145.	4.1	24
12	Selenol-catalyzed reduction of disulfide bonds in peptides and proteins. Techniques in Protein Chemistry, 1996, 7, 221-230.	0.3	1
13	Pectinase secretion by Aspergillus FP-180 and Aspergillus niger N-402 growing under stress induced by the pH of culture medium. Progress in Biotechnology, 1996, 14, 915-920.	0.2	4
14	Oxytetracycline production by free and immobilized cells of Streptomyces rimosus in batch and repeated batch cultures. Progress in Biotechnology, 1996, , 437-443.	0.2	1
15	Optimal hermite collocation solution of a forced convection-diffusion equation. Developments in Water Science, 2002, , 453-460.	0.1	0
16	Electronic states associated with bond disorder at ZnO grain boundaries. Advances in Quantum Chemistry, 2003, 42, 175-186.	0.4	0
17	Vertical root fractures. Journal of the American Dental Association, 2003, 134, 434-441.	0.7	123
18	Encapsulated pyridazine Cr(III) complexes prepared from biosorbents supported in zeolites. Studies in Surface Science and Catalysis, 2005, 158, 1073-1080.	1.5	4

#	ARTICLE	IF	CITATIONS
19	Mesostructured and mesoporous pure and substituted barium hexaferrite phases. <i>Studies in Surface Science and Catalysis</i> , 2005, 156, 287-294.	1.5	0
20	Effect of Space Flight on Circadian Rhythms. <i>Advances in Space Biology and Medicine</i> , 2005, 10, 165-174.	0.5	4
21	Pharmacological and biochemical profiling of lead compounds from traditional remedies: the case of <i>Croton cajucara</i> . <i>Advances in Phytomedicine</i> , 2006, 2, 225-253.	0.1	10
22	Synthesis of mesoporous alumina using anionic, nonionic and cationic surfactants. <i>Studies in Surface Science and Catalysis</i> , 2007, 165, 275-278.	1.5	1
23	Characterization of LTA- and CHA- type zeolites by means of solid state NMR. <i>Studies in Surface Science and Catalysis</i> , 2008, 174, 989-992.	1.5	0
24	Chapter 11 Geomorphometry in ESRI Packages. <i>Developments in Soil Science</i> , 2009, , 269-291.	0.5	7
25	A dynamic screening algorithm for multiple objective simulated annealing optimization. <i>Computer Aided Chemical Engineering</i> , 2010, 28, 349-354.	0.3	6
28	Approach of the patient with a liver mass. <i>Frontline Gastroenterology</i> , 2012, 3, 252-262.	0.9	6
29	Hepatocellular carcinoma surveillance in patients with alcoholic cirrhosis. <i>Expert Review of Gastroenterology and Hepatology</i> , 2012, 6, 651-653.	1.4	2
30	Effectiveness of $\hat{\pm}$ -fetoprotein for hepatocellular carcinoma surveillance: the return of the living-dead?. <i>Expert Review of Gastroenterology and Hepatology</i> , 2012, 6, 441-444.	1.4	13
31	Intrarenal Resistance Index as a Prognostic Parameter in Patients with Liver Cirrhosis Compared with Other Hepatic Scoring Systems. <i>Digestion</i> , 2012, 86, 349-354.	1.2	6
32	Effects of Antiplatelet Therapy on Mortality and Cardiovascular and Bleeding Outcomes in Persons With Chronic Kidney Disease. <i>Annals of Internal Medicine</i> , 2012, 157, 302.	2.0	2
33	Contemporary Strategies in the Management of Hepatocellular Carcinoma. <i>HPB Surgery</i> , 2012, 2012, 1-8.	2.2	4
34	Alpha-Fetoprotein and Novel Tumor Biomarkers as Predictors of Hepatocellular Carcinoma Recurrence after Surgery: A Brilliant Star Raises Again. <i>International Journal of Hepatology</i> , 2012, 2012, 1-9.	0.4	41
35	Chemoembolization in Patients with Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2012, 1, 41-50.	4.2	78
36	Japan's Successful Model of Nationwide Hepatocellular Carcinoma Surveillance Highlighting the Urgent Need for Global Surveillance. <i>Liver Cancer</i> , 2012, 1, 141-143.	4.2	69
37	How to Improve Treatment Outcomes for Hepatocellular Carcinoma of Intermediate and Advanced Stage. <i>Digestive Diseases</i> , 2012, 30, 598-602.	0.8	17
38	Clinical Impact of Ultrasound-Related Techniques on the Diagnosis of Focal Liver Lesions. <i>Liver Cancer</i> , 2012, 1, 238-246.	4.2	23

#	ARTICLE	IF	CITATIONS
39	Delayed Diagnosis of HCC with Chronic Alcoholic Liver Disease. <i>Liver Cancer</i> , 2012, 1, 257-266.	4.2	48
40	Invited Commentary. <i>Radiographics</i> , 2012, 32, 1995-1998.	1.4	1
41	Low-Dose Prednisone Inclusion in a Methotrexate-Based, Tight Control Strategy for Early Rheumatoid Arthritis. <i>Annals of Internal Medicine</i> , 2012, 157, 299.	2.0	3
42	Low-Dose Prednisone Inclusion in a Methotrexate-Based, Tight Control Strategy for Early Rheumatoid Arthritis. <i>Annals of Internal Medicine</i> , 2012, 157, 299.	2.0	3
43	Screening for Liver Cancer: The Rush to Judgment. <i>Annals of Internal Medicine</i> , 2012, 157, 300.	2.0	4
45	Effects of Antiplatelet Therapy on Mortality and Cardiovascular and Bleeding Outcomes in Persons With Chronic Kidney Disease. <i>Annals of Internal Medicine</i> , 2012, 157, 302.	2.0	1
46	Next-Generation Sequencing: Application in Liver Cancerâ€”Past, Present and Future?. <i>Biology</i> , 2012, 1, 383-394.	1.3	16
47	Hepatocellular carcinoma â€œ Authors' reply. <i>Lancet, The</i> , 2012, 380, 470-471.	6.3	29
48	Principles, effectiveness and caveats in screening for cancer. <i>British Journal of Surgery</i> , 2012, 100, 55-65.	0.1	67
49	Natural history and staging for hepatocellular carcinoma. <i>Clinical Liver Disease</i> , 2012, 1, 183-185.	1.0	6
50	Impact of intra-individual molecular heterogeneity in personalized treatment of hepatocellular carcinoma. <i>Hepatology</i> , 2012, 56, 2416-2419.	3.6	16
51	Reply to: â€œNetwork-based discovery of gene signature for vascular invasion prediction in HCCâ€: <i>Journal of Hepatology</i> , 2012, 56, 1424-1425.	1.8	0
52	Chemoembolization for Hepatocellular Carcinoma. <i>Seminars in Oncology</i> , 2012, 39, 503-509.	0.8	94
53	Percutaneous CT-guided radiofrequency ablation for unresectable hepatocellular carcinoma pulmonary metastases. <i>International Journal of Hyperthermia</i> , 2012, 28, 721-728.	1.1	21
54	Comparison of the prognostic value of inflammation-based prognostic scores in patients with hepatocellular carcinoma. <i>British Journal of Cancer</i> , 2012, 107, 988-993.	2.9	253
55	<scp>BCLC</scp> â€œ now also an internationally acclaimed prognostic system?. <i>Liver International</i> , 2012, 32, 1037-1038.	1.9	1
56	Focus. <i>Journal of Hepatology</i> , 2012, 57, 713-714.	1.8	3
57	Second-Line Therapies in Hepatocellular Carcinoma: Emergence of Resistance to Sorafenib. <i>Clinical Cancer Research</i> , 2012, 18, 1824-1826.	3.2	86

#	ARTICLE	IF	CITATIONS
58	Screening for hepatocellular carcinoma: The rationale for the American Association for the Study of Liver Diseases recommendations. <i>Hepatology</i> , 2012, 56, 793-796.	3.6	129
59	Biomarkers for early diagnosis of hepatocellular carcinoma. <i>Lancet Oncology</i> , The, 2012, 13, 750-751.	5.1	102
60	Gene Signatures in the Management of Hepatocellular Carcinoma. <i>Seminars in Oncology</i> , 2012, 39, 473-485.	0.8	68
61	Screening and Management of Hepatocellular Carcinoma: The Australian Perspective. <i>Current Hepatitis Reports</i> , 2012, 11, 197-205.	0.3	0
64	Comparison of International Guidelines for Noninvasive Diagnosis of Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2012, 1, 190-200.	4.2	78
65	Non-invasive diagnosis of focal liver lesions: an individualized approach. <i>Cancer Imaging</i> , 2012, 12, 365-372.	1.2	6
66	Imaging of hepatocellular carcinoma: diagnosis, staging and treatment monitoring. <i>Cancer Imaging</i> , 2012, 12, 530-547.	1.2	142
67	Contrast-enhanced ultrasonography parameters in neural network diagnosis of liver tumors. <i>World Journal of Gastroenterology</i> , 2012, 18, 4427.	1.4	54
68	Surveillance programs for early detection of hepatocellular carcinoma. <i>Wspolczesna Onkologia</i> , 2012, 4, 295-305.	0.7	2
69	Risks and Benefits of Liver Biopsy in Focal Liver Disease. , 2012, , .		1
70	Hepatocellular Carcinoma in the EU. <i>Annals of Oncology</i> , 2012, 23, ix63.	0.6	0
71	Screening for Liver Cancer: The Rush to Judgment. <i>Annals of Internal Medicine</i> , 2012, 157, 301.	2.0	1
72	Clinical factors related to long-term administration of sorafenib in patients with hepatocellular carcinoma. <i>Cancer Management and Research</i> , 2012, 4, 423.	0.9	7
73	Advances in haematology and oncology 2011: hepatocellular carcinoma (HCC). <i>Memo - Magazine of European Medical Oncology</i> , 2012, 5, 161-162.	0.3	0
74	Commentary: the impact of compact lipiodolisation following transarterial chemoembolisation for hepatocellular carcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 36, 74-75.	1.9	2
75	Commentary: the impact of compact lipiodolisation following transarterial chemoembolisation for hepatocellular carcinoma – authors’ reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 36, 75-75.	1.9	0
76	A prognostic model for patients with hepatocellular carcinoma within the Milan criteria undergoing non-transplant therapies, based on 1106 patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 36, 551-559.	1.9	11
77	Multi-institutional comparison of treatment planning using stereotactic ablative body radiotherapy for hepatocellular carcinoma – benchmark for a prospective multi-institutional study. <i>Radiation Oncology</i> , 2013, 8, 113.	1.2	17

#	ARTICLE	IF	CITATIONS
78	Diagnostic performance of alpha-fetoprotein, lens culinaris agglutinin-reactive alpha-fetoprotein, des-gamma carboxyprothrombin, and glypican-3 for the detection of hepatocellular carcinoma: a systematic review and meta-analysis protocol. <i>Systematic Reviews</i> , 2013, 2, 37.	2.5	31
79	Genetic variants associated with the progression of hepatocellular carcinoma in hepatitis C Egyptian patients. <i>Gene</i> , 2013, 527, 516-520.	1.0	15
80	Consensus Report of the Fifth International Forum for Liver MRI. <i>American Journal of Roentgenology</i> , 2013, 201, 97-107.	1.0	38
81	Imaging Assessment of Hepatocellular Carcinoma Response to Locoregional and Systemic Therapy. <i>American Journal of Roentgenology</i> , 2013, 201, 80-96.	1.0	73
82	Postprogression survival of patients with advanced hepatocellular carcinoma: Rationale for second-line trial design. <i>Hepatology</i> , 2013, 58, 2023-2031.	3.6	217
83	Clinical parameters predictive of outcomes in sorafenib-treated patients with advanced hepatocellular carcinoma. <i>Liver International</i> , 2013, 33, 950-957.	1.9	70
84	A Radiologist's Guide to Treatment Response Criteria in Oncologic Imaging: Functional, Molecular, and Disease-Specific Imaging Biomarkers. <i>American Journal of Roentgenology</i> , 2013, 201, 246-256.	1.0	17
85	The Glasgow Prognostic Score, an inflammation based prognostic score, predicts survival in patients with hepatocellular carcinoma. <i>BMC Cancer</i> , 2013, 13, 52.	1.1	84
86	Alpha-fetoprotein and modified response evaluation criteria in Solid Tumors progression after locoregional therapy as predictors of hepatocellular cancer recurrence and death after transplantation. <i>Liver Transplantation</i> , 2013, 19, 1108-1118.	1.3	168
87	Radioembolization for hepatocellular carcinoma with portal vein thrombosis: Impact of liver function on systemic treatment options at disease progression. <i>Journal of Hepatology</i> , 2013, 58, 73-80.	1.8	110
88	Milan Criteria, Multi-nodularity, and Microvascular Invasion Predict the Recurrence Patterns of Hepatocellular Carcinoma After Resection. <i>Journal of Gastrointestinal Surgery</i> , 2013, 17, 702-711.	0.9	28
89	Persistent elevated C-reactive protein after treatment is an independent marker of a poor prognosis in patients with hepatocellular carcinoma. <i>Clinical and Translational Oncology</i> , 2013, 15, 575-581.	1.2	6
90	Review article: the management of autoimmune hepatitis beyond consensus guidelines. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 38, 343-364.	1.9	50
91	Radiofrequency ablation in gastrointestinal cancer: obstacles and goals. <i>Memo - Magazine of European Medical Oncology</i> , 2013, 6, 212-214.	0.3	1
92	Hepatocellular Carcinoma and Other Malignancies in Autoimmune Hepatitis. <i>Digestive Diseases and Sciences</i> , 2013, 58, 1459-1476.	1.1	47
93	Volumetric Changes after 90Y Radioembolization for Hepatocellular Carcinoma in Cirrhosis: An Option to Portal Vein Embolization in a Preoperative Setting?. <i>Annals of Surgical Oncology</i> , 2013, 20, 2518-2525.	0.7	76
94	Phase I study investigating everolimus combined with sorafenib in patients with advanced hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2013, 59, 1271-1277.	1.8	66
95	Lipiodol Trans-arterial Chemoembolization of Hepatocellular Carcinoma with Idarubicin: First Experience. <i>CardioVascular and Interventional Radiology</i> , 2013, 36, 1039-1046.	0.9	25

#	ARTICLE	IF	CITATIONS
96	The efficiency of acoustic radiation force impulse imaging for the staging of liver fibrosis: a meta-analysis. <i>European Radiology</i> , 2013, 23, 3040-3053.	2.3	170
97	C-arm CT during hepatic arteriography tumour-to-liver contrast: intraindividual comparison of three different contrast media application protocols. <i>European Radiology</i> , 2013, 23, 938-942.	2.3	12
98	Prevention of recurrence after curative treatment for hepatocellular carcinoma. <i>Surgery Today</i> , 2013, 43, 1347-1354.	0.7	18
99	Carcinoma hepatocelular: epidemiologia, biologia, diagnÃ³stico e terapias. <i>Revista Da AssociaÃ§Ã£o MÃ©dica Brasileira</i> , 2013, 59, 514-524.	0.3	81
100	Long-term effectiveness of resection and radiofrequency ablation for single hepatocellular carcinoma ≤ 3 cm. Results of a multicenter Italian survey. <i>Journal of Hepatology</i> , 2013, 59, 89-97.	1.8	241
101	Early hepatocellular carcinoma – Is there such a thing as too early?. <i>Journal of Hepatology</i> , 2013, 58, 210-211.	1.8	2
102	Further evidence of the benefits associated with antiviral treatment in kidney allograft recipients with chronic hepatitis B virus infection. <i>Journal of Hepatology</i> , 2013, 58, 833-835.	1.8	3
103	Oncolytic immunotherapeutic virus in HCC: Can it compete with molecular therapies?. <i>Journal of Hepatology</i> , 2013, 59, 882-884.	1.8	7
104	Diagnostic and prognostic significance of cell death and macrophage activation markers in patients with hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2013, 59, 769-779.	1.8	68
105	The Size of the Problem: Clinical Algorithms. <i>Digestive Diseases</i> , 2013, 31, 95-103.	0.8	5
106	Consensus recommendations and review by an International Expert Panel on Interventions in Hepatocellular Carcinoma (<scp>EPOIHCC</scp>). <i>Liver International</i> , 2013, 33, 327-337.	1.9	70
107	Focus. <i>Journal of Hepatology</i> , 2013, 59, 643-645.	1.8	0
108	Hepatocellular Carcinoma: Illustrated Guide to Systematic Radiologic Diagnosis and Staging According to Guidelines of the American Association for the Study of Liver Diseases. <i>Radiographics</i> , 2013, 33, 1653-1668.	1.4	81
109	Early prediction of response to sorafenib in patients with advanced hepatocellular carcinoma: The role of dynamic contrast enhanced ultrasound. <i>Journal of Hepatology</i> , 2013, 59, 1014-1021.	1.8	75
110	The presence of hepatitis B core antibody is associated with more advanced liver disease in alcoholic patients with cirrhosis. <i>Alcohol</i> , 2013, 47, 553-558.	0.8	12
112	Contrast enhanced CT-scan to diagnose intrahepatic cholangiocarcinoma in patients with cirrhosis. <i>Journal of Hepatology</i> , 2013, 58, 1188-1193.	1.8	110
113	A randomised phase II/III trial of 3-weekly cisplatin-based sequential transarterial chemoembolisation vs embolisation alone for hepatocellular carcinoma. <i>British Journal of Cancer</i> , 2013, 108, 1252-1259.	2.9	121
114	New Insights in the Diagnosis, Pathogenesis and Treatment of Hepatitis B- and C-related Hepatocellular Carcinoma. <i>Current Hepatitis Reports</i> , 2013, 12, 297-304.	0.3	2

#	ARTICLE	IF	CITATIONS
115	Cost-effectiveness of liver cancer screening. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2013, 27, 961-972.	1.0	39
116	Advanced precancerous lesions in the liver. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2013, 27, 269-284.	1.0	46
117	Emerging treatments for hepatitis C. <i>Expert Opinion on Emerging Drugs</i> , 2013, 18, 461-475.	1.0	30
120	The ART of decision making: Retreatment with transarterial chemoembolization in patients with hepatocellular carcinoma. <i>Hepatology</i> , 2013, 57, 2261-2273.	3.6	288
121	A Phase-1b study of tivantinib (ARQ 197) in adult patients with hepatocellular carcinoma and cirrhosis. <i>British Journal of Cancer</i> , 2013, 108, 21-24.	2.9	69
122	Patient selection for liver transplantation. <i>Expert Review of Gastroenterology and Hepatology</i> , 2013, 7, 571-579.	1.4	6
123	Gastrointestinal imaging: Tips and traps in the diagnosis of small HCC. <i>Diagnostic and Interventional Imaging</i> , 2013, 94, 697-712.	1.8	7
124	Yttrium-90 Radioembolization for Hepatocellular Carcinoma: What We Know and What We Need to Know. <i>Oncology</i> , 2013, 84, 34-39.	0.9	16
126	Is the efficacy of sorafenib treatment in patients with hepatocellular carcinoma affected by age?. <i>Expert Review of Anticancer Therapy</i> , 2013, 13, 1355-1361.	1.1	14
127	Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study. <i>Journal of Clinical Oncology</i> , 2013, 31, 3517-3524.	0.8	675
128	A simple prognostic scoring system for patients receiving transarterial embolisation for hepatocellular cancer. <i>Annals of Oncology</i> , 2013, 24, 2565-2570.	0.6	275
129	Efficacy and Safety of Transarterial Radioembolization Versus Chemoembolization in Patients With Hepatocellular Carcinoma. <i>CardioVascular and Interventional Radiology</i> , 2013, 36, 714-723.	0.9	125
130	Transarterial therapies for hepatocellular carcinoma (HCC): A long way towards standardization. <i>Journal of Hepatology</i> , 2013, 58, 194.	1.8	3
131	Recurrent hepatocellular carcinoma after liver transplantation - an emerging clinical challenge. <i>Transplant International</i> , 2013, 26, 109-118.	0.8	121
132	How to decide about liver transplantation in patients with hepatocellular carcinoma: Size and number of lesions or response to TACE?. <i>Journal of Hepatology</i> , 2013, 59, 279-284.	1.8	100
133	PNPLA3 I148M variant and hepatocellular carcinoma: A common genetic variant for a rare disease. <i>Digestive and Liver Disease</i> , 2013, 45, 619-624.	0.4	55
134	Imagerie digestive: pièges et astuces « diagnostic du petit CHC. <i>Diagnostic and Interventional Imaging</i> , 2013, 94, 708-723.	0.0	0
135	Chemoembolization and Radioembolization for Hepatocellular Carcinoma. <i>Clinical Gastroenterology and Hepatology</i> , 2013, 11, 604-611.	2.4	83

#	ARTICLE	IF	CITATIONS
136	Towards new tools for refined management of patients with advanced hepatocellular carcinoma under systemic therapy: Some enthusiasm with a word of caution. <i>Journal of Hepatology</i> , 2013, 59, 924-925.	1.8	8
137	Reply to: "Further evidence of the benefits associated with antiviral treatment in kidney allograft recipients with chronic hepatitis B virus infection". <i>Journal of Hepatology</i> , 2013, 58, 835.	1.8	3
138	Non-invasive diagnosis of small nodules in cirrhosis. <i>Journal of Hepatology</i> , 2013, 59, 1360-1361.	1.8	1
139	Rethinking future development of molecular therapies in hepatocellular carcinoma: A bottom-up approach. <i>Journal of Hepatology</i> , 2013, 59, 392-395.	1.8	20
140	Debulking surgery followed by intraarterial 5-fluorouracil chemotherapy plus subcutaneous interferon alfa for massive hepatocellular carcinoma with multiple intrahepatic metastases: A pilot study. <i>European Journal of Surgical Oncology</i> , 2013, 39, 1364-1370.	0.5	13
141	Hepatitis C-associated B-cell non-Hodgkin lymphomas: The emerging role of miRNA-26b. <i>Journal of Hepatology</i> , 2013, 59, 1362-1363.	1.8	8
142	Hepatocellular carcinoma locoregional therapies for patients in the waiting list. Impact on transplantability and recurrence rate. <i>Journal of Hepatology</i> , 2013, 58, 609-618.	1.8	135
143	Radiculoneuropathy associated with acute hepatitis E. <i>Digestive and Liver Disease</i> , 2013, 45, 963-964.	0.4	10
144	Facing the dawn of immunotherapy for hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2013, 59, 9-10.	1.8	15
145	Hepatocellular carcinoma: epidemiology, biology, diagnosis, and therapies. <i>Revista Da Associação Médica Brasileira (English Edition)</i> , 2013, 59, 514-524.	0.1	2
146	Rupture in the vestibule of the bursa omentalis of a hepatocellular carcinoma of the caudate lobe in MRI. <i>Diagnostic and Interventional Imaging</i> , 2013, 94, 901-904.	1.8	1
147	THU-09 Hepatocellular carcinoma downstaging to transplantation. <i>Digestive and Liver Disease</i> , 2013, 45, S237.	0.4	0
148	Treatment of hepatocellular carcinoma in Child-Pugh B patients. <i>Digestive and Liver Disease</i> , 2013, 45, 852-858.	0.4	32
149	THU-07 Imaging follow-up after liver-directed therapies: Which method, which response criteria?. <i>Digestive and Liver Disease</i> , 2013, 45, S236.	0.4	0
150	Cost-effectiveness of hepatic resection versus percutaneous radiofrequency ablation for early hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2013, 59, 300-307.	1.8	323
151	Hepatocellular Carcinoma Responding to Superselective Transarterial Chemoembolization: An Issue of Nodule Dimension?. <i>Journal of Vascular and Interventional Radiology</i> , 2013, 24, 509-517.	0.2	95
152	Increased Quality of Life Among Hepatocellular Carcinoma Patients Treated With Radioembolization, Compared With Chemoembolization. <i>Clinical Gastroenterology and Hepatology</i> , 2013, 11, 1358-1365.e1.	2.4	220
153	Downstaging Disease in Patients with Hepatocellular Carcinoma Outside of Milan Criteria: Strategies Using Drug-eluting Bead Chemoembolization. <i>Journal of Vascular and Interventional Radiology</i> , 2013, 24, 1613-1622.	0.2	33

#	ARTICLE	IF	CITATIONS
155	THU-06 Does size matter in local ablation?. Digestive and Liver Disease, 2013, 45, S235-S236.	0.4	0
156	THU-10 Hepatocellular carcinoma: Resection or ablation. Digestive and Liver Disease, 2013, 45, S237-S238.	0.4	0
157	Brivanib in Patients With Advanced Hepatocellular Carcinoma Who Were Intolerant to Sorafenib or for Whom Sorafenib Failed: Results From the Randomized Phase III BRISK-PS Study. Journal of Clinical Oncology, 2013, 31, 3509-3516.	0.8	544
158	Integrating sorafenib into an algorithm for the management of post-transplant hepatocellular carcinoma recurrence. Journal of Hepatology, 2013, 59, 3-5.	1.8	33
159	Response assessment methodologies in hepatocellular carcinoma: Complexities in the era of local and systemic treatments. Journal of Hepatology, 2013, 58, 1260-1262.	1.8	16
163	Comparison of the survival and tolerability of radioembolization in elderly vs. younger patients with unresectable hepatocellular carcinoma. Journal of Hepatology, 2013, 59, 753-761.	1.8	82
164	Comparative efficacy of sorafenib versus best supportive care in recurrent hepatocellular carcinoma after liver transplantation: A case-control study. Journal of Hepatology, 2013, 59, 59-66.	1.8	128
166	Planning US for Percutaneous Radiofrequency Ablation of Small Hepatocellular Carcinomas (1â€“3 cm): Value of Fusion Imaging with Conventional US and CT/MR Images. Journal of Vascular and Interventional Radiology, 2013, 24, 958-965.	0.2	65
167	The impact of patient and tumour baseline characteristics on the overall survival of patients with advanced hepatocellular carcinoma treated with sorafenib. Digestive and Liver Disease, 2013, 45, 408-413.	0.4	31
168	Internal radiation by 131-iodine lipiodol in unresectable hepatocellular carcinoma. Digestive and Liver Disease, 2013, 45, 962-963.	0.4	0
169	Reply to: â€œNon-invasive diagnosis of small nodules in cirrhosisâ€. Journal of Hepatology, 2013, 59, 1361-1362.	1.8	0
170	685 ALPHA-FETOPROTEIN MEASUREMENT IN THE DIAGNOSIS OF HEPATOCELLULAR CARCINOMA IN REAL-LIFE PRACTICE: A MULTI-CENTRE, RETROSPECTIVE ANALYSIS. Journal of Hepatology, 2013, 58, S278.	1.8	0
171	Intratumoral Gas in Hepatocellular Carcinoma following Transarterial Chemoembolization: Associated Factors and Clinical Impact. Journal of Vascular and Interventional Radiology, 2013, 24, 1623-1631.	0.2	9
172	Liver resection is a therapeutic option for highly selected BCLC C patients in the context of an expert multidisciplinary setting. Digestive and Liver Disease, 2013, 45, 460-461.	0.4	3
173	249 HCC DIAGNOSED ON SURVEILLANCE PROGRAMMES: IMPACT ON STAGE AND OUTCOME. Journal of Hepatology, 2013, 58, S106-S107.	1.8	1
174	Use of Lipiodol as a drug-delivery system for transcatheter arterial chemoembolization of hepatocellular carcinoma: A review. Critical Reviews in Oncology/Hematology, 2013, 88, 530-549.	2.0	167
175	The Appropriate Allocation of CEUS in the Diagnostic Algorithm of Liver Lesions: A Debated Issue. Ultrasound in Medicine and Biology, 2013, 39, 183-185.	0.7	5
177	684 IMPACT OF REGIONAL Foxp3 EXPRESSION WITHIN THE TUMOR MICROENVIRONMENT ON TUMOR BIOLOGY AND MORTALITY IN HEPATITIS B-ASSOCIATED HEPATOCELLULAR CARCINOMA. Journal of Hepatology, 2013, 58, S278.	1.8	0

#	ARTICLE	IF	CITATIONS
178	Cancer Concepts and Principles: Primer for the Interventional Oncologistâ€™Part II. Journal of Vascular and Interventional Radiology, 2013, 24, 1167-1188.	0.2	26
179	HBV Infection and Hepatocellular Carcinoma. Clinics in Liver Disease, 2013, 17, 375-397.	1.0	34
180	Treatment of Hepatocellular Carcinoma with Radioembolization: Gathering Assumptions for Trial Design. Journal of Vascular and Interventional Radiology, 2013, 24, 1197-1199.	0.2	2
181	Ultrasonography-Guided Radiofrequency Ablation in Hepatocellular Carcinoma: Current Status and Future Perspectives. Journal of Medical Ultrasound, 2013, 21, 9-15.	0.2	3
182	THU-08 Molecular signature of prognosis and outcomes in hepatocellular carcinoma. Digestive and Liver Disease, 2013, 45, S236-S237.	0.4	1
183	T2-weighted MR imaging of the liver: Qualitative and quantitative comparison of SPACE MR imaging with turbo spin-echo MR imaging. European Journal of Radiology, 2013, 82, e655-e661.	1.2	8
184	Marked 25-hydroxyvitamin D deficiency is associated with poor prognosis in patients with alcoholic liver disease. Journal of Hepatology, 2013, 59, 344-350.	1.8	101
185	Molecular targeted therapy with transarterial chemoembolization. Gastrointestinal Intervention, 2013, 2, 78-81.	0.1	1
186	Elevated Alpha Fetoprotein, No Hepatocellular Carcinoma. Journal of Clinical and Experimental Hepatology, 2013, 3, 162-164.	0.4	15
187	Medical therapies for hepatocellular carcinoma: a critical view of the evidence. Nature Reviews Gastroenterology and Hepatology, 2013, 10, 34-42.	8.2	277
188	Toward a standardized system for hepatocellular carcinoma diagnosis using computed tomography and MRI. Expert Review of Gastroenterology and Hepatology, 2013, 7, 269-279.	1.4	39
189	Treatment of hepatocellular carcinoma: present and future. Expert Review of Anticancer Therapy, 2013, 13, 469-479.	1.1	23
190	A Hepatocellular Carcinoma 5-Gene Score Associated With Survival of Patients After Liver Resection. Gastroenterology, 2013, 145, 176-187.	0.6	302
191	Tivantinib: a new promising mesenchymalâ€™epithelial transition factor inhibitor in the treatment of hepatocellular carcinoma. Future Oncology, 2013, 9, 153-165.	1.1	17
192	Early Hepatocellular Carcinoma: Definition and Diagnosis. Liver Cancer, 2013, 2, 69-72.	4.2	58
193	A Prospective Randomized Controlled Trial to Compare Pringle Manoeuvre with Hemi-hepatic Vascular Inflow Occlusion in Liver Resection for Hepatocellular Carcinoma with Cirrhosis. Journal of Gastrointestinal Surgery, 2013, 17, 1414-1421.	0.9	24
194	Imaging-Based Diagnostic Systems for Hepatocellular Carcinoma. American Journal of Roentgenology, 2013, 201, 41-55.	1.0	61
196	Yttrium 90 radioembolization for the treatment of hepatocellular carcinoma: Biological lessons, current challenges, and clinical perspectives. Hepatology, 2013, 58, 2188-2197.	3.6	154

#	ARTICLE	IF	CITATIONS
197	Yttrium-90 radioembolization for intermediate-advanced hepatocellular carcinoma: A phase 2 study. <i>Hepatology</i> , 2013, 57, 1826-1837.	3.6	428
198	Diagnosis of hepatocellular carcinoma in cirrhotic patients: a proof-of-concept study using serum micro-Raman spectroscopy. <i>Analyst, The</i> , 2013, 138, 4006.	1.7	49
199	Glypican-3: a marker and a therapeutic target in hepatocellular carcinoma. <i>FEBS Journal</i> , 2013, 280, 2471-2476.	2.2	142
200	Hepatocellular Carcinoma from an Immunologic Perspective. <i>Clinical Cancer Research</i> , 2013, 19, 6678-6685.	3.2	89
201	Evidence of diagnostic enhancement pattern in hepatocellular carcinoma nodules according to the AASLD/EASL revised criteria. <i>Abdominal Imaging</i> , 2013, 38, 1245-1253.	2.0	12
202	Long-term effectiveness of Radiofrequency Ablation for solitary small Hepatocellular Carcinoma: A retrospective analysis of 363 patients. <i>Digestive and Liver Disease</i> , 2013, 45, 336-341.	0.4	44
203	A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. <i>Journal of Hepatology</i> , 2013, 59, 81-88.	1.8	816
205	Ultrasound Elastography for Fibrosis Surveillance Is Cost Effective in Patients with Chronic Hepatitis C Virus in the UK. <i>Digestive Diseases and Sciences</i> , 2013, 58, 2691-2704.	1.1	27
206	Association of Interleukin-28B Genotype and Hepatocellular Carcinoma Recurrence in Patients with Chronic Hepatitis C. <i>Clinical Cancer Research</i> , 2013, 19, 1827-1837.	3.2	57
207	A needle in a haystack: Identifying biomarkers to personalize systemic therapy in patients with hepatocellular carcinoma. <i>Hepatology</i> , 2013, 57, 1291-1293.	3.6	1
208	Local Ablation for Hepatocellular Carcinoma in Taiwan. <i>Liver Cancer</i> , 2013, 2, 73-83.	4.2	79
209	Antiviral therapy for prevention of hepatocellular carcinoma and mortality in chronic hepatitis B: systematic review and meta-analysis. <i>BMJ Open</i> , 2013, 3, e003265.	0.8	30
210	Surveillance of the patients at high risk for developing hepatocellular carcinoma in Europe - between guidelines and reality. <i>Ultraschall in Der Medizin</i> , 2013, 34, 483-484.	0.8	0
211	Fusion Imaging-Guided Radiofrequency Ablation for Hepatocellular Carcinomas Not Visible on Conventional Ultrasound. <i>American Journal of Roentgenology</i> , 2013, 201, 1141-1147.	1.0	93
212	Predictors of Dysplastic Nodule Diagnosis in Patients With Liver Cirrhosis on Unenhanced and Gadobenate Dimeglumine-Enhanced MRI With Dynamic and Hepatobiliary Phase. <i>American Journal of Roentgenology</i> , 2013, 200, 553-562.	1.0	25
213	Tumor Response on CT Following Hypofractionated Stereotactic Ablative Body Radiotherapy for Small Hypervascular Hepatocellular Carcinoma With Cirrhosis. <i>American Journal of Roentgenology</i> , 2013, 201, W812-W820.	1.0	36
214	Angiographic C-Arm CT Versus MDCT-Guided Stereotactic Punctures of Liver Lesions: Nonrigid Phantom Study. <i>American Journal of Roentgenology</i> , 2013, 201, 1136-1140.	1.0	10
215	Elevated Plasma Fibrinogen Levels Are Associated with a Poor Prognosis in Patients with Hepatocellular Carcinoma. <i>Oncology</i> , 2013, 85, 269-277.	0.9	49

#	ARTICLE	IF	CITATIONS
217	The Appropriate Allocation of CEUS in the Diagnostic Algorithm of Liver Lesions: A Debated Issue. <i>Ultraschall in Der Medizin</i> , 2013, 34, 8-10.	0.8	4
219	Transarterial Chemoembolization - Status Quo in Germany. <i>RoFo Fortschritte Auf Dem Gebiet Der Rontgenstrahlen Und Der Bildgebenden Verfahren</i> , 2013, 185, 1089-1094.	0.7	12
220	Early Prediction of Treatment Response to Sorafenib with Elastosonography in a Mice Xenograft Model of Hepatocellular Carcinoma: A Proof-of-Concept Study. <i>Ultraschall in Der Medizin</i> , 2013, 34, 541-549.	0.8	8
221	Nonadherence to guidelines in the management of hepatocellular carcinoma: an Italian or universal phenomenon?. <i>Future Oncology</i> , 2013, 9, 465-467.	1.1	5
223	Predicting Coverage of Transverse Subcostal Sonography With the Use of Previous Computed Tomography Before a Sonographic Liver Examination. <i>Journal of Ultrasound in Medicine</i> , 2013, 32, 2053-2061.	0.8	5
224	Heterogeneity of Patients with Intermediate (BCLC B) Hepatocellular Carcinoma: Proposal for a Subclassification to Facilitate Treatment Decisions. <i>Seminars in Liver Disease</i> , 2013, 32, 348-359.	1.8	508
225	Sorafenib combined with transarterial chemoembolization for the treatment of advanced hepatocellular carcinoma: a large-scale multicenter study of 222 patients. <i>Annals of Oncology</i> , 2013, 24, 1786-1792.	0.6	96
226	Hedgehog inhibition reduces angiogenesis by downregulation of tumoral VEGF expression in hepatocellular carcinoma. <i>United European Gastroenterology Journal</i> , 2013, 1, 265-275.	1.6	26
227	Sorafenib in combination with transarterial chemoembolization in Chinese patients with hepatocellular carcinoma: a subgroup interim analysis of the START trial. <i>Future Oncology</i> , 2013, 9, 403-410.	1.1	22
228	Sorafenib Alone versus Sorafenib Combined with Transarterial Chemoembolization for Advanced-Stage Hepatocellular Carcinoma: Results of Propensity Score Analyses. <i>Radiology</i> , 2013, 269, 603-611.	3.6	124
229	Ultrasonography Fusion Imaging System Increases the Chance of Radiofrequency Ablation for Hepatocellular Carcinoma with Poor Conspicuity on Conventional Ultrasonography. <i>Oncology</i> , 2013, 84, 44-50.	0.9	26
230	Surgical Management of HCC. , 2013, , .		1
231	Shaping the Future Management of Hepatocellular Carcinoma. <i>Seminars in Liver Disease</i> , 2013, 33, S20-S24.	1.8	5
232	Sorafenib suppresses the rapid progress of hepatocellular carcinoma after insufficient radiofrequency ablation therapy: An experiment <i>in vivo</i> . <i>Acta Radiologica</i> , 2013, 54, 199-204.	0.5	43
234	A Two-Step Right Hepatic Lobectomy with Portal Vein Ligation for Large Hepatocellular Carcinoma: Rapid Induction of Left-Lobe Regeneration and Clinicopathologic Correlation. <i>Seminars in Liver Disease</i> , 2013, 33, 293-297.	1.8	2
235	Sorafenib: from literature to clinical practice. <i>Annals of Oncology</i> , 2013, 24, 30-37.	0.6	65
236	Clinical Characteristics of Patients with Hepatocellular Carcinoma in a Middle Eastern Population. <i>Hepatitis Monthly</i> , 2013, 13, e7612.	0.1	21
237	Prognostic significance of tumor-associated trypsin inhibitor (TATI) and human chorionic gonadotropin- β (hCG β) in patients with hepatocellular carcinoma. <i>Scandinavian Journal of Gastroenterology</i> , 2013, 48, 1066-1073.	0.6	17

#	ARTICLE	IF	CITATIONS
238	Endovascular treatment of hepatocellular carcinoma with drug eluting microparticles (DC-Beads): CT evaluation of response to the treatment. <i>Indian Journal of Radiology and Imaging</i> , 2013, 23, 126-133.	0.3	12
239	Chemoembolization of Hepatocellular Carcinoma. <i>Seminars in Interventional Radiology</i> , 2013, 30, 003-011.	0.3	170
240	The biological implication of cancer stem cells in hepatocellular carcinoma: a possible target for future therapy. <i>Expert Review of Gastroenterology and Hepatology</i> , 2013, 7, 749-757.	1.4	7
241	Multidisciplinary approach for HCC patients: hepatology for the oncologists. <i>Annals of Oncology</i> , 2013, 24, 15-23.	0.6	31
242	HCC. Radioembolization Combined with Other Therapeutic Local and Systemic Treatment. <i>Medical Radiology</i> , 2013, , 119-127.	0.0	1
243	Intermediate hepatocellular carcinoma: current treatments and future perspectives. <i>Annals of Oncology</i> , 2013, 24, 24-29.	0.6	70
244	A Risk for Hepatocellular Carcinoma Persists Long-term After Sustained Virologic Response in Patients With Hepatitis C-Associated Liver Cirrhosis. <i>Clinical Infectious Diseases</i> , 2013, 57, 230-236.	2.9	206
245	Serum Insulin-like Growth Factor-I Level Is an Independent Predictor of Recurrence and Survival in Early Hepatocellular Carcinoma: A Prospective Cohort Study. <i>Clinical Cancer Research</i> , 2013, 19, 4218-4227.	3.2	28
246	Systemic Therapy and Synergies by Combination. <i>Digestive Diseases</i> , 2013, 31, 104-111.	0.8	11
247	Surveillance for hepatocellular carcinoma in chronic liver disease: Evidence and controversies. <i>World Journal of Gastroenterology</i> , 2013, 19, 6744.	1.4	50
248	Serum Proteoglycans as Prognostic Biomarkers of Hepatocellular Carcinoma in Patients with Alcoholic Cirrhosis. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2013, 22, 1343-1352.	1.1	65
249	New Data Supporting Modified RECIST (mRECIST) for Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , 2013, 19, 1312-1314.	3.2	104
250	Methodological assessment of HCC literature. <i>Annals of Oncology</i> , 2013, 24, 6-14.	0.6	1
251	Missed Opportunities for Hepatocellular Carcinoma Screening in an HIV/Hepatitis C Virus-Coinfected Cohort. <i>Clinical Infectious Diseases</i> , 2013, 57, 1339-1342.	2.9	4
252	Surveillance for early diagnosis of hepatocellular carcinoma: How best to do it?. <i>World Journal of Gastroenterology</i> , 2013, 19, 8808.	1.4	72
253	Hepatocellular carcinoma continues to be diagnosed in the advanced stage: profile of hepatocellular carcinoma in a tertiary care hospital in South India. <i>Tropical Doctor</i> , 2013, 43, 25-26.	0.2	10
254	Targeting the HGF/c-MET Pathway in Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , 2013, 19, 2310-2318.	3.2	276
255	Therapeutic Response Assessment of Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma: Ultrasonography, CT and MR Imaging. <i>Oncology</i> , 2013, 84, 58-63.	0.9	24

#	ARTICLE	IF	CITATIONS
256	Utility of computed tomography fusion imaging for the evaluation of the ablative margin of radiofrequency ablation for hepatocellular carcinoma and the correlation to local tumor progression. <i>Hepatology Research</i> , 2013, 43, 950-958.	1.8	33
257	Selective accumulation of platinum and formation of platinum-DNA adducts in hepatocellular carcinoma after transarterial chemoembolization with miriplatin. <i>Hepatology Research</i> , 2013, 43, 1093-1099.	1.8	5
258	Worse outcome of sorafenib therapy associated with ascites and Child-Pugh score in advanced hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2013, 28, 1756-1761.	1.4	43
259	Predictors of Health-Related Quality of Life in Outpatients with Cirrhosis: Results from a Prospective Cohort. <i>Hepatitis Research and Treatment</i> , 2013, 2013, 1-6.	2.0	19
260	Contrast enhanced ultrasound and magnetic resonance imaging in hepatocellular carcinoma diagnosis. <i>Medical Ultrasonography</i> , 2013, 15, 261-267.	0.4	16
261	Role of FNA and Core Biopsy of Primary and Metastatic Liver Disease. <i>International Journal of Hepatology</i> , 2013, 2013, 1-10.	0.4	13
262	The Role of Bridging Therapy in Hepatocellular Carcinoma. <i>International Journal of Hepatology</i> , 2013, 2013, 1-8.	0.4	23
263	Are Biomarkers Still Helpful in Hepatocellular Carcinoma?. <i>Digestion</i> , 2013, 87, 118-120.	1.2	1
264	Transarterial embolization as neoadjuvant therapy pretransplantation in patients with hepatocellular carcinoma. <i>Liver International</i> , 2013, 33, 944-949.	1.9	55
265	Transarterial chemoembolization in hepatocellular carcinoma with vascular invasion or extrahepatic metastasis: A systematic review. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2013, 9, 357-364.	0.7	33
266	Hepatocellular screening in hepatitis B infected Asian Americans. <i>Journal of Viral Hepatitis</i> , 2013, 20, 515-516.	1.0	3
267	Patterns of appearance and risk of misdiagnosis of intrahepatic cholangiocarcinoma in cirrhosis at contrast enhanced ultrasound. <i>Liver International</i> , 2013, 33, 771-779.	1.9	91
268	Influence of clinically significant portal hypertension on survival after hepatic resection for hepatocellular carcinoma in cirrhotic patients. <i>Liver International</i> , 2013, 33, 1594-1600.	1.9	46
269	Can the tyrosine kinase inhibitors trigger metabolic encephalopathy in cirrhotic patients?. <i>Liver International</i> , 2013, 33, 488-493.	1.9	13
270	Additive effect of sirolimus and anti-death receptor 5 agonistic antibody against hepatocellular carcinoma. <i>Liver International</i> , 2013, 33, 1441-1448.	1.9	4
271	Evoluci3n natural y estratificaci3n del carcinoma hepatoceleular. <i>Clinical Liver Disease</i> , 2013, 2, S333-S363.	1.0	0
272	Tivantinib in hepatocellular carcinoma. <i>Expert Opinion on Investigational Drugs</i> , 2013, 22, 141-147.	1.9	26
273	Adherence to American Association for the Study of Liver Diseases guidelines for the management of hepatocellular carcinoma: results of an Italian field practice multicenter study. <i>Future Oncology</i> , 2013, 9, 283-294.	1.1	54

#	ARTICLE	IF	CITATIONS
274	Impact of liver fibrosis on prognosis following liver resection for hepatitis B-associated hepatocellular carcinoma. <i>British Journal of Cancer</i> , 2013, 109, 573-581.	2.9	65
275	Effect of Antiviral Treatment With Nucleotide/Nucleoside Analogs on Postoperative Prognosis of Hepatitis B Virus-Related Hepatocellular Carcinoma: A Two-Stage Longitudinal Clinical Study. <i>Journal of Clinical Oncology</i> , 2013, 31, 3647-3655.	0.8	260
276	Hepatobiliary Malignancies: Lessons from Asia. <i>Digestive Diseases</i> , 2013, 31, 130-137.	0.8	10
277	Authors'™ Response. <i>Radiographics</i> , 2013, 33, 1670-1671.	1.4	0
278	Multidisciplinary strategies to improve treatment outcomes in hepatocellular carcinoma. <i>European Journal of Gastroenterology and Hepatology</i> , 2013, 25, 639-651.	0.8	34
279	Radiofrequency (thermal) ablation versus no intervention or other interventions for hepatocellular carcinoma. <i>The Cochrane Library</i> , 2013, , CD003046.	1.5	73
280	Reply:. <i>Hepatology</i> , 2013, 58, 452-453.	3.6	0
281	Yttrium 90 radioembolization: The horizon is changing for patients with intermediate and advanced hepatocellular carcinoma. <i>Hepatology</i> , 2013, 57, 1694-1696.	3.6	2
282	Intra-arterial injection of 131I-labeled Lipiodol for advanced hepatocellular carcinoma. <i>Nuclear Medicine Communications</i> , 2013, 34, 674-681.	0.5	18
283	Radiofrequency ablation. <i>European Journal of Gastroenterology and Hepatology</i> , 2013, 25, 842-849.	0.8	29
284	Validation of Organ Procurement and Transplant Network (OPTN)/United Network for Organ Sharing (UNOS) Criteria for Imaging Diagnosis of Hepatocellular Carcinoma. <i>Transplantation</i> , 2013, 95, 1506-1511.	0.5	28
285	Yttrium-90 radioembolization of liver tumors: what do the images tell us?. <i>Cancer Imaging</i> , 2013, 13, 645-657.	1.2	45
286	Cancer causing viruses and the role of laboratory medicine: literature review and perspectives. <i>Jornal Brasileiro De Patologia E Medicina Laboratorial</i> , 2013, 49, 109-114.	0.3	4
287	Use of contrast agents in oncological imaging: magnetic resonance imaging. <i>Cancer Imaging</i> , 2013, 13, 350-359.	1.2	9
288	Pretreatment Evaluation with Contrast-Enhanced Ultrasonography for Percutaneous Radiofrequency Ablation of Hepatocellular Carcinomas with Poor Conspicuity on Conventional Ultrasonography. <i>Korean Journal of Radiology</i> , 2013, 14, 754.	1.5	26
289	Is hepatic venous pressure gradient assessment required before liver resection in patients with cirrhosis and hepatocellular carcinoma?. <i>Clinics</i> , 2013, 68, 437-440.	0.6	0
290	Hepatocellular Carcinoma in Child-Pugh C Cirrhosis: Prognostic Factors and Survival Benefit of Nontransplant Treatments. <i>Digestive Diseases</i> , 2013, 31, 490-498.	0.8	25
291	Effect of alcohol consumption on liver stiffness measured by transient elastography. <i>World Journal of Gastroenterology</i> , 2013, 19, 516.	1.4	62

#	ARTICLE	IF	CITATIONS
292	The optimal follow-up period in patients with above 5-year disease-free survival after curative liver resection for hepatocellular carcinoma. [Chapchi] Journal Taehan Oekwa Hakhoe, 2013, 85, 269.	1.1	3
293	Recent advance of local ablation for hepatocellular carcinoma. Journal of the Korean Medical Association, 2013, 56, 964.	0.1	1
295	Status of Primary Liver Cancer Found through Routine Health Check-up. Journal of Korean Medical Science, 2013, 28, 1449.	1.1	1
296	EPIDEMIOLOGICAL ASPECTS OF HEPATOCELLULAR CARCINOMA IN A REFERRAL CENTER OF MINAS GERAIS, BRAZIL. Arquivos De Gastroenterologia, 2013, 50, 97-100.	0.3	9
300	Development of Biomarkers for Screening Hepatocellular Carcinoma Using Global Data Mining and Multiple Reaction Monitoring. PLoS ONE, 2013, 8, e63468.	1.1	30
301	Factors Associated with Compliance with Recommendations for Liver Cancer Screening in Korea: A Nationwide Survey in Korea. PLoS ONE, 2013, 8, e68315.	1.1	12
302	Survival of Patients with Hepatocellular Carcinoma (HCC) Treated by Percutaneous Radio-Frequency Ablation (RFA) Is Affected by Complete Radiological Response. PLoS ONE, 2013, 8, e70016.	1.1	29
303	The Expression of CD90/Thy-1 in Hepatocellular Carcinoma: An In Vivo and In Vitro Study. PLoS ONE, 2013, 8, e76830.	1.1	70
304	Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma: Prognostic Factors of Local Control, Overall Survival, and Toxicity. PLoS ONE, 2013, 8, e77472.	1.1	104
305	Post-Therapeutic Follow-Up and Early Detection of Recurrence in Hepatocellular Carcinoma. , 0, , .		1
306	Treatment for Hepatocellular Carcinoma in Elderly Patients: A Literature Review. Journal of Cancer, 2013, 4, 635-643.	1.2	90
307	Targeting Tyrosine Kinase Receptors in Hepatocellular Carcinoma. Current Cancer Drug Targets, 2013, 13, 300-312.	0.8	37
308	Results in Hepatocellular Carcinoma. Medical Radiology, 2013, , 105-117.	0.0	2
310	Image-Guided Therapies for Hepatocellular Carcinoma in Hepatocellular Carcinoma " Future Outlook. , 0, , .		0
311	The Prognostic Value of ¹⁸ F-FDG PET/CT for Hepatocellular Carcinoma Treated with Transarterial Chemoembolization (TACE). Theranostics, 2014, 4, 736-744.	4.6	32
312	Transarterial radioembolization using yttrium-90 microspheres in the treatment of hepatocellular carcinoma: a review on clinical utility and developments. Journal of Hepatocellular Carcinoma, 2014, 1, 163.	1.8	15
313	Radiofrequency Ablation versus Hepatic Resection for Small Hepatocellular Carcinomas: A Meta-Analysis of Randomized and Nonrandomized Controlled Trials. PLoS ONE, 2014, 9, e84484.	1.1	123
314	Concurrent Activation of Acetylation and Tri-Methylation of H3K27 in a Subset of Hepatocellular Carcinoma with Aggressive Behavior. PLoS ONE, 2014, 9, e91330.	1.1	34

#	ARTICLE	IF	CITATIONS
315	Sorafenib Combined with Transarterial Chemoembolization versus Transarterial Chemoembolization Alone for Advanced-Stage Hepatocellular Carcinoma: A Propensity Score Matching Study. PLoS ONE, 2014, 9, e96620.	1.1	55
316	Detailed Analysis of Temporal Features on Contrast Enhanced Ultrasound May Help Differentiate Intrahepatic Cholangiocarcinoma from Hepatocellular Carcinoma in Cirrhosis. PLoS ONE, 2014, 9, e98612.	1.1	51
317	A New Child-Turcotte-Pugh Class 0 for Patients with Hepatocellular Carcinoma: Determinants, Prognostic Impact and Ability to Improve the Current Staging Systems. PLoS ONE, 2014, 9, e99115.	1.1	8
318	Serum Autoantibody Measurement for the Detection of Hepatocellular Carcinoma. PLoS ONE, 2014, 9, e103867.	1.1	21
319	Does 18F-FDG Positron Emission Tomography-Computed Tomography Have a Role in Initial Staging of Hepatocellular Carcinoma?. PLoS ONE, 2014, 9, e105679.	1.1	43
320	Comparing Outcomes of Two Vascular Inflow Occlusion Techniques and Treatment without Vascular Occlusion during Major Hepatectomy in Patients with Hepatitis B-Related Hepatocellular Carcinoma. PLoS ONE, 2014, 9, e107303.	1.1	13
321	Expert Perspectives on Evidence-Based Treatment Planning for Patients with Hepatocellular Carcinoma. Cancer Control, 2014, 21, 5-16.	0.7	1
322	Hepatocellular Carcinoma in a Large Canadian Urban Centre: Stage at Treatment and Its Potential Determinants. Canadian Journal of Gastroenterology and Hepatology, 2014, 28, 150-154.	0.8	8
323	Clinical utility of imaging for evaluation of hepatocellular carcinoma. Journal of Hepatocellular Carcinoma, 2014, 1, 101.	1.8	0
324	Role of stereotactic body radiation therapy for hepatocellular carcinoma. World Journal of Gastroenterology, 2014, 20, 3100.	1.4	69
325	Radiological diagnosis of hepatocellular carcinoma. Journal of Hepatocellular Carcinoma, 2014, 1, 137.	1.8	14
326	Hepatocellular carcinoma review: Current treatment, and evidence-based medicine. World Journal of Gastroenterology, 2014, 20, 4115.	1.4	361
327	Regorafenib: an evidence-based review of its potential in patients with advanced liver cancer. Core Evidence, 2014, 9, 81.	4.7	20
328	Hepatocellular carcinoma in Australia's Northern Territory: high incidence and poor outcome. Medical Journal of Australia, 2014, 201, 470-474.	0.8	39
329	Contrast-enhanced ultrasound in the diagnosis of nodules in liver cirrhosis. World Journal of Gastroenterology, 2014, 20, 3590.	1.4	63
330	Laser ablation for small hepatocellular carcinoma: State of the art and future perspectives. World Journal of Hepatology, 2014, 6, 704.	0.8	55
331	Monopolar Radiofrequency Ablation Using a Dual-Switching System and a Separable Clustered Electrode: Evaluation of the In Vivo Efficiency. Korean Journal of Radiology, 2014, 15, 235.	1.5	24
332	Non invasive tools for the diagnosis of liver cirrhosis. World Journal of Gastroenterology, 2014, 20, 18131.	1.4	76

#	ARTICLE	IF	CITATIONS
333	Emerging role of dual antiplatelet therapy in the prevention of hepatitis B virus-associated hepatocellular carcinoma. <i>Journal of Hepatocellular Carcinoma</i> , 2014, 1, 183.	1.8	3
334	Heterogeneity of The CD90+ Population in Different Stages of Hepatocarcinogenesis. <i>Journal of Proteomics and Bioinformatics</i> , 2014, 07, 296-302.	0.4	10
336	The Metabolic Syndrome and Chronic Liver Disease. <i>Current Pharmaceutical Design</i> , 2014, 20, 5010-5024.	0.9	35
337	Role of stereotactic body radiotherapy for oligometastasis from colorectal cancer. <i>World Journal of Gastroenterology</i> , 2014, 20, 4220.	1.4	53
338	Interventional treatment for unresectable hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2014, 20, 13453.	1.4	39
339	Molecular Determinants of Prognosis in Hepatocellular Carcinoma. <i>Journal of Clinical and Translational Hepatology</i> , 2014, 2, 31-6.	0.7	3
340	Survival after ¹³¹ I-labeled lipiodol therapy for hepatocellular carcinoma. <i>Nuklearmedizin - NuclearMedicine</i> , 2014, 53, 46-53.	0.3	7
341	A Role for Acyclic Retinoid in the Chemoprevention of Hepatocellular Carcinoma: Therapeutic Strategy Targeting Phosphorylated Retinoid X Receptor- β . <i>Diseases (Basel, Switzerland)</i> , 2014, 2, 226-242.	1.0	2
343	Latin American Association for the Study of the Liver (LAASL) Clinical Practice Guidelines: Management of Hepatocellular Carcinoma. <i>Annals of Hepatology</i> , 2014, 13, S4-S40.	0.6	34
344	m-RECIST at 1 month and Child A are survival predictors after percutaneous ethanol injection of hepatocellular carcinoma. <i>Annals of Hepatology</i> , 2014, 13, 796-802.	0.6	2
345	Factors affecting screening for hepatocellular carcinoma. <i>Annals of Hepatology</i> , 2014, 13, 204-210.	0.6	14
346	Epidemiology of HCC in Brazil: Incidence and risk factors in a ten-year cohort. <i>Annals of Hepatology</i> , 2014, 13, 386-393.	0.6	47
347	Long term nucleotide and nucleoside analogs treatment in chronic hepatitis B HBeAg negative genotype D patients and risk for hepatocellular carcinoma. <i>Annals of Hepatology</i> , 2014, 13, 376-385.	0.6	7
348	Liver transplantation for malignancy: Current treatment strategies and future perspectives. <i>World Journal of Gastroenterology</i> , 2014, 20, 5331.	1.4	34
349	Perspectives of TGF- β 2 inhibition in pancreatic and hepatocellular carcinomas. <i>Oncotarget</i> , 2014, 5, 78-94.	0.8	125
350	Liver-Directed Therapies: Surgical Approaches, Alone and in Combination with Other Interventions. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2014, , 101-110.	1.8	9
351	The ART Score Is Not Effective to Select Patients for Transarterial Chemoembolization Retreatment in an Italian Series. <i>Digestive Diseases</i> , 2014, 32, 711-716.	0.8	47
352	Transarterial embolization with or without chemotherapy for advanced hepatocellular carcinoma: a systematic review. <i>Tumor Biology</i> , 2014, 35, 8451-8459.	0.8	25

#	ARTICLE	IF	CITATIONS
353	Hepatocellular carcinoma and cholangiocarcinoma: an update. Expert Review of Gastroenterology and Hepatology, 2014, 8, 63-82.	1.4	16
354	Transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: a systematic review and meta-analysis. Molecular Biology Reports, 2014, 41, 6575-6582.	1.0	37
355	SIR-Spheres yttrium-90 radioembolization for the treatment of unresectable liver cancers. Hepatic Oncology, 2014, 1, 265-283.	4.2	12
356	Surveillance and Diagnostic Algorithm for Hepatocellular Carcinoma Proposed by the Liver Cancer Study Group of Japan: 2014 Update. Oncology, 2014, 87, 7-21.	0.9	73
357	Differential Expression of Drug Uptake and Efflux Transporters in Japanese Patients with Hepatocellular Carcinoma. Drug Metabolism and Disposition, 2014, 42, 2033-2040.	1.7	38
359	JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan. Liver Cancer, 2014, 3, 458-468.	4.2	512
360	Hepatic resection associated with good survival for selected patients with multinodular hepatocellular carcinoma. Tumor Biology, 2014, 35, 8355-8358.	0.8	17
361	EASL- and mRECIST-Evaluated Responses to Combination Therapy of Sorafenib with Transarterial Chemoembolization Predict Survival in Patients with Hepatocellular Carcinoma. Clinical Cancer Research, 2014, 20, 1623-1631.	3.2	31
362	Postoperative therapy options for hepatocellular carcinoma. Scandinavian Journal of Gastroenterology, 2014, 49, 649-661.	0.6	53
363	Risk factors for early intrahepatic distant recurrence after radiofrequency ablation for hepatocellular carcinoma in Egyptian patients. Journal of Digestive Diseases, 2014, 15, 676-683.	0.7	7
364	A nomogram predicting pulmonary metastasis of hepatocellular carcinoma following partial hepatectomy. British Journal of Cancer, 2014, 110, 1110-1117.	2.9	52
365	Oxaliplatin/5-fluorouracil in advanced hepatocellular carcinoma: case report and single-center retrospective review. Future Oncology, 2014, 10, 2007-2014.	1.1	8
366	Tivantinib: critical review with a focus on hepatocellular carcinoma. Expert Opinion on Investigational Drugs, 2014, 23, 1563-1574.	1.9	18
367	A correlation of computed tomography perfusion and histopathology in tumor edges of hepatocellular carcinoma. Hepatobiliary and Pancreatic Diseases International, 2014, 13, 612-617.	0.6	7
368	2014 KLCSSG-NCC Korea Practice Guidelines for the Management of Hepatocellular Carcinoma: HCC Diagnostic Algorithm. Digestive Diseases, 2014, 32, 764-777.	0.8	60
369	Efficacy of Sorafenib in Intermediate-Stage Hepatocellular Carcinoma Patients Refractory to Transarterial Chemoembolization. Oncology, 2014, 87, 330-341.	0.9	161
370	Alternative Response Criteria (Choi, European Association for the Study of the Liver, and Modified) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 Hepatocellular Carcinoma Treated With Sorafenib. Oncologist, 2014, 19, 394-402.	1.9	134
371	Mexican consensus on the diagnosis and management of hepatocellular carcinoma. Revista De Gastroenterología De México (English Edition), 2014, 79, 250-262.	0.1	3

#	ARTICLE	IF	CITATIONS
373	Identification of Responders to Sorafenib in Hepatocellular Carcinoma: Is Tumor Volume Measurement the Way Forward?. <i>Oncology</i> , 2014, 86, 191-198.	0.9	18
374	Challenging clinical cases in HCV infection. <i>BMC Infectious Diseases</i> , 2014, 14, S7.	1.3	1
375	Hepatocellular Carcinoma Screening and Diagnosis. <i>Seminars in Liver Disease</i> , 2014, 34, 389-397.	1.8	15
377	The Complex Relationship between Liver Cancer and the Cell Cycle: A Story of Multiple Regulations. <i>Cancers</i> , 2014, 6, 79-111.	1.7	82
378	Imaging Techniques for the Diagnosis of Hepatocellular Carcinoma and the Evaluation of Response to Treatment. <i>Seminars in Liver Disease</i> , 2014, 34, 398-414.	1.8	11
379	Diagnosis System for Hepatocellular Carcinoma Based on Fractal Dimension of Morphometric Elements Integrated in an Artificial Neural Network. <i>BioMed Research International</i> , 2014, 2014, 1-10.	0.9	16
380	Early Hepatocellular Carcinoma on the Procrustean Bed of Ablation, Resection, and Transplantation. <i>Seminars in Liver Disease</i> , 2014, 34, 415-426.	1.8	60
381	Complete remission of hepatocellular carcinoma after transarterial Chemoembolization combined with brivanib. <i>Journal of Cancer Research and Therapeutics</i> , 2014, 10, 1112.	0.3	3
382	Stereotactic body radiotherapy for small hepatocellular carcinoma: A retrospective outcome analysis in 185 patients. <i>Acta Oncologica</i> , 2014, 53, 399-404.	0.8	222
383	Sorafenib for the treatment of hepatocellular carcinoma. <i>Hepatic Oncology</i> , 2014, 1, 189-204.	4.2	7
384	New advances in precision medicine for hepatocellular carcinoma recurrence prediction and treatment. <i>Hepatology</i> , 2014, 60, 1812-1814.	3.6	29
385	Exposure to ionizing radiation during liver transplantation evaluation, waitlist time, and in the postoperative period: A cause for concern. <i>Hepatology</i> , 2014, 59, 496-504.	3.6	10
386	The Addition of C-Reactive Protein to Validated Staging Systems Improves Their Prognostic Ability in Patients with Hepatocellular Carcinoma. <i>Oncology</i> , 2014, 86, 308-317.	0.9	16
387	Incidence of Hepatocellular Carcinoma in HIV-Infected Patients With Cirrhosis. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014, 65, 82-86.	0.9	10
388	Uncompromised Treatment Efficacy in Elderly Patients With Hepatocellular Carcinoma. <i>Medicine (United States)</i> , 2014, 93, e264.	0.4	20
389	Non-Hypervascular Hypointense Nodules ≥ 1 cm on the Hepatobiliary Phase of Gadoteric Acid-Enhanced Magnetic Resonance Imaging in Cirrhotic Livers. <i>Digestive Diseases</i> , 2014, 32, 678-689.	0.8	26
392	Contrast-Enhanced Ultrasound (CEUS) For The Evaluation Of Focal Liver Lesions – A Prospective Multicenter Study Of Its Usefulness In Clinical Practice. <i>Ultraschall in Der Medizin</i> , 2014, 35, 259-266.	0.8	72
393	Managing hepatitis B to prevent liver cancer: recent advances. <i>Expert Review of Gastroenterology and Hepatology</i> , 2014, 8, 409-415.	1.4	3

#	ARTICLE	IF	CITATIONS
394	Consenso mexicano de diagnóstico y manejo del carcinoma hepatocelular. Revista De Gastroenterología De México, 2014, 79, 250-262.	0.4	13
395	Evidence-based integration of selective internal radiation therapy into hepatocellular carcinoma management. Future Oncology, 2014, 10, 7-11.	1.1	1
396	The effectiveness of selective internal radiation therapy in challenging cases of liver-predominant unresectable hepatocellular carcinoma. Future Oncology, 2014, 10, 17-27.	1.1	10
397	Mechanically assisted 3D ultrasound for pre-operative assessment and guiding percutaneous treatment of focal liver tumors. , 2014, , .		0
398	State of the art: hepatocellular carcinoma. Future Oncology, 2014, 10, 1-6.	1.1	31
399	Stereotactic body radiotherapy: an effective local treatment modality for hepatocellular carcinoma. Future Oncology, 2014, 10, 2227-2241.	1.1	15
401	Dynamic Contrast-Enhanced Ultrasound (DCE-US) for the Characterization of Hepatocellular Carcinoma and Cholangiocellular Carcinoma. Ultraschall in Der Medizin, 2014, 35, 522-527.	0.8	70
402	Non-alcoholic fatty liver disease and hepatocellular carcinoma in a 7-year-old obese boy: coincidence or comorbidity?. Pediatric Obesity, 2014, 9, e99-e102.	1.4	42
403	Changes in plasma vascular endothelial growth factor at 8 weeks after sorafenib administration as predictors of survival for advanced hepatocellular carcinoma. Cancer, 2014, 120, 229-237.	2.0	57
404	Perivascular versus Nonperivascular Small HCC Treated with Percutaneous RF Ablation: Retrospective Comparison of Long-term Therapeutic Outcomes. Radiology, 2014, 270, 888-899.	3.6	77
405	Factors associated with early cancer-related death after curative hepatectomy for solitary small hepatocellular carcinoma without macroscopic vascular invasion. Journal of Hepato-Biliary-Pancreatic Sciences, 2014, 21, 142-147.	1.4	8
406	Small Single-Nodule Hepatocellular Carcinoma: Comparison of Transarterial Chemoembolization, Radiofrequency Ablation, and Hepatic Resection by Using Inverse Probability Weighting. Radiology, 2014, 271, 909-918.	3.6	97
407	Post Hepatectomy Liver Failure: Concept of Management. Journal of Gastrointestinal Cancer, 2014, 45, 405-413.	0.6	17
408	Randomized Trial of [131I] Metuximab in Treatment of Hepatocellular Carcinoma After Percutaneous Radiofrequency Ablation. Journal of the National Cancer Institute, 2014, 106, .	3.0	62
409	Transarterial chemoembolization is safe and effective for elderly advanced hepatocellular carcinoma patients: results from an international database. Liver International, 2014, 34, 1109-1117.	1.9	19
410	Risk prediction of hepatocellular carcinoma in patients with cirrhosis: The ADDRESS-HCC risk model. Cancer, 2014, 120, 3485-3493.	2.0	125
411	Vitamin D deficiency and liver cancer: More than just an epidemiological association?. Hepatology, 2014, 60, 1130-1132.	3.6	14
412	Synergistic effect of simvastatin plus NS398 on inhibition of proliferation and survival in hepatocellular carcinoma cell line. Journal of Gastroenterology and Hepatology (Australia), 2014, 29, 1299-1307.	1.4	11

#	ARTICLE	IF	CITATIONS
413	Rationality and effectiveness of transarterial chemoembolization as an initial treatment for ^B stage ^{HBV}-related hepatocellular carcinoma. Liver International, 2014, 34, 612-620.	1.9	17
414	Validation of a model to estimate survival in ambulatory patients with hepatocellular carcinoma: a single-centre cohort study. Liver International, 2014, 34, e317-23.	1.9	19
415	Clinical outcomes of a cohort series of patients with hepatocellular carcinoma in a hepatitis ^B virus-endemic area. Journal of Gastroenterology and Hepatology (Australia), 2014, 29, 820-829.	1.4	44
416	Bland embolization versus chemoembolization of hepatocellular carcinoma before transplantation. Liver Transplantation, 2014, 20, 536-543.	1.3	28
417	Oral antiviral therapy improves the diagnostic accuracy of alpha-fetoprotein levels in patients with chronic hepatitis ^B. Journal of Gastroenterology and Hepatology (Australia), 2014, 29, 1699-1705.	1.4	23
418	Transplantation for hepatocellular carcinoma-worth waiting for?. Liver Transplantation, 2014, 20, 871-873.	1.3	1
419	Radiologic-Pathologic Analysis of Contrast-enhanced and Diffusion-weighted MR Imaging in Patients with HCC after TACE: Diagnostic Accuracy of 3D Quantitative Image Analysis. Radiology, 2014, 273, 746-758.	3.6	98
420	Toward a Better Liver Graft Allocation That Accounts for Candidates With and Without Hepatocellular Carcinoma. American Journal of Transplantation, 2014, 14, 2221-2227.	2.6	54
421	Assessing patients with hepatocellular carcinoma meeting the milan criteria: Is liver 3 tesla MR with gadoxetic acid necessary in addition to liver CT?. Journal of Magnetic Resonance Imaging, 2014, 39, 842-852.	1.9	19
422	Survival of hepatocellular carcinoma patients is significantly improving: a population-based study from southern Switzerland. Cancer Epidemiology, 2014, 38, 679-685.	0.8	5
423	Yttrium-90 radioembolization is a safe and effective treatment for unresectable hepatocellular carcinoma: A single centre experience of 45 consecutive patients. International Journal of Surgery, 2014, 12, 1403-1408.	1.1	20
424	Low use of surveillance and early diagnosis of hepatocellular carcinoma in Norway—a population-based cohort study. Cancer Epidemiology, 2014, 38, 741-747.	0.8	14
425	Have we finally found the ultimate staging system for HCC?. Nature Reviews Gastroenterology and Hepatology, 2014, 11, 334-336.	8.2	32
426	Conundrum of treatment for early-stage hepatocellular carcinoma: Radiofrequency ablation instead of liver transplantation as the first-line treatment?. Liver Transplantation, 2014, 20, 257-260.	1.3	8
427	A Prospective Phase 2 Multicenter Study for the Efficacy of Radiation Therapy Following Incomplete Transarterial Chemoembolization in Unresectable Hepatocellular Carcinoma. International Journal of Radiation Oncology Biology Physics, 2014, 90, 1051-1060.	0.4	32
428	Diagnostic accuracy of des-gamma-carboxy prothrombin versus alpha-fetoprotein for hepatocellular carcinoma: A systematic review. Hepatology Research, 2014, 44, E11-25.	1.8	62
429	Positioning of ¹⁸ F-fluorodeoxyglucose-positron emission tomography imaging in the management algorithm of hepatocellular carcinoma. Journal of Gastroenterology and Hepatology (Australia), 2014, 29, 1722-1727.	1.4	14
430	Liver splenosis mimicking hepatocellular carcinoma in cirrhotic liver. Liver International, 2014, 34, 162-162.	1.9	8

#	ARTICLE	IF	CITATIONS
431	The microRNA-200 family-A potential diagnostic marker in hepatocellular carcinoma?. Journal of Surgical Oncology, 2014, 110, 430-438.	0.8	39
432	Clinical significance of therapy using branched-chain amino acid granules in patients with liver cirrhosis and hepatocellular carcinoma. Hepatology Research, 2014, 44, 149-158.	1.8	34
433	Severe 25-hydroxyvitamin D deficiency identifies a poor prognosis in patients with hepatocellular carcinoma - a prospective cohort study. Alimentary Pharmacology and Therapeutics, 2014, 39, 1204-1212.	1.9	70
434	Optimal Liver Allocation for Hepatocellular Carcinoma: Hurry up AND wait, but which one when?. American Journal of Transplantation, 2014, 14, 1479-1480.	2.6	1
435	Hepatocellular carcinoma in thalassaemia: an update of the Italian Registry. British Journal of Haematology, 2014, 167, 121-126.	1.2	69
436	Epidemiological Trends of Hepatocellular Carcinoma in Austria. Digestive Diseases, 2014, 32, 664-669.	0.8	10
437	Computed tomography of Lipiodol-loaded biodegradable pasty polymer for implant visualization. Contrast Media and Molecular Imaging, 2014, 9, 246-251.	0.4	4
438	Unresectable solitary hepatocellular carcinoma not amenable to radiofrequency ablation: Multicenter radiology-pathology correlation and survival of radiation segmentectomy. Hepatology, 2014, 60, 192-201.	3.6	237
439	Diagnostic and prognostic role of <sc>SCCA</sc> and <sc>IgM</sc> serum levels in hepatocellular carcinoma (<sc>HCC</sc>). Journal of Gastroenterology and Hepatology (Australia), 2014, 29, 1637-1644.	1.4	44
440	Sorafenib use in the transplant setting. Liver Transplantation, 2014, 20, 1021-1028.	1.3	12
441	Hepatocellular Carcinoma Surveillance: A National Survey of Current Practices in the USA. Digestive Diseases and Sciences, 2014, 59, 3073-3077.	1.1	25
442	Consensus report from the 6th International forum for liver MRI using gadoxetic acid. Journal of Magnetic Resonance Imaging, 2014, 40, 516-529.	1.9	40
443	Liver Transplantation for Hepatocellular Carcinoma. Current Transplantation Reports, 2014, 1, 215-223.	0.9	0
444	Potential Role of Positron Emission Tomography/Magnetic Resonance Imaging in Gastrointestinal and Abdominal Malignancies: Preliminary Experience. Seminars in Roentgenology, 2014, 49, 321-333.	0.2	3
445	Emerging Trends in Hepatocellular Carcinoma: Focus on Diagnosis and Therapeutics. Clinical Medicine Insights: Oncology, 2014, 8, CMO.S9926.	0.6	127
446	Percutaneous radiofrequency ablation for early hepatocellular carcinoma: Risk factors for survival. World Journal of Gastroenterology, 2014, 20, 1585.	1.4	22
447	Treatment Strategies of Intermediate-Stage Hepatocellular Carcinomas in Japan (Barcelona Clinic Liver) Tj ETQq0 0 0 rgBT /Overlock 10	0.9	14
448	A study on the vibration induced transport of nanoabrasives in liquid medium. Powder Technology, 2014, 268, 150-157.	2.1	6

#	ARTICLE	IF	CITATIONS
452	Addition of Local Hepatic Therapy to Sorafenib in Patients with Advanced Hepatocellular Carcinoma (Stage BCLC C). <i>Digestion</i> , 2014, 90, 219-228.	1.2	9
453	Sorafenib for once age is not an issue. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2014, 11, 273-274.	8.2	4
454	Optimized contrast-enhanced ultrasonography for characterization of focal liver lesions in cirrhosis: A single-center retrospective study. <i>United European Gastroenterology Journal</i> , 2014, 2, 279-287.	1.6	29
455	Noninvasive Biomarkers of Liver Fibrosis: Clinical Applications and Future Directions. <i>Current Pathobiology Reports</i> , 2014, 2, 245-256.	1.6	30
456	Treatment of intermediate stage hepatocellular carcinoma: a review of intrahepatic doxorubicin drug-delivery systems. <i>Therapeutic Delivery</i> , 2014, 5, 447-466.	1.2	30
457	Radioembolisation with yttrium-90 microspheres versus sorafenib for treatment of advanced hepatocellular carcinoma (SARAH): study protocol for a randomised controlled trial. <i>Trials</i> , 2014, 15, 474.	0.7	38
458	Non-alcoholic fatty liver disease: a practical approach to treatment. <i>Frontline Gastroenterology</i> , 2014, 5, 277-286.	0.9	90
459	Quality Assurance in Ultrasound Screening for Hepatocellular Carcinoma Using a Standardized Phantom and Standard Clinical Images. <i>Journal of Ultrasound in Medicine</i> , 2014, 33, 985-995.	0.8	8
460	Radiofrequency Ablation Versus Hepatic Resection for Small Hepatocellular Carcinoma. <i>Journal of Clinical Gastroenterology</i> , 2014, 48, 450-457.	1.1	55
461	Differences in Surgical Outcomes Between Hepatitis B- and Hepatitis C-Related Hepatocellular Carcinoma. <i>Annals of Surgery</i> , 2014, 260, 650-658.	2.1	77
462	Systemic Cytotoxic Chemotherapy of Patients With Advanced Hepatocellular Carcinoma in the Era of Sorafenib Nonavailability. <i>Journal of Clinical Gastroenterology</i> , 2014, 48, e22-e29.	1.1	18
464	Long-term Survival of Fibrolamellar Hepatocellular Carcinoma Versus Conventional Hepatocellular Carcinoma. <i>Journal of Clinical Gastroenterology</i> , 2014, 48, 385-386.	1.1	2
465	Serum levels of preoperative α -fetoprotein and CA19-9 predict survival of hepatic carcinoma patients after liver transplantation. <i>European Journal of Gastroenterology and Hepatology</i> , 2014, 26, 553-561.	0.8	12
466	Therapeutic effects of artesunate in hepatocellular carcinoma. <i>European Journal of Gastroenterology and Hepatology</i> , 2014, 26, 861-870.	0.8	39
467	Hepatocellular cancer. <i>Current Opinion in Organ Transplantation</i> , 2014, 19, 229-234.	0.8	42
468	Diagnostic accuracy of abdominal ultrasound in the screening of esophageal varices in patients with cirrhosis. <i>European Journal of Gastroenterology and Hepatology</i> , 2014, 26, 1335-1341.	0.8	3
469	Occult Hepatitis B Virus Infection in Chinese Cryptogenic Intrahepatic Cholangiocarcinoma Patient Population. <i>Journal of Clinical Gastroenterology</i> , 2014, 48, 878-882.	1.1	13
470	Vascular Invasion in Hepatocellular Carcinoma. <i>Journal of Clinical Gastroenterology</i> , 2014, 48, 734-741.	1.1	68

#	ARTICLE	IF	CITATIONS
471	Radiofrequency ablation of hepatocellular carcinoma in elderly patients fitting the Milan criteria: A single centre with 13 years experience. <i>International Journal of Hyperthermia</i> , 2014, 30, 471-479.	1.1	21
472	Hepatitis C Virus and Liver Transplantation. , 2014, , .		1
473	Predisposing factors for recurrence of HBV-related small hepatocellular carcinoma after percutaneous radiofrequency ablation. <i>Scandinavian Journal of Gastroenterology</i> , 2014, 49, 373-380.	0.6	7
474	Circulating RNA Molecules as Biomarkers in Liver Disease. <i>International Journal of Molecular Sciences</i> , 2014, 15, 17644-17666.	1.8	50
475	Current biomarkers for hepatocellular carcinoma: Surveillance, diagnosis and prediction of prognosis. <i>World Journal of Hepatology</i> , 2014, 7, 139.	0.8	72
476	Systemic Therapy for Hepatocellular Carcinoma: The Issue of Treatment Stage Migration and Registration of Progression Using the BCLC-Refined RECIST. <i>Seminars in Liver Disease</i> , 2014, 34, 444-455.	1.8	112
477	Treatment of Hepatocellular Carcinoma. <i>Digestive Diseases</i> , 2014, 32, 554-563.	0.8	33
478	Missed opportunities: Peripartum hepatic failure in a Chinese immigrant. <i>Obstetric Medicine</i> , 2014, 7, 165-167.	0.5	0
480	Prognostic factors for hepatocellular carcinoma recurrence. <i>World Journal of Gastroenterology</i> , 2014, 20, 5935.	1.4	143
481	Model-guided therapy for hepatocellular carcinoma: a role for information technology in predictive, preventive and personalized medicine. <i>EPMA Journal</i> , 2014, 5, 16.	3.3	12
482	Molecular Profiling of Liver Tumors: Classification and Clinical Translation for Decision Making. <i>Seminars in Liver Disease</i> , 2014, 34, 363-375.	1.8	47
483	Transarterial therapy: An evolving treatment modality of hepatocellular carcinoma. <i>Saudi Journal of Gastroenterology</i> , 2014, 20, 333.	0.5	6
484	Transarterial Chemoembolization for the Treatment of Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis: Prognostic Factors in a Single-Center Study of 188 Patients. <i>BioMed Research International</i> , 2014, 2014, 1-8.	0.9	38
485	Feasibility and efficacy of hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma after sorafenib. <i>Hepatology Research</i> , 2014, 44, 1179-1185.	1.8	40
486	DNA markers in molecular diagnostics for hepatocellular carcinoma. <i>Expert Review of Molecular Diagnostics</i> , 2014, 14, 803-817.	1.5	21
487	Advances in Clinical Application of Cryoablation Therapy for Hepatocellular Carcinoma and Metastatic Liver Tumor. <i>Journal of Clinical Gastroenterology</i> , 2014, 48, 830-836.	1.1	33
488	Do the epidemiology, physiological mechanisms and characteristics of hepatocellular carcinoma in HIV-infected patients justify specific screening policies?. <i>Aids</i> , 2014, 28, 1379-1391.	1.0	25
489	HIV/Hepatitis C Virus-Coinfected Patients and Cirrhosis: How to Diagnose It and What to Do Next?. <i>Clinical Infectious Diseases</i> , 2014, 58, 840-847.	2.9	6

#	ARTICLE	IF	CITATIONS
490	An overview of hepatitis B prevalence, prevention, and management in the Pacific Islands and Territories. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 1854-1866.	1.4	15
491	Multimodal treatment of hepatocellular carcinoma. <i>European Journal of Internal Medicine</i> , 2014, 25, 430-437.	1.0	72
492	An explorative data-analysis to support the choice between hepatic resection and radiofrequency ablation in the treatment of hepatocellular carcinoma. <i>Digestive and Liver Disease</i> , 2014, 46, 257-263.	0.4	43
493	Threshold Doses for Focal Liver Reaction After Stereotactic Ablative Body Radiation Therapy for Small Hepatocellular Carcinoma Depend on Liver Function: Evaluation on Magnetic Resonance Imaging With Gd-EOB-DTPA. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 88, 306-311.	0.4	64
494	Estimation of lead-time bias and its impact on the outcome of surveillance for the early diagnosis of hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2014, 61, 333-341.	1.8	110
495	The emerging questionable benefit of sorafenib as a neo-adjuvant in HCC patients treated with Y-90 radioembolization pending liver transplantation. <i>Journal of Hepatology</i> , 2014, 61, 190-192.	1.8	0
496	A blood-based three-gene signature for the non-invasive detection of early human hepatocellular carcinoma. <i>European Journal of Cancer</i> , 2014, 50, 928-936.	1.3	70
497	Factors That Affect Efficacy of Ultrasound Surveillance for Early Stage Hepatocellular Carcinoma in Patients With Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 1927-1933.e2.	2.4	108
498	High preoperative serum aminotransferase levels predict local recurrence after curative resection of hepatocellular carcinoma. <i>Advances in Digestive Medicine</i> , 2014, 1, 14-20.	0.1	0
499	Predictive factors of transarterial chemoembolisation toxicity in unresectable hepatocellular carcinoma. <i>Digestive and Liver Disease</i> , 2014, 46, 358-362.	0.4	15
500	Role of Supportive Care for Terminal Stage Hepatocellular Carcinoma. <i>Journal of Clinical and Experimental Hepatology</i> , 2014, 4, S130-S139.	0.4	37
501	Clinical and economical impact of 2010 AASLD guidelines for the diagnosis of hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2014, 60, 995-1001.	1.8	61
502	Laparoscopic resection of hepatocellular carcinoma: a French survey in 351 patients. <i>Hpb</i> , 2014, 16, 357-365.	0.1	104
503	Trends in Utilization of Transarterial Treatments for Hepatocellular Carcinoma: Results of a Survey by the Italian Society of Interventional Radiology. <i>CardioVascular and Interventional Radiology</i> , 2014, 37, 438-444.	0.9	46
504	Liver transplantation for hepatocellular carcinoma exceeding the Milan criteria: a single-center experience. <i>Journal of Cancer Research and Clinical Oncology</i> , 2014, 140, 341-348.	1.2	9
505	Primary Surgical Resection Versus Liver Transplantation for Transplant-Eligible Hepatocellular Carcinoma Patients. <i>Digestive Diseases and Sciences</i> , 2014, 59, 183-191.	1.1	12
506	Single measurement of hemoglobin predicts outcome of HCC patients. <i>Medical Oncology</i> , 2014, 31, 806.	1.2	23
507	Chemoembolization and the arcuate ligament: How to manage it?. <i>Diagnostic and Interventional Imaging</i> , 2014, 95, 1105-1107.	1.8	5

#	ARTICLE	IF	CITATIONS
508	Hepatocellular carcinoma: clinical frontiers and perspectives. <i>Gut</i> , 2014, 63, 844-855.	6.1	1,180
509	Stereotactic ablative body radiotherapy for previously untreated solitary hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 372-379.	1.4	74
510	Role of serum glypican-3 in the diagnosis and differentiation of small hepatocellular carcinoma from hepatitis-C virus cirrhosis. <i>Alexandria Journal of Medicine</i> , 2014, 50, 221-226.	0.4	18
511	Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. <i>Journal of Hepatology</i> , 2014, 60, 1268-1289.	1.8	1,151
512	Prognosis of hepatocellular carcinoma patients with extrahepatic metastasis and the controllability of intrahepatic lesions. <i>Clinical and Experimental Metastasis</i> , 2014, 31, 475-482.	1.7	26
513	MEK in cancer and cancer therapy. , 2014, 141, 160-171.		200
515	Molecular Therapies in Hepatocellular Carcinoma: What Can We Target?. <i>Digestive Diseases and Sciences</i> , 2014, 59, 1688-1697.	1.1	39
516	The dosimetric importance of the number of 90Y microspheres in liver transarterial radioembolization (TARE). <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 634-638.	3.3	25
517	Surgical Resection Versus Transarterial Chemoembolization for Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis: A Propensity Score Analysis. <i>Annals of Surgical Oncology</i> , 2014, 21, 1825-1833.	0.7	93
519	The ALPPS Procedure: A Surgical Option for Hepatocellular Carcinoma with Major Vascular Invasion. <i>World Journal of Surgery</i> , 2014, 38, 1498-1503.	0.8	52
520	Evaluation of hepatic focal lesions using diffusion-weighted MR imaging: Comparison of apparent diffusion coefficient and intravoxel incoherent motion-derived parameters. <i>Journal of Magnetic Resonance Imaging</i> , 2014, 39, 276-285.	1.9	93
521	MicroRNAs and liver disease: viral hepatitis, liver fibrosis and hepatocellular carcinoma. <i>Postgraduate Medical Journal</i> , 2014, 90, 106-112.	0.9	18
522	Sequential transcriptome analysis of human liver cancer indicates late stage acquisition of malignant traits. <i>Journal of Hepatology</i> , 2014, 60, 346-353.	1.8	85
523	Determinants of alpha-fetoprotein levels in patients with hepatocellular carcinoma: Implications for its clinical use. <i>Cancer</i> , 2014, 120, 2150-2157.	2.0	56
524	Transjugular intrahepatic portosystemic shunt for symptomatic portal hypertension in hepatocellular carcinoma with portal vein tumor thrombosis. <i>Hepatology Research</i> , 2014, 44, 621-630.	1.8	36
525	The ART-strategy: Sequential assessment of the ART score predicts outcome of patients with hepatocellular carcinoma re-treated with TACE. <i>Journal of Hepatology</i> , 2014, 60, 118-126.	1.8	105
526	Baseline gamma-glutamyl transferase levels strongly correlate with hepatocellular carcinoma development in non-cirrhotic patients with successful hepatitis C virus eradication. <i>Journal of Hepatology</i> , 2014, 61, 67-74.	1.8	110
527	The feasibility of combined transcatheter arterial chemoembolization and radiotherapy for advanced hepatocellular carcinoma. <i>Liver International</i> , 2014, 34, 795-801.	1.9	51

#	ARTICLE	IF	CITATIONS
528	Hepatocellular carcinoma (HCC) in non-cirrhotic liver: clinical, radiological and pathological findings. <i>European Radiology</i> , 2014, 24, 1446-1454.	2.3	42
529	The ALPPS procedure for hepatocellular carcinoma. <i>European Journal of Surgical Oncology</i> , 2014, 40, 982-988.	0.5	53
530	Serum ferritin as a new prognostic factor in hepatocellular carcinoma patients treated with radiofrequency ablation. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 1905-1910.	1.4	68
531	Diagnostic accuracy of ¹⁸ F-methylcholine positron emission tomography/computed tomography for intra- and extrahepatic hepatocellular carcinoma. <i>Hepatology</i> , 2014, 59, 996-1006.	3.6	38
532	Small ($\leq 1\text{-cm}$) Hepatocellular Carcinoma: Diagnostic Performance and Imaging Features at Gadoteric Acid-enhanced MR Imaging. <i>Radiology</i> , 2014, 271, 748-760.	3.6	104
533	Evaluation of a method for improving the detection of hepatocellular carcinoma. <i>European Radiology</i> , 2014, 24, 250-255.	2.3	4
534	Liver Masses: A Clinical, Radiologic, and Pathologic Perspective. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 1414-1429.	2.4	73
535	Hepatocellular carcinoma vascularization: From the most common to the lesser known arteries. <i>Diagnostic and Interventional Imaging</i> , 2014, 95, 27-36.	1.8	41
536	Vascularisation artérielle du carcinome hépatocellulaire: des artères classiques aux plus rares. <i>Diagnostic and Interventional Imaging</i> , 2014, 95, 30-39.	0.0	0
537	Radiology Illustrated: Hepatobiliary and Pancreatic Radiology. <i>Radiology Illustrated</i> , 2014, , .	0.0	3
538	Liver Transplantation for Hepatocellular Carcinoma in HCV-Infected Patients. , 2014, , 77-93.		0
539	Pathogenesis and prevention of hepatitis C virus-induced hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2014, 61, S79-S90.	1.8	181
540	Significance of plasma osteopontin in diagnosis of hepatitis C virus-related hepatocellular carcinoma. <i>Arab Journal of Gastroenterology</i> , 2014, 15, 103-107.	0.4	14
541	Liver lesion conspicuity during real-time MR-guided radiofrequency applicator placement using spoiled gradient echo and balanced steady-state free precession imaging. <i>Journal of Magnetic Resonance Imaging</i> , 2014, 40, 432-439.	1.9	25
542	Therapeutic benefit of radiotherapy in huge ($\geq 10\text{cm}$) unresectable hepatocellular carcinoma. <i>Liver International</i> , 2014, 34, 784-794.	1.9	26
543	Recurrence of Hepatocellular Carcinoma: Importance of mRECIST Response to Chemoembolization and Tumor Size. <i>American Journal of Transplantation</i> , 2014, 14, 1383-1390.	2.6	75
544	Hepatitis C Virus Infection and Kidney Transplantation in 2014: What's New?. <i>American Journal of Transplantation</i> , 2014, 14, 2206-2220.	2.6	67
545	Infarctus intestino-mésentérique aigu révélant une tumeur endocrine de l'œnon mßtastatique. <i>Diagnostic and Interventional Imaging</i> , 2014, 95, 1096-1098.	0.0	0

#	ARTICLE	IF	CITATIONS
546	Recurrence predictive models for patients with hepatocellular carcinoma after radiofrequency ablation using support vector machines with feature selection methods. <i>Computer Methods and Programs in Biomedicine</i> , 2014, 117, 425-434.	2.6	36
547	Increased survival in hepatocellular carcinoma with iodine-125 implantation plus radiofrequency ablation: A prospective randomized controlled trial. <i>Journal of Hepatology</i> , 2014, 61, 1304-1311.	1.8	48
548	How to STATE suitability and START transarterial chemoembolization in patients with intermediate stage hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2014, 61, 1287-1296.	1.8	139
549	Hyper-IL-15 suppresses metastatic and autochthonous liver cancer by promoting tumour-specific CD8+ T cell responses. <i>Journal of Hepatology</i> , 2014, 61, 1297-1303.	1.8	43
550	Dynamic enhancement pattern of <scp>HCC</scp> smaller than 3Âcm in diameter on gadoxetic acid-enhanced <scp>MRI</scp>: comparison with multiphasic <scp>MDCT</scp>. <i>Liver International</i> , 2014, 34, 1593-1602.	1.9	30
551	Focal Lesions in the Cirrhotic Liver: Their Pivotal Role in Gadoxetic Acid-Enhanced MRI and Recognition by the Western Guidelines. <i>Digestive Diseases</i> , 2014, 32, 696-704.	0.8	49
552	HCC therapiesâ”lessons learned. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2014, 11, 447-452.	8.2	128
553	Prevalence and Prediction of Coronary Artery Disease in Patients With Liver Cirrhosis. <i>Circulation</i> , 2014, 130, 1353-1362.	1.6	87
554	Post-recurrence survival in hepatocellular carcinoma after percutaneous radiofrequency ablation. <i>Digestive and Liver Disease</i> , 2014, 46, 1014-1019.	0.4	58
555	Repeated Percutaneous Radiofrequency Ablation for Hepatocellular Carcinoma in Patients with Cirrhosis: Assessment of Safety Based on Liver Function and Portal Hypertension Parameters. <i>Journal of Vascular and Interventional Radiology</i> , 2014, 25, 1573-1579.	0.2	7
556	Telomerase reverse transcriptase promoter mutation is an early somatic genetic alteration in the transformation of premalignant nodules in hepatocellular carcinoma on cirrhosis. <i>Hepatology</i> , 2014, 60, 1983-1992.	3.6	268
557	Above 5Âcm, Size Does Not Matter Anymore in Patients with Hepatocellular Carcinoma. <i>World Journal of Surgery</i> , 2014, 38, 2910-2918.	0.8	59
558	Discovery and validation of urinary metabotypes for the diagnosis of hepatocellular carcinoma in West Africans. <i>Hepatology</i> , 2014, 60, 1291-1301.	3.6	67
559	Genome-scale metabolic models for hepatocellular carcinoma. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2014, 11, 336-337.	8.2	19
560	Long-term outcomes of second treatment after initial transarterial chemoembolization in patients with hepatocellular carcinoma. <i>Liver International</i> , 2014, 34, 1278-1286.	1.9	7
561	Hepatocellular Carcinoma: Reasons for Phase III Failure and Novel Perspectives on Trial Design. <i>Clinical Cancer Research</i> , 2014, 20, 2072-2079.	3.2	341
562	The Effects of Lipiodol and Cyclosporin A on the Hepatobiliary Disposition of Doxorubicin in Pigs. <i>Molecular Pharmaceutics</i> , 2014, 11, 1301-1313.	2.3	9
563	A systematic assessment of the quality of systematic reviews/meta-analyses in radiofrequency ablation versus hepatic resection for small hepatocellular carcinoma. <i>Journal of Evidence-Based Medicine</i> , 2014, 7, 103-120.	2.4	9

#	ARTICLE	IF	CITATIONS
564	Systemic treatment. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2014, 28, 921-935.	1.0	9
565	On-treatment alpha-fetoprotein is a specific tumor marker for hepatocellular carcinoma in patients with chronic hepatitis B receiving entecavir. <i>Hepatology</i> , 2014, 59, 986-995.	3.6	114
566	TACE plus sorafenib for the treatment of hepatocellular carcinoma: results of the multicenter, phase II SOCRATES trial. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 74, 947-954.	1.1	60
567	A common polymorphism in the NCAN gene is associated with hepatocellular carcinoma in alcoholic liver disease. <i>Journal of Hepatology</i> , 2014, 61, 1073-1079.	1.8	35
568	Surveillance for hepatocellular carcinoma. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2014, 28, 783-793.	1.0	48
569	Chemoembolization and radioembolization. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2014, 28, 909-919.	1.0	19
570	Presurgical Planning for Hepatobiliary Malignancies. <i>Magnetic Resonance Imaging Clinics of North America</i> , 2014, 22, 447-465.	0.6	8
571	Diagnostic du carcinome h�patocellulaire. <i>Diagnostic and Interventional Imaging</i> , 2014, 95, 697-707.	0.0	0
573	Treatment of intermediate-stage hepatocellular carcinoma. <i>Nature Reviews Clinical Oncology</i> , 2014, 11, 525-535.	12.5	377
574	Hepatocellular carcinoma. <i>Wiener Medizinische Wochenschrift</i> , 2014, 164, 450-455.	0.5	24
575	Lin28b Is Sufficient to Drive Liver Cancer and Necessary for Its Maintenance in Murine Models. <i>Cancer Cell</i> , 2014, 26, 248-261.	7.7	176
576	Comparison of therapeutic efficacy and safety of radiofrequency ablation of hepatocellular carcinomas between internally cooled 15-G and 17-G single electrodes. <i>British Journal of Radiology</i> , 2014, 87, 20130534.	1.0	7
577	Transarterial chemoembolization and sorafenib in hepatocellular carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2014, 14, 831-845.	1.1	21
578	Hepatocellular carcinoma: Diagnostic criteria by imaging techniques. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2014, 28, 795-812.	1.0	37
579	Prognosis prediction and staging. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2014, 28, 855-865.	1.0	20
580	CT and MR Imaging Diagnosis and Staging of Hepatocellular Carcinoma: Part II. Extracellular Agents, Hepatobiliary Agents, and Ancillary Imaging Features. <i>Radiology</i> , 2014, 273, 30-50.	3.6	430
581	CT and MR Imaging Diagnosis and Staging of Hepatocellular Carcinoma: Part I. Development, Growth, and Spread: Key Pathologic and Imaging Aspects. <i>Radiology</i> , 2014, 272, 635-654.	3.6	401
582	TACE performed in patients with a single nodule of Hepatocellular Carcinoma. <i>BMC Cancer</i> , 2014, 14, 601.	1.1	36

#	ARTICLE	IF	CITATIONS
583	High expression of thymosin beta 10 predicts poor prognosis for hepatocellular carcinoma after hepatectomy. <i>World Journal of Surgical Oncology</i> , 2014, 12, 226.	0.8	9
584	[18F]Fluorodeoxyglucose PET/Computed Tomography in Gastrointestinal Malignancies. <i>PET Clinics</i> , 2014, 9, 421-441.	1.5	21
585	Brivanib for Hepatocellular Carcinoma Trials: Selection Bias From Barcelona Clinic Liver Cancer Stage?. <i>Journal of Clinical Oncology</i> , 2014, 32, 968-968.	0.8	3
586	Reply to X. Qi et al. <i>Journal of Clinical Oncology</i> , 2014, 32, 968-969.	0.8	0
587	Hepatocellular carcinoma tumour markers: Current role and expectations. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2014, 28, 843-853.	1.0	89
588	Pathogenesis of hepatocellular carcinoma according to aetiology. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2014, 28, 937-947.	1.0	59
589	Role of biopsy sampling for diagnosis of early and progressed hepatocellular carcinoma. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2014, 28, 813-829.	1.0	18
590	Diagnosis of hepatocellular carcinoma. <i>Diagnostic and Interventional Imaging</i> , 2014, 95, 709-719.	1.8	24
593	Hepatocellular Carcinomas within the Milan Criteria: Predictors of Histologic Necrosis after Drug-eluting Beads Transarterial Chemoembolization. <i>CardioVascular and Interventional Radiology</i> , 2014, 37, 1018-1026.	0.9	18
594	Hepatobiliary magnetic resonance imaging in patients with liver disease: correlation of liver enhancement with biochemical liver function tests. <i>European Radiology</i> , 2014, 24, 2482-2490.	2.3	43
595	ACG Clinical Guideline: The Diagnosis and Management of Focal Liver Lesions. <i>American Journal of Gastroenterology</i> , 2014, 109, 1328-1347.	0.2	328
596	Integration of genomic information in the clinical management of HCC. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2014, 28, 831-842.	1.0	19
597	Tumour-related neoangiogenesis: Functional dynamic perfusion computed tomography for diagnosis and treatment efficacy assessment in hepatocellular carcinoma. <i>Digestive and Liver Disease</i> , 2014, 46, 916-922.	0.4	10
598	Small Hepatocellular Carcinoma. <i>Academic Radiology</i> , 2014, 21, 1455-1464.	1.3	13
599	Preliminary experience of a new perspective view technology for the detection of portal vein thrombus in hepatocellular carcinoma patients. <i>Abdominal Imaging</i> , 2014, 39, 1145-1152.	2.0	2
600	Arsenic trioxide: marked suppression of tumor metastasis potential by inhibiting the transcription factor Twist in vivo and in vitro. <i>Journal of Cancer Research and Clinical Oncology</i> , 2014, 140, 1125-1136.	1.2	11
601	A phase I/II trial of capecitabine combined with peginterferon α -2a in Patients with sorafenib-refractory advanced hepatocellular carcinoma. <i>Investigational New Drugs</i> , 2014, 32, 762-768.	1.2	5
602	HBV DNA and HBsAg Levels as Risk Predictors of Early and Late Recurrence after Curative Resection of HBV-related Hepatocellular Carcinoma. <i>Annals of Surgical Oncology</i> , 2014, 21, 2429-2435.	0.7	90

#	ARTICLE	IF	CITATIONS
603	Is Resection or Transplantation the ideal Treatment in Patients with Hepatocellular Carcinoma in Cirrhosis if Both Are Possible? A Systematic Review and Metaanalysis. <i>Annals of Surgical Oncology</i> , 2014, 21, 3096-3107.	0.7	57
604	Survival Advantage of Radiofrequency Ablation Over Transarterial Chemoembolization for Patients with Hepatocellular Carcinoma and Good Performance Status Within the Milan Criteria. <i>Annals of Surgical Oncology</i> , 2014, 21, 3835-3843.	0.7	19
605	Indeterminate solid hepatic lesions identified on non-diagnostic contrast-enhanced computed tomography: Assessment of the additional diagnostic value of contrast-enhanced ultrasound in the non-cirrhotic liver. <i>European Journal of Radiology</i> , 2014, 83, 456-462.	1.2	33
606	Invasive and Non-invasive Diagnosis of Portal Hypertension in Cirrhosis. <i>Current Hepatology Reports</i> , 2014, 13, 180-188.	0.4	2
607	Imaging of Liver Tumors in Patients with Chronic Liver Disease. <i>Current Radiology Reports</i> , 2014, 2, 1.	0.4	3
608	Prediction of poorly differentiated hepatocellular carcinoma using contrast computed tomography. <i>Cancer Imaging</i> , 2014, 14, 7.	1.2	19
609	Local effect of stereotactic body radiotherapy for primary and metastatic liver tumors in 130 Japanese patients. <i>Radiation Oncology</i> , 2014, 9, 112.	1.2	38
610	Time to evolve trial design after everolimus failure. <i>Nature Reviews Clinical Oncology</i> , 2014, 11, 506-507.	12.5	53
611	Epidemiology of Hepatocellular Carcinoma in India. <i>Journal of Clinical and Experimental Hepatology</i> , 2014, 4, S27-S33.	0.4	69
612	Incidental Hepatocellular Carcinoma: Risk Factors and Long-Term Outcome After Liver Transplantation. <i>Transplantation Proceedings</i> , 2014, 46, 1426-1429.	0.3	23
613	TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease. <i>Nature Communications</i> , 2014, 5, 4309.	5.8	478
614	Transarterial Chemoembolization-induced Tumor Lysis Syndrome: Different Results in the Same Hepatocellular Carcinoma Patient. <i>International Journal of Gerontology</i> , 2014, 8, 171-174.	0.7	2
615	EGFR has a tumour-promoting role in liver macrophages during hepatocellular carcinoma formation. <i>Nature Cell Biology</i> , 2014, 16, 972-981.	4.6	198
616	Surgical salvage for sudden quadriplegia due to recurrent hepatocellular carcinoma with spinal metastasis. <i>Tzu Chi Medical Journal</i> , 2014, 26, 94-96.	0.4	0
617	Radiofrequency ablation for hepatocellular carcinoma. <i>Gastrointestinal Intervention</i> , 2014, 3, 35-39.	0.1	13
618	Imaging in clinical decision-making for portal vein thrombosis. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2014, 11, 308-316.	8.2	64
619	Reply to: "Virtual portal pressure from anatomic CT angiography". <i>Journal of Hepatology</i> , 2014, 61, 182.	1.8	1
621	Efficacy and Nontarget Effects of Transarterial Chemoembolization in Bridging of Hepatocellular Carcinoma Patients to Liver Transplantation: A Histopathologic Study. <i>Journal of Vascular and Interventional Radiology</i> , 2014, 25, 1018-1026.e4.	0.2	17

#	ARTICLE	IF	CITATIONS
623	Adherence to AASLD guidelines for the treatment of hepatocellular carcinoma in clinical practice: Experience of the Bologna Liver Oncology Group. <i>Digestive and Liver Disease</i> , 2014, 46, 549-555.	0.4	57
624	Mortality, Liver Transplantation, and Hepatocellular Carcinoma Among Patients With Chronic Hepatitis B Treated With Entecavir vs Lamivudine. <i>Gastroenterology</i> , 2014, 147, 152-161.	0.6	133
625	TACE vs. surgical resection for BCLC stage B HCC. <i>Journal of Hepatology</i> , 2014, 61, 3-4.	1.8	24
626	Percutaneous microwave ablation for hepatocellular carcinoma adjacent to large vessels: A long-term follow-up. <i>European Journal of Radiology</i> , 2014, 83, 552-558.	1.2	83
627	Mistargeting after Fusion Imagingâ€“Guided Percutaneous Radiofrequency Ablation of Hepatocellular Carcinomas. <i>Journal of Vascular and Interventional Radiology</i> , 2014, 25, 307-314.	0.2	31
628	Phase 2 Study of Combined Sorafenib and Radiation Therapy in Patients With Advanced Hepatocellular Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 88, 1041-1047.	0.4	118
629	Carriage of the PNPLA3 rs738409 C >G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2014, 61, 75-81.	1.8	431
630	The clinical management of hepatocellular carcinoma in the United States, Europe, and Asia: A comprehensive and evidenceâ€“based comparison and review. <i>Cancer</i> , 2014, 120, 2824-2838.	2.0	212
631	Role of Surveillance in Prevention of Hepatocellular Carcinoma. <i>Journal of Clinical and Experimental Hepatology</i> , 2014, 4, S43-S49.	0.4	5
632	LI-RADS Categorization of Benign and Likely Benign Findings in Patients at Risk of Hepatocellular Carcinoma: A Pictorial Atlas. <i>American Journal of Roentgenology</i> , 2014, 203, W48-W69.	1.0	43
633	Hepatocellular carcinoma screening in patients with compensated hepatitis C virus (HCV)-related cirrhosis aware of their HCV status improves survival: A modeling approach. <i>Hepatology</i> , 2014, 59, 1471-1481.	3.6	52
634	Role of Transcatheter Intra-arterial Therapies for Hepatocellular Carcinoma. <i>Journal of Clinical and Experimental Hepatology</i> , 2014, 4, S112-S121.	0.4	24
635	Identification of prognostic biomarkers in hepatitis B virus-related hepatocellular carcinoma and stratification by integrative multi-omics analysis. <i>Journal of Hepatology</i> , 2014, 61, 840-849.	1.8	131
636	TERT promoter mutations: Gatekeeper and driver of hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2014, 61, 685-687.	1.8	40
637	Staging of Hepatocellular Carcinoma. <i>Journal of Clinical and Experimental Hepatology</i> , 2014, 4, S74-S79.	0.4	68
638	Tumor-associated macrophages promote cancer stem cell-like properties via transforming growth factor-beta1-induced epithelialâ€“mesenchymal transition in hepatocellular carcinoma. <i>Cancer Letters</i> , 2014, 352, 160-168.	3.2	346
639	Treatment Algorithms for Managing Hepatocellular Carcinoma. <i>Journal of Clinical and Experimental Hepatology</i> , 2014, 4, S80-S89.	0.4	54
640	The Indian National Association for Study of the Liver (INASL) Consensus on Prevention, Diagnosis and Management of Hepatocellular Carcinoma in India: TheÂ“Puri Recommendations. <i>Journal of Clinical and Experimental Hepatology</i> , 2014, 4, S3-S26.	0.4	50

#	ARTICLE	IF	CITATIONS
641	Management of Hepatitis B: Our Practice and How It Relates to the Guidelines. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 16-26.	2.4	94
642	Partial liver volume radioembolization induces hypertrophy in the spared hemiliver and no major signs of portal hypertension. <i>Hpb</i> , 2014, 16, 243-249.	0.1	69
646	The Role of Bridge Therapy Prior to Orthotopic Liver Transplantation. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 1183-1191.	2.3	20
647	Hepatocellular carcinoma: Surgical perspectives beyond the barcelona clinic liver cancer recommendations. <i>World Journal of Gastroenterology</i> , 2014, 20, 7525.	1.4	50
648	Focal liver lesions detection and characterization: The advantages of gadoxetic acid-enhanced liver MRI. <i>World Journal of Hepatology</i> , 2014, 6, 477.	0.8	33
649	Drug Therapy for Advanced-Stage Liver Cancer. <i>Liver Cancer</i> , 2014, 3, 125-131.	4.2	70
650	Sorafenib and locoregional deep electro-hyperthermia in advanced hepatocellular carcinoma: A phase II study. <i>Oncology Letters</i> , 2014, 8, 1783-1787.	0.8	38
652	How to Define Transarterial Chemoembolization Failure or Refractoriness: A European Perspective. <i>Liver Cancer</i> , 2014, 3, 119-124.	4.2	118
653	Clinical Trials of Combined Molecular Targeted Therapy and Locoregional Therapy in Hepatocellular Carcinoma: Past, Present, and Future. <i>Liver Cancer</i> , 2014, 3, 9-17.	4.2	52
654	Hepatocellular Carcinoma: Current Concepts in Diagnosis, Staging and Treatment. <i>Gastrointestinal Tumors</i> , 2014, 1, 84-92.	0.3	19
655	Multimodality Management for Barcelona Clinic Liver Cancer Stage C Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2014, 3, 405-416.	4.2	16
656	Increased metastatic potential of residual carcinoma after transarterial embolization in rat with McA-RH7777 hepatoma. <i>Oncology Reports</i> , 2014, 31, 95-102.	1.2	10
657	Comparison of standard-dose and half-dose sorafenib therapy on clinical outcome in patients with unresectable hepatocellular carcinoma in field practice: A propensity score matching analysis. <i>International Journal of Oncology</i> , 2014, 45, 2295-2302.	1.4	26
658	GALNT14 genotype, α -fetoprotein and therapeutic side effects predict post-chemotherapy survival in patients with advanced hepatocellular carcinoma. <i>Molecular and Clinical Oncology</i> , 2014, 2, 630-640.	0.4	16
660	Low Alpha-Fetoprotein HCC and the Role of GGTP. <i>International Journal of Biological Markers</i> , 2014, 29, 395-402.	0.7	21
661	Hepatocellular Carcinoma: Basic and Transitional Research. <i>Gastrointestinal Tumors</i> , 2014, 1, 76-83.	0.3	9
663	Hepatic Resection Associated With Good Survival for Selected Patients With Intermediate and Advanced-Stage Hepatocellular Carcinoma. <i>Annals of Surgery</i> , 2014, 260, 329-340.	2.1	382
664	Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy in patients with peritoneal hepatocellular carcinoma. <i>Journal of Surgical Oncology</i> , 2014, 110, 786-790.	0.8	25

#	ARTICLE	IF	CITATIONS
665	Management of hepatocellular carcinoma: time to be resilient. <i>Hepatic Oncology</i> , 2014, 1, 261-263.	4.2	0
666	Rationale of transcatheter intra-arterial therapies of hepatic cancers. <i>Hepatic Oncology</i> , 2014, 1, 285-291.	4.2	2
667	Validation of the Criteria of Transcatheter Arterial Chemoembolization Failure or Refractoriness in Patients with Advanced Hepatocellular Carcinoma Proposed by the LCSCG. <i>Oncology</i> , 2014, 87, 32-36.	0.9	45
668	New frontier in liver cancer treatment: Oncolytic viral therapy. <i>Hepatology</i> , 2014, 59, 343-346.	3.6	7
669	Imaging Hepatocellular Carcinoma with Dynamic CT Before and After Transarterial Chemoembolization. <i>Academic Radiology</i> , 2015, 22, 1516-1521.	1.3	2
670	Hepatocellular Carcinoma Patients With Performance Status 1 Deserve New Classification and Treatment Algorithm in the BCLC System. <i>Medicine (United States)</i> , 2015, 94, e1223.	0.4	11
671	When to Perform Surgical Resection or Radiofrequency Ablation for Early Hepatocellular Carcinoma?. <i>Medicine (United States)</i> , 2015, 94, e1808.	0.4	26
672	Second Hepatectomy Improves Survival in Patients With Microvascular Invasive Hepatocellular Carcinoma Meeting the Milan Criteria. <i>Medicine (United States)</i> , 2015, 94, e2070.	0.4	17
673	Hepatocellular carcinoma: management of a complex and challenging condition. <i>Gastrointestinal Nursing</i> , 2015, 13, S20-S26.	0.0	1
674	Laparoscopic resection of recurrent ectopic hepatocellular carcinoma: A case report with review of the literature and guidelines for follow-up. <i>International Journal of Surgery Case Reports</i> , 2015, 17, 92-95.	0.2	6
675	Prognostic Value of 18-Fluorodeoxyglucose-Positron Emission Tomography After Transarterial Chemoembolization in Patients With Hepatocellular Carcinoma Undergoing Orthotopic Liver Transplantation. <i>Transplantation Proceedings</i> , 2015, 47, 2374-2376.	0.3	11
676	Traitement radiologique du CHCÂ: la radiologie interventionnelle au centre de la prise en charge. <i>Diagnostic and Interventional Imaging</i> , 2015, 96, 180-191.	0.0	0
678	Genetic variants in adult liver diseases. <i>Zeitschrift Fur Gastroenterologie</i> , 2015, 53, 1436-1446.	0.2	14
679	Balloon-Occluded Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma: A Single-Center Experience. <i>Oncology</i> , 2015, 89, 27-32.	0.9	20
680	Personalized management of hepatocellular carcinoma based on molecular information: Future prospects. <i>Clinical Liver Disease</i> , 2015, 5, 132-135.	1.0	4
681	Proposal of Japan Red Cross score for sorafenib therapy in hepatocellular carcinoma. <i>Hepatology Research</i> , 2015, 45, E130-40.	1.8	13
682	Sorafenib for Hepatocellular Carcinoma: From Randomized Controlled Trials to Clinical Practice. <i>Digestive Diseases</i> , 2015, 33, 668-674.	0.8	10
683	Treatment for hepatocellular carcinoma in Japan over the last three decades: Our experience and published work review. <i>Hepatology Research</i> , 2015, 45, 59-74.	1.8	72

#	ARTICLE	IF	CITATIONS
684	Conditional survival analysis of hepatocellular carcinoma patients treated with radiofrequency ablation. <i>Hepatology Research</i> , 2015, 45, E62-72.	1.8	20
685	Editorial: dynamic changes of the inflammation-based index predict mortality following chemoembolisation for hepatocellular carcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 1216-1217.	1.9	2
686	Radiofrequency ablation as an alternative to hepatic resection for single small hepatocellular carcinomas. <i>British Journal of Surgery</i> , 2015, 103, 126-135.	0.1	85
687	Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study. <i>Liver International</i> , 2015, 35, 2155-2166.	1.9	813
688	Real-Life Clinical Practice with Sorafenib in Advanced Hepatocellular Carcinoma: A Single-Center Experience Second Analysis. <i>Digestive Diseases</i> , 2015, 33, 728-734.	0.8	10
689	Validation of a Modified Substaging System (Kinki Criteria) for Patients with Intermediate-Stage Hepatocellular Carcinoma. <i>Oncology</i> , 2015, 89, 47-52.	0.9	31
690	Predictors of hepatocellular carcinoma in patients with liver cirrhosis. <i>Acta Marisiensis - Seria Medica</i> , 2015, 61, 47-50.	0.3	0
693	Delta-slope of alpha-fetoprotein improves the ability to select liver transplant patients with hepatocellular cancer. <i>Hpb</i> , 2015, 17, 1085-1095.	0.1	19
694	Transient elastography using Fibroscan is the most reliable noninvasive method for the diagnosis of advanced fibrosis and cirrhosis in alcoholic liver disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2015, 27, 1074-1079.	0.8	52
695	Transient elastography improves detection of liver cirrhosis compared to routine screening tests. <i>World Journal of Gastroenterology</i> , 2015, 21, 953.	1.4	10
698	Effectiveness of Sorafenib in Patients with Transcatheter Arterial Chemoembolization (TACE) Refractory and Intermediate-Stage Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2015, 4, 253-262.	4.2	172
699	Hepatectomy Versus Hepatectomy With Lymphadenectomy in Hepatocellular Carcinoma. <i>Journal of Clinical Gastroenterology</i> , 2015, 49, 520-528.	1.1	10
700	Challenges of Clinical Research on Hepatocellular Carcinoma. <i>Digestive Diseases</i> , 2015, 33, 780-790.	0.8	5
701	Contrast-Enhanced Ultrasound for the Characterization of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. <i>Liver Cancer</i> , 2015, 4, 241-252.	4.2	76
702	A training program for primary care physicians improves the effectiveness of ultrasound surveillance of hepatocellular carcinoma. <i>European Journal of Gastroenterology and Hepatology</i> , 2015, 27, 1103-1108.	0.8	17
703	Survival and risk factors related to death in outpatients with cirrhosis treated in a clinic in Southern Brazil. <i>European Journal of Gastroenterology and Hepatology</i> , 2015, 27, 1372-1377.	0.8	8
704	Rates of cirrhosis and hepatocellular carcinoma in chronic hepatitis B and the role of surveillance. <i>European Journal of Gastroenterology and Hepatology</i> , 2015, 27, 638-643.	0.8	61
705	Transcatheter arterial chemoembolization as an examination method for hepatocellular carcinoma undetected by B-mode ultrasound, computed tomography and digital subtraction angiography: A case report. <i>Oncology Letters</i> , 2015, 10, 1759-1762.	0.8	4

#	ARTICLE	IF	CITATIONS
706	Keratin 19 protein expression is an independent predictor of survival in human hepatocellular carcinoma. <i>European Journal of Gastroenterology and Hepatology</i> , 2015, 27, 1094-1102.	0.8	25
707	Differential proteomic and tissue expression analyses identify valuable diagnostic biomarkers of hepatocellular differentiation and hepatoid adenocarcinomas. <i>Pathology</i> , 2015, 47, 543-550.	0.3	28
709	Reply to "Response assessment for HCC patients treated with repeated TACE: The optimal time-point is still an open issue". <i>Journal of Hepatology</i> , 2015, 63, 1532.	1.8	0
710	Stratified screening of hepatocellular carcinoma in high-risk populations. <i>Radiology of Infectious Diseases</i> , 2015, 2, 109-112.	2.4	2
711	Liver-specific gadoxetic acid-enhanced magnetic resonance for focal lesion evaluation. <i>Revista De Gastroenterología De México (English Edition)</i> , 2015, 80, 267-275.	0.1	2
713	Transarterial injection of recombinant human type-5 adenovirus H101 in combination with transarterial chemoembolization (TACE) improves overall and progressive-free survival in unresectable hepatocellular carcinoma (HCC). <i>BMC Cancer</i> , 2015, 15, 707.	1.1	28
714	Reproducibility of mRECIST in assessing response to transarterial radioembolization therapy in hepatocellular carcinoma. <i>Hepatology</i> , 2015, 62, 1111-1121.	3.6	51
715	Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009. <i>Hepatology</i> , 2015, 62, 1723-1730.	3.6	633
716	Prognostic performance of preoperative gadoxetic acid-enhanced MRI in resectable hepatocellular carcinoma. <i>Journal of Magnetic Resonance Imaging</i> , 2015, 41, 1115-1123.	1.9	7
717	Microvasculature alters the dispersion properties of shear waves - a multi-frequency MR elastography study. <i>NMR in Biomedicine</i> , 2015, 28, 1763-1771.	1.6	20
718	PET-avid hepatocellular adenomas: incidental findings associated with HNF1- β mutated lesions. <i>Hpb</i> , 2015, , n/a-n/a.	0.1	0
719	Role of ablation: should it be used as primary therapy for early-stage hepatocellular carcinoma?. <i>Hepatic Oncology</i> , 2015, 2, 339-342.	4.2	0
720	Resection versus ablation for hepatocellular carcinoma: role of initial treatment. <i>Hepatic Oncology</i> , 2015, 2, 101-103.	4.2	0
721	Hepatic lesions. <i>Cancer Imaging</i> , 2015, 15, .	1.2	0
722	Serum lipidomic profiling as a useful tool for screening potential biomarkers of hepatitis B-related hepatocellular carcinoma by ultraperformance liquid chromatography-mass spectrometry. <i>BMC Cancer</i> , 2015, 15, 985.	1.1	21
723	Aldolase B inhibits metastasis through TenEleven Translocation 1 and serves as a prognostic biomarker in hepatocellular carcinoma. <i>Molecular Cancer</i> , 2015, 14, 170.	7.9	64
724	microRNA-150: a promising novel biomarker for hepatitis B virus-related hepatocellular carcinoma. <i>Diagnostic Pathology</i> , 2015, 10, 129.	0.9	45
725	Modified response evaluation criteria in solid tumors is superior to response evaluation criteria in solid tumors for assessment of responses to sorafenib in patients with advanced hepatocellular carcinoma. <i>BMC Research Notes</i> , 2015, 8, 609.	0.6	30

#	ARTICLE	IF	CITATIONS
726	The clinical course of cirrhosis: The importance of multistate models and competing risks analysis. <i>Hepatology</i> , 2015, 62, 292-302.	3.6	136
727	Application of hepatocellular carcinoma surveillance in a European setting. What can we learn from clinical practice?. <i>Liver International</i> , 2015, 35, 1862-1871.	1.9	55
728	Value of microwave ablation in treatment of large lesions of hepatocellular carcinoma. <i>Journal of Digestive Diseases</i> , 2015, 16, 456-463.	0.7	38
729	Radioembolization for hepatocellular carcinoma: current role and future directions – the medical oncologist's perspective. <i>Hepatic Oncology</i> , 2015, 2, 117-132.	4.2	0
730	Molecular markers predicting outcome in hepatocellular carcinoma treated by liver transplantation. <i>Liver Transplantation</i> , 2015, 21, S25-S26.	1.3	2
731	No increased risk of hepatocellular carcinoma in cirrhosis due to Wilson disease during long-term follow-up. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 535-539.	1.4	45
732	Prediction of risk for hepatocellular carcinoma by response of serum alpha-fetoprotein to entecavir therapy. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 1175-1182.	1.4	17
733	Forns index predicts recurrence and death in patients with hepatitis B-related hepatocellular carcinoma after curative resection. <i>Liver International</i> , 2015, 35, 1992-2000.	1.9	15
734	Extended survival of patients with persistently suppressed hepatitis B transplanted for hepatocellular carcinoma. <i>Liver International</i> , 2015, 35, 2187-2193.	1.9	2
735	Review of Commonly Used Serum Tumor Markers and Their Relevance for Image Interpretation. <i>Journal of Computer Assisted Tomography</i> , 2015, 39, 825-834.	0.5	22
736	Therapeutic value of transcatheter arterial chemoembolization combined with portal vein embolization for primary hepatocellular carcinoma with portal vein tumor thrombus: A pilot study. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2015, 11, e6-e12.	0.7	9
737	Radioembolization With Yttrium-90 Resin Microspheres in Hepatocellular Carcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2015, 38, 495-501.	0.6	36
738	The Effect of Hepatocellular Carcinoma Surveillance in an Urban Population With Liver Cirrhosis. <i>Journal of Clinical Gastroenterology</i> , 2015, 49, e91-e95.	1.1	8
739	Reply to Letter. <i>Annals of Surgery</i> , 2015, 262, e30-e31.	2.1	14
740	Reply to Letter. <i>Annals of Surgery</i> , 2015, 262, e18-e19.	2.1	13
741	Transarterial chemoembolization with drug-eluting beads is effective for the maintenance of the Milan status in patients with a small hepatocellular carcinoma. <i>Liver Transplantation</i> , 2015, 21, 1259-1269.	1.3	35
742	Validation of models in patients with hepatocellular carcinoma. <i>European Journal of Gastroenterology and Hepatology</i> , 2015, 27, 1180-1186.	0.8	30
743	Reply to Letter. <i>Annals of Surgery</i> , 2015, 261, e105-e106.	2.1	1

#	ARTICLE	IF	CITATIONS
744	Recurrence of Hepatocellular Cancer After Resection. <i>Annals of Surgery</i> , 2015, 261, 947-955.	2.1	576
745	Efficacy and safety of transjugular intrahepatic portosystemic shunt (TIPSS) in 40 patients with hepatocellular carcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 126-136.	1.9	42
746	Impact of renal insufficiency on patients with hepatocellular carcinoma undergoing radiofrequency ablation. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 192-198.	1.4	4
747	53 gene therapy-based transarterial chemoembolization for unresectable hepatocellular carcinoma: A prospective cohort study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 1651-1656.	1.4	13
748	Open-label prospective study of the safety and efficacy of glass-based yttrium 90 radioembolization for infiltrative hepatocellular carcinoma with portal vein thrombosis. <i>Cancer</i> , 2015, 121, 2164-2174.	2.0	51
749	Laser ablation: an alternative to radiofrequency ablation for hepatocellular carcinoma in cirrhotic patients?. <i>Hepatic Oncology</i> , 2015, 2, 111-115.	4.2	1
750	Surveillance for hepatocellular carcinoma in chronic hepatitis B virus infection: for whom. <i>Hepatic Oncology</i> , 2015, 2, 225-229.	4.2	1
751	Does diffusion-weighted imaging improve therapy response evaluation in patients with hepatocellular carcinoma after radioembolization? comparison of MRI using Gd-EOB-DTPA with and without DWI. <i>Journal of Magnetic Resonance Imaging</i> , 2015, 42, 818-827.	1.9	12
752	Early and resectable HCC: Definition and validation of a subgroup of patients who could avoid liver transplantation. <i>Journal of Surgical Oncology</i> , 2015, 111, 1007-1015.	0.8	15
753	Cryoablation Versus Radiofrequency Ablation for Hepatic Malignancies. <i>Medicine (United States)</i> , 2015, 94, e2252.	0.4	45
754	Reply. <i>Hepatology</i> , 2015, 62, 978-979.	3.6	0
755	Impact of clinically evident portal hypertension on the course of hepatocellular carcinoma in patients listed for liver transplantation. <i>Hepatology</i> , 2015, 62, 179-187.	3.6	36
756	Angiotensin receptor blockers improve survival outcomes after radiofrequency ablation in hepatocarcinoma patients. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 1643-1650.	1.4	54
757	Active Treatments Prolong the Survival in Patients With Hepatocellular Carcinoma and Performance Status 3 or 4. <i>Journal of Clinical Gastroenterology</i> , 2015, 49, 878-884.	1.1	3
758	Hepatic Resection as a Safe and Effective Treatment for Hepatocellular Carcinoma Involving a Single Large Tumor, Multiple Tumors, or Macrovascular Invasion. <i>Medicine (United States)</i> , 2015, 94, e396.	0.4	110
759	Historical Comparison of Overall Survival after Hepatic Resection for Patients With Large and/or Multinodular Hepatocellular Carcinoma. <i>Medicine (United States)</i> , 2015, 94, e1426.	0.4	26
760	Adherence to diagnostic guidelines of hepatocellular carcinoma. <i>European Journal of Gastroenterology and Hepatology</i> , 2015, 27, 846-852.	0.8	5
761	Appropriate treatment strategies for intrahepatic recurrence after curative resection of hepatocellular carcinoma initially within the Milan criteria. <i>European Journal of Gastroenterology and Hepatology</i> , 2015, 27, 933-940.	0.8	47

#	ARTICLE	IF	CITATIONS
762	Update on the Liver Imaging Reporting and Data System. <i>Advances in Anatomic Pathology</i> , 2015, 22, 314-322.	2.4	22
763	A Snapshot of the Effective Indications and Results of Surgery for Hepatocellular Carcinoma in Tertiary Referral Centers. <i>Annals of Surgery</i> , 2015, 262, e30.	2.1	23
764	Value of Transient Elastography Measured With Fibroscan in Predicting the Outcome of Hepatic Resection for Hepatocellular Carcinoma. <i>Annals of Surgery</i> , 2015, 261, e105.	2.1	8
765	Dissecting EASL/AASLD Recommendations With a More Careful Knife. <i>Annals of Surgery</i> , 2015, 262, e17-e18.	2.1	16
766	Prognostic Nomograms for Prediction of Recurrence and Survival After Curative Liver Resection for Hepatocellular Carcinoma. <i>Annals of Surgery</i> , 2015, 261, 939-946.	2.1	188
769	Hepatocellular carcinoma treatment strategies – a case-based review. <i>Journal of Solid Tumors</i> , 2015, 5, .	0.1	3
770	2014 Korean Liver Cancer Study Group-National Cancer Center Korea Practice Guideline for the Management of Hepatocellular Carcinoma. <i>Korean Journal of Radiology</i> , 2015, 16, 465.	1.5	168
771	Patterns of treatment and costs of intermediate and advanced hepatocellular carcinoma management in four Italian centers. <i>Therapeutics and Clinical Risk Management</i> , 2015, 11, 1603.	0.9	12
772	Transarterial chemoembolization versus hepatic resection in hepatocellular carcinoma treatment: a meta-analysis. <i>Drug Design, Development and Therapy</i> , 2015, 9, 4431.	2.0	7
773	Comment on a meta-analysis comparing hepatic resection or transarterial chemoembolization as initial treatment for hepatocellular carcinoma. <i>Drug Design, Development and Therapy</i> , 2015, 9, 5623.	2.0	2
774	Hepatocellular Carcinoma: Risk Factors, Diagnosis and Treatment. <i>Open Access Macedonian Journal of Medical Sciences</i> , 2015, 3, 732-736.	0.1	118
775	A Surgical Perspective on Targeted Therapy of Hepatocellular Carcinoma. <i>Diseases (Basel)</i> , 2015, 3, 360-381.	1.0	41
776	Systemic Chemotherapy for Advanced Hepatocellular Carcinoma: Past, Present, and Future. <i>Diseases (Basel, Switzerland)</i> , 2015, 3, 360-381.	1.0	41
777	Cirrhosis and portal hypertension: The importance of risk stratification, the role of hepatic venous pressure gradient measurement. <i>World Journal of Hepatology</i> , 2015, 7, 688.	0.8	52
778	Percutaneous microwave ablation vs radiofrequency ablation in the treatment of hepatocellular carcinoma. <i>World Journal of Hepatology</i> , 2015, 7, 1054.	0.8	258
779	Real-time two-dimensional shear wave ultrasound elastography of the liver is a reliable predictor of clinical outcomes and the presence of esophageal varices in patients with compensated liver cirrhosis. <i>Croatian Medical Journal</i> , 2015, 56, 470-481.	0.2	50
780	Sorafenib continuation or discontinuation in patients with unresectable hepatocellular carcinoma after a complete response. <i>Oncotarget</i> , 2015, 6, 24550-24559.	0.8	7
781	Guide for diagnosis and treatment of hepatocellular carcinoma. <i>World Journal of Hepatology</i> , 2015, 7, 1632.	0.8	185

#	ARTICLE	IF	CITATIONS
782	Cyberknife treatment for advanced or terminal stage hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2015, 21, 13101.	1.4	15
783	Microwave ablation of hepatocellular carcinoma. <i>World Journal of Hepatology</i> , 2015, 7, 2578.	0.8	94
784	HEPATOCELLULAR CARCINOMA IN A NON-CIRRHOTIC PATIENT WITH SUSTAINED VIROLOGICAL RESPONSE AFTER HEPATITIS C TREATMENT. <i>Revista Do Instituto De Medicina Tropical De Sao Paulo</i> , 2015, 57, 519-522.	0.5	6
785	Transarterial Y90 radioembolization versus chemoembolization for patients with hepatocellular carcinoma: A meta-analysis. <i>BioScience Trends</i> , 2015, 9, 289-298.	1.1	56
786	Imaging of HCC—Current State of the Art. <i>Diagnostics</i> , 2015, 5, 513-545.	1.3	40
787	Hepatocellular carcinoma: A comprehensive review. <i>World Journal of Hepatology</i> , 2015, 7, 2648.	0.8	161
788	Targeting FGF19/FGFR4 Pathway: A Novel Therapeutic Strategy for Hepatocellular Carcinoma. <i>Diseases (Basel, Switzerland)</i> , 2015, 3, 294-305.	1.0	64
789	Hepatoma-Derived Growth Factor: Its Possible Involvement in the Progression of Hepatocellular Carcinoma. <i>International Journal of Molecular Sciences</i> , 2015, 16, 14086-14097.	1.8	31
790	Hepatocellular Carcinoma in Patients with a Sustained Response to Anti-Hepatitis C Therapy. <i>International Journal of Molecular Sciences</i> , 2015, 16, 19698-19712.	1.8	57
791	JNK-Bcl-2/Bcl-xL-Bax/Bak Pathway Mediates the Crosstalk between Matrine-Induced Autophagy and Apoptosis via Interplay with Beclin 1. <i>International Journal of Molecular Sciences</i> , 2015, 16, 25744-25758.	1.8	85
792	Recent advances in surgical treatment of hepatocellular carcinoma. <i>Drug Discoveries and Therapeutics</i> , 2015, 9, 319-330.	0.6	32
793	Advanced hepatocellular carcinoma and sorafenib: Diagnosis, indications, clinical and radiological follow-up. <i>World Journal of Hepatology</i> , 2015, 7, 1041.	0.8	42
794	Sorafenib for the treatment of hepatocellular carcinoma with portal vein tumour thrombosis: a systematic review of comparative studies. <i>Przegląd Gastroenterologiczny</i> , 2015, 3, 142-147.	0.3	9
795	Contrast Enhanced MRI in the Diagnosis of HCC. <i>Diagnostics</i> , 2015, 5, 383-398.	1.3	29
796	Potential Molecular Targeted Therapeutics: Role of PI3-K/Akt/mTOR Inhibition in Cancer. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2015, 16, 29-37.	0.9	16
797	Staging systems for hepatocellular carcinoma: Current status and future perspectives. <i>World Journal of Hepatology</i> , 2015, 7, 406.	0.8	109
798	Long-Term Outcomes of Percutaneous Cryoablation for Patients with Hepatocellular Carcinoma within Milan Criteria. <i>PLoS ONE</i> , 2015, 10, e0123065.	1.1	63
799	A Prognostic Score for Patients with Intermediate-Stage Hepatocellular Carcinoma Treated with Transarterial Chemoembolization. <i>PLoS ONE</i> , 2015, 10, e0125244.	1.1	34

#	ARTICLE	IF	CITATIONS
800	Circulating microRNAs, miR-939, miR-595, miR-519d and miR-494, Identify Cirrhotic Patients with HCC. PLoS ONE, 2015, 10, e0141448.	1.1	113
801	Management of hepatocellular carcinoma with portal vein thrombosis. World Journal of Gastroenterology, 2015, 21, 3462.	1.4	90
802	Portal vein thrombosis in cirrhosis: Controversies and latest developments. World Journal of Gastroenterology, 2015, 21, 6769-6784.	1.4	83
803	Transarterial chemoembolization for hepatocellular carcinoma: an evidence-based review of its place in therapy. Journal of Hepatocellular Carcinoma, 2015, 2, 123.	1.8	17
804	Brazilian society of hepatology recommendations for the diagnosis and treatment of hepatocellular carcinoma. Arquivos De Gastroenterologia, 2015, 52, 2-14.	0.3	12
805	HULC and H19 Played Different Roles in Overall and Disease-Free Survival from Hepatocellular Carcinoma after Curative Hepatectomy: A Preliminary Analysis from Gene Expression Omnibus. Disease Markers, 2015, 2015, 1-9.	0.6	66
806	Port site metastases following laparoscopic liver resection for hepatocellular carcinoma. Annals of the Royal College of Surgeons of England, 2015, 97, e52-e53.	0.3	10
807	The Effectiveness of Ultrasound Surveillance for Hepatocellular Carcinoma in a Canadian Centre and Determinants of Its Success. Canadian Journal of Gastroenterology and Hepatology, 2015, 29, 267-273.	0.8	15
808	Hepatocellular Carcinoma in Liver Cirrhosis: Surgical Resection versus Transarterial Chemoembolization – A Meta-Analysis. Gastroenterology Research and Practice, 2015, 2015, 1-8.	0.7	20
809	Diagnostic Challenges in Primary Hepatocellular Carcinoma: Case Reports and Review of the Literature. Case Reports in Oncological Medicine, 2015, 2015, 1-5.	0.2	8
810	Transarterial Embolization for Hepatocellular Carcinoma: A Comparison between Nonspherical PVA and Microspheres. BioMed Research International, 2015, 2015, 1-5.	0.9	10
811	Hepatocellular Carcinoma: Consensus, Controversies and Future Directions: A Report from the Canadian Association for the Study of the Liver Hepatocellular Carcinoma Meeting. Canadian Journal of Gastroenterology and Hepatology, 2015, 29, 178-184.	0.8	37
812	CT Appearance of Hepatocellular Carcinoma after Locoregional Treatments: A Comprehensive Review. Gastroenterology Research and Practice, 2015, 2015, 1-10.	0.7	20
813	Stereotactic body radiation therapy: A novel treatment modality for inoperable hepatocellular carcinoma. Drug Discoveries and Therapeutics, 2015, 9, 372-379.	0.6	19
814	The Value of Serum Midkine Level in Diagnosis of Hepatocellular Carcinoma. International Journal of Hepatology, 2015, 2015, 1-6.	0.4	46
815	Albumin-to-Alkaline Phosphatase Ratio: A Novel Prognostic Index for Hepatocellular Carcinoma. Disease Markers, 2015, 2015, 1-10.	0.6	83
816	Semiannual Imaging Surveillance Is Associated with Better Survival in Patients with Non-B, Non-C Hepatocellular Carcinoma. Mediators of Inflammation, 2015, 2015, 1-7.	1.4	4
817	Badanie ultrasonograficzne w...troby i dr...ciowych – oczekiwania klinicysty. , 2015, 15, 292-306.		12

#	ARTICLE	IF	CITATIONS
818	Current management of hepatocellular carcinoma: An Eastern perspective. <i>World Journal of Gastroenterology</i> , 2015, 21, 3826.	1.4	48
819	Comparative analysis of intraoperative radiofrequency ablation versus non-anatomical hepatic resection for small hepatocellular carcinoma: short-term result. <i>Korean Journal of Hepato-biliary-pancreatic Surgery</i> , 2015, 19, 173.	1.0	6
820	New challenges in clinical research on hepatocellular carcinoma. <i>Revista Espanola De Enfermedades Digestivas</i> , 2015, 108, 485-93.	0.1	12
821	Oxaliplatin and 5-fluorouracil hepatic infusion with lipiodolized chemoembolization in large hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2015, 21, 3970.	1.4	19
822	Diagnostic and therapeutic management of hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2015, 21, 12003.	1.4	66
823	Current and future treatments for hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2015, 21, 8478.	1.4	140
824	Prevention of Liver Fibrosis and Cancer in Africa: The PROLIFICA project “a collaborative study of hepatitis B-related liver disease in West Africa. <i>South African Medical Journal</i> , 2015, 105, 185.	0.2	3
825	Magnetic resonance imaging of the cirrhotic liver: An update. <i>World Journal of Hepatology</i> , 2015, 7, 468.	0.8	29
826	Risk for hepatocellular carcinoma in the course of chronic hepatitis B virus infection and the protective effect of therapy with nucleos(t)ide analogues. <i>World Journal of Hepatology</i> , 2015, 7, 1064.	0.8	46
827	Transarterial chemoembolization in hepatocellular carcinoma treatment: Barcelona clinic liver cancer staging system. <i>World Journal of Gastroenterology</i> , 2015, 21, 10327.	1.4	132
828	Diagnosis of liver nodules within and outside screening programs. <i>Annals of Hepatology</i> , 2015, 14, 304-309.	0.6	7
829	Intermediate hepatocellular carcinoma: How to choose the best treatment modality?. <i>World Journal of Hepatology</i> , 2015, 7, 1184.	0.8	20
830	Evaluation of alpha-fetoprotein as a screening marker for hepatocellular carcinoma in hepatitis prevalent areas. <i>Annals of Hepatology</i> , 2015, 14, 881-887.	0.6	17
831	Transarterial chemoembolization: Evidences from the literature and applications in hepatocellular carcinoma patients. <i>World Journal of Hepatology</i> , 2015, 7, 2009.	0.8	77
832	Adjuvant Immunotherapy With Autologous Cytokine-Induced Killer Cells for Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2015, 148, 1383-1391.e6.	0.6	371
833	Risk factors for hepatocellular carcinoma in Caucasian patients with non-viral cirrhosis: the importance of prior obesity. <i>Liver International</i> , 2015, 35, 1872-1876.	1.9	19
834	Biomarkers in HCV Infection. <i>Advances in Clinical Chemistry</i> , 2015, 70, 131-196.	1.8	4
835	A structured proteomic approach identifies 14-3-3Sigma as a novel and reliable protein biomarker in panel based differential diagnostics of liver tumors. <i>Biochimica Et Biophysica Acta - Proteins and Proteomics</i> , 2015, 1854, 641-650.	1.1	23

#	ARTICLE	IF	CITATIONS
836	Transarterial approaches to primary and secondary hepatic malignancies. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 481-489.	12.5	37
837	Evaluation of the Effect of Cumulative Operator Experience on Hepatocellular Carcinoma Recurrence after Primary Treatment with Radiofrequency Ablation. <i>Radiology</i> , 2015, 276, 294-301.	3.6	22
838	Comprehensive DNA methylation analysis of hepatitis B virus genome in infected liver tissues. <i>Scientific Reports</i> , 2015, 5, 10478.	1.6	41
839	Advances in targeted therapies for hepatocellular carcinoma in the genomic era. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 408-424.	12.5	456
840	Can we use HCC risk scores to individualize surveillance in chronic hepatitis B infection?. <i>Journal of Hepatology</i> , 2015, 63, 722-732.	1.8	97
841	Evaluation of serum endoglin as noninvasive marker in hepatocellular carcinoma. <i>The Egyptian Journal of Internal Medicine</i> , 2015, 27, 15-20.	0.3	4
842	Ascites and alpha-fetoprotein improve prognostic performance of Barcelona Clinic Liver Cancer staging. <i>World Journal of Gastroenterology</i> , 2015, 21, 5654.	1.4	9
843	When to perform hepatic resection for intermediate-stage hepatocellular carcinoma. <i>Hepatology</i> , 2015, 61, 905-914.	3.6	69
844	Hepatocellular carcinoma in variegate porphyria: a case report and literature review. <i>Annals of Clinical Biochemistry</i> , 2015, 52, 407-412.	0.8	11
845	The challenge of inoperable hepatocellular carcinoma (HCC): results of a single-institutional experience on stereotactic body radiation therapy (SBRT). <i>Journal of Cancer Research and Clinical Oncology</i> , 2015, 141, 1301-1309.	1.2	135
846	Combination of individualized local control and target-specific agent to improve unresectable liver cancer managements: a matched case-control study. <i>Targeted Oncology</i> , 2015, 10, 287-295.	1.7	10
847	Complete Response to Full-Dose Sorafenib Treatment in an Elderly HCC Patient: a Case Report. <i>Journal of Gastrointestinal Cancer</i> , 2015, 46, 430-433.	0.6	2
848	Clinical management of chronic hepatitis B infection: results from a registry at a German tertiary referral center. <i>Infection</i> , 2015, 43, 153-162.	2.3	4
849	Radiological treatment of HCC: Interventional radiology at the heart of management. <i>Diagnostic and Interventional Imaging</i> , 2015, 96, 625-636.	1.8	18
850	Optimal methods for measuring eligibility for liver transplant in hepatocellular carcinoma patients undergoing transarterial chemoembolization. <i>Journal of Hepatology</i> , 2015, 62, 1076-1084.	1.8	21
851	Role of ultrasound in the diagnosis and treatment of nonalcoholic fatty liver disease and its complications. <i>Expert Review of Gastroenterology and Hepatology</i> , 2015, 9, 603-627.	1.4	102
852	Evolution from WHO to EASL and mRECIST for hepatocellular carcinoma: considerations for tumor response assessment. <i>Expert Review of Gastroenterology and Hepatology</i> , 2015, 9, 335-348.	1.4	51
853	Diagnostic Per-Patient Accuracy of an Abbreviated Hepatobiliary Phase Gadoteric Acid-Enhanced MRI for Hepatocellular Carcinoma Surveillance. <i>American Journal of Roentgenology</i> , 2015, 204, 527-535.	1.0	105

#	ARTICLE	IF	CITATIONS
854	Cellular prognostic markers in hepatocellular carcinoma. <i>Future Oncology</i> , 2015, 11, 1591-1598.	1.1	20
855	Clinical outcomes of patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective study of routine clinical practice in multi-institutions. <i>BMC Cancer</i> , 2015, 15, 236.	1.1	16
856	Phase I/II study of temsirolimus for patients with unresectable Hepatocellular Carcinoma (HCC)- a correlative study to explore potential biomarkers for response. <i>BMC Cancer</i> , 2015, 15, 395.	1.1	96
857	Severity of liver cirrhosis: a key role in the selection of surgical modality for Child-Pugh A hepatocellular carcinoma. <i>World Journal of Surgical Oncology</i> , 2015, 13, 148.	0.8	24
858	Identifying Staging Markers for Hepatocellular Carcinoma before Transarterial Chemoembolization: Comparison of Three-dimensional Quantitative versus Non-contrast three-dimensional Imaging Markers. <i>Radiology</i> , 2015, 275, 438-447.	3.6	48
859	Seroprevalence of hepatitis A,B, and C viruses in Turkish alcoholic cirrhotics and the impact of hepatitis B on clinical profile. <i>Journal of Infection in Developing Countries</i> , 2015, 9, 254-258.	0.5	6
860	Biomarkers for hepatocellular carcinoma: diagnostic and therapeutic utility. <i>Hepatic Medicine: Evidence and Research</i> , 2015, 7, 1.	0.9	25
861	The Effectiveness of ART Score in Selecting Patients for Transarterial Chemoembolization Retreatment. <i>Medicine (United States)</i> , 2015, 94, e1659.	0.4	8
862	Determinants of Survival After Sorafenib Failure in Patients With BCLC-C Hepatocellular Carcinoma in Real-World Practice. <i>Medicine (United States)</i> , 2015, 94, e688.	0.4	30
863	Resonancia magnética con Ácido gadolínico "contraste hepatoespecífico" para la evaluación de lesiones focales. <i>Revista De Gastroenterología De México</i> , 2015, 80, 267-275.	0.4	0
864	Hong Kong Liver Cancer Staging System Is Associated With Better Performance for Hepatocellular Carcinoma. <i>Medicine (United States)</i> , 2015, 94, e1772.	0.4	21
865	Liver Fibrosis in HIV Patients Receiving a Modern cART. <i>Medicine (United States)</i> , 2015, 94, e2127.	0.4	31
866	Atypical Presentation of Hepatocellular Carcinoma Mimicking a Gastric Hepatoid Adenocarcinoma. <i>Medicine (United States)</i> , 2015, 94, e1101.	0.4	3
867	Reply. <i>Hepatology</i> , 2015, 61, 1092-1093.	3.6	0
868	Should hepatocellular carcinoma screening with ultrasound be recommended in hepatocellular carcinoma high-incidence areas?. <i>Hepatology</i> , 2015, 61, 1091-1092.	3.6	2
869	Combining Sorafenib with the antivasular action of microbubbles for the treatment of hepatocellular carcinoma. , 2015, , .		1
870	Stratification of Hepatocellular Carcinoma Patients Based on Acetate Utilization. <i>Cell Reports</i> , 2015, 13, 2014-2026.	2.9	113
871	Intermediate hepatocellular carcinoma: the role of transarterial therapy. <i>Hepatic Oncology</i> , 2015, 2, 399-408.	4.2	10

#	ARTICLE	IF	CITATIONS
872	Ultrasound-guided ablation for hepatocellular carcinoma: time for a reappraisal?. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 147-150.	1.1	1
873	The changing epidemiology of Asian digestive cancers: From etiologies and incidences to preventive strategies. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2015, 29, 843-853.	1.0	19
874	Cytohistology of hepatocellular carcinoma. <i>Diagnostic Histopathology</i> , 2015, 21, 470-480.	0.2	3
875	Application of the Barcelona Clinic Liver Cancer therapeutic strategy and impact on survival. <i>United European Gastroenterology Journal</i> , 2015, 3, 284-293.	1.6	4
876	A phase I/IIa study of adjuvant immunotherapy with tumour antigen-pulsed dendritic cells in patients with hepatocellular carcinoma. <i>British Journal of Cancer</i> , 2015, 113, 1666-1676.	2.9	73
877	Critical review of resveratrol in xenobiotic-induced hepatotoxicity. <i>Food and Chemical Toxicology</i> , 2015, 86, 309-318.	1.8	46
878	Cholangiocarcinoma in Cirrhosis: Value of Hepatocyte Specific Magnetic Resonance Imaging. <i>Digestive Diseases</i> , 2015, 33, 735-744.	0.8	19
879	Subclassification of BCLC B Stage Hepatocellular Carcinoma and Treatment Strategies: Proposal of Modified Bolondi's Subclassification (Kinki Criteria). <i>Digestive Diseases</i> , 2015, 33, 751-758.	0.8	167
880	Multiple Tumors Located in the Same Section Are Associated with Better Outcomes After Hepatic Resection for HCC Patients Meeting the Milan Criteria. <i>Journal of Gastrointestinal Surgery</i> , 2015, 19, 2207-2214.	0.9	13
881	Post-embolization syndrome as an early predictor of overall survival after transarterial chemoembolization for hepatocellular carcinoma. <i>Hpb</i> , 2015, 17, 1137-1144.	0.1	44
882	Role of Transarterial Chemoembolization to Downstage Hepatocellular Carcinoma Within the Milan Criteria. <i>Transplantation Proceedings</i> , 2015, 47, 2631-2633.	0.3	6
883	Fucoidan protects hepatocytes from apoptosis and inhibits invasion of hepatocellular carcinoma by up-regulating p42/44 MAPK-dependent NDRG-1/CAP43. <i>Acta Pharmaceutica Sinica B</i> , 2015, 5, 544-553.	5.7	36
884	Yttrium-90 Radioembolization of Hepatocellular Carcinoma—Performance, Technical Advances, and Future Concepts. <i>Seminars in Interventional Radiology</i> , 2015, 32, 388-397.	0.3	7
885	⁹⁰ Y-glass microspheres for hepatic neoplasia. <i>Future Oncology</i> , 2015, 11, 1343-1354.	1.1	1
886	Hepatic Resection Improves Long-Term Survival of Patients with Large and/or Multinodular Hepatocellular Carcinoma. <i>Journal of Gastrointestinal Surgery</i> , 2015, 19, 2288-2289.	0.9	2
887	Hepatic stellate cells promote upregulation of epithelial cell adhesion molecule and epithelial-mesenchymal transition in hepatic cancer cells. <i>Oncology Reports</i> , 2015, 34, 1169-1177.	1.2	11
888	Inter-observer variability of response evaluation criteria for hepatocellular carcinoma treated with chemoembolization. <i>Digestive and Liver Disease</i> , 2015, 47, 682-688.	0.4	5
889	Liver function assessment according to the Albumin-Bilirubin (ALBI) grade in sorafenib-treated patients with advanced hepatocellular carcinoma. <i>Investigational New Drugs</i> , 2015, 33, 1257-1262.	1.2	75

#	ARTICLE	IF	CITATIONS
890	Hepatic Resection for Hepatocellular Carcinoma with Tumor Thrombus in the Major Portal Vein. <i>Digestive Surgery</i> , 2015, 32, 413-420.	0.6	31
891	Evaluating Treatment Response of Radioembolization in Intermediate-Stage Hepatocellular Carcinoma Patients Using ¹⁸ F-Fluoroethylcholine PET/CT. <i>Journal of Nuclear Medicine</i> , 2015, 56, 1661-1666.	2.8	28
892	Trans-arterial chemoembolization with doxorubicin-eluting particles versus conventional trans-arterial chemoembolization in unresectable hepatocellular carcinoma: A study of effectiveness, safety and costs. <i>Radiologia</i> , 2015, 57, 496-504.	0.3	15
893	Yttrium-90 Microsphere Radioembolization for Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2015, 4, 16-25.	4.2	40
894	Consensus Development from the 5th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2014). <i>Liver Cancer</i> , 2015, 4, 96-105.	4.2	19
895	Pancreatic Atrophy in Hepatocellular Carcinoma Patients Receiving Long-Term Treatment with Sorafenib. <i>Oncology</i> , 2015, 89, 88-94.	0.9	8
896	Prognosis of untreated hepatocellular carcinoma. <i>Hepatology</i> , 2015, 61, 184-190.	3.6	188
897	Does hepatitis B virus therapy reduce the risk of hepatocellular carcinoma?. <i>Expert Opinion on Drug Safety</i> , 2015, 14, 439-451.	1.0	5
898	Assessing tumor response after loco-regional liver cancer therapies: the role of 3D MRI. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 199-205.	1.1	33
899	De novo hepatocellular carcinoma of liver allograft: A neglected issue. <i>Cancer Letters</i> , 2015, 357, 47-54.	3.2	27
900	The Revolution of Hepatitis C Treatments: Review for Nurse Practitioners. <i>Journal for Nurse Practitioners</i> , 2015, 11, 116-123.	0.4	1
901	Survival analysis of proposed BCLC subgroups in hepatocellular carcinoma patients. <i>Liver International</i> , 2015, 35, 591-600.	1.9	60
902	Epidemiology, Screening, and Pretreatment Evaluation of the Patient With Chronic Hepatitis C Infection. <i>Journal for Nurse Practitioners</i> , 2015, 11, 109-115.	0.4	2
903	In intermediate stage hepatocellular carcinoma: radioembolization with yttrium 90 or chemoembolization?. <i>Liver International</i> , 2015, 35, 627-635.	1.9	84
904	Optimal Imaging Surveillance Schedules after Liver-Directed Therapy for Hepatocellular Carcinoma. <i>Journal of Vascular and Interventional Radiology</i> , 2015, 26, 69-73.	0.2	55
905	Validation and modification of a proposed substaging system for patients with intermediate hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 358-363.	1.4	39
906	Complete response at first chemoembolization is still the most robust predictor for favorable outcome in hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2015, 62, 1304-1310.	1.8	148
907	Comparison of Chemoembolization with and without Radiation Therapy and Sorafenib for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis: A Propensity Score Analysis. <i>Journal of Vascular and Interventional Radiology</i> , 2015, 26, 320-329.e6.	0.2	75

#	ARTICLE	IF	CITATIONS
908	Risk Factors of Hepatocellular Carcinoma Recurrence After Liver Transplantation: Accuracy of the Alpha-Fetoprotein Model in a Single-Center Experience. <i>Transplantation Proceedings</i> , 2015, 47, 84-89.	0.3	38
909	Authors'™ response to the letter: Liver resection for patients with hepatocellular carcinoma and macrovascular invasion, multiple tumours or portal hypertension by Zhong<i>et al</i>. <i>Gut</i> , 2015, 64, 522-522.	6.1	5
910	Proton pump inhibitor treatment is associated with the severity of liver disease and increased mortality in patients with cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 459-466.	1.9	93
911	Republished: Non-alcoholic fatty liver disease: a practical approach to treatment. <i>Postgraduate Medical Journal</i> , 2015, 91, 92-101.	0.9	20
912	Reappraisal of serum alpha-foetoprotein as a surveillance test for hepatocellular carcinoma during entecavir treatment. <i>Liver International</i> , 2015, 35, 232-239.	1.9	35
913	Contrast-enhanced ultrasound in the diagnosis of hepatocellular carcinoma. <i>Radiologia Medica</i> , 2015, 120, 627-633.	4.7	15
914	Image-guided ablation of primary liver and renal tumours. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 175-186.	12.5	72
915	Occult cirrhosis diagnosed by transient elastography is a frequent and under-monitored clinical entity. <i>Liver International</i> , 2015, 35, 2285-2293.	1.9	13
916	Predictors of survival in patients with advanced hepatocellular carcinoma who permanently discontinued sorafenib. <i>Hepatology</i> , 2015, 62, 784-791.	3.6	110
917	Safety and toxicity of radioembolization plus Sorafenib in advanced hepatocellular carcinoma: analysis of the European multicentre trial <scp>SORAMIC</scp>. <i>Liver International</i> , 2015, 35, 620-626.	1.9	74
918	Radiofrequency ablation plus drug-eluting beads transcatheter arterial chemoembolization for the treatment of single large hepatocellular carcinoma. <i>Digestive and Liver Disease</i> , 2015, 47, 242-248.	0.4	53
919	Genetic polymorphism of IL-23R influences susceptibility to HCV-related hepatocellular carcinoma. <i>Cellular Immunology</i> , 2015, 294, 21-24.	1.4	13
920	Target patients for partial hepatectomy and relationship between PLT and prognosis in BCLC B HCC. <i>Journal of Hepatology</i> , 2015, 62, 750.	1.8	5
921	Molecularly targeted therapies for human hepatocellular carcinoma: Should we start from β -catenin inhibition?. <i>Journal of Hepatology</i> , 2015, 62, 257-259.	1.8	5
922	Survival benefit of liver resection for patients with hepatocellular carcinoma across different Barcelona Clinic Liver Cancer stages: A multicentre study. <i>Journal of Hepatology</i> , 2015, 62, 617-624.	1.8	184
924	Early intrahepatic recurrence of hepatocellular carcinoma after hepatectomy treated with re-hepatectomy, ablation or chemoembolization: A prospective cohort study. <i>European Journal of Surgical Oncology</i> , 2015, 41, 236-242.	0.5	53
925	Current concepts of immune based treatments for patients with HCC: from basic science to novel treatment approaches. <i>Gut</i> , 2015, 64, 842-848.	6.1	155
926	Small Hepatocellular Carcinoma: Radiofrequency Ablation versus Nonanatomic Resection-Propensity Score Analyses of Long-term Outcomes. <i>Radiology</i> , 2015, 275, 908-919.	3.6	127

#	ARTICLE	IF	CITATIONS
928	Ablation for Recurrent Hepatocellular Carcinoma: A Systematic Review of Clinical Efficacy and Prognostic Factors. <i>World Journal of Surgery</i> , 2015, 39, 1150-1160.	0.8	29
931	Outcomes of Locoregional Tumor Therapy for Patients with Hepatocellular Carcinoma and Transjugular Intrahepatic Portosystemic Shunts. <i>CardioVascular and Interventional Radiology</i> , 2015, 38, 913-921.	0.9	17
932	Utility and cost-effectiveness of screening for hepatocellular carcinoma in a resource-limited setting. <i>Medical Oncology</i> , 2015, 32, 432.	1.2	19
933	DNA methylation-based prognosis and epidrivers in hepatocellular carcinoma. <i>Hepatology</i> , 2015, 61, 1945-1956.	3.6	367
934	New imaging techniques for liver diseases. <i>Journal of Hepatology</i> , 2015, 62, 690-700.	1.8	100
935	Unique Genomic Profile of Fibrolamellar Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2015, 148, 806-818.e10.	0.6	109
936	Classification of Hypervascular Liver Lesions Based on Hepatic Artery and Portal Vein Blood Supply Coefficients Calculated from Triphasic CT Scans. <i>Journal of Digital Imaging</i> , 2015, 28, 213-223.	1.6	31
937	Temporal Trends of Nonalcoholic Fatty Liver Disease-Related Hepatocellular Carcinoma in the Veteran Affairs Population. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 594-601.e1.	2.4	215
938	Performance of PIVKA-II for early hepatocellular carcinoma diagnosis and prediction of microvascular invasion. <i>Journal of Hepatology</i> , 2015, 62, 848-854.	1.8	228
939	New molecularly targeted therapies against advanced hepatocellular carcinoma: From molecular pathogenesis to clinical trials and future directions. <i>Hepatology Research</i> , 2015, 45, E1-E11.	1.8	67
940	Biopsy for liver cancer: How to balance research needs with evidence-based clinical practice. <i>Hepatology</i> , 2015, 61, 433-436.	3.6	36
941	Utility of the FIB Index for hepatocarcinogenesis in hepatitis C virus carriers with normal alanine aminotransferase levels. <i>Journal of Viral Hepatitis</i> , 2015, 22, 777-783.	1.0	13
942	Results of laparoscopic radiofrequency ablation for HCC. Could the location of the tumour influence a complete response to treatment? A single European centre experience. <i>Hpb</i> , 2015, 17, 387-393.	0.1	44
943	Survival outcomes after stereotactic body radiotherapy for 79 Japanese patients with hepatocellular carcinoma. <i>Journal of Radiation Research</i> , 2015, 56, 561-567.	0.8	57
944	Prognostic impact of hepatic resection for hepatocellular carcinoma: The role of the surgeon in achieving R0 resection - A retrospective cohort study. <i>International Journal of Surgery</i> , 2015, 13, 297-301.	1.1	10
945	Preferential Targeting of Disseminated Liver Tumors Using a Recombinant Adeno-Associated Viral Vector. <i>Human Gene Therapy</i> , 2015, 26, 94-103.	1.4	29
946	Seroprevalence of occult hepatitis B among Egyptian paediatric hepatitis C cancer patients. <i>Journal of Viral Hepatitis</i> , 2015, 22, 103-111.	1.0	10
947	Modulation of the unfolded protein response impedes tumor cell adaptation to proteotoxic stress: a PERK for hepatocellular carcinoma therapy. <i>Hepatology International</i> , 2015, 9, 93-104.	1.9	58

#	ARTICLE	IF	CITATIONS
948	A new approach to the use of α -fetoprotein as surveillance test for hepatocellular carcinoma in patients with cirrhosis. <i>British Journal of Cancer</i> , 2015, 112, 69-76.	2.9	66
949	Sustained virologic response achieved after curative treatment of hepatitis C virus-related hepatocellular carcinoma as an independent prognostic factor. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 1197-1204.	1.4	36
950	The clinical application of 320-detector row CT in transcatheter arterial chemoembolization (TACE) for hepatocellular carcinoma. <i>Radiologia Medica</i> , 2015, 120, 690-694.	4.7	6
951	Randomized Comparison of Selective Internal Radiotherapy (SIRT) Versus Drug-Eluting Bead Transarterial Chemoembolization (DEB-TACE) for the Treatment of Hepatocellular Carcinoma. <i>CardioVascular and Interventional Radiology</i> , 2015, 38, 352-360.	0.9	95
953	Aggressive Therapeutic Strategies Improve the Survival of Hepatocellular Carcinoma Patients with Performance Status 1 or 2: A Propensity Score Analysis. <i>Annals of Surgical Oncology</i> , 2015, 22, 1324-1331.	0.7	18
954	Consensus Statements From a Multidisciplinary Expert Panel on the Utilization and Application of a Liver-Specific MRI Contrast Agent (Gadoxetic Acid). <i>American Journal of Roentgenology</i> , 2015, 204, 498-509.	1.0	76
955	Randomized Controlled Trial of the Prophylactic Effect of Urea-Based Cream on Sorafenib-Associated Hand-Foot Skin Reactions in Patients With Advanced Hepatocellular Carcinoma. <i>Journal of Clinical Oncology</i> , 2015, 33, 894-900.	0.8	114
956	Surveillance, Diagnosis, Treatment, and Outcome of Liver Cancer in Japan. <i>Liver Cancer</i> , 2015, 4, 39-50.	4.2	175
957	Elevated Alpha-Fetoprotein. <i>Clinics in Liver Disease</i> , 2015, 19, 309-323.	1.0	118
958	FIB-4 index for assessing the prognosis of hepatocellular carcinoma in patients with Child-Pugh class A liver function. <i>Journal of Cancer Research and Clinical Oncology</i> , 2015, 141, 1311-1319.	1.2	11
959	A serum microRNA classifier for early detection of hepatocellular carcinoma: a multicentre, retrospective, longitudinal biomarker identification study with a nested case-control study. <i>Lancet Oncology</i> , 2015, 16, 804-815.	5.1	237
960	New molecular therapies for hepatocellular carcinoma. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2015, 39, S80-S85.	0.7	30
961	Postoperative neutrophil-to-lymphocyte ratio plus platelet-to-lymphocyte ratio predicts the outcomes of hepatocellular carcinoma. <i>Journal of Surgical Research</i> , 2015, 198, 73-79.	0.8	57
962	Systematic review of guidelines for management of intermediate hepatocellular carcinoma using the Appraisal of Guidelines Research and Evaluation II instrument. <i>Digestive and Liver Disease</i> , 2015, 47, 877-883.	0.4	10
963	Cancer Imaging Training in the 21st Century: An Overview of Where We Are, and Where We Need To Be. <i>Journal of the American College of Radiology</i> , 2015, 12, 714-720.	0.9	9
965	Surgical treatment of hepatocellular carcinoma: should resection be performed according to Barcelona Clinic Liver Cancer classification?. <i>Hepatic Oncology</i> , 2015, 2, 245-253.	4.2	3
966	Clinical applications for dual energy CT versus dynamic contrast enhanced CT in oncology. <i>European Journal of Radiology</i> , 2015, 84, 2368-2379.	1.2	16
967	Systemic Treatment: Expecting Further Success. <i>Digestive Diseases</i> , 2015, 33, 590-597.	0.8	1

#	ARTICLE	IF	CITATIONS
968	Progenitor cell markers predict outcome of patients with hepatocellular carcinoma beyond Milan criteria undergoing liver transplantation. <i>Journal of Hepatology</i> , 2015, 63, 1368-1377.	1.8	64
969	Contrast-Enhanced Ultrasound of Focal Liver Lesions. <i>American Journal of Roentgenology</i> , 2015, 205, W56-W66.	1.0	175
970	The long-term benefits of nucleos(t)ide analogs in compensated HBV cirrhotic patients with no or small esophageal varices: A 12-year prospective cohort study. <i>Journal of Hepatology</i> , 2015, 63, 1118-1125.	1.8	74
971	Successful Living Donor Liver Transplantation Between Septuagenarians. <i>American Journal of Transplantation</i> , 2015, 15, 274-277.	2.6	16
972	Hepatocellular carcinoma surveillance with miRNAs. <i>Lancet Oncology</i> , The, 2015, 16, 743-745.	5.1	31
973	Optimizing the management of patients with BCLC stage-B hepatocellular carcinoma: Modern surgical resection as a feasible alternative to transarterial chemoembolization. <i>European Journal of Surgical Oncology</i> , 2015, 41, 1153-1161.	0.5	63
974	Novel drugs in clinical development for hepatocellular carcinoma. <i>Expert Opinion on Investigational Drugs</i> , 2015, 24, 1075-1082.	1.9	34
975	Surveillance for hepatocellular carcinoma is associated with increased survival: Results from a large cohort in the Netherlands. <i>Journal of Hepatology</i> , 2015, 63, 1156-1163.	1.8	117
976	MEK 1/2 inhibitors in the treatment of hepatocellular carcinoma. <i>Expert Review of Gastroenterology and Hepatology</i> , 2015, 9, 993-1003.	1.4	27
977	An integrated model-based software for FUS in moving abdominal organs. <i>International Journal of Hyperthermia</i> , 2015, 31, 240-250.	1.1	21
978	Treatment of Liver Cancer. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2015, 5, a021535.	2.9	241
979	Genetic Landscape and Biomarkers of Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2015, 149, 1226-1239.e4.	0.6	980
980	Comparison of Transarterial Chemoembolization and Hepatic Resection for Large Solitary Hepatocellular Carcinoma: A Propensity Score Analysis. <i>Journal of Vascular and Interventional Radiology</i> , 2015, 26, 651-659.	0.2	32
981	An orthotopic mouse model of hepatocellular carcinoma with underlying liver cirrhosis. <i>Nature Protocols</i> , 2015, 10, 1264-1274.	5.5	82
982	Tumor Markers for Hepatocellular Carcinoma: Simple and Significant Predictors of Outcome in Patients with HCC. <i>Liver Cancer</i> , 2015, 4, 126-136.	4.2	125
983	Liver cancer: Approaching a personalized care. <i>Journal of Hepatology</i> , 2015, 62, S144-S156.	1.8	239
984	Alterations in hepatic lobar function in regenerating rat liver. <i>Journal of Surgical Research</i> , 2015, 197, 307-317.	0.8	5
985	The Dixon technique and the frequency-selective fat suppression technique in three-dimensional T1-weighted MRI of the liver: a comparison of contrast-to-noise ratios of hepatocellular carcinomas-to-liver. <i>British Journal of Radiology</i> , 2015, 88, 20150117.	1.0	17

#	ARTICLE	IF	CITATIONS
986	Inpatient Treatment Patterns and Health Care Expenditures for Hepatocellular Carcinoma among the Population with Urban Basic Health Insurance in China. <i>Value in Health Regional Issues</i> , 2015, 6, 132-140.	0.5	1
987	Optimal Cut Points for Quality of Life Questionnaire-Core 30 (QLQ-C30) Scales: Utility for Clinical Trials and Updates of Prognostic Systems in Advanced Hepatocellular Carcinoma. <i>Oncologist</i> , 2015, 20, 62-71.	1.9	13
988	Imaging in Hepatocellular Carcinoma: Radiologic Assessment. <i>Advances in Predictive, Preventive and Personalised Medicine</i> , 2015, , 33-44.	0.6	1
989	Transarterial chemoembolization for hepatocellular carcinoma: An old method, now flavor of the day. <i>Diagnostic and Interventional Imaging</i> , 2015, 96, 607-615.	1.8	20
990	The Circulating IGF System in Hepatocellular Carcinoma: The Impact of Liver Status and Treatment. <i>Growth Hormone and IGF Research</i> , 2015, 25, 174-181.	0.5	17
991	Imagiological Diagnosis of Gastrointestinal Diseases – Diagnostic Criteria of Hepatocellular Carcinoma. <i>GE Portuguese Journal of Gastroenterology</i> , 2015, 22, 153-160.	0.3	8
992	Liver resection with thrombectomy as a treatment of hepatocellular carcinoma with major vascular invasion: results from a retrospective multicentric study. <i>American Journal of Surgery</i> , 2015, 210, 35-44.	0.9	40
993	Retrobulbar metastasis and intracranial invasion from postoperative hepatocellular carcinoma: A case report and review of the literature. <i>Oncology Letters</i> , 2015, 9, 721-726.	0.8	7
994	List and Liver Transplant Survival According to Waiting Time in Patients With Hepatocellular Carcinoma. <i>American Journal of Transplantation</i> , 2015, 15, 668-677.	2.6	21
995	Diagnosing Borderline Hepatic Nodules in Hepatocarcinogenesis: Imaging Performance. <i>American Journal of Roentgenology</i> , 2015, 205, 10-21.	1.0	38
996	Radiofrequency ablation versus resection for the treatment of early stage hepatocellular carcinoma: a multicenter Australian study. <i>Scandinavian Journal of Gastroenterology</i> , 2015, 50, 567-576.	0.6	29
998	Surgical resection for hepatocellular carcinoma: Moving from what can be done to what is worth doing. <i>Hepatology</i> , 2015, 62, 340-342.	3.6	22
999	Locoregional Therapy of Hepatocellular Carcinoma. <i>Clinics in Liver Disease</i> , 2015, 19, 401-420.	1.0	28
1000	Hepatocellular carcinoma as a second primary cancer in patients with chronic hepatitis C virus infection. <i>Digestive and Liver Disease</i> , 2015, 47, 348-349.	0.4	4
1001	Incidence of hepatocellular carcinoma after HBsAg seroclearance in chronic hepatitis B patients: A need for surveillance. <i>Journal of Hepatology</i> , 2015, 62, 1092-1099.	1.8	114
1002	Percutaneous ultrasonography-guided radiofrequency ablation of hepatocellular carcinomas: usefulness of image fusion with three-dimensional ultrasonography. <i>Clinical Radiology</i> , 2015, 70, 387-394.	0.5	11
1003	Survival of patients treated with sorafenib for hepatocellular carcinoma recurrence after liver transplantation: A systematic review and meta-analysis. <i>Digestive and Liver Disease</i> , 2015, 47, 324-330.	0.4	43
1004	Quimioembolizaci3n transarterial con part3culas liberadoras de doxorubicina frente a quimioembolizaci3n transarterial convencional en carcinomas hepatocelulares irresecables: un estudio de eficacia, seguridad y gastos. <i>Radiologia</i> , 2015, 57, 496-504.	0.3	23

#	ARTICLE	IF	CITATIONS
1005	Metronomic capecitabine as second-line treatment in hepatocellular carcinoma after sorafenib failure. <i>Digestive and Liver Disease</i> , 2015, 47, 518-522.	0.4	63
1006	Intermediate-stage HCC—upfront resection can be feasible. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 295-295.	12.5	21
1007	Gene Expression in Hepatocellular Carcinoma: Pilot Study of Potential Transarterial Chemoembolization Response Biomarkers. <i>Journal of Vascular and Interventional Radiology</i> , 2015, 26, 723-732.	0.2	19
1008	Recurrent hepatocellular carcinoma: A Western strategy that emphasizes the impact of pathologic profile of the first resection. <i>Surgery</i> , 2015, 157, 454-462.	1.0	64
1010	18F-FDG PET-derived parameters as prognostic indices in hepatic malignancies after 90Y radioembolization: is there a role?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 367-369.	3.3	4
1011	Dynamic enhancement pattern of intrahepatic cholangiocarcinoma on contrast-enhanced ultrasound: the correlation with cirrhosis and tumor size. <i>Abdominal Imaging</i> , 2015, 40, 1558-1566.	2.0	28
1012	Sorafenib use in elderly patients with hepatocellular carcinoma: caution about use of platelet aggregation inhibitors. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 75, 215-219.	1.1	23
1013	Volumetric assessment of tumour response using functional MR imaging in patients with hepatocellular carcinoma treated with a combination of doxorubicin-eluting beads and sorafenib. <i>European Radiology</i> , 2015, 25, 380-390.	2.3	24
1014	Monocarboxylate transporter 4 predicts poor prognosis in hepatocellular carcinoma and is associated with cell proliferation and migration. <i>Journal of Cancer Research and Clinical Oncology</i> , 2015, 141, 1151-1162.	1.2	46
1015	A comparative study between sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis. <i>Journal of Gastroenterology</i> , 2015, 50, 445-454.	2.3	121
1016	Sorafenib treatment in Child—Pugh A and B patients with advanced hepatocellular carcinoma: safety, efficacy and prognostic factors. <i>Investigational New Drugs</i> , 2015, 33, 729-739.	1.2	75
1017	Cryotherapy for cirrhosis-based hepatocellular carcinoma: a single center experience from 1595 treated cases. <i>Frontiers of Medicine</i> , 2015, 9, 63-71.	1.5	12
1018	Liver Transplantation for Hepatocellular Carcinoma. <i>Current Gastroenterology Reports</i> , 2015, 17, 11.	1.1	7
1019	Time to update radiological criteria for non-invasive diagnosis of hepatocellular carcinoma. <i>Hepatology International</i> , 2015, 9, 1-2.	1.9	6
1020	Value of dynamic contrast enhanced MRI in predicting outcomes of HCC receiving radiotherapy. <i>Hepatology International</i> , 2015, 9, 155-156.	1.9	0
1021	Incidental tumor necrosis caused by the interventional alteration of hepatic arterial flow in patients with advanced hepatocellular carcinoma. <i>Clinical Journal of Gastroenterology</i> , 2015, 8, 41-46.	0.4	2
1022	MicroRNA-34a expression is predictive of recurrence after radiofrequency ablation in early hepatocellular carcinoma. <i>Tumor Biology</i> , 2015, 36, 3887-3893.	0.8	16
1023	Alpha-Fetoprotein Measurement Benefits Hepatocellular Carcinoma Surveillance in Patients with Cirrhosis. <i>American Journal of Gastroenterology</i> , 2015, 110, 836-844.	0.2	108

#	ARTICLE	IF	CITATIONS
1024	The endless SEARCH for a better medical treatment of advanced hepatocellular carcinoma. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2015, 39, 535-537.	0.7	0
1025	The role of clinically significant portal hypertension in hepatic resection for hepatocellular carcinoma patients: a propensity score matching analysis. <i>BMC Cancer</i> , 2015, 15, 263.	1.1	25
1026	Prognostic Nutritional Index (PNI) Predicts Tumor Recurrence of Very Early/Early Stage Hepatocellular Carcinoma After Surgical Resection. <i>Annals of Surgical Oncology</i> , 2015, 22, 4138-4148.	0.7	206
1027	DNA-PKâ€”A Candidate Driver of Hepatocarcinogenesis and Tissue Biomarker That Predicts Response to Treatment and Survival. <i>Clinical Cancer Research</i> , 2015, 21, 925-933.	3.2	74
1028	Percutaneous ethanol injection or percutaneous acetic acid injection for early hepatocellular carcinoma. <i>The Cochrane Library</i> , 2019, 2019, CD006745.	1.5	27
1029	Association between portal vein thrombosis and risk of bleeding in liver cirrhosis: A systematic review of the literature. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2015, 39, 683-691.	0.7	34
1030	A genetic linkage map of hexaploid naked oat constructed with SSR markers. <i>Crop Journal</i> , 2015, 3, 353-357.	2.3	10
1031	Cluster Based Outlier Detection Algorithm for Healthcare Data. <i>Procedia Computer Science</i> , 2015, 50, 209-215.	1.2	56
1032	Breather interactions and higher-order nonautonomous rogue waves for the inhomogeneous nonlinear Schrödinger Maxwellâ€”Bloch equations. <i>Annals of Physics</i> , 2015, 359, 97-114.	1.0	113
1033	Similar products different processes: Exploring the orchestration of digital resources in a primary school project. <i>Computers and Education</i> , 2015, 81, 247-258.	5.1	6
1034	Synthesis of metallic Ni-Co/graphene catalysts with enhanced hydrodesulfurization activity via a low-temperature plasma approach. <i>Catalysis Today</i> , 2015, 256, 203-208.	2.2	27
1035	Insights on accelerated skeletal repair in Cushing's disease. <i>Bone Reports</i> , 2015, 2, 32-35.	0.2	8
1036	Cross-country variations in capital structure adjustmentâ€”The role of credit ratings. <i>International Review of Economics and Finance</i> , 2015, 39, 277-294.	2.2	22
1037	2055867 Diagnosis of Gastric Varices by Endoscopic Ultrasonography. <i>Ultrasound in Medicine and Biology</i> , 2015, 41, S106.	0.7	0
1039	Effects of boron supplementation on the severity and duration of pain in primary dysmenorrhea. <i>Complementary Therapies in Clinical Practice</i> , 2015, 21, 79-83.	0.7	10
1040	Surgical success of boomerang-shaped chondroperichondrial graft in pediatric chronic otitis media cases. <i>International Journal of Pediatric Otorhinolaryngology</i> , 2015, 79, 808-811.	0.4	2
1041	An Optimization Model for Carbon Efficiency of a Job-shop Manufacturing System. <i>Procedia CIRP</i> , 2015, 28, 113-118.	1.0	2
1042	Ticagrelor potentiates adenosine-induced stimulation of neutrophil chemotaxis and phagocytosis. <i>Vascular Pharmacology</i> , 2015, 71, 201-207.	1.0	29

#	ARTICLE	IF	CITATIONS
1043	Factors that affect voluntary vaccination of children in Japan. <i>Vaccine</i> , 2015, 33, 1406-1411.	1.7	16
1044	Potential interactions between pericytes and oligodendrocyte precursor cells in perivascular regions of cerebral white matter. <i>Neuroscience Letters</i> , 2015, 597, 164-169.	1.0	87
1045	Lifelong Learning for Improving Customs Education System in Latvia and the World. <i>Procedia, Social and Behavioral Sciences</i> , 2015, 174, 3547-3556.	0.5	0
1046	Long-term impact of childhood-onset type 1 diabetes on social life, quality of life and sexuality. <i>Diabetes and Metabolism</i> , 2015, 41, 489-497.	1.4	18
1047	A pathophysiological approach for FeNO: A biomarker for asthma. <i>Allergologia Et Immunopathologia</i> , 2015, 43, 609-616.	1.0	19
1048	Theoretical study of iron acyl complexes modeling the active site of [Fe]-hydrogenase: Solvation effects play a significant role. <i>Computational and Theoretical Chemistry</i> , 2015, 1064, 45-50.	1.1	0
1049	Numerical study of the effects of Planetary Boundary Layer structure on the pollutant dispersion within built-up areas. <i>Journal of Environmental Sciences</i> , 2015, 32, 168-179.	3.2	19
1050	Slab track: Review of existing systems and optimization potentials including very high speed. <i>Construction and Building Materials</i> , 2015, 92, 9-15.	3.2	129
1051	Neoproterozoic collisional S-type granitoids of the Yenisei Ridge: petrogeochemical composition and Uâ€“Pb, Arâ€“Ar, and Smâ€“Nd isotope data. <i>Russian Geology and Geophysics</i> , 2015, 56, 689-695.	0.3	8
1052	Eficacia del tratamiento para la afasia de Wernicke en pacientes con sintomatologÃa grave. <i>Revista De Logopedia, Foniatria Y Audiologia</i> , 2015, 35, 123-133.	0.4	0
1053	Laboratory Automation and Middleware. <i>Surgical Pathology Clinics</i> , 2015, 8, 175-186.	0.7	8
1056	Plan Restructuring in Multi Agent Planning. <i>Procedia Computer Science</i> , 2015, 46, 396-401.	1.2	2
1057	Enfermedad hemolÃtica perinatal causada por anticuerpos anti-M y tratada con inmunoglobulinas intravenosas fetales. <i>Progresos En Obstetricia Y Ginecologia</i> , 2015, 58, 327-329.	0.0	1
1058	Molecular markers in penile cancer. <i>Current Problems in Cancer</i> , 2015, 39, 137-145.	1.0	8
1059	A novel route for surface zwitterionic functionalization of polyamide nanofiltration membranes with improved performance. <i>Journal of Membrane Science</i> , 2015, 490, 311-320.	4.1	138
1060	Sleep in Traumatic Brain Injury. <i>Critical Care Clinics</i> , 2015, 31, 551-561.	1.0	13
1061	A New Algorithm for the Diagnosis of Hypertension inÃCanada. <i>Canadian Journal of Cardiology</i> , 2015, 31, 620-630.	0.8	88
1062	Treatment of Breast and Prostate Cancer by Hypofractionated Radiotherapy: Potential Risks and Benefits. <i>Clinical Oncology</i> , 2015, 27, 420-426.	0.6	44

#	ARTICLE	IF	CITATIONS
1063	Carboxyl-terminated butadiene-acrylonitrile-modified carbon paper for use of gas diffusion layer in PEM fuel cells. International Journal of Hydrogen Energy, 2015, 40, 14345-14352.	3.8	13
1064	Production of liquid hydrocarbons from pretreated bio-oil via catalytic deoxygenation with syngas. Renewable Energy, 2015, 80, 251-258.	4.3	23
1065	Chronotherapeutic drug delivery of Tamarind gum, Chitosan and Okra gum controlled release colon targeted directly compressed Propranolol HCl matrix tablets and in-vitro evaluation. International Journal of Biological Macromolecules, 2015, 79, 290-299.	3.6	43
1066	Hemorragias digestivas no traumáticas del adulto. EMC - Anestesia-Reanimación, 2015, 41, 1-13.	0.1	0
1067	Modified SCS-CN and Green-Ampt Methods in Surface Runoff Modelling for the Kundahpallam Watershed, Nilgiris, Western Ghats, India. Aquatic Procedia, 2015, 4, 677-684.	0.9	20
1068	Application of mathematical models and genetic algorithm to simulate the response characteristics of an ion selective electrode array for system recalibration. Chemometrics and Intelligent Laboratory Systems, 2015, 144, 24-30.	1.8	9
1069	Cannabinoïdes de synthèse: méthodes analytiques. Toxicologie Analytique Et Clinique, 2015, 27, 184-194.	0.1	3
1070	Hong Kong Consensus Recommendations on the Management of Hepatocellular Carcinoma. Liver Cancer, 2015, 4, 51-69.	4.2	43
1071	An Evaluation of Building Sets Designed for Modular Machine Tool Structures to Support Sustainable Manufacturing. Procedia CIRP, 2015, 26, 612-617.	1.0	12
1072	Assessment of Groundwater Quality using GIS Techniques in Vaniyar Watershed, Ponnaiyar River, Tamil Nadu. Aquatic Procedia, 2015, 4, 1283-1290.	0.9	22
1073	Chlorinated pollutants in blood of White stork nestlings (Ciconia ciconia) in different colonies in Spain. Chemosphere, 2015, 118, 367-372.	4.2	13
1074	Dielectric, mechanical, and microstructural characterization of HA/BST composites. Ceramics International, 2015, 41, S481-S486.	2.3	7
1075	Interferon-free therapy for hepatitis C: The hurdles amid a golden era. Digestive and Liver Disease, 2015, 47, 727-733.	0.4	11
1076	Diagnostic accuracy of 11C-choline PET/CT in comparison with CT and/or MRI in patients with hepatocellular carcinoma. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 1399-1407.	3.3	33
1077	Notch signaling in hepatocellular carcinoma: molecular targeting in an advanced disease. Hepatoma Research, 2015, 1, 11.	0.6	10
1078	Surgical resection versus transarterial chemoembolization for BCLC stage C hepatocellular carcinoma. Journal of Surgical Oncology, 2015, 111, 404-409.	0.8	25
1079	Preclinical Study of Locoregional Therapy of Hepatocellular Carcinoma by Bioelectric Ablation with Microsecond Pulsed Electric Fields (µsPEFs). Scientific Reports, 2015, 5, 9851.	1.6	8
1080	Perfusion computed tomography for detection of hepatocellular carcinoma in patients with liver cirrhosis. European Radiology, 2015, 25, 3123-3132.	2.3	43

#	ARTICLE	IF	CITATIONS
1081	Systematic review of catheter-based intra-arterial therapies in hepatocellular carcinoma: state of the art and future directions. <i>British Journal of Radiology</i> , 2015, 88, 20140564.	1.0	26
1082	Objective Measurement of Arterial Flow Before and After Transcatheter Arterial Chemoembolization: A Feasibility Study Using Quantitative Color-Coding Analysis. <i>CardioVascular and Interventional Radiology</i> , 2015, 38, 1494-1501.	0.9	8
1083	Imaging features of subcentimeter hypointense nodules on gadoxetic acid-enhanced hepatobiliary phase MR imaging that progress to hypervascular hepatocellular carcinoma in patients with chronic liver disease. <i>Acta Radiologica</i> , 2015, 56, 526-535.	0.5	39
1085	Therapeutic Strategies for Hepatocellular Carcinoma: New Advances and Challenges. <i>Current Treatment Options in Gastroenterology</i> , 2015, 13, 219-234.	0.3	17
1086	Infiltrative Hepatocellular Carcinoma: What Radiologists Need to Know. <i>Radiographics</i> , 2015, 35, 371-386.	1.4	105
1087	Clinical observation of liver cancer patients treated with axitinib and cabozantinib after failed sorafenib treatment: a case report and literature review. <i>Cancer Biology and Therapy</i> , 2015, 16, 215-218.	1.5	11
1088	Nonsurgical multidisciplinary approach for recurrent hepatocellular carcinoma after surgical resection. <i>Hepatic Oncology</i> , 2015, 2, 29-38.	4.2	2
1089	Clinical Practice Guidelines for Hepatocellular Carcinoma Differ between Japan, United States, and Europe. <i>Liver Cancer</i> , 2015, 4, 85-95.	4.2	83
1090	Antiviral therapy in the improvement of survival of patients with hepatitis B virus-related hepatocellular carcinoma treated with sorafenib. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 1032-1039.	1.4	22
1091	2014 KLCSG-NCC Korea Practice Guideline for the Management of Hepatocellular Carcinoma. <i>Gut and Liver</i> , 2015, 9, 267-317.	1.4	167
1092	Transarterial chemoembolization: Modalities, indication, and patient selection. <i>Journal of Hepatology</i> , 2015, 62, 1187-1195.	1.8	250
1093	Liver cancer oncogenomics: opportunities and dilemmas for clinical applications. <i>Hepatic Oncology</i> , 2015, 2, 79-93.	4.2	16
1094	Hepatic Resection Improved the Long-Term Survival of Patients with BCLC Stage B Hepatocellular Carcinoma in Asia: a Systematic Review and Meta-Analysis. <i>Journal of Gastrointestinal Surgery</i> , 2015, 19, 1271-1280.	0.9	35
1095	Do primary nasopharyngeal atypical carcinoid tumours really exist?. <i>Pathology</i> , 2015, 47, 175-178.	0.3	0
1096	Radiofrequency Ablation is Better Than Surgical Resection in Patients With Hepatocellular Carcinoma Within the Milan Criteria and Preserved Liver Function. <i>Journal of Clinical Gastroenterology</i> , 2015, 49, 242-249.	1.1	33
1097	Use of immunohistochemistry for SSTR2A to support a diagnosis of phosphaturic mesenchymal tumour. <i>Pathology</i> , 2015, 47, 173-175.	0.3	6
1098	Metastatic colon adenocarcinoma to the placenta. <i>Pathology</i> , 2015, 47, 181-184.	0.3	4
1099	Intraductal tubulopapillary neoplasm of pancreas with associated invasive carcinoma, lymph node, rectal and hepatic metastases. <i>Pathology</i> , 2015, 47, 169-171.	0.3	12

#	ARTICLE	IF	CITATIONS
1100	Time-Resolved Perfusion Imaging at the Angiography Suite. <i>Investigative Radiology</i> , 2015, 50, 108-113.	3.5	5
1101	A concurrent primary hepatic MALT lymphoma and hepatocellular carcinoma. <i>Pathology</i> , 2015, 47, 178-181.	0.3	11
1102	Estimation of Hepatic Extracellular Volume Fraction Using Multiphasic Liver Computed Tomography for Hepatic Fibrosis Grading. <i>Investigative Radiology</i> , 2015, 50, 290-296.	3.5	70
1103	Downregulation of discoidin domain receptor 2 decreases tumor growth of hepatocellular carcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2015, 141, 1973-1983.	1.2	18
1104	Evaluation of the red cell distribution width as a biomarker of early mortality in hepatocellular carcinoma. <i>Digestive and Liver Disease</i> , 2015, 47, 488-494.	0.4	30
1105	Noninvasive diagnosis of hepatocellular carcinoma on gadoteric acid-enhanced MRI: can hypointensity on the hepatobiliary phase be used as an alternative to washout?. <i>European Radiology</i> , 2015, 25, 2859-2868.	2.3	117
1106	Significant biomarkers for the management of hepatocellular carcinoma. <i>Clinical Journal of Gastroenterology</i> , 2015, 8, 109-115.	0.4	18
1107	Liver Imaging Reporting and Data System with MR Imaging: Evaluation in Nodules 20 mm or Smaller Detected in Cirrhosis at Screening US. <i>Radiology</i> , 2015, 275, 698-707.	3.6	115
1108	Proteomic and metabonomic biomarkers for hepatocellular carcinoma: a comprehensive review. <i>British Journal of Cancer</i> , 2015, 112, 1141-1156.	2.9	106
1109	Local ablative procedures of the liver. <i>Zeitschrift Fur Gastroenterologie</i> , 2015, 53, 579-590.	0.2	19
1110	Development of Conventional Transarterial Chemoembolization for Hepatocellular Carcinomas in Japan: Historical, Strategic, and Technical Review. <i>American Journal of Roentgenology</i> , 2015, 205, 764-773.	1.0	27
1111	CEUS in Hepatocellular Carcinoma and Intrahepatic Cholangiocellular Carcinoma in 320 Patients – Early or Late Washout Matters: A Subanalysis of the DEGUM Multicenter Trial. <i>Ultraschall in Der Medizin</i> , 2015, 36, 132-139.	0.8	123
1112	Hepatobiliary tumours. <i>Medicine</i> , 2015, 43, 619-623.	0.2	1
1113	Evaluation of Early-Stage Hepatocellular Carcinoma by Magnetic Resonance Imaging With Gadoteric Acid Detects Additional Lesions and Increases Overall Survival. <i>Gastroenterology</i> , 2015, 148, 1371-1382.	0.6	106
1114	Hepatic stellate cells: central modulators of hepatic carcinogenesis. <i>BMC Gastroenterology</i> , 2015, 15, 63.	0.8	85
1115	A new cluster-based oversampling method for improving survival prediction of hepatocellular carcinoma patients. <i>Journal of Biomedical Informatics</i> , 2015, 58, 49-59.	2.5	154
1116	Surveillance for hepatocellular carcinoma in a mixed-aetiology UK cohort with cirrhosis: does Î±-fetoprotein still have a role?. <i>Clinical Medicine</i> , 2015, 15, 139-144.	0.8	3
1117	Severely Impaired and Dysregulated Cytochrome P450 Expression and Activities in Hepatocellular Carcinoma: Implications for Personalized Treatment in Patients. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 2874-2886.	1.9	74

#	ARTICLE	IF	CITATIONS
1118	Sorafenib With and Without Transarterial Chemoembolization for Advanced Hepatocellular Carcinoma With Main Portal Vein Tumor Thrombosis: A Retrospective Analysis. <i>Oncologist</i> , 2015, 20, 1417-1424.	1.9	68
1119	Comparison of Outcomes of Hepatic Resection and Radiofrequency Ablation for Hepatocellular Carcinoma Patients with Multifocal Tumors Meeting the Barcelona-Clinic Liver Cancer Stage A Classification. <i>Journal of the American College of Surgeons</i> , 2015, 221, 951-961.	0.2	32
1120	Local Recurrence after Radiofrequency Ablation of Hepatocellular Carcinoma: Treatment Choice and Outcome. <i>Journal of Gastrointestinal Surgery</i> , 2015, 19, 1466-1475.	0.9	34
1121	A Patient-Based Nomogram for Predicting Overall Survival after Radiofrequency Ablation for Hepatocellular Carcinoma. <i>Journal of Vascular and Interventional Radiology</i> , 2015, 26, 1787-1794.e1.	0.2	13
1122	Evaluating the role of treatment-related toxicities in the challenges facing targeted therapies for advanced hepatocellular carcinoma. <i>Cancer and Metastasis Reviews</i> , 2015, 34, 497-509.	2.7	18
1123	Incidentally Discovered Hepatocellular Carcinoma in Explanted Liver: Clinical, Histopathologic Features and Outcome. <i>Transplantation Proceedings</i> , 2015, 47, 1051-1054.	0.3	12
1124	Adjuvant Transarterial Chemoembolization Following Liver Resection for Intrahepatic Cholangiocarcinoma Based on Survival Risk Stratification. <i>Oncologist</i> , 2015, 20, 640-647.	1.9	41
1125	Hepatic resection versus transcatheter arterial chemoembolization for the treatment of hepatocellular carcinoma with hepatic vein tumor thrombus. <i>Japanese Journal of Clinical Oncology</i> , 2015, 45, 837-843.	0.6	21
1126	Incidence and risk factors of hepatocellular carcinoma in patients with hepatic venous outflow tract obstruction. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 961-971.	1.9	40
1127	Time to define a new strategy for management of hepatocellular carcinoma in thalassaemia?. <i>British Journal of Haematology</i> , 2015, 168, 304-305.	1.2	10
1128	The Ras/ MAPK pathway and hepatocarcinoma: pathogenesis and therapeutic implications. <i>European Journal of Clinical Investigation</i> , 2015, 45, 609-623.	1.7	193
1129	Signal intensity of small hepatocellular carcinoma on apparent diffusion coefficient mapping and outcome after radiofrequency ablation. <i>Hepatology Research</i> , 2015, 45, 75-87.	1.8	12
1130	Stereotactic body radiotherapy for patients with small hepatocellular carcinoma ineligible for resection or ablation therapies. <i>Hepatology Research</i> , 2015, 45, 378-386.	1.8	68
1131	Tumor markers are more useful in patients undergoing surveillance for hepatocellular carcinoma with unreliable results by ultrasonography. <i>Hepatology Research</i> , 2015, 45, 415-422.	1.8	7
1132	Influence of liver toxicities on prognosis after stereotactic body radiation therapy for hepatocellular carcinoma. <i>Hepatology Research</i> , 2015, 45, 540-547.	1.8	42
1133	Systematic review comparing the safety and efficacy of conventional and drug-eluting bead transarterial chemoembolization for inoperable hepatocellular carcinoma. <i>Hepatology Research</i> , 2015, 45, 190-200.	1.8	73
1134	Hepatocellular carcinoma risk in HBsAg-negative chronic hepatitis B patients with or without cirrhosis treated with entecavir: HepNet.Greece cohort. <i>Journal of Viral Hepatitis</i> , 2015, 22, 120-127.	1.0	38
1135	Hepatobiliary malignancies in Wilson disease. <i>Liver International</i> , 2015, 35, 1615-1622.	1.9	78

#	ARTICLE	IF	CITATIONS
1136	Prognostic role of magnetic resonance imaging vs. computed tomography for hepatocellular carcinoma undergoing chemoembolization. <i>Liver International</i> , 2015, 35, 1722-1730.	1.9	22
1137	Nomograms for Predicting Outcomes after Chemoembolization in Patients with Nonmetastatic Hepatocellular Carcinoma. <i>Journal of Vascular and Interventional Radiology</i> , 2015, 26, 1093-1101.e1.	0.2	4
1138	Immunological landscape and immunotherapy of hepatocellular carcinoma. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2015, 12, 681-700.	8.2	478
1139	The role of hepatic resection in the treatment of hepatocellular cancer. <i>Hepatology</i> , 2015, 62, 440-451.	3.6	310
1140	Predictors of intrahepatic cholangiocarcinoma in cirrhotic patients scanned by gadobenate dimeglumine-enhanced magnetic resonance imaging: diagnostic accuracy and confidence. <i>Clinical Imaging</i> , 2015, 39, 1032-1038.	0.8	7
1141	Assessment and monitoring of liver function by ¹³ C-aminopyrine breath test after selective transarterial chemoembolisation of hepatocellular carcinoma. <i>Zeitschrift Fur Gastroenterologie</i> , 2015, 53, 21-27.	0.2	2
1142	Plasma osteopontin is a biomarker for the severity of alcoholic liver cirrhosis, not for hepatocellular carcinoma screening. <i>BMC Gastroenterology</i> , 2015, 15, 73.	0.8	21
1143	The Genetics of Nonalcoholic Fatty Liver Disease: Spotlight on PNPLA3 and TM6SF2. <i>Seminars in Liver Disease</i> , 2015, 35, 270-290.	1.8	135
1144	PET/Computed Tomography in Evaluation of Transarterial Chemoembolization. <i>PET Clinics</i> , 2015, 10, 507-517.	1.5	6
1145	Refining sorafenib therapy: lessons from clinical practice. <i>Future Oncology</i> , 2015, 11, 449-465.	1.1	17
1146	The Degree of Contrast Washout on Contrast-Enhanced Ultrasound in Distinguishing Intrahepatic Cholangiocarcinoma from Hepatocellular Carcinoma. <i>Ultrasound in Medicine and Biology</i> , 2015, 41, 3088-3095.	0.7	42
1148	Recurrence of hepatocellular carcinoma after liver transplantation: an update. <i>Future Oncology</i> , 2015, 11, 2923-2936.	1.1	40
1149	Radiofrequency ablation versus surgical resection for hepatocellular carcinoma within the Milan criteria: A study of 281 Western patients. <i>International Journal of Hyperthermia</i> , 2015, 31, 749-757.	1.1	42
1150	Impact of Hepatitis C Virus Infection on Hepatocellular Carcinoma. <i>Gastroenterology Clinics of North America</i> , 2015, 44, 761-773.	1.0	14
1151	Current issues on genomic heterogeneity in hepatocellular carcinoma and its implication in clinical practice. <i>Hepatic Oncology</i> , 2015, 2, 291-302.	4.2	6
1152	Quality of Cancer Care in Patients with Cirrhosis and Hepatocellular Carcinoma. <i>Current Gastroenterology Reports</i> , 2015, 17, 34.	1.1	7
1153	Imaging in Patients with Cirrhosis. <i>Radiologic Clinics of North America</i> , 2015, 53, 919-931.	0.9	4
1154	Assessing Imaging Response to Therapy. <i>Radiologic Clinics of North America</i> , 2015, 53, 1077-1088.	0.9	17

#	ARTICLE	IF	CITATIONS
1155	Scientific and industrial challenges of developing nanoparticle-based theranostics and multiple-modality contrast agents for clinical application. <i>Nanoscale</i> , 2015, 7, 16146-16150.	2.8	24
1156	Recent Advances in Tumor Ablation for Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2015, 4, 176-187.	4.2	97
1157	Abdominal Solid Organ Transplantation. , 2015, , .		1
1159	Quantification and comparison of visibility and image artifacts of a new liquid fiducial marker in a lung phantom for image-guided radiation therapy. <i>Medical Physics</i> , 2015, 42, 2818-2826.	1.6	28
1160	Hepatocellular Carcinoma: A Phase II Randomized Controlled Double-Blind Trial of Transarterial Chemoembolization in Combination with Biweekly Intravenous Administration of Bevacizumab or a Placebo. <i>Radiology</i> , 2015, 277, 903-912.	3.6	60
1161	Transarterial chemoembolization and sorafenib in patients with intermediate-stage hepatocellular carcinoma: time to enter routine clinical practice?. <i>Future Oncology</i> , 2015, 11, 2371-2373.	1.1	11
1162	Imaging the liver and biliary tract. <i>Medicine</i> , 2015, 43, 562-567.	0.2	0
1164	Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. <i>Lancet Oncology</i> , The, 2015, 16, 1344-1354.	5.1	809
1165	Irreversible Electroporation in the Treatment of Hepatocellular Carcinoma. <i>Techniques in Vascular and Interventional Radiology</i> , 2015, 18, 135-139.	0.4	17
1166	Novel X-Ray Imaging Technology Allows Substantial Patient Radiation Reduction without Image Quality Impairment in Repetitive Transarterial Chemoembolization for Hepatocellular Carcinoma. <i>Academic Radiology</i> , 2015, 22, 1361-1367.	1.3	8
1167	Survival in relation to hospital type after resection or sorafenib treatment for hepatocellular carcinoma in The Netherlands. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2015, 39, 725-735.	0.7	6
1168	Visceral fat area predicts survival in patients with advanced hepatocellular carcinoma treated with tyrosine kinase inhibitors. <i>Digestive and Liver Disease</i> , 2015, 47, 869-876.	0.4	46
1169	Reply to: "Poor contrast enhanced ultrasonography! There is no limit to its decline in the diagnosis of hepatocellular carcinoma on cirrhosis!" <i>Journal of Hepatology</i> , 2015, 62, 1453-1454.	1.8	0
1170	Prospective Longitudinal Assessment of Quality of Life for Liver Cancer Patients Treated With Stereotactic Body Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 93, 16-25.	0.4	63
1171	Clinical and Imaging Follow-up Practices after Transarterial Therapy for Primary and Secondary Hepatic Malignancies. <i>Academic Radiology</i> , 2015, 22, 1510-1515.	1.3	11
1172	Biomarkers for the early diagnosis of bacterial infection and the surveillance of hepatocellular carcinoma in cirrhosis. <i>Biomarkers in Medicine</i> , 2015, 9, 1343-1351.	0.6	18
1173	Efficacy of Transcatheter Arterial Chemoembolization Followed by Sorafenib for Intermediate/Advanced Hepatocellular Carcinoma in Patients in Japan: A Retrospective Analysis. <i>Clinical Drug Investigation</i> , 2015, 35, 751-759.	1.1	26
1174	Classification and prediction of HCC tissues by Raman imaging with identification of fatty acids as potential lipid biomarkers. <i>Journal of Cancer Research and Clinical Oncology</i> , 2015, 141, 407-418.	1.2	23

#	ARTICLE	IF	CITATIONS
1175	Heterogeneity of intermediate-stage HCC necessitates personalized management including surgery. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 10-10.	12.5	20
1176	Multicenter randomized controlled trial of percutaneous cryoablation versus radiofrequency ablation in hepatocellular carcinoma. <i>Hepatology</i> , 2015, 61, 1579-1590.	3.6	205
1177	Managing complications in cirrhotic patients. <i>United European Gastroenterology Journal</i> , 2015, 3, 80-94.	1.6	9
1178	Lack of arterial hypervascularity at contrast-enhanced ultrasound should not define the priority for diagnostic work-up of nodules <2cm. <i>Journal of Hepatology</i> , 2015, 62, 150-155.	1.8	46
1179	Sorafenib therapy for hepatocellular carcinoma with extrahepatic spread: Treatment outcome and prognostic factors. <i>Journal of Hepatology</i> , 2015, 62, 1112-1121.	1.8	50
1180	Journal watch—a new laboratory-based algorithm to predict development of hepatocellular carcinoma in patients with hepatitis C and cirrhosis. <i>Frontline Gastroenterology</i> , 2015, 6, 154-155.	0.9	0
1181	Role of diffusion-weighted imaging, apparent diffusion coefficient and correlation with hepatobiliary phase findings in the differentiation of hepatocellular carcinoma from dysplastic nodules in cirrhotic liver. <i>European Radiology</i> , 2015, 25, 1087-1096.	2.3	39
1182	Malnutrition is a prognostic factor in patients with hepatocellular carcinoma (HCC). <i>Clinical Nutrition</i> , 2015, 34, 1122-1127.	2.3	98
1183	Clinical and economic impact of drug eluting beads in transarterial chemoembolization for hepatocellular carcinoma. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2015, 40, 83-90.	0.7	13
1184	Concordance of hypervascular liver nodule characterization between the organ procurement and transplant network and liver imaging reporting and data system classifications. <i>Journal of Magnetic Resonance Imaging</i> , 2015, 42, 305-314.	1.9	42
1185	5-Fluorouracil combined with apigenin enhances anticancer activity through mitochondrial membrane potential (ΔΨ _m)-mediated apoptosis in hepatocellular carcinoma. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2015, 42, 146-153.	0.9	56
1186	Portal hypertension and the outcome of surgery for hepatocellular carcinoma in compensated cirrhosis: A systematic review and meta-analysis. <i>Hepatology</i> , 2015, 61, 526-536.	3.6	286
1187	Biological markers of hepatocellular carcinoma for use as selection criteria in liver transplantation. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2015, 22, 279-286.	1.4	21
1188	Evaluation and Management of Hepatocellular Carcinoma. <i>Clinics in Liver Disease</i> , 2015, 19, 23-43.	1.0	49
1189	Reports from the International Liver Cancer Association (ILCA) congress 2014. <i>Journal of Hepatology</i> , 2015, 62, 477-482.	1.8	7
1190	Heterogeneity of intermediate-stage HCC necessitates personalized management including surgery. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 10-10.	12.5	33
1191	Improved Surveillance for Hepatocellular Carcinoma With a Primary Care-Oriented Clinical Reminder. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 172-179.	2.4	92
1192	Yttrium-90 radioembolization vs sorafenib for intermediate-locally advanced hepatocellular carcinoma: a cohort study with propensity score analysis. <i>Liver International</i> , 2015, 35, 1036-1047.	1.9	94

#	ARTICLE	IF	CITATIONS
1193	Psychopathological profile and health-related quality of life (HRQOL) in patients with hepatocellular carcinoma (HCC) and cirrhosis. <i>Clinical and Experimental Medicine</i> , 2015, 15, 65-72.	1.9	27
1194	Suboptimal Surveillance for and Knowledge of Hepatocellular Carcinoma Among Primary Care Providers. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 799-804.	2.4	47
1195	Influence of hepatitis B virus reactivation on the recurrence of <scp>HBV</scp>-related hepatocellular carcinoma after curative resection in patients with low viral load. <i>Journal of Viral Hepatitis</i> , 2015, 22, 539-550.	1.0	18
1196	Serum soluble urokinase plasminogen activator receptor as a screening test for the early diagnosis of hepatocellular carcinoma. <i>Liver International</i> , 2015, 35, 601-607.	1.9	35
1197	Survival Benefit of Liver Transplantation Versus Resection for Hepatocellular Carcinoma: Impact of MELD Score. <i>Annals of Surgical Oncology</i> , 2015, 22, 1901-1907.	0.7	43
1198	Impact of multiple transarterial chemoembolization treatments on hepatocellular carcinoma for patients awaiting liver transplantation. <i>Liver Transplantation</i> , 2015, 21, 248-257.	1.3	25
1199	Transarterial Chemoembolization for Primary Liver Malignancies and Colorectal Liver Metastasis. <i>Surgical Oncology Clinics of North America</i> , 2015, 24, 149-166.	0.6	15
1200	Drug-Eluting Beads Loaded With Doxorubicin (DEBDOX) Chemoembolisation Before Liver Transplantation for Hepatocellular Carcinoma: An Imaging/Histologic Correlation Study. <i>CardioVascular and Interventional Radiology</i> , 2015, 38, 685-692.	0.9	10
1201	A genomic and clinical prognostic index for hepatitis C-related early-stage cirrhosis that predicts clinical deterioration. <i>Gut</i> , 2015, 64, 1296-1302.	6.1	70
1202	Liver resection for patients with hepatocellular carcinoma and macrovascular invasion, multiple tumours, or portal hypertension: Table A1. <i>Gut</i> , 2015, 64, 520.2-521.	6.1	48
1203	Hepatobiliary MR contrast agents in hypovascular hepatocellular carcinoma. <i>Journal of Magnetic Resonance Imaging</i> , 2015, 41, 251-265.	1.9	46
1204	Multiparametric Gd-EOB-DTPA magnetic resonance in diagnosis of HCC: dynamic study, hepatobiliary phase, and diffusion-weighted imaging compared to histology after orthotopic liver transplantation. <i>Abdominal Imaging</i> , 2015, 40, 46-55.	2.0	23
1205	The C-Reactive Protein/Albumin Ratio, a Novel Inflammation-Based Prognostic Score, Predicts Outcomes in Patients with Hepatocellular Carcinoma. <i>Annals of Surgical Oncology</i> , 2015, 22, 803-810.	0.7	343
1206	Transarterial Chemoembolization for Hepatocellular Carcinoma with a New Generation of Beads: Clinical Radiological Outcomes and Safety Profile. <i>CardioVascular and Interventional Radiology</i> , 2015, 38, 129-134.	0.9	59
1207	Percutaneous transcatheter embolisation of active haemorrhage following radiofrequency ablation of hepatocellular carcinoma. <i>BMJ Case Reports</i> , 2016, 2016, bcr2016215466.	0.2	1
1208	Mixed Hepatocellular Carcinoma, Neuroendocrine Carcinoma of the Liver. <i>American Surgeon</i> , 2016, 82, 1121-1125.	0.4	24
1209	Advanced imaging techniques in the therapeutic response of transarterial chemoembolization for hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2016, 22, 4835.	1.4	26
1210	Immunohistochemical analysis of metastasising hepatocellular carcinomas in dogs. <i>Veterinari Medicina</i> , 2016, 61, 546-552.	0.2	1

#	ARTICLE	IF	CITATIONS
1211	Review of imaging techniques in the diagnosis of hepatocellular carcinoma in patients who require a liver transplant. <i>European Journal of Gastroenterology and Hepatology</i> , 2016, 28, 412-420.	0.8	7
1212	A Decade-old Change in the Screening Rate for Hepatocellular Carcinoma Among a Hepatitis B Virus-infected Population in Korea. <i>Chinese Medical Journal</i> , 2016, 129, 15-21.	0.9	7
1213	Improving Outcome in Gastrointestinal and Hepatopancreaticobiliary Surgical Oncology by Preoperative Risk Assessment and Optimization of Perioperative Care. , 2016, , .		1
1214	Current status and perspectives of immune-based therapies for hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2016, 22, 253.	1.4	34
1215	Immunohistochemical markers of CYP3A4 and CYP3A7: a new tool towards personalized pharmacotherapy of hepatocellular carcinoma. <i>European Journal of Histochemistry</i> , 2016, 60, 2614.	0.6	15
1216	Portal vein tumor thrombus is a bottleneck in the treatment of hepatocellular carcinoma. <i>Cancer Biology and Medicine</i> , 2016, 13, 452.	1.4	35
1217	Evolving Role of Radiopharmaceuticals in Hepatocellular Carcinoma Treatment. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2016, 16, 1155-1165.	0.9	11
1218	A concise review of updated guidelines regarding the management of hepatocellular carcinoma around the world: 2010-2016. <i>Clinical and Molecular Hepatology</i> , 2016, 22, 7-17.	4.5	232
1219	New advances in hepatocellular carcinoma. <i>World Journal of Hepatology</i> , 2016, 8, 421.	0.8	115
1220	Trends in Health Care Utilization and Costs Attributable to Hepatocellular Carcinoma, 2002â€“2009: A Population-Based Cohort Study. <i>Current Oncology</i> , 2016, 23, 196-220.	0.9	9
1221	Computed tomography texture analysis to facilitate therapeutic decision making in hepatocellular carcinoma. <i>Oncotarget</i> , 2016, 7, 13248-13259.	0.8	35
1222	Advanced Stage Hepatocellular Carcinoma with Multiple Metastasis and Vascular Thrombosis: A Case of Complete Response to Sorafenib. <i>Acta Medica Portuguesa</i> , 2016, 29, 139.	0.2	5
1223	Survival outcomes of hepatic resection compared with transarterial chemoembolization or sorafenib for hepatocellular carcinoma with portal vein tumor thrombosis. <i>Clinical and Molecular Hepatology</i> , 2016, 22, 160-167.	4.5	86
1224	Laparoscopic versus open liver resection for hepatocellular carcinoma: initial experience in Greece. <i>Annals of Gastroenterology</i> , 2016, 29, 521-529.	0.4	10
1225	Role of regorafenib as second-line therapy and landscape of investigational treatment options in advanced hepatocellular carcinoma. <i>Journal of Hepatocellular Carcinoma</i> , 2016, Volume 3, 31-36.	1.8	32
1227	Postoperative hepatitis B virus reactivation in hepatitis B virus-related hepatocellular carcinoma patients with hepatitis B virus DNA levels <500 copies/mL. <i>OncoTargets and Therapy</i> , 2016, Volume 9, 4593-4603.	1.0	10
1228	Focal liver lesions found incidentally. <i>World Journal of Hepatology</i> , 2016, 8, 446.	0.8	13
1229	Development and novel therapeutics in hepatocellular carcinoma: a review. <i>Therapeutics and Clinical Risk Management</i> , 2016, 12, 445.	0.9	32

#	ARTICLE	IF	CITATIONS
1230	Noninvasive Diagnosis of Hepatocellular Carcinoma: Elaboration on Korean Liver Cancer Study Group-National Cancer Center Korea Practice Guidelines Compared with Other Guidelines and Remaining Issues. Korean Journal of Radiology, 2016, 17, 7.	1.5	48
1231	A Focal Liver Lesion in a Patient with Chronic Hepatitis B and Cirrhosis not always Hepatocellular Carcinoma. , 2016, 06, .		0
1232	Clinical Utility of Liver Stiffness Measurements on Magnetic Resonance Elastography in Patients with Hepatocellular Carcinoma Treated with Radiofrequency Ablation. Investigative Magnetic Resonance Imaging, 2016, 20, 231.	0.2	1
1233	Mean platelet volume and mean platelet volume/platelet count ratio as markers for hepatocellular carcinoma in patients with chronic hepatitis C virus related cirrhosis. Journal of Cancer Research and Experimental Oncology, 2016, 8, 33-40.	0.1	2
1234	Local ablative treatments for hepatocellular carcinoma: An updated review. World Journal of Gastrointestinal Pharmacology and Therapeutics, 2016, 7, 477.	0.6	100
1235	Transarterial chemoembolization with drug-eluting beads in hepatocellular carcinoma. World Journal of Gastroenterology, 2016, 22, 8853.	1.4	31
1236	Management of hepatocellular carcinoma: an overview of major findings from meta-analyses. Oncotarget, 2016, 7, 34703-34751.	0.8	56
1237	Effect of oral antiviral treatment on long-term outcomes of radiofrequency ablation therapy for hepatitis B virus-related hepatocellular carcinoma. Oncotarget, 2016, 7, 47794-47807.	0.8	24
1238	Improved survival of patients with hepatocellular carcinoma and disparities by age, race, and socioeconomic status by decade, 1983-2012. Oncotarget, 2016, 7, 59820-59833.	0.8	43
1239	Prediction of hepatocellular carcinoma biological behavior in patient selection for liver transplantation. World Journal of Gastroenterology, 2016, 22, 232.	1.4	35
1240	Liver transplantation for small hepatocellular carcinoma. Hepatobiliary Surgery and Nutrition, 2016, 5, 391-398.	0.7	8
1241	Acute myeloid leukemia masquerading as hepatocellular carcinoma. Journal of Gastrointestinal Oncology, 2016, 7, E31-E35.	0.6	6
1242	A genetic database can be utilized to identify potential biomarkers for biphenotypic hepatocellular carcinoma-cholangiocarcinoma. Journal of Gastrointestinal Oncology, 2016, 7, 570-579.	0.6	7
1243	Bridging and downstaging therapy in patients suffering from hepatocellular carcinoma waiting on the list of liver transplantation. Translational Gastroenterology and Hepatology, 2016, 1, 34-34.	1.5	20
1244	Circulating predictive and diagnostic biomarkers for hepatitis B virus-associated hepatocellular carcinoma. World Journal of Gastroenterology, 2016, 22, 8271.	1.4	33
1245	Usefulness of staging systems and prognostic scores for hepatocellular carcinoma treatments. World Journal of Hepatology, 2016, 8, 703.	0.8	27
1246	Prognostic nomogram for post-surgical treatment with adjuvant TACE in hepatitis B virus-related hepatocellular carcinoma. Oncotarget, 2016, 7, 58302-58314.	0.8	11
1247	Elevated Serum Levels of the Antiapoptotic Protein Decoy-Receptor 3 Are Associated with Advanced Liver Disease. Canadian Journal of Gastroenterology and Hepatology, 2016, 2016, 1-8.	0.8	6

#	ARTICLE	IF	CITATIONS
1248	A Comparison between Three-Dimensional Visualization Guided Hepatectomy and Ultrasonography Guided Radiofrequency Ablation in the Treatment of Small Hepatocellular Carcinoma within the Milan Criteria. <i>BioMed Research International</i> , 2016, 2016, 1-10.	0.9	4
1249	Therapeutic Strategies in HCC: Radiation Modalities. <i>BioMed Research International</i> , 2016, 2016, 1-11.	0.9	21
1250	Treatment of Huge Hepatocellular Carcinoma Using Cinobufacini Injection in Transarterial Chemoembolization: A Retrospective Study. <i>Evidence-based Complementary and Alternative Medicine</i> , 2016, 2016, 1-6.	0.5	17
1251	Feasibility and Efficacy of S-Adenosyl-L-methionine in Patients with HBV-Related HCC with Different BCLC Stages. <i>Gastroenterology Research and Practice</i> , 2016, 2016, 1-9.	0.7	5
1252	Multi-OMICs and Genome Editing Perspectives on Liver Cancer Signaling Networks. <i>BioMed Research International</i> , 2016, 2016, 1-14.	0.9	7
1253	Quality of Life in Hepatocellular Carcinoma Patients Treated with Transarterial Chemoembolization. <i>HPB Surgery</i> , 2016, 2016, 1-9.	2.2	31
1254	Current Treatment Approaches to HCC with a Special Consideration to Transplantation. <i>Journal of Transplantation</i> , 2016, 2016, 1-9.	0.3	15
1255	Clinical Presentation, Risk Factors, and Treatment Modalities of Hepatocellular Carcinoma: A Single Tertiary Care Center Experience. <i>Gastroenterology Research and Practice</i> , 2016, 2016, 1-9.	0.7	22
1256	Ligand-based targeted therapy: a novel strategy for hepatocellular carcinoma. <i>International Journal of Nanomedicine</i> , 2016, Volume 11, 5645-5669.	3.3	108
1257	Yttrium-90 Selective Internal Radiation Therapy with Glass Microspheres for Hepatocellular Carcinoma: Current and Updated Literature Review. <i>Korean Journal of Radiology</i> , 2016, 17, 472.	1.5	32
1258	Controversies regarding and perspectives on clinical utility of biomarkers in hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2016, 22, 262.	1.4	96
1259	Radiofrequency ablation versus resection for Barcelona clinic liver cancer very early/early stage hepatocellular carcinoma: a systematic review. <i>Therapeutics and Clinical Risk Management</i> , 2016, 12, 295.	0.9	15
1260	Nonalcoholic steatohepatitis and hepatocellular carcinoma: Brazilian survey. <i>Clinics</i> , 2016, 71, 281-284.	0.6	24
1261	Hepatocellular Carcinoma in Pakistan: National Trends and Global Perspective. <i>Gastroenterology Research and Practice</i> , 2016, 2016, 1-10.	0.7	26
1262	Hepatocellular carcinoma in elderly patients: challenges and solutions. <i>Journal of Hepatocellular Carcinoma</i> , 2016, 3, 9.	1.8	36
1263	Transcatheter arterial chemoembolisation (TACE) plus S-1 for the treatment of BCLC stage B hepatocellular carcinoma refractory to TACE. <i>Wspolczesna Onkologia</i> , 2016, 6, 468-474.	0.7	5
1264	Hepatocellular carcinoma: a review. <i>Journal of Hepatocellular Carcinoma</i> , 2016, Volume 3, 41-53.	1.8	842
1265	Differentiation of hepatocellular carcinoma from its various mimickers in liver magnetic resonance imaging: What are the tips when using hepatocyte-specific agents?. <i>World Journal of Gastroenterology</i> , 2016, 22, 284.	1.4	28

#	ARTICLE	IF	CITATIONS
1266	Computed Tomography and Ultrasounds for the Follow-up of Hepatocellular Carcinoma Ablation: What You Need to Know. <i>Diagnostics</i> , 2016, 6, 9.	1.3	4
1267	Surveillance for Hepatocellular Carcinoma in Patients with NASH. <i>Diagnostics</i> , 2016, 6, 22.	1.3	30
1268	Association between Pre-Transplant Serum Malondialdehyde Levels and Survival One Year after Liver Transplantation for Hepatocellular Carcinoma. <i>International Journal of Molecular Sciences</i> , 2016, 17, 500.	1.8	23
1269	Prognostic Value of Serum Caspase-Cleaved Cytokeratin-18 Levels before Liver Transplantation for One-Year Survival of Patients with Hepatocellular Carcinoma. <i>International Journal of Molecular Sciences</i> , 2016, 17, 1524.	1.8	16
1270	HBx-induced MiR-1269b in NF- κ B dependent manner upregulates cell division cycle 40 homolog (CDC40) to promote proliferation and migration in hepatoma cells. <i>Journal of Translational Medicine</i> , 2016, 14, 189.	1.8	30
1271	Extremely elevated alpha-fetoprotein due to acute exacerbation of chronic hepatitis B without malignancy: a case report. <i>Journal of Medical Case Reports</i> , 2016, 10, 140.	0.4	5
1272	The current management of cholangiocarcinoma: A comparison of current guidelines. <i>BioScience Trends</i> , 2016, 10, 92-102.	1.1	61
1273	Added Value of a Gadoteric Acid-enhanced Hepatocyte-phase Image to the LI-RADS System for Diagnosing Hepatocellular Carcinoma. <i>Magnetic Resonance in Medical Sciences</i> , 2016, 15, 49-59.	1.1	55
1274	Heterogeneity and Subclassification of Barcelona Clinic Liver Cancer Stage B. <i>Liver Cancer</i> , 2016, 5, 91-96.	4.2	32
1275	Midkine Increases Diagnostic Yield in AFP Negative and NASH-Related Hepatocellular Carcinoma. <i>PLoS ONE</i> , 2016, 11, e0155800.	1.1	54
1276	Serological Tests Do Not Predict Residual Fibrosis in Hepatitis C Cirrhotics with a Sustained Virological Response to Interferon. <i>PLoS ONE</i> , 2016, 11, e0155967.	1.1	23
1277	Predictors of Increased Risk of Hepatocellular Carcinoma in Patients with Type 2 Diabetes. <i>PLoS ONE</i> , 2016, 11, e0158066.	1.1	12
1278	TLR4 Deficiency Protects against Hepatic Fibrosis and Diethylnitrosamine-Induced Pre-Carcinogenic Liver Injury in Fibrotic Liver. <i>PLoS ONE</i> , 2016, 11, e0158819.	1.1	28
1279	Estimating the Impact of Expanding Treatment Coverage and Allocation Strategies for Chronic Hepatitis C in a Direct Antiviral Agent Era. <i>PLoS ONE</i> , 2016, 11, e0163095.	1.1	10
1280	The choice of treatment and efficacy for the advanced hepatocellular carcinoma with inferior vena cava tumor thrombus (IVC-TT): a retrospective study. <i>Acta Hepatologica Japonica</i> , 2016, 57, 205-212.	0.0	0
1281	Circulating microRNAs as Potential Biomarkers in Non-Alcoholic Fatty Liver Disease and Hepatocellular Carcinoma. <i>Journal of Clinical Medicine</i> , 2016, 5, 30.	1.0	77
1282	The Therapeutic Efficacy and Safety of Compound Kushen Injection Combined with Transarterial Chemoembolization in Unresectable Hepatocellular Carcinoma: An Update Systematic Review and Meta-Analysis. <i>Frontiers in Pharmacology</i> , 2016, 7, 70.	1.6	58
1283	Application of radiotherapy for hepatocellular carcinoma in current clinical practice guidelines. <i>Radiation Oncology Journal</i> , 2016, 34, 160-167.	0.7	60

#	ARTICLE	IF	CITATIONS
1284	The Evolution of the Use of Serum Alpha-fetoprotein in Clinical Liver Cancer Surveillance. <i>Journal of Immunobiology</i> , 2016, 01, .	0.3	5
1285	The Changes of HIF-1 α and VEGF Expression After TACE in Patients With Hepatocellular Carcinoma. <i>Journal of Clinical Medicine Research</i> , 2016, 8, 297-302.	0.6	96
1286	Treatment allocation in hepatocellular carcinoma: Assessment of the BCLC algorithm. <i>Annals of Hepatology</i> , 2016, 15, 82-90.	0.6	35
1287	Preoperative Ratio of Neutrophils to Lymphocytes Predicts Postresection Survival in Selected Patients With Early or Intermediate Stage Hepatocellular Carcinoma. <i>Medicine (United States)</i> , 2016, 95, e2722.	0.4	38
1288	Multimodality Treatment for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus. <i>Medicine (United States)</i> , 2016, 95, e3015.	0.4	94
1289	Comparison of survival, safety, and efficacy after transarterial chemoembolization and radioembolization of Barcelona Clinic Liver Cancer stage B-C hepatocellular cancer patients. <i>Nuclear Medicine Communications</i> , 2016, 37, 646-649.	0.5	26
1290	Intraobserver and Interobserver Agreement in the Evaluation of Tumor Vascularization With Computed Tomography Perfusion in Cirrhotic Patients With Hepatocellular Carcinoma. <i>Journal of Computer Assisted Tomography</i> , 2016, 40, 152-159.	0.5	8
1291	The MoRAL Path Beyond Milan. <i>Annals of Surgery</i> , 2016, 263, 851-852.	2.1	3
1292	Nomogram of the Barcelona Clinic Liver Cancer System: external validation in European patients. <i>Liver International</i> , 2016, 36, 1716-1717.	1.9	6
1293	Reply. <i>Hepatology</i> , 2016, 63, 671-672.	3.6	0
1294	Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: A multicenter prospective study. <i>Hepatology</i> , 2016, 63, 827-838.	3.6	467
1295	Concurrent sorafenib therapy extends the interval to subsequent TACE for patients with unresectable hepatocellular carcinoma. <i>Journal of Surgical Oncology</i> , 2016, 113, 672-677.	0.8	19
1296	Postâ€‘progression survival and progressionâ€‘free survival in patients with advanced hepatocellular carcinoma treated by sorafenib. <i>Hepatology Research</i> , 2016, 46, 650-656.	1.8	66
1297	The increasing burden of potentially preventable liver disease among adult liver transplant recipients: A comparative analysis of liver transplant indication by era in Australia and New Zealand. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 434-441.	1.4	14
1298	Association between nucleos(t)ide analog and tumor recurrence in hepatitis B virusâ€‘related hepatocellular carcinoma after radiofrequency ablation. <i>Hepatology</i> , 2016, 63, 1517-1527.	3.6	66
1299	Outcomes Between Elderly and Young Hepatocellular Carcinoma Living Donor Liver Transplantation Recipients. <i>Medicine (United States)</i> , 2016, 95, e2499.	0.4	4
1300	BCLC stage B is a better designation for single large hepatocellular carcinoma than BCLC stage A. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 467-474.	1.4	47
1301	Reply to â€‘prognostic model for patients receiving arterialâ€‘embolization for hepatocellular carcinoma: issues to considerâ€‘™. <i>Liver International</i> , 2016, 36, 312-312.	1.9	0

#	ARTICLE	IF	CITATIONS
1302	Refining prognosis after transarterial chemoembolization for hepatocellular carcinoma. <i>Liver International</i> , 2016, 36, 729-736.	1.9	62
1303	Liver transplantation for hepatocellular carcinoma: evaluation of the alpha-fetoprotein model in a multicenter cohort from Latin America. <i>Liver International</i> , 2016, 36, 1657-1667.	1.9	71
1304	Proposed New Sub-Grouping for Intermediate-Stage Hepatocellular Carcinoma Using Albumin-Bilirubin Grade. <i>Oncology</i> , 2016, 91, 153-161.	0.9	36
1305	Stereotactic body radiation therapy for small primary or recurrent hepatocellular carcinoma in 132 Chinese patients. <i>Journal of Surgical Oncology</i> , 2016, 113, 181-187.	0.8	76
1306	Hepatocellular carcinoma: asphyxiate and then cook. <i>Hepatic Oncology</i> , 2016, 3, 1-3.	4.2	0
1307	Clinical outcomes after spontaneous and nucleos(t)ide analogue-treated HBsAg seroclearance in chronic HBV infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 43, 1311-1318.	1.9	36
1308	Length time bias in surveillance for hepatocellular carcinoma and how to avoid it. <i>Hepatology Research</i> , 2016, 46, 1275-1280.	1.8	20
1309	Portal response related to shunt occlusion by balloon-occluded retrograde transvenous obliteration may determine the prognosis of cirrhosis. <i>Hepatology Research</i> , 2016, 46, 1321-1329.	1.8	3
1310	Propensity score analysis of outcomes following laparoscopic or open liver resection for hepatocellular carcinoma. <i>British Journal of Surgery</i> , 2016, 103, 871-880.	0.1	130
1311	Phase 2 study of stereotactic body radiotherapy and optional transarterial chemoembolization for solitary hepatocellular carcinoma not amenable to resection and radiofrequency ablation. <i>Cancer</i> , 2016, 122, 2041-2049.	2.0	160
1312	Novel population-based study finding higher than reported hepatocellular carcinoma incidence suggests an updated approach is needed. <i>Hepatology</i> , 2016, 63, 1205-1212.	3.6	51
1313	Prospective validation of ab initio liver transplantation in hepatocellular carcinoma upon detection of risk factors for recurrence after resection. <i>Hepatology</i> , 2016, 63, 839-849.	3.6	101
1314	A Case of Sphenoid Sinus Metastasis in Hepatocellular Carcinoma. <i>Hepatology</i> , 2016, 63, 2050-2053.	3.6	4
1315	Excellent post-transplant survival in patients with intermediate stage hepatocellular carcinoma responding to neoadjuvant therapy. <i>Liver International</i> , 2016, 36, 688-695.	1.9	38
1316	Inducing tolerability of adverse events increases sorafenib exposure and optimizes patient's outcome in advanced hepatocellular carcinoma. <i>Liver International</i> , 2016, 36, 1033-1042.	1.9	28
1317	A multicentre comparison between Child Pugh and Albumin-Bilirubin scores in patients treated with sorafenib for Hepatocellular Carcinoma. <i>Liver International</i> , 2016, 36, 1821-1828.	1.9	85
1318	Hepatocellular Carcinoma Surveillance. <i>Journal of Clinical Gastroenterology</i> , 2016, 50, e8-e12.	1.1	9
1319	Comparison between alcohol- and hepatitis C virus-related hepatocellular carcinoma: clinical presentation, treatment and outcome. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 43, 385-399.	1.9	59

#	ARTICLE	IF	CITATIONS
1320	Patients with chronic hepatitis B should be screened for hepatocellular carcinoma regardless of liver stiffness measurement. <i>Hepatology</i> , 2016, 63, 672-672.	3.6	3
1321	Lipiodol transarterial chemoembolization for hepatocellular carcinoma: A systematic review of efficacy and safety data. <i>Hepatology</i> , 2016, 64, 106-116.	3.6	502
1322	Which Is Better Local Therapy for HCC, RFA or TACE?. <i>Difficult Decisions in Surgery: an Evidence-based Approach</i> , 2016, , 139-147.	0.0	0
1323	The importance of surgical margins in primary malignancies of the liver. <i>Journal of Surgical Oncology</i> , 2016, 113, 296-303.	0.8	50
1324	Diagnostics and Treatment of Hepatocellular Carcinoma in 2016: Standards and Developments. <i>Visceral Medicine</i> , 2016, 32, 116-120.	0.5	35
1325	Functional imaging in liver tumours. <i>Journal of Hepatology</i> , 2016, 65, 1017-1030.	1.8	45
1326	Effect of ischaemic preconditioning on recurrence of hepatocellular carcinoma in an experimental model of liver steatosis. <i>British Journal of Surgery</i> , 2016, 103, 417-426.	0.1	26
1327	A prognostic index for patients within the intermediate stage of hepatocellular carcinoma. <i>European Journal of Gastroenterology and Hepatology</i> , 2016, 28, 592-598.	0.8	1
1328	Surgical Resection Versus Radiofrequency Ablation for Single Hepatocellular Carcinoma ≤ 2 cm in a Propensity Score Model. <i>Annals of Surgery</i> , 2016, 263, 538-545.	2.1	148
1329	Drug-eluting beads versus conventional chemoembolization for the treatment of unresectable hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 645-653.	1.4	71
1330	Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma. <i>The Cochrane Library</i> , 2016, 2, CD011313.	1.5	27
1331	Cost-effectiveness of whole-body bone scans in the pre-liver transplant assessment of patients with hepatocellular carcinoma in Southern Brazil. <i>Clinical Transplantation</i> , 2016, 30, 399-406.	0.8	5
1332	Efficacy of additional radiofrequency ablation after transcatheter arterial chemoembolization for intermediate hepatocellular carcinoma. <i>Hepatology Research</i> , 2016, 46, 312-319.	1.8	26
1333	Percutaneous thermal ablation for primary hepatocellular carcinoma: A systematic review and meta-analysis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 294-301.	1.4	86
1334	Radiofrequency ablation of hepatocellular carcinoma: Mono or multipolar?. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 654-660.	1.4	24
1335	Assessment of the Hong Kong Liver Cancer Staging System in Europe. <i>Liver International</i> , 2016, 36, 911-917.	1.9	16
1336	Resection vs. ablation for alpha-fetoprotein positive hepatocellular carcinoma within the Milan criteria: a propensity score analysis. <i>Liver International</i> , 2016, 36, 1677-1687.	1.9	20
1337	Temperature profile of <i>ex-vivo</i> organs during radio frequency thermal ablation by fiber Bragg gratings. <i>Journal of Biomedical Optics</i> , 2016, 21, 117003.	1.4	37

#	ARTICLE	IF	CITATIONS
1338	Survival Benefit of Locoregional Treatment for Hepatocellular Carcinoma with Advanced Liver Cirrhosis. <i>Liver Cancer</i> , 2016, 5, 175-189.	4.2	34
1340	Tratamiento personalizado del carcinoma hepatocelular basado en informaci3n molecular: perspectivas futuras. <i>Clinical Liver Disease</i> , 2016, 8, S43-S48.	1.0	0
1341	Regorafenib as Second-Line Systemic Therapy May Change the Treatment Strategy and Management Paradigm for Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2016, 5, 235-244.	4.2	43
1343	Paralytic Ileus due to Superior Mesenteric Venous Thrombosis after Transarterial Injection for Hepatocellular Carcinoma. <i>Internal Medicine</i> , 2016, 55, 37-42.	0.3	3
1344	Early Decreases in α -Fetoprotein and Des- γ -carboxy Prothrombin Predict the Antitumor Effects of Hepatic Transarterial Infusion Chemotherapy with Cisplatin (CDDP) Powder in Patients with Advanced Hepatocellular Carcinoma. <i>Internal Medicine</i> , 2016, 55, 2163-2171.	0.3	3
1345	A national survey of the provision of ultrasound surveillance for the detection of hepatocellular carcinoma. <i>Frontline Gastroenterology</i> , 2016, 7, 82-89.	0.9	23
1346	Opportunities to improve surveillance for hepatocellular carcinoma in the UK. <i>Frontline Gastroenterology</i> , 2016, 7, 78-79.	0.9	1
1348	Clinical parameters for predicting radiation-induced liver disease after intrahepatic reirradiation for hepatocellular carcinoma. <i>Radiation Oncology</i> , 2016, 11, 89.	1.2	26
1349	Microwave ablation of hepatocellular carcinoma as first-line treatment: long term outcomes and prognostic factors in 221 patients. <i>Scientific Reports</i> , 2016, 6, 32728.	1.6	29
1350	Application of the Immunoscore as prognostic tool for hepatocellular carcinoma. , 2016, 4, 71.		12
1351	Prognostic Value of Pre-transplantation Serum Alpha-Fetoprotein Levels in Hepatocellular Carcinoma Recurrence. <i>Transplantation Proceedings</i> , 2016, 48, 2966-2968.	0.3	5
1352	The GALAD scoring algorithm based on AFP, AFP-L3, and DCP significantly improves detection of BCLC early stage hepatocellular carcinoma. <i>Zeitschrift Fur Gastroenterologie</i> , 2016, 54, 1296-1305.	0.2	83
1353	Looking Beyond Sorafenib to Treat Advanced Hepatocellular Carcinoma. <i>Journal of Clinical and Experimental Hepatology</i> , 2016, 6, 339-342.	0.4	1
1354	Hepatic resection for hepatocellular carcinoma in cirrhotic patients with portal hypertension. <i>Surgical Practice</i> , 2016, 20, 149-156.	0.1	2
1355	Impact of endoscopic ultrasound-guided fine-needle aspiration in prospective liver transplant recipients with hepatocellular carcinoma and lymphadenopathy. <i>Indian Journal of Gastroenterology</i> , 2016, 35, 465-468.	0.7	7
1356	Dynamic enhancement patterns of intrahepatic cholangiocarcinoma in cirrhosis on contrast-enhanced computed tomography: risk of misdiagnosis as hepatocellular carcinoma. <i>Scientific Reports</i> , 2016, 6, 26772.	1.6	26
1357	Efficacy of PIVKA-II in prediction and early detection of hepatocellular carcinoma: a nested case-control study in Chinese patients. <i>Scientific Reports</i> , 2016, 6, 35050.	1.6	16
1358	Is Salvage Liver Resection Necessary for Initially Unresectable Hepatocellular Carcinoma Patients Downstaged by Transarterial Chemoembolization? Ten Years of Experience. <i>Oncologist</i> , 2016, 21, 1442-1449.	1.9	50

#	ARTICLE	IF	CITATIONS
1359	New molecular therapies in patients with advanced Hepatocellular Cancer in second line of treatment: Is a real defeat?: Results from a literature based meta-analysis of randomized trials. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 108, 62-68.	2.0	2
1360	Focal Liver Lesions Classification and Characterization. <i>Journal of Computer Assisted Tomography</i> , 2016, 40, 701-708.	0.5	11
1361	A Novel Prognostic Index in Patients With Hepatocellular Cancer Waiting for Liver Transplantation. <i>Annals of Surgery</i> , 2016, 264, 787-796.	2.1	82
1362	Liver Stiffness and Serum Alpha-Fetoprotein in Discriminating Small Hepatocellular Carcinoma from Cirrhotic Nodule. <i>Ultrasound Quarterly</i> , 2016, 32, 319-326.	0.3	3
1363	Percutaneous radiofrequency ablation for hepatocellular carcinoma: Shortened duration does not comprise its efficacy. <i>Advances in Digestive Medicine</i> , 2016, 3, 149-150.	0.1	0
1364	Consideraciones perioperatorias en el paciente oncológico sometido a hepatectomía. <i>Gaceta Mexicana De Oncología</i> , 2016, 15, 358-365.	0.0	0
1365	Survival of patients with intermediate stage hepatocellular carcinoma treated with superselective transarterial chemoembolization using doxorubicin-loaded DC Bead under cone-beam computed tomography control. <i>Radiology and Oncology</i> , 2016, 50, 418-426.	0.6	15
1366	Comparison between cryoablation and irreversible electroporation of rabbit livers at a location close to the gallbladder. <i>Radiology and Oncology</i> , 2016, 51, 40-46.	0.6	8
1367	Efficacy and safety of radiofrequency ablation and transcatheter arterial chemoembolization for treatment of hepatocellular carcinoma: A meta-analysis. <i>Hepatology Research</i> , 2016, 46, 58-71.	1.8	35
1368	Clinical Impact of Gadoteric Acid-Enhanced Magnetic Resonance Imaging on Hepatoma Management: A Prospective Study. <i>Digestive Diseases and Sciences</i> , 2016, 61, 1197-1205.	1.1	17
1369	Squaring the circle of selection and allocation in liver transplantation for HCC: An adaptive approach. <i>Hepatology</i> , 2016, 63, 1707-1717.	3.6	110
1370	High levels of the soluble programmed death-ligand (sPD-L1) identify hepatocellular carcinoma patients with a poor prognosis. <i>European Journal of Cancer</i> , 2016, 59, 152-159.	1.3	174
1371	Long-term impact of liver function on curative therapy for hepatocellular carcinoma: application of the ALBI grade. <i>British Journal of Cancer</i> , 2016, 114, 744-750.	2.9	150
1372	Capitalising on improved rates of diagnosis of early hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2016, 64, 260-261.	1.8	2
1373	Protein induced by vitamin K absence or antagonist-II (PIVKA-II) specifically increased in Italian hepatocellular carcinoma patients. <i>Scandinavian Journal of Gastroenterology</i> , 2016, 51, 1257-1262.	0.6	14
1374	PET-avid hepatocellular adenomas: incidental findings associated with HNF1 β mutated lesions. <i>Hpb</i> , 2016, 18, 41-48.	0.1	14
1375	14-3-3 β is a novel growth-promoting and angiogenic factor in hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2016, 65, 953-962.	1.8	24
1376	Multifunctional microbeads for drug delivery in TACE. <i>Expert Opinion on Drug Delivery</i> , 2016, 13, 1289-1300.	2.4	25

#	ARTICLE	IF	CITATIONS
1377	The role of three-dimensional imaging in optimizing diagnosis, classification and surgical treatment of hepatocellular carcinoma with portal vein tumor thrombus. <i>Hpb</i> , 2016, 18, 287-295.	0.1	25
1378	Surveillance for hepatocellular carcinoma: A tale of two countries. <i>Journal of Hepatology</i> , 2016, 64, 754-755.	1.8	0
1379	Three-Dimensional Measurement of Hepatocellular Carcinoma Ablation Zones and Margins for Predicting Local Tumor Progression. <i>Journal of Vascular and Interventional Radiology</i> , 2016, 27, 1038-1045.e2.	0.2	37
1380	Hepatitis por el virus C. <i>Medicine</i> , 2016, 12, 484-493.	0.0	0
1381	Mechanism of Hepatitis B Virus Persistence in Hepatocytes and Its Carcinogenic Potential. <i>Clinical Infectious Diseases</i> , 2016, 62, S281-S288.	2.9	38
1382	Extra-hepatic feeding arteries of hepatocellular carcinoma: An investigation based on intra-arterial CT aortography images using an angio-MDCT system. <i>European Journal of Radiology</i> , 2016, 85, 1400-1406.	1.2	7
1383	Antiviral Therapy in Patients with Viral Hepatitis and Hepatocellular Carcinoma: Indications and Prognosis. <i>Visceral Medicine</i> , 2016, 32, 121-126.	0.5	14
1384	Interventional oncology for hepatocellular carcinoma. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2016, 40, 530-537.	0.7	9
1385	Design of cholesterol arabinogalactan anchored liposomes for asialoglycoprotein receptor mediated targeting to hepatocellular carcinoma: In silico modeling, in vitro and in vivo evaluation. <i>International Journal of Pharmaceutics</i> , 2016, 509, 149-158.	2.6	28
1386	Urinary Metabotyping of Hepatocellular Carcinoma in a UK Cohort Using Proton Nuclear Magnetic Resonance Spectroscopy. <i>Journal of Clinical and Experimental Hepatology</i> , 2016, 6, 186-194.	0.4	13
1387	Rate of observation and inter-observer agreement for LI-RADS major features at CT and MRI in 184 pathology proven hepatocellular carcinomas. <i>Abdominal Radiology</i> , 2016, 41, 963-969.	1.0	73
1388	Hepatocellular Carcinoma in Chronic Hepatitis B Patients on Third Generation Nucleos(t)ides Analogs: Risk Factors and Performance of a Risk Score. <i>GE Portuguese Journal of Gastroenterology</i> , 2016, 23, 233-242.	0.3	4
1389	Current role of selective internal radiation with yttrium-90 in liver tumors. <i>Future Oncology</i> , 2016, 12, 1193-1204.	1.1	13
1390	Functional imaging of hepatocellular carcinoma. <i>Hepatic Oncology</i> , 2016, 3, 137-153.	4.2	1
1391	Comparative analysis of current guidelines for the treatment of hepatocellular carcinoma. <i>Hepatic Oncology</i> , 2016, 3, 119-136.	4.2	14
1392	Drug-eluting beads versus conventional chemoembolization for the treatment of unresectable hepatocellular carcinoma: A meta-analysis. <i>Digestive and Liver Disease</i> , 2016, 48, 571-577.	0.4	168
1393	NAFLD causes selective CD4+ T lymphocyte loss and promotes hepatocarcinogenesis. <i>Nature</i> , 2016, 531, 253-257.	13.7	552
1394	Microwave versus Radiofrequency Ablation Treatment for Hepatocellular Carcinoma: A Comparison of Efficacy at a Single Center. <i>Journal of Vascular and Interventional Radiology</i> , 2016, 27, 631-638.	0.2	77

#	ARTICLE	IF	CITATIONS
1395	Reply. <i>Hepatology</i> , 2016, 63, 345-345.	3.6	0
1396	Incorporating the hepatobiliary phase of gadobenate dimeglumine-enhanced MRI in the diagnosis of hepatocellular carcinoma: increasing the sensitivity without compromising specificity. <i>Acta Radiologica</i> , 2016, 57, 923-931.	0.5	11
1397	Hepatocellular carcinoma: To resect or to transplant?. <i>Hepatology</i> , 2016, 63, 344-345.	3.6	1
1398	Transarterial Radioembolization with Yttrium-90 for the Treatment of Hepatocellular Carcinoma. <i>Advances in Therapy</i> , 2016, 33, 699-714.	1.3	123
1399	<i>Surgical Oncology Manual</i> , 2016, , .		1
1400	Transarterial chemoembolization versus transarterial radioembolization in hepatocellular carcinoma: optimization of selecting treatment modality. <i>Hepatology International</i> , 2016, 10, 883-892.	1.9	37
1401	The role of liver transplantation or resection for patients with early hepatocellular carcinoma. <i>Tumor Biology</i> , 2016, 37, 4193-4201.	0.8	16
1402	NAFLD-Associated Hepatocellular Carcinoma: a Threat to Patients with Metabolic Disorders. <i>Current Hepatology Reports</i> , 2016, 15, 103-112.	0.4	3
1403	Preliminary Outcome of Microwave Ablation of Hepatocellular Carcinoma: Breaking the 3-cm Barrier?. <i>Journal of Vascular and Interventional Radiology</i> , 2016, 27, 623-630.	0.2	39
1404	Ongoing challenges in the diagnosis of hepatocellular carcinoma. <i>Expert Review of Gastroenterology and Hepatology</i> , 2016, 10, 451-463.	1.4	5
1405	Imaging Outcomes of Liver Imaging Reporting and Data System Version 2014 Category 2, 3, and 4 Observations Detected at CT and MR Imaging. <i>Radiology</i> , 2016, 281, 129-139.	3.6	85
1406	EFSUMB Guidelines on Interventional Ultrasound (INVUS), Part III – Abdominal Treatment Procedures (Long Version). <i>Ultraschall in Der Medizin</i> , 2016, 37, E1-E32.	0.8	36
1407	Liver Imaging Reporting and Data System: Review of Major Imaging Features. <i>Seminars in Roentgenology</i> , 2016, 51, 292-300.	0.2	5
1408	Image-guided thermal therapy with a dual-contrast magnetic nanoparticle formulation: A feasibility study. <i>International Journal of Hyperthermia</i> , 2016, 32, 543-557.	1.1	20
1409	[⁶⁸ Ga]NODAGA-RGD – Metabolic stability, biodistribution, and dosimetry data from patients with hepatocellular carcinoma and liver cirrhosis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 2005-2013.	3.3	38
1410	Virologic Cure of Hepatitis C: Impact on Hepatic Fibrosis and Patient Outcomes. <i>Current Gastroenterology Reports</i> , 2016, 18, 32.	1.1	23
1411	Reliability, Validity, and Reader Acceptance of LI-RADS – An In-depth Analysis. <i>Academic Radiology</i> , 2016, 23, 1145-1153.	1.3	39
1412	Pathogenesis, Diagnosis and Treatment of Hemochromatosis. <i>Digestive Diseases</i> , 2016, 34, 364-373.	0.8	15

#	ARTICLE	IF	CITATIONS
1413	Role of Immunity in Pathogenesis and Treatment of Hepatocellular Carcinoma. Digestive Diseases, 2016, 34, 429-437.	0.8	21
1414	Extended Abstract: Management of Liver Cancer. Digestive Diseases, 2016, 34, 438-439.	0.8	7
1415	HIV, Aging, and Viral Coinfections: Taking the Long View. Current HIV/AIDS Reports, 2016, 13, 269-278.	1.1	21
1416	Serum markers for hepatocellular carcinoma. Clinical Liver Disease, 2016, 8, 29-33.	1.0	11
1417	Nontumor Prognostic Factors in Hepatocellular Carcinoma. , 2016, , 139-147.		2
1418	Unresectable Hepatocellular Carcinoma: Radioembolization Versus Chemoembolization: A Systematic Review and Meta-analysis. CardioVascular and Interventional Radiology, 2016, 39, 1580-1588.	0.9	91
1419	Systemic treatment for advanced hepatocellular carcinoma: the search of new agents to join sorafenib in the effective therapeutic armamentarium. Expert Opinion on Pharmacotherapy, 2016, 17, 1923-1936.	0.9	15
1420	Imaging prediction of residual hepatocellular carcinoma after locoregional therapy in patients undergoing liver transplantation or partial hepatectomy. Abdominal Radiology, 2016, 41, 2161-2168.	1.0	12
1421	Hepatitis B and Hepatocellular Carcinoma. Clinics in Liver Disease, 2016, 20, 703-720.	1.0	28
1422	Role of Sorafenib in Patients With Recurrent Hepatocellular Carcinoma After Liver Transplantation. Progress in Transplantation, 2016, 26, 348-355.	0.4	27
1423	Sequential transarterial chemoembolization and portal vein embolization before resection is a valid oncological strategy for unilobar hepatocellular carcinoma regardless of the tumor burden. Hpb, 2016, 18, 684-690.	0.1	35
1424	The Effect of Bridging Locoregional Therapy and Sociodemographics on Survival in Hepatocellular Carcinoma Patients Undergoing Orthotopic Liver Transplantation: A United Network for Organ Sharing Population Study. Journal of Vascular and Interventional Radiology, 2016, 27, 1822-1828.	0.2	8
1426	Progress in surgical and nonsurgical approaches for hepatocellular carcinoma treatment. Hepatobiliary and Pancreatic Diseases International, 2016, 15, 234-256.	0.6	41
1427	Screening and surveillance for hepatocellular carcinoma: perspective of a new era?. Expert Review of Anticancer Therapy, 2016, 16, 1291-1302.	1.1	4
1428	Clinical Features and Clinicianâ€™s Diagnostic Approach to Hepatocellular Carcinoma. , 2016, , 409-423.		0
1429	Alpha-foetoprotein (AFP): A multi-purpose marker in hepatocellular carcinoma. Clinica Chimica Acta, 2016, 463, 39-44.	0.5	194
1430	Utility of prognostic scoring systems in management of hepatocellular carcinoma. European Journal of Cancer, 2016, 68, 206-207.	1.3	1
1431	Role of dual energy spectral computed tomography in characterization of hepatocellular carcinoma: Initial experience from a tertiary liver care institute. European Journal of Radiology Open, 2016, 3, 162-171.	0.7	24

#	ARTICLE	IF	CITATIONS
1432	Evaluating the risk of hepatocellular carcinoma in patients with prominently elevated liver stiffness measurements by FibroScan: a multicentre study. <i>Hpb</i> , 2016, 18, 678-683.	0.1	19
1433	Indicaciones y contraindicaciones del trasplante hepático. <i>Medicine</i> , 2016, 12, 693-697.	0.0	1
1434	Diagnosis and treatment of hepatocellular carcinoma. Update consensus document from the AEEH, SEOM, SERAM, SERVEI and SETH. <i>Medicina Clínica (English Edition)</i> , 2016, 146, 511.e1-511.e22.	0.1	2
1435	Aspects of Hepatocellular Tumor Pathology. , 2016, , 305-329.		0
1436	Distinctive features of hepatocellular carcinoma in non-alcoholic fatty liver disease. <i>The Lancet Gastroenterology and Hepatology</i> , 2016, 1, 156-164.	3.7	116
1437	InÂVitro Release Mechanisms of Doxorubicin From a Clinical Bead Drug-Delivery System. <i>Journal of Pharmaceutical Sciences</i> , 2016, 105, 3387-3398.	1.6	37
1438	Hepatocellular Carcinoma Treatment With Sorafenib: Real-Life Evaluation of Prognostic Factors and a Practical Clue for Patient Management. <i>GE Portuguese Journal of Gastroenterology</i> , 2016, 23, 243-248.	0.3	7
1439	Superb microvascular imaging technology for ultrasound examinations: Initial experiences for hepatic tumors. <i>European Journal of Radiology</i> , 2016, 85, 2090-2095.	1.2	79
1440	Massive and life-threatening upper gastrointestinal bleeding due to invasive hepatocellular carcinoma: A case report. <i>International Journal of Surgery Case Reports</i> , 2016, 26, 69-72.	0.2	2
1441	2-[18 F]fluoro-2-deoxy- D -galactose PET/CT of hepatocellular carcinoma is not improved by co-administration of galactose. <i>Nuclear Medicine and Biology</i> , 2016, 43, 577-580.	0.3	2
1443	Combined hepatectomy and radiofrequency ablation versus TACE in improving survival of patients with unresectable BCLC stage B HCC. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2016, 15, 378-385.	0.6	21
1444	Intermediate-stage hepatocellular carcinoma treated with hepatic resection: the NSP score as an aid to decision-making. <i>British Journal of Cancer</i> , 2016, 115, 1039-1047.	2.9	20
1445	Transarterial Chemoembolization for the Treatment of Advanced-Stage Hepatocellular Carcinoma. <i>Journal of Gastrointestinal Surgery</i> , 2016, 20, 2002-2009.	0.9	27
1446	High incidence of hepatocellular carcinoma following successful interferon-free antiviral therapy for hepatitis C associated cirrhosis. <i>Journal of Hepatology</i> , 2016, 65, 1070-1071.	1.8	120
1447	Time for paradigm change in management of hepatocellular carcinoma: is a personalized approach on the horizon?. <i>Personalized Medicine</i> , 2016, 13, 455-467.	0.8	11
1448	Effectiveness of surveillance for hepatocellular carcinoma in clinical practice: A United States cohort. <i>Journal of Hepatology</i> , 2016, 65, 1148-1154.	1.8	114
1449	The relationship between liver stiffness measurement and outcome in patients with chronic hepatitis C and cirrhosis: a retrospective longitudinal hospital study. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 44, 505-513.	1.9	19
1450	Current Guidelines for the Diagnosis and Management of Hepatocellular Carcinoma: A Comparative Review. <i>American Journal of Roentgenology</i> , 2016, 207, W88-W98.	1.0	33

#	ARTICLE	IF	CITATIONS
1451	Melatonin-induced increase in sensitivity of human hepatocellular carcinoma cells to sorafenib is associated with reactive oxygen species production and mitophagy. <i>Journal of Pineal Research</i> , 2016, 61, 396-407.	3.4	114
1452	Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 2553-2562.	1.9	50
1453	Gene expression analysis of biopsy samples reveals critical limitations of transcriptome-based molecular classifications of hepatocellular carcinoma. <i>Journal of Pathology: Clinical Research</i> , 2016, 2, 80-92.	1.3	65
1454	Reversion-Inducing Cysteine-Rich Protein With Kazal Motifs (RECK) Gene Single Nucleotide Polymorphism With Hepatocellular Carcinoma: A Case-Control Study. <i>Journal of Clinical Laboratory Analysis</i> , 2016, 30, 36-40.	0.9	6
1455	The impact of viral hepatitis-related hepatocellular carcinoma to post-transplant outcomes. <i>Journal of Viral Hepatitis</i> , 2016, 23, 53-61.	1.0	10
1456	The story of <scp>HCC</scp> in <scp>NAFLD</scp>: from epidemiology, across pathogenesis, to prevention and treatment. <i>Liver International</i> , 2016, 36, 317-324.	1.9	196
1457	Should surveillance for liver cancer be modified in hepatitis C patients after treatment-related cirrhosis regression?. <i>Liver International</i> , 2016, 36, 783-790.	1.9	29
1458	Proposal of a new diagnostic algorithm for hepatocellular carcinoma based on the Japanese guidelines but adapted to the <scp>W</scp>estern world for patients under surveillance for chronic liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 69-80.	1.4	41
1459	Early diagnosis of liver cancer: an appraisal of international recommendations and future perspectives. <i>Liver International</i> , 2016, 36, 166-176.	1.9	19
1460	Hepatocellular Carcinoma: the Impact of NAFLD. <i>Current Hepatology Reports</i> , 2016, 15, 190-198.	0.4	2
1461	Gender-Related Differences in Hepatocellular Carcinoma: Does Sex Matter?. <i>Journal of Vascular and Interventional Radiology</i> , 2016, 27, 1338-1341.	0.2	11
1462	Effect of HCV clearance with direct-acting antiviral agents on HCC. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2016, 13, 561-562.	8.2	67
1463	Correlation of tumor response on computed tomography with pathological necrosis in hepatocellular carcinoma treated by chemoembolization before liver transplantation. <i>Liver Transplantation</i> , 2016, 22, 1491-1500.	1.3	31
1464	A novel sulfamethazine-based pH-sensitive copolymer for injectable radiopaque embolic hydrogels with potential application in hepatocellular carcinoma therapy. <i>Polymer Chemistry</i> , 2016, 7, 5805-5818.	1.9	29
1465	Avoiding Pitfalls in the Interpretation of Gadoteric Acid-Enhanced Magnetic Resonance Imaging. <i>Seminars in Ultrasound, CT and MRI</i> , 2016, 37, 561-572.	0.7	12
1466	LI-RADS-CEUS "Proposal for a Contrast-Enhanced Ultrasound Algorithm for the Diagnosis of Hepatocellular Carcinoma in High-Risk Populations. <i>Ultraschall in Der Medizin</i> , 2016, 37, 627-634.	0.8	32
1468	Long-term liver-related morbidity and mortality related to chronic hepatitis C virus infection in Swedish patients with inherited bleeding disorders. <i>Haemophilia</i> , 2016, 22, e494-e501.	1.0	4
1469	Parametric imaging with contrast-enhanced ultrasound for differentiating hepatocellular carcinoma from metastatic liver cancer. <i>Clinical Hemorheology and Microcirculation</i> , 2016, 64, 177-188.	0.9	34

#	ARTICLE	IF	CITATIONS
1470	Comparison of hepatocellular carcinoma in <sc>E</sc>astern versus <sc>W</sc>estern populations. <i>Cancer</i> , 2016, 122, 3430-3446.	2.0	221
1471	Squamous Cell Carcinoma Antigen-Immunoglobulin M (SCCA-IgM) as Biomarker in Liver Disease: Biological Aspects and Clinical Applications. <i>Exposure and Health</i> , 2016, , 1-22.	2.8	0
1472	Radiofrequency ablation for HCC patients with multifocal tumours meeting the Milan criteria: A single-centre experience. <i>Digestive and Liver Disease</i> , 2016, 48, 1485-1491.	0.4	15
1474	Circulating Tumor Cells (Liquid Tumor Biopsy) in Hepatocellular Carcinoma: Biology, Methodologies, and Clinical Implications. , 2016, , 167-197.		0
1475	Peretinoin as an adjuvant therapy for hepatocellular carcinoma. <i>Expert Review of Gastroenterology and Hepatology</i> , 2016, 10, 1201-1210.	1.4	4
1476	Patientsâ€™ misconceptions about surveillance for hepatocellular carcinoma: Education is needed. <i>Journal of Hepatology</i> , 2016, 65, 653-654.	1.8	0
1477	Complete Response of Hepatocellular Carcinoma in a Patient With End-stage Liver Disease treated With Nivolumab: Wishful thinking or Possible?. <i>American Journal of Gastroenterology</i> , 2016, 111, 1208-1209.	0.2	10
1478	Y90 Radioembolization Significantly Prolongs Time to Progression Compared With Chemoembolization in Patients With Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2016, 151, 1155-1163.e2.	0.6	498
1479	Integrative Genomic Analysis Identifies the Core Transcriptional Hallmarks of Human Hepatocellular Carcinoma. <i>Cancer Research</i> , 2016, 76, 6374-6381.	0.4	48
1480	Management of HBV and HBV/HDV-Associated Liver Cirrhosis. <i>Visceral Medicine</i> , 2016, 32, 86-94.	0.5	16
1481	The clinical effect and relevant mechanism of combined sorafenib and radiofrequency ablation in the treatment of early small hepatocellular carcinoma. <i>Oncology Letters</i> , 2016, 12, 951-955.	0.8	8
1482	Wide variation in estimates of global prevalence and burden of chronic hepatitis B and C infection cited in published literature. <i>Journal of Viral Hepatitis</i> , 2016, 23, 545-559.	1.0	43
1483	Nomogram for individualized prediction of hepatocellular carcinoma occurrence in hepatitis C virus cirrhosis (ANRS CO12 CirVir). <i>Hepatology</i> , 2016, 64, 1136-1147.	3.6	75
1484	Surveillance of Hepatocellular Carcinoma and Diagnostic Algorithms in Patients with Liver Cirrhosis. <i>Visceral Medicine</i> , 2016, 32, 110-115.	0.5	9
1485	Stereotactic body radiation therapy for primary and metastatic liver tumors: From technological evolution to improved patient care. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2016, 30, 603-616.	1.0	28
1486	Steatotic hepatocellular carcinoma: a variant associated with metabolic factors and late tumour relapse. <i>Histopathology</i> , 2016, 69, 971-984.	1.6	21
1487	Programmed death ligand 1 expression in hepatocellular carcinoma: Relationship With clinical and pathological features. <i>Hepatology</i> , 2016, 64, 2038-2046.	3.6	343
1488	Clinical application of protein induced by vitamin K antagonist-II as a biomarker in hepatocellular carcinoma. <i>Tumor Biology</i> , 2016, 37, 15447-15456.	0.8	22

#	ARTICLE	IF	CITATIONS
1489	Nomogram of the Barcelona clinic liver cancer system: on the go. <i>Liver International</i> , 2016, 36, 1717-1718.	1.9	2
1490	Expanded Criteria for Resection: Are Current Guidelines Too Conservative?. <i>Current Hepatology Reports</i> , 2016, 15, 323-326.	0.4	3
1491	Cancer and liver cirrhosis: implications on prognosis and management. <i>ESMO Open</i> , 2016, 1, e000042.	2.0	194
1492	Hereditary hemorrhagic telangiectasia: to transplant or not to transplant?. <i>Liver International</i> , 2016, 36, 1741-1744.	1.9	12
1494	The Prognostic Value of Alpha-Fetoprotein Response for Advanced-Stage Hepatocellular Carcinoma Treated with Sorafenib Combined with Transarterial Chemoembolization. <i>Scientific Reports</i> , 2016, 6, 19851.	1.6	35
1495	Validation of Kinki Criteria, a Modified Substaging System, in Patients with Intermediate Stage Hepatocellular Carcinoma. <i>Digestive Diseases</i> , 2016, 34, 671-678.	0.8	22
1496	Pro-apoptotic and cytotoxic effects of enriched fraction of <i>Elytranthe parasitica</i> (L.) Danser against HepG2 Hepatocellular carcinoma. <i>BMC Complementary and Alternative Medicine</i> , 2016, 16, 420.	3.7	9
1497	Identification and Validation of HCC-specific Gene Transcriptional Signature for Tumor Antigen Discovery. <i>Scientific Reports</i> , 2016, 6, 29258.	1.6	22
1498	Liver stiffness measurement using acoustic radiation force impulse elastography in overweight and obese patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 44, 366-379.	1.9	27
1499	Long-term survival analysis in combined transarterial embolization and stereotactic body radiation therapy versus stereotactic body radiation monotherapy for unresectable hepatocellular carcinoma >5Åcm. <i>BMC Cancer</i> , 2016, 16, 834.	1.1	54
1500	RFA plus lyso-thermosensitive liposomal doxorubicin: in search of the optimal approach to cure intermediate-size hepatocellular carcinoma. <i>Hepatic Oncology</i> , 2016, 3, 193-200.	4.2	30
1501	Hepatocellular carcinoma. <i>Nature Reviews Disease Primers</i> , 2016, 2, 16018.	18.1	1,863
1502	Which factors affect the long-term survival of patients with hepatocellular carcinoma UICC stage IV?. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016, 142, 2593-2601.	1.2	3
1503	Recent Trends in the Management of Hepatocellular Carcinoma with Special Emphasis on Treatment with Regorafenib and Immune Checkpoint Inhibitors. <i>Digestive Diseases</i> , 2016, 34, 714-730.	0.8	7
1504	pH-Sensitive Pt Nanocluster Assembly Overcomes Cisplatin Resistance and Heterogeneous Stemness of Hepatocellular Carcinoma. <i>ACS Central Science</i> , 2016, 2, 802-811.	5.3	101
1505	Controversies and evidence of hepatic resection for hepatocellular carcinoma. <i>BBA Clinical</i> , 2016, 6, 125-130.	4.1	16
1506	Surveillance for hepatocellular carcinoma. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2016, 30, 1001-1010.	1.0	25
1507	Hepatocellular Carcinoma â€” Liver Transplantation, Hepatic Resection, and Regional Treatment Options. , 2016, , 391-421.		0

#	ARTICLE	IF	CITATIONS
1508	Transarterial Radioembolization for Hepatocellular Carcinoma: Who, When and Y(90)? Gastroenterology, 2016, 151, 1062-1065.	0.6	1
1509	Importance of activated hepatic stellate cells and angiopoietin-1 in the pathogenesis of hepatocellular carcinoma. Molecular Medicine Reports, 2016, 14, 1721-1725.	1.1	12
1510	Prevention of Hepatocellular Carcinoma. Gastrointestinal Tumors, 2016, 3, 37-43.	0.3	17
1511	Fever within 2 Weeks of Sorafenib Therapy Predicts Favorable Treatment Efficacy in Patients with Advanced Hepatocellular Carcinoma. Oncology, 2016, 91, 261-266.	0.9	11
1512	Irregular vascular pattern by contrast-enhanced ultrasonography and high serum Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein level predict poor outcome after successful radiofrequency ablation in patients with early-stage hepatocellular carcinoma. Cancer Medicine, 2016, 5, 3111-3120.	1.3	17
1513	Recent Advances in the Imaging Diagnosis of Hepatocellular Carcinoma: Value of Gadoxetic Acid-Enhanced MRI. Liver Cancer, 2016, 5, 67-87.	4.2	68
1514	A Recent Advance in Image-Guided Locoregional Therapy for Hepatocellular Carcinoma. Gastrointestinal Tumors, 2016, 3, 90-102.	0.3	17
1515	Pathway of care of hepatocellular carcinoma in 2017. Hepatic Oncology, 2016, 3, 217-221.	4.2	1
1516	Dynamic Contrast-Enhanced Magnetic Resonance Imaging With Gadolinium Ethoxybenzyl Diethylenetriamine Pentaacetic Acid for Quantitative Assessment of Vascular Effects on Hepatocellular-Carcinoma Lesions Treated by Transarterial Chemoembolization or Radiofrequency Ablation. Journal of Computer Assisted Tomography, 2016, 40, 692-700.	0.5	11
1517	Quantitative assessment of washout in hepatocellular carcinoma using MRI. BMC Cancer, 2016, 16, 758.	1.1	10
1518	Perioperative and long-term outcomes of liver resection for hepatitis B virus-related hepatocellular carcinoma without versus with hepatic inflow occlusion: study protocol for a prospective randomized controlled trial. Trials, 2016, 17, 492.	0.7	7
1520	Differences in Patient Characteristics and Midterm Outcome Between Asian and European Patients Treated with Radiofrequency Ablation for Hepatocellular Carcinoma. CardioVascular and Interventional Radiology, 2016, 39, 1708-1715.	0.9	3
1521	Percutaneous ethanol injection therapy is comparable to radiofrequency ablation in hepatocellular carcinoma smaller than 1.5 cm. Medicine (United States), 2016, 95, e4551.	0.4	13
1522	Assessment of the diagnostic role of annexin A2 (ANXA2) and insulin-like growth factor-1 as serum markers for hepatocellular carcinoma. Egyptian Liver Journal, 2016, 6, 1-6.	0.3	1
1523	Combination of transcatheter arterial chemoembolization and CT-guided percutaneous segment ablation for hepatocellular carcinoma therapy. Medicine (United States), 2016, 95, e5422.	0.4	3
1524	Postsurgical treatment with adjuvant transarterial chemoembolization in patients with hepatitis B-related hepatocellular carcinoma. Medicine (United States), 2016, 95, e5517.	0.4	2
1525	Elevated liver fibrosis index FIB-4 is not reliable for HCC risk stratification in predominantly non-Asian CHB patients. Medicine (United States), 2016, 95, e4602.	0.4	6
1526	Poor adherence and low persistency rates for hepatocellular carcinoma surveillance in patients with chronic hepatitis B. Medicine (United States), 2016, 95, e4744.	0.4	30

#	ARTICLE	IF	CITATIONS
1527	Acute kidney injury in cirrhotic patients undergoing contrast-enhanced computed tomography. <i>Medicine (United States)</i> , 2016, 95, e4836.	0.4	11
1528	Diagnostic performance of gadoxetic acid (Primovist)-enhanced MR imaging versus CT during hepatic arteriography and portography for small hypervascular hepatocellular carcinoma. <i>Medicine (United States)</i> , 2016, 95, e4836.	0.7	14
1529	The Effectiveness of Multiple Electrode Radiofrequency Ablation in Patients with Hepatocellular Carcinoma with Lesions More than 3 cm in Size and Barcelona Clinic Liver Cancer Stage A to B2. <i>Liver Cancer</i> , 2016, 5, 8-20.	4.2	55
1530	A therapeutic conundrum: Delaying ablation of small nonresectable early hepatocellular carcinoma to facilitate liver transplantation. <i>Liver Transplantation</i> , 2016, 22, 161-162.	1.3	2
1531	Clinical characteristics and survival outcomes of super-elderly hepatocellular carcinoma patients not indicated for surgical resection. <i>Hepatology Research</i> , 2016, 46, E5-E14.	1.8	5
1532	Usefulness of early vascular phase images from contrast-enhanced ultrasonography using Sonazoid for the diagnosis of hypovascular hepatocellular carcinoma. <i>Hepatology Research</i> , 2016, 46, 497-504.	1.8	9
1533	Prognostic role of 25-hydroxyvitamin D in patients with liver metastases from colorectal cancer treated with radiofrequency ablation. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 1483-1488.	1.4	18
1534	Applicability of albumin-bilirubin-based Japan integrated staging score in hepatitis B-associated hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 1766-1772.	1.4	47
1535	Liver-infiltrating CD8 ⁺ lymphocytes as prognostic factor for tumour recurrence in hepatitis C virus-related hepatocellular carcinoma. <i>Liver International</i> , 2016, 36, 434-444.	1.9	41
1536	The recommended treatment algorithms of the BCLC and HKLC staging systems: does following these always improve survival rates for HCC patients?. <i>Liver International</i> , 2016, 36, 1490-1497.	1.9	51
1537	Target lesion response predicts survival of patients with hepatocellular carcinoma retreated with transarterial chemoembolization. <i>Liver International</i> , 2016, 36, 1516-1524.	1.9	1
1538	Dynamic Contrast-enhanced MR Imaging of Advanced Hepatocellular Carcinoma: Comparison with the Liver Parenchyma and Correlation with the Survival of Patients Receiving Systemic Therapy. <i>Radiology</i> , 2016, 281, 454-464.	3.6	33
1539	Placental growth factor inhibition modulates the interplay between hypoxia and unfolded protein response in hepatocellular carcinoma. <i>BMC Cancer</i> , 2016, 16, 9.	1.1	26
1540	Natural history of liver imaging reporting and data system category 4 nodules in MRI. <i>Abdominal Radiology</i> , 2016, 41, 1758-1766.	1.0	33
1541	Hierarchic Interaction of Factors Associated With Liver Decompensation After Resection for Hepatocellular Carcinoma. <i>JAMA Surgery</i> , 2016, 151, 846.	2.2	106
1542	Proposal and validation of a new model to estimate survival for hepatocellular carcinoma patients. <i>European Journal of Cancer</i> , 2016, 63, 25-33.	1.3	40
1543	New Approaches in Locoregional Therapies for Hepatocellular Carcinoma. <i>Journal of Gastrointestinal Cancer</i> , 2016, 47, 239-246.	0.6	5
1544	Diagnostic performance of contrast-enhanced multidetector computed tomography and gadoxetic acid disodium-enhanced magnetic resonance imaging in detecting hepatocellular carcinoma: direct comparison and a meta-analysis. <i>Abdominal Radiology</i> , 2016, 41, 1960-1972.	1.0	57

#	ARTICLE	IF	CITATIONS
1545	Poor outcome of hepatocellular carcinoma with stemness marker under hypoxia: resistance to transarterial chemoembolization. <i>Modern Pathology</i> , 2016, 29, 1038-1049.	2.9	52
1546	Hepatocellular Carcinoma Surveillance Among Cirrhotic Patients With Commercial Health Insurance. <i>Journal of Clinical Gastroenterology</i> , 2016, 50, 258-265.	1.1	38
1547	Contribution of Contrast-Enhanced Sonography With Perfluorobutane Microbubbles for Diagnosis of Recurrent Hepatocellular Carcinoma. <i>Journal of Ultrasound in Medicine</i> , 2016, 35, 1383-1391.	0.8	8
1548	Conclusive HCC diagnosis with hepatocyte-specific contrast-enhanced magnetic resonance imaging? Not yet. <i>Journal of Hepatology</i> , 2016, 65, 648-649.	1.8	2
1549	The CRP level and STATE score predict survival in cirrhotic patients with hepatocellular carcinoma treated by transarterial embolization. <i>Digestive and Liver Disease</i> , 2016, 48, 1088-1092.	0.4	14
1550	Iodine-125 implantation plus transarterial chemoembolization for the treatment of hepatocellular carcinoma of 3-5cm: A propensity score matching study. <i>Digestive and Liver Disease</i> , 2016, 48, 1082-1087.	0.4	16
1551	Effects of Microwave Ablation on Arterial and Venous Vasculature after Treatment of Hepatocellular Carcinoma. <i>Radiology</i> , 2016, 281, 617-624.	3.6	42
1552	Cost-effectiveness of doxorubicin-eluting beads versus conventional trans-arterial chemo-embolization for hepatocellular carcinoma. <i>Digestive and Liver Disease</i> , 2016, 48, 798-805.	0.4	46
1553	4 Hepatocellular Carcinoma: Ablation. , 2016, , .		0
1554	The arterial tumor enhancement pattern on contrast-enhanced computed tomography is associated with primary cancer death after radiofrequency ablation for small hepatocellular carcinoma. <i>Hepatology International</i> , 2016, 10, 328-339.	1.9	14
1555	Propensity score-based comparison of hepatic resection and transarterial chemoembolization for patients with advanced hepatocellular carcinoma. <i>Tumor Biology</i> , 2016, 37, 2435-2441.	0.8	22
1556	Subclassification of patients with solitary hepatocellular carcinoma based on post-hepatectomy survival: a large retrospective study. <i>Tumor Biology</i> , 2016, 37, 5327-5335.	0.8	6
1557	Hepatocellular carcinoma with main portal vein tumor thrombus: a comparative study comparing hepatectomy with or without neoadjuvant radiotherapy. <i>Hpb</i> , 2016, 18, 549-556.	0.1	42
1558	Combination Therapies in the Management of Large (>= 5 cm) Hepatocellular Carcinoma: Microwave Ablation Immediately Followed by Transarterial Chemoembolization. <i>Journal of Vascular and Interventional Radiology</i> , 2016, 27, 1577-1583.	0.2	23
1559	Diffusion weighted magnetic resonance imaging in assessment of hepatocellular carcinoma after chemoembolization. <i>Egyptian Journal of Radiology and Nuclear Medicine</i> , 2016, 47, 61-71.	0.3	4
1560	Imagestream detection and characterisation of circulating tumour cells - A liquid biopsy for hepatocellular carcinoma?. <i>Journal of Hepatology</i> , 2016, 65, 305-313.	1.8	98
1561	Hepatocellular carcinoma recurrence after treatment with direct-acting antivirals: First, do no harm by withdrawing treatment. <i>Journal of Hepatology</i> , 2016, 65, 862-864.	1.8	73
1562	Genetic profiling of hepatocellular carcinoma using next-generation sequencing. <i>Journal of Hepatology</i> , 2016, 65, 1031-1042.	1.8	219

#	ARTICLE	IF	CITATIONS
1563	Reply to "Direct antiviral agents and risk for hepatocellular carcinoma (HCC) early recurrence: Much ado about nothing". <i>Journal of Hepatology</i> , 2016, 65, 864-865.	1.8	6
1564	Independent Analysis of Albumin-Bilirubin Grade in a 765-Patient Cohort Treated with Transarterial Locoregional Therapy for Hepatocellular Carcinoma. <i>Journal of Vascular and Interventional Radiology</i> , 2016, 27, 795-802.	0.2	64
1565	Combination of radiofrequency ablation with transarterial chemoembolization for treatment of hepatocellular carcinoma: experience from a Danish tertiary liver center. <i>Acta Radiologica</i> , 2016, 57, 844-851.	0.5	6
1566	Evaluation of combined Gd-EOB-DTPA and gadobutrol magnetic resonance imaging for the prediction of hepatocellular carcinoma grading. <i>Acta Radiologica</i> , 2016, 57, 932-938.	0.5	9
1567	Organic Cation Transporter 1 (OCT1) mRNA expression in hepatocellular carcinoma as a biomarker for sorafenib treatment. <i>BMC Cancer</i> , 2016, 16, 94.	1.1	37
1568	Hepatic resection provided long-term survival for patients with intermediate and advanced-stage resectable hepatocellular carcinoma. <i>World Journal of Surgical Oncology</i> , 2016, 14, 62.	0.8	36
1569	Benefits of stereotactic ablative radiotherapy combined with incomplete transcatheter arterial chemoembolization in hepatocellular carcinoma. <i>Radiation Oncology</i> , 2016, 11, 22.	1.2	20
1570	Percutaneous radiofrequency ablation for patients with malignant lung tumors: a phase II prospective multicenter study (JIVROSG-0702). <i>Japanese Journal of Radiology</i> , 2016, 34, 556-563.	1.0	13
1571	ART score and hepatocellular carcinoma: An appraisal of its applicability. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2016, 40, 705-714.	0.7	12
1572	Diabetes and Cirrhosis Are Risk Factors for Hepatocellular Carcinoma After Successful Treatment of Chronic Hepatitis C. <i>Clinical Infectious Diseases</i> , 2016, 63, 723-729.	2.9	41
1573	Discrimination of cirrhotic nodules, dysplastic lesions and hepatocellular carcinoma by their vibrational signature. <i>Journal of Translational Medicine</i> , 2016, 14, 9.	1.8	16
1574	Renal versus splenic maximum slope based perfusion CT modelling in patients with portal-hypertension. <i>European Radiology</i> , 2016, 26, 4030-4036.	2.3	10
1575	TACE vs DEB-TACE: Who wins?. <i>Digestive and Liver Disease</i> , 2016, 48, 796-797.	0.4	10
1576	Reply. <i>Hepatology</i> , 2016, 63, 1051-1051.	3.6	0
1577	How reader perception of capsule affects interpretation of washout in hypervascular liver nodules in patients at risk for hepatocellular carcinoma. <i>Journal of Magnetic Resonance Imaging</i> , 2016, 43, 1337-1345.	1.9	35
1578	Integration of albumin-bilirubin (ALBI) score into Barcelona Clinic Liver Cancer (BCLC) system for hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 1300-1306.	1.4	103
1579	Addition of tumor multiplicity improves the prognostic performance of the hepatoma arterial embolization prognostic score. <i>Liver International</i> , 2016, 36, 100-107.	1.9	76
1580	Clinicopathological indices to predict hepatocellular carcinoma molecular classification. <i>Liver International</i> , 2016, 36, 108-118.	1.9	93

#	ARTICLE	IF	CITATIONS
1581	Regional differences in sorafenib-treated patients with hepatocellular carcinoma: <sc>GIDEON</sc> observational study. <i>Liver International</i> , 2016, 36, 1196-1205.	1.9	44
1582	A comparison of survival in patients with hepatocellular carcinoma and portal vein invasion treated by radioembolization or sorafenib. <i>Liver International</i> , 2016, 36, 1206-1212.	1.9	52
1583	Nomogram of the Barcelona Clinic Liver Cancer system for individual prognostic prediction in hepatocellular carcinoma. <i>Liver International</i> , 2016, 36, 1498-1506.	1.9	25
1584	Treatment of Hepatocellular Carcinoma. <i>Digestive Diseases</i> , 2016, 34, 597-602.	0.8	72
1585	Impact of Visceral Obesity on Microvascular Invasion in Hepatocellular Carcinoma. <i>Cancer Investigation</i> , 2016, 34, 271-278.	0.6	2
1586	Highly sensitive alpha-fetoprotein, <i>Lens culinaris</i> agglutinin-reactive fraction of alpha-fetoprotein and des-gamma-carboxyprothrombin for hepatocellular carcinoma detection. <i>Hepatology Research</i> , 2016, 46, E130-5.	1.8	52
1587	Reassessing the boundaries of liver transplantation for hepatocellular carcinoma: Where do we stand with tumor down-staging?. <i>Hepatology</i> , 2016, 63, 1014-1025.	3.6	124
1588	Neovascularization-related genes are hallmarks of fast-growing hepatocellular carcinomas and worst survival. Results from a prospective study. <i>Gut</i> , 2016, 65, 861-869.	6.1	207
1589	Association between ultrasonography screening and mortality in patients with hepatocellular carcinoma: a nationwide cohort study. <i>Gut</i> , 2016, 65, 693-701.	6.1	53
1590	Stratification of hepatocellular carcinoma risk in primary biliary cirrhosis: a multicentre international study. <i>Gut</i> , 2016, 65, 321-329.	6.1	139
1592	Postoperative Adjuvant Transcatheter Arterial Chemoembolization After R0 Hepatectomy Improves Outcomes of Patients Who have Hepatocellular Carcinoma with Microvascular Invasion. <i>Annals of Surgical Oncology</i> , 2016, 23, 1344-1351.	0.7	134
1593	Prognostic Significance of ¹⁸F-FDG Uptake in Hepatocellular Carcinoma Treated with Transarterial Chemoembolization or Concurrent Chemoradiotherapy: A Multicenter Retrospective Cohort Study. <i>Journal of Nuclear Medicine</i> , 2016, 57, 509-516.	2.8	42
1594	Effect of MRI Versus MDCT on Milan Criteria Scores and Liver Transplantation Eligibility. <i>American Journal of Roentgenology</i> , 2016, 206, 726-733.	1.0	12
1595	Advances in the management of HIV/HCV coinfection. <i>Hepatology International</i> , 2016, 10, 424-435.	1.9	47
1596	Post-progression survival in patients with advanced hepatocellular carcinoma resistant to sorafenib. <i>Investigational New Drugs</i> , 2016, 34, 255-260.	1.2	40
1597	Preclinical pharmacokinetics and tissue distribution of a novel multikinase inhibitor BZG by validated UPLC-MS/MS assay. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2016, 121, 107-113.	1.4	4
1598	Developing an in situ forming polyphosphate coacervate as a new liquid embolic agent: From experimental design to pilot animal study. <i>Acta Biomaterialia</i> , 2016, 32, 286-297.	4.1	20
1599	Partial liver resection results in a significantly better long-term survival than locally ablative procedures even in elderly patients. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016, 142, 1099-1108.	1.2	16

#	ARTICLE	IF	CITATIONS
1600	Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial. <i>Journal of Hepatology</i> , 2016, 64, 1090-1098.	1.8	567
1601	Identifying Compensated Advanced Chronic Liver Disease: When (Not) to Start Screening for Varices and Clinically Significant Portal Hypertension. , 2016, , 39-49.		11
1602	3D Quantitative tumour burden analysis in patients with hepatocellular carcinoma before TACE: comparing single-lesion vs. multi-lesion imaging biomarkers as predictors of patient survival. <i>European Radiology</i> , 2016, 26, 3243-3252.	2.3	24
1603	Extracellular signal-regulated kinase 1 and 2 in cancer therapy: a focus on hepatocellular carcinoma. <i>Molecular Biology Reports</i> , 2016, 43, 107-116.	1.0	18
1604	Imaging Diagnosis of Hepatocellular Carcinoma: Recent Advances of Contrast-Enhanced Ultrasonography with SonoVue®. <i>Liver Cancer</i> , 2016, 5, 55-66.	4.2	20
1605	Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2016, 150, 835-853.	0.6	1,365
1606	Differentiation of intrahepatic mass-forming cholangiocarcinoma from hepatocellular carcinoma on gadoxetic acid-enhanced liver MR imaging. <i>European Radiology</i> , 2016, 26, 1808-1817.	2.3	73
1607	Screening for hepatocellular carcinoma in high-risk populations. <i>Clinical Imaging</i> , 2016, 40, 311-314.	0.8	14
1608	Comparison of magnetic resonance elastography and diffusion-weighted imaging for differentiating benign and malignant liver lesions. <i>European Radiology</i> , 2016, 26, 398-406.	2.3	52
1609	Evaluating the current surgical strategies for hepatocellular carcinoma. <i>Expert Review of Gastroenterology and Hepatology</i> , 2016, 10, 341-357.	1.4	7
1610	Minimally invasive surgery versus percutaneous radio frequency ablation for the treatment of single small ($\leq 3\text{ cm}$) hepatocellular carcinoma: a case-control study. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2016, 30, 2301-2307.	1.3	40
1611	Curative therapies for hepatocellular carcinoma: an update and perspectives. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 169-175.	1.1	8
1612	Impact of portal hemodynamics on Doppler ultrasonography for predicting decompensation and long-term outcomes in patients with cirrhosis. <i>Scandinavian Journal of Gastroenterology</i> , 2016, 51, 236-244.	0.6	13
1613	Liver Imaging Reporting and Data System v2014 With Gadoxetate Disodium-Enhanced Magnetic Resonance Imaging. <i>Investigative Radiology</i> , 2016, 51, 483-490.	3.5	72
1614	Corona Enhancement and Mosaic Architecture for Prognosis and Selection Between of Liver Resection Versus Transcatheter Arterial Chemoembolization in Single Hepatocellular Carcinomas >5 cm Without Extrahepatic Metastases. <i>Medicine (United States)</i> , 2016, 95, e2458.	0.4	16
1615	Antitumoral Effect of Sunitinib-eluting Beads in the Rabbit VX2 Tumor Model. <i>Radiology</i> , 2016, 280, 425-435.	3.6	30
1616	Hepatocellular carcinoma: From diagnosis to treatment. <i>Surgical Oncology</i> , 2016, 25, 74-85.	0.8	369
1617	A Review and Update of Treatment Options and Controversies in the Management of Hepatocellular Carcinoma. <i>Annals of Surgery</i> , 2016, 263, 1112-1125.	2.1	233

#	ARTICLE	IF	CITATIONS
1618	Hepatic Tumor Ablation. <i>Surgical Clinics of North America</i> , 2016, 96, 315-339.	0.5	21
1619	A Modified Model for Assessment for Retreatment with Transarterial Chemoembolization in Chinese Hepatocellular Carcinoma Patients. <i>Journal of Vascular and Interventional Radiology</i> , 2016, 27, 1288-1297.	0.2	6
1620	A combination of sorafenib and SC-43 is a synergistic SHP-1 agonist duo to advance hepatocellular carcinoma therapy. <i>Cancer Letters</i> , 2016, 371, 205-213.	3.2	31
1621	Morbidity of hepatic resection for intermediate and advanced hepatocellular carcinoma. <i>Langenbeck's Archives of Surgery</i> , 2016, 401, 43-53.	0.8	6
1622	Yttrium-90 Radioembolization for Hepatocellular Carcinoma. <i>Seminars in Nuclear Medicine</i> , 2016, 46, 105-108.	2.5	14
1623	Microwave ablation for liver tumors. <i>Abdominal Radiology</i> , 2016, 41, 650-658.	1.0	32
1624	A Gene Expression Signature Associated with Overall Survival in Patients with Hepatocellular Carcinoma Suggests a New Treatment Strategy. <i>Molecular Pharmacology</i> , 2016, 89, 263-272.	1.0	21
1625	Significant association between FasL gene -844T/C polymorphism and risk to hepatocellular carcinoma in Egyptian patients. <i>Immunology Letters</i> , 2016, 172, 84-88.	1.1	7
1626	Squamous cell carcinoma antigen-IgM is associated with hepatocellular carcinoma in patients with cirrhosis: A prospective study. <i>Digestive and Liver Disease</i> , 2016, 48, 197-202.	0.4	14
1627	Three cases of hepatocellular carcinoma in Fontan patients: Review of the literature and suggestions for hepatic screening. <i>International Journal of Cardiology</i> , 2016, 206, 21-26.	0.8	53
1628	Safety and Pharmacokinetics of Lenvatinib in Patients with Advanced Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , 2016, 22, 1385-1394.	3.2	150
1629	Microvascular invasion patterns affect survival in hepatocellular carcinoma patients after second hepatectomy. <i>Journal of Surgical Research</i> , 2016, 200, 82-90.	0.8	14
1630	Transcatheter Therapy for Hepatic Malignancy: Standardization of Terminology and Reporting Criteria. <i>Journal of Vascular and Interventional Radiology</i> , 2016, 27, 457-473.	0.2	98
1631	Surgical Approaches to Hepatocellular Carcinoma. <i>Seminars in Roentgenology</i> , 2016, 51, 88-94.	0.2	2
1632	Combinatorial immunotherapy strategies for hepatocellular carcinoma. <i>Current Opinion in Immunology</i> , 2016, 39, 103-113.	2.4	52
1633	Long-term Therapeutic Outcomes of Radiofrequency Ablation for Subcapsular versus Nonsubcapsular Hepatocellular Carcinoma: A Propensity Score Matched Study. <i>Radiology</i> , 2016, 280, 300-312.	3.6	84
1634	Advances in Local and Systemic Therapies for Hepatocellular Cancer. <i>Current Oncology Reports</i> , 2016, 18, 9.	1.8	14
1635	Diagnostic criteria for hepatocellular carcinoma ≤ 3 cm with hepatocyte-specific contrast-enhanced magnetic resonance imaging. <i>Journal of Hepatology</i> , 2016, 64, 1099-1107.	1.8	93

#	ARTICLE	IF	CITATIONS
1636	A novel anti-alpha-fetoprotein single-chain variable fragment displays anti-tumor effects in HepG2 cells as a single agent or in combination with paclitaxel. <i>Tumor Biology</i> , 2016, 37, 10085-10096.	0.8	12
1637	Comparison of hepatocellular carcinoma conspicuity on hepatobiliary phase images with gadoxetate disodium vs. delayed phase images with extracellular cellular contrast agent. <i>Abdominal Radiology</i> , 2016, 41, 1522-1531.	1.0	9
1638	Percutaneous Endovascular Radiofrequency Ablation for Malignant Portal Obstruction: An Initial Clinical Experience. <i>CardioVascular and Interventional Radiology</i> , 2016, 39, 994-1000.	0.9	3
1640	Clinical trials of antiangiogenic therapy for hepatocellular carcinoma. <i>International Journal of Clinical Oncology</i> , 2016, 21, 213-218.	1.0	22
1641	Comparison of tumor vascularity and hemodynamics in three rat hepatoma models. <i>Abdominal Radiology</i> , 2016, 41, 257-264.	1.0	15
1642	Different expression of VEGF and EGFL7 in human hepatocellular carcinoma. <i>Digestive and Liver Disease</i> , 2016, 48, 76-80.	0.4	14
1643	Kupffer Imaging by Contrast-Enhanced Sonography With Perfluorobutane Microbubbles Is Associated With Outcomes After Radiofrequency Ablation of Hepatocellular Carcinoma. <i>Journal of Ultrasound in Medicine</i> , 2016, 35, 359-371.	0.8	7
1644	Selective internal radiation therapy compared with sorafenib for hepatocellular carcinoma with portal vein thrombosis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 635-643.	3.3	74
1645	Hepatocellular Carcinoma in Obesity, Type 2 Diabetes, and NAFLD. <i>Digestive Diseases and Sciences</i> , 2016, 61, 1234-1245.	1.1	111
1646	TACE Treatment in Patients with Sorafenib-treated Unresectable Hepatocellular Carcinoma in Clinical Practice: Final Analysis of GIDEON. <i>Radiology</i> , 2016, 279, 630-640.	3.6	109
1647	ACR Appropriateness Criteria Radiologic Management of Hepatic Malignancy. <i>Journal of the American College of Radiology</i> , 2016, 13, 265-273.	0.9	9
1648	Percutaneous Treatment of Localized Infiltrative Hepatocellular Carcinoma Developing on Cirrhosis. <i>Annals of Surgical Oncology</i> , 2016, 23, 1906-1915.	0.7	8
1649	Non-AIDS-related malignancies: expert consensus review and practical applications from the multidisciplinary CANCERVIH Working Group. <i>Annals of Oncology</i> , 2016, 27, 397-408.	0.6	37
1650	Prognostic value of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with Barcelona Clinic Liver Cancer stages 0 and A hepatocellular carcinomas: a multicenter retrospective cohort study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 1638-1645.	3.3	35
1651	Correlation between Dual-Energy and Perfusion CT in Patients with Hepatocellular Carcinoma. <i>Radiology</i> , 2016, 280, 78-87.	3.6	65
1652	Radiofrequency and microwave ablation of subcapsular hepatocellular carcinoma accessed by direct puncture: Safety and efficacy. <i>European Journal of Radiology</i> , 2016, 85, 739-743.	1.2	29
1653	Impact of the Interval between Transarterial Chemoembolization Sessions on Survival in Patients with Unresectable Hepatocellular Carcinoma. <i>Journal of Vascular and Interventional Radiology</i> , 2016, 27, 504-513.	0.2	4
1654	Hepatocellular Carcinoma Screening and Surveillance. <i>Journal of Clinical Gastroenterology</i> , 2016, 50, 120-133.	1.1	53

#	ARTICLE	IF	CITATIONS
1655	Application of the Intermediate-Stage Subclassification to Patients With Untreated Hepatocellular Carcinoma. <i>American Journal of Gastroenterology</i> , 2016, 111, 70-77.	0.2	59
1656	Microwave ablation of hepatocellular carcinoma with portal vein tumor thrombosis after transarterial chemoembolization: a prospective study. <i>Hepatology International</i> , 2016, 10, 175-184.	1.9	24
1657	Compatibility of epirubicin-loaded DC bead [®] with different non-ionic contrast media. <i>Journal of Oncology Pharmacy Practice</i> , 2016, 22, 749-756.	0.5	4
1659	Reply to "Surveillance for hepatocellular carcinoma: A tale of two countries" <i>Journal of Hepatology</i> , 2016, 64, 755-756.	1.8	2
1660	Effectiveness of Transarterial Embolization of Hepatocellular Carcinoma as a Bridge to Transplantation. <i>Journal of Vascular and Interventional Radiology</i> , 2016, 27, 39-45.	0.2	15
1661	Cone-Beam CT Angiography for Determination of Tumor-Feeding Vessels During Chemoembolization of Liver Tumors: Comparison of Conventional and Dedicated-Software Analysis. <i>Journal of Vascular and Interventional Radiology</i> , 2016, 27, 32-38.	0.2	28
1662	Effects of sorafenib combined with low-dose interferon therapy for advanced hepatocellular carcinoma: a pilot study. <i>International Journal of Clinical Oncology</i> , 2016, 21, 676-683.	1.0	4
1663	PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy. <i>Journal of Hepatology</i> , 2016, 64, 800-806.	1.8	358
1664	The clinical role of "liquid biopsy"™ in hepatocellular carcinoma. <i>Hepatic Oncology</i> , 2016, 3, 45-55.	4.2	7
1665	Prognosis of hepatocellular carcinoma: Assessment of eleven staging systems. <i>Journal of Hepatology</i> , 2016, 64, 601-608.	1.8	220
1666	Morphophenotypic changes in human multistep hepatocarcinogenesis with translational implications. <i>Journal of Hepatology</i> , 2016, 64, 87-93.	1.8	40
1667	Quercetin induces apoptosis and enhances 5-FU therapeutic efficacy in hepatocellular carcinoma. <i>Tumor Biology</i> , 2016, 37, 6307-6313.	0.8	53
1668	CT imaging findings in patients with advanced hepatocellular carcinoma treated with sorafenib: Alternative response criteria (Choi, European Association for the Study of the Liver, and modified) <i>Tj ETQq0 0 0 rgBT /Overlock_10 Tf 50 Radiology</i> , 2016, 85, 103-112.	1.2	27
1669	Pseudogene integrator complex subunit 6 pseudogene 1 (INTS6P1) as a novel plasma-based biomarker for hepatocellular carcinoma screening. <i>Tumor Biology</i> , 2016, 37, 1253-1260.	0.8	12
1670	Liver Cancer: Connections with Obesity, Fatty Liver, and Cirrhosis. <i>Annual Review of Medicine</i> , 2016, 67, 103-117.	5.0	535
1671	Radiofrequency ablation-combined multimodel therapies for hepatocellular carcinoma: Current status. <i>Cancer Letters</i> , 2016, 370, 78-84.	3.2	55
1672	Combined use of AFP, PIVKA-II, and AFP-L3 as tumor markers enhances diagnostic accuracy for hepatocellular carcinoma in cirrhotic patients. <i>Scandinavian Journal of Gastroenterology</i> , 2016, 51, 344-353.	0.6	68
1673	Hepatic venous pressure gradient in the preoperative assessment of patients with resectable hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2016, 64, 79-86.	1.8	83

#	ARTICLE	IF	CITATIONS
1674	Low-level expression of microRNA-375 predicts poor prognosis in hepatocellular carcinoma. <i>Tumor Biology</i> , 2016, 37, 2145-2152.	0.8	12
1675	Comparison of Existing Response Criteria in Patients with Hepatocellular Carcinoma Treated with Transarterial Chemoembolization Using a 3D Quantitative Approach. <i>Radiology</i> , 2016, 278, 275-284.	3.6	85
1676	Cone Beam Computed Tomography (CBCT) in the Field of Interventional Oncology of the Liver. <i>CardioVascular and Interventional Radiology</i> , 2016, 39, 8-20.	0.9	63
1677	Predictive factors for complete response of chemoembolization with drug-eluting beads (DEB-TACE) for hepatocellular carcinoma. <i>European Radiology</i> , 2016, 26, 1640-1648.	2.3	65
1678	Cirrhotic liver: What's that nodule? The LI-RADS approach. <i>Journal of Magnetic Resonance Imaging</i> , 2016, 43, 281-294.	1.9	33
1679	Safety and efficacy of TACE and gamma knife on hepatocellular carcinoma with portal vein invasion. <i>Gut</i> , 2016, 65, 715-716.	6.1	20
1680	Histogram Analysis of CT Perfusion of Hepatocellular Carcinoma for Predicting Response to Transarterial Radioembolization: Value of Tumor Heterogeneity Assessment. <i>CardioVascular and Interventional Radiology</i> , 2016, 39, 400-408.	0.9	27
1681	The progress and prospects of routine prophylactic antiviral treatment in hepatitis B-related hepatocellular carcinoma. <i>Cancer Letters</i> , 2016, 379, 262-267.	3.2	14
1682	Role of chemokine pathways in hepatobiliary cancer. <i>Cancer Letters</i> , 2016, 379, 173-183.	3.2	64
1683	Consensus report from the 7th International Forum for Liver Magnetic Resonance Imaging. <i>European Radiology</i> , 2016, 26, 674-682.	2.3	86
1684	Developments in cancer vaccines for hepatocellular carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2016, 65, 93-99.	2.0	55
1685	Radiologic-pathologic analysis of quantitative 3D tumour enhancement on contrast-enhanced MR imaging: a study of ROI placement. <i>European Radiology</i> , 2016, 26, 103-113.	2.3	26
1686	Patient stratification and therapy in atypical haemolytic uraemic syndrome (aHUS). <i>Immunobiology</i> , 2016, 221, 715-718.	0.8	6
1687	Combining crowd consensus and user trustworthiness for managing collective tasks. <i>Future Generation Computer Systems</i> , 2016, 54, 378-388.	4.9	14
1688	Risk prediction for patients with hepatocellular carcinoma undergoing chemoembolization: development of a prediction model. <i>Liver International</i> , 2016, 36, 92-99.	1.9	64
1689	Tumour initiating cells and IGF/FGF signalling contribute to sorafenib resistance in hepatocellular carcinoma. <i>Gut</i> , 2017, 66, 530-540.	6.1	161
1690	Liver transplantation for hepatobiliary malignancies: a new era of "Transplant Oncology" has begun. <i>Surgery Today</i> , 2017, 47, 403-415.	0.7	48
1691	Adding Liver Stiffness Measurement to the Routine Evaluation of Hepatocellular Carcinoma Resectability Can Optimize Clinical Outcome. <i>Ultraschall in Der Medizin</i> , 2017, 38, 515-522.	0.8	3

#	ARTICLE	IF	CITATIONS
1692	Regresi3n espont3nea de carcinoma hepatocelular. A prop3sito de un caso. Gastroenterolog3a Y Hepatolog3a, 2017, 40, 286-288.	0.2	2
1693	Clinical features and prognosis of elderly patients with hepatocellular carcinoma not indicated for surgical resection. Geriatrics and Gerontology International, 2017, 17, 189-201.	0.7	22
1694	Semiquantitative prediction of early response of conventional transcatheter arterial chemoembolization for hepatocellular carcinoma using postprocedural plain cone-beam computed tomography. Hepatology Research, 2017, 47, E113-E119.	1.8	2
1695	Incorporating albumin3bilirubin grade into the cancer of the liver Italian program system for hepatocellular carcinoma. Journal of Gastroenterology and Hepatology (Australia), 2017, 32, 221-228.	1.4	47
1696	Effect of yttrium90 radioembolization on outcomes in Asian patients with early to advanced stage hepatocellular carcinoma. Hepatology Research, 2017, 47, 387-397.	1.8	6
1697	Arterio-portal shunts in the cirrhotic liver: perfusion computed tomography for distinction of arterialized pseudolesions from hepatocellular carcinoma. European Radiology, 2017, 27, 1074-1080.	2.3	11
1698	Evaluation of antiangiogenic and antiproliferative effects of sorafenib by sequential histology and intravoxel incoherent motion diffusion-weighted imaging in an orthotopic hepatocellular carcinoma xenograft model. Journal of Magnetic Resonance Imaging, 2017, 45, 270-280.	1.9	29
1699	Prognostic Scoring Models for Patients Undergoing Sorafenib Treatment for Advanced Stage Hepatocellular Carcinoma in Real-Life Practice. American Journal of Clinical Oncology: Cancer Clinical Trials, 2017, 40, 167-174.	0.6	5
1700	Surveillance rates for hepatocellular carcinoma among patients with cirrhosis, chronic hepatitis B, and chronic hepatitis C based on Japanese claims database. Hepatology Research, 2017, 47, 283-292.	1.8	8
1701	Should we routinely use DEBTACE for unresectable HCC? cTACE versus DEBTACE: a single-center survival analysis. Updates in Surgery, 2017, 69, 67-73.	0.9	15
1702	Integration of Contrast-enhanced US into a Multimodality Approach to Imaging of Nodules in a Cirrhotic Liver: How I Do It. Radiology, 2017, 282, 317-331.	3.6	70
1703	Virus-induced hepatocellular carcinoma with special emphasis on HBV. Hepatology International, 2017, 11, 171-180.	1.9	57
1704	Clinical impact of preoperative brain MR angiography and MR imaging in candidates for liver transplantation: a propensity score-matching study in a single institution. European Radiology, 2017, 27, 3532-3541.	2.3	6
1705	Targeted Proteomics Predicts a Sustained Complete-Response after Transarterial Chemoembolization and Clinical Outcomes in Patients with Hepatocellular Carcinoma: A Prospective Cohort Study. Journal of Proteome Research, 2017, 16, 1239-1248.	1.8	27
1706	Diagnostic histopathology of hepatocellular carcinoma: A case-based review. Seminars in Diagnostic Pathology, 2017, 34, 126-137.	1.0	17
1707	Thermal Ablation versus Surgical Resection for the Treatment of Stage T1 Hepatocellular Carcinoma in the Surveillance, Epidemiology, and End Results Database Population. Journal of Vascular and Interventional Radiology, 2017, 28, 325-333.	0.2	14
1708	Bridging Locoregional Therapy Prolongs Survival in Patients Listed for Liver Transplant with Hepatocellular Carcinoma. Cardiovascular and Interventional Radiology, 2017, 40, 410-420.	0.9	13
1709	The clinical role of circulating free tumor DNA in gastrointestinal malignancy. Translational Research, 2017, 183, 137-154.	2.2	14

#	ARTICLE	IF	CITATIONS
1710	Serum microRNA profiles as diagnostic biomarkers for HBV-positive hepatocellular carcinoma. <i>Liver International</i> , 2017, 37, 888-896.	1.9	56
1711	A meta-analysis of single HCV-untreated arm of studies evaluating outcomes after curative treatments of HCV-related hepatocellular carcinoma. <i>Liver International</i> , 2017, 37, 1157-1166.	1.9	70
1712	Intra-arterial therapies for liver cancer: assessing tumor response. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 119-127.	1.1	11
1713	Complications after Hepatectomy for Hepatocellular Carcinoma Independently Shorten Survival: A Western, Single-Center Audit. <i>Annals of Surgical Oncology</i> , 2017, 24, 1569-1578.	0.7	26
1714	Liver Transplantation for HCC: The Milan Criteria. , 2017, , 267-286.		0
1715	Interventional Radiology for the Pre-transplant Patient. , 2017, , 427-438.		0
1716	Transarterial Embolization With or Without Chemotherapy: What Should Be the Indication for Patients With Hepatocellular Carcinoma?. <i>Journal of Clinical Oncology</i> , 2017, 35, 257-258.	0.8	5
1717	Is the Hong Kong Liver Cancer Staging System Ready to Replace the Barcelona Clinic Liver Cancer System?. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 756-758.	2.4	1
1719	Assessment of hepatic function decline after stereotactic body radiation therapy for primary liver cancer. <i>Practical Radiation Oncology</i> , 2017, 7, 173-182.	1.1	42
1720	mRECIST to predict survival in advanced hepatocellular carcinoma: Analysis of two randomised phase II trials comparing nintedanib vs sorafenib. <i>Liver International</i> , 2017, 37, 1047-1055.	1.9	58
1721	Effects of LncRNA-HOST2 on cell proliferation, migration, invasion and apoptosis of human hepatocellular carcinoma cell line SMMC-7721. <i>Bioscience Reports</i> , 2017, 37, .	1.1	36
1722	Single-institution experience of radioembolization with yttrium-90 microspheres for unresectable metastatic neuroendocrine liver tumors. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 1617-1623.	1.4	24
1723	Non-transplant therapies for patients with hepatocellular carcinoma and Child-Pugh-Turcotte class B cirrhosis. <i>Lancet Oncology</i> , The, 2017, 18, e101-e112.	5.1	123
1724	Effects of nucleoside analogue prescription for hepatitis B on the incidence of liver cancer in Hong Kong: a territory-wide ecological study. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 501-509.	1.9	30
1725	Systemic Chemotherapy in Orthotopic Liver Transplantation. , 2017, , 303-316.		0
1726	Clinical validity of Metroticket calculator in transplant patients undergoing prior chemoembolization for hepatocellular carcinoma. <i>Hepatology International</i> , 2017, 11, 209-219.	1.9	1
1727	MicroRNA-155 is upregulated in ascites in patients with spontaneous bacterial peritonitis. <i>Scientific Reports</i> , 2017, 7, 40556.	1.6	10
1728	Radiofrequency ablation combined with transarterial chemoembolization versus hepatectomy for patients with hepatocellular carcinoma within Milan criteria: a retrospective case-control study. <i>Clinical and Translational Oncology</i> , 2017, 19, 844-852.	1.2	33

#	ARTICLE	IF	CITATIONS
1729	Impact of disease stage and aetiology on survival in hepatocellular carcinoma: implications for surveillance. <i>British Journal of Cancer</i> , 2017, 116, 441-447.	2.9	46
1730	Prognostic factors of hepatocellular carcinoma patients with portal vein tumor thrombosis treated with transcatheter arterial chemoembolization. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2017, 13, e331-e341.	0.7	6
1731	Comparative effectiveness of first-line radiofrequency ablation versus surgical resection and transplantation for patients with early hepatocellular carcinoma. <i>Cancer</i> , 2017, 123, 1817-1827.	2.0	68
1732	The microRNA-449 family inhibits TGF- β -mediated liver cancer cell migration by targeting SOX4. <i>Journal of Hepatology</i> , 2017, 66, 1012-1021.	1.8	102
1733	Transarterial Therapies for Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2017, 6, 27-33.	4.2	44
1734	The albumin-bilirubin grade improves hepatic reserve estimation post-sorafenib failure: implications for drug development. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 714-722.	1.9	37
1735	Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC. <i>Journal of Hepatology</i> , 2017, 66, 1166-1172.	1.8	178
1736	Immunosuppression strategies in liver transplantation patient; patients with hepatocellular carcinoma. <i>Immunotherapy</i> , 2017, 9, 197-206.	1.0	1
1737	Lymphocyte to monocyte ratio and neutrophil to lymphocyte ratio are superior inflammation-based predictors of recurrence in patients with hepatocellular carcinoma after hepatic resection. <i>Journal of Surgical Oncology</i> , 2017, 115, 718-728.	0.8	51
1739	Management and prognosis of hepatocellular carcinoma in the elderly: Results of an in-field multicenter cohort study. <i>Liver International</i> , 2017, 37, 1184-1192.	1.9	15
1740	Wnt signalling modulates transcribed-ultraconserved regions in hepatobiliary cancers. <i>Gut</i> , 2017, 66, 1268-1277.	6.1	75
1741	Advances in Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma. <i>Seminars in Radiation Oncology</i> , 2017, 27, 247-255.	1.0	79
1743	Validation of the Risk Prediction Models STATE-Score and START-Strategy to Guide TACE Treatment in Patients with Hepatocellular Carcinoma. <i>CardioVascular and Interventional Radiology</i> , 2017, 40, 1017-1025.	0.9	17
1744	Vascular CXCR4 Expression Promotes Vessel Sprouting and Sensitivity to Sorafenib Treatment in Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , 2017, 23, 4482-4492.	3.2	38
1745	Microwave ablation of liver malignancies: comparison of effects and early outcomes of percutaneous and intraoperative approaches with different liver conditions. <i>Medical Oncology</i> , 2017, 34, 49.	1.2	45
1746	Texture analysis of baseline multiphase hepatic computed tomography images for the prognosis of single hepatocellular carcinoma after hepatectomy: A retrospective pilot study. <i>European Journal of Radiology</i> , 2017, 90, 198-204.	1.2	44
1747	Prediction of hepatocellular carcinoma recurrence after liver transplantation: Comparison of four explant-based prognostic models. <i>Liver International</i> , 2017, 37, 717-726.	1.9	21
1748	Developing a liver cancer program in the nonacademic medical center. <i>Clinical Liver Disease</i> , 2017, 9, 25-28.	1.0	2

#	ARTICLE	IF	CITATIONS
1749	The impact of esophagogastric varices on the prognosis of patients with hepatocellular carcinoma. <i>Scientific Reports</i> , 2017, 7, 42577.	1.6	25
1750	Hepatic decompensation is the major driver of death in HCV-infected cirrhotic patients with successfully treated early hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2017, 67, 65-71.	1.8	83
1751	Parametric response mapping of dynamic CT: enhanced prediction of survival in hepatocellular carcinoma patients treated with transarterial chemoembolization. <i>Abdominal Radiology</i> , 2017, 42, 1871-1879.	1.0	5
1752	Bridging locoregional therapy: Longitudinal trends and outcomes in patients with hepatocellular carcinoma. <i>Transplantation Reviews</i> , 2017, 31, 136-143.	1.2	10
1753	Metronomic capecitabine versus best supportive care as second-line treatment in hepatocellular carcinoma: a retrospective study. <i>Scientific Reports</i> , 2017, 7, 42499.	1.6	30
1754	Imaging of hepatocellular carcinoma and image guided therapies - how we do it. <i>Cancer Imaging</i> , 2017, 17, 9.	1.2	23
1755	External beam radiotherapy for unresectable hepatocellular carcinoma. <i>The Cochrane Library</i> , 2017, 3, CD011314.	1.5	14
1756	Cancer-associated circulating large extracellular vesicles in cholangiocarcinoma and hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2017, 67, 282-292.	1.8	123
1757	Value of contrast-enhanced sonography of small hepatocellular carcinoma with sonazoid prior to radiofrequency ablation. <i>Journal of Clinical Ultrasound</i> , 2017, 45, 383-390.	0.4	6
1758	Assessment of treatment efficacy in hepatocellular carcinoma: Response rate, delay in progression or none of them. <i>Journal of Hepatology</i> , 2017, 66, 1114-1117.	1.8	26
1759	Management of people with intermediate-stage hepatocellular carcinoma. <i>The Cochrane Library</i> , 2017, 3, CD011649.	1.5	16
1760	Incidental Findings on Abdominal CT. <i>Medical Radiology</i> , 2017, , 127-168.	0.0	0
1762	Clinical utility of multipolar ablation with a 3D simulator system for patients with liver cancer. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 1852-1858.	1.4	9
1763	Loco-regional treatment of HCC: current status. <i>Clinical Radiology</i> , 2017, 72, 626-635.	0.5	72
1764	Long-Term Survival Analysis of Stereotactic Ablative Radiotherapy Versus Liver Resection for Small Hepatocellular Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 98, 639-646.	0.4	90
1765	Survival benefit of hepatic resection for hepatocellular carcinoma beyond the Barcelona Clinic Liver Cancer classification. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2017, 24, 199-205.	1.4	15
1766	Seek and destroy: targeted adeno-associated viruses for gene delivery to hepatocellular carcinoma. <i>Drug Delivery</i> , 2017, 24, 289-299.	2.5	18
1767	Early detection and curative treatment of hepatocellular carcinoma: A cost-effectiveness analysis in France and in the United States. <i>Hepatology</i> , 2017, 65, 1237-1248.	3.6	93

#	ARTICLE	IF	CITATIONS
1768	Liver Transplantation is a Preferable Alternative to Palliative Therapy for Selected Patients with Advanced Hepatocellular Carcinoma. <i>Annals of Surgical Oncology</i> , 2017, 24, 1843-1851.	0.7	14
1769	Radiofrequency ablation of hepatocellular carcinoma as bridge therapy to liver transplantation: A 10-year intention-to-treat analysis. <i>Hepatology</i> , 2017, 65, 1979-1990.	3.6	87
1770	Cirrhose et carcinome hépatocellulaire : diagnostic et suivi biologique. <i>Revue Francophone Des Laboratoires</i> , 2017, 2017, 64-71.	0.0	0
1771	Diagnostic value of dynamic contrast-enhanced CT with perfusion imaging in the quantitative assessment of tumor response to sorafenib in patients with advanced hepatocellular carcinoma: A feasibility study. <i>European Journal of Radiology</i> , 2017, 90, 34-41.	1.2	18
1772	Early response evaluation using CT-perfusion one day after transarterial chemoembolization for HCC predicts treatment response and long-term disease control. <i>European Journal of Radiology</i> , 2017, 90, 73-80.	1.2	22
1773	On-target sorafenib toxicity predicts improved survival in hepatocellular carcinoma: a multi-centre, prospective study. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 1146-1155.	1.9	47
1774	Diagnosis of Hepatocellular Carcinoma with Non-Invasive Imaging: a Plea for Worldwide Adoption of Standard and Precise Terminology for Describing Enhancement Criteria. <i>Ultraschall in Der Medizin</i> , 2017, 38, 9-11.	0.8	16
1775	Diagnostic efficacy of ultrasound in hepatocellular carcinoma diagnosis. <i>Expert Review of Gastroenterology and Hepatology</i> , 2017, 11, 277-279.	1.4	20
1776	Improved Performance of Serum Alpha-Fetoprotein for Hepatocellular Carcinoma Diagnosis in HCV Cirrhosis with Normal Alanine Transaminase. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017, 26, 1085-1092.	1.1	43
1777	Sorafenib therapy following resection prolongs disease-free survival in patients with advanced hepatocellular carcinoma at a high risk of recurrence. <i>Oncology Letters</i> , 2017, 13, 984-992.	0.8	18
1778	Recurrence of hepatocellular carcinoma after liver transplantation: Is there a place for resection?. <i>Liver Transplantation</i> , 2017, 23, 440-447.	1.3	75
1780	Diagnosis of hepatocellular carcinoma: An update on international guidelines. <i>Diagnostic and Interventional Imaging</i> , 2017, 98, 379-391.	1.8	41
1781	Early complications after percutaneous radiofrequency ablation for hepatocellular carcinoma: an analysis of 1,843 ablations in 1,211 patients in a single centre: experience over 10 years. <i>Clinical Radiology</i> , 2017, 72, 692.e9-692.e15.	0.5	23
1782	Radiofrequency vs Microwave Ablation After Neoadjuvant Transarterial Bland and Drug-Eluting Microsphere Chemoembolization for the Treatment of Hepatocellular Carcinoma. <i>Current Problems in Diagnostic Radiology</i> , 2017, 46, 402-409.	0.6	18
1783	Percutaneous radiofrequency ablation of hepatocellular carcinoma in cirrhosis: analysis of complications in a single centre over 20 years. <i>British Journal of Radiology</i> , 2017, 90, 20160804.	1.0	15
1784	Differentiation between cholangiocarcinoma and hepatocellular carcinoma with target sign on diffusion-weighted imaging and hepatobiliary phase gadoteric acid-enhanced MR imaging: Classification tree analysis applying capsule and septum. <i>European Journal of Radiology</i> , 2017, 92, 1-10.	1.2	33
1785	Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. <i>Lancet, The</i> , 2017, 389, 2492-2502.	6.3	3,224
1786	Improved survival of patients with hepatocellular carcinoma and compensated hepatitis C virus-related cirrhosis who attained sustained virological response. <i>Liver International</i> , 2017, 37, 1526-1534.	1.9	34

#	ARTICLE	IF	CITATIONS
1787	Non-coding RNA in hepatocellular carcinoma: Mechanisms, biomarkers and therapeutic targets. <i>Journal of Hepatology</i> , 2017, 67, 603-618.	1.8	292
1788	Hepatocellular carcinoma in Danish patients: a single Copenhagen center experience. <i>Scandinavian Journal of Gastroenterology</i> , 2017, 52, 768-772.	0.6	1
1789	Functional image-guided stereotactic body radiation therapy planning for patients with hepatocellular carcinoma. <i>Medical Dosimetry</i> , 2017, 42, 97-103.	0.4	14
1790	Effect of threshold growth as a major feature on LI-RADS categorization. <i>Abdominal Radiology</i> , 2017, 42, 2089-2100.	1.0	14
1791	Short-Term Results of Laparoscopic Radiofrequency Ablation Using a Multipolar System for Localized Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2017, 6, 137-145.	4.2	5
1792	Chemoembolization for Hepatocellular Carcinoma in Patients with Extrahepatic Spread: Prognostic Determinants and Appropriate Candidates. <i>Journal of Vascular and Interventional Radiology</i> , 2017, 28, 956-962.	0.2	1
1793	EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. <i>Journal of Hepatology</i> , 2017, 67, 145-172.	1.8	889
1794	Higher PKD3 expression in hepatocellular carcinoma (HCC) tissues predicts poorer prognosis for HCC patients. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2017, 41, 554-563.	0.7	6
1795	Validation of <sc>PAGE</sc> model in Asian chronic hepatitis B patients receiving entecavir or tenofovir. <i>Liver International</i> , 2017, 37, 1788-1795.	1.9	37
1796	Potential ultrastructure predicting factors for hepatocellular carcinoma in HCV infected patients. <i>Ultrastructural Pathology</i> , 2017, 41, 209-226.	0.4	5
1797	Should AFP (or Any Biomarkers) Be Used for HCC Surveillance?. <i>Current Hepatology Reports</i> , 2017, 16, 137-145.	0.4	26
1798	Controlling liver cancer mortality on a global scale: Still a long way to go. <i>Journal of Hepatology</i> , 2017, 67, 216-217.	1.8	8
1799	Higher risk of hepatocellular carcinoma in chronic hepatitis B vs chronic hepatitis C after achievement of virologic response. <i>Journal of Viral Hepatitis</i> , 2017, 24, 990-997.	1.0	9
1800	The occurrence of hepatocellular carcinoma in different risk stratifications of clinically noncirrhotic nonalcoholic fatty liver disease. <i>International Journal of Cancer</i> , 2017, 141, 1307-1314.	2.3	70
1801	Imaging of liver transplantation. <i>European Journal of Radiology</i> , 2017, 93, 295-307.	1.2	21
1802	Giant hepatocellular carcinoma with bone metastasis in a young adult, emerged from pigmented adenoma with beta-Catenin activation: A case report. <i>International Journal of Surgery Case Reports</i> , 2017, 36, 18-21.	0.2	5
1803	Cirrhosis Patients with Nonalcoholic Steatohepatitis Are Significantly Less Likely to Receive Surveillance for Hepatocellular Carcinoma. <i>Digestive Diseases and Sciences</i> , 2017, 62, 2174-2181.	1.1	22
1804	Contrast-enhanced US with Perfluorobutane(Sonazoid) used as a surveillance test for Hepatocellular Carcinoma (HCC) in Cirrhosis (SCAN): an exploratory cross-sectional study for a diagnostic trial. <i>BMC Cancer</i> , 2017, 17, 279.	1.1	13

#	ARTICLE	IF	CITATIONS
1805	Primary Biliary Cholangitis: advances in management and treatment of the disease. <i>Digestive and Liver Disease</i> , 2017, 49, 841-846.	0.4	23
1806	Comparison Between Child-Turcotte-Pugh and Albumin-Bilirubin Scores in Assessing the Prognosis of Hepatocellular Carcinoma After Stereotactic Ablative Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 99, 145-152.	0.4	29
1807	JOURNAL CLUB: Four-Dimensional Flow MRI-Based Splenic Flow Index for Predicting Cirrhosis-Associated Hypersplenism. <i>American Journal of Roentgenology</i> , 2017, 209, 46-54.	1.0	14
1808	Survival benefit of liver resection for Barcelona Clinic Liver Cancer stage B hepatocellular carcinoma. <i>British Journal of Surgery</i> , 2017, 104, 1045-1052.	0.1	60
1809	Mechanism and prediction of HCC development in HBV infection. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2017, 31, 291-298.	1.0	22
1810	Downregulation of tumor protein 53-inducible nuclear protein 1 expression in hepatocellular carcinoma correlates with poor prognosis. <i>Oncology Letters</i> , 2017, 13, 1228-1234.	0.8	2
1811	NIACE score for hepatocellular carcinoma patients treated by surgery or transarterial chemoembolization. <i>European Journal of Gastroenterology and Hepatology</i> , 2017, 29, 706-715.	0.8	15
1812	Liver fibrosis, cirrhosis, and cirrhosis-related nodules: Imaging diagnosis and surveillance. <i>Diagnostic and Interventional Imaging</i> , 2017, 98, 455-468.	1.8	26
1813	Systematic review and meta-analysis of hepatic resection versus transarterial chemoembolization for solitary large hepatocellular carcinoma. <i>Hpb</i> , 2017, 19, 653-658.	0.1	24
1814	Treating Hepatobiliary Cancers: The Oncology Way. <i>Digestive Diseases</i> , 2017, 35, 384-386.	0.8	8
1816	Effect of smoking on survival of patients with hepatocellular carcinoma. <i>Liver International</i> , 2017, 37, 1682-1687.	1.9	26
1817	Surgical Procedures on the Cirrhotic Patient. , 2017, , .		1
1818	Spontaneous regression of hepatocellular carcinoma. A case report. <i>GastroenterologÏa Y HepatologÏa (English Edition)</i> , 2017, 40, 286-288.	0.0	1
1819	Other non-surgical treatments for liver cancer. <i>Reports of Practical Oncology and Radiotherapy</i> , 2017, 22, 181-192.	0.3	13
1820	Survival analysis after liver resection for hepatocellular carcinoma: A consecutive cohort of 1002 patients. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 1055-1063.	1.4	46
1821	Nardilysin promotes hepatocellular carcinoma through activation of signal transducer and activator of transcription 3. <i>Cancer Science</i> , 2017, 108, 910-917.	1.7	9
1822	Comparison of ultrasonography-guided percutaneous microwave ablation for subcapsular and nonsubcapsular hepatocellular carcinoma. <i>European Journal of Radiology</i> , 2017, 91, 93-98.	1.2	11
1823	Microwave ablation for hepatocellular carcinoma associated with Budd-Chiari syndrome after transarterial chemoembolization: an analysis of ten cases. <i>Abdominal Radiology</i> , 2017, 42, 962-968.	1.0	3

#	ARTICLE	IF	CITATIONS
1824	Validation of the AFP model as a predictor of HCC recurrence in patients with viral hepatitis-related cirrhosis who had received a liver transplant for HCC. <i>Journal of Hepatology</i> , 2017, 66, 552-559.	1.8	166
1825	Secondary prophylaxis of hepatocellular carcinoma: the comparison of direct-acting antivirals with pegylated interferon and untreated cohort. <i>Journal of Viral Hepatitis</i> , 2017, 24, 13-16.	1.0	5
1826	Hepatocellular Carcinoma: Therapeutic Guidelines and Medical Treatment. <i>Liver Cancer</i> , 2017, 6, 16-26.	4.2	97
1827	Surgery and Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2017, 6, 44-50.	4.2	42
1828	EWALT: East Meets West in a Multidisciplinary Setting to Improve the Management of Liver Tumors. <i>Liver Cancer</i> , 2017, 6, 13-15.	4.2	1
1829	Multidisciplinary Concurrent Management of Recurrent Hepatocellular Therapy is Superior to Sequential Therapy. <i>World Journal of Surgery</i> , 2017, 41, 1331-1339.	0.8	8
1830	Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet, The</i> , 2017, 389, 56-66.	6.3	2,771
1831	Early Response of Hepatocellular Carcinoma to Chemoembolization. <i>Journal of Computer Assisted Tomography</i> , 2017, 41, 315-320.	0.5	14
1832	Surgical treatment for advanced hepatocellular carcinoma with portal vein tumor thrombus. <i>Hepatology Research</i> , 2017, 47, 957-962.	1.8	48
1833	Antiplatelet therapy and the risk of hepatocellular carcinoma in chronic hepatitis B patients on antiviral treatment. <i>Hepatology</i> , 2017, 66, 1556-1569.	3.6	92
1834	The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B. <i>Hepatology</i> , 2017, 66, 1444-1453.	3.6	239
1835	Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. <i>Hepatology International</i> , 2017, 11, 317-370.	1.9	1,537
1836	Increasing burden of liver cancer despite extensive use of antiviral agents in a hepatitis B virus-endemic population. <i>Hepatology</i> , 2017, 66, 1454-1463.	3.6	92
1837	Elevated serum myostatin level is associated with worse survival in patients with liver cirrhosis. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2017, 8, 915-925.	2.9	150
1838	HKLC Triages More Hepatocellular Carcinoma Patients to Curative Therapies Compared to BCLC and Is Associated with Better Survival. <i>Digestive Diseases and Sciences</i> , 2017, 62, 2182-2192.	1.1	19
1839	Liver Stiffness Assessed by Shear Wave Elastography Predicts Postoperative Liver Failure in Patients with Hepatocellular Carcinoma. <i>Journal of Gastrointestinal Surgery</i> , 2017, 21, 1471-1479.	0.9	35
1840	Prognostic Nomograms Stratify Survival of Patients with Hepatocellular Carcinoma Without Portal Vein Tumor Thrombosis After Curative Resection. <i>Oncologist</i> , 2017, 22, 561-569.	1.9	35
1841	Postoperative Prognostic Nutritional Index Predicts Survival of Patients with Hepatocellular Carcinoma within Milan Criteria and Hypersplenism. <i>Journal of Gastrointestinal Surgery</i> , 2017, 21, 1626-1634.	0.9	20

#	ARTICLE	IF	CITATIONS
1842	Adjuvant immunotherapy with autologous dendritic cells for hepatocellular carcinoma, randomized phase II study. <i>Oncology</i> , 2017, 6, e1328335.	2.1	38
1843	Hepatic Surgery in Patients with Cirrhosis: Mitigating Risk. , 2017, , 161-173.		0
1844	Meta-analysis of determinants of survival following treatment of recurrent hepatocellular carcinoma. <i>British Journal of Surgery</i> , 2017, 104, 1433-1442.	0.1	91
1845	New trends on obesity and NAFLD in Asia. <i>Journal of Hepatology</i> , 2017, 67, 862-873.	1.8	759
1846	HCC Locoregional Therapies: Yttrium-90 (Y-90) Selective Internal Radiation Therapy (SIRT). <i>Journal of Gastrointestinal Cancer</i> , 2017, 48, 276-280.	0.6	2
1847	Trends in net survival from liver cancer in six European Latin countries: results from the SUDCAN population-based study. <i>European Journal of Cancer Prevention</i> , 2017, 26, S56-S62.	0.6	3
1848	Prognostic Value of FDG Uptake of Portal Vein Tumor Thrombosis in Patients With Locally Advanced Hepatocellular Carcinoma. <i>Clinical Nuclear Medicine</i> , 2017, 42, e35-e40.	0.7	13
1849	How to Differentiate Borderline Hepatic Nodules in Hepatocarcinogenesis: Emphasis on Imaging Diagnosis. <i>Liver Cancer</i> , 2017, 6, 189-203.	4.2	55
1850	Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 565-575.	3.7	362
1851	Focal lesions in cirrhosis: Not always HCC. <i>European Journal of Radiology</i> , 2017, 93, 157-168.	1.2	21
1852	Transarterial Radioembolization Versus Concurrent Chemoradiation Therapy for Locally Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 99, 396-406.	0.4	15
1853	Regorafenib for the treatment of unresectable hepatocellular carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 567-576.	1.1	26
1854	New intermediate-stage subclassification for patients with hepatocellular carcinoma treated with transarterial chemoembolization. <i>Liver International</i> , 2017, 37, 1861-1868.	1.9	69
1855	Precision medicine for hepatocellular carcinoma using molecular pattern diagnostics: results from a preclinical pilot study. <i>Cell Death and Disease</i> , 2017, 8, e2867-e2867.	2.7	8
1856	Advances in management of hepatocellular carcinoma. <i>Current Opinion in Oncology</i> , 2017, 29, 288-295.	1.1	50
1857	Doxorubicin Drug-Eluting Embolic Chemoembolization of Hepatocellular Carcinoma: Study of Midterm Doxorubicin Delivery in Resected Liver Specimens. <i>Journal of Vascular and Interventional Radiology</i> , 2017, 28, 804-810.	0.2	7
1858	Chemoembolization Adopting Polyethylene Glycol Drug-Eluting Embolics Loaded With Doxorubicin for the Treatment of Hepatocellular Carcinoma. <i>American Journal of Roentgenology</i> , 2017, 209, 430-434.	1.0	21
1859	Dropout rate from the liver transplant waiting list because of hepatocellular carcinoma progression in hepatitis C virus-infected patients treated with direct-acting antivirals. <i>Liver Transplantation</i> , 2017, 23, 1103-1112.	1.3	46

#	ARTICLE	IF	CITATIONS
1860	Comparative study of post-transplant outcomes in hepatocellular carcinoma patients treated with chemoembolization or radioembolization. <i>European Journal of Radiology</i> , 2017, 93, 100-106.	1.2	30
1861	Comparison of efficacy between TACE combined with apatinib and TACE alone in the treatment of intermediate and advanced hepatocellular carcinoma: A single-center randomized controlled trial. <i>Cancer Biology and Therapy</i> , 2017, 18, 433-438.	1.5	91
1862	Prediction of long-term clinical outcome in a diverse chronic hepatitis B population: Role of the PAGE-B score. <i>Journal of Viral Hepatitis</i> , 2017, 24, 1023-1031.	1.0	24
1863	Role of hepatic resection in patients with intermediate-stage hepatocellular carcinoma: A multicenter study from Japan. <i>Cancer Science</i> , 2017, 108, 1414-1420.	1.7	40
1864	Hepatocellular Carcinoma: Nomograms Based on the Albumin-Bilirubin Grade to Assess the Outcomes of Radiofrequency Ablation. <i>Radiology</i> , 2017, 285, 670-680.	3.6	88
1865	Transarterial Radioembolization for Hepatocellular Carcinoma Is Safe, but Is It Effective?. <i>American Journal of Roentgenology</i> , 2017, 208, W241-W241.	1.0	0
1866	Long non-coding RNA AB019562 promotes cell proliferation and metastasis in human hepatocellular carcinoma. <i>Molecular Medicine Reports</i> , 2017, 16, 69-74.	1.1	6
1867	Modeling the benefits and harms of surveillance for hepatocellular carcinoma: Information to support informed choices. <i>Hepatology</i> , 2017, 66, 1546-1555.	3.6	32
1868	Conditional Survival Analysis Demonstrates that Recurrence Risk of Surgically Treated Hepatocellular Carcinoma Evolves with Time. <i>Journal of Gastrointestinal Surgery</i> , 2017, 21, 1237-1244.	0.9	7
1869	Emerging tyrosine kinase inhibitors for the treatment of hepatocellular carcinoma. <i>Expert Opinion on Emerging Drugs</i> , 2017, 22, 175-190.	1.0	30
1870	Computed Tomography Perfusion Following Transarterial Chemoembolization of Hepatocellular Carcinoma. <i>Journal of Computer Assisted Tomography</i> , 2017, 41, 708-712.	0.5	5
1871	Sorafenib vs surgical resection for hepatocellular carcinoma with macrovascular invasion: A propensity score analysis. <i>Liver International</i> , 2017, 37, 1869-1876.	1.9	22
1872	Diagnostic Performance of Gadoxetic Acid-enhanced Liver MR Imaging versus Multidetector CT in the Detection of Dysplastic Nodules and Early Hepatocellular Carcinoma. <i>Radiology</i> , 2017, 285, 134-146.	3.6	78
1873	Subtraction Images of Gadoxetic Acid-enhanced MRI: Effect on the Diagnostic Performance for Focal Hepatic Lesions in Patients at Risk for Hepatocellular Carcinoma. <i>American Journal of Roentgenology</i> , 2017, 209, 584-591.	1.0	20
1874	Management of people with early- or very early-stage hepatocellular carcinoma. <i>The Cochrane Library</i> , 2017, 3, CD011650.	1.5	59
1876	Clinical utility of bioimpedance analysis in liver cirrhosis. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2017, 24, 409-416.	1.4	28
1877	Hepatocellular Carcinoma After Sustained Virologic Response: Leave No One Behind. <i>Gastroenterology</i> , 2017, 152, 1282-1284.	0.6	1
1878	Artificial Intelligence and Automatic Image Interpretation in Modern Medicine. <i>Translational Medicine Research</i> , 2017, , 371-407.	0.0	3

#	ARTICLE	IF	CITATIONS
1879	Hepatocellular carcinoma in patients with B and C virus hepatitis without cirrhosis. <i>Brazilian Journal of Infectious Diseases</i> , 2017, 21, 367.	0.3	1
1880	Características clínicas del carcinoma hepatocelular en España. Comparación con el período 2008-2009 y análisis de las causas del diagnóstico fuera de cribado. <i>Estudio de 686 casos en 73 centros. Medicina Clínica</i> , 2017, 149, 61-71.	0.3	17
1881	Use of inhibitors of the renin-angiotensin system is associated with longer survival in patients with hepatocellular carcinoma. <i>United European Gastroenterology Journal</i> , 2017, 5, 987-996.	1.6	49
1882	Gender differences in liver disease and the drug-dose gender gap. <i>Pharmacological Research</i> , 2017, 120, 97-108.	3.1	66
1883	From Detection to Resection: Photoacoustic Tomography and Surgery Guidance with Indocyanine Green Loaded Gold Nanorod@liposome Core-Shell Nanoparticles in Liver Cancer. <i>Bioconjugate Chemistry</i> , 2017, 28, 1221-1228.	1.8	52
1884	<sc>EASL</sc> and <sc>AASLD</sc> recommendations for the diagnosis of <sc>HCC</sc> to the test of daily practice. <i>Liver International</i> , 2017, 37, 1515-1525.	1.9	102
1885	Quantitative proteomics by SWATH-MS reveals sophisticated metabolic reprogramming in hepatocellular carcinoma tissues. <i>Scientific Reports</i> , 2017, 7, 45913.	1.6	61
1886	Hepatocellular carcinoma. <i>Aids</i> , 2017, 31, 603-611.	1.0	30
1887	Diagnostic value of PIVKA-II in detecting hepatocellular carcinoma. <i>Future Virology</i> , 2017, 12, 259-267.	0.9	4
1888	Molecular analysis of Hepatitis B virus subgenotypes and incidence of preS1/preS2 region mutations in HBV-infected Egyptian patients from Mansoura. <i>Journal of Medical Virology</i> , 2017, 89, 1559-1566.	2.5	18
1889	Editorial: is surveillance for hepatocellular carcinoma really required for all British cirrhotics?. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 1277-1278.	1.9	1
1890	Identification of the resection severity index as a significant independent prognostic factor for early mortality and observed survival >5 and >10 years after liver resection for hepatocellular carcinoma. <i>Surgical Oncology</i> , 2017, 26, 178-187.	0.8	12
1891	Serum Wisteria Floribunda Agglutinin-Positive Sialylated Mucin 1 as a Marker of Progenitor/Biliary Features in Hepatocellular Carcinoma. <i>Scientific Reports</i> , 2017, 7, 244.	1.6	14
1892	Biomarkers in hepatocellular carcinoma: an overview. <i>Expert Review of Gastroenterology and Hepatology</i> , 2017, 11, 549-558.	1.4	31
1893	Liver-Directed Therapy for Hepatocellular Carcinoma: An Overview of Techniques, Outcomes, and Posttreatment Imaging Findings. <i>American Journal of Roentgenology</i> , 2017, 209, 67-76.	1.0	27
1894	Tailored Algorithms for Hepatocellular Carcinoma Surveillance: Is One-Size-Fits-All Strategy Outdated?. <i>Current Hepatology Reports</i> , 2017, 16, 64-71.	0.4	17
1895	Survival and prognostic factors after adjuvant ¹³¹ Iodine-labeled lipiodol for hepatocellular carcinoma: a retrospective analysis of 106 patients over 20 years. <i>Annals of Nuclear Medicine</i> , 2017, 31, 379-389.	1.2	1
1896	Cirrhotic Liver. <i>Medical Radiology</i> , 2017, , 447-489.	0.0	1

#	ARTICLE	IF	CITATIONS
1897	Evaluation of sorafenib in Chinese unresectable hepatocellular carcinoma patients with prior surgery and portal vein tumor thrombosis: A subset analysis of GIDEON study data. <i>Tumor Biology</i> , 2017, 39, 101042831769503.	0.8	11
1899	Treatment Options in Patients Awaiting Liver Transplantation with Hepatocellular Carcinoma and Cholangiocarcinoma. <i>Clinics in Liver Disease</i> , 2017, 21, 231-251.	1.0	7
1900	Liver transplantation versus liver resection for hepatocellular carcinoma in intention to treat: An attempt to perform an ideal meta-analysis. <i>Liver Transplantation</i> , 2017, 23, 836-844.	1.3	84
1901	Stabilization Improves Theranostic Properties of Lipiodol®-Based Emulsion During Liver Trans-arterial Chemo-embolization in a VX2 Rabbit Model. <i>CardioVascular and Interventional Radiology</i> , 2017, 40, 907-913.	0.9	12
1902	Sorafenib: A Review in Hepatocellular Carcinoma. <i>Targeted Oncology</i> , 2017, 12, 243-253.	1.7	224
1903	New concepts in embolotherapy of HCC. <i>Medical Oncology</i> , 2017, 34, 58.	1.2	53
1904	mRECIST for systemic therapies: More evidence is required before recommendations can be made. <i>Journal of Hepatology</i> , 2017, 67, 195.	1.8	5
1905	Reply to: "mRECIST for systemic therapies: More evidence is required before recommendations could be made". <i>Journal of Hepatology</i> , 2017, 67, 196-197.	1.8	3
1906	Salvage Liver Transplantation Leads to Poorer Outcome in Hepatocellular Carcinoma Compared with Primary Liver Transplantation. <i>Scientific Reports</i> , 2017, 7, 44652.	1.6	18
1907	Albumin-Bilirubin grade predicts prognosis of HCC patients with sorafenib use. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 1975-1981.	1.4	50
1908	The treatment of intermediate stage tumours beyond TACE: From surgery to systemic therapy. <i>Journal of Hepatology</i> , 2017, 67, 173-183.	1.8	165
1909	Cone Beam CT-Guided Chemoembolization of Probable Hepatocellular Carcinomas Smaller than 1 cm in Patients at High Risk of Hepatocellular Carcinoma. <i>Journal of Vascular and Interventional Radiology</i> , 2017, 28, 795-803.e1.	0.2	12
1910	Intravoxel incoherent motion MRI for monitoring the therapeutic response of hepatocellular carcinoma to sorafenib treatment in mouse xenograft tumor models. <i>Acta Radiologica</i> , 2017, 58, 1045-1053.	0.5	14
1911	Percutaneous microwave ablation of exophytic tumours in hepatocellular carcinoma patients: Safe or not?. <i>Liver International</i> , 2017, 37, 1365-1372.	1.9	15
1912	Distribution of tumor stage and initial treatment modality in patients with primary hepatocellular carcinoma. <i>Clinical and Translational Oncology</i> , 2017, 19, 891-897.	1.2	22
1913	Imaging patterns and focal lesions in fatty liver: a pictorial review. <i>Abdominal Radiology</i> , 2017, 42, 1374-1392.	1.0	32
1914	Treatment efficacy of CT-guided percutaneous microwave ablation for primary hepatocellular carcinoma. <i>Clinical Radiology</i> , 2017, 72, 136-140.	0.5	13
1915	<i>In Vivo</i> Drug Delivery Performance of Lipiodol-Based Emulsion or Drug-Eluting Beads in Patients with Hepatocellular Carcinoma. <i>Molecular Pharmaceutics</i> , 2017, 14, 448-458.	2.3	30

#	ARTICLE	IF	CITATIONS
1916	Aldehyde dehydrogenase (ALDH2) opposes hepatocellular carcinoma progression by regulating AMP-activated protein kinase signaling in mice. <i>Hepatology</i> , 2017, 65, 1628-1644.	3.6	52
1917	Sorafenib for the Treatment of Advanced Hepatocellular Cancer – a UK Audit. <i>Clinical Oncology</i> , 2017, 29, 256-262.	0.6	28
1918	Outcome of hepatitis B and C virus-associated hepatocellular carcinoma occurring after renal transplantation. <i>Journal of Viral Hepatitis</i> , 2017, 24, 430-435.	1.0	4
1919	MRI of Small Hepatocellular Carcinoma: Typical Features Are Less Frequent Below a Size Cutoff of 1.5 cm. <i>American Journal of Roentgenology</i> , 2017, 208, 544-551.	1.0	24
1920	Liver Cancer Cell of Origin, Molecular Class, and Effects on Patient Prognosis. <i>Gastroenterology</i> , 2017, 152, 745-761.	0.6	838
1921	Suberoylanilide hydroxamic Acid, a histone deacetylase inhibitor, alters multiple signaling pathways in hepatocellular carcinoma cell lines. <i>American Journal of Surgery</i> , 2017, 213, 645-651.	0.9	9
1922	Lipiodol does not affect the tissue distribution of intravenous doxorubicin infusion in pigs. <i>Journal of Pharmacy and Pharmacology</i> , 2017, 69, 135-142.	1.2	6
1923	Antiviral Therapy Inhibits Viral Reactivation and Improves Survival after Repeat Hepatectomy for Hepatitis B Virus-Related Recurrent Hepatocellular Carcinoma. <i>Journal of the American College of Surgeons</i> , 2017, 224, 283-293e4.	0.2	21
1924	Radiation Segmentectomy versus TACE Combined with Microwave Ablation for Unresectable Solitary Hepatocellular Carcinoma Up to 3 cm: A Propensity Score Matching Study. <i>Radiology</i> , 2017, 283, 895-905.	3.6	75
1925	Patients with hepatocellular carcinoma: Your address matters!. <i>Journal of Hepatology</i> , 2017, 66, 480-481.	1.8	1
1926	Cost-effectiveness of Stereotactic Body Radiation Therapy versus Radiofrequency Ablation for Hepatocellular Carcinoma: A Markov Modeling Study. <i>Radiology</i> , 2017, 283, 460-468.	3.6	36
1927	CYP1A2 is a predictor of HCC recurrence in HCV-related chronic liver disease: A retrospective multicentric validation study. <i>Digestive and Liver Disease</i> , 2017, 49, 434-439.	0.4	9
1928	Liver transplantation for hepatocellular carcinoma: outcomes and novel surgical approaches. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2017, 14, 203-217.	8.2	304
1929	A Glycomics-Based Test Predicts the Development of Hepatocellular Carcinoma in Cirrhosis. <i>Clinical Cancer Research</i> , 2017, 23, 2750-2758.	3.2	31
1930	The diagnosis and treatment of hepatocellular carcinoma. <i>Seminars in Diagnostic Pathology</i> , 2017, 34, 153-159.	1.0	484
1931	Diagnosing liver fibrosis: a narrative review of current literature for dermatologists. <i>British Journal of Dermatology</i> , 2017, 177, 637-644.	1.4	8
1932	Multimodal and sequential treatment improves survival in patients with hepatocellular carcinoma. <i>Zeitschrift Fur Gastroenterologie</i> , 2017, 55, 251-259.	0.2	3
1933	Time-trends in incidence and prognosis of hepatocellular carcinoma in Denmark: A nationwide register-based cohort study. <i>Liver International</i> , 2017, 37, 871-878.	1.9	20

#	ARTICLE	IF	CITATIONS
1934	Value of MR elastography for the preoperative estimation of liver regeneration capacity in patients with hepatocellular carcinoma. <i>Journal of Magnetic Resonance Imaging</i> , 2017, 45, 1627-1636.	1.9	18
1935	The role of imaging in the surveillance and diagnosis of hepatocellular cancer. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2017, 61, 171-179.	0.9	13
1936	The status of transarterial chemoembolization treatment in the era of precision oncology. <i>Hepatic Oncology</i> , 2017, 4, 55-63.	4.2	11
1937	Nucleos(t)ide Analogue Treatment for Patients With Hepatitis B Virus (HBV) e Antigenâ€“Positive Chronic HBV Genotype C Infection: A Nationwide, Multicenter, Retrospective Study. <i>Journal of Infectious Diseases</i> , 2017, 216, 1407-1414.	1.9	33
1938	Neutrophil-lymphocyte Ratio Plus Prognostic Nutritional Index Predicts the Outcomes of Patients with Unresectable Hepatocellular Carcinoma After Transarterial Chemoembolization. <i>Scientific Reports</i> , 2017, 7, 13873.	1.6	20
1939	Imaging of Hepatocellular Carcinoma Response After ⁹⁰ Y Radioembolization. <i>American Journal of Roentgenology</i> , 2017, 209, W263-W276.	1.0	29
1940	Screening and Surveillance of Hepatocellular Carcinoma. <i>Radiologic Clinics of North America</i> , 2017, 55, 1197-1209.	0.9	28
1941	Local Arterial Therapies in the Management of Unresectable Hepatocellular Carcinoma. <i>Current Treatment Options in Oncology</i> , 2017, 18, 67.	1.3	4
1942	Contribution of hepatitis B virus and hepatitis C virus to liver cancer in China north areas: Experience of the Chinese National Cancer Center. <i>International Journal of Infectious Diseases</i> , 2017, 65, 15-21.	1.5	66
1943	A New Treatment-integrated Prognostic Nomogram of the Barcelona Clinic Liver Cancer System for Hepatocellular Carcinoma. <i>Scientific Reports</i> , 2017, 7, 7914.	1.6	6
1944	Transarterial Chemoembolization with Small Drug-Eluting Beads in Patients with Hepatocellular Carcinoma: Experience from a Cohort of 421 Patients at an Italian Center. <i>Journal of Vascular and Interventional Radiology</i> , 2017, 28, 1495-1502.	0.2	40
1945	The ART-SCORE is not an effective tool for optimizing patient selection for DEB-TACE retreatment. A multicentre Spanish study. <i>GastroenterologÃa Y HepatologÃa (English Edition)</i> , 2017, 40, 515-524.	0.0	0
1947	â€“Hug signâ€“™: a new radiological sign of intraprocedural success after combined treatment for hepatocellular carcinoma. <i>Hepatic Oncology</i> , 2017, 4, 69-73.	4.2	4
1948	Randomized clinical trial of hepatic resection <i>versus</i> radiofrequency ablation for early-stage hepatocellular carcinoma. <i>British Journal of Surgery</i> , 2017, 104, 1775-1784.	0.1	229
1949	Surgical resection versus liver transplantation for hepatocellular carcinoma within the Hangzhou criteria: a preoperative nomogram-guided treatment strategy. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2017, 16, 480-486.	0.6	13
1950	Targeting the renin-angiotensin system to improve cancer treatment: Implications for immunotherapy. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	232
1951	Liver-Directed Therapies for Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. <i>Cancer Control</i> , 2017, 24, 107327481772924.	0.7	29
1952	Risk factors for non-alcoholic fatty liver disease are common in patients with non-B non-C hepatocellular carcinoma in India. <i>Indian Journal of Gastroenterology</i> , 2017, 36, 373-379.	0.7	20

#	ARTICLE	IF	CITATIONS
1953	The prognostic correlation of AFP level at diagnosis with pathological grade, progression, and survival of patients with hepatocellular carcinoma. <i>Scientific Reports</i> , 2017, 7, 12870.	1.6	156
1954	Transarterial infusion of epirubicin and cisplatin combined with systemic infusion of 5-fluorouracil versus transarterial chemoembolization using doxorubicin for unresectable hepatocellular carcinoma with portal vein tumor thrombosis: a retrospective analysis. <i>Therapeutic Advances in Medical Oncology</i> , 2017, 9, 615-626.	1.4	7
1955	Predisposing factors for hepatocellular carcinoma recurrence following initial remission after transcatheter arterial chemoembolization. <i>Oncology Letters</i> , 2017, 14, 3028-3034.	0.8	16
1956	Liver investigations: Updating on US technique and contrast-enhanced ultrasound (CEUS). <i>European Journal of Radiology</i> , 2017, 96, 65-73.	1.2	30
1957	Selective internal radiation therapy for liver tumours. <i>Clinical Medicine</i> , 2017, 17, 449-453.	0.8	19
1958	Con: Treating hepatitis C virus With direct-acting antivirals: Fear not the perceived threat of hepatocellular carcinoma. <i>Liver Transplantation</i> , 2017, 23, 1596-1600.	1.3	4
1959	Prognostic value of the combination of serum levels of vascular endothelial growth factor, C-reactive protein and contrast-enhanced ultrasound in patients with primary liver cancer who underwent transcatheter arterial chemoembolization. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 1169-1178.	1.1	6
1960	Current immunotherapeutic strategies in hepatocellular carcinoma: recent advances and future directions. <i>Therapeutic Advances in Gastroenterology</i> , 2017, 10, 805-814.	1.4	13
1961	Impact of Tumor Factors on Survival in Patients with Hepatocellular Carcinoma Classified Based on Kinki Criteria Stage B2. <i>Digestive Diseases</i> , 2017, 35, 583-588.	0.8	7
1962	Prognostic scores for sorafenib-treated hepatocellular carcinoma patients: A new application for the hepatoma arterial embolisation prognostic score. <i>European Journal of Cancer</i> , 2017, 86, 135-142.	1.3	19
1963	Non-invasive quantitative imaging of hepatocellular carcinoma growth in mice by micro-CT using liver-targeted iodinated nano-emulsions. <i>Scientific Reports</i> , 2017, 7, 13935.	1.6	22
1964	Does Sorafenib Fit for All?. <i>Radiology</i> , 2017, 284, 919-921.	3.6	0
1965	Perioperative safety analysis of transcatheter arterial chemoembolization for hepatocellular carcinoma patients with preprocedural leukopenia or thrombocytopenia. <i>Molecular and Clinical Oncology</i> , 2017, 7, 435-442.	0.4	9
1966	Tumor Volume Doubling Time as a Dynamic Prognostic Marker for Patients with Hepatocellular Carcinoma. <i>Digestive Diseases and Sciences</i> , 2017, 62, 2923-2931.	1.1	29
1967	Signaling Pathways as Potential Therapeutic Targets in Hepatocarcinogenesis. <i>Journal of Gastrointestinal Cancer</i> , 2017, 48, 225-237.	0.6	2
1968	Proton beam therapy for hepatocellular carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 911-924.	1.1	23
1969	Diagnostic and Prognostic Performance of Liquid Biopsy in Hepatocellular Carcinoma. <i>Current Clinical Pathology</i> , 2017, , 125-135.	0.0	3
1970	Fibrosis-4 Index Helps Identify HBV Carriers With the Lowest Risk of Hepatocellular Carcinoma. <i>American Journal of Gastroenterology</i> , 2017, 112, 1564-1574.	0.2	44

#	ARTICLE	IF	CITATIONS
1971	Retrograde portal vein flow and transarterial chemoembolization in patients with hepatocellular carcinoma – a case–control study. <i>Scandinavian Journal of Gastroenterology</i> , 2017, 52, 1398-1406.	0.6	1
1972	Temporal trends, clinical patterns and outcomes of <sc>NAFLD</sc>-related <sc>HCC</sc> in patients undergoing liver resection over a 20-year period. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 856-863.	1.9	91
1973	Staging and Prognostic Models for Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. <i>Cancer Control</i> , 2017, 24, 107327481772923.	0.7	24
1974	Transarterial (chemo)embolisation versus chemotherapy for colorectal cancer liver metastases. <i>The Cochrane Library</i> , 0, , .	1.5	1
1975	A model to estimate survival in ambulatory patients with hepatocellular carcinoma: Can it predict the natural course of hepatocellular carcinoma?. <i>Digestive and Liver Disease</i> , 2017, 49, 1273-1279.	0.4	5
1976	Functional hepatic imaging as a biomarker of primary and secondary tumor response to loco-regional therapies. <i>Surgical Oncology</i> , 2017, 26, 411-422.	0.8	10
1977	Misdiagnosis of hepatocellular carcinoma in patients receiving no local–regional therapy prior to liver transplant: An analysis of the Organ Procurement and Transplantation Network explant pathology form. <i>Clinical Transplantation</i> , 2017, 31, e13107.	0.8	5
1978	A Simple Noninvasive Index Can Predict Hepatocellular Carcinoma in Patients with Chronic Hepatitis B. <i>Scientific Reports</i> , 2017, 7, 8954.	1.6	4
1979	Treatment for intrahepatic recurrence after curative resection of hepatocellular carcinoma: Salvage liver transplantation or re-resection/radiofrequency ablation? A Retrospective Cohort Study. <i>International Journal of Surgery</i> , 2017, 46, 178-185.	1.1	16
1980	Alcohol, smoking and the liver disease patient. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2017, 31, 537-543.	1.0	21
1981	Transjugular biopsy case report of inferior vena cava hepatocellular carcinoma with intracardiac extension. <i>International Journal of Surgery Case Reports</i> , 2017, 39, 324-327.	0.2	4
1982	Viral hepatitis and liver cancer. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2017, 372, 20160274.	1.8	265
1983	Is there a standard for surgical therapy of hepatocellular carcinoma in healthy and cirrhotic liver? A comparison of eight guidelines. <i>BMJ Open Gastroenterology</i> , 2017, 4, e000129.	1.1	17
1984	Combination of transcatheter arterial chemoembolization and interrupted dosing sorafenib improves patient survival in early–intermediate stage hepatocellular carcinoma. <i>Medicine (United States)</i> , 2017, 96, e7655.	0.4	16
1985	Utility of percutaneous radiofrequency ablation alone or combined with transarterial chemoembolization for early hepatocellular carcinoma. <i>Oncology Letters</i> , 2017, 14, 3199-3206.	0.8	14
1986	Expression of P62 in hepatocellular carcinoma involving hepatitis B virus infection and aflatoxin B1 exposure. <i>Cancer Medicine</i> , 2017, 6, 2357-2369.	1.3	42
1987	Development of an Affimer-antibody combined immunological diagnosis kit for glypican-3. <i>Scientific Reports</i> , 2017, 7, 9608.	1.6	24
1988	Characteristics and Prognosis of Hepatocellular Carcinoma in Japanese Patients Undergoing Dialysis. <i>Therapeutic Apheresis and Dialysis</i> , 2017, 21, 465-472.	0.4	12

#	ARTICLE	IF	CITATIONS
1989	Telomerase reverse transcriptase germline mutations and hepatocellular carcinoma in patients with nonalcoholic fatty liver disease. <i>Cancer Medicine</i> , 2017, 6, 1930-1940.	1.3	43
1990	Hepatocellular carcinoma recurrence after direct antiviral agent treatment: A European multicentre study. <i>Journal of Hepatology</i> , 2017, 67, 876-878.	1.8	41
1991	Diagnostic value of long noncoding RNAs for hepatocellular carcinoma. <i>Medicine (United States)</i> , 2017, 96, e7496.	0.4	13
1992	Liver Resection versus Radiofrequency Ablation plus Transcatheter Arterial Chemoembolization in Cirrhotic Patients with Solitary Large Hepatocellular Carcinoma. <i>Journal of Vascular and Interventional Radiology</i> , 2017, 28, 1512-1519.	0.2	26
1993	Refining the management of patients with hepatocellular carcinoma integrating 11C-choline PET/CT scan into the multidisciplinary team discussion. <i>Nuclear Medicine Communications</i> , 2017, 38, 826-836.	0.5	11
1994	Treatment-stage migration maximizes survival outcomes in patients with hepatocellular carcinoma treated with sorafenib: an observational study. <i>Journal of Hepatology</i> , 2017, 66, S223-S224.	1.8	9
1995	Polymorphisms in POLG were associated with the prognosis and mtDNA content in hepatocellular carcinoma patients. <i>Bulletin Du Cancer</i> , 2017, 104, 500-507.	0.6	6
1997	The ART-SCORE is not an effective tool for optimizing patient selection for DEB-TACE retreatment. A multicentre Spanish study. <i>GastroenterologÅa Y HepatologÅa</i> , 2017, 40, 515-524.	0.2	7
1999	Clinical characteristics of hepatocellular carcinoma in Spain. Comparison with the 2008â€“2009 period and analysis of the causes of diagnosis out of screening programs. Analysis of 686 cases in 73 centers. <i>Medicina ClÅnica (English Edition)</i> , 2017, 149, 61-71.	0.1	4
2000	Prognostic nomogram for patients with non-B non-C hepatocellular carcinoma after curative liver resection. <i>International Journal of Surgery</i> , 2017, 44, 160-165.	1.1	7
2001	Long-term Nucleos(t)ides Analogues for Chronic Hepatitis B Improve Liver and Spleen Size: A Noninvasive Sonographic Study. <i>Journal of Medical Ultrasound</i> , 2017, 25, 161-166.	0.2	1
2002	Liquid Biopsy in Cancer Patients. <i>Current Clinical Pathology</i> , 2017, , .	0.0	6
2003	All-treatment array of hepatocellular carcinoma from initial diagnosis to death: observation of cumulative treatments. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 2327-2339.	1.2	12
2004	Bridging to liver transplantation in HCC patients. <i>Langenbeck's Archives of Surgery</i> , 2017, 402, 863-871.	0.8	38
2005	Treatment options for unresectable HCC with a focus on SIRT with Yttrium-90 resin microspheres. <i>International Journal of Clinical Practice</i> , 2017, 71, e12972.	0.8	39
2006	Plasma DNA methylation marker and hepatocellular carcinoma risk prediction model for the general population. <i>Carcinogenesis</i> , 2017, 38, 1021-1028.	1.3	37
2007	Radiation Therapy for Hepatocellular Carcinoma: Clinical Data. , 2017, , 179-198.		0
2008	Assessment of Liver Function: Focus on the ALBI Score. , 2017, , 31-38.		0

#	ARTICLE	IF	CITATIONS
2009	The Quest for Relevant Hepatocellular Carcinoma Biomarkers. Cellular and Molecular Gastroenterology and Hepatology, 2017, 4, 283-284.	2.3	7
2010	Screening for hepatocellular carcinoma: What is missing?. Hepatology Communications, 2017, 1, 18-22.	2.0	11
2011	Nonalcoholic fatty liver disease-related cirrhosis is commonly unrecognized and associated with hepatocellular carcinoma. Hepatology Communications, 2017, 1, 53-60.	2.0	59
2012	Long-term survival after surveillance and treatment in patients with chronic viral hepatitis and hepatocellular carcinoma. Hepatology Communications, 2017, 1, 595-608.	2.0	19
2013	Deciphering the epidemiology of hepatocellular carcinoma through the passage of time: A study of 1,401 patients across 3 decades. Hepatology Communications, 2017, 1, 564-571.	2.0	18
2014	A systematic review and meta-analysis comparing the prognosis of multicentric occurrence and vs. intrahepatic metastasis in patients with recurrent hepatocellular carcinoma after hepatectomy. Hpb, 2017, 19, 835-842.	0.1	47
2015	Validation of a Simple Scoring System to Predict Sorafenib Effectiveness in Patients with Hepatocellular Carcinoma. Targeted Oncology, 2017, 12, 795-803.	1.7	23
2016	Treatment of hepatocellular carcinoma using transarterial chemoembolization. European Journal of Gastroenterology and Hepatology, 2017, 29, 225-230.	0.8	2
2017	Real-life experience with sorafenib for the treatment of hepatocellular carcinoma in HIV-infected patients. Aids, 2017, 31, 89-95.	1.0	14
2018	Performance of Gadoteric Acid-Enhanced Liver Magnetic Resonance Imaging for Predicting Patient Eligibility for Liver Transplantation Based on the Milan Criteria. Journal of Computer Assisted Tomography, 2017, 41, 25-31.	0.5	3
2019	Adult to adult right lobe living donor liver transplantation. Medicine (United States), 2017, 96, e4139.	0.4	4
2020	Prognostic significance of nonprotein respiratory quotient in patients with liver cirrhosis. Medicine (United States), 2017, 96, e5800.	0.4	10
2021	Clinical features of hepatitis B and C virus infections, with high α -fetoprotein levels but not hepatocellular carcinoma. Medicine (United States), 2017, 96, e5844.	0.4	8
2022	Liver resection associated with better outcomes for single large hepatocellular carcinoma located in the same section. Medicine (United States), 2017, 96, e6246.	0.4	4
2023	Surgical outcomes of laparoscopic versus open liver resection for hepatocellular carcinoma for various resection extent. Medicine (United States), 2017, 96, e6460.	0.4	47
2024	Effect of psoas muscle mass after endoscopic therapy for patients with esophageal varices. Medicine (United States), 2017, 96, e6868.	0.4	3
2025	The PDGFR α -laminin B1-keratin 19 cascade drives tumor progression at the invasive front of human hepatocellular carcinoma. Oncogene, 2017, 36, 6605-6616.	2.6	47
2026	Benign nodules in post-Fontan livers can show imaging features considered diagnostic for hepatocellular carcinoma. Abdominal Radiology, 2017, 42, 2623-2631.	1.0	75

#	ARTICLE	IF	CITATIONS
2027	Albumin-Bilirubin Grade and Hepatocellular Carcinoma Treatment Algorithm. <i>Liver Cancer</i> , 2017, 6, 185-188.	4.2	11
2028	Noncirrhotic hepatocellular carcinoma: etiology and occult hepatitis B virus infection in a hepatitis B virus-endemic area. <i>Therapeutic Advances in Gastroenterology</i> , 2017, 10, 529-536.	1.4	26
2029	Prognostic significance of sarcopenia in patients with hepatocellular carcinoma undergoing sorafenib therapy. <i>Oncology Letters</i> , 2017, 14, 1637-1647.	0.8	70
2030	Is early recurrence of hepatocellular carcinoma in HCV cirrhotic patients affected by treatment with direct-acting antivirals? A prospective multicentre study. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 688-695.	1.9	124
2031	Nomogram for individualized prediction of recurrence after postoperative adjuvant TACE for hepatitis B virus-related hepatocellular carcinoma. <i>Medicine (United States)</i> , 2017, 96, e7390.	0.4	5
2032	Vascular Invasion and Metastasis is Predictive of Outcome in Barcelona Clinic Liver Cancer Stage C Hepatocellular Carcinoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 197-204.	2.3	31
2033	Sustained Virological Response by Direct Antiviral Agents in HCV Leads to an Early and Significant Improvement of Liver Fibrosis. <i>Antiviral Therapy</i> , 2018, 23, 129-138.	0.6	33
2034	Contrast-enhanced ultrasound features of hepatocellular carcinoma not detected during the screening procedure. <i>Zeitschrift Fur Gastroenterologie</i> , 2017, 55, 748-753.	0.2	6
2035	Parameters for Stable Water-in-Oil Lipiodol Emulsion for Liver Trans-Arterial Chemo-Eembolization. <i>CardioVascular and Interventional Radiology</i> , 2017, 40, 1927-1932.	0.9	30
2036	Arteriopathy after transarterial chemo-lipiodolization for hepatocellular carcinoma. <i>Diagnostic and Interventional Imaging</i> , 2017, 98, 827-835.	1.8	4
2037	Adoption of Sorafenib for the Treatment of Advanced-Stage Hepatocellular Carcinoma in Oncology Practices in the United States. <i>Liver Cancer</i> , 2017, 6, 216-226.	4.2	17
2038	Efficacy and Safety of Systemic Therapies for Advanced Hepatocellular Carcinoma: A Network Meta-Analysis of Phase III Trials. <i>Liver Cancer</i> , 2017, 6, 337-348.	4.2	18
2039	Hepatocellular Carcinoma with Macrovascular Invasion: Defining the Optimal Treatment Strategy. <i>Liver Cancer</i> , 2017, 6, 360-374.	4.2	66
2040	Prospective Comparison of Gd-EOB-DTPA-Enhanced MRI with Dynamic CT for Detecting Recurrence of HCC after Radiofrequency Ablation. <i>Liver Cancer</i> , 2017, 6, 349-359.	4.2	29
2041	Managing HCC in NAFLD. <i>Current Hepatology Reports</i> , 2017, 16, 374-381.	0.4	1
2042	Biomarker development for hepatocellular carcinoma early detection: current and future perspectives. <i>Hepatic Oncology</i> , 2017, 4, 111-122.	4.2	59
2043	Use of Liver Imaging and Biopsy in Clinical Practice. <i>New England Journal of Medicine</i> , 2017, 377, 2295-2297.	13.9	29
2044	Alternate Fractionation for Hepatic Tumors. <i>Medical Radiology</i> , 2017, , 173-201.	0.0	0

#	ARTICLE	IF	CITATIONS
2045	Transarterial chemoembolization with DC Bead LUMIâ,ç radiopaque beads for primary liver cancer treatment: preliminary experience. <i>Future Oncology</i> , 2017, 13, 2243-2252.	1.1	32
2047	Circular RNA expression is suppressed by androgen receptor (AR)-regulated adenosine deaminase that acts on RNA (ADAR1) in human hepatocellular carcinoma. <i>Cell Death and Disease</i> , 2017, 8, e3171-e3171.	2.7	125
2048	Neutrophil-to-lymphocyte and aspartate-to-alanine aminotransferase ratios predict hepatocellular carcinoma prognosis after transarterial embolization. <i>Medicine (United States)</i> , 2017, 96, e8512.	0.4	32
2049	Liver immunotolerance and hepatocellular carcinoma: Patho-physiological mechanisms and therapeutic perspectives. <i>European Journal of Cancer</i> , 2017, 87, 101-112.	1.3	56
2050	Long-term follow-up of complete remission of advanced hepatocellular carcinoma following sorafenib therapy: A case report. <i>Oncology Letters</i> , 2017, 14, 4853-4856.	0.8	6
2051	Nonsurgical options for localized hepatocellular carcinoma. <i>Clinical Liver Disease</i> , 2017, 10, 103-106.	1.0	1
2052	Genetics of Hepatocellular Carcinoma: Risk Stratification, Clinical Outcome, and Implications for Therapy. <i>Digestive Disease Interventions</i> , 2017, 01, 055-065.	0.3	2
2053	Adjuvant transarterial chemoembolization after radical resection contributed to the outcomes of hepatocellular carcinoma patients with high-risk factors. <i>Medicine (United States)</i> , 2017, 96, e7426.	0.4	25
2054	Percutaneous Ablation for Hepatocellular Carcinoma and Peritoneal Dialysis. <i>Peritoneal Dialysis International</i> , 2017, 37, 656-658.	1.1	2
2055	Communicative reprogramming non-curative hepatocellular carcinoma with low-dose metronomic chemotherapy, COX-2 inhibitor and PPAR-gamma agonist: a phase II trial. <i>Medical Oncology</i> , 2017, 34, 192.	1.2	26
2056	Serum levels of antiâ€spermaâ€associated antigen 9 antibody are elevated in patients with hepatocellular carcinoma. <i>Oncology Letters</i> , 2017, 14, 7608-7614.	0.8	5
2057	Survival benefit of radiofrequency ablation for solitary (3â€“5â€Šcm) hepatocellular carcinoma. <i>Medicine (United States)</i> , 2017, 96, e8486.	0.4	13
2058	Impact of age and gender on risk of hepatocellular carcinoma after hepatitis B surface antigen seroclearance. <i>Journal of Hepatology</i> , 2017, 67, 902-908.	1.8	112
2059	Eradication of hepatitis C virus profoundly prolongs survival in hepatocellular carcinoma patients receiving transarterial chemoembolization. <i>Journal of Viral Hepatitis</i> , 2017, 24, 1160-1167.	1.0	10
2060	Surface expression of antiâ€CD3scfv stimulates locoregional immunotherapy against hepatocellular carcinoma depending on the E1Aâ€engineered human umbilical cord mesenchymal stem cells. <i>International Journal of Cancer</i> , 2017, 141, 1445-1457.	2.3	10
2061	Adherence to a Semiannual Surveillance Program for Hepatocellular Carcinoma in Patients With Liver Cirrhosis. <i>Journal of Clinical Gastroenterology</i> , 2017, 51, 557-563.	1.1	17
2062	The value of [11C]-acetate PET and [18F]-FDG PET in hepatocellular carcinoma before and after treatment with transarterial chemoembolization and bevacizumab. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 1732-1741.	3.3	20
2063	Natural History of T1N0M0 Hepatocellular Carcinoma: Large-Scale Study in the United States. <i>Oncology</i> , 2017, 93, 233-242.	0.9	1

#	ARTICLE	IF	CITATIONS
2064	Transarterial Chemoembolization Monotherapy Versus Combined Transarterial Chemoembolization and Microwave Ablation Therapy for Hepatocellular Carcinoma Tumors: A Propensity Analysis at a Single Center. CardioVascular and Interventional Radiology, 2017, 40, 1748-1755.	0.9	47
2065	Effect of ultrasonography surveillance in patients with liver cancer: a population-based longitudinal study. BMJ Open, 2017, 7, e015936.	0.8	2
2066	Evaluation of the current guidelines for resection of hepatocellular carcinoma using the Appraisal of Guidelines for Research and Evaluation II instrument. Journal of Hepatology, 2017, 67, 991-998.	1.8	26
2067	Interobserver variability in target volume delineation of hepatocellular carcinoma. Strahlentherapie Und Onkologie, 2017, 193, 823-830.	1.0	6
2068	Volumetric parameters on FDG PET can predict early intrahepatic recurrence-free survival in patients with hepatocellular carcinoma after curative surgical resection. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 1984-1994.	3.3	12
2069	Sorafenib in Patients with Hepatocellular Carcinoma: Results of the Observational INSIGHT Study. Clinical Cancer Research, 2017, 23, 5720-5728.	3.2	67
2070	Postsorafenib systemic treatments for hepatocellular carcinoma: questions and opportunities after the regorafenib trial. Future Oncology, 2017, 13, 1893-1905.	1.1	9
2071	Metabolic and microbial signatures in rat hepatocellular carcinoma treated with caffeic acid and chlorogenic acid. Scientific Reports, 2017, 7, 4508.	1.6	33
2072	Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies. Journal of Hepatology, 2017, 67, 999-1008.	1.8	465
2073	MBOAT7 rs641738 variant and hepatocellular carcinoma in non-cirrhotic individuals. Scientific Reports, 2017, 7, 4492.	1.6	193
2074	SurvivalNet: Predicting patient survival from diffusion weighted magnetic resonance images using cascaded fully convolutional and 3D Convolutional Neural Networks. , 2017, , .		11
2075	Safety and Efficacy of Transarterial Radioembolisation in Patients with Intermediate or Advanced Stage Hepatocellular Carcinoma Refractory to Chemoembolisation. CardioVascular and Interventional Radiology, 2017, 40, 1882-1890.	0.9	17
2076	Choice of Intra-arterial Therapy for Hepatocellular Carcinoma: Evidence and Future Horizons. Digestive Disease Interventions, 2017, 01, 105-114.	0.3	1
2077	State of the ablation nation: a review of ablative therapies for cure in the treatment of hepatocellular carcinoma. Future Oncology, 2017, 13, 1437-1448.	1.1	29
2078	Effect of treatment support on preventing local recurrence of hepatocellular carcinoma directly adjacent to the diaphragm. Molecular and Clinical Oncology, 2017, 7, 61-66.	0.4	4
2079	The detection of hepatocellular carcinoma (HCC) from patients' breath using canine scent detection: a proof-of-concept study. Journal of Breath Research, 2017, 11, 046002.	1.5	17
2081	Role of curative treatment in patients with intermediate-stage hepatocellular carcinoma. Japanese Journal of Radiology, 2017, 35, 254-261.	1.0	2
2082	Impact of Non-alcoholic Fatty Liver Disease on Chronic Hepatitis B Infection. Current Hepatology Reports, 2017, 16, 97-104.	0.4	1

#	ARTICLE	IF	CITATIONS
2083	Microvascular invasion has limited clinical values in hepatocellular carcinoma patients at Barcelona Clinic Liver Cancer (BCLC) stages 0 or B. <i>BMC Cancer</i> , 2017, 17, 58.	1.1	42
2084	High expression of micro RNA-135A in hepatocellular carcinoma is associated with recurrence within 12 months after resection. <i>BMC Cancer</i> , 2017, 17, 60.	1.1	24
2085	External beam radiotherapy for unresectable hepatocellular carcinoma, an international multicenter phase I trial, SAKK 77/07 and SASL 26. <i>Radiation Oncology</i> , 2017, 12, 12.	1.2	8
2086	Highlights from the 3rd international HIV/viral hepatitis Co-infection meeting - HIV/viral hepatitis: improving diagnosis, antiviral therapy and access. <i>Hepatology, Medicine and Policy</i> , 2017, 2, 8.	1.7	6
2089	Hepatocellular carcinoma: Therapeutic strategy in 2017. <i>Oncologie</i> , 2017, 19, 177-183.	0.2	0
2091	Diagnostic efficacy of the Liver Imaging-Reporting and Data System (LI-RADS) with CT imaging in categorising small nodules (10–20 mm) detected in the cirrhotic liver at screening ultrasound. <i>Clinical Radiology</i> , 2017, 72, 901.e1-901.e11.	0.5	32
2092	New vaccination strategies in liver cancer. <i>Cytokine and Growth Factor Reviews</i> , 2017, 36, 125-129.	3.2	20
2093	Quality Improvement Guidelines for Transarterial Chemoembolization and Embolization of Hepatic Malignancy. <i>Journal of Vascular and Interventional Radiology</i> , 2017, 28, 1210-1223.e3.	0.2	103
2094	Cost-Effectiveness of Risk Score–Stratified Hepatocellular Carcinoma Screening in Patients with Cirrhosis. <i>Clinical and Translational Gastroenterology</i> , 2017, 8, e101.	1.3	124
2095	Prognostic Value of Metabolic Tumor Volume and Total Lesion Glycolysis on Preoperative 18F-FDG PET/CT in Patients With Very Early and Early Hepatocellular Carcinoma. <i>Clinical Nuclear Medicine</i> , 2017, 42, 34-39.	0.7	15
2096	MicroRNA-138 enhances TRAIL-induced apoptosis through interferon-stimulated gene 15 downregulation in hepatocellular carcinoma cells. <i>Tumor Biology</i> , 2017, 39, 101042831771041.	0.8	11
2097	Radiofrequency ablation and transarterial chemoembolisation as first-line treatment for recurrent hepatocellular carcinoma or isolated intrahepatic recurrent hepatocellular carcinoma in transplanted livers. <i>Clinical Radiology</i> , 2017, 72, 141-149.	0.5	11
2098	To treat or not to treat – Successful hepatitis C virus eradication in a patient with advanced hepatocellular carcinoma and complete response to sorafenib. <i>Zeitschrift Fur Gastroenterologie</i> , 2017, 55, 564-568.	0.2	2
2099	Resin-based Yttrium-90 microspheres for unresectable and failed first-line chemotherapy intrahepatic cholangiocarcinoma: preliminary results. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 481-489.	1.2	31
2100	Liver failure after hepatectomy: A risk assessment using the pre-hepatectomy shear wave elastography technique. <i>European Journal of Radiology</i> , 2017, 86, 234-240.	1.2	18
2101	Microwave ablation versus hepatic resection for the treatment of hepatocellular carcinoma and oesophageal variceal bleeding in cirrhotic patients. <i>International Journal of Hyperthermia</i> , 2017, 33, 255-262.	1.1	12
2102	New chemical treatment options in second-line hepatocellular carcinoma: what to do when sorafenib fails?. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 35-44.	0.9	19
2103	Stereotactic CT-Guided Percutaneous Microwave Ablation of Liver Tumors With the Use of High-Frequency Jet Ventilation: An Accuracy and Procedural Safety Study. <i>American Journal of Roentgenology</i> , 2017, 208, 193-200.	1.0	72

#	ARTICLE	IF	CITATIONS
2104	Validation of the Hong Kong Liver Cancer Staging System in Determining Prognosis of the North American Patients Following Intra-arterial Therapy. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 746-755.e4.	2.4	33
2105	Predictors of adequate ultrasound quality for hepatocellular carcinoma surveillance in patients with cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 169-177.	1.9	243
2106	Factors predicting outcomes of microwave ablation of small hepatocellular carcinoma. <i>Radiologia Medica</i> , 2017, 122, 81-87.	4.7	11
2107	Diagnostic accuracy of desâ€gammaâ€™carboxy prothrombin for hepatocellular carcinoma in a French cohort using the Lumipulse^{Â®} G600 analyzer. <i>Journal of Viral Hepatitis</i> , 2017, 24, 80-85.	1.0	19
2108	Redox proteomics screening cellular factors associated with oxidative stress in hepatocarcinogenesis. <i>Proteomics - Clinical Applications</i> , 2017, 11, 1600089.	0.8	10
2109	Subclassification of patients with intermediate-stage (Barcelona Clinic Liver Cancer stage-B) hepatocellular carcinoma using the up-to-seven criteria and serum tumor markers. <i>Hepatology International</i> , 2017, 11, 105-114.	1.9	40
2110	An assessment of benefits and harms of hepatocellular carcinoma surveillance in patients with cirrhosis. <i>Hepatology</i> , 2017, 65, 1196-1205.	3.6	188
2111	Development of Risk Prediction Model for Hepatocellular Carcinoma Progression of Indeterminate Nodules in Hepatitis B Virus-Related Cirrhotic Liver. <i>American Journal of Gastroenterology</i> , 2017, 112, 460-470.	0.2	23
2112	Increased interreader agreement in diagnosis of hepatocellular carcinoma using an adapted LI-RADS algorithm. <i>European Journal of Radiology</i> , 2017, 86, 33-40.	1.2	29
2113	Hepatocellular carcinoma recurrence in patients with curative resection or ablation: impact of <sc>HCV</sc> eradication does not depend on the use of interferon. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 160-168.	1.9	70
2114	Outcome of hypovascular hepatic nodules with positive uptake of gadoxetic acid in patients with cirrhosis. <i>European Radiology</i> , 2017, 27, 518-525.	2.3	10
2115	Intrahepatic Cholangiocarcinoma in Patients with Cirrhosis: Differentiation from Hepatocellular Carcinoma by Using Gadoxetic Acidâ€™enhanced MR Imaging and Dynamic CT. <i>Radiology</i> , 2017, 282, 771-781.	3.6	73
2116	¹⁸F-FDG PET/CT Can Predict Survival of Advanced Hepatocellular Carcinoma Patients: A Multicenter Retrospective Cohort Study. <i>Journal of Nuclear Medicine</i> , 2017, 58, 730-736.	2.8	42
2117	CT Perfusion for Early Response Evaluation of Radiofrequency Ablation of Focal Liver Lesions: First Experience. <i>CardioVascular and Interventional Radiology</i> , 2017, 40, 90-98.	0.9	19
2118	Primary liver resection for patients with cirrhosis and hepatocellular carcinoma: the role of surgery in BCLC early (A) and intermediate stages (B). <i>Langenbeck's Archives of Surgery</i> , 2017, 402, 575-583.	0.8	7
2119	Natural History of Untreated Hepatocellular Carcinoma in a US Cohort and the Role of Cancer Surveillance. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 273-281.e1.	2.4	106
2120	A model predicting survival of patients with recurrent or progressive hepatocellular carcinoma: the MORE score. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 651-658.	1.4	3
2121	Risks factors for severe pain after selective liver transarterial chemoembolization. <i>Liver International</i> , 2017, 37, 583-591.	1.9	21

#	ARTICLE	IF	CITATIONS
2122	Targeting Alpha-Fetoprotein (AFP)â€”MHC Complex with CAR T-Cell Therapy for Liver Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 478-488.	3.2	158
2123	The underreporting of hepatocellular carcinoma to the cancer register and a logâ€”linear model to estimate a more correct incidence. <i>Hepatology</i> , 2017, 65, 885-892.	3.6	37
2124	Hepatocellular carcinoma detection: diagnostic performance of a simulated abbreviated MRI protocol combining diffusion-weighted and T1-weighted imaging at the delayed phase post gadoxetic acid. <i>Abdominal Radiology</i> , 2017, 42, 179-190.	1.0	113
2125	Conventional versus drugâ€”eluting beads chemoembolization for hepatocellular carcinoma: Emphasis on the impact of tumor size. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 487-496.	1.4	36
2126	Concurrent fatty liver increases risk of hepatocellular carcinoma among patients with chronic hepatitis B. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 667-676.	1.4	152
2127	Transarterial chemoembolization of hepatocellular carcinoma with segmental portal vein tumour thrombus. <i>European Radiology</i> , 2017, 27, 1448-1458.	2.3	31
2128	Prognostic value of the albuminâ€”bilirubin grade in patients with hepatocellular carcinoma: Validation in a Chinese cohort. <i>Hepatology Research</i> , 2017, 47, 731-741.	1.8	52
2129	Identification of clinical biomarkers for patients with advanced hepatocellular carcinoma receiving sorafenib. <i>Clinical and Translational Oncology</i> , 2017, 19, 364-372.	1.2	11
2130	Curative therapies are superior to standard of care (transarterial chemoembolization) for intermediate stage hepatocellular carcinoma. <i>Liver International</i> , 2017, 37, 423-433.	1.9	46
2131	Meta-analysis: adjusted indirect comparison of drug-eluting bead transarterial chemoembolization versus 90Y-radioembolization for hepatocellular carcinoma. <i>European Radiology</i> , 2017, 27, 2031-2041.	2.3	24
2132	The Pathology and Molecular Pathology of Hepatocellular Carcinoma. , 2017, , 455-469.		0
2133	Application of radiofrequency ablation for the treatment of intermediateâ€”stage hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 695-700.	1.4	23
2134	Surveillance of Hepatocellular Carcinoma by Magnetic Resonance Imaging With Liver-Specific Contrast. <i>JAMA Oncology</i> , 2017, 3, 446.	3.4	3
2135	MRI With Liver-Specific Contrast for Surveillance of Patients With Cirrhosis at High Risk of Hepatocellular Carcinoma. <i>JAMA Oncology</i> , 2017, 3, 456.	3.4	241
2136	Technical feasibility and safety of laparoscopic right hepatectomy for hepatocellular carcinoma following sequential TACEâ€”PVE: a comparative study. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2017, 31, 2340-2349.	1.3	26
2137	Experience from a real-life cohort: outcome of 606 patients with hepatocellular carcinoma following transarterial chemoembolization. <i>Scandinavian Journal of Gastroenterology</i> , 2017, 52, 116-124.	0.6	13
2138	The ALBI grade provides objective hepatic reserve estimation across each BCLC stage of hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2017, 66, 338-346.	1.8	299
2139	Liver imaging reporting and data system v2014 categorization of hepatocellular carcinoma on gadoxetic acidâ€”enhanced MRI: Comparison with multiphasic multidetector computed tomography. <i>Journal of Magnetic Resonance Imaging</i> , 2017, 45, 731-740.	1.9	55

#	ARTICLE	IF	CITATIONS
2140	Real-time US-CT/MR fusion imaging for percutaneous radiofrequency ablation of hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2017, 66, 347-354.	1.8	103
2141	Personalized treatment of patients with very early hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2017, 66, 412-423.	1.8	119
2142	Direct antiviral agent treatment of chronic hepatitis C results in rapid regression of transient elastography and fibrosis markers fibrosis score and aspartate aminotransferase-platelet ratio index. <i>Liver International</i> , 2017, 37, 369-376.	1.9	207
2143	Yttrium-90 Radioembolization for Hepatocellular Carcinoma Prior to Liver Transplantation. <i>World Journal of Surgery</i> , 2017, 41, 241-249.	0.8	57
2144	mRECIST response combined with sorafenib-related adverse events is superior to either criterion alone in predicting survival in HCC patients treated with TACE plus sorafenib. <i>International Journal of Cancer</i> , 2017, 140, 390-399.	2.3	15
2145	Radiofrequency ablation combined with percutaneous ethanol injection for hepatocellular carcinoma: a systematic review and meta-analysis. <i>International Journal of Hyperthermia</i> , 2017, 33, 237-246.	1.1	20
2146	The impact of clinically significant portal hypertension on the prognosis of patients with hepatocellular carcinoma after radiofrequency ablation: a propensity score matching analysis. <i>European Radiology</i> , 2017, 27, 2600-2609.	2.3	13
2147	Haemodynamic changes in hepatocellular carcinoma and liver parenchyma under balloon occlusion of the hepatic artery. <i>European Radiology</i> , 2017, 27, 2474-2481.	2.3	2
2148	ALBI and PALBI grade predict survival for HCC across treatment modalities and BCLC stages in the MELD Era. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 879-886.	1.4	126
2149	The evolutionary scenario of hepatocellular carcinoma in Italy: an update. <i>Liver International</i> , 2017, 37, 259-270.	1.9	67
2150	Comparison of no-touch multi-bipolar vs. monopolar radiofrequency ablation for small HCC. <i>Journal of Hepatology</i> , 2017, 66, 67-74.	1.8	123
2151	Predicting Outcomes After Chemo-Embolization in Patients with Advanced-Stage Hepatocellular Carcinoma: An Evaluation of Different Radiologic Response Criteria. <i>CardioVascular and Interventional Radiology</i> , 2017, 40, 61-68.	0.9	4
2152	Transarterial chemoembolization vs bland embolization in hepatocellular carcinoma: A meta-analysis of randomized trials. <i>United European Gastroenterology Journal</i> , 2017, 5, 511-518.	1.6	67
2153	Hepatocellular carcinomas with intracellular hyaline bodies have a poor prognosis. <i>Liver International</i> , 2017, 37, 600-610.	1.9	21
2154	The IR Evolution in Oncology: Tools, Treatments, and Guidelines. <i>CardioVascular and Interventional Radiology</i> , 2017, 40, 3-8.	0.9	11
2155	Prognostic significance of low skeletal muscle mass compared with protein-energy malnutrition in liver cirrhosis. <i>Hepatology Research</i> , 2017, 47, 1042-1052.	1.8	14
2156	Ultrasound-guided percutaneous microwave ablation for hepatocellular carcinoma: clinical outcomes and prognostic factors. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 131-142.	1.2	28
2157	Biomarkers for Hepatocellular Carcinoma. <i>Biomarkers in Cancer</i> , 2017, 9, 1179299X1668464.	3.6	115

#	ARTICLE	IF	CITATIONS
2158	Analysis of expression profile data identifies key genes and pathways in hepatocellular carcinoma. <i>Oncology Letters</i> , 2018, 15, 2625-2630.	0.8	6
2159	2017 Version of LI-RADS for CT and MR Imaging: An Update. <i>Radiographics</i> , 2017, 37, 1994-2017.	1.4	185
2160	ACR Appropriateness Criteria Â® Chronic LiverÂDisease. <i>Journal of the American College of Radiology</i> , 2017, 14, S391-S405.	0.9	18
2161	Role of diffusion-weighted magnetic resonance imaging in the evaluation of hepatocellular carcinoma response to transcatheter arterial chemoembolization using drug eluting beads; correlation with dynamic MRI. <i>Egyptian Journal of Radiology and Nuclear Medicine</i> , 2017, 48, 817-824.	0.3	6
2162	Early sorafenib induction after transarterial chemoembolization for unresectable hepatocellular carcinoma: Can sorafenib after TACE improve locoâ€regional control?. <i>Molecular and Clinical Oncology</i> , 2017, 7, 1135-1141.	0.4	4
2163	VEGF overexpression predicts poor survival in hepatocellular carcinoma. <i>Open Medicine (Poland)</i> , 2017, 12, 430-439.	0.6	22
2164	Magnetic resonance imaging performed with gadoxetate disodium for the diagnosis of hepatocellular carcinoma in cirrhotic and non-cirrhotic patients. <i>The Cochrane Library</i> , 0, , .	1.5	3
2165	Treatment Stage Migration Maximizes Survival Outcomes in Patients with Hepatocellular Carcinoma Treated with Sorafenib: An Observational Study. <i>Liver Cancer</i> , 2017, 6, 313-324.	4.2	21
2166	Overdiagnosis: An Understudied Issue in Hepatocellular Carcinoma Surveillance. <i>Seminars in Liver Disease</i> , 2017, 37, 296-304.	1.8	29
2167	Computed tomographic perfusion imaging for the prediction of response and survival to transarterial chemoembolization of hepatocellular carcinoma. <i>Radiology and Oncology</i> , 2017, 52, 14-22.	0.6	11
2169	Measurement of Portal Pressure and its Application in the Clinical Setting. <i>Digestive Disease Interventions</i> , 2017, 01, 241-247.	0.3	0
2170	Baseline tumor Lipiodol uptake after transarterial chemoembolization for hepatocellular carcinoma: identification of a threshold value predicting tumor recurrence. <i>Radiology and Oncology</i> , 2017, 51, 393-400.	0.6	11
2171	Comparison of biannual ultrasonography and annual non-contrast liver magnetic resonance imaging as surveillance tools for hepatocellular carcinoma in patients with liver cirrhosis (MAGNUS-HCC): a study protocol. <i>BMC Cancer</i> , 2017, 17, 877.	1.1	30
2172	A hepatic stem cell vaccine is superior to an embryonic stem cell vaccine in the prophylaxis and treatment of murine hepatocarcinoma. <i>Oncology Reports</i> , 2017, 37, 1716-1724.	1.2	4
2173	Rate of seeding with biopsies and ablations of hepatocellular carcinoma: A retrospective cohort study. <i>Hepatology Communications</i> , 2017, 1, 841-851.	2.0	31
2174	Bone metastases as initial presentation of hepatocellular carcinoma. <i>World Journal of Hepatology</i> , 2017, 9, 1158-1165.	0.8	8
2175	Management of chronic hepatitis C in 2017. <i>Hamostaseologie</i> , 2017, 37, 186-195.	0.9	3
2176	Management of Hepatocellular Carcinoma in the Setting of Liver Cirrhosis. , 0, , .		0

#	ARTICLE	IF	CITATIONS
2177	Liver Transplantation for Hepatocellular Carcinoma: Impact of Wait Time at a Single Center. <i>Annals of Hepatology</i> , 2017, 16, 402-411.	0.6	7
2178	Surveillance for Hepatocellular Carcinoma Reduces Mortality: an Inverse Probability of Treatment Weighted Analysis. <i>Annals of Hepatology</i> , 2017, 16, 421-429.	0.6	8
2179	Minimally Invasive Treatments for Liver Cancer. , 2017, , .		0
2180	Living Donor Liver Transplantation for Hepatocellular Carcinoma. , 0, , .		1
2181	Interventional Radiology in China. <i>Chinese Medical Journal</i> , 2017, 130, 1371-1375.	0.9	3
2182	Surgical treatment of liver tumors – own experience and literature review. <i>Clinical and Experimental Hepatology</i> , 2017, 1, 1-8.	0.6	8
2183	Transarterial chemoembolization for the treatment of hepatocellular carcinoma: a review. <i>Journal of Hepatocellular Carcinoma</i> , 2017, Volume 4, 105-110.	1.8	56
2184	Hepatocellular carcinoma: early-stage management challenges. <i>Journal of Hepatocellular Carcinoma</i> , 2017, Volume 4, 81-92.	1.8	60
2185	The Anti-Tumor Effects of M1 Macrophage-Loaded Poly (ethylene glycol) and Gelatin-Based Hydrogels on Hepatocellular Carcinoma. <i>Theranostics</i> , 2017, 7, 3732-3744.	4.6	60
2186	Add-On Therapy with Traditional Chinese Medicine Improves Outcomes and Reduces Adverse Events in Hepatocellular Carcinoma: A Meta-Analysis of Randomized Controlled Trials. <i>Evidence-based Complementary and Alternative Medicine</i> , 2017, 2017, 1-13.	0.5	29
2187	Transarterial chemoembolization for hepatocellular carcinoma: state of the art. <i>Sang Thrombose Vaisseaux</i> , 2017, 29, 187-194.	0.1	0
2188	The importance of a multidisciplinary approach to hepatocellular carcinoma. <i>Journal of Multidisciplinary Healthcare</i> , 2017, Volume 10, 95-100.	1.1	52
2189	Hepatic artery embolization and chemoembolization of liver tumors. , 2017, , 1398-1416.e4.		0
2190	Imaging of primary liver tumors with positron-emission tomography. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 61, 292-300.	0.4	32
2191	Serum Golgi protein 73 is not a suitable diagnostic marker for hepatocellular carcinoma. <i>Oncotarget</i> , 2017, 8, 16498-16506.	0.8	35
2192	Diagnosis of Hepatocellular Carcinoma with Gadoteric Acid-Enhanced MRI: 2016 Consensus Recommendations of the Korean Society of Abdominal Radiology. <i>Korean Journal of Radiology</i> , 2017, 18, 427.	1.5	42
2193	Comparison of Prognostic Impact between the Child-Pugh Score and Skeletal Muscle Mass for Patients with Liver Cirrhosis. <i>Nutrients</i> , 2017, 9, 595.	1.7	14
2194	Tissue Biomarkers in Hepatocellular Tumors: Which, When, and How. <i>Frontiers in Medicine</i> , 2017, 4, 10.	1.2	21

#	ARTICLE	IF	CITATIONS
2195	Histological Grading of Hepatocellular Carcinoma—A Systematic Review of Literature. <i>Frontiers in Medicine</i> , 2017, 4, 193.	1.2	103
2196	Drug Treatment for Chronic Hepatitis C Infection and Cancer Risk. <i>Deutsches A&#x0308;rztblatt International</i> , 2017, 114, 597-602.	0.6	9
2197	Surveillance Program for Diagnosis of HCC in Liver Cirrhosis: Role of Ultrasound Echo Patterns. <i>BioMed Research International</i> , 2017, 2017, 1-8.	0.9	13
2198	Use of Ultrasmall Superparamagnetic Iron Oxide Enhanced Susceptibility Weighted Imaging and Mean Vessel Density Imaging to Monitor Antiangiogenic Effects of Sorafenib on Experimental Hepatocellular Carcinoma. <i>Contrast Media and Molecular Imaging</i> , 2017, 2017, 1-10.	0.4	9
2199	Oncolytic Virus-Based Immunotherapies for Hepatocellular Carcinoma. <i>Mediators of Inflammation</i> , 2017, 2017, 1-12.	1.4	37
2200	Resection or Transplant in Early Hepatocellular Carcinoma. <i>Deutsches A&#x0308;rztblatt International</i> , 2017, 114, 519-526.	0.6	20
2201	Liver-related morbidity and mortality in patients with chronic hepatitis C and cirrhosis with and without sustained virologic response. <i>Clinical Epidemiology</i> , 2017, Volume 9, 501-516.	1.5	25
2202	Screening for hepatocellular carcinoma: patient selection and perspectives. <i>Journal of Hepatocellular Carcinoma</i> , 2017, Volume 4, 71-79.	1.8	27
2203	Diagnostic Imaging of Hepatocellular Carcinoma - A Pictorial Essay. <i>Current Medical Imaging</i> , 2017, 13, 140-153.	0.4	27
2204	From diagnosis to treatment of hepatocellular carcinoma: An epidemic problem for both developed and developing world. <i>World Journal of Gastroenterology</i> , 2017, 23, 5282.	1.4	232
2205	Liver resection in cirrhosis. , 2017, , 1578-1586.e3.		0
2206	Overexpression of LAMC1 predicts poor prognosis and enhances tumor cell invasion and migration in hepatocellular carcinoma. <i>Journal of Cancer</i> , 2017, 8, 2992-3000.	1.2	40
2207	Harms and benefits of adoptive immunotherapy for postoperative hepatocellular carcinoma: an updated review. <i>Oncotarget</i> , 2017, 8, 18537-18549.	0.8	9
2208	Predictive factors in patients with hepatocellular carcinoma receiving sorafenib therapy using time-dependent receiver operating characteristic analysis. <i>Journal of Cancer</i> , 2017, 8, 378-387.	1.2	6
2209	The effect of antiviral therapy on patients with hepatitis B virus-related hepatocellular carcinoma after curative resection: a systematic review and meta-analysis. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 5363-5375.	1.0	14
2210	Oral Medications Enhance Adherence to Surveillance for Hepatocellular Carcinoma and Survival in Chronic Hepatitis B Patients. <i>PLoS ONE</i> , 2017, 12, e0166188.	1.1	8
2211	Impact of Radiofrequency Ablation-Induced Glissonâ€™s Capsule-Associated Complications in Patients with Hepatocellular Carcinoma. <i>PLoS ONE</i> , 2017, 12, e0170153.	1.1	15
2212	Prognostic impact of diabetes mellitus on hepatocellular carcinoma: Special emphasis from the BCLC perspective. <i>PLoS ONE</i> , 2017, 12, e0174333.	1.1	14

#	ARTICLE	IF	CITATIONS
2213	Incidental hepatocellular carcinoma after liver transplantation: Prevalence, histopathological features and prognostic impact. <i>PLoS ONE</i> , 2017, 12, e0175010.	1.1	17
2214	Hepatocellular carcinoma in elderly: Clinical characteristics, treatments and outcomes compared with younger adults. <i>PLoS ONE</i> , 2017, 12, e0184160.	1.1	27
2215	Risk of recurrence in chronic hepatitis B patients developing hepatocellular carcinoma with antiviral secondary prevention failure. <i>PLoS ONE</i> , 2017, 12, e0188552.	1.1	6
2216	Radiologic criteria of response to systemic treatments for hepatocellular carcinoma. <i>Hepatic Oncology</i> , 2017, 4, 129-137.	4.2	16
2217	Sorafenib combined with hepatectomy in patients with intermediate-stage and advanced hepatocellular carcinoma. <i>Archives of Medical Science</i> , 2017, 6, 1383-1393.	0.4	17
2218	Recommendations for the treatment of hepatitis B in 2017. <i>Clinical and Experimental Hepatology</i> , 2017, 2, 35-46.	0.6	15
2219	Diagnostic accuracy of contrast-enhanced ultrasound for the differential diagnosis of hepatocellular carcinoma: ESCULAP versus CEUS-LI-RADS. <i>European Journal of Gastroenterology and Hepatology</i> , 2017, 29, 1036-1044.	0.8	62
2220	The safety and efficacy of transarterial chemoembolization combined with sorafenib and sorafenib mono-therapy in patients with BCLC stage B/C hepatocellular carcinoma. <i>BMC Cancer</i> , 2017, 17, 645.	1.1	41
2221	Effectiveness of PIVKA-II in the detection of hepatocellular carcinoma based on real-world clinical data. <i>BMC Cancer</i> , 2017, 17, 608.	1.1	60
2222	Integrator complex subunit 6 (INTS6) inhibits hepatocellular carcinoma growth by Wnt pathway and serve as a prognostic marker. <i>BMC Cancer</i> , 2017, 17, 644.	1.1	14
2223	Induction of apoptosis and proliferation inhibition of hepatocellular carcinoma by 6-chloro-2-methoxy-N-(phenylmethyl)-9-acridinamine (BA): in vitro and vivo studies. <i>Cancer Cell International</i> , 2017, 17, 66.	1.8	5
2224	Long-term survival of hepatocellular carcinoma after percutaneous radiofrequency ablation guided by ultrasound. <i>World Journal of Surgical Oncology</i> , 2017, 15, 122.	0.8	15
2225	PD-1/PD-L blockade in gastrointestinal cancers: lessons learned and the road toward precision immunotherapy. <i>Journal of Hematology and Oncology</i> , 2017, 10, 146.	6.9	77
2226	Preoperative Carbohydrate Antigen 19-9: Its Neglected Role in Alpha-Fetoprotein-Negative Hepatocellular Carcinoma Patients. <i>Journal of Gastrointestinal Surgery</i> , 2017, 21, 2025-2032.	0.9	13
2227	Survival benefit of transarterial chemoembolization in patients with metastatic hepatocellular carcinoma: a single center experience. <i>BMC Gastroenterology</i> , 2017, 17, 98.	0.8	18
2228	Hepatic artery infusion chemotherapy using mFOLFOX versus transarterial chemoembolization for massive unresectable hepatocellular carcinoma: a prospective non-randomized study. <i>Chinese Journal of Cancer</i> , 2017, 36, 83.	4.9	90
2229	The preventive effect of the impaired liver function for antiemetic therapy against chemotherapy-induced nausea and vomiting in hepatocellular carcinoma patients. <i>Journal of Clinical Biochemistry and Nutrition</i> , 2017, 61, 222-227.	0.6	3
2230	Transarterial chemoembolization combined with recombinant human adenovirus type 5 H101 prolongs overall survival of patients with intermediate to advanced hepatocellular carcinoma: a prognostic nomogram study. <i>Chinese Journal of Cancer</i> , 2017, 36, 59.	4.9	24

#	ARTICLE	IF	CITATIONS
2231	Current Status and Future Prospects of Biomarkers in the Diagnosis of Hepatocellular Carcinoma. International Journal of Biological Markers, 2017, 32, 361-369.	0.7	12
2232	Hepatocellular Carcinoma: Diagnosis, Treatment Algorithms, and Imaging Appearance after Transarterial Chemoembolization. Journal of Clinical and Translational Hepatology, 2017, 6, 1-14.	0.7	17
2233	Needle track seeding after radiofrequency ablation for hepatocellular carcinoma: prevalence, impact, and management challenge. Journal of Hepatocellular Carcinoma, 2017, Volume 4, 23-27.	1.8	26
2234	The prognostic value of inflammation-based scores in advanced hepatocellular carcinoma patients prior to treatment with sorafenib. Oncotarget, 2017, 8, 95853-95864.	0.8	28
2235	The Role of Palliative Care in the Management of Patients with Advanced Hepatocellular Carcinoma: A Single Institution Experience. Journal of Patient Care, 2017, 02, .	0.1	1
2236	False Positive Diagnosis of Hepatocellular Carcinoma in Liver Resection Patients. Journal of Korean Medical Science, 2017, 32, 315.	1.1	15
2237	Biologic therapy-induced pemphigus. Anais Brasileiros De Dermatologia, 2017, 92, 591-593.	0.5	15
2238	HYPERVASCULAR LIVER LESIONS IN RADIOLOGICALLY NORMAL LIVER. Arquivos Brasileiros De Cirurgia Digestiva: ABCD = Brazilian Archives of Digestive Surgery, 2017, 30, 21-26.	0.5	2
2239	Adherence to BCLC recommendations for the treatment of hepatocellular carcinoma: impact on survival according to stage. Clinics, 2017, 72, 454-460.	0.6	21
2240	Yttrium-90 radioembolization of unresectable hepatocellular carcinoma – a single center experience. OncoTargets and Therapy, 2017, Volume 10, 4773-4785.	1.0	9
2241	Prognostic Impact of Indocyanine Green Plasma Disappearance Rate in Hepatocellular Carcinoma Patients after Radiofrequency Ablation: A Prognostic Nomogram Study. Internal Medicine, 2017, 56, 1001-1007.	0.3	3
2242	Predictors of Micrometastases in Patients with Barcelona Clinic Liver Cancer Classification B Hepatocellular Carcinoma. Yonsei Medical Journal, 2017, 58, 737.	0.9	12
2243	Clinical Impact of Vitamin K Dosing on Sorafenib Treatment for Hepatocellular Carcinoma. Journal of Cancer, 2017, 8, 1988-1994.	1.2	12
2244	From Clinical Standards to Translating Next-Generation Sequencing Research into Patient Care Improvement for Hepatobiliary and Pancreatic Cancers. International Journal of Molecular Sciences, 2017, 18, 180.	1.8	16
2245	Defining Radiation-Induced Hepatic Toxicity in Hepatocellular Carcinoma Patients Treated with Stereotactic Body Radiotherapy. Journal of Cancer, 2017, 8, 4155-4161.	1.2	17
2246	Chemotherapy for hepatocellular carcinoma: The present and the future. World Journal of Hepatology, 2017, 9, 907.	0.8	142
2247	Targeted therapy and personalized medicine in hepatocellular carcinoma: drug resistance, mechanisms, and treatment strategies. Journal of Hepatocellular Carcinoma, 2017, Volume 4, 93-103.	1.8	58
2248	Locoregional and systemic therapy for hepatocellular carcinoma. Journal of Gastrointestinal Oncology, 2017, 8, 215-228.	0.6	64

#	ARTICLE	IF	CITATIONS
2249	Prognostic factors after curative resection hepatocellular carcinoma and the surgeon's role. <i>Annals of Surgical Treatment and Research</i> , 2017, 93, 252.	0.4	19
2250	Overexpression of SMOC2 Attenuates the Tumorigenicity of Hepatocellular Carcinoma Cells and Is Associated With a Positive Postoperative Prognosis in Human Hepatocellular Carcinoma. <i>Journal of Cancer</i> , 2017, 8, 3812-3827.	1.2	16
2251	No-Touch Radiofrequency Ablation: A Comparison of Switching Bipolar and Switching Monopolar Ablation in Ex Vivo Bovine Liver. <i>Korean Journal of Radiology</i> , 2017, 18, 279.	1.5	25
2252	An Explorative Analysis for the Role of Serum miR-10b-3p Levels in Predicting Response to Sorafenib in Patients with Advanced Hepatocellular Carcinoma. <i>Journal of Korean Medical Science</i> , 2017, 32, 212.	1.1	34
2253	Implication of Psoas Muscle Index on Survival for Hepatocellular Carcinoma Undergoing Radiofrequency Ablation Therapy. <i>Journal of Cancer</i> , 2017, 8, 1507-1516.	1.2	29
2254	Efficacy of postoperative adjuvant transcatheter arterial chemoembolization in hepatocellular carcinoma patients with microvascular invasion. <i>World Journal of Gastroenterology</i> , 2017, 23, 7415-7424.	1.4	70
2255	Percutaneous electrochemotherapy in the treatment of portal vein tumor thrombosis at hepatic hilum in patients with hepatocellular carcinoma in cirrhosis: A feasibility study. <i>World Journal of Gastroenterology</i> , 2017, 23, 906.	1.4	51
2256	Texture analysis of intermediate-advanced hepatocellular carcinoma: prognosis and patients' selection of transcatheter arterial chemoembolization and sorafenib. <i>Oncotarget</i> , 2017, 8, 37855-37865.	0.8	30
2257	Efficacy and safety of apatinib combined with transarterial chemoembolization for hepatocellular carcinoma with portal venous tumor thrombus: a retrospective study. <i>Oncotarget</i> , 2017, 8, 100734-100745.	0.8	23
2258	Sarcopenia Predicts Reduced Survival in Patients with Hepatocellular Carcinoma at First Diagnosis. <i>Annals of Hepatology</i> , 2017, 16, 107-114.	0.6	59
2259	Combination of TACE and Sorafenib Improves Outcomes in BCLC Stages B/C of Hepatocellular Carcinoma: A Single Centre Experience. <i>Annals of Hepatology</i> , 2017, 16, 247-254.	0.6	56
2260	Analysis of the MELD Score Impact in the Outcome of Endovascular Portal Vein Reconstruction. <i>Annals of Hepatology</i> , 2017, 16, 950-958.	0.6	0
2261	Metastases of Hepatocellular Carcinoma Misdiagnosed as Isolated Hypertrophic Cardiomyopathy. <i>Annals of Hepatology</i> , 2017, 16, 966-969.	0.6	2
2262	Delusional Beliefs and Hepatocellular Carcinoma. <i>Journal of Clinical Oncology</i> , 2017, 35, 256-256.	0.8	4
2263	Chemoembolization of liver cancer with drug-loading microsphere 50-100 μ m. <i>Oncotarget</i> , 2017, 8, 5392-5399.	0.8	13
2264	Survival differences among patients with hepatocellular carcinoma based on the stage of disease and therapy received: pre and post sorafenib era. <i>Journal of Gastrointestinal Oncology</i> , 2017, 8, 789-798.	0.6	29
2265	Intensity-modulated radiotherapy for hepatocellular carcinoma: dosimetric and clinical results. <i>Oncotarget</i> , 2017, 8, 59965-59976.	0.8	22
2266	Nurse-led surveillance for liver cancer in stable cirrhosis. <i>Gastrointestinal Nursing</i> , 2017, 15, S12-S14.	0.0	0

#	ARTICLE	IF	CITATIONS
2267	Tumor thrombus: incidence, imaging, prognosis and treatment. <i>Cardiovascular Diagnosis and Therapy</i> , 2017, 7, S165-S177.	0.7	129
2268	Appropriate surgical therapy for patients with hepatocellular carcinoma beyond Milan criteria. <i>Hepatobiliary Surgery and Nutrition</i> , 2017, 6, 327-328.	0.7	0
2269	NAFLD which patients should have hepatocellular carcinoma surveillance?. <i>Hepatobiliary Surgery and Nutrition</i> , 2017, 6, 353-355.	0.7	4
2270	The growing impact of alpha-fetoprotein in the field of liver transplantation for hepatocellular cancer: time for a revolution. <i>Translational Gastroenterology and Hepatology</i> , 2017, 2, 72-72.	1.5	21
2271	Trans-arterial radio-embolization: a new chance for patients with hepatocellular cancer to access liver transplantation, a world review. <i>Translational Gastroenterology and Hepatology</i> , 2017, 2, 98-98.	1.5	20
2272	Downstaging for hepatocellular cancer: harm or benefit?. <i>Translational Gastroenterology and Hepatology</i> , 2017, 2, 106-106.	1.5	26
2273	Diagnosis of Hepatocellular Carcinoma. , 2017, , .		1
2274	Aggressive tumor recurrence after radiofrequency ablation for hepatocellular carcinoma. <i>Clinical and Molecular Hepatology</i> , 2017, 23, 95-101.	4.5	40
2275	The role of autophagy in hepatocellular carcinoma: friend or foe. <i>Oncotarget</i> , 2017, 8, 57707-57722.	0.8	124
2276	Selective internal radiation therapy using yttrium-90 resin microspheres in patients with unresectable hepatocellular carcinoma: a retrospective study. <i>Journal of Gastrointestinal Oncology</i> , 2017, 8, 799-807.	0.6	23
2277	Single injection dual phase CBCT technique ameliorates results of trans-arterial chemoembolization for hepatocellular cancer. <i>Translational Gastroenterology and Hepatology</i> , 2017, 2, 83-83.	1.5	16
2278	Bridging patients with hepatocellular cancer waiting for liver transplant: all the patients are the same?. <i>Translational Gastroenterology and Hepatology</i> , 2017, 2, 78-78.	1.5	22
2280	Fibrosis score impacts survival following resection for hepatocellular carcinoma (HCC): A Surveillance, End Results and Epidemiology (SEER) database analysis. <i>Asian Journal of Surgery</i> , 2018, 41, 551-561.	0.2	22
2281	Hepatocellular carcinoma abutting large vessels: comparison of four percutaneous ablation systems. <i>International Journal of Hyperthermia</i> , 2018, 34, 1171-1178.	1.1	25
2282	Liver Imaging Reporting and Data System: Patient Outcomes for Category 4 and 5 Nodules. <i>Radiology</i> , 2018, 287, 515-524.	3.6	17
2283	Letter: innovative use of the alpump system to treat a small hepatocellular carcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 695-696.	1.9	2
2284	Co-Upregulation of 14-3-3 σ and P-Akt is Associated with Oncogenesis and Recurrence of Hepatocellular Carcinoma. <i>Cellular Physiology and Biochemistry</i> , 2018, 45, 1097-1107.	1.1	12
2286	Preoperative prediction of microvascular invasion of hepatocellular carcinoma using 18F-FDG PET/CT: a multicenter retrospective cohort study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 720-726.	3.3	57

#	ARTICLE	IF	CITATIONS
2287	Efficacy and Safety of apatinib in patients with intermediate/advanced hepatocellular carcinoma. <i>Medicine (United States)</i> , 2018, 97, e9704.	0.4	35
2288	Radiofrequency ablation vs. surgery for perivascular hepatocellular carcinoma: Propensity score analyses of long-term outcomes. <i>Journal of Hepatology</i> , 2018, 69, 70-78.	1.8	106
2289	Adherence to Barcelona Clinic Liver Cancer therapeutic algorithm for hepatocellular carcinoma in the daily practice. <i>European Journal of Gastroenterology and Hepatology</i> , 2018, 30, 376-383.	0.8	13
2290	Adding ancillary features to enhancement patterns of hepatocellular carcinoma on gadoxetic acid-enhanced magnetic resonance imaging improves diagnostic performance. <i>Abdominal Radiology</i> , 2018, 43, 2309-2320.	1.0	9
2291	Pickering-Emulsion for Liver Trans-Arterial Chemo-Embolization with Oxaliplatin. <i>CardioVascular and Interventional Radiology</i> , 2018, 41, 781-788.	0.9	28
2292	Transarterial chemoembolization versus sorafenib in patients with hepatocellular carcinoma and extrahepatic disease. <i>United European Gastroenterology Journal</i> , 2018, 6, 238-246.	1.6	17
2293	Positron emission tomography/computed tomography with 18F-fluorocholine improve tumor staging and treatment allocation in patients with hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2018, 69, 336-344.	1.8	47
2294	Novel Albumin-Bilirubin Grade-Based Risk Prediction Model for Patients with Hepatocellular Carcinoma Undergoing Chemoembolization. <i>Digestive Diseases and Sciences</i> , 2018, 63, 1062-1071.	1.1	23
2295	Long-term shunt patency and overall survival of transjugular intrahepatic portosystemic shunt placement using covered stents with bare stents versus covered stents alone. <i>Clinical Radiology</i> , 2018, 73, 580-587.	0.5	11
2296	Antiviral Therapy Reduces Hepatocellular Carcinoma Recurrence in Patients With Low HBV-DNA Levels. <i>Annals of Surgery</i> , 2018, 268, 943-954.	2.1	97
2297	Next-Generation Sequencing of Circulating Tumor DNA Reveals Frequent Alterations in Advanced Hepatocellular Carcinoma. <i>Oncologist</i> , 2018, 23, 586-593.	1.9	75
2298	Prognostic Role of Liver Stiffness Measurements Using Magnetic Resonance Elastography in Patients with Compensated Chronic Liver Disease. <i>European Radiology</i> , 2018, 28, 3513-3521.	2.3	24
2299	Predictors of failure to detect early hepatocellular carcinoma in patients with chronic hepatitis B who received regular surveillance. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 1201-1212.	1.9	14
2300	Reproducibility of European Association for the Study of the Liver criteria and modified Response Evaluation Criteria in Solid Tumors in patients treated with sorafenib. <i>Liver International</i> , 2018, 38, 1655-1663.	1.9	16
2301	Coefficient of variation on Gd-EOB MR imaging: Correlation with the presence of early-stage hepatocellular carcinoma in patients with chronic hepatitis B. <i>European Journal of Radiology</i> , 2018, 102, 95-101.	1.2	4
2302	Patient prioritisation in HCC treatment: All (good) things come in threes. <i>Journal of Hepatology</i> , 2018, 68, 1311-1312.	1.8	3
2303	The role of molecular enrichment on future therapies in hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2018, 69, 237-247.	1.8	95
2304	Stopping nucleos(t)ide analogue treatment in Caucasian hepatitis B patients after HBsAg seroconversion is associated with high relapse rates and fatal outcomes. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 1170-1180.	1.9	45

#	ARTICLE	IF	CITATIONS
2305	Radiofrequency Ablation of Liver Tumors: No Difference in the Ablation Zone Volume Between Cirrhotic and Healthy Liver. <i>CardioVascular and Interventional Radiology</i> , 2018, 41, 905-911.	0.9	21
2306	Efficacy of microwave ablation versus radiofrequency ablation for the treatment of hepatocellular carcinoma in patients with chronic liver disease: a randomised controlled phase 2 trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 317-325.	3.7	207
2307	Suspicious liver nodule in chronic liver disease: Usefulness of a second biopsy. <i>Diagnostic and Interventional Imaging</i> , 2018, 99, 493-499.	1.8	12
2308	Hepatocellular carcinoma risk assessment by the measurement of liver stiffness variations in HCV cirrhotics treated with direct acting antivirals. <i>Digestive and Liver Disease</i> , 2018, 50, 573-579.	0.4	56
2309	Risk of de novo Hepatocellular Carcinoma after HCV Treatment with Direct-Acting Antivirals. <i>Liver Cancer</i> , 2018, 7, 190-204.	4.2	28
2310	Early development of de novo hepatocellular carcinoma after direct-acting agent therapy: Comparison with pegylated interferon-based therapy in chronic hepatitis C patients. <i>Journal of Viral Hepatitis</i> , 2018, 25, 1189-1196.	1.0	8
2311	Hepatocellular carcinoma: Prospects for natural killer cell immunotherapy. <i>Hla</i> , 2018, 92, 3-11.	0.4	10
2312	Performance of protein induced by vitamin K absence or antagonist-II assessed by chemiluminescence enzyme immunoassay for hepatocellular carcinoma detection: a meta-analysis. <i>Scandinavian Journal of Gastroenterology</i> , 2018, 53, 734-740.	0.6	34
2313	Hepatocellular carcinoma: Present and future. <i>Medicina Clínica (English Edition)</i> , 2018, 150, 390-397.	0.1	14
2314	Liver Stiffness Measured by Two-Dimensional Shear-Wave Elastography: Prognostic Value after Radiofrequency Ablation for Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2018, 7, 65-75.	4.2	23
2315	Clinical outcomes of sorafenib treatment failure for advanced hepatocellular carcinoma and candidates for regorafenib treatment in real-world practice. <i>Hepatology Research</i> , 2018, 48, 814-820.	1.8	41
2316	IL-17A promotes the invasion-metastasis cascade via the AKT pathway in hepatocellular carcinoma. <i>Molecular Oncology</i> , 2018, 12, 936-952.	2.1	19
2317	HCC Radioembolization with Yttrium-90 Glass Microspheres (TheraSphere)., 2018, , 119-125.		1
2318	Parametric response mapping cut-off values that predict survival of hepatocellular carcinoma patients after TACE. <i>Abdominal Radiology</i> , 2018, 43, 3288-3300.	1.0	3
2319	Characterization of long non-coding RNAs to reveal potential prognostic biomarkers in hepatocellular carcinoma. <i>Gene</i> , 2018, 663, 148-156.	1.0	26
2320	Utilisation of hepatocellular carcinoma screening in Australians at risk of hepatitis B virus-related carcinoma and prescribed anti-viral therapy. <i>Journal of Clinical Nursing</i> , 2018, 27, 2673-2683.	1.4	4
2321	Radiation Segmentectomy: Potential Curative Therapy for Early Hepatocellular Carcinoma. <i>Radiology</i> , 2018, 287, 1050-1058.	3.6	168
2322	Response Assessment by Volumetric Iodine Uptake Measurement: Preliminary Experience in Patients with Intermediate-Advanced Hepatocellular Carcinoma Treated with Yttrium-90 Radioembolization. <i>CardioVascular and Interventional Radiology</i> , 2018, 41, 1373-1383.	0.9	6

#	ARTICLE	IF	CITATIONS
2323	Extrahepatic cancers are the leading cause of death in patients achieving hepatitis B virus control or hepatitis C virus eradication. <i>Hepatology</i> , 2018, 68, 1245-1259.	3.6	33
2324	Radiofrequency Ablation versus Resection for Small Hepatocellular Carcinoma: Are Randomized Controlled Trials Still Needed?. <i>Radiology</i> , 2018, 287, 473-475.	3.6	9
2325	Patient Selection for Transarterial Chemoembolization in Hepatocellular Carcinoma: Importance of Benefit/Risk Assessment. <i>Liver Cancer</i> , 2018, 7, 104-119.	4.2	95
2326	Liver Calcifications and Calcified Liver Masses: Pattern Recognition Approach on CT. <i>American Journal of Roentgenology</i> , 2018, 211, 76-86.	1.0	29
2327	Transarterial chemoembolization (TACE) in the management of hepatocellular carcinoma: Results of a French national survey on current practices. <i>Diagnostic and Interventional Imaging</i> , 2018, 99, 527-535.	1.8	19
2328	Pretreatment Lesions on Magnetic Resonance Imaging in Patients With Hepatitis C Virus Infection Diagnosed With Hepatocellular Carcinoma After Initiating Direct-Acting Antiviral Therapy. <i>Gastroenterology</i> , 2018, 154, 1848-1850.	0.6	3
2329	Intensity of surveillance for hepatocellular carcinoma determines survival in patients at risk in a hepatitis B endemic area. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 1490-1501.	1.9	22
2330	CRIPTO promotes an aggressive tumour phenotype and resistance to treatment in hepatocellular carcinoma. <i>Journal of Pathology</i> , 2018, 245, 297-310.	2.1	25
2331	Combined percutaneous radiofrequency ablation and ethanol injection versus hepatic resection for 2.1-5.0 cm solitary hepatocellular carcinoma: a retrospective comparative multicentre study. <i>European Radiology</i> , 2018, 28, 3651-3660.	2.3	15
2332	EASL Clinical Practice Guidelines: Management of alcohol-related liver disease. <i>Journal of Hepatology</i> , 2018, 69, 154-181.	1.8	591
2333	EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2018, 69, 182-236.	1.8	6,153
2334	Results of 15-Year Experience in Liver Transplant for Hepatocellular Carcinoma. <i>Transplantation Proceedings</i> , 2018, 50, 617-618.	0.3	2
2335	Diabetes impacts prediction of cirrhosis and prognosis by noninvasive fibrosis models in nonalcoholic fatty liver disease. <i>Liver International</i> , 2018, 38, 1793-1802.	1.9	79
2336	Metastasis in patients with hepatocellular carcinoma: Prevalence, determinants, prognostic impact and ability to improve the Barcelona Clinic Liver Cancer system. <i>Liver International</i> , 2018, 38, 1803-1811.	1.9	18
2337	Hepatocellular carcinoma is diagnosed at a later stage in alcoholic patients: Results of a prospective, nationwide study. <i>Cancer</i> , 2018, 124, 1964-1972.	2.0	46
2338	Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. <i>Hepatology</i> , 2018, 68, 723-750.	3.6	3,096
2339	Etiology of hepatocellular carcinoma in West Africa, a case-control study. <i>International Journal of Cancer</i> , 2018, 143, 869-877.	2.3	12
2340	Biomechanics-based graph matching for augmented CT-CBCT. <i>International Journal of Computer Assisted Radiology and Surgery</i> , 2018, 13, 805-813.	1.7	3

#	ARTICLE	IF	CITATIONS
2341	Hepatocellular carcinoma after direct-acting antiviral agents: Can liver stiffness kinetics help identify patients at lower risk?. <i>Digestive and Liver Disease</i> , 2018, 50, 580-582.	0.4	0
2342	Documento de consenso. Manejo de la enfermedad hepática grasa no alcohólica (EHGNA). <i>Guía de práctica clínica. Gastroenterología Y Hepatología</i> , 2018, 41, 328-349.	0.2	71
2343	Treatment for occult hepatocellular carcinoma: does it offer survival advantages over symptom-driven treatment?. <i>Scandinavian Journal of Gastroenterology</i> , 2018, 53, 727-733.	0.6	5
2344	Anti-viral therapy can be delayed or avoided in a significant proportion of HBsAg-negative Caucasian patients in the Grey Zone. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 1397-1408.	1.9	46
2345	Hepatocellular carcinoma over three decades in Victoria, Australia: epidemiology, diagnosis and trends, 1984-2013. <i>Internal Medicine Journal</i> , 2018, 48, 835-844.	0.5	15
2346	Treatment of hepatocellular carcinoma: a cost analysis of yttrium-90 transarterial radioembolization versus sorafenib. <i>Future Oncology</i> , 2018, 14, 727-735.	1.1	5
2347	LI-RADS 2017: An update. <i>Journal of Magnetic Resonance Imaging</i> , 2018, 47, 1459-1474.	1.9	34
2348	A pilot study of ultra-deep targeted sequencing of plasma DNA identifies driver mutations in hepatocellular carcinoma. <i>Oncogene</i> , 2018, 37, 3740-3752.	2.6	89
2349	Data set for the reporting of intrahepatic cholangiocarcinoma, perihilar cholangiocarcinoma and hepatocellular carcinoma: recommendations from the International Collaboration on Cancer Reporting (ICCR). <i>Histopathology</i> , 2018, 73, 369-385.	1.6	35
2350	Cost-effectiveness of antiviral treatment after resection in hepatitis B virus-related hepatocellular carcinoma patients with compensated cirrhosis. <i>Hepatology</i> , 2018, 68, 1476-1486.	3.6	17
2351	Plasma mSEPT9: A Novel Circulating Cell-free DNA-Based Epigenetic Biomarker to Diagnose Hepatocellular Carcinoma. <i>EBioMedicine</i> , 2018, 30, 138-147.	2.7	116
2352	Influence of Progenitor-Derived Regeneration Markers on Hepatitis C Virus-Related Cirrhosis Outcome (ANRS CO12 CirVir Cohort). <i>Hepatology</i> , 2018, 68, 1534-1548.	3.6	16
2353	LI-RADS for MR Imaging Diagnosis of Hepatocellular Carcinoma: Performance of Major and Ancillary Features. <i>Radiology</i> , 2018, 288, 118-128.	3.6	96
2354	Prognostic value of postoperative complication for early recurrence after curative resection of hepatocellular carcinoma. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2018, 17, 323-329.	0.6	16
2355	Impact of remnant vital tissue after locoregional treatment and liver transplant in hepatocellular cancer patients, a multicentre cohort study. <i>Transplant International</i> , 2018, 31, 988-998.	0.8	18
2356	Liver Resection Surgery: Anesthetic Management, Monitoring, Fluids and Electrolytes. , 2018, , 349-366.		1
2357	Histological expression of methionine adenosyl transferase (MAT) 2A as a post-surgical prognostic surrogate in patients with hepatocellular carcinoma. <i>Journal of Surgical Oncology</i> , 2018, 117, 892-901.	0.8	5
2358	Hepatocellular carcinoma surveillance with ultrasound: cost-effectiveness, high-risk populations, uptake. <i>British Journal of Radiology</i> , 2018, 91, 20170436.	1.0	7

#	ARTICLE	IF	CITATIONS
2359	Dual-phase Cone-beam CT-based Navigation Imaging Significantly Enhances Tumor Detectability and Aids Superselective Transarterial Chemoembolization of Liver Cancer. <i>Academic Radiology</i> , 2018, 25, 1031-1037.	1.3	21
2361	Preoperative detection of malignant liver tumors: Comparison of 3D-T2-weighted sequences with T2-weighted turbo spin-echo and single shot T2 at 1.5T. <i>European Journal of Radiology</i> , 2018, 100, 7-13.	1.2	2
2362	FACT-Hep increases the accuracy of survival prediction in HCC patients when added to ECOG Performance Status. <i>Liver International</i> , 2018, 38, 1468-1474.	1.9	14
2363	Dendritic Cells Pulsed with Exosomes in Combination with PD-1 Antibody Increase the Efficacy of Sorafenib in Hepatocellular Carcinoma Model. <i>Translational Oncology</i> , 2018, 11, 250-258.	1.7	57
2364	Clinical significance of soluble programmed cell death ligand-1 (sPD-L1) in hepatocellular carcinoma patients treated with radiotherapy. <i>Radiotherapy and Oncology</i> , 2018, 129, 130-135.	0.3	69
2365	Diagnosis and staging of hepatocellular carcinoma (HCC): current guidelines. <i>European Journal of Radiology</i> , 2018, 101, 72-81.	1.2	263
2366	Intra-arterial idarubicin_lipiodol without embolisation in hepatocellular carcinoma: The LIDA-B phase I trial. <i>Journal of Hepatology</i> , 2018, 68, 1163-1171.	1.8	15
2367	The potential role of statins in treating liver disease. <i>Expert Review of Gastroenterology and Hepatology</i> , 2018, 12, 331-339.	1.4	17
2368	New hallmark of hepatocellular carcinoma, early hepatocellular carcinoma and high-grade dysplastic nodules on Gd-EOB-DTPA MRI in patients with cirrhosis: a new diagnostic algorithm. <i>Gut</i> , 2018, 67, 1674-1682.	6.1	114
2369	Management of Chronic Hepatitis B: Knowledge and Practices of Physicians in Pakistan. <i>Journal of Clinical and Experimental Hepatology</i> , 2018, 8, 342-351.	0.4	2
2370	Role of interventional radiology in managing pediatric liver tumors. <i>Pediatric Radiology</i> , 2018, 48, 555-564.	1.1	24
2371	Targeting Pin1 by inhibitor API-1 regulates microRNA biogenesis and suppresses hepatocellular carcinoma development. <i>Hepatology</i> , 2018, 68, 547-560.	3.6	55
2372	Incidence and risk factors associated with hepatocellular carcinoma surveillance failure. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 1524-1529.	1.4	18
2373	A radiofrequency device for tract ablation after liver biopsy: a single-institution human feasibility study. <i>British Journal of Radiology</i> , 2018, 91, 20170585.	1.0	4
2374	Multicenter, randomized, controlled trial of S1 monotherapy versus S1 and interferon-1 combination therapy for hepatocellular carcinoma with extrahepatic metastases. <i>Hepatology Research</i> , 2018, 48, 717-726.	1.8	11
2375	Advanced Recurrent Hepatocellular Carcinoma: Treatment with Sorafenib Alone or in Combination with Transarterial Chemoembolization and Radiofrequency Ablation. <i>Radiology</i> , 2018, 287, 705-714.	3.6	59
2376	Adjuvant Transarterial Chemoembolization for HBV-Related Hepatocellular Carcinoma After Resection: A Randomized Controlled Study. <i>Clinical Cancer Research</i> , 2018, 24, 2074-2081.	3.2	181
2377	Microvascular invasion of single small hepatocellular carcinoma ≤ 3 cm: Predictors and optimal treatments. <i>Annals of Gastroenterological Surgery</i> , 2018, 2, 197-203.	1.2	40

#	ARTICLE	IF	CITATIONS
2378	Long-term outcome of stereotactic body radiotherapy for patients with small hepatocellular carcinoma. <i>Hepatology Research</i> , 2018, 48, 701-707.	1.8	23
2379	Stereotactic body radiation therapy (SBRT) for hepatocellular carcinoma: imaging evaluation post treatment. <i>British Journal of Radiology</i> , 2018, 91, 20170118.	1.0	17
2380	Correlation between Resection Margin and Disease Recurrence with a Restricted Cubic Spline Model in Patients with Resected Hepatocellular Carcinoma. <i>Digestive Surgery</i> , 2018, 35, 520-531.	0.6	14
2381	Prognostic Performance of Ten Liver Function Models in Patients with Hepatocellular Carcinoma Undergoing Radiofrequency Ablation. <i>Scientific Reports</i> , 2018, 8, 843.	1.6	25
2382	Cirrhosis, high age and high body mass index are risk factors for persisting advanced fibrosis after sustained virological response in chronic hepatitis C. <i>Journal of Viral Hepatitis</i> , 2018, 25, 802-810.	1.0	14
2383	Multipronged ethanol ablation combined with TACE for intermediate hepatocellular carcinoma. <i>Minimally Invasive Therapy and Allied Technologies</i> , 2018, 27, 300-308.	0.6	2
2384	Hepatocellular carcinoma in Gaucher disease: an international case series. <i>Journal of Inherited Metabolic Disease</i> , 2018, 41, 819-827.	1.7	37
2385	Electrochemotherapy as treatment option for hepatocellular carcinoma, a prospective pilot study. <i>European Journal of Surgical Oncology</i> , 2018, 44, 651-657.	0.5	71
2386	No-touch multipolar radiofrequency ablation vs. surgical resection for solitary hepatocellular carcinoma ranging from 2 to 5 cm. <i>Journal of Hepatology</i> , 2018, 68, 1172-1180.	1.8	79
2387	Eight-year survival in chronic hepatitis B patients under long-term entecavir or tenofovir therapy is similar to the general population. <i>Journal of Hepatology</i> , 2018, 68, 1129-1136.	1.8	88
2388	The impact of treatment of hepatitis C with DAA's on the occurrence of HCC. <i>Liver International</i> , 2018, 38, 139-145.	1.9	109
2389	Liver diseases: A major, neglected global public health problem requiring urgent actions and large-scale screening. <i>Liver International</i> , 2018, 38, 2-6.	1.9	361
2390	The emerging role of stereotactic radiotherapy in gastrointestinal malignancies: a review of the literature and analysis from the Irish perspective. <i>Irish Journal of Medical Science</i> , 2018, 187, 887-894.	0.8	0
2391	A Fair Chance for Everyone: Total Tumor Volume as a Selection Tool in Liver Transplantation for Hepatocellular Carcinoma. <i>Digestive Surgery</i> , 2018, 35, 539-548.	0.6	3
2392	Utility of Tumor Burden Score to Stratify Prognosis of Patients with Hepatocellular Cancer: Results of 4759 Cases from ITA.LI.CA Study Group. <i>Journal of Gastrointestinal Surgery</i> , 2018, 22, 859-871.	0.9	38
2393	Diagnosis and Management of Hepatitis C Infection in Primary Care Settings. <i>Journal of General Internal Medicine</i> , 2018, 33, 551-557.	1.3	36
2394	Non-Invasive Diagnostic Criteria for Hepatocellular Carcinoma in Hepatitis B Virus-Endemic Areas: Is Cirrhosis Indispensable?. <i>Digestive Diseases</i> , 2018, 36, 228-235.	0.8	2
2395	Fusion imaging with contrast-enhanced ultrasonography for evaluating the early therapeutic efficacy of radiofrequency ablation for small hypervascular hepatocellular carcinomas with iso-echoic or unclear margins on conventional ultrasonography. <i>Journal of Medical Ultrasonics (2001)</i> , 2018, 45, 405-415.	0.6	18

#	ARTICLE	IF	CITATIONS
2396	A Model for Adaptive Decision Making of "Ablate-and-Wait" Versus Transplantation in Patients With Hepatocellular Carcinoma. <i>Journal of Clinical Gastroenterology</i> , 2018, 52, 655-661.	1.1	1
2397	chCC–CCA: Consensus terminology for primary liver carcinomas with both hepatocytic and cholangiocytic differentiation. <i>Hepatology</i> , 2018, 68, 113-126.	3.6	244
2398	Liver resection for hepatocellular carcinoma: personal experiences in a series of 1330 consecutive cases in China. <i>ANZ Journal of Surgery</i> , 2018, 88, E713-E717.	0.3	13
2399	Impact of resection and ablation for single hypovascular hepatocellular carcinoma – analysed with propensity score weighting. <i>Liver International</i> , 2018, 38, 484-493.	1.9	38
2400	Comparison of the accuracy of AASLD and LI-RADS criteria for the non-invasive diagnosis of HCC smaller than 3–cm. <i>Journal of Hepatology</i> , 2018, 68, 715-723.	1.8	83
2401	Response to Intermediate stage treatment: Is TACE enough?. <i>Liver International</i> , 2018, 38, 188-189.	1.9	1
2402	The earlier, the better: the effects of different administration timepoints of sorafenib in suppressing the carcinogenesis of VEGF in rats. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 81, 207-216.	1.1	4
2403	The Impact of Race on Survival After Hepatocellular Carcinoma in a Diverse American Population. <i>Digestive Diseases and Sciences</i> , 2018, 63, 515-528.	1.1	37
2404	Nomogram to Predict Survival of Patients With Recurrence of Hepatocellular Carcinoma After Surgery. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 756-764.e10.	2.4	47
2405	Effects of Diabetes and Glycemic Control on Risk of Hepatocellular Carcinoma After Seroclearance of Hepatitis B Surface Antigen. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 765-773.e2.	2.4	48
2406	Diagnostic per-lesion performance of a simulated gadoxetate disodium-enhanced abbreviated MRI protocol for hepatocellular carcinoma screening. <i>Clinical Radiology</i> , 2018, 73, 485-493.	0.5	63
2407	Development of a prognostic score to predict response to Yttrium-90 radioembolization for hepatocellular carcinoma with portal vein invasion. <i>Journal of Hepatology</i> , 2018, 68, 724-732.	1.8	100
2408	Tratamiento del hepatocarcinoma: ablaci–n y embolizaci–n arterial. <i>Radiologia</i> , 2018, 60, 156-166.	0.3	4
2409	Up–to–seven criteria as a useful predictor for tumor downstaging to within Milan criteria and Child–Pugh grade deterioration after initial conventional transarterial chemoembolization. <i>Hepatology Research</i> , 2018, 48, 442-450.	1.8	49
2410	Macrotrabecular–massive hepatocellular carcinoma: A distinctive histological subtype with clinical relevance. <i>Hepatology</i> , 2018, 68, 103-112.	3.6	159
2411	Outcomes of surgery for hepatocellular carcinoma with tumor thrombus in the inferior vena cava or right atrium. <i>Surgery Today</i> , 2018, 48, 819-824.	0.7	41
2412	Impact of etiology of chronic liver disease on hepatocellular carcinoma biomarkers. <i>Cancer Biomarkers</i> , 2018, 21, 603-612.	0.8	24
2413	Irreversible Electroporation of Liver Tumors. , 2018, , 139-166.		1

#	ARTICLE	IF	CITATIONS
2414	Outcomes of Salvage Liver Transplantation and Re-resection/Radiofrequency Ablation for Intrahepatic Recurrent Hepatocellular Carcinoma: A New Surgical Strategy Based on Recurrence Pattern. <i>Digestive Diseases and Sciences</i> , 2018, 63, 502-514.	1.1	14
2415	The Clinical Implications of Liver Resection Margin Size in Patients with Hepatocellular Carcinoma in Terms of Positron Emission Tomography Positivity. <i>World Journal of Surgery</i> , 2018, 42, 1514-1522.	0.8	14
2416	The role of liver resection in the management of intermediate and advanced stage hepatocellular carcinoma. A systematic review. <i>European Journal of Surgical Oncology</i> , 2018, 44, 195-208.	0.5	66
2417	The role of albuminâ€“bilirubin grade and inflammation-based index in patients with hepatocellular carcinoma treated with stereotactic body radiotherapy. <i>Strahlentherapie Und Onkologie</i> , 2018, 194, 403-413.	1.0	20
2418	Phase II Study of Sorafenib Combined with Concurrent Hepatic Arterial Infusion of Oxaliplatin, 5-Fluorouracil and Leucovorin for Unresectable Hepatocellular Carcinoma with Major Portal Vein Thrombosis. <i>CardioVascular and Interventional Radiology</i> , 2018, 41, 734-743.	0.9	35
2419	Frequency, Morbidity, and Mortality of Bone Metastases in Advanced Hepatocellular Carcinoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 50-58.	2.3	41
2421	The epigenetically regulated miR-494 associates with stem-cell phenotype and induces sorafenib resistance in hepatocellular carcinoma. <i>Cell Death and Disease</i> , 2018, 9, 4.	2.7	68
2422	Chemotherapy for hepatocellular carcinoma: current status and future perspectives. <i>Japanese Journal of Clinical Oncology</i> , 2018, 48, 103-114.	0.6	192
2423	Immune Regulation in HCC and the Prospect of Immunotherapy. <i>Molecular Pathology Library</i> , 2018, , 175-194.	0.1	0
2424	Locoregional Therapies for Hepatocellular Carcinoma. <i>Molecular Pathology Library</i> , 2018, , 213-233.	0.1	0
2425	Biomarker Discovery and Validation in HCC Diagnosis, Prognosis, and Therapy. <i>Molecular Pathology Library</i> , 2018, , 95-113.	0.1	1
2428	Impact of clinically evident portal hypertension on clinical outcome of patients with hepatocellular carcinoma treated by transarterial chemoembolization. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 1397-1406.	1.4	15
2429	Entecavir and tenofovir reduce hepatitis B virusâ€“related hepatocellular carcinoma recurrence more effectively than other antivirals. <i>Journal of Viral Hepatitis</i> , 2018, 25, 707-717.	1.0	23
2430	Cirrhosis with ascites in the last year of life: a nationwide analysis of factors shaping costs, health-care use, and place of death in England. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 95-103.	3.7	39
2431	Reply to: â€œDetecting microvascular invasion in HCC with contrast-enhanced MRI: Is it a good idea?â€• <i>Journal of Hepatology</i> , 2018, 68, 863-864.	1.8	2
2432	Hepatocellular carcinoma. <i>Lancet, The</i> , 2018, 391, 1301-1314.	6.3	3,878
2433	Using nomogram of the Barcelona Clinic Liver Cancer system for treatment selection in patients with stage C hepatocellular carcinoma. <i>BMC Cancer</i> , 2018, 18, 289.	1.1	19
2434	Stereotactic body radiation therapy as an effective and safe treatment for small hepatocellular carcinoma. <i>BMC Cancer</i> , 2018, 18, 451.	1.1	14

#	ARTICLE	IF	CITATIONS
2435	Cellular prognostic markers in hepatitis-related hepatocellular carcinoma. <i>Infectious Agents and Cancer</i> , 2018, 13, 10.	1.2	18
2437	Current allocation policy is favorable for patients with hepatocellular carcinoma waiting for liver transplantation. <i>Digestive and Liver Disease</i> , 2018, 50, 1345-1350.	0.4	4
2438	Novel biomarker-based model for the prediction of sorafenib response and overall survival in advanced hepatocellular carcinoma: a prospective cohort study. <i>BMC Cancer</i> , 2018, 18, 307.	1.1	18
2439	The surgical challenges of salvage living donor liver transplantation for Hepatocellular carcinoma; The cumulative experience of 100 cases - A retrospective cohort study and a propensity score analysis. <i>International Journal of Surgery</i> , 2018, 54, 187-192.	1.1	13
2440	siRNA drug development against hepatitis B virus infection. <i>Expert Opinion on Biological Therapy</i> , 2018, 18, 609-617.	1.4	27
2441	Extrahepatic Portal Vein Obstruction: Asian and Global Perspective. , 2018, , 271-300.		0
2442	A meta-analysis of long-term survival outcomes between surgical resection and radiofrequency ablation in patients with single hepatocellular carcinoma ≤ 2 cm (BCLC very early stage). <i>International Journal of Surgery</i> , 2018, 56, 61-67.	1.1	29
2443	Individual State Hepatitis C Data Supports Expanding Screening Beyond Baby Boomers to All Adults. <i>Gastroenterology</i> , 2018, 154, 1850-1851.e2.	0.6	33
2444	Microwave ablation with chemoembolization for large hepatocellular carcinoma in patients with cirrhosis. <i>International Journal of Hyperthermia</i> , 2018, 34, 1351-1358.	1.1	30
2445	High efficacy of direct-acting anti-viral agents in hepatitis C virus-infected cirrhotic patients with successfully treated hepatocellular carcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 1705-1712.	1.9	26
2446	LI-RADS pour le diagnostic de carcinome hépatocellulaire en TDM et IRM. <i>Journal D'imagerie Diagnostique Et Interventionnelle</i> , 2018, 1, 195-206.	0.0	0
2447	Diagnostic accuracy of <sc>SCCA</sc> and <sc>SCCA</sc>â€gM for hepatocellular carcinoma: A meta-analysis. <i>Liver International</i> , 2018, 38, 1820-1831.	1.9	18
2448	Percutaneous Ablation for Hepatocellular Carcinoma. <i>American Journal of Roentgenology</i> , 2018, 210, 1368-1375.	1.0	21
2449	Cost-Effectiveness of Sorafenib Monotherapy and Selected Combination Therapy with Sorafenib in Patients with Advanced Hepatocellular Carcinoma. <i>Value in Health Regional Issues</i> , 2018, 15, 120-126.	0.5	7
2450	How We Approach it: Treatment Options For Hepatocellular Carcinoma. <i>American Journal of Gastroenterology</i> , 2018, 113, 791-794.	0.2	16
2451	A multicentre, open-label, phase-I/randomised phase-II study to evaluate safety, pharmacokinetics, and efficacy of nintedanib vs. sorafenib in European patients with advanced hepatocellular carcinoma. <i>British Journal of Cancer</i> , 2018, 118, 1162-1168.	2.9	22
2452	Transarterial chemoembolization in children to treat unresectable hepatocellular carcinoma. <i>Pediatric Transplantation</i> , 2018, 22, e13187.	0.5	21
2453	Surveillance for hepatocellular cancer. <i>Clinical Medicine</i> , 2018, 18, s66-s69.	0.8	11

#	ARTICLE	IF	CITATIONS
2454	External beam radiation therapy to hepatocellular carcinoma involving inferior vena cava and/or right atrium: A meta-analysis and systemic review. <i>Radiotherapy and Oncology</i> , 2018, 129, 123-129.	0.3	43
2455	TransArterial ChemoEmbolization (TACE) with platinum versus anthracyclines for hepatocellular carcinoma: A meta-analysis. <i>International Journal of Surgery</i> , 2018, 53, 151-158.	1.1	13
2456	Model Prediction and Validation of an Order Mechanism Controlling the Spatiotemporal Phenotype of Early Hepatocellular Carcinoma. <i>Bulletin of Mathematical Biology</i> , 2018, 80, 1134-1171.	0.9	21
2457	Hepatocellular carcinoma after sustained virological response with interferon-free regimens in HIV/hepatitis C virus-coinfected patients. <i>Aids</i> , 2018, 32, 1423-1430.	1.0	17
2458	The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines. <i>Gut</i> , 2018, 67, 1568-1594.	6.1	217
2459	Hepatocellular carcinoma with en bloc diaphragmatic resection: A single-center experience over 14 years. <i>International Journal of Surgery</i> , 2018, 53, 93-97.	1.1	11
2460	Efficacy and Safety of Transarterial Chemoembolization Plus External Beam Radiotherapy vs Sorafenib in Hepatocellular Carcinoma With Macroscopic Vascular Invasion. <i>JAMA Oncology</i> , 2018, 4, 661.	3.4	311
2461	Hepatic resection compared to chemoembolization in intermediate- to advanced-stage hepatocellular carcinoma: A meta-analysis of high-quality studies. <i>Hepatology</i> , 2018, 68, 977-993.	3.6	142
2462	Selective internal radiation therapy (SIRT) before partial hepatectomy or radiofrequency destruction for treatment of hepatocellular carcinoma in cirrhotic patients: a feasibility and safety pilot study. <i>Hpb</i> , 2018, 20, 641-648.	0.1	12
2463	Volumineux carcinome h�patocellulaire: quel est l'impact de la fibrose sur le pronostic apr�s r�section?. <i>Journal De Chirurgie Visc�rale</i> , 2018, 155, 267-277.	0.0	0
2465	Re: Immuno-oncology and Its Opportunities for Interventional Radiologists: Immune Checkpoint Inhibition and Potential Synergies with Interventional Oncology Procedures. <i>Journal of Vascular and Interventional Radiology</i> , 2018, 29, 586.	0.2	0
2466	Role of liver resection in treating intermediate and advanced stage adolescent and young adult hepatocellular carcinoma patients: A propensity-matching cohort study. <i>International Journal of Surgery</i> , 2018, 54, 259-264.	1.1	12
2467	Advanced Hepatocellular Carcinoma: Pretreatment Contrast-enhanced CT Texture Parameters as Predictive Biomarkers of Survival in Patients Treated with Sorafenib. <i>Radiology</i> , 2018, 288, 445-455.	3.6	84
2469	Hepatic resection vs. transarterial chemoembolization for hepatocellular carcinoma beyond the Milan criteria with portal hypertension. <i>Digestive and Liver Disease</i> , 2018, 50, 713-719.	0.4	6
2470	When and how should we perform a biopsy for HCC in patients with liver cirrhosis in 2018? A review. <i>Digestive and Liver Disease</i> , 2018, 50, 640-646.	0.4	59
2471	Comparison of twelve liver functional reserve models for outcome prediction in patients with hepatocellular carcinoma undergoing surgical resection. <i>Scientific Reports</i> , 2018, 8, 4773.	1.6	26
2472	Proposal of Prognostic Survival Models before and after Liver Resection for Hepatocellular Carcinoma in Potentially Transplantable Patients. <i>Journal of the American College of Surgeons</i> , 2018, 226, 1147-1159.	0.2	13
2473	Evaluation of the Glypican 3 promoter for transcriptional targeting of hepatocellular carcinoma. <i>Gene Therapy</i> , 2018, 25, 115-128.	2.3	13

#	ARTICLE	IF	CITATIONS
2474	Evidence Supporting LI-RADS Major Features for CT- and MR Imagingâ€‘based Diagnosis of Hepatocellular Carcinoma: A Systematic Review. <i>Radiology</i> , 2018, 286, 29-48.	3.6	230
2475	Palliative Care for People With Hepatocellular Carcinoma, and Specific Benefits for Older Adults. <i>Clinical Therapeutics</i> , 2018, 40, 512-525.	1.1	36
2476	A multimodality imaging-compatible insertion robot with a respiratory motion calibration module designed for ablation of liver tumors: a preclinical study. <i>International Journal of Hyperthermia</i> , 2018, 34, 1194-1201.	1.1	9
2477	A prospective cohort study of hepatic toxicity after stereotactic body radiation therapy for hepatocellular carcinoma. <i>Radiotherapy and Oncology</i> , 2018, 129, 136-142.	0.3	29
2478	An efficient model for auxiliary diagnosis of hepatocellular carcinoma based on gene expression programming. <i>Medical and Biological Engineering and Computing</i> , 2018, 56, 1771-1779.	1.6	10
2479	Diagnosis of hepatocellular carcinoma with MRI. <i>Gut</i> , 2018, 67, 1563-1565.	6.1	2
2480	Newly diagnosed hepatocellular carcinoma in patients with advanced hepatitis C treated with DAAs: A prospective population study. <i>Journal of Hepatology</i> , 2018, 69, 345-352.	1.8	128
2481	Predicting Treatment Response to Intra-arterial Therapies for Hepatocellular Carcinoma with the Use of Supervised Machine Learningâ€‘An Artificial Intelligence Concept. <i>Journal of Vascular and Interventional Radiology</i> , 2018, 29, 850-857.e1.	0.2	124
2482	Evolution of indeterminate hepatocellular nodules at Gd-EOB-DPTA-enhanced MRI in cirrhotic patients. <i>Radiologia Medica</i> , 2018, 123, 489-497.	4.7	7
2483	Large hepatocellular carcinoma: Does fibrosis really impact prognosis after resection?. <i>Journal of Visceral Surgery</i> , 2018, 155, 265-273.	0.4	5
2484	Genetic variants in PNPLA3 and TM6SF2 predispose to the development of hepatocellular carcinoma in individuals with alcohol-related cirrhosis. <i>American Journal of Gastroenterology</i> , 2018, 113, 1475-1483.	0.2	82
2485	Assessment of the Albumin-Bilirubin (ALBI) Grade as a Prognostic Indicator for Hepatocellular Carcinoma Patients Treated With Radioembolization. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 861-866.	0.6	57
2486	The outcome of sorafenib monotherapy on hepatocellular carcinoma with portal vein tumor thrombosis. <i>Investigational New Drugs</i> , 2018, 36, 307-314.	1.2	27
2487	Temporal improvement in survival of patients with hepatocellular carcinoma in a hepatitis <scp>B</scp> virusâ€‘endemic population. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 475-483.	1.4	46
2488	Hepatocellular carcinoma in South America: Evaluation of risk factors, demographics and therapy. <i>Liver International</i> , 2018, 38, 136-143.	1.9	58
2489	Computerâ€‘aided diagnosis program for classifying the risk of hepatocellular carcinoma on MR images following liver imaging reporting and data system (LIâ€‘RADS). <i>Journal of Magnetic Resonance Imaging</i> , 2018, 47, 710-722.	1.9	15
2490	Selfâ€‘gated 4Dâ€‘MRI of the liver: Initial clinical results of continuous multiphase imaging of hepatic enhancement. <i>Journal of Magnetic Resonance Imaging</i> , 2018, 47, 459-467.	1.9	11
2491	Liver involvement in kidney disease and vice versa. <i>Pediatric Nephrology</i> , 2018, 33, 957-971.	0.9	8

#	ARTICLE	IF	CITATIONS
2492	Epidemiology of hepatocellular carcinoma: target population for surveillance and diagnosis. <i>Abdominal Radiology</i> , 2018, 43, 13-25.	1.0	338
2493	LI-RADS [®] ancillary features on CT and MRI. <i>Abdominal Radiology</i> , 2018, 43, 82-100.	1.0	55
2494	A randomized placebo-controlled trial of prophylactic dexamethasone for transcatheter arterial chemoembolization. <i>Hepatology</i> , 2018, 67, 575-585.	3.6	57
2495	Hepatocellular carcinoma in patients with chronic hepatitis C and cirrhosis in Denmark: A nationwide cohort study. <i>Journal of Viral Hepatitis</i> , 2018, 25, 47-55.	1.0	7
2496	Validation of the albumin-bilirubin grade-based integrated model as a predictor for sorafenib-failed hepatocellular carcinoma. <i>Liver International</i> , 2018, 38, 321-330.	1.9	37
2497	Combinations of single nucleotide polymorphisms <i>W</i> WOX and rs13338697, <i>G</i> ALNT14 and rs9679162 and rs6025211 effectively stratify outcomes of chemotherapy in advanced hepatocellular carcinoma. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2018, 14, e54-e63.	0.7	10
2498	Unravelling the pharmacologic opportunities and future directions for targeted therapies in gastro-intestinal cancers part 2: Neuroendocrine tumours, hepatocellular carcinoma, and gastro-intestinal stromal tumours. , 2018, 181, 49-75.		9
2499	Combined resection and radiofrequency ablation versus transarterial embolization for intermediate-stage hepatocellular carcinoma: A propensity score matching study. <i>Journal of the Formosan Medical Association</i> , 2018, 117, 197-203.	0.8	9
2500	Diagnostic value of alpha-1-fetoprotein (AFP) as a biomarker for hepatocellular carcinoma recurrence after liver transplantation. <i>Clinical Biochemistry</i> , 2018, 52, 20-25.	0.8	24
2501	High risk of hepatocellular carcinoma and death in patients with immune-tolerant-phase chronic hepatitis B. <i>Gut</i> , 2018, 67, 945-952.	6.1	176
2502	Transjugular intrahepatic portosystemic shunt placement before abdominal intervention in cirrhotic patients with portal hypertension: lessons from a pilot study. <i>European Journal of Gastroenterology and Hepatology</i> , 2018, 30, 21-26.	0.8	20
2503	Management consensus guideline for hepatocellular carcinoma: 2016 updated by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan. <i>Journal of the Formosan Medical Association</i> , 2018, 117, 381-403.	0.8	92
2504	Targeting AMPK, mTOR and β -Catenin by Combined Metformin and Aspirin Therapy in HCC: An Appraisal in Egyptian HCC Patients. <i>Molecular Diagnosis and Therapy</i> , 2018, 22, 115-127.	1.6	22
2505	Performing Gadoteric Acid-Enhanced MRI After CT for Guiding Curative Treatment of Early-Stage Hepatocellular Carcinoma: A Cost-Effectiveness Analysis. <i>American Journal of Roentgenology</i> , 2018, 210, W63-W69.	1.0	11
2506	Management of subcentimetre arterially enhancing and hepatobiliary hypointense lesions on gadoteric acid-enhanced MRI in patients at risk for HCC. <i>European Radiology</i> , 2018, 28, 1476-1484.	2.3	16
2507	Orantinib versus placebo combined with transcatheter arterial chemoembolisation in patients with unresectable hepatocellular carcinoma (ORIENTAL): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 37-46.	3.7	127
2508	Socio-economic deprivation significantly impacts clinical management and survival in hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2018, 68, 623-625.	1.8	5
2510	Does the Pringle maneuver affect survival and recurrence following surgical resection for hepatocellular carcinoma? A western series of 441 patients. <i>Journal of Surgical Oncology</i> , 2018, 117, 198-206.	0.8	23

#	ARTICLE	IF	CITATIONS
2511	Ring-Like Enhancement of Hepatocellular Carcinoma in Gadoteric Acid-Enhanced Multiphasic Hepatic Arterial Phase Imaging With Differential Subsampling With Cartesian Ordering. <i>Investigative Radiology</i> , 2018, 53, 191-199.	3.5	16
2512	Impact of surveillance for hepatocellular carcinoma on survival in patients with compensated cirrhosis. <i>Hepatology</i> , 2018, 68, 78-88.	3.6	45
2513	Percutaneous treatment of hepatocellular carcinoma: State of the art and innovations. <i>Journal of Hepatology</i> , 2018, 68, 783-797.	1.8	271
2514	The albumin-bilirubin grade uncovers the prognostic relationship between hepatic reserve and immune dysfunction in HIV-associated hepatocellular carcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 95-103.	1.9	20
2515	Clinical Outcomes of Radiofrequency Ablation for Early Hypovascular HCC: A Multicenter Retrospective Study. <i>Radiology</i> , 2018, 286, 338-349.	3.6	27
2516	Reply to: "Response to the flexible therapeutic approach to the BCLC B stage™: Time for scoring systems?" <i>Journal of Hepatology</i> , 2018, 68, 216-217.	1.8	0
2517	Reduction effect of the quantity of radiation exposure and contrast media by image support system in transarterial chemoembolization for the treatment of hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 1115-1122.	1.4	1
2518	Adherence to Barcelona Clinic Liver Cancer guidelines in field practice: Results of Progetto Epatocarcinoma Campania. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 1123-1130.	1.4	18
2519	Impact of surgical complications on the risk of hepatocellular carcinoma recurrence after hepatic resection. <i>Updates in Surgery</i> , 2018, 70, 57-66.	0.9	13
2520	LI-RADS technical requirements for CT, MRI, and contrast-enhanced ultrasound. <i>Abdominal Radiology</i> , 2018, 43, 56-74.	1.0	58
2521	Initial radiofrequency ablation failure for hepatocellular carcinoma: repeated radiofrequency ablation versus transarterial chemoembolisation. <i>Clinical Radiology</i> , 2018, 73, 216.e1-216.e8.	0.5	7
2522	Contribution of virtual biopsy to the screening of microvascular invasion in hepatocellular carcinoma: A pilot study. <i>Liver International</i> , 2018, 38, 687-694.	1.9	17
2524	Microbiota, Liver Diseases, and Alcohol. <i>Microbiology Spectrum</i> , 2017, 5, .	1.2	18
2525	Projections of primary liver cancer to 2030 in 30 countries worldwide. <i>Hepatology</i> , 2018, 67, 600-611.	3.6	219
2526	Rate of Nonsurveillance and Advanced Hepatocellular Carcinoma at Diagnosis in Chronic Liver Disease. <i>Journal of Clinical Gastroenterology</i> , 2018, 52, 551-556.	1.1	14
2527	Toronto HCC risk index: A validated scoring system to predict 10-year risk of HCC in patients with cirrhosis. <i>Journal of Hepatology</i> , 2018, 68, 92-99.	1.8	126
2528	Impact of Individual Components of the Metabolic Syndrome on the Outcome of Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib. <i>Digestive Diseases</i> , 2018, 36, 78-88.	0.8	7
2529	Hepatocellular carcinoma imaging systems: why they exist, how they have evolved, and how they differ. <i>Abdominal Radiology</i> , 2018, 43, 3-12.	1.0	47

#	ARTICLE	IF	CITATIONS
2530	Quantification of perfusion reduction by using 2D-perfusion angiography following transarterial chemoembolization with drug-eluting beads. <i>Abdominal Radiology</i> , 2018, 43, 1245-1253.	1.0	12
2531	Poor adherence to hepatocellular carcinoma surveillance: A systematic review and meta-analysis of a complex issue. <i>Liver International</i> , 2018, 38, 503-514.	1.9	61
2532	LI-RADS major features: CT, MRI with extracellular agents, and MRI with hepatobiliary agents. <i>Abdominal Radiology</i> , 2018, 43, 75-81.	1.0	55
2533	Computed tomography-guided percutaneous microwave ablation of hepatocellular carcinoma in challenging locations: safety and efficacy of high-power microwave platforms. <i>International Journal of Hyperthermia</i> , 2018, 34, 863-869.	1.1	36
2534	Clinical profile of hepatitis C virus infection in a developing country: India. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 926-933.	1.4	20
2535	Quality of life as a prognostic factor for survival in hepatocellular carcinoma. <i>Liver International</i> , 2018, 38, 885-894.	1.9	25
2536	US LI-RADS: ultrasound liver imaging reporting and data system for screening and surveillance of hepatocellular carcinoma. <i>Abdominal Radiology</i> , 2018, 43, 41-55.	1.0	81
2537	Impact of Splenic Volume and Splenectomy on Prognosis of Hepatocellular Carcinoma Within Milan Criteria After Curative Hepatectomy. <i>World Journal of Surgery</i> , 2018, 42, 1120-1128.	0.8	20
2538	Imaging features of microvascular invasion in hepatocellular carcinoma developed after direct-acting antiviral therapy in HCV-related cirrhosis. <i>European Radiology</i> , 2018, 28, 506-513.	2.3	63
2539	High serum soluble CD40L levels previously to liver transplantation in patients with hepatocellular carcinoma are associated with mortality at one year. <i>Journal of Critical Care</i> , 2018, 43, 316-320.	1.0	7
2540	From large to small: the immunohistochemical panel in the diagnosis of early hepatocellular carcinoma. <i>Histopathology</i> , 2018, 72, 414-422.	1.6	13
2541	Characteristics of patients with sorafenib-treated advanced hepatocellular carcinoma eligible for second-line treatment. <i>Investigational New Drugs</i> , 2018, 36, 332-339.	1.2	52
2542	Targeting STAT3 to Suppress Systemic Pro-Oncogenic Effects from Hepatic Radiofrequency Ablation. <i>Radiology</i> , 2018, 286, 524-536.	3.6	29
2543	Complete response under sorafenib in patients with hepatocellular carcinoma: Relationship with dermatologic adverse events. <i>Hepatology</i> , 2018, 67, 612-622.	3.6	55
2544	Metroticket 2.0 Model for Analysis of Competing Risks of Death After Liver Transplantation for Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2018, 154, 128-139.	0.6	417
2545	Which Criteria Applied in Multi-Phasic CT Can Predict Early Tumor Response in Patients with Hepatocellular Carcinoma Treated Using Conventional TACE: RECIST, mRECIST, EASL or qEASL?. <i>CardioVascular and Interventional Radiology</i> , 2018, 41, 433-442.	0.9	19
2546	External validation of the ITA.LI.CA prognostic system for patients with hepatocellular carcinoma: A multicenter cohort study. <i>Hepatology</i> , 2018, 67, 2215-2225.	3.6	40
2547	Proposal of a New Preoperative Prognostic Model for Solitary Hepatocellular Carcinoma Incorporating 18F-FDG-PET Imaging with the ALBI Grade. <i>Annals of Surgical Oncology</i> , 2018, 25, 542-549.	0.7	25

#	ARTICLE	IF	CITATIONS
2548	Safety and Feasibility of Chemoembolization with Doxorubicin-Loaded Small Calibrated Microspheres in Patients with Hepatocellular Carcinoma: Results of the MIRACLE I Prospective Multicenter Study. <i>CardioVascular and Interventional Radiology</i> , 2018, 41, 587-593.	0.9	40
2549	Radiation Segmentectomy versus Selective Chemoembolization in the Treatment of Early-Stage Hepatocellular Carcinoma. <i>Journal of Vascular and Interventional Radiology</i> , 2018, 29, 30-37.e2.	0.2	51
2550	Carcinoma hepatocelular: presente y futuro. <i>Medicina Clínica</i> , 2018, 150, 390-397.	0.3	35
2551	Liver transplantation beyond or downstaging within the Milan criteria for hepatocellular carcinoma. <i>Expert Review of Gastroenterology and Hepatology</i> , 2018, 12, 265-275.	1.4	24
2552	Diagnostic accuracy of prospective application of the Liver Imaging Reporting and Data System (LI-RADS) in gadoxetate-enhanced MRI. <i>European Radiology</i> , 2018, 28, 2038-2046.	2.3	67
2553	Metronomic capecitabine as second-line treatment for hepatocellular carcinoma after sorafenib discontinuation. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 403-414.	1.2	45
2554	Institutional decision to adopt Y90 as primary treatment for hepatocellular carcinoma informed by a 1,000â€patient 15â€year experience. <i>Hepatology</i> , 2018, 68, 1429-1440.	3.6	174
2555	Comment on "In Vivo Drug Delivery Performance of Lipiodol-Based Emulsion or Drug-Eluting Beads in Patients with Hepatocellular Carcinoma". <i>Molecular Pharmaceutics</i> , 2018, 15, 332-335.	2.3	5
2556	Liver resection for HCC outside the BCLC criteria. <i>Langenbeck's Archives of Surgery</i> , 2018, 403, 37-44.	0.8	22
2557	Benefits of laparoscopic liver resection in patients with hepatocellular carcinoma and portal hypertension: a case-matched study. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2018, 32, 2345-2354.	1.3	28
2558	Portal hypertension is associated with poor outcome of transarterial chemoembolization in patients with hepatocellular carcinoma. <i>European Radiology</i> , 2018, 28, 2184-2193.	2.3	31
2559	Impact of tumor size on the prognosis of hepatocellular carcinoma in patients who underwent liver resection. <i>Journal of the Chinese Medical Association</i> , 2018, 81, 155-163.	0.6	42
2560	Should we undertake surveillance for HCC in patients with NAFLD?. <i>Journal of Hepatology</i> , 2018, 68, 326-334.	1.8	145
2561	Impact of surgical treatment after sorafenib therapy for advanced hepatocellular carcinoma. <i>Surgery Today</i> , 2018, 48, 431-438.	0.7	16
2562	Transarterial chemoembolization for hepatocellular carcinoma: development and external validation of the Munich-TACE score. <i>European Journal of Gastroenterology and Hepatology</i> , 2018, 30, 44-53.	0.8	10
2563	The Effect of Transarterial Chemoembolization in Combination With Kangâ€™ai Injection on Patients With Intermediate Stage Hepatocellular Carcinoma: A Prospective Study. <i>Integrative Cancer Therapies</i> , 2018, 17, 477-485.	0.8	10
2564	Pilot study of living donor liver transplantation for patients with hepatocellular carcinoma exceeding Milan Criteria (Barcelona Clinic Liver Cancer extended criteria). <i>Liver Transplantation</i> , 2018, 24, 369-379.	1.3	47
2565	Extracellular contrast agent-enhanced MRI: 15-min delayed phase may improve the diagnostic performance for hepatocellular carcinoma in patients with chronic liver disease. <i>European Radiology</i> , 2018, 28, 1551-1559.	2.3	17

#	ARTICLE	IF	CITATIONS
2566	New insights into the role of vitamin D in hepatocellular carcinoma. Expert Review of Gastroenterology and Hepatology, 2018, 12, 287-294.	1.4	21
2567	Pictorial essay: imaging findings following Y90 radiation segmentectomy for hepatocellular carcinoma. Abdominal Radiology, 2018, 43, 1723-1738.	1.0	25
2568	The risk of hepatocellular carcinoma in cirrhotic patients with hepatitis C and sustained viral response: Role of the treatment regimen. Journal of Hepatology, 2018, 68, 646-654.	1.8	82
2569	Patients with advanced hepatocellular carcinoma need a personalized management: A lesson from clinical practice. Hepatology, 2018, 67, 1784-1796.	3.6	93
2570	Pretransplant Intra-arterial Liver-Directed Therapy Does Not Increase the Risk of Hepatic Arterial Complications in Liver Transplantation: A Single-Center 10-Year Experience. CardioVascular and Interventional Radiology, 2018, 41, 231-238.	0.9	10
2571	Predictors of Futile Liver Resection for Patients with Barcelona Clinic Liver Cancer Stage B/C Hepatocellular Carcinoma. Journal of Gastrointestinal Surgery, 2018, 22, 496-502.	0.9	15
2572	Contrast ultrasound LI-RADS LR-5 identifies hepatocellular carcinoma in cirrhosis in a multicenter retrospective study of 1,006 nodules. Journal of Hepatology, 2018, 68, 485-492.	1.8	195
2573	Outcomes of treatment with sorafenib in Egyptian patients with hepatocellular carcinoma: a retrospective cohort study. Expert Review of Gastroenterology and Hepatology, 2018, 12, 99-107.	1.4	5
2574	Combined transcatheter arterial chemoembolization and radiofrequency ablation in single-session for solitary hepatocellular carcinoma larger than 7cm. Asia-Pacific Journal of Clinical Oncology, 2018, 14, 300-309.	0.7	13
2575	Immunotherapy of Hepatocellular Carcinoma: Facts and Hopes. Clinical Cancer Research, 2018, 24, 1518-1524.	3.2	194
2576	Hepatocellular carcinoma with central scar on gadoxetic acid-enhanced and diffusion-weighted magnetic resonance imaging. Acta Radiologica, 2018, 59, 393-401.	0.5	1
2577	Nomogram for individualised prediction of liver failure risk after hepatectomy in patients with resectable hepatocellular carcinoma: the evidence from ultrasound data. European Radiology, 2018, 28, 877-885.	2.3	29
2578	Current controversies in cholangiocarcinoma. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2018, 1864, 1461-1467.	1.8	34
2579	Curative salvage liver transplantation in patients with cirrhosis and hepatocellular carcinoma: An intention-to-treat analysis. Hepatology, 2018, 67, 204-215.	3.6	52
2580	Albumin-bilirubin grade predicts the outcomes of liver resection versus radiofrequency ablation for very early/early stage of hepatocellular carcinoma. Journal of the Royal College of Surgeons of Edinburgh, 2018, 16, 163-170.	0.8	21
2581	Initial Alpha-Fetoprotein Response Predicts Prognosis in Hepatitis B-related Solitary HCC Patients After Radiofrequency Ablation. Journal of Clinical Gastroenterology, 2018, 52, e18-e26.	1.1	13
2582	Results of Liver Transplantation for Hepatocellular Carcinoma in a Multicenter Latin American Cohort Study. Annals of Hepatology, 2018, 17, 256-267.	0.6	9
2583	Prognostic ability of BCLC-B Subclassification in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization. Annals of Hepatology, 2018, 17, 110-118.	0.6	20

#	ARTICLE	IF	CITATIONS
2584	A new scoring model predicting macroscopic vascular invasion of early-intermediate hepatocellular carcinoma. <i>Medicine (United States)</i> , 2018, 97, e13536.	0.4	6
2585	Diagnostically Challenging Case: Metastatic Hepatocellular Carcinoma With No Liver Lesion at Imaging. <i>Journal of Global Oncology</i> , 2018, 4, 1-5.	0.5	2
2586	Better surgical treatment method for hepatocellular carcinoma with portal vein tumor thrombus. <i>World Journal of Gastroenterology</i> , 2018, 24, 4527-4535.	1.4	29
2587	Transarterial embolization and low-dose continuous hepatic arterial infusion chemotherapy with oxaliplatin and raltitrexed for hepatocellular carcinoma with major portal vein tumor thrombus. <i>World Journal of Gastroenterology</i> , 2018, 24, 2501-2507.	1.4	8
2588	Changing role of histopathology in the diagnosis and management of hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2018, 24, 4000-4013.	1.4	64
2589	Non-invasive in vivo Imaging Grading of Liver Fibrosis. <i>Journal of Clinical and Translational Hepatology</i> , 2018, 6, 1-10.	0.7	22
2590	The Changing Face of the Diagnosis of Chronic and Malignant Liver Diseases: Potential New Biomarkers. <i>Annals of Hepatology</i> , 2018, 17, 14-17.	0.6	2
2591	Hepatocellular Carcinoma Surveillance: Benefit of Serum Alfa-fetoprotein in Real-world Practice. <i>Euroasian Journal of Hepato-gastroenterology</i> , 2018, 8, 83-87.	0.1	19
2592	Tumor Recurrence in Hepatocellular Carcinoma Patients after Radiofrequency Ablation: Portal Hypertension as an Indicator of Recurrence of Hepatocellular Carcinoma. <i>Journal of the Korean Society of Radiology</i> , 2018, 79, 264.	0.1	0
2594	Expansion of the hepatocellular carcinoma Milan criteria in liver transplantation: Future directions. <i>World Journal of Gastroenterology</i> , 2018, 24, 3626-3636.	1.4	38
2595	Are Head-to-Head Comparisons Between Radiofrequency Ablation and Stereotactic Body Radiotherapy Really Necessary for Localized Hepatocellular Carcinoma?. <i>Journal of Clinical Oncology</i> , 2018, 36, 2563-2564.	0.8	9
2596	Loco-regional treatments on the liver transplant waiting list: unmasking hepatocellular carcinoma (HCC) biology. <i>Hepatobiliary Surgery and Nutrition</i> , 2018, 7, 199-201.	0.7	1
2597	Liver resection for hepatocellular carcinoma associated with hepatic vein invasion: is it time to reconsider the current treatment guidelines?. <i>Hepatobiliary Surgery and Nutrition</i> , 2018, 7, 300-301.	0.7	3
2598	Tailored treatment of patients with hepatocellular carcinoma with portal vein invasion: experience from a multidisciplinary hepatobiliary tumor program within a NCI comprehensive cancer center. <i>Journal of Gastrointestinal Oncology</i> , 2018, 9, 1074-1083.	0.6	1
2599	Needle track seeding in hepatocellular carcinoma after local ablation by high-dose-rate brachytherapy: a retrospective study of 588 catheter placements. <i>Journal of Contemporary Brachytherapy</i> , 2018, 10, 516-521.	0.4	10
2600	Bridging to liver transplantation patients with a hepatocellular carcinoma within Milan criteria: how worth is it?. <i>Hepatobiliary Surgery and Nutrition</i> , 2018, 7, 202-205.	0.7	0
2601	Postoperative adjuvant transarterial chemoembolization for multinodular hepatocellular carcinoma within the Barcelona Clinic Liver Cancer early stage and microvascular invasion. <i>Hepatobiliary Surgery and Nutrition</i> , 2018, 7, 418-428.	0.7	59
2602	Prolonged survival of metastatic hepatocellular carcinoma: a case report. <i>Journal of Gastrointestinal Oncology</i> , 2018, 9, E6-E8.	0.6	0

#	ARTICLE	IF	CITATIONS
2603	Stereotactic body radiation therapy following transarterial chemoembolization for unresectable hepatocellular carcinoma. <i>Journal of Gastrointestinal Oncology</i> , 2018, 9, 734-740.	0.6	22
2604	Evaluating the Potential Benefits of Using Sustained Response as a Prognostic Factor in Intermediate Hepatocellular Carcinoma Following Treatment With Conventional Chemoembolization. <i>JAMA Network Open</i> , 2018, 1, e183209.	2.8	0
2605	Resection for hepatocellular cancer: overpassing old barriers. <i>Translational Gastroenterology and Hepatology</i> , 2018, 3, 64-64.	1.5	7
2606	Efficacy and safety of megestrol in the management of hepatocellular carcinoma: a systematic review of the literature. <i>Wspolczesna Onkologia</i> , 2018, 22, 209-214.	0.7	3
2607	Efficacy of radiofrequency ablation of hepatocellular carcinoma prior to liver transplantation and the need for competing-risk analysis. <i>Hepatobiliary Surgery and Nutrition</i> , 2018, 7, 294-296.	0.7	3
2608	Validation of modified fibrosis-4 index for predicting hepatocellular carcinoma in patients with compensated alcoholic liver cirrhosis. <i>Medicine (United States)</i> , 2018, 97, e13438.	0.4	15
2609	Early experience of seven hepatocellular carcinoma cases treated with regorafenib. <i>Clinical Case Reports (discontinued)</i> , 2018, 6, 2217-2223.	0.2	4
2610	State of the art in magnetic resonance imaging of hepatocellular carcinoma. <i>Radiology and Oncology</i> , 2018, 52, 353-364.	0.6	18
2611	Drug-eluting beads transarterial chemoembolization for hepatocellular carcinoma: Current state of the art. <i>World Journal of Gastroenterology</i> , 2018, 24, 161-169.	1.4	96
2612	Improvement of clinical management and outcome in hepatocellular carcinoma nowadays compared with historical cohorts. <i>European Journal of Gastroenterology and Hepatology</i> , 2018, 30, 1422-1427.	0.8	3
2613	Hepatocellular carcinoma: one world, one cancer—different guidelines?. <i>Hepatobiliary Surgery and Nutrition</i> , 2018, 7, 41-43.	0.7	4
2614	New prognostic biomarkers of mortality in patients undergoing liver transplantation for hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2018, 24, 4230-4242.	1.4	15
2615	Clinical nurse specialist role in setting up a joint hepatocellular carcinoma clinic at a specialist liver unit. <i>Gastrointestinal Nursing</i> , 2018, 16, S20-S28.	0.0	0
2616	Hepatectomy plus adjuvant transcatheter arterial chemoembolization improves the survival rate of patients with multicentric occurrence of hepatocellular carcinoma. <i>Oncology Letters</i> , 2018, 16, 5882-5890.	0.8	5
2617	circRNA of AR ¹ suppressed PABPC1 91i ₂ bp enhances the cytotoxicity of natural killer cells against hepatocellular carcinoma via upregulating UL16 binding protein 1. <i>Oncology Letters</i> , 2019, 17, 388-397.	0.8	43
2618	Preoperative short-term fasting protects liver injury in patients undergoing hepatectomy. <i>Annals of Translational Medicine</i> , 2018, 6, 449-449.	0.7	9
2619	Complete response of hepatocellular carcinoma with right atrium and pulmonary metastases treated by combined treatments (a possible treatment effect of natural killer cell). <i>Medicine (United States)</i> , 2018, 97, e12866.	0.4	6
2620	Epidemiological trends in digestive cancers compared to trends in alcohol consumption. Facts from Romania: correlation or coincidence?. <i>Medicine and Pharmacy Reports</i> , 2018, 91, 376-386.	0.2	2

#	ARTICLE	IF	CITATIONS
2621	3D segmentation of liver and its lesions using optimized geometric contours. <i>Procedia Computer Science</i> , 2018, 133, 240-247.	1.2	6
2623	HCC in Elderly Patients. <i>Curative Intraoperative Strategies and Management in Recurrences.</i> , 2018, , .		2
2625	Regorafenib treatment for patients with hepatocellular carcinoma who progressed on sorafenibâ€™A cost-effectiveness analysis. <i>PLoS ONE</i> , 2018, 13, e0207132.	1.1	38
2626	The efficacy and safety of long- versus short-interval transarterial chemoembolization in unresectable hepatocellular carcinoma. <i>Journal of Cancer</i> , 2018, 9, 4000-4008.	1.2	7
2627	Portal vein thrombosis in cirrhosis: diagnosis, natural history, and therapeutic challenges. <i>Annals of Gastroenterology</i> , 2018, 31, 315-329.	0.4	42
2628	ALBI Score as a Predictor of Survival in Patients with Compensated Cirrhosis Resected for Hepatocellular Carcinoma: Exploratory Evaluation in Relationship to PALBI and MELD Liver Function Scores. <i>Acta Clinica Croatica</i> , 2018, 57, 292-300.	0.1	5
2629	Complications of Transarterial Chemoembolization (TACE) in the Treatment of Liver Tumors. <i>CirurgÃa EspaÃola (English Edition)</i> , 2018, 96, 560-567.	0.1	24
2630	Association of Sustained Response Duration With Survival After Conventional Transarterial Chemoembolization in Patients With Hepatocellular Carcinoma. <i>JAMA Network Open</i> , 2018, 1, e183213.	2.8	19
2631	Factors associated with tumor size of hepatocellular carcinoma. <i>IOP Conference Series: Earth and Environmental Science</i> , 2018, 125, 012137.	0.2	1
2632	Ultrasonography in Gastroenterology: The Need for Training. <i>GE Portuguese Journal of Gastroenterology</i> , 2018, 25, 308-316.	0.3	3
2633	Radiomics score: a potential prognostic imaging feature for postoperative survival of solitary HCC patients. <i>BMC Cancer</i> , 2018, 18, 1148.	1.1	113
2634	Yttrium-90 transarterial radioembolization versus conventional transarterial chemoembolization for patients with hepatocellular carcinoma: a systematic review and meta-analysis. <i>Cancer Biology and Medicine</i> , 2018, 15, 299.	1.4	38
2635	Comparison of the efficacy and safety of Transarterial chemoembolization with and without Apatinib for the treatment of BCLC stage C hepatocellular carcinoma. <i>BMC Cancer</i> , 2018, 18, 1131.	1.1	36
2636	Update in global trends and aetiology of hepatocellular carcinoma. <i>Wspolczesna Onkologia</i> , 2018, 22, 141-150.	0.7	175
2637	Evaluation of Serum Des-Gamma-Carboxy Prothrombin for the Diagnosis of Hepatitis B Virus-Related Hepatocellular Carcinoma: A Meta-Analysis. <i>Disease Markers</i> , 2018, 2018, 1-10.	0.6	20
2638	Risks of hepatocellular carcinoma and cirrhosis-associated complications in patients with rheumatoid arthritis: a 10-year population-based cohort study in Taiwan. <i>Hepatology International</i> , 2018, 12, 531-543.	1.9	5
2639	Progression of Hepatic Hypovascular Nodules with Hypointensity in the Hepatobiliary Phase of Gd-EOB-DTPA-enhanced MRI in Hepatocellular Carcinoma Cases. <i>Internal Medicine</i> , 2018, 57, 165-171.	0.3	5
2640	Treatment of Liver Tumors with Transarterial Chemoembolization. <i>Seminars in Interventional Radiology</i> , 2018, 35, 350-355.	0.3	3

#	ARTICLE	IF	CITATIONS
2641	Treatment choice for early-stage hepatocellular carcinoma in real-world practice: impact of treatment stage migration to transarterial chemoembolization and treatment response on survival. <i>Scandinavian Journal of Gastroenterology</i> , 2018, 53, 1368-1375.	0.6	14
2642	MR-Guided Liver Interventions. <i>Topics in Magnetic Resonance Imaging</i> , 2018, 27, 163-170.	0.7	8
2643	L-Carnitine for the Treatment of Overt Hepatic Encephalopathy in Patients with Advanced Liver Cirrhosis. <i>Journal of Nutritional Science and Vitaminology</i> , 2018, 64, 321-328.	0.2	10
2644	Complicaciones de la quimioembolización transarterial (QETA) en el tratamiento de los tumores hepáticos. <i>Cirugía Española</i> , 2018, 96, 560-567.	0.1	28
2645	HIGHER VALUES IN LIVER ELASTOGRAPHY AND MELD SCORE ARE MORTALITY PREDICTORS ON LIVER TRANSPLANT WAITING LIST. <i>Arquivos Brasileiros De Cirurgia Digestiva: ABCD = Brazilian Archives of Digestive Surgery</i> , 2018, 31, e1360.	0.5	4
2646	Aptamer: A potential oligonucleotide nanomedicine in the diagnosis and treatment of hepatocellular carcinoma. <i>Oncotarget</i> , 2018, 9, 2951-2961.	0.8	40
2647	Multipotent mesenchymal stromal cells play critical roles in hepatocellular carcinoma initiation, progression and therapy. <i>Molecular Cancer</i> , 2018, 17, 178.	7.9	49
2648	Hand grip strength and adductor pollicis muscle thickness in patients on palliative care for hepatocellular carcinoma. <i>Clinical Nutrition Experimental</i> , 2018, 22, 30-35.	2.0	2
2649	Natural product pectolarigenin inhibits proliferation, induces apoptosis, and causes G2/M phase arrest of HCC via PI3K/AKT/mTOR/ERK signaling pathway. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 8633-8642.	1.0	25
2650	Alpha-fetoprotein screening in patients with hepatitis C-induced cirrhosis who achieved a sustained virologic response in the direct-acting antiviral agents era. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2018, 17, 570-574.	0.6	2
2651	Dynamics of Axl Receptor Shedding in Hepatocellular Carcinoma and Its Implication for Theranostics. <i>International Journal of Molecular Sciences</i> , 2018, 19, 4111.	1.8	19
2652	Staging systems of hepatocellular carcinoma: A review. <i>Indian Journal of Gastroenterology</i> , 2018, 37, 481-491.	0.7	88
2653	The Effects of Thoracic Epidural Analgesia during Percutaneous Radiofrequency Ablation for Hepatocellular Carcinoma. <i>Pain Research and Management</i> , 2018, 2018, 1-6.	0.7	6
2654	Combination Therapy after TACE for Hepatocellular Carcinoma with Macroscopic Vascular Invasion: Stereotactic Body Radiotherapy versus Sorafenib. <i>Cancers</i> , 2018, 10, 516.	1.7	20
2655	Serum human endothelial cell-specific molecule-1 (endocan) and vascular endothelial growth factor in cirrhotic HCV patients with hepatocellular carcinoma as predictors of mortality. <i>Clinical and Experimental Gastroenterology</i> , 2018, Volume 11, 431-438.	1.0	10
2656	Efficacy of combination therapy with transcatheter arterial chemoembolization and radiofrequency ablation for intermediate-stage hepatocellular carcinoma. <i>Scandinavian Journal of Gastroenterology</i> , 2018, 53, 1575-1583.	0.6	28
2657	Sorafenib Monotherapy Versus Sorafenib Combined with Regional Therapies for Hepatocellular Carcinoma Patients with Pulmonary Oligometastases: A Propensity Score-matched Analysis. <i>Journal of Cancer</i> , 2018, 9, 1745-1753.	1.2	14
2658	Exosomes derived from HBV-associated liver cancer promote chemoresistance by upregulating chaperone-mediated autophagy. <i>Oncology Letters</i> , 2018, 17, 323-331.	0.8	26

#	ARTICLE	IF	CITATIONS
2659	Enolase-1 serves as a biomarker of diagnosis and prognosis in hepatocellular carcinoma patients. <i>Cancer Management and Research</i> , 2018, Volume 10, 5735-5745.	0.9	35
2660	Transarterial chemoembolization with radiofrequency ablation versus hepatectomy in hepatocellular carcinoma beyond the Milan criteria: a retrospective study. <i>Cancer Management and Research</i> , 2018, Volume 10, 5545-5552.	0.9	7
2661	20 Ablation of Malignant Liver Tumors. , 2018, , .		0
2662	Micro-RNAs in hepatitis B virus-related chronic liver diseases and hepatocellular carcinoma. <i>World Journal of Hepatology</i> , 2018, 10, 558-570.	0.8	23
2663	Human Hepatic Stem/Progenitor Cells in Cancer and Liver Disease. <i>Stem Cells in Clinical Applications</i> , 2018, , 71-83.	0.4	1
2664	MRI texture analysis for differentiation of malignant and benign hepatocellular tumors in the non-cirrhotic liver. <i>Heliyon</i> , 2018, 4, e00987.	1.4	32
2665	Radioembolization versus chemoembolization for unresectable hepatocellular carcinoma: a meta-analysis of randomized trials. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 7315-7321.	1.0	54
2666	5 Liver. , 2018, , .		0
2667	Multidisciplinary management of recurrent and metastatic hepatocellular carcinoma after resection: an international expert consensus. <i>Hepatobiliary Surgery and Nutrition</i> , 2018, 7, 353-371.	0.7	73
2668	A novel long-sustaining system of apatinib for long-term inhibition of the proliferation of hepatocellular carcinoma cells. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 8529-8541.	1.0	26
2669	Transcatheter arterial chemoembolization combined with radiofrequency or microwave ablation for hepatocellular carcinoma: a review. <i>Hepatic Oncology</i> , 2018, 5, HEP07.	4.2	19
2670	Treatment and Cost of Hepatocellular Carcinoma: A Population-Based Cohort Study in Taiwan. <i>International Journal of Environmental Research and Public Health</i> , 2018, 15, 2655.	1.2	13
2671	Carcinogenesis on the background of liver fibrosis: Implications for the management of hepatocellular cancer. <i>World Journal of Gastroenterology</i> , 2018, 24, 4436-4447.	1.4	105
2672	Precise nanomedicine for intelligent therapy of cancer. <i>Science China Chemistry</i> , 2018, 61, 1503-1552.	4.2	336
2673	Cyclin A2/E1 activation defines a hepatocellular carcinoma subclass with a rearrangement signature of replication stress. <i>Nature Communications</i> , 2018, 9, 5235.	5.8	118
2674	LI-RADS Version 2018 Ancillary Features at MRI. <i>Radiographics</i> , 2018, 38, 1973-2001.	1.4	83
2675	Hepatocellular carcinoma: a practical review for the surgical pathologist. <i>Diagnostic Histopathology</i> , 2018, 24, 500-507.	0.2	4
2676	A novel inflammation-based nomogram system to predict survival of patients with hepatocellular carcinoma. <i>Cancer Medicine</i> , 2018, 7, 5027-5035.	1.3	22

#	ARTICLE	IF	CITATIONS
2677	Can acoustic radiation force imaging of the liver and spleen predict the presence of gastroesophageal varices?. <i>Clinical Radiology</i> , 2018, 73, 1046-1051.	0.5	4
2678	Protein induced by vitamin K absence or antagonist-II versus alpha-fetoprotein in the diagnosis of hepatocellular carcinoma: A systematic review with meta-analysis. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2018, 17, 487-495.	0.6	36
2679	The role of external beam radiotherapy for hepatocellular carcinoma patients with lymph node metastasis: a meta-analysis of observational studies. <i>Cancer Management and Research</i> , 2018, Volume 10, 3305-3315.	0.9	14
2680	Short-course carbon-ion radiotherapy for hepatocellular carcinoma: A multi-institutional retrospective study. <i>Liver International</i> , 2018, 38, 2239-2247.	1.9	38
2681	Multimodal Meta-Analysis of 1,494 Hepatocellular Carcinoma Samples Reveals Significant Impact of Consensus Driver Genes on Phenotypes. <i>Clinical Cancer Research</i> , 2019, 25, 463-472.	3.2	41
2682	Systemic treatment for hepatocellular carcinoma. <i>Chronic Diseases and Translational Medicine</i> , 2018, 4, 148-155.	0.9	8
2683	Noncontrast magnetic resonance imaging versus ultrasonography for hepatocellular carcinoma surveillance (MIRACLE-HCC): study protocol for a prospective randomized trial. <i>BMC Cancer</i> , 2018, 18, 915.	1.1	31
2684	Impact of the Uridine-Cytidine Kinase Like-1 Protein and IL28B rs12979860 and rs8099917 SNPs on the Development of Hepatocellular Carcinoma in Cirrhotic Chronic Hepatitis C Patientsâ€”A Pilot Study. <i>Medicina (Lithuania)</i> , 2018, 54, 67.	0.8	3
2685	Post Locoregional Therapy Treatment Imaging in Hepatocellular Carcinoma Patients: A Literature-based Review. <i>Journal of Clinical and Translational Hepatology</i> , 2018, 6, 1-9.	0.7	24
2686	Hepatocellular carcinoma treatment: hurdles, advances and prospects. <i>Hepatic Oncology</i> , 2018, 5, HEP08.	4.2	59
2687	Long-versus short-interval follow-up after resection of hepatocellular carcinoma: a retrospective cohort study. <i>Cancer Communications</i> , 2018, 38, 1-11.	3.7	15
2688	Two Nomograms to Select Hepatocellular Carcinoma Patients with Macroscopic Vascular Invasion for Hepatic Resection. <i>Journal of Cancer</i> , 2018, 9, 3287-3294.	1.2	9
2689	Liver Imaging Reporting and Data System (LI-RADS) Version 2018: Imaging of Hepatocellular Carcinoma in At-Risk Patients. <i>Radiology</i> , 2018, 289, 816-830.	3.6	634
2690	Transforming Growth Factor- β -Induced Cell Plasticity in Liver Fibrosis and Hepatocarcinogenesis. <i>Frontiers in Oncology</i> , 2018, 8, 357.	1.3	243
2691	Cytokine-mediated modulation of the hepatic miRNome: miR-146b-5p is an IL-6-inducible miRNA with multiple targets. <i>Journal of Leukocyte Biology</i> , 2018, 104, 987-1002.	1.5	17
2692	Association Between Type 2 Diabetes Mellitus, HbA1c and the Risk for Spontaneous Bacterial Peritonitis in Patients with Decompensated Liver Cirrhosis and Ascites. <i>Clinical and Translational Gastroenterology</i> , 2018, 9, e189.	1.3	23
2693	Minor laparoscopic liver resection for Hepatocellular Carcinoma is safer than minor open resection, especially for less compensated cirrhotic patients: Propensity score analysis. <i>Surgical Oncology</i> , 2018, 27, 722-729.	0.8	41
2694	4Mu Decreases CD47 Expression on Hepatic Cancer Stem Cells and Primes a Potent Antitumor T Cell Response Induced by Interleukin-12. <i>Molecular Therapy</i> , 2018, 26, 2738-2750.	3.7	53

#	ARTICLE	IF	CITATIONS
2695	Quantitative dynamic contrast-enhanced ultrasound may help predict the outcome of hepatocellular carcinoma after microwave ablation. <i>International Journal of Hyperthermia</i> , 2018, 35, 105-111.	1.1	12
2696	Adjuvant transcatheter arterial chemoembolization after curative resection for hepatocellular carcinoma patients with solitary tumor and microvascular invasion: a randomized clinical trial of efficacy and safety. <i>Cancer Communications</i> , 2018, 38, 1-12.	3.7	92
2697	Fatty Liver Disease and Hepatocellular Carcinoma: The Pathologist's View. <i>Advances in Experimental Medicine and Biology</i> , 2018, 1032, 55-69.	0.8	7
2698	CT/MRI LI-RADS v2017 " review of the guidelines. <i>Polish Journal of Radiology</i> , 2018, 83, 355-365.	0.5	11
2700	Combined therapy of transarterial chemoembolization and stereotactic body radiation therapy versus transarterial chemoembolization for ≤ 5 cm hepatocellular carcinoma: Propensity score matching analysis. <i>PLoS ONE</i> , 2018, 13, e0206381.	1.1	30
2701	Comparison of α -Fetoprotein Criteria and Modified Response Evaluation Criteria in Solid Tumors for the Prediction of Overall Survival of Patients with Hepatocellular Carcinoma after Transarterial Chemoembolization. <i>Journal of Vascular and Interventional Radiology</i> , 2018, 29, 1654-1661.	0.2	16
2702	A Nomogram Predicting Extrahepatic Metastases for Patients with Adjuvant Transarterial Chemoembolization after Hepatectomy. <i>Journal of Cancer</i> , 2018, 9, 4223-4233.	1.2	5
2703	Current noninvasive liver reserve models do not predict histological fibrosis severity in hepatocellular carcinoma. <i>Scientific Reports</i> , 2018, 8, 15074.	1.6	8
2704	Recent advances in non-invasive magnetic resonance imaging assessment of hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2018, 24, 2413-2426.	1.4	24
2705	Transarterial chemoembolization extends long-term survival in patients with unresectable hepatocellular carcinoma. <i>Medicine (United States)</i> , 2018, 97, e11872.	0.4	29
2706	The impact of antiviral therapy on hepatocellular carcinoma epidemiology. <i>Hepatic Oncology</i> , 2018, 5, HEP03.	4.2	14
2707	Tumor Location Influences Oncologic Outcomes of Hepatocellular Carcinoma Patients Undergoing Radiofrequency Ablation. <i>Cancers</i> , 2018, 10, 378.	1.7	36
2708	Clinical Case Panel: Treatment Alternatives for Inoperable Hepatocellular Carcinoma. <i>Seminars in Radiation Oncology</i> , 2018, 28, 295-308.	1.0	4
2709	Cistanche tubulosa phenylethanoid glycosides induce apoptosis in H22 hepatocellular carcinoma cells through both extrinsic and intrinsic signaling pathways. <i>BMC Complementary and Alternative Medicine</i> , 2018, 18, 275.	3.7	13
2710	Treatment of Elderly Patients with Chronic Hepatitis C: A Retrospective Cohort Study. <i>Acta Clinica Croatica</i> , 2018, 57, 61-70.	0.1	6
2711	Health education helps to relieve postembolization pain during hepatic arterial chemoembolization therapy. <i>Journal of Pain Research</i> , 2018, Volume 11, 2115-2121.	0.8	3
2712	Alcohol and Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2018, , .	0.8	0
2713	Risk factors for developing liver cancer in people with and without liver disease. <i>PLoS ONE</i> , 2018, 13, e0206374.	1.1	24

#	ARTICLE	IF	CITATIONS
2714	Narrow Band Imaging: A Novel Technique for Immediate Evaluation of Efficacy in Laparoscopic Radiofrequency Ablation of Exophytic Hepatocellular Carcinoma. <i>Surgical Laparoscopy, Endoscopy and Percutaneous Techniques</i> , 2018, 28, 282-286.	0.4	1
2715	Laparoscopic Versus Open Major Hepatectomy for Hepatocellular Carcinoma: A Meta-Analysis. <i>Surgical Laparoscopy, Endoscopy and Percutaneous Techniques</i> , 2018, 28, 267-274.	0.4	24
2716	D-dimer plasmatic levels as a marker for diagnosis and prognosis of hepatocellular carcinoma patients with portal vein thrombosis. <i>Clinical and Experimental Gastroenterology</i> , 2018, Volume 11, 373-380.	1.0	18
2717	Perivascular Tumor-Infiltrating Leukocyte Scoring for Prognosis of Resected Hepatocellular Carcinoma Patients. <i>Cancers</i> , 2018, 10, 389.	1.7	27
2718	Comments on: Perioperative von Willebrand factor dynamics are associated with liver regeneration and predict outcome after liver resection. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2018, 17, 485-486.	0.6	0
2719	Tumor Targeting and Three-Dimensional Voxel-Based Dosimetry to Predict Tumor Response, Toxicity, and Survival after Yttrium-90 Resin Microsphere Radioembolization in Hepatocellular Carcinoma. <i>Journal of Vascular and Interventional Radiology</i> , 2018, 29, 1662-1670.e4.	0.2	46
2720	18F-FCH and 90Y PET/CT data for the early evaluation of HCC radioembolisation. <i>Clinical and Translational Imaging</i> , 2018, 6, 357-367.	1.1	0
2721	The Safety and Efficacy of Combination Therapy of Sorafenib and Radiotherapy for Advanced Hepatocellular Carcinoma: A Retrospective Study. <i>Internal Medicine</i> , 2018, 57, 1345-1353.	0.3	29
2722	Significant predictors of overall survival in patients with hepatocellular carcinoma after surgical resection. <i>PLoS ONE</i> , 2018, 13, e0202650.	1.1	15
2723	Efficacy of loco-regional treatment for hepatocellular carcinoma prior to living donor liver transplantation: a report from a single center in Egypt. <i>Journal of Hepatocellular Carcinoma</i> , 2018, Volume 5, 29-36.	1.8	4
2724	Detection of hepatocellular carcinoma by tissue resonance interaction method (TRIM). <i>Przegląd Gastroenterologiczny</i> , 2018, 13, 40-46.	0.3	0
2725	Spontaneous Regression of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus. <i>Case Reports in Gastroenterology</i> , 2018, 12, 411-419.	0.3	4
2726	Transarterial chemoembolization plus sorafenib for the management of unresectable hepatocellular carcinoma: a systematic review and meta-analysis. <i>BMC Gastroenterology</i> , 2018, 18, 138.	0.8	48
2727	Stereotactic Body Radiotherapy: Does It Have a Role in Management of Hepatocellular Carcinoma?. <i>Yonsei Medical Journal</i> , 2018, 59, 912.	0.9	14
2728	U-CatcHCC: An Accurate HCC Detector in Hepatic DCE-MRI Sequences Based on an U-Net Framework. <i>Lecture Notes in Computer Science</i> , 2018, , 319-328.	1.0	7
2729	Long-term remission in advanced stage hepatocellular carcinoma? A chance for cure?. <i>Memo - Magazine of European Medical Oncology</i> , 2018, 11, 185-192.	0.3	6
2730	Development of pre and post-operative models to predict early recurrence of hepatocellular carcinoma after surgical resection. <i>Journal of Hepatology</i> , 2018, 69, 1284-1293.	1.8	360
2731	Dynamic Three-Dimensional Contrast-Enhanced Ultrasound to Predict Therapeutic Response of Radiofrequency Ablation in Hepatocellular Carcinoma: Preliminary Findings. <i>BioMed Research International</i> , 2018, 2018, 1-8.	0.9	13

#	ARTICLE	IF	CITATIONS
2732	Liver transplantation and alcoholic liver disease: History, controversies, and considerations. <i>World Journal of Gastroenterology</i> , 2018, 24, 2785-2805.	1.4	94
2733	Novel biomarkers in hepatocellular carcinoma. <i>Digestive and Liver Disease</i> , 2018, 50, 1115-1123.	0.4	104
2734	Dual-Energy CTâ€‘Derived Volumetric Iodine Concentration for the Assessment of Therapeutic Response after Microwave Ablation in a Rabbit Model with Intrahepatic VX2 Tumor. <i>Journal of Vascular and Interventional Radiology</i> , 2018, 29, 1455-1461.	0.2	8
2735	Current and Future Treatment of Hepatocellular Carcinoma: An Updated Comprehensive Review. <i>Journal of Clinical and Translational Hepatology</i> , 2018, 6, 1-10.	0.7	218
2736	Imaging evaluation of sorafenib for treatment of advanced hepatocellular carcinoma. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2018, 30, 382-394.	0.7	2
2737	Regorafenib in hepatocellular carcinoma: latest evidence and clinical implications. <i>Drugs in Context</i> , 2018, 7, 1-10.	1.0	34
2738	Early postoperative controlling nutritional status (CONUT) score is associated with complication III-V after hepatectomy in hepatocellular carcinoma: A retrospective cohort study of 1,334 patients. <i>Scientific Reports</i> , 2018, 8, 13406.	1.6	27
2739	Oncologic superiority of anatomic resection of hepatocellular carcinoma by ultrasound-guided compression of the portal tributaries compared with nonanatomic resection: An analysis of patients matched for tumor characteristics and liver function. <i>Surgery</i> , 2018, 164, 1006-1013.	1.0	22
2740	Effect of KI-67 positive cellular index on prognosis after hepatectomy in Barcelona Clinic Liver Cancer stage A and B hepatocellular carcinoma with microvascular invasion. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 4747-4754.	1.0	23
2741	Accuracy of Computed Tomography in the Assessment of Milan Criteria in Liver Transplantation for Hepatocellular Carcinoma. <i>Transplantation Proceedings</i> , 2018, 50, 2002-2005.	0.3	5
2742	Hepatocellular carcinoma after prior sorafenib treatment: incidence, healthcare utilisation and costs from German statutory health insurance claims data. <i>Health Economics Review</i> , 2018, 8, 18.	0.8	6
2743	Surgical resection improves long-term survival of patients with hepatocellular carcinoma across different Barcelona Clinic Liver Cancer stages. <i>Cancer Management and Research</i> , 2018, Volume 10, 361-369.	0.9	40
2744	Differentially expressed serum host proteins in hepatitis B and C viral infections. <i>VirusDisease</i> , 2018, 29, 468-477.	1.0	6
2745	Serum Stem Cell Growth Factor Beta for the Prediction of Therapy Response in Hepatocellular Carcinoma. <i>BioMed Research International</i> , 2018, 2018, 1-8.	0.9	23
2746	Overexpression of c-kit(CD117), relevant with microvessel density, is an independent survival prognostic factor for patients with HBV-related hepatocellular carcinoma. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 1285-1292.	1.0	11
2747	A Novel Risk prediction Model for Patients with Combined Hepatocellular-Cholangiocarcinoma. <i>Journal of Cancer</i> , 2018, 9, 1025-1032.	1.2	14
2748	No Association Between Screening for Hepatocellular Carcinoma and Reduced Cancer-Related Mortality in Patients With Cirrhosis. <i>Gastroenterology</i> , 2018, 155, 1128-1139.e6.	0.6	80
2749	Microbiota, Liver Diseases, and Alcohol. , 2018, , 187-212.		2

#	ARTICLE	IF	CITATIONS
2750	Surgical techniques and strategies for the treatment of primary liver tumours: hepatocellular and cholangiocellular carcinoma. <i>European Surgery - Acta Chirurgica Austriaca</i> , 2018, 50, 100-112.	0.3	15
2751	Chimeric antigen receptor-engineered T-cell therapy for liver cancer. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2018, 17, 301-309.	0.6	59
2752	Are Non-HIV Malignancies Increased in the HIV-Infected Population?. <i>Current Infectious Disease Reports</i> , 2018, 20, 22.	1.3	26
2754	Impact of Early Initiated Everolimus on the Recurrence of Hepatocellular Carcinoma After Liver Transplantation. <i>Transplantation</i> , 2018, 102, 2056-2064.	0.5	31
2755	Remaining hepatocellular carcinoma risk in chronic hepatitis B patients receiving entecavir/tenofovir in South Korea. <i>Hepatology Research</i> , 2018, 48, 862-871.	1.8	23
2756	Clinical practice guidelines for the treatment of primary liver cancer with integrative traditional Chinese and Western medicine. <i>Journal of Integrative Medicine</i> , 2018, 16, 236-248.	1.4	61
2757	Protein phosphatase 1 regulatory subunit 3B gene variation protects against hepatic fat accumulation and fibrosis in individuals at high risk of nonalcoholic fatty liver disease. <i>Hepatology Communications</i> , 2018, 2, 666-675.	2.0	38
2758	Benign and Malignant Lesions of the Liver. , 2018, , 335-346.		0
2759	Consensus document. Management of non-alcoholic fatty liver disease (NAFLD). Clinical practice guideline. <i>Gastroenterology & Hepatology (English Edition)</i> , 2018, 41, 328-349.	0.0	7
2760	Multimodality treatment of hepatocellular carcinoma: How field practice complies with international recommendations. <i>Liver International</i> , 2018, 38, 1624-1634.	1.9	25
2761	Influence of arm position and respiration technique during liver examinations on the detectability of mammary lesions. <i>Radiological Physics and Technology</i> , 2018, 11, 328-337.	1.0	2
2762	Pharmacodynamic and pharmacokinetic characteristics of YMR-65, a tubulin inhibitor, in tumor-bearing mice. <i>European Journal of Pharmaceutical Sciences</i> , 2018, 121, 74-84.	1.9	9
2763	Value of Î±-fetoprotein as an early biomarker for treatment response to sorafenib therapy in advanced hepatocellular carcinoma. <i>Oncology Letters</i> , 2018, 15, 8863-8870.	0.8	20
2764	The Prognostic Ability of Major Hepatocellular Carcinoma Staging Systems Is Improved by Including a Treatment Variable. <i>Digestive Diseases and Sciences</i> , 2018, 63, 2277-2284.	1.1	1
2765	Value of texture analysis based on enhanced MRI for predicting an early therapeutic response to transcatheter arterial chemoembolisation combined with high-intensity focused ultrasound treatment in hepatocellular carcinoma. <i>Clinical Radiology</i> , 2018, 73, 758.e9-758.e18.	0.5	34
2767	Prognosis of patients with hepatocellular carcinoma treated with sorafenib: a comparison of five models in a large Canadian database. <i>Cancer Medicine</i> , 2018, 7, 2816-2825.	1.3	17
2768	Systemic therapy for intermediate and advanced hepatocellular carcinoma: Sorafenib and beyond. <i>Cancer Treatment Reviews</i> , 2018, 68, 16-24.	3.4	124
2769	Hepatectomy versus stereotactic body radiotherapy for primary early hepatocellular carcinoma: A propensity-matched analysis in a single institution. <i>Surgery</i> , 2018, 164, 219-226.	1.0	27

#	ARTICLE	IF	CITATIONS
2770	Impact of Insufficient Response with an Increase in Tumor Number in Predicting Transcatheter Arterial Chemoembolization Refractoriness for Hepatocellular Carcinoma. <i>Digestive Diseases</i> , 2018, 36, 385-394.	0.8	3
2771	Ablation treatment of primary and secondary liver tumors under contrast-enhanced ultrasound guidance in field practice of interventional ultrasound centers. A multicenter study. <i>European Journal of Radiology</i> , 2018, 105, 96-101.	1.2	37
2772	Metronomic capecitabine vs. best supportive care in Child-Pugh B hepatocellular carcinoma: a proof of concept. <i>Scientific Reports</i> , 2018, 8, 9997.	1.6	84
2773	Efficacy and Safety of Sorafenib in a Racially Diverse Patient Population with Advanced Hepatocellular Carcinoma. <i>Anticancer Research</i> , 2018, 38, 4027-4034.	0.5	9
2774	Primary Hepatic Lymphoma Mimicking a Hepatocellular Carcinoma in a Cirrhotic Patient: Case Report and Systematic Review of the Literature. <i>Case Reports in Surgery</i> , 2018, 2018, 1-6.	0.2	15
2775	Editorial: frequency of surveillance and survival in hepatocellular carcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 228-229.	1.9	1
2776	Are we SHARP enough? The importance of adequate patient selection in sorafenib treatment for hepatocellular carcinoma. <i>Acta Oncologica</i> , 2018, 57, 1467-1474.	0.8	13
2777	Efficacy of Stereotactic Body Radiotherapy for Recurrent or Residual Hepatocellular Carcinoma after Transcatheter Arterial Chemoembolization. <i>BioMed Research International</i> , 2018, 2018, 1-6.	0.9	6
2778	Survival and tolerance to sorafenib in Child-Pugh B patients with hepatocellular carcinoma: a prospective study. <i>Investigational New Drugs</i> , 2018, 36, 911-918.	1.2	18
2779	Long-term survival after partial hepatectomy for sub-stage patients with intermediate stage hepatocellular carcinoma. <i>International Journal of Surgery</i> , 2018, 56, 256-263.	1.1	12
2780	Multicenter Phase II Clinical Trial of Sorafenib Combined with Transarterial Chemoembolization for Advanced Stage Hepatocellular Carcinomas (Barcelona Clinic Liver Cancer Stage C): STAB Study. <i>Journal of Vascular and Interventional Radiology</i> , 2018, 29, 1061-1067.	0.2	11
2781	Percutaneous thermal ablation of hepatocellular carcinomas located in the hepatic dome using artificial carbon dioxide pneumothorax: retrospective evaluation of safety and efficacy. <i>International Journal of Hyperthermia</i> , 2018, 35, 90-96.	1.1	21
2782	An ethyl acetate fraction of <i>Artemisia capillaris</i> (ACE63) induced apoptosis and antiangiogenesis via inhibition of PI3K/AKT signaling in hepatocellular carcinoma. <i>Phytotherapy Research</i> , 2018, 32, 2034-2046.	2.8	21
2783	Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma. <i>New England Journal of Medicine</i> , 2018, 379, 54-63.	13.9	1,677
2784	Phase II Studies with Refametinib or Refametinib plus Sorafenib in Patients with <i>RAS</i> -Mutated Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , 2018, 24, 4650-4661.	3.2	63
2785	Hepatocellular Carcinoma in Obesity: Finding a Needle in the Haystack?. <i>Advances in Experimental Medicine and Biology</i> , 2018, 1061, 63-77.	0.8	6
2786	Differential Effects of Three Techniques for Hepatic Vascular Exclusion during Resection for Liver Cirrhosis on Hepatic Ischemia-Reperfusion Injury in Rats. <i>Gastroenterology Research and Practice</i> , 2018, 2018, 1-10.	0.7	5
2787	Obesity, Fatty Liver and Liver Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2018, , .	0.8	17

#	ARTICLE	IF	CITATIONS
2788	Compliance With Hepatocellular Carcinoma Surveillance Guidelines Associated With Increased Lead-Time Adjusted Survival of Patients With Compensated Viral Cirrhosis: A Multi-Center Cohort Study. <i>Gastroenterology</i> , 2018, 155, 431-442.e10.	0.6	81
2789	Studying the frequency of aberrant DNA methylation of APC, P14, and E-cadherin genes in HCV-related hepatocarcinogenesis. <i>Cancer Biomarkers</i> , 2018, 22, 503-509.	0.8	8
2790	Sustained complete response of advanced hepatocellular carcinoma with metronomic capecitabine: a report of three cases. <i>Cancer Communications</i> , 2018, 38, 1-7.	3.7	4
2791	Liver resection versus transarterial chemoembolization for the initial treatment of Barcelona Clinic Liver Cancer stage B hepatocellular carcinoma. <i>Hepatology International</i> , 2018, 12, 417-428.	1.9	22
2792	Combination Ipsilateral Lobar and Segmental Radioembolization Using Glass Yttrium-90 Microspheres for Treatment of Multifocal Hepatic Malignancies. <i>Journal of Vascular and Interventional Radiology</i> , 2018, 29, 1110-1116.	0.2	4
2793	Microwave vs radiofrequency ablation for hepatocellular carcinoma within the Milan criteria: a propensity score analysis. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 671-681.	1.9	69
2794	Effect of dendritic cell-based immunotherapy on hepatocellular carcinoma: A systematic review and meta-analysis. <i>Cytotherapy</i> , 2018, 20, 975-989.	0.3	27
2795	Five-year outcome of conventional and drug-eluting transcatheter arterial chemoembolization in patients with hepatocellular carcinoma. <i>BMC Gastroenterology</i> , 2018, 18, 124.	0.8	33
2796	Non-alcoholic fatty liver disease-associated hepatocellular carcinoma: effect of hepatic steatosis on major hepatocellular carcinoma features at MRI. <i>British Journal of Radiology</i> , 2018, 91, 20180345.	1.0	22
2797	Estimate of hepatocellular carcinoma incidence in patients with alcoholic cirrhosis. <i>Journal of Hepatology</i> , 2018, 69, 1274-1283.	1.8	86
2798	CLC-3 chloride channel protein induces G1 [~] 2 arrest in hepatocellular carcinoma Hep3B cells. <i>Oncology Reports</i> , 2018, 40, 472-478.	1.2	3
2799	Propensity score-matched comparison of non-anatomical resection and radiofrequency ablation for hepatocellular carcinoma in patients with up to three tumours, each measuring up to 3 cm in diameter. <i>BJS Open</i> , 2018, 2, 213-219.	0.7	3
2800	Radiofrequency Ablation Combined With Transarterial Chemoembolization for Specially Located Small Hepatocellular Carcinoma. <i>Technology in Cancer Research and Treatment</i> , 2018, 17, 153303381878852.	0.8	11
2801	Potentiating cancer vaccine efficacy in liver cancer. <i>Oncolmmunology</i> , 2018, 7, e1488564.	2.1	26
2802	<i>Wisteria floribunda</i> agglutinin-positive Mac-2 binding protein predicts early occurrence of hepatocellular carcinoma after sustained virologic response by direct-acting antivirals for hepatitis C virus. <i>Hepatology Research</i> , 2018, 48, 1131-1139.	1.8	40
2803	Radiofrequency Ablation Combined with Transcatheter Arterial Chemoembolization Therapy Versus Surgical Resection for Hepatocellular Carcinoma within the Milan Criteria: A Meta-Analysis. <i>Korean Journal of Radiology</i> , 2018, 19, 613.	1.5	21
2804	Restaging Patients With Hepatocellular Carcinoma Before Additional Treatment Decisions: A Multicenter Cohort Study. <i>Hepatology</i> , 2018, 68, 1232-1244.	3.6	26
2805	Characterization of hepatocellular carcinoma in Mexico. <i>Revista De GastroenterologÃa De MÃ©xico (English Edition)</i> , 2018, 83, 223-227.	0.1	3

#	ARTICLE	IF	CITATIONS
2806	Serum levels of ferritin do not affect the prognosis of patients with hepatocellular carcinoma undergoing radiofrequency ablation. <i>PLoS ONE</i> , 2018, 13, e0200943.	1.1	4
2807	High-density single cell mRNA sequencing to characterize circulating tumor cells in hepatocellular carcinoma. <i>Scientific Reports</i> , 2018, 8, 11570.	1.6	64
2808	The Diagnostic Performance of Liver MRI without Intravenous Contrast for Detecting Hepatocellular Carcinoma: A Case-Controlled Feasibility Study. <i>Korean Journal of Radiology</i> , 2018, 19, 568.	1.5	33
2809	Multicentric Assessment of the Hong Kong Liver Cancer Staging System in Chinese Patients Following Transarterial Chemoembolization. <i>CardioVascular and Interventional Radiology</i> , 2018, 41, 1867-1876.	0.9	1
2810	Modified PAGE-B score predicts the risk of hepatocellular carcinoma in Asians with chronic hepatitis B on antiviral therapy. <i>Journal of Hepatology</i> , 2018, 69, 1066-1073.	1.8	160
2812	Use of Mass Spectrometry to Screen Glycan Early Markers in Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2017, 7, 328.	1.3	18
2813	Quality of life in patients undergoing repetitive TACE for the treatment of intermediate stage HCC. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 1991-1999.	1.2	13
2814	Role of caveolin-1 in hepatocellular carcinoma arising from non-alcoholic fatty liver disease. <i>Cancer Science</i> , 2018, 109, 2401-2411.	1.7	17
2815	Recent Advances in the Image-Guided Tumor Ablation of Liver Malignancies: Radiofrequency Ablation with Multiple Electrodes, Real-Time Multimodality Fusion Imaging, and New Energy Sources. <i>Korean Journal of Radiology</i> , 2018, 19, 545.	1.5	53
2816	Liver Transplantation for Alcoholic Liver Disease and Hepatocellular Carcinoma. <i>Cancers</i> , 2018, 10, 46.	1.7	26
2817	Impact of hepatocellular carcinoma aetiology and liver function on the benefit of surveillance: A novel approach for the adjustment of lead-time bias. <i>Liver International</i> , 2018, 38, 2260-2268.	1.9	8
2818	Integrative analysis of DNA methylation and gene expression reveals hepatocellular carcinoma-specific diagnostic biomarkers. <i>Genome Medicine</i> , 2018, 10, 42.	3.6	95
2819	CT-MRI LI-RADS v2017: A Comprehensive Guide for Beginners. <i>Journal of Clinical and Translational Hepatology</i> , 2018, 6, 1-15.	0.7	14
2820	Circulating hypoxia marker carbonic anhydrase IX (CA9) in patients with hepatocellular carcinoma and patients with cirrhosis. <i>PLoS ONE</i> , 2018, 13, e0200855.	1.1	24
2821	Clinical application of magnetic resonance elastography in chronic liver disease. <i>Hepatology Research</i> , 2018, 48, 780-787.	1.8	10
2822	Randomized, prospective, comparative study on the effects and safety of sorafenib vs. hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma with portal vein tumor thrombosis. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 82, 469-478.	1.1	88
2823	Sustained virological response to direct-acting antiviral regimens reduces the risk of hepatocellular carcinoma in HIV/HCV-coinfected patients with cirrhosis. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 2435-2443.	1.3	16
2824	DEB-TACE: a standard review. <i>Future Oncology</i> , 2018, 14, 2969-2984.	1.1	76

#	ARTICLE	IF	CITATIONS
2825	Role of Imaging in Surveillance and Diagnosis of Hepatocellular Carcinoma. <i>Gastroenterology Clinics of North America</i> , 2018, 47, 585-602.	1.0	20
2826	Recent developments with immunotherapy for hepatocellular carcinoma. <i>Expert Opinion on Biological Therapy</i> , 2018, 18, 905-910.	1.4	89
2827	Role of circulating miR-182 and miR-150 as biomarkers for cirrhosis and hepatocellular carcinoma post HCV infection in Egyptian patients. <i>Virus Research</i> , 2018, 255, 77-84.	1.1	25
2828	Monocyte/granulocyte to lymphocyte ratio and the MELD score as predictors for early recurrence of hepatocellular carcinoma after trans-arterial chemoembolization. <i>British Journal of Biomedical Science</i> , 2018, 75, 187-191.	1.2	17
2829	Serum biomarkers for diagnosis and monitoring viral hepatitis and hepatocellular carcinoma. <i>Expert Review of Molecular Diagnostics</i> , 2018, 18, 713-722.	1.5	6
2830	A parallel framework for HCC detection in DCE-MRI sequences with wavelet-based description and SVM classification. , 2018, , .		7
2831	Independent risk factors that predict bile leakage after hepatectomy for hepatocellular carcinoma: Cohort study. <i>International Journal of Surgery</i> , 2018, 57, 1-7.	1.1	8
2832	LI-RADS v2017 for liver nodules: how we read and report. <i>Cancer Imaging</i> , 2018, 18, 14.	1.2	15
2833	High expression of ubiquitin-conjugating enzyme E2A predicts poor prognosis in hepatocellular carcinoma. <i>Oncology Letters</i> , 2018, 15, 7362-7368.	0.8	15
2834	Cholesterol inhibits hepatocellular carcinoma invasion and metastasis by promoting CD44 localization in lipid rafts. <i>Cancer Letters</i> , 2018, 429, 66-77.	3.2	58
2835	Analysis of Preoperative Portal Vein Embolization Outcomes in Patients with Hepatocellular Carcinoma: A Single-Center Experience. <i>Journal of Vascular and Interventional Radiology</i> , 2018, 29, 920-926.	0.2	13
2836	Application of a novel liquid biopsy in patients with hepatocellular carcinoma undergoing liver transplantation. <i>Oncology Letters</i> , 2018, 15, 5481-5488.	0.8	22
2837	Image quality of arterial phase and parenchymal blood volume (PBV) maps derived from C-arm computed tomography in the evaluation of transarterial chemoembolization. <i>Cancer Imaging</i> , 2018, 18, 16.	1.2	1
2838	Validation of the SNACOR clinical scoring system after transarterial chemoembolisation in patients with hepatocellular carcinoma. <i>BMC Cancer</i> , 2018, 18, 489.	1.1	16
2839	Metabolic disorders across hepatocellular carcinoma in Italy. <i>Liver International</i> , 2018, 38, 2028-2039.	1.9	10
2842	Leaflet manual of external beam radiation therapy for hepatocellular carcinoma: a review of the indications, evidences, and clinical trials. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 2865-2874.	1.0	30
2843	Lower alpha fetoprotein and higher risk of hepatocellular carcinoma, study from the type 2 diabetes mellitus patients. <i>Diabetes Research and Clinical Practice</i> , 2018, 143, 239-244.	1.1	8
2844	Dynamic contrast enhanced perfusion CT imaging: A diagnostic biomarker tool for survival prediction of tumour response to antiangiogenetic treatment in patients with advanced HCC lesions. <i>European Journal of Radiology</i> , 2018, 106, 62-68.	1.2	9

#	ARTICLE	IF	CITATIONS
2845	Geriatric nutritional risk index predicts prognosis after hepatectomy in elderly patients with hepatitis B virus-related hepatocellular carcinoma. <i>Scientific Reports</i> , 2018, 8, 12561.	1.6	37
2847	Systematic review with meta-analysis: risk of hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis compared to other liver diseases. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 696-703.	1.9	211
2848	Polymorphisms in the Toll-like receptor 3 (TLR3) gene are associated with the natural course of hepatitis B virus infection in Caucasian population. <i>Scientific Reports</i> , 2018, 8, 12737.	1.6	20
2849	Albumin-to-Alkaline Phosphatase Ratio as an Independent Prognostic Factor for Overall Survival of Advanced Hepatocellular Carcinoma Patients without Receiving Standard Anti-Cancer Therapies. <i>Journal of Cancer</i> , 2018, 9, 189-197.	1.2	38
2852	Human leukocyte antigen gene polymorphisms are associated with systemic inflammation in hepatitis B virus-related hepatocellular carcinoma. <i>Cancer Management and Research</i> , 2018, Volume 10, 2315-2324.	0.9	4
2853	Diagnostic value of serum PIVKA-II levels for BCLC early hepatocellular carcinoma and correlation with HBV DNA. <i>Cancer Biomarkers</i> , 2018, 23, 235-242.	0.8	19
2854	Apatinib targets both tumor and endothelial cells in hepatocellular carcinoma. <i>Cancer Medicine</i> , 2018, 7, 4570-4583.	1.3	55
2855	Prospective Intraindividual Comparison of Magnetic Resonance Imaging With Gadoxetic Acid and Extracellular Contrast for Diagnosis of Hepatocellular Carcinomas Using the Liver Imaging Reporting and Data System. <i>Hepatology</i> , 2018, 68, 2254-2266.	3.6	87
2856	Can microvascular invasion in hepatocellular carcinoma be predicted by diagnostic imaging? A critical review. <i>Future Oncology</i> , 2018, 14, 2985-2994.	1.1	23
2857	Significance of hepatic resection and adjuvant hepatic arterial infusion chemotherapy for hepatocellular carcinoma with portal vein tumor thrombus in the first branch of portal vein and the main portal trunk: a project study for hepatic surgery of the Japanese Society of Hepato-Biliary-Pancreatic Surgery. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2018, 25, 395-402.	1.4	26
2858	Downstaging with Localized Concurrent Chemoradiotherapy Can Identify Optimal Surgical Candidates in Hepatocellular Carcinoma with Portal Vein Tumor Thrombus. <i>Annals of Surgical Oncology</i> , 2018, 25, 3308-3315.	0.7	42
2859	Identifying the Best Anticancer Agent Combination in TACE for HCC Patients: A Network Meta-analysis. <i>Journal of Cancer</i> , 2018, 9, 2640-2649.	1.2	11
2860	Prognostic value of subcutaneous adipose tissue volume in hepatocellular carcinoma treated with transcatheter intra-arterial therapy. <i>Cancer Management and Research</i> , 2018, Volume 10, 2231-2239.	0.9	21
2861	Comparison of LI-RADS v.2017 and ESGAR Guidelines Imaging Criteria in HCC Diagnosis Using MRI with Hepatobiliary Contrast Agents. <i>BioMed Research International</i> , 2018, 2018, 1-6.	0.9	12
2862	Prognostic importance of bile duct invasion in surgical resection with curative intent for hepatocellular carcinoma using PSM analysis. <i>Oncology Letters</i> , 2018, 16, 3593-3602.	0.8	8
2863	Nitroglycerine use in transcatheter arterial (chemo) embolization in patients with hepatocellular carcinoma: Five-year retrospective study. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2018, 42, 542-552.	0.7	4
2864	Premalignant and Early Malignant Hepatocellular Lesions in Chronic Hepatitis/Cirrhosis. , 2018, , 487-505.		1
2865	Transarterial Radioembolization (TARE). , 2018, , 389-396.		1

#	ARTICLE	IF	CITATIONS
2866	Intention-to-treat analysis of liver transplantation, resection and thermal ablation for hepatocellular carcinoma in a single centre. <i>Hpb</i> , 2018, 20, 966-976.	0.1	4
2867	Caracterizaci3n del carcinoma hepatocelular en M3xico. <i>Revista De Gastroenterolog3a De M3xico</i> , 2018, 83, 223-227.	0.4	6
2868	Nomograms to Predict the Disease-free Survival and Overall Survival after Radiofrequency Ablation for Hepatocellular Carcinoma. <i>Internal Medicine</i> , 2018, 57, 457-468.	0.3	14
2869	HCC. , 2018, , 43-82.		0
2870	CT-Guided Microwave Ablation of Liver Tumors in Anatomically Challenging Locations. <i>CardioVascular and Interventional Radiology</i> , 2018, 41, 1520-1529.	0.9	22
2871	Evolution of nodule stiffness might predict response to local ablative therapy: A series of patients with hepatocellular carcinoma. <i>PLoS ONE</i> , 2018, 13, e0192897.	1.1	16
2872	Comparison of switching bipolar ablation with multiple cooled wet electrodes and switching monopolar ablation with separable clustered electrode in treatment of small hepatocellular carcinoma: A randomized controlled trial. <i>PLoS ONE</i> , 2018, 13, e0192173.	1.1	14
2873	Incidental Findings in Multislice CT of the Body. <i>Medical Radiology</i> , 2018, , 1107-1137.	0.0	0
2874	Expression signature of lysosomal-associated transmembrane protein 4B in hepatitis C virus-induced hepatocellular carcinoma. <i>International Journal of Biological Markers</i> , 2018, 33, 283-292.	0.7	2
2875	Dynamically prognosticating patients with hepatocellular carcinoma through survival paths mapping based on time-series data. <i>Nature Communications</i> , 2018, 9, 2230.	5.8	26
2877	Open Liver Resection, Laparoscopic Liver Resection, and Percutaneous Thermal Ablation for Patients with Solitary Small Hepatocellular Carcinoma (30 mm): Review of the Literature and Proposal for a Therapeutic Strategy. <i>Digestive Surgery</i> , 2018, 35, 359-371.	0.6	26
2878	Liver volume-based prediction model stratifies risks for hepatocellular carcinoma in chronic hepatitis B patients on surveillance. <i>PLoS ONE</i> , 2018, 13, e0190261.	1.1	5
2879	Serum total antioxidant capacity prior to liver transplantation for hepatocellular carcinoma is associated with 1-year liver transplantation survival. <i>Journal of International Medical Research</i> , 2018, 46, 2641-2649.	0.4	3
2880	Optimal <i>M</i>-Switch Surveillance Policies for Liver Cancer in a Hepatitis Câ€“Infected Population. <i>Operations Research</i> , 2018, 66, 673-696.	1.2	18
2881	Percutaneous US/MRI Fusionâ€“guided Radiofrequency Ablation for Recurrent Subcentimeter Hepatocellular Carcinoma: Technical Feasibility and Therapeutic Outcomes. <i>Radiology</i> , 2018, 288, 878-886.	3.6	68
2882	Triple Arterial Phase CT of the Liver with Radiation Dose Equivalent to That of Single Arterial Phase CT: Initial Experience. <i>Radiology</i> , 2018, 289, 111-118.	3.6	13
2883	Role of Adult Living Donor Liver Transplantation in the Treatment of Hepatocellular Carcinoma Within and Beyond Milan Criteria: A Comparative Study. <i>Transplantation Proceedings</i> , 2018, 50, 1386-1395.	0.3	4
2884	A novel risk score for hepatocellular carcinoma in Asian cirrhotic patients: a multicentre prospective cohort study. <i>Scientific Reports</i> , 2018, 8, 8608.	1.6	4

#	ARTICLE	IF	CITATIONS
2885	Multimodal radiofrequency ablation versus laparoscopic hepatic resection for the treatment of primary hepatocellular carcinoma within Milan criteria in severely cirrhotic patients: long-term favorable outcomes over 10 years. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2019, 33, 46-51.	1.3	15
2886	Varices on computed tomography are surrogate of clinically significant portal hypertension and can predict survival in compensated cirrhosis patients. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 450-457.	1.4	10
2887	Anticancer effects of echinacoside in hepatocellular carcinoma mouse model and HepG2 cells. <i>Journal of Cellular Physiology</i> , 2019, 234, 1880-1888.	2.0	35
2888	LI-RADS v2017 categorisation of HCC using CT: Does moderate to severe fatty liver affect accuracy?. <i>European Radiology</i> , 2019, 29, 186-194.	2.3	10
2889	Computed tomographic perfusion with 160-mm coverage: comparative analysis of hepatocellular carcinoma treated by two transarterial chemoembolization courses relative to magnetic resonance imaging findings. <i>Abdominal Radiology</i> , 2019, 44, 85-94.	1.0	2
2890	Pre-TACE kurtosis of ADCtotal derived from histogram analysis for diffusion-weighted imaging is the best independent predictor of prognosis in hepatocellular carcinoma. <i>European Radiology</i> , 2019, 29, 213-223.	2.3	22
2891	Transjugular Intrahepatic Portosystemic Shunt: The Impact of Portal Venous Pressure Declines on Shunt Patency and Clinical Efficacy. <i>Academic Radiology</i> , 2019, 26, 188-195.	1.3	9
2892	Impact of clinically significant portal hypertension on outcomes after partial hepatectomy for hepatocellular carcinoma: a systematic review and meta-analysis. <i>Hpb</i> , 2019, 21, 1-13.	0.1	23
2893	Association of coffee consumption and liver fibrosis progression in patients with HBeAg-negative chronic hepatitis B: A 5-year population-based cohort study. <i>Journal of the Formosan Medical Association</i> , 2019, 118, 628-635.	0.8	10
2894	Influence of liver fibrosis on prognosis after surgical resection for resectable single hepatocellular carcinoma. <i>ANZ Journal of Surgery</i> , 2019, 89, 211-215.	0.3	13
2895	Perfusion-CT analysis for assessment of hepatocellular carcinoma lesions: diagnostic value of different perfusion maps. <i>Acta Radiologica</i> , 2019, 60, 561-568.	0.5	10
2896	Liver Resection for Solitary Transplantable Hepatocellular Carcinoma: The Role of AFP Score. <i>World Journal of Surgery</i> , 2019, 43, 221-229.	0.8	5
2897	Virologic control and severity of liver disease determine survival after radiofrequency ablation of hepatocellular carcinoma on cirrhosis. <i>Digestive and Liver Disease</i> , 2019, 51, 86-94.	0.4	14
2898	Epigenome modifiers and metabolic rewiring: New frontiers in therapeutics. , 2019, 193, 178-193.		13
2899	Pitfalls and problems to be solved in the diagnostic CT/MRI Liver Imaging Reporting and Data System (LI-RADS). <i>European Radiology</i> , 2019, 29, 1124-1132.	2.3	23
2900	Animal models for hepatocellular carcinoma. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2019, 1865, 993-1002.	1.8	28
2901	Adjuvant transarterial chemoembolization for patients with hepatocellular carcinoma involving microvascular invasion. <i>American Journal of Surgery</i> , 2019, 217, 739-744.	0.9	53
2902	Pathological variants of hepatocellular carcinoma on MRI: emphasis on histopathologic correlation. <i>Abdominal Radiology</i> , 2019, 44, 493-508.	1.0	10

#	ARTICLE	IF	CITATIONS
2903	Added Value of sequentially performed gadoteric acid-enhanced liver MRI for the diagnosis of small (10-19mm) or atypical hepatic observations at contrast-enhanced CT: A prospective comparison. <i>Journal of Magnetic Resonance Imaging</i> , 2019, 49, 574-587.	1.9	18
2904	Safety of laparoscopic hepatectomy in patients with hepatocellular carcinoma and portal hypertension: interim analysis of an open prospective study. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2019, 33, 811-820.	1.3	26
2905	Optimal criteria for hepatocellular carcinoma diagnosis using CT in patients undergoing liver transplantation. <i>European Radiology</i> , 2019, 29, 1022-1031.	2.3	9
2906	CalliSpheres® drug-eluting beads (DEB) transarterial chemoembolization (TACE) is equally efficient and safe in liver cancer patients with different times of previous conventional TACE treatments: a result from CTILC study. <i>Clinical and Translational Oncology</i> , 2019, 21, 167-177.	1.2	30
2908	Chemoprevention of elite tea variety CFT-1 rich in EGCG against chemically induced liver cancer in rats. <i>Food Science and Nutrition</i> , 2019, 7, 2647-2665.	1.5	12
2909	Tspan15 Is a New Stemness-Related Marker in Hepatocellular Carcinoma. <i>Proteomics</i> , 2019, 19, e1900025.	1.3	16
2910	Effectiveness of Noninvasive Fibrosis Markers for the Prediction of Hepatocellular Carcinoma in Chronic Hepatitis B and Chronic Hepatitis B+D Induced Cirrhosis. <i>Transplantation Proceedings</i> , 2019, 51, 2397-2402.	0.3	6
2911	Metformin prevents liver tumorigenesis by attenuating fibrosis in a transgenic mouse model of hepatocellular carcinoma. <i>Oncogene</i> , 2019, 38, 7035-7045.	2.6	55
2912	Comparison of macrovascular invasion-free survival in early-intermediate hepatocellular carcinoma after different interventions: A propensity score-based analysis. <i>Journal of Cancer</i> , 2019, 10, 4063-4071.	1.2	4
2913	A Nomogram Predicting Microvascular Invasion Risk in BCLC 0/A Hepatocellular Carcinoma after Curative Resection. <i>BioMed Research International</i> , 2019, 2019, 1-8.	0.9	14
2914	Prognostic Value of DEPDC1 Expression in Tumor and Non-tumor Tissue of Patients With Hepatocellular Carcinoma. <i>Anticancer Research</i> , 2019, 39, 4423-4430.	0.5	11
2915	A comparison of carbon ion radiotherapy and transarterial chemoembolization treatment outcomes for single hepatocellular carcinoma: a propensity score matching study. <i>Radiation Oncology</i> , 2019, 14, 137.	1.2	20
2916	Diagnostic value of angiotensin-like protein 2 for CHB-related hepatocellular carcinoma. <i>Cancer Management and Research</i> , 2019, Volume 11, 7159-7169.	0.9	6
2917	New Insight into Therapies Targeting Angiogenesis in Hepatocellular Carcinoma. <i>Cancers</i> , 2019, 11, 1086.	1.7	41
2918	MicroRNA Biogenesis is enhanced by Liposome- Encapsulated Pin1 Inhibitor in Hepatocellular Carcinoma. <i>Theranostics</i> , 2019, 9, 4704-4716.	4.6	13
2920	Locoregional Therapy of Hepatocellular-Cholangiocarcinoma versus Hepatocellular Carcinoma: A Propensity Score-Matched Study. <i>Journal of Vascular and Interventional Radiology</i> , 2019, 30, 1317-1324.	0.2	5
2921	Preclinical efficacy of a novel dual PI3K/mTOR inhibitor, CMG002, alone and in combination with sorafenib in hepatocellular carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 84, 809-817.	1.1	19
2922	Hepatitis C virus genotype affects survival in patients with hepatocellular carcinoma. <i>BMC Cancer</i> , 2019, 19, 822.	1.1	12

#	ARTICLE	IF	CITATIONS
2923	Radiological Diagnosis and Characterization of HCC. <i>Molecular and Translational Medicine</i> , 2019, , 71-92.	0.4	9
2924	Efficacy and Safety of Baviximab in Combination with Sorafenib in Advanced Hepatocellular Carcinoma: A Single-Arm, Open-Label, Phase II Clinical Trial. <i>Targeted Oncology</i> , 2019, 14, 541-550.	1.7	18
2925	The impact of socioeconomic status on outcomes in hepatocellular carcinoma: Inferences from primary insurance. <i>Cancer Medicine</i> , 2019, 8, 5948-5958.	1.3	11
2926	Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2019, 71, 1164-1174.	1.8	249
2927	Clinical conditions and treatment requirements for long-term survival among hepatitis B-related hepatocellular carcinoma initially treated with chemoembolization. <i>Cancer Medicine</i> , 2019, 8, 5097-5107.	1.3	7
2928	Identifying Clonal Origin of Multifocal Hepatocellular Carcinoma and Its Clinical Implications. <i>Clinical and Translational Gastroenterology</i> , 2019, 10, e00006.	1.3	36
2929	Minimal increases of serum alpha-fetoprotein herald HCC detection in Caucasian HBV cirrhotic patients under long-term oral therapy. <i>Liver International</i> , 2019, 39, 1964-1974.	1.9	11
2930	Capecitabine in advanced hepatocellular carcinoma: A multicenter experience. <i>Digestive and Liver Disease</i> , 2019, 51, 1713-1719.	0.4	18
2931	Study on Diagnostic Values of Astrocyte Elevated Gene 1 (AEG-1) and Glypican 3 (GPC-3) in Hepatocellular Carcinoma. <i>American Journal of Clinical Pathology</i> , 2019, 152, 647-655.	0.4	12
2932	Lipiodol-based emulsions used for transarterial chemoembolization and drug delivery: Effects of composition on stability and product quality. <i>Journal of Drug Delivery Science and Technology</i> , 2019, 53, 101143.	1.4	14
2933	Clinical practice guidelines on liver transplantation for hepatocellular carcinoma in China (2018) <i>Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 3</i>	0.6	26
2934	Stereotactic body radio therapy for inoperable large hepatocellular cancers: results from a clinical audit. <i>British Journal of Radiology</i> , 2019, 92, 20181053.	1.0	12
2935	A Simple-to-Use Nomogram for Predicting the Survival of Early Hepatocellular Carcinoma Patients. <i>Frontiers in Oncology</i> , 2019, 9, 584.	1.3	38
2936	Theranostic application of lipiodol for transarterial chemoembolization in a VX2 rabbit liver tumor model. <i>Theranostics</i> , 2019, 9, 3674-3686.	4.6	28
2937	Hepatocellular Carcinoma Xenografts Established From Needle Biopsies Preserve the Characteristics of the Originating Tumors. <i>Hepatology Communications</i> , 2019, 3, 971-986.	2.0	24
2938	Relative Efficacy of Systemic Treatments for Patients with Advanced Hepatocellular Carcinoma According to Viral Status: A Systematic Review and Network Meta-Analysis. <i>Targeted Oncology</i> , 2019, 14, 395-403.	1.7	10
2939	An investigation of efficacy, safety, and prognostic factors of drug-eluting beads-transarterial chemoembolization operation with CalliSpheres A® Microspheres in treating Chinese hepatocellular carcinoma patients. <i>Journal of Clinical Laboratory Analysis</i> , 2019, 33, e22975.	0.9	12
2940	Jiedu Granule Combined with Transcatheter Arterial Chemoembolization and Gamma Knife Radiosurgery in Treating Hepatocellular Carcinoma with Portal Vein Tumor Thrombus. <i>BioMed Research International</i> , 2019, 2019, 1-8.	0.9	8

#	ARTICLE	IF	CITATIONS
2941	Inhibition of cyclin E1 sensitizes hepatocellular carcinoma cells to regorafenib by mcl-1 suppression. <i>Cell Communication and Signaling</i> , 2019, 17, 85.	2.7	19
2942	Angiographic Findings in Patients with Hepatocellular Carcinoma Previously Treated Using Proton Beam Therapy. <i>Journal of Oncology</i> , 2019, 2019, 1-7.	0.6	4
2943	Preliminary experience on safety of regorafenib after sorafenib failure in recurrent hepatocellular carcinoma after liver transplantation. <i>American Journal of Transplantation</i> , 2019, 19, 3176-3184.	2.6	60
2944	Platelet count increases after viral elimination in chronic HCV, independent of the presence or absence of cirrhosis. <i>Liver International</i> , 2019, 39, 2061-2065.	1.9	12
2945	Role of Baseline Albumin-Bilirubin Grade on Predict Overall Survival Among Sorafenib-Treated Patients With Hepatocellular Carcinoma in Vietnam. <i>Cancer Control</i> , 2019, 26, 107327481986526.	0.7	7
2946	Multidisciplinary Management of Patients with Unresectable Hepatocellular Carcinoma: A Critical Appraisal of Current Evidence. <i>Cancers</i> , 2019, 11, 873.	1.7	19
2947	Alpha-fetoprotein assessment for hepatocellular carcinoma after transarterial chemoembolization. <i>Abdominal Radiology</i> , 2019, 44, 3304-3311.	1.0	9
2948	The prognostic factors between different viral etiologies among advanced hepatocellular carcinoma patients receiving sorafenib treatment. <i>Kaohsiung Journal of Medical Sciences</i> , 2019, 35, 624-632.	0.8	8
2949	Adjuvant transarterial chemoembolization improves survival outcomes in hepatocellular carcinoma with microvascular invasion: A systematic review and meta-analysis. <i>European Journal of Surgical Oncology</i> , 2019, 45, 2188-2196.	0.5	53
2950	Comparison of the current international guidelines on the management of HCC. <i>JHEP Reports</i> , 2019, 1, 114-119.	2.6	30
2951	Prognosis After Resection of Barcelona Clinic Liver Cancer (BCLC) Stage 0, A, and B Hepatocellular Carcinoma: A Comprehensive Assessment of the Current BCLC Classification. <i>Annals of Surgical Oncology</i> , 2019, 26, 3693-3700.	0.7	117
2952	Liquid biopsy in hepatocellular carcinoma: circulating tumor cells and circulating tumor DNA. <i>Molecular Cancer</i> , 2019, 18, 114.	7.9	241
2953	Postoperative adjuvant sorafenib improves survival outcomes in hepatocellular carcinoma patients with microvascular invasion after R0 liver resection: a propensity score matching analysis. <i>Hpb</i> , 2019, 21, 1687-1696.	0.1	57
2954	Early Detection of Pancreatic Cancer in Patients With Chronic Liver Disease Under Hepatocellular Carcinoma Surveillance. <i>Mayo Clinic Proceedings</i> , 2019, 94, 2004-2010.	1.4	6
2955	Rethinking the Role of Radiation Therapy in the Treatment of Unresectable Hepatocellular Carcinoma: A Data Driven Treatment Algorithm for Optimizing Outcomes. <i>Frontiers in Oncology</i> , 2019, 9, 345.	1.3	10
2956	Local Tumor Control and Patient Outcome Using Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma: iRECIST as a Potential Substitute for Traditional Criteria. <i>American Journal of Roentgenology</i> , 2019, 213, 1232-1239.	1.0	9
2957	Harms of Hepatocellular Carcinoma Surveillance. <i>Current Hepatology Reports</i> , 2019, 18, 383-389.	0.4	14
2958	Stereotactic Radiofrequency Ablation of Liver Tumors in Octogenarians. <i>Frontiers in Oncology</i> , 2019, 9, 929.	1.3	10

#	ARTICLE	IF	CITATIONS
2959	Pathobiological and Radiological Approach For Hepatocellular Carcinoma Subclassification. <i>Scientific Reports</i> , 2019, 9, 14749.	1.6	9
2960	Longitudinal assessment of alpha-fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis. <i>Scandinavian Journal of Gastroenterology</i> , 2019, 54, 1283-1290.	0.6	13
2961	Diagnostic accuracy of midkine on hepatocellular carcinoma: A meta-analysis. <i>PLoS ONE</i> , 2019, 14, e0223514.	1.1	11
2962	Adjuvant therapy after radical surgery for hepatocellular carcinoma: still an unmet need. <i>Hepatobiliary Surgery and Nutrition</i> , 2019, 8, 414-416.	0.7	6
2963	Hepatobiliary versus Extracellular MRI Contrast Agents in Hepatocellular Carcinoma Detection: Hepatobiliary Phase Features in Relation to Disease-free Survival. <i>Radiology</i> , 2019, 293, 594-604.	3.6	11
2964	Dose perturbation and inhomogeneity of multi-arrays of 125I seed-loaded stent for treatment of portal vein tumor thrombosis. <i>Physica Medica</i> , 2019, 66, 1-7.	0.4	2
2965	Commentary on: "Dynamic liver function is an independent predictor of recurrence-free survival after curative liver resection for HCC - a retrospective cohort study". <i>International Journal of Surgery</i> , 2019, 71, 168.	1.1	0
2966	The risk factors for long-term survival outcome in solitary hepatocellular carcinoma up to 2 cm: Propensity score matching analysis in a population cohort with a high rate of HBV infection. <i>International Journal of Surgery</i> , 2019, 72, 1-6.	1.1	5
2967	Comparative Tumor RNA Sequencing Analysis for Difficult-to-Treat Pediatric and Young Adult Patients With Cancer. <i>JAMA Network Open</i> , 2019, 2, e1913968.	2.8	38
2968	The clinical behavior and survival of patients with hepatocellular carcinoma and a family history of the disease. <i>Cancer Medicine</i> , 2019, 8, 6624-6633.	1.3	6
2969	Research on the Adsorption Behaviour of Crystal Violet Simulated Wastewater on Fallen Willow Leaves. <i>IOP Conference Series: Earth and Environmental Science</i> , 2019, 267, 032092.	0.2	1
2970	Identification of Key Hydroxymethylated Genes and Transcription Factors Associated with Alpha-Fetoprotein-Negative Hepatocellular Carcinoma. <i>DNA and Cell Biology</i> , 2019, 38, 1346-1356.	0.9	9
2971	Photomedicine Lights Up the Future of Fighting Cancer. <i>Technology in Cancer Research and Treatment</i> , 2019, 18, 153303381985297.	0.8	0
2972	Lenvatinib combined nivolumab injection followed by extended right hepatectomy is a feasible treatment for patients with massive hepatocellular carcinoma: a case report. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 7355-7359.	1.0	30
2973	A Novel and Accurate Method for Moisture Adsorption Isotherm Determination of Sultana Raisins. <i>Food Analytical Methods</i> , 2019, 12, 2491-2499.	1.3	4
2974	Unsteady numerical simulation on helium cooldown process for the 650 MHz two-cell superconducting cavity. <i>Radiation Detection Technology and Methods</i> , 2019, 3, 1.	0.4	3
2975	Hepatocellular carcinoma and non-alcoholic fatty liver disease. <i>Hepatology International</i> , 2019, 13, 688-694.	1.9	56
2976	Individualized Ablation of Hepatocellular Carcinoma: Tailored Approaches across the Phenotype Spectrum. <i>Seminars in Interventional Radiology</i> , 2019, 36, 287-297.	0.3	1

#	ARTICLE	IF	CITATIONS
2977	Radiological appearance of hepatocellular carcinoma predicts the response to trans-arterial chemoembolization in patients undergoing liver transplantation. <i>BMC Cancer</i> , 2019, 19, 1041.	1.1	13
2978	Sequential drug delivery for liver diseases. <i>Advanced Drug Delivery Reviews</i> , 2019, 149-150, 72-84.	6.6	7
2979	Evaluation of Targeted Agents for Advanced and Unresectable Hepatocellular Carcinoma: A Network Meta-Analysis. <i>Journal of Cancer</i> , 2019, 10, 4671-4678.	1.2	7
2980	Direct Conversion of Methane with Carbon Dioxide Mediated by RhVO ₃ Cluster Anions. <i>Angewandte Chemie</i> , 2019, 131, 17447-17452.	1.6	14
2981	Performance of Hong Kong Liver Cancer staging system in patients of hepatocellular carcinoma treated with surgical resection: An Indian validation study. <i>Journal of Surgical Oncology</i> , 2019, 120, 1119-1125.	0.8	4
2982	Surgical resection versus radiofrequency ablation very early-stage HCC (≤2cm Single HCC): A propensity score analysis. <i>Liver International</i> , 2019, 39, 2397-2407.	1.9	36
2983	Changes in real-life practice for hepatocellular carcinoma patients in the Republic of Korea over a 12-year period: A nationwide random sample study. <i>PLoS ONE</i> , 2019, 14, e0223678.	1.1	14
2984	RAS/RAF/MEK/ERK, PI3K/PTEN/AKT/mTORC1 and TP53 pathways and regulatory miRs as therapeutic targets in hepatocellular carcinoma. <i>Expert Opinion on Therapeutic Targets</i> , 2019, 23, 915-929.	1.5	59
2985	The emergence of non-hypervascular hypointense nodules on Gd-EOB-DTPA-enhanced MRI in patients with chronic hepatitis C. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 1232-1238.	1.9	7
2986	State of the Art: LI-RADS for Contrast-enhanced US. <i>Radiology</i> , 2019, 293, 4-14.	3.6	18
2987	Incorporation of biochemical factors for survival analysis of transarterial chemoembolization in patients with hepatocellular carcinoma: A retrospective cohort study. <i>Journal of International Medical Research</i> , 2019, 47, 4862-4871.	0.4	2
2988	MRI assessment of hepatocellular carcinoma after locoregional therapy. <i>Insights Into Imaging</i> , 2019, 10, 8.	1.6	22
2989	Tumor Response Criteria in Oncoimaging: RECIST Criteria and beyond—Part 2. <i>Journal of Gastrointestinal and Abdominal Radiology</i> , 2019, 02, 107-115.	0.2	1
2990	HBV DNA levels impact the prognosis of hepatocellular carcinoma patients with microvascular invasion. <i>Medicine (United States)</i> , 2019, 98, e16308.	0.4	6
2991	Baseline and Early Predictors of Good Patient Candidates for Second-Line after Sorafenib Treatment in Unresectable Hepatocellular Carcinoma. <i>Cancers</i> , 2019, 11, 1256.	1.7	17
2992	Etiology-Specific Analysis of Hepatocellular Carcinoma Transcriptome Reveals Genetic Dysregulation in Pathways Implicated in Immunotherapy Efficacy. <i>Cancers</i> , 2019, 11, 1273.	1.7	10
2993	Effective prediction of postoperative complications for patients after open hepatectomy: a simplified scoring system based on perioperative parameters. <i>BMC Surgery</i> , 2019, 19, 128.	0.6	11
2994	Classification of early and late stage liver hepatocellular carcinoma patients from their genomics and epigenomics profiles. <i>PLoS ONE</i> , 2019, 14, e0221476.	1.1	46

#	ARTICLE	IF	CITATIONS
2995	Apatinib for Patients With Sorafenib-Refractory Advanced Hepatitis B Virus Related Hepatocellular Carcinoma: Results of a Pilot Study. <i>Cancer Control</i> , 2019, 26, 107327481987221.	0.7	17
2996	Circulating microRNA-301 as a promising diagnostic biomarker of hepatitis C virus-related hepatocellular carcinoma. <i>Molecular Biology Reports</i> , 2019, 46, 5759-5765.	1.0	10
2997	Incidence and risk factors of early HCC occurrence in HCV patients treated with direct acting antivirals: a prospective multicentre study. <i>Journal of Translational Medicine</i> , 2019, 17, 292.	1.8	49
2998	Complement factor H-related 3 overexpression affects hepatocellular carcinoma proliferation and apoptosis. <i>Molecular Medicine Reports</i> , 2019, 20, 2694-2702.	1.1	13
2999	Sequential dual-phase cone-beam CT is able to intra-procedurally predict the one-month treatment outcome of multi-focal HCC, in course of degradable starch microsphere TACE. <i>Radiologia Medica</i> , 2019, 124, 1212-1219.	4.7	9
3000	Chemoembolization Combined with Radiofrequency Ablation for Medium-Sized Hepatocellular Carcinoma: A Propensity-Score Analysis. <i>Journal of Vascular and Interventional Radiology</i> , 2019, 30, 1533-1543.	0.2	38
3001	High possibility of hepatocarcinogenesis in HBV genotype C1 infected Cambodians is indicated by 340 HBV C1 full-genomes analysis from GenBank. <i>Scientific Reports</i> , 2019, 9, 12186.	1.6	10
3002	Percutaneous microwave ablation combined with simultaneous transarterial chemoembolization for hepatocellular carcinoma with macrovascular invasion or extrahepatic metastases. <i>Journal of Interventional Medicine</i> , 2019, 2, 55-59.	0.2	1
3003	Towards a personalized approach to hepatic resection in cirrhotic patients. <i>Journal of Hepatology</i> , 2019, 71, 859-861.	1.8	6
3004	Combined transarterial chemoembolization and radiotherapy as a first-line treatment for hepatocellular carcinoma with macroscopic vascular invasion: Necessity to subclassify Barcelona Clinic Liver Cancer stage C. <i>Radiotherapy and Oncology</i> , 2019, 141, 95-100.	0.3	17
3005	Prevalence of Hepatitis B Virus Infection in Shenzhen, China, 2015–2018. <i>Scientific Reports</i> , 2019, 9, 13948.	1.6	21
3006	Color coded perfusion analysis and microcirculation imaging with contrast enhanced ultrasound (CEUS) for post-interventional success control following thermal ablative techniques of primary and secondary liver malignancies. <i>Clinical Hemorheology and Microcirculation</i> , 2019, 73, 73-83.	0.9	25
3007	<p>CTHRC1 May Serve As A Prognostic Biomarker For Hepatocellular Carcinoma</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 7823-7831.	1.0	16
3008	Liver transplantation for hepatic tumors: A small center experience. <i>Transplantation Reports</i> , 2019, 4, 100033.	0.3	1
3009	Treatment of Advanced Hepatocellular Carcinoma with Somatostatin Analogues: A Review of the Literature. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4811.	1.8	13
3010	The role of EUS in diagnosis and treatment of liver disorders. <i>Endoscopy International Open</i> , 2019, 07, E1262-E1275.	0.9	25
3011	Feasibility and safety of liver transplantation or resection after transarterial radioembolization with Yttrium-90 for unresectable hepatocellular carcinoma. <i>Hpb</i> , 2019, 21, 1497-1504.	0.1	30
3012	Microwave ablation <i>versus</i> resection for hepatocellular carcinoma within the Milan criteria: a propensity-score analysis. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591987465.	1.4	24

#	ARTICLE	IF	CITATIONS
3013	Quantitative Volumetric Assessment of Ablative Margins in Hepatocellular Carcinoma: Predicting Local Tumor Progression Using Nonrigid Registration Software. <i>Journal of Oncology</i> , 2019, 2019, 1-8.	0.6	14
3014	Comparison Between Low Mechanical Index and High Mechanical Index Contrast Modes of Contrast-enhanced Ultrasonography: Evaluation of Perfusion Defects of Hypervascular Hepatocellular Carcinomas During the Post-vascular Phase. <i>Journal of Ultrasound in Medicine</i> , 2019, 38, 2329-2338.	0.8	13
3015	Body Composition Is an Independent Predictor of Outcome in Patients with Hepatocellular Carcinoma Treated with Sorafenib. <i>Liver Cancer</i> , 2019, 8, 255-270.	4.2	30
3016	An Efficient Combination Immunotherapy for Primary Liver Cancer by Harmonized Activation of Innate and Adaptive Immunity in Mice. <i>Hepatology</i> , 2019, 69, 2518-2532.	3.6	47
3017	Biodegradable Pickering emulsions of Lipiodol for liver trans-arterial chemo-embolization. <i>Acta Biomaterialia</i> , 2019, 87, 177-186.	4.1	30
3018	Should we invariably follow the current guidelines to treat our HCC patients?. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2019, 18, 301-302.	0.6	0
3019	Activated hepatic stellate cells promote progression of post-heat residual hepatocellular carcinoma from autophagic survival to proliferation. <i>International Journal of Hyperthermia</i> , 2019, 36, 252-262.	1.1	11
3020	Chinese consensus on the clinical application of hepatobiliary magnetic resonance imaging contrast agent: Gadoteric acid disodium. <i>Journal of Digestive Diseases</i> , 2019, 20, 54-61.	0.7	7
3021	Gross and microscopic changes of liver neoplasms and background hepatic structures following neoadjuvant therapy. <i>Journal of Clinical Pathology</i> , 2019, 72, 112-119.	1.0	1
3022	Robotic versus Freehand Needle Positioning in CT-guided Ablation of Liver Tumors: A Randomized Controlled Trial. <i>Radiology</i> , 2019, 290, 826-832.	3.6	39
3023	Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: Relevance of non-characterized nodules. <i>Journal of Hepatology</i> , 2019, 70, 874-884.	1.8	67
3024	Validation of a novel model for the early detection of hepatocellular carcinoma. <i>Clinical Proteomics</i> , 2019, 16, 2.	1.1	21
3025	Identification of Arterial Hyperenhancement in CT and MRI in Patients with Hepatocellular Carcinoma: Value of Unenhanced Images. <i>Korean Journal of Radiology</i> , 2019, 20, 236.	1.5	12
3026	¹⁸ F-FDG PET/CT predicts microvascular invasion and early recurrence after liver resection for hepatocellular carcinoma. <i>Hpb</i> , 2019, 21, 739-747.	0.1	37
3027	LI-RADS: a great opportunity not to be missed. <i>European Journal of Gastroenterology and Hepatology</i> , 2019, 31, 283-288.	0.8	11
3028	Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased Î±-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 282-296.	5.1	1,202
3029	Outcomes of treatment for hepatitis C in prisoners using a nurse-led, statewide model of care. <i>Journal of Hepatology</i> , 2019, 70, 839-846.	1.8	80
3030	Development of a prognostic score for recommended TACE candidates with hepatocellular carcinoma: A multicentre observational study. <i>Journal of Hepatology</i> , 2019, 70, 893-903.	1.8	153

#	ARTICLE	IF	CITATIONS
3031	A circular RNA hsa_circ_0079929 inhibits tumor growth in hepatocellular carcinoma. <i>Cancer Management and Research</i> , 2019, Volume 11, 443-454.	0.9	38
3032	Experience with Sorafenib in 3 Hospitals in Sao Paulo. <i>Annals of Hepatology</i> , 2019, 18, 172-176.	0.6	0
3033	Local Ablation Does Not Worsen Perioperative Outcomes After Liver Transplant for Hepatocellular Carcinoma. <i>American Journal of Roentgenology</i> , 2019, 213, 702-709.	1.0	5
3034	Regression discontinuity analysis of alpha-fetoprotein with a cutoff of 20 ng/mL in hepatocellular carcinoma surveillance for chronic hepatitis B. <i>GastroHep</i> , 2019, 1, 70-75.	0.3	0
3035	Liver Imaging Reporting and Data System Category 5: MRI Predictors of Microvascular Invasion and Recurrence After Hepatectomy for Hepatocellular Carcinoma. <i>American Journal of Roentgenology</i> , 2019, 213, 821-830.	1.0	56
3037	Models estimating risk of hepatocellular carcinoma in patients with alcohol or NAFLD-related cirrhosis for risk stratification. <i>Journal of Hepatology</i> , 2019, 71, 523-533.	1.8	124
3038	Predictive factors for the benefit of triple-drug transarterial chemoembolization for patients with unresectable hepatocellular carcinoma. <i>Cancer Medicine</i> , 2019, 8, 4200-4213.	1.3	9
3039	Serum sphingolipids predict de novo hepatocellular carcinoma in hepatitis C cirrhotic patients with sustained virologic response. <i>Liver International</i> , 2019, 39, 2174-2183.	1.9	17
3040	Ganji Formulation for Patients with Hepatocellular Carcinoma Who Have Undergone Surgery: A Multicenter, Randomized, Double-Blind, Controlled Trial. <i>Evidence-based Complementary and Alternative Medicine</i> , 2019, 2019, 1-6.	0.5	2
3041	Development and validation of a new tumor-based gene signature predicting prognosis of HBV/HCV-included resected hepatocellular carcinoma patients. <i>Journal of Translational Medicine</i> , 2019, 17, 203.	1.8	18
3042	Chemoembolization of HCC: Time for Technical Standardization, or Is It Too Late?. <i>CardioVascular and Interventional Radiology</i> , 2019, 42, 1329-1330.	0.9	0
3043	Identification of mutations in circulating cell-free tumour DNA as a biomarker in hepatocellular carcinoma. <i>European Journal of Cancer</i> , 2019, 116, 56-66.	1.3	48
3044	A novel prognostic score model based on combining systemic and hepatic inflammation markers in the prognosis of HBV-associated hepatocellular carcinoma patients. <i>Artificial Cells, Nanomedicine and Biotechnology</i> , 2019, 47, 2246-2255.	1.9	14
3045	Acidic pH-Activated Gas-Generating Nanoparticles with Pullulan Decorating for Hepatoma-Targeted Ultrasound Imaging. <i>ACS Applied Materials & Interfaces</i> , 2019, 11, 22194-22205.	4.0	31
3046	Color coded perfusion imaging with contrast enhanced ultrasound (CEUS) for post-interventional success control following trans-arterial chemoembolization (TACE) of hepatocellular carcinoma. <i>PLoS ONE</i> , 2019, 14, e0217599.	1.1	13
3047	A simplified prediction model for early intrahepatic recurrence after hepatectomy for patients with unilobar hepatocellular carcinoma without macroscopic vascular invasion: An implication for adjuvant therapy and postoperative surveillance. <i>Surgical Oncology</i> , 2019, 30, 6-12.	0.8	15
3048	The short-term efficacy of no-touch radiofrequency ablation in treating cirrhosis-based small hepatocellular carcinoma. <i>BMC Cancer</i> , 2019, 19, 497.	1.1	11
3049	Preoperative serum ferritin is an independent prognostic factor for liver cancer after hepatectomy. <i>Surgical Oncology</i> , 2019, 29, 159-167.	0.8	11

#	ARTICLE	IF	CITATIONS
3050	Machine-learning Approach for the Development of a Novel Predictive Model for the Diagnosis of Hepatocellular Carcinoma. <i>Scientific Reports</i> , 2019, 9, 7704.	1.6	82
3051	Alcohol and hepatocellular carcinoma. <i>BMJ Open Gastroenterology</i> , 2019, 6, e000260.	1.1	46
3052	Yttrium-90 trans-arterial radioembolization in advanced-stage HCC: The impact of portal vein thrombosis on survival. <i>PLoS ONE</i> , 2019, 14, e0216935.	1.1	31
3053	From a Philosophical Framework to a Valid Prognostic Staging System of the New "Comprehensive Assessment" for Transplantable Hepatocellular Carcinoma. <i>Cancers</i> , 2019, 11, 741.	1.7	17
3054	Comparison of diffusion kurtosis imaging versus diffusion weighted imaging in predicting the recurrence of early stage single nodules of hepatocellular carcinoma treated by radiofrequency ablation. <i>Cancer Imaging</i> , 2019, 19, 30.	1.2	9
3055	CircRNA-100338 Is Associated With mTOR Signaling Pathway and Poor Prognosis in Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2019, 9, 392.	1.3	62
3056	Additional fibrate treatment in UDCA-refractory PBC patients. <i>Liver International</i> , 2019, 39, 1776-1785.	1.9	24
3057	The Combination of Stereotactic Body Radiation Therapy and Immunotherapy in Primary Liver Tumors. <i>Journal of Oncology</i> , 2019, 2019, 1-13.	0.6	21
3058	Optimal lexicon of gadoxetic acid-enhanced magnetic resonance imaging for the diagnosis of hepatocellular carcinoma modified from LI-RADS. <i>Abdominal Radiology</i> , 2019, 44, 3078-3088.	1.0	20
3059	Dynamic of systemic immunity and its impact on tumor recurrence after radiofrequency ablation of hepatocellular carcinoma. <i>Oncolmmunology</i> , 2019, 8, 1615818.	2.1	34
3060	Preoperative MRI features and clinical laboratory indicators for predicting the early therapeutic response of hepatocellular carcinoma to transcatheter arterial chemoembolization combined with High-intensity focused ultrasound treatment. <i>British Journal of Radiology</i> , 2019, 92, 20190073.	1.0	9
3061	Transarterial Chemoembolization in Treatment-Naïve and Recurrent Hepatocellular Carcinoma: A Propensity-Matched Outcome Analysis. <i>Digestive Diseases and Sciences</i> , 2019, 64, 3660-3668.	1.1	8
3062	Impact of the Prognostic Nutritional Index on the Survival of Japanese Patients with Hepatocellular Carcinoma Treated with Sorafenib: A Multicenter Retrospective Study. <i>Internal Medicine</i> , 2019, 58, 1835-1844.	0.3	12
3063	Sorafenib versus hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma: a systematic review and meta-analysis. <i>Japanese Journal of Clinical Oncology</i> , 2019, 49, 845-855.	0.6	23
3064	Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion. <i>JAMA Oncology</i> , 2019, 5, 953.	3.4	292
3065	NIACE score refines the overall survival of hepatocellular carcinoma by Barcelona clinic liver cancer staging. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 2179-2186.	1.4	4
3066	Preoperative Neutrophil-to-Lymphocyte Ratio Plus Platelet-to-Lymphocyte Ratio Predicts the Outcomes after Curative Resection for Hepatocellular Carcinoma. <i>International Journal of Hepatology</i> , 2019, 2019, 1-9.	0.4	28
3067	The association of liver function and quality of life of patients with liver cancer. <i>BMC Gastroenterology</i> , 2019, 19, 66.	0.8	21

#	ARTICLE	IF	CITATIONS
3068	Subgroup analysis of efficacy and safety of orantinib in combination with TACE in Japanese HCC patients in a randomized phase III trial (ORIENTAL). <i>Medical Oncology</i> , 2019, 36, 52.	1.2	9
3069	Genetic variants of <i>XRCC1</i> and risk of hepatocellular carcinoma in chronic hepatitis C patients. <i>British Journal of Biomedical Science</i> , 2019, 76, 64-69.	1.2	8
3070	High serum caspase-3 levels in hepatocellular carcinoma prior to liver transplantation and high mortality risk during the first year after liver transplantation. <i>Expert Review of Molecular Diagnostics</i> , 2019, 19, 635-640.	1.5	2
3071	PRDM1 levels are associated with clinical diseases in chronic HBV infection and survival of patients with HBV-related hepatocellular carcinoma. <i>International Immunopharmacology</i> , 2019, 73, 156-162.	1.7	15
3072	Yttrium-90 Radioembolization: Current Clinical Practice and Review of the Recent Literature. <i>Journal of Radiology Nursing</i> , 2019, 38, 86-91.	0.2	2
3073	Inflammation and nutrition score predicts prognosis of patients with resectable hepatocellular carcinoma. <i>International Journal of Clinical Oncology</i> , 2019, 24, 825-835.	1.0	8
3074	Lipiodol deposition in portal vein tumour thrombus predicts treatment outcome in HCC patients after transarterial chemoembolisation. <i>European Radiology</i> , 2019, 29, 5752-5762.	2.3	24
3075	Pharmacokinetics and Pharmacodynamics of Once-daily Prolonged-release Tacrolimus in Liver Transplant Recipients. <i>Clinical Therapeutics</i> , 2019, 41, 882-896.e3.	1.1	5
3076	Transarterial chemoembolization versus best supportive care for patients with hepatocellular carcinoma with portal vein tumor thrombus: a multicenter study. <i>European Journal of Surgical Oncology</i> , 2019, 45, 1460-1467.	0.5	49
3077	Risk factors and prognosis of patients with recurrent hepatocellular carcinoma who undergo liver re-resections. <i>European Journal of Surgical Oncology</i> , 2019, 45, 1684-1690.	0.5	16
3078	Antitumor Effects of Intra-Arterial Delivery of Albumin-Doxorubicin Nanoparticle Conjugated Microbubbles Combined with Ultrasound-Targeted Microbubble Activation on VX2 Rabbit Liver Tumors. <i>Cancers</i> , 2019, 11, 581.	1.7	19
3079	Single Hepatocellular Carcinoma approached by curative-intent treatment: A propensity score analysis comparing radiofrequency ablation and liver resection. <i>European Journal of Surgical Oncology</i> , 2019, 45, 1691-1699.	0.5	24
3080	GLS1 promotes proliferation in hepatocellular carcinoma cells via AKT/GSK3 β /CyclinD1 pathway. <i>Experimental Cell Research</i> , 2019, 381, 1-9.	1.2	32
3081	Multi-omics discovery of exome-derived neoantigens in hepatocellular carcinoma. <i>Genome Medicine</i> , 2019, 11, 28.	3.6	107
3082	External validation of the modified PAGE-B score in Asian chronic hepatitis B patients receiving antiviral therapy. <i>Liver International</i> , 2019, 39, 1624-1630.	1.9	29
3083	A different gut microbiome linked to inflammation found in cirrhotic patients with and without hepatocellular carcinoma. <i>Annals of Hepatology</i> , 2019, 18, 480-487.	0.6	50
3084	Inhibition of PI3K/mTOR increased the sensitivity of hepatocellular carcinoma cells to cisplatin via interference with mitochondrial lysosomal crosstalk. <i>Cell Proliferation</i> , 2019, 52, e12609.	2.4	33
3085	Contrast imaging techniques to diagnose hepatocellular carcinoma in cirrhotics outside regular surveillance. <i>Annals of Hepatology</i> , 2019, 18, 318-324.	0.6	4

#	ARTICLE	IF	CITATIONS
3086	Hepatitis C virus infection and non-hepatocellular malignancies in the DAA era: A systematic review and meta-analysis. <i>Liver International</i> , 2019, 39, 1292-1306.	1.9	35
3087	Hepatocellular Carcinoma in Africa. , 2019, , 149-162.		0
3088	A nomogram to predict early postoperative recurrence of hepatocellular carcinoma with portal vein tumour thrombus after R0 liver resection: A large-scale, multicenter study. <i>European Journal of Surgical Oncology</i> , 2019, 45, 1644-1651.	0.5	29
3089	From NASH to HCC: current concepts and future challenges. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2019, 16, 411-428.	8.2	872
3090	Combination of radiofrequency ablation and transcatheter arterial chemoembolization to treat hepatocellular carcinoma: measurement of distance from needle tip to nodule for assessment of local tumor progression. <i>Journal of International Medical Research</i> , 2019, 47, 2516-2523.	0.4	2
3091	Hepatocellular Carcinoma: Texture Analysis of Preoperative Computed Tomography Images Can Provide Markers of Tumor Grade and Disease-Free Survival. <i>Korean Journal of Radiology</i> , 2019, 20, 569.	1.5	43
3092	Molecular Diagnostics in Liver Cancer. , 2019, , 293-303.		3
3093	A 17 β -Hydroxysteroid Dehydrogenase 13 Variant Protects From Hepatocellular Carcinoma Development in Alcoholic Liver Disease. <i>Hepatology</i> , 2019, 70, 231-240.	3.6	75
3094	Novel immunotherapeutic approaches for hepatocellular carcinoma treatment. <i>Expert Review of Clinical Pharmacology</i> , 2019, 12, 453-470.	1.3	28
3095	<p>ARQ-197 enhances the antitumor effect of sorafenib in hepatocellular carcinoma cells via decelerating its intracellular clearance</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 1629-1640.	1.0	23
3096	Cost Effectiveness of Hepatocellular Carcinoma Surveillance After a Sustained Virologic Response to Therapy in Patients With Hepatitis C Virus Infection and Advanced Fibrosis. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1840-1849.e16.	2.4	82
3097	Technical Aspects and Practical Approach Toward Same-Day Y90 Radioembolization in the Management of Hepatocellular Carcinoma. <i>Techniques in Vascular and Interventional Radiology</i> , 2019, 22, 93-99.	0.4	13
3098	Intrathecal Morphine Administration Does Not Affect Survival After Liver Resection for Hepatocellular Carcinoma. <i>Seminars in Cardiothoracic and Vascular Anesthesia</i> , 2019, 23, 309-318.	0.4	4
3099	HCC: Transarterial Therapies "What the Interventional Radiologist Can Offer. <i>Digestive Diseases and Sciences</i> , 2019, 64, 959-967.	1.1	19
3100	Postoperative α -fetoprotein response predicts tumor recurrence and survival after hepatectomy for hepatocellular carcinoma: A propensity score matching analysis. <i>Surgery</i> , 2019, 165, 1161-1167.	1.0	13
3101	High Acceleration Three-Dimensional T1-Weighted Dual Echo Dixon Hepatobiliary Phase Imaging Using Compressed Sensing-Sensitivity Encoding: Comparison of Image Quality and Solid Lesion Detectability with the Standard T1-Weighted Sequence. <i>Korean Journal of Radiology</i> , 2019, 20, 438.	1.5	32
3102	Diagnosis of recurrent HCC: intraindividual comparison of gadoxetic acid MRI and extracellular contrast-enhanced MRI. <i>Abdominal Radiology</i> , 2019, 44, 2366-2376.	1.0	10
3103	Efficacy and safety of transarterial chemoembolisation with cone-beam CT in patients with hepatocellular carcinoma within the Milan criteria: a retrospective cohort study. <i>Clinical Radiology</i> , 2019, 74, 407.e19-407.e28.	0.5	3

#	ARTICLE	IF	CITATIONS
3104	Recent advances in the management of hepatocellular carcinoma: First, cut is the deepest or is it and exercise?. Journal of Gastroenterology and Hepatology (Australia), 2019, 34, 481-482.	1.4	0
3105	Laparoscopic Microwave Ablation of Hepatocellular Carcinoma at Liver Surface: Technique Effectiveness and Long-Term Outcomes. Technology in Cancer Research and Treatment, 2019, 18, 153303381882433.	0.8	14
3106	Antiviral therapy predicts the outcomes following resection of hepatocellular carcinoma in patients negative for HBV DNA: a propensity score matching analysis. World Journal of Surgical Oncology, 2019, 17, 45.	0.8	9
3107	Ultrasound Screening and Surveillance in Hepatocellular Carcinoma. Current Radiology Reports, 2019, 7, 1.	0.4	0
3108	Nomogram and Artificial Neural Network for Prognostic Performance on the Albumin-Bilirubin Grade for Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization. Journal of Vascular and Interventional Radiology, 2019, 30, 330-338.	0.2	24
3109	Development of colorectal cancer predicts increased risk of subsequent hepatocellular carcinoma in patients with alcoholic liver disease: case-control and cohort study. Scientific Reports, 2019, 9, 3236.	1.6	1
3110	Rare Pathogenic Variants Predispose to Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease. Scientific Reports, 2019, 9, 3682.	1.6	85
3111	Albumin-Indocyanine Green Evaluation (ALICE) grade combined with portal hypertension to predict post-hepatectomy liver failure. Hepatology Research, 2019, 49, 942-949.	1.8	22
3112	Impact of Anatomical Versus Non-anatomical Liver Resection on Short- and Long-Term Outcomes for Patients with Intrahepatic Cholangiocarcinoma. Annals of Surgical Oncology, 2019, 26, 1841-1850.	0.7	51
3113	Dissecting the multinodular hepatocellular carcinoma subset: is there a survival benefit after hepatectomy?. Updates in Surgery, 2019, 71, 57-66.	0.9	7
3114	Liver resection versus transarterial chemoembolization for the treatment of intermediate-stage hepatocellular carcinoma. Cancer Medicine, 2019, 8, 1530-1539.	1.3	14
3115	Efficacy of Hepatic Resection vs. Radiofrequency Ablation for Patients With Very-Early-Stage or Early-Stage Hepatocellular Carcinoma: A Population-Based Study With Stratification by Age and Tumor Size. Frontiers in Oncology, 2019, 9, 113.	1.3	35
3116	Loco-regional hepatocellular carcinoma treatment services as a bridge to liver transplantation. Hepatobiliary and Pancreatic Diseases International, 2019, 18, 228-236.	0.6	2
3117	Impact of immigration in presentation and outcomes of hepatocellular carcinoma in the USA. European Journal of Gastroenterology and Hepatology, 2019, 31, 24-28.	0.8	8
3118	The prognostic and predictive value of the combination of the neutrophil-to-lymphocyte ratio and the platelet-to-lymphocyte ratio in patients with hepatocellular carcinoma who receive transarterial chemoembolization therapy. Cancer Management and Research, 2019, Volume 11, 1391-1400.	0.9	27
3119	Ultrasound-Guided 125I Seed Implantation in Treatment of Abdominal Wall Metastases. Cancer Biotherapy and Radiopharmaceuticals, 2019, 34, 218-223.	0.7	1
3120	Effect of microvascular invasion on the postoperative long-term prognosis of solitary small HCC: a systematic review and meta-analysis. Hpb, 2019, 21, 935-944.	0.1	53
3121	Balloon-Occluded Transcatheter Arterial Chemoembolization (b-TACE) for Hepatocellular Carcinoma Performed with Polyethylene-Glycol Epirubicin-Loaded Drug-Eluting Embolics: Safety and Preliminary Results. CardioVascular and Interventional Radiology, 2019, 42, 853-862.	0.9	26

#	ARTICLE	IF	CITATIONS
3122	Dynamic Computed Tomography Perfusion Imaging: Complementary Diagnostic Tool in Hepatocellular Carcinoma Assessment From Diagnosis to Treatment Follow-up. <i>Academic Radiology</i> , 2019, 26, 1675-1685.	1.3	12
3123	Accuracy of Pretransplant Imaging Diagnostic for Hepatocellular Carcinoma: A Retrospective German Multicenter Study. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2019, 2019, 1-9.	0.8	5
3124	Prognostic assessment using a new substaging system for Barcelona clinic liver cancer stage C hepatocellular carcinoma: A nationwide study. <i>Liver International</i> , 2019, 39, 1109-1119.	1.9	6
3125	Development of a New Nomogram Including Neutrophil-to-Lymphocyte Ratio to Predict Survival in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization. <i>Cancers</i> , 2019, 11, 509.	1.7	37
3126	Increased multimodality treatment options has improved survival for Hepatocellular carcinoma but poor survival for biliary tract cancers remains unchanged. <i>European Journal of Surgical Oncology</i> , 2019, 45, 1660-1667.	0.5	41
3127	Low Serum Melatonin Levels Prior to Liver Transplantation in Patients with Hepatocellular Carcinoma are Associated with Lower Survival after Liver Transplantation. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1696.	1.8	3
3128	Immobilized Transforming Growth Factor-Beta 1 in a Stiffness-Tunable Artificial Extracellular Matrix Enhances Mechanotransduction in the Epithelial Mesenchymal Transition of Hepatocellular Carcinoma. <i>ACS Applied Materials & Interfaces</i> , 2019, 11, 14660-14671.	4.0	17
3129	In silico molecular docking of astaxanthin and sorafenib with different apoptotic proteins involved in hepatocellular carcinoma. <i>Biocatalysis and Agricultural Biotechnology</i> , 2019, 19, 101076.	1.5	12
3130	Fontan-associated liver disease: A review. <i>Journal of Cardiology</i> , 2019, 74, 223-232.	0.8	126
3131	Liver Cancer Gene Discovery Using Gene Targeting, Sleeping Beauty, and CRISPR/Cas9. <i>Seminars in Liver Disease</i> , 2019, 39, 261-274.	1.8	21
3132	Microwave Responsive Nanoplatfrom via P-Selectin Mediated Drug Delivery for Treatment of Hepatocellular Carcinoma with Distant Metastasis. <i>Nano Letters</i> , 2019, 19, 2914-2927.	4.5	66
3133	Surgical and oncological outcomes of hepatic resection for BCLC-B hepatocellular carcinoma: a retrospective multicenter analysis among 474 consecutive cases. <i>Updates in Surgery</i> , 2019, 71, 285-293.	0.9	25
3134	Albumin - bilirubin (ALBI) versus Child-Turcotte-Pugh (CTP) in prognosis of HCC after stereotactic body radiation therapy. <i>Radiation Oncology</i> , 2019, 14, 50.	1.2	33
3135	Role of Liver Stiffness Measurement in Predicting HCC Occurrence in Direct-Acting Antivirals Setting: A Real-Life Experience. <i>Digestive Diseases and Sciences</i> , 2019, 64, 3013-3019.	1.1	33
3136	Late presentation of hepatitis B among patients with newly diagnosed hepatocellular carcinoma: a national cohort study. <i>BMC Cancer</i> , 2019, 19, 286.	1.1	11
3137	Refractoriness to transarterial chemoembolization in patients with recurrent hepatocellular carcinoma after curative resection. <i>PLoS ONE</i> , 2019, 14, e0214613.	1.1	7
3138	Predictors of Radiation-Induced Liver Disease in Eastern and Western Patients With Hepatocellular Carcinoma Undergoing Proton Beam Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, 73-86.	0.4	41
3139	Influence of HIV Infection on the Natural History of Hepatocellular Carcinoma: Results From a Global Multicohort Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 296-304.	0.8	36

#	ARTICLE	IF	CITATIONS
3140	Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients. <i>Journal of Hepatology</i> , 2019, 71, 265-273.	1.8	138
3141	A multicenter study of entecavir vs. tenofovir on prognosis of treatment-naïve chronic hepatitis B in South Korea. <i>Journal of Hepatology</i> , 2019, 71, 456-464.	1.8	131
3142	Identification of the feeding arteries of hepatocellular carcinomas by performing dual arterial phase CT during pre-transarterial chemoembolization angiography. <i>Abdominal Radiology</i> , 2019, 44, 2276-2282.	1.0	2
3143	Clinical outcomes in patients with hepatitis D, cirrhosis and persistent hepatitis B virus replication, and receiving long-term tenofovir or entecavir. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 1071-1076.	1.9	35
3144	Cost-effectiveness analysis of lenvatinib treatment for patients with unresectable hepatocellular carcinoma (uHCC) compared with sorafenib in Japan. <i>Journal of Gastroenterology</i> , 2019, 54, 558-570.	2.3	59
3145	A Clinical Scoring System for Predicting Microvascular Invasion in Patients with Hepatocellular Carcinoma Within the Milan Criteria. <i>Journal of Gastrointestinal Surgery</i> , 2019, 23, 779-787.	0.9	39
3146	125I seeds implantation for treating residual hepatocellular carcinoma located beneath the diaphragm after transcatheter arterial chemoembolization. <i>Brachytherapy</i> , 2019, 18, 420-425.	0.2	8
3147	Timely eradication of HCV viremia by PegIFN/RBV is crucial in prevention of post RFA recurrence in CHC-HCC patients. <i>Journal of the Formosan Medical Association</i> , 2019, 118, 1239-1246.	0.8	4
3148	The Role of Radioembolization in Bridging and Downstaging Hepatocellular Carcinoma to Curative Therapy. <i>Seminars in Nuclear Medicine</i> , 2019, 49, 189-196.	2.5	18
3149	CircSETD3 (Hsa_circ_0000567) acts as a sponge for microRNA-421 inhibiting hepatocellular carcinoma growth. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 98.	3.5	151
3150	Radiotherapy for Hepatocellular Carcinoma Results in Comparable Survival to Radiofrequency Ablation: A Propensity Score Analysis. <i>Hepatology</i> , 2019, 69, 2533-2545.	3.6	115
3152	A variant in the MICA gene is associated with liver fibrosis progression in chronic hepatitis C through TGF- β 1 dependent mechanisms. <i>Scientific Reports</i> , 2019, 9, 1439.	1.6	7
3153	Phase 1 Trial With the Cell-Based Immune Primer Ilixadencel, Alone, and Combined With Sorafenib, in Advanced Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2019, 9, 19.	1.3	34
3154	The different effects of adefovir dipivoxil and telbivudine on the prognosis of hepatitis b virus-related hepatocellular carcinoma patients after curative resection. <i>Medicine (United States)</i> , 2019, 98, e14386.	0.4	4
3155	Should Patients With NAFLD/NASH Be Surveyed for HCC?. <i>Transplantation</i> , 2019, 103, 39-44.	0.5	52
3156	Whole tumor ablation of locally recurred hepatocellular carcinoma including retained iodized oil after transarterial chemoembolization improves progression-free survival. <i>European Radiology</i> , 2019, 29, 5052-5062.	2.3	7
3157	Ultrasound Evaluation in Patients at Risk for Hepatocellular Carcinoma. <i>Radiologic Clinics of North America</i> , 2019, 57, 563-583.	0.9	7
3158	Can we ablate liver lesions close to large portal and hepatic veins with MR-guided HIFU? An experimental study in a porcine model. <i>European Radiology</i> , 2019, 29, 5013-5021.	2.3	6

#	ARTICLE	IF	CITATIONS
3159	Comparison between chronic hepatitis B patients with untreated immune-tolerant phase vs. those with virological response by antivirals. <i>Scientific Reports</i> , 2019, 9, 2508.	1.6	20
3160	Hepatic Cancers Overview: Surgical and Chemotherapeutic Options, How Do Y-90 Microspheres Fit in?. <i>Seminars in Nuclear Medicine</i> , 2019, 49, 170-181.	2.5	8
3161	Comparison of Radioembolization and Sorafenib for the Treatment of Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis: A Systematic Review and Meta-Analysis of Safety and Efficacy. <i>Korean Journal of Radiology</i> , 2019, 20, 385.	1.5	29
3162	Efficacy and safety of external-beam radiation therapy for hepatocellular carcinoma: An overview of current evidence according to the different target population. <i>BioScience Trends</i> , 2019, 13, 10-22.	1.1	15
3166	Effect of Nucleos(t)ide Analogs on Patients with Intermediate and Advanced Hepatitis B Virus-Related Hepatocellular Carcinoma. <i>Digestive Diseases and Sciences</i> , 2019, 64, 2187-2198.	1.1	6
3167	Emerging Role of the Pathologist in Precision Medicine for HCC. <i>Digestive Diseases and Sciences</i> , 2019, 64, 928-933.	1.1	5
3168	Synchronous hepatectomy and splenectomy vs hepatectomy for selected patients with hepatocellular carcinoma and clinically significant portal hypertension: A systematic review and meta-analysis. <i>Journal of Surgical Oncology</i> , 2019, 119, 964-973.	0.8	9
3169	Comparative liver function models for ruptured hepatocellular carcinoma: A 10-year single center experience. <i>Asian Journal of Surgery</i> , 2019, 42, 874-882.	0.2	12
3170	Histologic severity of liver cirrhosis: A key factor affecting surgical outcomes of hepatocellular carcinoma in patients with portal hypertension. <i>Asian Journal of Surgery</i> , 2019, 42, 981-989.	0.2	8
3171	Identifying novel biomarkers in hepatocellular carcinoma by weighted gene co-expression network analysis. <i>Journal of Cellular Biochemistry</i> , 2019, 120, 11418-11431.	1.2	38
3172	Emerging roles of long non-coding RNAs in cancer. <i>Journal of Biosciences</i> , 2019, 44, 1.	0.5	21
3173	Can the Injection of Adjuvant Gels Accelerate Heating for More Robust Thermal Ablation of Tumors?. <i>Radiology</i> , 2019, 291, 511-512.	3.6	2
3174	Serum AP-endonuclease 1 (sAPE1) as novel biomarker for hepatocellular carcinoma. <i>Oncotarget</i> , 2019, 10, 383-394.	0.8	33
3175	Introduction to the Liver Imaging Reporting and Data System for Hepatocellular Carcinoma. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1228-1238.	2.4	41
3176	Liver Transplantation in China. , 0, , .		2
3177	HCC complicated by PVT: Outcome and the role of anticoagulation therapy. <i>Canadian Liver Journal</i> , 2019, 2, 121-126.	0.3	3
3179	An Eastern Hepatobiliary Surgery Hospital Microvascular Invasion Scoring System in Predicting Prognosis of Patients with Hepatocellular Carcinoma and Microvascular Invasion After RO Liver Resection: A Large-Scale, Multicenter Study. <i>Oncologist</i> , 2019, 24, e1476-e1488.	1.9	46
3180	<p>Transarterial Chemoembolization and Sorafenib Combined with Microwave Ablation for Advanced Primary Hepatocellular Carcinoma: A Preliminary Investigation of Safety and Efficacy</p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 9939-9950.	0.9	8

#	ARTICLE	IF	CITATIONS
3181	Stratification of risk of recurrence after curative-intent treatment for small hepatocellular carcinoma. <i>Hepatobiliary Surgery and Nutrition</i> , 2019, 8, 649-650.	0.7	1
3182	Validation of an algorithm using inpatient electronic health records to determine the presence and severity of cirrhosis in patients with hepatocellular carcinoma in England: an observational study. <i>BMJ Open</i> , 2019, 9, e028571.	0.8	14
3183	Aberrant p16 methylation as an early diagnostic marker in blood of hepatocellular carcinoma patients. <i>Egyptian Journal of Medical Human Genetics</i> , 2019, 20, .	0.5	4
3184	Efficacy and safety of CT-guided percutaneous thermal ablation for hepatocellular carcinoma adjacent to the second porta hepatis. <i>International Journal of Hyperthermia</i> , 2019, 36, 1121-1127.	1.1	9
3185	Computed tomography for the diagnosis of hepatocellular carcinoma in chronic advanced liver disease. <i>The Cochrane Library</i> , 0, , .	1.5	7
3186	Staging of Biliary and Primary Liver Tumors. <i>Surgical Oncology Clinics of North America</i> , 2019, 28, 663-683.	0.6	6
3187	Inoperable Biliary Tract and Primary Liver Tumors. <i>Surgical Oncology Clinics of North America</i> , 2019, 28, 745-762.	0.6	2
3188	Application of the Albumin-Bilirubin Grade in Predicting the Prognosis of Patients With Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. <i>Transplantation Proceedings</i> , 2019, 51, 3338-3346.	0.3	16
3189	MT1G serves as a tumor suppressor in hepatocellular carcinoma by interacting with p53. <i>Oncogenesis</i> , 2019, 8, 67.	2.1	24
3190	Abdominal ultrasound and alpha-fetoprotein for the diagnosis of hepatocellular carcinoma. <i>The Cochrane Library</i> , 0, , .	1.5	3
3191	Hepatocellular carcinoma in alcoholic and non-alcoholic fatty liver disease—“one of a kind or two different enemies?”. <i>Translational Gastroenterology and Hepatology</i> , 2019, 4, 72-72.	1.5	31
3192	STAT3: An Emerging Therapeutic Target for Hepatocellular Carcinoma. <i>Cancers</i> , 2019, 11, 1646.	1.7	79
3193	Fluorodeoxyglucose PET for Monitoring Response to Embolotherapy (Transarterial) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 262 Td (Chem 1.5 3	1.5	3
3194	Radiofrequency Ablation, Where It Stands in Interventional Radiology Today. <i>Seminars in Interventional Radiology</i> , 2019, 36, 398-404.	0.3	4
3195	Diagnostic accuracy of serum dickkopf-1 protein in diagnosis hepatocellular carcinoma. <i>Medicine (United States)</i> , 2019, 98, e16725.	0.4	12
3196	High incidence of hepatocellular carcinoma and postoperative complications in patients with nonalcoholic steatohepatitis as a primary indication for deceased liver transplantation. <i>European Journal of Gastroenterology and Hepatology</i> , 2019, 31, 205-210.	0.8	11
3197	Embolization of variant hepatic arteries in patients undergoing percutaneous hepatic perfusion for unresectable liver metastases from ocular melanoma. <i>Diagnostic and Interventional Radiology</i> , 2019, 25, 451-458.	0.7	7
3198	Lymphovascular invasion on explant is associated with presenting tumor characteristics and not direct acting antiviral utilization in hepatitis C candidates undergoing liver transplantation. <i>Clinical and Experimental Hepatology</i> , 2019, 5, 279-284.	0.6	2

#	ARTICLE	IF	CITATIONS
3199	High Somatic Mutation and Neoantigen Burden Do Not Correlate with Decreased Progression-Free Survival in HCC Patients not Undergoing Immunotherapy. <i>Cancers</i> , 2019, 11, 1824.	1.7	36
3200	Direct-acting antivirals for patients with chronic hepatitis C and hepatocellular carcinoma in Taiwan. <i>Journal of Microbiology, Immunology and Infection</i> , 2021, 54, 385-395.	1.5	14
3201	Complex interaction networks of cytokines after transarterial chemotherapy in patients with hepatocellular carcinoma. <i>PLoS ONE</i> , 2019, 14, e0224318.	1.1	20
3202	Patterns of Care and Outcomes of Definitive External Beam Radiotherapy and Radioembolization for Localized Hepatocellular Carcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2019, 42, 564-572.	0.6	0
3203	Decreased liver stiffness by transient elastography indicates lower incidence of hepatocellular carcinoma in patients with chronic hepatitis B. <i>Medicine (United States)</i> , 2019, 98, e13929.	0.4	4
3204	Sarcopenia impairs health-related quality of life in cirrhotic patients. <i>European Journal of Gastroenterology and Hepatology</i> , 2019, 31, 1550-1556.	0.8	21
3205	Diagnostic Value of Quantitative Perfusion Computed Tomography Technique in the Assessment of Tumor Response to Sorafenib in Patients With Advanced Hepatocellular Carcinoma. <i>Journal of Computer Assisted Tomography</i> , 2019, 43, 206-213.	0.5	7
3206	BCLC-B Subclassification and the Hong Kong Liver Cancer System in Intermediate Hepatocellular Carcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2019, 42, 466-471.	0.6	5
3207	90Y-TheraSpheres. <i>American Journal of Surgical Pathology</i> , 2019, 43, 688-694.	2.1	11
3208	The Diagnostic Value of MicroRNAs as a Biomarker for Hepatocellular Carcinoma: A Meta-Analysis. <i>BioMed Research International</i> , 2019, 2019, 1-14.	0.9	9
3209	Image-guided intensity-modulated radiotherapy improves short-term survival for abdominal lymph node metastases from hepatocellular carcinoma. <i>Annals of Palliative Medicine</i> , 2019, 8, 717-727.	0.5	6
3210	UEG Week 2019 Poster Presentations. <i>United European Gastroenterology Journal</i> , 2019, 7, 189-1030.	1.6	6
3211	Prognosis of Untreated Minimally Active Chronic Hepatitis B Patients in Comparison With Virological Responders by Antivirals. <i>Clinical and Translational Gastroenterology</i> , 2019, 10, e00036.	1.3	17
3212	An Albumin-Bilirubin (ALBI) Grade-based Prognostic Model For Patients With Hepatocellular Carcinoma Within Milan Criteria. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2019, 42, 698-704.	0.6	15
3213	Apatinib treatment of advanced hepatocellular carcinoma with portal vein and inferior vena cava tumor thrombus. <i>Medicine (United States)</i> , 2019, 98, e14582.	0.4	3
3214	The clinical significance of microRNA-122 in predicting the prognosis of patients with hepatocellular carcinoma. <i>Medicine (United States)</i> , 2019, 98, e14810.	0.4	16
3215	Comparison of survival outcomes of alcohol-related hepatocellular carcinoma with or without liver cirrhosis; a ten-year experience. <i>Medicine (United States)</i> , 2019, 98, e18020.	0.4	3
3216	Long-term follow-up after cure from chronic hepatitis C virus infection shows occult hepatitis and a risk of hepatocellular carcinoma in noncirrhotic patients. <i>European Journal of Gastroenterology and Hepatology</i> , 2019, 31, 506-513.	0.8	16

#	ARTICLE	IF	CITATIONS
3217	68Ga-DOTANOC PET/CT Detects Multifocal Hepatocellular Carcinoma. <i>Clinical Nuclear Medicine</i> , 2019, 44, 238-239.	0.7	2
3218	Combination therapy. <i>Medicine (United States)</i> , 2019, 98, e18030.	0.4	7
3219	NAFLD-Associated Comorbidities in Advanced Stage HCC Do Not Alter the Safety and Efficacy of Yttrium-90 Radioembolization. <i>Liver Cancer</i> , 2019, 8, 491-504.	4.2	12
3220	Impact of Cytomegalovirus Infection on the Outcome of Patients With Cirrhosis. <i>Journal of Clinical Gastroenterology</i> , 2019, 53, 236-241.	1.1	6
3221	The Role of Interventional Radiology in the Pretransplant Management of Hepatocellular Carcinoma and Portal Vein Thrombosis. <i>Digestive Disease Interventions</i> , 2019, 03, 263-269.	0.3	0
3222	<p>Comparison of Microwave Ablation and Transarterial Chemoembolization for Single-Nodule Hepatocellular Carcinoma Smaller Than 5cm: A Propensity Score Matching Analysis</p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 10695-10704.	0.9	6
3223	Longitudinal Assessment of Three Serum Biomarkers to Detect Very Earlyâ€Stage Hepatocellular Carcinoma. <i>Hepatology</i> , 2019, 69, 1983-1994.	3.6	127
3224	Aiming for the elimination of viral hepatitis in Australia, New Zealand, and the Pacific Islands and Territories: Where are we now and barriers to meeting World Health Organization targets by 2030. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 40-48.	1.4	39
3225	TACE with degradable starch microspheres (DSM-TACE) as second-line treatment in HCC patients dismissing or ineligible for sorafenib. <i>European Radiology</i> , 2019, 29, 1285-1292.	2.3	22
3226	Downstaging prior to liver transplantation for hepatocellular carcinoma: advisable but at the price of an increased risk of cancer recurrence - a retrospective study. <i>Transplant International</i> , 2019, 32, 163-172.	0.8	20
3227	3D MR Elastography of Hepatocellular Carcinomas as a Potential Biomarker for Predicting Tumor Recurrence. <i>Journal of Magnetic Resonance Imaging</i> , 2019, 49, 719-730.	1.9	48
3228	Stereotactic Body Radiation Therapy as an Alternative Treatment for Patients with Hepatocellular Carcinoma Compared to Sorafenib: A Propensity Score Analysis. <i>Liver Cancer</i> , 2019, 8, 281-294.	4.2	31
3229	Diagnostic accuracy of MRI with extracellular vs. hepatobiliary contrast material for detection of residual hepatocellular carcinoma after locoregional treatment. <i>Abdominal Radiology</i> , 2019, 44, 549-558.	1.0	10
3230	ALBI and P-ALBI grade in Child-Pugh A patients treated with drug eluting embolic chemoembolization for hepatocellular carcinoma. <i>Acta Radiologica</i> , 2019, 60, 702-709.	0.5	13
3231	Safety and Effectiveness of Suture-mediated Arterial Closure Device in Hepatocellular Carcinoma Patients Who Underwent Drug-Eluting Beads Transarterial Chemoembolization. <i>Annals of Vascular Surgery</i> , 2019, 55, 203-209.	0.4	1
3232	Comprehensive treatments for hepatocellular carcinoma with portal vein tumor thrombosis. <i>Journal of Cellular Physiology</i> , 2019, 234, 1062-1070.	2.0	36
3233	Combined Transarterial Embolization/Chemoembolization-Based Locoregional Treatment with Sorafenib Prolongs the Survival in Patients with Advanced Hepatocellular Carcinoma and Preserved Liver Function: A Propensity Score Matching Study. <i>Liver Cancer</i> , 2019, 8, 186-202.	4.2	16
3234	Association of Platelet Count and Mean Platelet Volume with Overall Survival in Patients with Cirrhosis and Unresectable Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2019, 8, 203-217.	4.2	48

#	ARTICLE	IF	CITATIONS
3235	Imaging features related with prognosis of hepatocellular carcinoma. <i>Abdominal Radiology</i> , 2019, 44, 509-516.	1.0	27
3236	Efficacy of stereotactic body radiotherapy for unresectable or recurrent cholangiocarcinoma: a meta-analysis and systematic review. <i>Strahlentherapie Und Onkologie</i> , 2019, 195, 93-102.	1.0	37
3237	Intra-tumoral tertiary lymphoid structures are associated with a low risk of early recurrence of hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2019, 70, 58-65.	1.8	219
3238	SIUMB guidelines and recommendations for the correct use of ultrasound in the management of patients with focal liver disease. <i>Journal of Ultrasound</i> , 2019, 22, 41-51.	0.7	23
3239	Novel Hepatitis B Virus Capsid-Targeting Antiviral That Aggregates Core Particles and Inhibits Nuclear Entry of Viral Cores. <i>ACS Infectious Diseases</i> , 2019, 5, 750-758.	1.8	13
3240	Frequency and Outcomes of Abnormal Imaging in Patients With Cirrhosis Enrolled in a Hepatocellular Carcinoma Surveillance Program. <i>Liver Transplantation</i> , 2019, 25, 369-379.	1.3	40
3241	Radiofrequency ablation for subcardiac hepatocellular carcinoma: therapeutic outcomes and risk factors for technical failure. <i>European Radiology</i> , 2019, 29, 2706-2715.	2.3	17
3242	Epidemiology and Management of Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2019, 156, 477-491.e1.	0.6	1,133
3243	Improved Prediction of Survival by a Risk Factor-Integrating Inflammatory Score in Sorafenib-Treated Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2019, 8, 387-402.	4.2	18
3244	Liver-related Events in Human Immunodeficiency Virus-infected Persons With Occult Cirrhosis. <i>Clinical Infectious Diseases</i> , 2019, 69, 1422-1430.	2.9	14
3245	Impact of albumin-bilirubin grade on survival in patients with hepatocellular carcinoma who received sorafenib: An analysis using time-dependent receiver operating characteristic. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 1066-1073.	1.4	40
3246	Goals and targets for personalized therapy for HCC. <i>Hepatology International</i> , 2019, 13, 125-137.	1.9	358
3247	Lessons learnt from pathologic imaging correlation in the liver: an historical perspective. <i>British Journal of Radiology</i> , 2019, 92, 20180701.	1.0	2
3248	Albumin-bilirubin (ALBI) grade-based nomogram to predict tumor recurrence in patients with hepatocellular carcinoma. <i>European Journal of Surgical Oncology</i> , 2019, 45, 776-781.	0.5	38
3249	Association between rs738409 polymorphism in patatin-like phospholipase domain-containing protein 3 (PNPLA3) gene and hepatocellular carcinoma susceptibility: Evidence from case-control studies. <i>Gene</i> , 2019, 685, 143-148.	1.0	17
3250	Imaging of combined hepatocellular-cholangiocarcinoma in cirrhosis and risk of false diagnosis of hepatocellular carcinoma. <i>United European Gastroenterology Journal</i> , 2019, 7, 69-77.	1.6	31
3251	Assessment of Radiofrequency Ablation Efficacy for Hepatocellular Carcinoma by Histology and Pretransplant Radiology. <i>Liver Transplantation</i> , 2019, 25, 88-97.	1.3	18
3252	Updated use of TACE for hepatocellular carcinoma treatment: How and when to use it based on clinical evidence. <i>Cancer Treatment Reviews</i> , 2019, 72, 28-36.	3.4	342

#	ARTICLE	IF	CITATIONS
3253	A radiomics-based nomogram for the preoperative prediction of posthepatectomy liver failure in patients with hepatocellular carcinoma. <i>Surgical Oncology</i> , 2019, 28, 78-85.	0.8	46
3254	A Novel Score Predicts HBV-Related Hepatocellular Carcinoma Recurrence After Hepatectomy: a Retrospective Multicenter Study. <i>Journal of Gastrointestinal Surgery</i> , 2019, 23, 922-932.	0.9	8
3255	GALAD Score for Hepatocellular Carcinoma Detection in Comparison with Liver Ultrasound and Proposal of GALADUS Score. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019, 28, 531-538.	1.1	135
3256	Multidisciplinary approach is associated with improved survival of hepatocellular carcinoma patients. <i>PLoS ONE</i> , 2019, 14, e0210730.	1.1	64
3257	Therapeutic advances for patients with intermediate hepatocellular carcinoma. <i>Journal of Cellular Physiology</i> , 2019, 234, 12116-12121.	2.0	30
3258	Non-hypervascular hepatobiliary phase hypointense nodules on gadoteric acid-enhanced MR can help determine the treatment method for HCC. <i>European Radiology</i> , 2019, 29, 3122-3131.	2.3	17
3259	Circulating miR-26a, miR-106b, miR-107 and miR-133b stratify hepatocellular carcinoma patients according to their response to transarterial chemoembolization. <i>Clinical Biochemistry</i> , 2019, 65, 45-52.	0.8	23
3260	The utility of diffusion-weighted imaging in improving the sensitivity of LI-RADS classification of small hepatic observations suspected of malignancy. <i>Abdominal Radiology</i> , 2019, 44, 1773-1784.	1.0	16
3261	Factors Associated With Increased Risk of De Novo or Recurrent Hepatocellular Carcinoma in Patients With Cirrhosis Treated With Direct-Acting Antivirals for HCV Infection. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1183-1191.e7.	2.4	79
3262	Time-to-progression following conventional compared with drug-eluting-bead transcatheter arterial chemoembolisation in patients with large hepatocellular carcinoma. <i>Clinical Radiology</i> , 2019, 74, 295-300.	0.5	6
3263	Laparoscopic Right Hepatectomy for Hepatocellular Carcinoma: A Propensity Score Matching Analysis of Outcomes Compared with Conventional Open Surgery. <i>Journal of Laparoendoscopic and Advanced Surgical Techniques - Part A</i> , 2019, 29, 503-512.	0.5	15
3264	Transarterial Chemoembolization related to Good Survival for Selected Patients with advanced Hepatocellular Carcinoma. <i>Journal of Cancer</i> , 2019, 10, 665-671.	1.2	13
3265	Validated nomogram for the prediction of disease-free survival after hepatectomy for hepatocellular carcinoma within the Milan criteria: individualizing a surveillance strategy. <i>Surgery Today</i> , 2019, 49, 521-528.	0.7	9
3266	Diabetic Retinopathy as a Risk Factor Associated with the Development of Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease. <i>Digestive Diseases</i> , 2019, 37, 247-254.	0.8	9
3267	Critical systematic review on hepatic resection and transarterial chemoembolization for hepatocellular carcinoma. <i>Future Oncology</i> , 2019, 15, 439-449.	1.1	2
3268	Laparoscopic Hepatectomy Versus Open Hepatectomy for the Management of Hepatocellular Carcinoma: A Comparative Study Using a Propensity Score Matching. <i>World Journal of Surgery</i> , 2019, 43, 615-625.	0.8	17
3269	Synthesis of new thiazolo-pyrrolidine (spirooxindole) tethered to 3-acylindole as anticancer agents. <i>Bioorganic Chemistry</i> , 2019, 82, 423-430.	2.0	66
3270	Improved survival following splenectomy combined with curative treatments for hepatocellular carcinoma in Child B patients: A propensity score matching study. <i>Hepatology Research</i> , 2019, 49, 177-188.	1.8	4

#	ARTICLE	IF	CITATIONS
3271	Current trends in the treatment of hepatocellular carcinoma with transarterial embolization: a cross-sectional survey of techniques. <i>European Radiology</i> , 2019, 29, 3287-3295.	2.3	42
3272	Primary Care Provider Practice Patterns and Barriers to Hepatocellular Carcinoma Surveillance. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 766-773.	2.4	76
3273	Magnetic Resonance Imaging Is Cost-Effective for Hepatocellular Carcinoma Surveillance in High-Risk Patients With Cirrhosis. <i>Hepatology</i> , 2019, 69, 1599-1613.	3.6	70
3274	Combination therapy of sorafenib with mesenchymal stem cells as a novel cancer treatment regimen in xenograft models of hepatocellular carcinoma. <i>Journal of Cellular Physiology</i> , 2019, 234, 9495-9503.	2.0	13
3275	Identification of Protein Abundance Changes in Hepatocellular Carcinoma Tissues Using PCT-SWATH. <i>Proteomics - Clinical Applications</i> , 2019, 13, e1700179.	0.8	32
3276	Hydrodissection of the Retrohepatic Space: A Technique to Physically Separate a Liver Tumour from the Inferior Vena Cava and the Ostia of the Hepatic Veins. <i>CardioVascular and Interventional Radiology</i> , 2019, 42, 137-144.	0.9	4
3277	Role of liver and spleen stiffness in predicting the recurrence of hepatocellular carcinoma after resection. <i>Journal of Hepatology</i> , 2019, 70, 440-448.	1.8	126
3278	New horizons in hepatitis B and C in the older adult. <i>Age and Ageing</i> , 2019, 48, 32-37.	0.7	10
3279	Non-virological factors are drivers of hepatocellular carcinoma in viro-suppressed hepatitis B cirrhosis: Results of ANRS CO12 CirVir cohort. <i>Journal of Viral Hepatitis</i> , 2019, 26, 384-396.	1.0	16
3280	The impact of HCV eradication by direct-acting antivirals on the transition of precancerous hepatic nodules to HCC: A prospective observational study. <i>Liver International</i> , 2019, 39, 448-454.	1.9	26
3281	Comparison of health-related quality of life after transarterial chemoembolization and transarterial radioembolization in patients with unresectable hepatocellular carcinoma. <i>Abdominal Radiology</i> , 2019, 44, 1554-1561.	1.0	21
3282	The present profile of chronic hepatitis B virus infection highlights future challenges. <i>Digestive and Liver Disease</i> , 2019, 51, 438-442.	0.4	17
3283	miRNA-448 inhibits cell growth by targeting BCL-2 in hepatocellular carcinoma. <i>Digestive and Liver Disease</i> , 2019, 51, 703-711.	0.4	25
3284	Hepatocellular carcinoma in acute hepatic porphyrias: A Damocles Sword. <i>Molecular Genetics and Metabolism</i> , 2019, 128, 236-241.	0.5	32
3285	Extent of portal vein tumour thrombosis in patients with hepatocellular carcinoma: The more, the worse?. <i>Liver International</i> , 2019, 39, 324-331.	1.9	55
3286	Serum Metabolites as Diagnostic Biomarkers for Cholangiocarcinoma, Hepatocellular Carcinoma, and Primary Sclerosing Cholangitis. <i>Hepatology</i> , 2019, 70, 547-562.	3.6	112
3287	Circulating exosomal noncoding RNAs as prognostic biomarkers in human hepatocellular carcinoma. <i>International Journal of Cancer</i> , 2019, 144, 1444-1452.	2.3	186
3288	Analgesic-antitumor peptide inhibits angiogenesis by suppressing AKT activation in hepatocellular carcinoma. <i>Molecular and Cellular Biochemistry</i> , 2019, 455, 119-125.	1.4	4

#	ARTICLE	IF	CITATIONS
3289	Liver Cancers. , 2019, , .		2
3290	Benefits of Splenectomy and Curative Treatments for Patients with Hepatocellular Carcinoma and Portal Hypertension: a Retrospective Study. <i>Journal of Gastrointestinal Surgery</i> , 2019, 23, 2151-2162.	0.9	11
3291	Stereotactic Radiofrequency Ablation of Hepatocellular Carcinoma: a Histopathological Study in Explanted Livers. <i>Hepatology</i> , 2019, 70, 840-850.	3.6	61
3292	Histone demethylase KDM3B regulates the transcriptional network of cell-cycle genes in hepatocarcinoma HepG2 cells. <i>Biochemical and Biophysical Research Communications</i> , 2019, 508, 576-582.	1.0	19
3293	Dietary components modulate the risk of hepatocellular carcinoma in cirrhotic patients. <i>Nutrition Research</i> , 2019, 61, 82-94.	1.3	16
3294	Radiation Therapy in HCC: What Data Exist and What Data Do We Need to Incorporate into Guidelines?. <i>Seminars in Liver Disease</i> , 2019, 39, 043-052.	1.8	10
3295	Microporous cellulosic scaffold as a spheroid culture system modulates chemotherapeutic responses and stemness in hepatocellular carcinoma. <i>Journal of Cellular Biochemistry</i> , 2019, 120, 5244-5255.	1.2	6
3296	PNPLA3 and TM6SF2 variants as risk factors of hepatocellular carcinoma across various etiologies and severity of underlying liver diseases. <i>International Journal of Cancer</i> , 2019, 144, 533-544.	2.3	72
3297	Liver Transplantation in Wilson Disease. , 2019, , 391-398.		0
3298	The ALPPS procedure: hepatocellular carcinoma as a main indication. An Italian single-center experience. <i>Updates in Surgery</i> , 2019, 71, 67-75.	0.9	20
3299	Immune inflammation indicators and ALBI score to predict liver cancer in HCV-patients treated with direct-acting antivirals. <i>Digestive and Liver Disease</i> , 2019, 51, 681-688.	0.4	49
3300	Long-term survival comparison between primary transplant and upfront curative treatment with salvage transplant for early stage hepatocellular carcinoma. <i>Asian Journal of Surgery</i> , 2019, 42, 433-442.	0.2	4
3301	The Munich-Transarterial Chemoembolisation Score Holds Superior Prognostic Capacities Compared to TACE-Tailored Modifications of 9 Established Staging Systems for Hepatocellular Carcinoma. <i>Digestion</i> , 2019, 100, 15-26.	1.2	5
3302	Hepatocellular Carcinoma Surveillanceâ€”Experience from Croatian Referral Centre for Chronic Liver Diseases. <i>Journal of Gastrointestinal Cancer</i> , 2019, 50, 48-53.	0.6	0
3303	Low Rates of Retention Into Hepatocellular Carcinoma (HCC) Surveillance Program After Initial HCC Screening. <i>Journal of Clinical Gastroenterology</i> , 2019, 53, 65-70.	1.1	23
3304	Hepatocellular Carcinoma Is Associated With Gut Microbiota Profile and Inflammation in Nonalcoholic Fatty Liver Disease. <i>Hepatology</i> , 2019, 69, 107-120.	3.6	433
3305	Assessment of a highâ€”SNR chemicalâ€”shiftâ€”encoded MRI with complex reconstruction for proton density fat fraction (PDFF) estimation overall and in the lowâ€”fat range. <i>Journal of Magnetic Resonance Imaging</i> , 2019, 49, 229-238.	1.9	9
3306	Clinico-Psychosocial Factors Predicting Hepatocellular Carcinoma Related Knowledge Among Patients with Chronic Liver Disease. <i>Journal of Cancer Education</i> , 2020, 35, 937-945.	0.6	4

#	ARTICLE	IF	CITATIONS
3307	Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy for Unresectable Hepatitis B Virus-related Hepatocellular Carcinoma. <i>Annals of Surgery</i> , 2020, 271, 534-541.	2.1	88
3308	Comparison of FIB-4 Index and Child-Pugh Score in Predicting the Outcome of Hepatic Resection for Hepatocellular Carcinoma. <i>Journal of Gastrointestinal Surgery</i> , 2020, 24, 823-831.	0.9	22
3309	Downstaging unresectable hepatocellular carcinoma by radioembolization using 90-yttrium resin microspheres: a single center experience. <i>Journal of Gastrointestinal Oncology</i> , 2020, 11, 84-90.	0.6	20
3310	Factors to transcatheter arterial chemoembolization Liver Cancer stage C. <i>Minimally Invasive Therapy and Allied Technologies</i> , 2020, 29, 49-55.	0.6	3
3311	The Model to Estimate Survival in Ambulatory Hepatocellular Carcinoma Patients Aids in the Decision for TACE Retreatment. <i>Journal of Clinical Gastroenterology</i> , 2020, 54, 370-377.	1.1	0
3312	C14orf166 Is a Biomarker for Predicting Hepatocellular Carcinoma Recurrence. <i>Journal of Investigative Surgery</i> , 2020, 33, 914-923.	0.6	2
3313	Degradable starch microspheres transarterial chemoembolization (DSMs-TACE) in patients with unresectable hepatocellular carcinoma (HCC): long-term results from a single-center 137-patient cohort prospective study. <i>Radiologia Medica</i> , 2020, 125, 98-106.	4.7	25
3314	Phase angle as a severity indicator for liver diseases. <i>Nutrition</i> , 2020, 70, 110607.	1.1	24
3316	Recent Progress of In Situ Transmission Electron Microscopy for Energy Materials. <i>Advanced Materials</i> , 2020, 32, e1904094.	11.1	59
3317	Feasibility of Yttrium-90 Radioembolization Dose Calculation Utilizing Intra-procedural Open Trajectory Cone Beam CT. <i>CardioVascular and Interventional Radiology</i> , 2020, 43, 295-301.	0.9	10
3318	Hepatic Arterial Bland Embolization Increases Th17 Cell Infiltration in a Syngeneic Rat Model of Hepatocellular Carcinoma. <i>CardioVascular and Interventional Radiology</i> , 2020, 43, 311-321.	0.9	15
3319	Yin Yang Gong Ji pill is an ancient formula with antitumor activity against hepatoma cells. <i>Journal of Ethnopharmacology</i> , 2020, 248, 112267.	2.0	5
3320	Prognostic Analysis of Hepatocellular Carcinoma With Hepatitis C Virus Infection Using Epithelial-Mesenchymal Transition Gene Profiles. <i>Journal of Surgical Research</i> , 2020, 245, 302-308.	0.8	3
3321	Impact of Surveillance in Chronic Hepatitis B Patients on Long-Term Outcomes After Curative Liver Resection for Hepatocellular Carcinoma. <i>Journal of Gastrointestinal Surgery</i> , 2020, 24, 1987-1995.	0.9	3
3322	Outcomes of Non-B Non-C Hepatocellular Carcinoma with Reference to Patients with Interferon-Induced Hepatitis C Virus Eradication. <i>Journal of Gastrointestinal Surgery</i> , 2020, 24, 1809-1817.	0.9	3
3323	Efficacy of transarterial chemoembolization compared with radiofrequency ablation for the treatment of recurrent hepatocellular carcinoma after radiofrequency ablation. <i>Minimally Invasive Therapy and Allied Technologies</i> , 2020, 29, 344-352.	0.6	5
3324	Hepatocellular metastasis recurrence in liver transplant after treatment with direct antiviral agents. <i>Clinical Journal of Gastroenterology</i> , 2020, 13, 260-266.	0.4	1
3325	Hepatobiliary Diseases. , 2020, , 27-33.		0

#	ARTICLE	IF	CITATIONS
3326	Dynamic CT angiography for therapy evaluation after transarterial chemoembolization of hepatocellular carcinoma. <i>Acta Radiologica</i> , 2020, 61, 148-155.	0.5	0
3327	Sequence and Observer Variability in Gadoteric Acid-Enhanced MRI Lesion Measurements in Hepatocellular Carcinoma. <i>Academic Radiology</i> , 2020, 27, e64-e71.	1.3	1
3328	Prevalence and clinical significance of discordant LI-RADS® observations on multiphase contrast-enhanced MRI in patients with cirrhosis. <i>Abdominal Radiology</i> , 2020, 45, 177-187.	1.0	10
3329	C1GALT1C1/COSMC is a novel prognostic biomarker for hepatocellular carcinoma. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2020, 44, 310-320.	0.7	2
3330	Clinical evaluation of in silico planning and real-time simulation of hepatic radiofrequency ablation (ClinicIMPACT Trial). <i>European Radiology</i> , 2020, 30, 934-942.	2.3	10
3331	Predicting Hepatocellular Carcinoma Recurrence Beyond Milan Criteria After Liver Resection for Solitary Hepatocellular Carcinoma. <i>Journal of Gastrointestinal Surgery</i> , 2020, 24, 2219-2227.	0.9	15
3332	Circulating hematopoietic stem cells, endothelial progenitor cells and cancer stem cells in hepatocellular carcinoma patients: contribution to diagnosis and prognosis. <i>Acta Oncologica</i> , 2020, 59, 33-39.	0.8	21
3333	Feasibility, safety, and long-term efficacy of stereotactic radiofrequency ablation for tumors adjacent to the diaphragm in the hepatic dome: a case-control study. <i>European Radiology</i> , 2020, 30, 950-960.	2.3	16
3334	Impact of sustained virological response with DAAs on gastroesophageal varices and Baveno criteria in HCV cirrhotic patients. <i>Journal of Gastroenterology</i> , 2020, 55, 205-216.	2.3	19
3335	Transarterial Chemoembolization of Hepatocellular Carcinoma: Propensity Score Matching Study Comparing Survival and Complications in Patients with Nonalcoholic Steatohepatitis Versus Other Causes Cirrhosis. <i>CardioVascular and Interventional Radiology</i> , 2020, 43, 65-75.	0.9	7
3336	Improved Local Tumor Control and Survival Rates by Obtaining a 3D-Safety Margin in Superselective Transarterial Chemoembolization for Small Hepatocellular Carcinoma. <i>CardioVascular and Interventional Radiology</i> , 2020, 43, 423-433.	0.9	9
3337	REFLECT® a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset. <i>Journal of Gastroenterology</i> , 2020, 55, 113-122.	2.3	123
3338	A novel treatment strategy using indocyanine green for transarterial chemoembolization in BCLC stage C hepatocellular carcinoma. <i>Cancer Medicine</i> , 2020, 9, 62-76.	1.3	8
3339	MRI-guided targeted needle placement during motion using hydrostatic actuators. <i>International Journal of Medical Robotics and Computer Assisted Surgery</i> , 2020, 16, e2041.	1.2	6
3340	Validation of the CAMD Score in Patients With Chronic Hepatitis B Virus Infection Receiving Antiviral Therapy. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 693-699.e1.	2.4	24
3341	No-Touch Multi-bipolar Radiofrequency Ablation for the Treatment of Subcapsular Hepatocellular Carcinoma Not Puncturable via the Non-tumorous Liver Parenchyma. <i>CardioVascular and Interventional Radiology</i> , 2020, 43, 273-283.	0.9	23
3342	Diagnostic performance of a minimized protocol of non-contrast MRI for hepatocellular carcinoma surveillance. <i>Abdominal Radiology</i> , 2020, 45, 211-219.	1.0	15
3343	Veliparib overcomes multidrug resistance in liver cancer cells. <i>Biochemical and Biophysical Research Communications</i> , 2020, 521, 596-602.	1.0	6

#	ARTICLE	IF	CITATIONS
3344	Validation of the Liver Imaging Reporting and Data System Treatment Response Criteria After Thermal Ablation for Hepatocellular Carcinoma. <i>Liver Transplantation</i> , 2020, 26, 203-214.	1.3	26
3345	GALAD Score Detects Early Hepatocellular Carcinoma in an International Cohort of Patients With Nonalcoholic Steatohepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 728-735.e4.	2.4	167
3346	CT-Based Hepatic Residual Volume and Predictors of Outcomes of Patients with Hepatocellular Carcinoma Unsuited for Surgical Therapy Undergoing Transarterial Chemoembolization. <i>Academic Radiology</i> , 2020, 27, 807-814.	1.3	4
3347	Value of contrast-enhanced ultrasound (CEUS) in Focal Liver Lesions (FLL) with inconclusive findings on cross-sectional imaging. <i>Clinical Hemorheology and Microcirculation</i> , 2020, 74, 327-339.	0.9	17
3348	Safety and efficacy of lenvatinib in elderly patients with unresectable hepatocellular carcinoma: A multicenter analysis with propensity score matching. <i>Hepatology Research</i> , 2020, 50, 75-83.	1.8	44
3349	Comparisons of recurrence-free survival and overall survival between microwave versus radiofrequency ablation treatment for hepatocellular carcinoma: A multiple centers retrospective cohort study with propensity score matching. <i>PLoS ONE</i> , 2020, 15, e0227242.	1.1	10
3350	Therapeutic Endoscopic Ultrasound. , 2020, , .		4
3351	Precision pathology analysis of the development and progression of hepatocellular carcinoma: Implication for precision diagnosis of hepatocellular carcinoma. <i>Pathology International</i> , 2020, 70, 140-154.	0.6	7
3352	Impact of cirrhosis in patients undergoing laparoscopic liver resection in a nationwide multicentre survey. <i>British Journal of Surgery</i> , 2020, 107, 268-277.	0.1	46
3353	Intra-procedural dual phase cone beam computed tomography has a better diagnostic accuracy over pre-procedural MRI and MDCT in detection and characterization of HCC in cirrhotic patients undergoing TACE procedure. <i>European Journal of Radiology</i> , 2020, 124, 108806.	1.2	13
3354	Using circulating tumor DNA as a novel biomarker to screen and diagnose hepatocellular carcinoma: A systematic review and meta-analysis. <i>Cancer Medicine</i> , 2020, 9, 1349-1364.	1.3	30
3355	Assessment of tumor volume and density as a measure of the response of advanced hepatocellular carcinoma to sorafenib: Application of automated measurements on computed tomography scans. <i>JGH Open</i> , 2020, 4, 145-152.	0.7	4
3356	Comparative analysis of outcomes after liver resection and liver transplantation for early stages hepatocellular carcinoma in HIV-infected patients. An intention-to-treat analysis. <i>Hpb</i> , 2020, 22, 900-910.	0.1	0
3357	Nomogram based on inflammatory indices for differentiating intrahepatic cholangiocarcinoma from hepatocellular carcinoma. <i>Cancer Medicine</i> , 2020, 9, 1451-1461.	1.3	20
3358	Is laparoscopic liver resection suitable for selected patients with BCLC stage B HCC? A propensity score-matched analysis. <i>Hpb</i> , 2020, 22, 595-602.	0.1	5
3359	Subgroup analysis of the predictive ability of aspartate aminotransferase to platelet ratio index (APRI) and fibrosis-4 (FIB-4) for assessing hepatic fibrosis among patients with chronic hepatitis C. <i>Journal of Microbiology, Immunology and Infection</i> , 2020, 53, 542-549.	1.5	13
3360	Percutaneous thermal ablation of subcapsular hepatocellular carcinomas: influence of tumor-surface contact and protrusion on therapeutic efficacy and safety. <i>European Radiology</i> , 2020, 30, 1813-1821.	2.3	17
3361	Role of Biomarkers in Guiding Cure of Viral Hepatitis B. <i>Seminars in Liver Disease</i> , 2020, 40, 049-060.	1.8	13

#	ARTICLE	IF	CITATIONS
3362	Targeting adenosinergic pathway enhances the anti-tumor efficacy of sorafenib in hepatocellular carcinoma. <i>Hepatology International</i> , 2020, 14, 80-95.	1.9	15
3363	Indicator for local recurrence of hepatocellular carcinoma after proton beam therapy: analysis of attenuation difference between the irradiated tumor and liver parenchyma on contrast enhancement CT. <i>British Journal of Radiology</i> , 2020, 93, 20190375.	1.0	2
3364	A large real-world cohort study examining the effects of long-term entecavir on hepatocellular carcinoma and HBsAg seroclearance. <i>Journal of Viral Hepatitis</i> , 2020, 27, 397-406.	1.0	16
3365	Candidate lncRNA-miRNA-mRNA network in predicting hepatocarcinogenesis with cirrhosis: an integrated bioinformatics analysis. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 87-96.	1.2	33
3366	Long-term Effects of Repeat Hepatectomy vs Percutaneous Radiofrequency Ablation Among Patients With Recurrent Hepatocellular Carcinoma. <i>JAMA Oncology</i> , 2020, 6, 255.	3.4	120
3367	Neutrophil-lymphocyte ratio predicts the therapeutic benefit of neoadjuvant transarterial chemoembolization in patients with resectable hepatocellular carcinoma. <i>European Journal of Gastroenterology and Hepatology</i> , 2020, 32, 1186-1191.	0.8	5
3368	Paper Alert. <i>European Journal of Gastroenterology and Hepatology</i> , 2019, 31, 1295-1298.	0.8	14
3369	Comparison of feature selection in radiomics for the prediction of overall survival after radiotherapy for hepatocellular carcinoma. , 2020, 2020, 1667-1670.		3
3370	Evaluation of the Combined Application of AFP, AFP-L3%, and DCP for Hepatocellular Carcinoma Diagnosis: A Meta-analysis. <i>BioMed Research International</i> , 2020, 2020, 1-10.	0.9	22
3371	Upregulation of Serum Sphingosine (d18:1)-1-P Potentially Contributes to Distinguish HCC Including AFP-Negative HCC From Cirrhosis. <i>Frontiers in Oncology</i> , 2020, 10, 1759.	1.3	9
3372	Novel Model to Predict HCC Recurrence after Liver Transplantation Obtained Using Deep Learning: A Multicenter Study. <i>Cancers</i> , 2020, 12, 2791.	1.7	25
3373	Downstaging to Liver Transplant. <i>Clinics in Liver Disease</i> , 2020, 24, 665-679.	1.0	0
3374	Hepatic Decompensation in Cirrhotic Patients Receiving Antiviral Therapy for Chronic Hepatitis B. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1950-1958.e7.	2.4	18
3375	Virtual navigation-guided radiofrequency ablation for recurrent hepatocellular carcinoma invisible on ultrasound after hepatic resection. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2020, 19, 532-540.	0.6	4
3376	The use of minimally invasive biomarkers for the diagnosis and prognosis of hepatocellular carcinoma. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2020, 1874, 188451.	3.3	36
3377	Liver Resection for Early Hepatocellular Carcinoma. <i>Annals of Surgery</i> , 2020, 272, 820-826.	2.1	19
3378	Angiotensin Receptor 1 Blockers Prolong Time to Recurrence after Radiofrequency Ablation in Hepatocellular Carcinoma patients: A Retrospective Study. <i>Biomedicines</i> , 2020, 8, 399.	1.4	7
3379	Feasibility and clinical value of TIPS combined with subsequent antitumor treatment in HCC patients with refractory ascites. <i>Translational Oncology</i> , 2020, 13, 100864.	1.7	7

#	ARTICLE	IF	CITATIONS
3380	Provider Attitudes Toward Risk-Based Hepatocellular Carcinoma Surveillance in Patients With Cirrhosis in the United States. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 183-193.	2.4	15
3381	Efficacy and Safety of Transarterial Chemoembolization Combined With Anlotinib for Unresectable Hepatocellular Carcinoma: A Retrospective Study. <i>Technology in Cancer Research and Treatment</i> , 2020, 19, 153303382096558.	0.8	13
3382	Mitochondrial apurinic/apyrimidinic endonuclease 1 enhances mtDNA repair contributing to cell proliferation and mitochondrial integrity in early stages of hepatocellular carcinoma. <i>BMC Cancer</i> , 2020, 20, 969.	1.1	15
3384	Development and Assessment of Novel Predictive Nomograms Based on APRI for Hepatitis B Virus-associated Small Solitary Hepatocellular Carcinoma with Stereotactic Body Radiotherapy. <i>Journal of Cancer</i> , 2020, 11, 6642-6652.	1.2	6
3386	Can LI-RADS imaging features at gadoxetic acid-enhanced MRI predict aggressive features on pathology of single hepatocellular carcinoma?. <i>European Journal of Radiology</i> , 2020, 132, 109312.	1.2	34
3387	Limitation of non-transplant treatment and proper timing for liver transplantation in patients with hepatocellular carcinoma considering long-term survival. <i>Medicine (United States)</i> , 2020, 99, e21161.	0.4	3
3388	Liver transplantation for hepatocellular carcinoma after successful treatment of macrovascular invasion – a multi-center retrospective cohort study. <i>Transplant International</i> , 2020, 33, 567-575.	0.8	44
3389	Novel Models Predict Postsurgical Recurrence and Overall Survival for Patients with Hepatitis B Virus-Related Solitary Hepatocellular Carcinoma ≤10 cm and Without Portal Venous Tumor Thrombus. <i>Oncologist</i> , 2020, 25, e1552-e1561.	1.9	13
3390	Advances in the early diagnosis of hepatocellular carcinoma. <i>Genes and Diseases</i> , 2020, 7, 308-319.	1.5	189
3391	Abbreviated Magnetic Resonance Imaging Protocols in the Abdomen and Pelvis. <i>Magnetic Resonance Imaging Clinics of North America</i> , 2020, 28, 381-394.	0.6	2
3392	Radiofrequency and microwave ablation in a porcine liver model: non-contrast CT and ultrasound radiologic-pathologic correlation. <i>International Journal of Hyperthermia</i> , 2020, 37, 799-807.	1.1	10
3393	Synchronous Hepatocellular Carcinoma in a Patient with Primary Gastric Cancer: An Exceptional Association. <i>Case Reports in Gastroenterology</i> , 2020, 14, 299-305.	0.3	1
3394	The alpha-fetoprotein serum is still reliable as a biomarker for the surveillance of hepatocellular carcinoma in Indonesia. <i>BMC Gastroenterology</i> , 2020, 20, 215.	0.8	18
3395	Predictor of outcome after living donor liver transplantation for patients with hepatocellular carcinoma beyond the Japan criteria. <i>Annals of Gastroenterological Surgery</i> , 2020, 4, 413-421.	1.2	5
3396	A Telephone and Mail Outreach Program Successfully Increases Uptake of Hepatocellular Carcinoma Surveillance. <i>Hepatology Communications</i> , 2020, 4, 825-833.	2.0	11
3397	OPN is a promising serological biomarker for hepatocellular carcinoma diagnosis. <i>Journal of Medical Virology</i> , 2020, 92, 3596-3603.	2.5	28
3398	Incidence of HCC recurrence after DAA treatment for HCV in a multicentre Italian cohort study. <i>Liver Cancer International</i> , 2020, 1, 12-24.	0.2	2
3399	Clinical and contrast-enhanced image features in the prediction model for the detection of small hepatocellular carcinomas. <i>Journal of Cancer</i> , 2020, 11, 7166-7175.	1.2	3

#	ARTICLE	IF	CITATIONS
3400	Treatment of Barcelona Clinic Liver Cancer Stage C hepatocellular carcinoma: liver resection versus TACE and beyond. <i>Annals of Translational Medicine</i> , 2020, 8, 1209-1209.	0.7	0
3401	Prognostic significance of controlling nutritional status score- based nomogram for hepatocellular carcinoma within Milan criteria after radiofrequency ablation. <i>Journal of Gastrointestinal Oncology</i> , 2020, 11, 1024-1039.	0.6	10
3402	Serum Myostatin Predicts the Risk of Hepatocellular Carcinoma in Patients with Alcoholic Cirrhosis: A Multicenter Study. <i>Cancers</i> , 2020, 12, 3347.	1.7	9
3403	Alteration of contrast enhanced ultrasound (CEUS) of hepatocellular carcinoma in patients with cirrhosis and transjugular intrahepatic portosystemic shunt (TIPS). <i>Scientific Reports</i> , 2020, 10, 20682.	1.6	7
3404	Real Life Prospective Evaluation of New Drug-Eluting Platform for Chemoembolization of Patients with Hepatocellular Carcinoma: PARIS Registry. <i>Cancers</i> , 2020, 12, 3405.	1.7	10
3405	Periostin Circulating Levels and Genetic Variants in Patients with Non-Alcoholic Fatty Liver Disease. <i>Diagnostics</i> , 2020, 10, 1003.	1.3	0
3406	Radioembolizaci3n de hepatocarcinomas: a prop3sito de 53 casos. <i>Radiologia</i> , 2020, , .	0.3	0
3407	A radiomics nomogram for the prediction of overall survival in patients with hepatocellular carcinoma after hepatectomy. <i>Cancer Imaging</i> , 2020, 20, 82.	1.2	33
3408	Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline. <i>Journal of Clinical Oncology</i> , 2020, 38, 4317-4345.	0.8	350
3409	Targeted Inhibition of Purine Metabolism Is Effective in Suppressing Hepatocellular Carcinoma Progression. <i>Hepatology Communications</i> , 2020, 4, 1362-1381.	2.0	22
3410	Sorafenib Plus Hepatic Arterial Infusion Chemotherapy in Advanced Hepatocellular Carcinoma. <i>Journal of Clinical Gastroenterology</i> , 2020, 54, 675-681.	1.1	10
3411	A novel application of drug-eluting transarterial chemoembolization in treating non-liver cancers. <i>Medicine (United States)</i> , 2020, 99, e20878.	0.4	2
3412	Serum Vitamin D Levels and Risk of Liver Cancer: A Systematic Review and Dose-Response Meta-Analysis of Cohort Studies. <i>Nutrition and Cancer</i> , 2021, 73, 1-9.	0.9	44
3413	Child-Pugh, MELD, MELD-Na, and ALBI scores: which liver function models best predicts prognosis for HCC patient with ascites?. <i>Scandinavian Journal of Gastroenterology</i> , 2020, 55, 951-957.	0.6	15
3414	Preoperative Imaging Characteristics in Histology-Proven Resected Intrahepatic Cholangiocarcinoma. <i>World Journal of Surgery</i> , 2020, 44, 3862-3867.	0.8	3
3415	Is transcatheter arterial chemoembolization plus sorafenib better than chemoembolization plus placebo in the treatment of hepatocellular carcinoma?. <i>Tumori</i> , 2021, 107, 292-303.	0.6	5
3416	Long-Term Survival Analysis of Transarterial Chemoembolization Plus Radiotherapy vs. Radiotherapy for Hepatocellular Carcinoma With Macroscopic Vascular Invasion. <i>Frontiers in Oncology</i> , 2020, 10, 1205.	1.3	8
3417	Embolotherapy for Hepatic Oncology: Current Perspectives and Future Directions. <i>Digestive Disease Interventions</i> , 2020, 04, 134-147.	0.3	3

#	ARTICLE	IF	CITATIONS
3418	Clinical impact of sarcopenia assessment in patients with hepatocellular carcinoma undergoing treatments. <i>Journal of Gastroenterology</i> , 2020, 55, 927-943.	2.3	70
3419	Ultrasound Liver Imaging Reporting and Data System (US LI-RADS): An Overview with Technical and Practical Applications. <i>Academic Radiology</i> , 2021, 28, 1464-1476.	1.3	11
3420	Advances in the treatment of hepatocellular carcinoma using drug-eluting beads. <i>Journal of Interventional Medicine</i> , 2020, 3, 122-127.	0.2	4
3421	Apatinib treatment may improve survival outcomes of patients with hepatitis B virus-related sorafenib-resistant hepatocellular carcinoma. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592093742.	1.4	9
3422	Predictors of outcome after liver transplantation for hepatocellular carcinoma (HCC) beyond Milan criteria. <i>International Journal of Surgery</i> , 2020, 82, 61-69.	1.1	15
3423	Contemporary Techniques and Applications of Radioembolization in Patients with Hepatocellular Carcinoma. <i>Advances in Clinical Radiology</i> , 2020, 2, 113-125.	0.1	2
3424	Iodine-125 seed implantation for residual hepatocellular carcinoma or cholangiocellular carcinoma in challenging locations after transcatheter arterial chemoembolization. Initial experience and findings. <i>Journal of Contemporary Brachytherapy</i> , 2020, 12, 233-240.	0.4	4
3425	Classification of hepatocellular carcinoma and intrahepatic cholangiocarcinoma based on multi-phase CT scans. <i>Medical and Biological Engineering and Computing</i> , 2020, 58, 2497-2515.	1.6	29
3426	NRF2 Dysregulation in Hepatocellular Carcinoma and Ischemia: A Cohort Study and Laboratory Investigation. <i>Radiology</i> , 2020, 297, 225-234.	3.6	15
3427	A Comparison of Biannual Two-Phase Low-Dose Liver CT and US for HCC Surveillance in a Group at High Risk of HCC Development. <i>Liver Cancer</i> , 2020, 9, 503-517.	4.2	40
3428	TERT promoter mutated circulating tumor DNA as a biomarker for prognosis in hepatocellular carcinoma. <i>Scandinavian Journal of Gastroenterology</i> , 2020, 55, 1433-1440.	0.6	28
3429	Variation in textural parameters of hepatic lesions during contrast medium injection. <i>Acta Radiologica</i> , 2021, 62, 1317-1323.	0.5	1
3430	The utility of ^{99m} Tc-mebrofenin hepatobiliary scintigraphy with SPECT/CT for selective internal radiation therapy in hepatocellular carcinoma. <i>Nuclear Medicine Communications</i> , 2020, 41, 740-749.	0.5	8
3431	Epidemiology, clinical treatment patterns, and survival of hepatocellular carcinoma in Manitoba. <i>Canadian Liver Journal</i> , 2020, 3, 194-202.	0.3	2
3432	Super-selective transarterial chemoembolization of hepatocellular carcinoma with doxorubicin-eluting beads sized 40-75 microns: assessment of efficacy and safety. <i>Diagnostic and Interventional Radiology</i> , 2020, 26, 482-487.	0.7	5
3433	Transarterial Chemoembolization Combined with Sorafenib in Patients with BCLC Stage C Hepatocellular Carcinoma. <i>Drug Design, Development and Therapy</i> , 2020, Volume 14, 3461-3468.	2.0	17
3434	Quality of life analysis after stereotactic radiofrequency ablation of liver tumors. <i>Scientific Reports</i> , 2020, 10, 12809.	1.6	2
3435	TACE-Sorafenib With Thermal Ablation Has Survival Benefits in Patients With Huge Unresectable Hepatocellular Carcinoma. <i>Frontiers in Pharmacology</i> , 2020, 11, 1130.	1.6	7

#	ARTICLE	IF	CITATIONS
3436	Stereotactic body radiotherapy versus hepatic resection for hepatocellular carcinoma (a propensity score analysis. <i>Hepatology International</i> , 2020, 14, 788-797.	1.9	19
3437	Breath Biopsy Assessment of Liver Disease Using an Exogenous Volatile Organic Compound Toward Improved Detection of Liver Impairment. <i>Clinical and Translational Gastroenterology</i> , 2020, 11, e00239.	1.3	34
3438	Comparison on the efficacy and prognosis of different strategies for intrahepatic recurrent hepatocellular carcinoma: A systematic review and Bayesian network meta-analysis. <i>International Journal of Surgery</i> , 2020, 83, 196-204.	1.1	31
3440	Challenges of BCLC stage C hepatocellular carcinoma. <i>Medicine (United States)</i> , 2020, 99, e21561.	0.4	2
3441	Ascitic Calprotectin as an early predictor of hepatocellular carcinoma in patients with cirrhotic ascites. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 3207-3214.	1.2	2
3442	A multicentre study of trends in hepatitis B virus-related hepatocellular carcinoma risk over time during long-term entecavir therapy. <i>Journal of Viral Hepatitis</i> , 2020, 27, 1352-1358.	1.0	7
3443	Continued value of the serum alpha-fetoprotein test in surveilling at-risk populations for hepatocellular carcinoma. <i>PLoS ONE</i> , 2020, 15, e0238078.	1.1	1
3444	Epidemiological and Clinical Patterns of Newly Diagnosed Hepatocellular Carcinoma in Brazil: the Need for Liver Disease Screening Programs Based on Real-World Data. <i>Journal of Gastrointestinal Cancer</i> , 2021, 52, 952-958.	0.6	11
3445	Sedation and Analgesia for Liver Cancer Percutaneous Radiofrequency Ablation: Fentanyl and Oxycodone Comparison. <i>International Journal of Medical Sciences</i> , 2020, 17, 2194-2199.	1.1	4
3446	Association between objective response rate and overall survival in metastatic neuroendocrine tumors treated with radioembolization: a systematic literature review and regression analysis. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 997-1009.	1.1	4
3447	The Prognostic Value of Inflammation Factors in Hepatocellular Carcinoma Patients with Hepatic Artery Interventional Treatments: A Retrospective Study. <i>Cancer Management and Research</i> , 2020, Volume 12, 7173-7188.	0.9	15
3448	Prognostic value of vascular endothelial growth factor in both conventional and drug eluting beads transarterial chemoembolization for treatment of unresectable hepatocellular carcinoma in HCV patients. <i>Expert Review of Gastroenterology and Hepatology</i> , 2020, 14, 1203-1214.	1.4	16
3449	SIRT Compared with DEB-TACE for Hepatocellular Carcinoma: a Real-world Study (the SITAR Study). <i>Journal of Gastrointestinal Cancer</i> , 2021, 52, 907-914.	0.6	6
3450	Evaluating the role of transient elastography post chronic hepatitis C treatment to predict hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2020, 73, 1287-1289.	1.8	2
3451	Clinical impact of Hypofractionated carbon ion radiotherapy on locally advanced hepatocellular carcinoma. <i>Radiation Oncology</i> , 2020, 15, 195.	1.2	14
3452	Liver resection of hepatocellular carcinoma within and beyond the Barcelona Clinic Liver Cancer guideline recommendations: Results from a high-volume liver surgery center in East Asia. <i>Journal of Surgical Oncology</i> , 2020, 122, 1587-1594.	0.8	16
3453	Hypermethylation of SCAND3 and Myo1g Gene Are Potential Diagnostic Biomarkers for Hepatocellular Carcinoma. <i>Cancers</i> , 2020, 12, 2332.	1.7	8
3454	Prognostic Nomogram for Patients with Hepatocellular Carcinoma After Thermal Ablation. <i>CardioVascular and Interventional Radiology</i> , 2020, 43, 1621-1630.	0.9	7

#	ARTICLE	IF	CITATIONS
3455	Bevacizumab Augments the Antitumor Efficacy of Infigratinib in Hepatocellular Carcinoma. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9405.	1.8	9
3456	Survival benefits from adjuvant transcatheter arterial chemoembolization in patients undergoing liver resection for hepatocellular carcinoma: a systematic review and meta-analysis. <i>Therapeutic Advances in Gastroenterology</i> , 2020, 13, 175628482097769.	1.4	25
3457	A Prospective Phase II Study Evaluating Intraoperative Electrochemotherapy of Hepatocellular Carcinoma. <i>Cancers</i> , 2020, 12, 3778.	1.7	22
3458	The CD68+ macrophages to CD8+ T-cell ratio is associated with clinical outcomes in hepatitis B virus (HBV)-related hepatocellular carcinoma. <i>Hpb</i> , 2021, 23, 1061-1071.	0.1	12
3459	Circulating Exosomal MicroRNA-1307-5p as a Predictor for Metastasis in Patients with Hepatocellular Carcinoma. <i>Cancers</i> , 2020, 12, 3819.	1.7	19
3460	Efficacy and biomarker analysis of CD133-directed CAR T cells in advanced hepatocellular carcinoma: a single-arm, open-label, phase II trial. <i>Oncolmmunology</i> , 2020, 9, 1846926.	2.1	74
3461	Hepatocellular carcinoma clinical update: Current standards and therapeutic strategies. <i>Liver Research</i> , 2020, 4, 180-190.	0.5	6
3462	<p></p>Timing of DAA Initiation After Curative Treatment and Its Relationship with the Recurrence of HCV-Related HCC</p>. <i>Journal of Hepatocellular Carcinoma</i> , 2020, Volume 7, 347-360.	1.8	9
3463	Percutaneous Radiofrequency Ablation With a Multiple-Electrode Switching System for Medium-Sized Hepatocellular Carcinomas. <i>International Surgery</i> , 2021, 105, 489-496.	0.0	0
3464	Response assessment of hepatocellular carcinoma treated with yttrium-90 radioembolization: inter-reader variability, comparison with 3D quantitative approach, and role in the prediction of clinical outcomes. <i>European Journal of Radiology</i> , 2020, 133, 109351.	1.2	8
3465	Management of patients with intermediate stage hepatocellular carcinoma. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592097084.	1.4	25
3466	Efficacy and safety of percutaneous microwave ablation for hepatocellular carcinomas <4 cm in difficult location. <i>British Journal of Radiology</i> , 2020, 93, 20191025.	1.0	9
3467	Recent Updates of Transarterial Chemoembolization in Hepatocellular Carcinoma. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8165.	1.8	147
3468	The Real Impact of Bridging or Downstaging on Survival Outcomes after Liver Transplantation for Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2020, 9, 721-733.	4.2	15
3469	Effects of general anesthesia versus local anesthesia in primary hepatocellular carcinoma patients presenting for thermal ablation surgery: a multiple center retrospective cohort study with propensity score matching. <i>Annals of Translational Medicine</i> , 2020, 8, 277-277.	0.7	8
3470	NEMESIS: Noninferiority, Individual-Patient Metaanalysis of Selective Internal Radiation Therapy with ⁹⁰Y Resin Microspheres Versus Sorafenib in Advanced Hepatocellular Carcinoma. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1736-1742.	2.8	27
3471	<p></p>Long-Term Survival in Patients Receiving Combination Therapy with Resection and Radiofrequency Ablation for Multi-Focal Hepatocellular Carcinoma Classified as Barcelona Clinic Liver Cancer Stage B: A Retrospective Controlled Study</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 2613-2621.	0.9	3
3472	Comparison of albumin-bilirubin grade versus Child-Pugh score in predicting the outcome of transarterial chemoembolization for hepatocellular carcinoma using time-dependent ROC. <i>Annals of Translational Medicine</i> , 2020, 8, 538-538.	0.7	13

#	ARTICLE	IF	CITATIONS
3473	The diagnostic value of the combination of Golgi protein 73, glypican-3 and alpha-fetoprotein in hepatocellular carcinoma: a diagnostic meta-analysis. <i>Annals of Translational Medicine</i> , 2020, 8, 536-536.	0.7	27
3474	A reduction and pH dual-sensitive nanodrug for targeted theranostics in hepatocellular carcinoma. <i>Biomaterials Science</i> , 2020, 8, 3485-3499.	2.6	30
3475	Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictors of tumor response in hepatocellular carcinoma after DEB-TACE. <i>European Radiology</i> , 2020, 30, 5663-5673.	2.3	62
3476	<p>Angiogenesis in Hepatocellular Carcinoma; Pathophysiology, Targeted Therapy, and Role of Imaging</p>. <i>Journal of Hepatocellular Carcinoma</i> , 2020, Volume 7, 77-89.	1.8	44
3477	Combined hepatocellular-cholangiocarcinoma: which preoperative clinical data and conventional MRI characteristics have value for the prediction of microvascular invasion and clinical significance?. <i>European Radiology</i> , 2020, 30, 5337-5347.	2.3	35
3478	CircZNF609 enhances hepatocellular carcinoma cell proliferation, metastasis, and stemness by activating the Hedgehog pathway through the regulation of miR-15a-5p/15b-5p and GLI2 expressions. <i>Cell Death and Disease</i> , 2020, 11, 358.	2.7	48
3479	Perioperative blood transfusion has distinct postsurgical oncologic impact on patients with different stage of hepatocellular carcinoma. <i>BMC Cancer</i> , 2020, 20, 487.	1.1	11
3480	The Comprehensive Analysis of Efficacy and Safety of CalliSpheres [®] Drug-Eluting Beads Transarterial Chemoembolization in 367 Liver Cancer Patients: A Multiple-Center, Cohort Study. <i>Oncology Research</i> , 2020, 28, 249-271.	0.6	20
3481	Liver fibrosis is a major risk factor for liver regeneration. <i>Medicine (United States)</i> , 2020, 99, e20003.	0.4	12
3482	The Different Effects of Nucleotide and Nucleoside Analogues on the Prognosis of HBV-Related HCC After Curative Resection. <i>Journal of Gastrointestinal Surgery</i> , 2021, 25, 1419-1429.	0.9	5
3483	The neutrophil-to-lymphocyte ratio is a predictive factor for the survival of patients with hepatocellular carcinoma undergoing transarterial chemoembolization. <i>Annals of Translational Medicine</i> , 2020, 8, 541-541.	0.7	18
3484	Prognostic value of the albumin-bilirubin grade in patients with hepatocellular carcinoma and other liver diseases. <i>Annals of Translational Medicine</i> , 2020, 8, 553-553.	0.7	37
3485	Comparison between Child-Pugh score and Albumin-Bilirubin grade in the prognosis of patients with HCC after liver resection using time-dependent ROC. <i>Annals of Translational Medicine</i> , 2020, 8, 539-539.	0.7	25
3486	Percutaneous Intraductal Microwave Ablation of Malignant Biliary Strictures: Initial Experience. <i>American Journal of Roentgenology</i> , 2020, 215, 753-759.	1.0	7
3487	Autophagy inhibition by reversine and its suppressive effects on human hepatocellular carcinoma cells. <i>Biochemical and Biophysical Research Communications</i> , 2020, 528, 105-111.	1.0	6
3488	Long term outcomes of stereotactic body radiation therapy for hepatocellular carcinoma without macrovascular invasion. <i>European Journal of Cancer</i> , 2020, 134, 41-51.	1.3	46
3489	Locoregional Therapy Protocols With and Without Radioembolization for Hepatocellular Carcinoma as Bridge to Liver Transplantation. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2020, 43, 325-333.	0.6	15
3490	Bis-benzylidene Piperidone RA190 treatment of hepatocellular carcinoma via binding RPN13 and inhibiting NF- κ B signaling. <i>BMC Cancer</i> , 2020, 20, 386.	1.1	13

#	ARTICLE	IF	CITATIONS
3491	A Predictive Model Using N-Glycan Biosignatures for Clinical Diagnosis of Early Hepatocellular Carcinoma Related to Hepatitis B Virus. <i>OMICS A Journal of Integrative Biology</i> , 2020, 24, 415-423.	1.0	9
3492	ACR Appropriateness Criteria® Chronic Liver Disease. <i>Journal of the American College of Radiology</i> , 2020, 17, S70-S80.	0.9	12
3493	Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B. <i>Journal of Hepatology</i> , 2020, 73, 1037-1045.	1.8	69
3494	The blooming intersection of transcatheter hepatic artery chemoembolization and nanomedicine. <i>Chinese Chemical Letters</i> , 2020, 31, 1375-1381.	4.8	12
3495	Identifying optimal candidates of transarterial chemoembolization (TACE) vs. sorafenib in patients with unresectable hepatocellular carcinoma. <i>Annals of Translational Medicine</i> , 2020, 8, 587-587.	0.7	6
3496	Identifying optimal candidates for liver resection or transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma. <i>Annals of Translational Medicine</i> , 2020, 8, 586-586.	0.7	6
3497	<i>LHPP</i> inhibits hepatocellular carcinoma cell growth and metastasis. <i>Cell Cycle</i> , 2020, 19, 1846-1854.	1.3	14
3498	Understanding fundamentals of hepatocellular carcinoma to design next-generation chitosan nano-formulations: Beyond chemotherapy stride. <i>Journal of Drug Delivery Science and Technology</i> , 2020, 58, 101723.	1.4	0
3499	Effects of oxymatrine on the proliferation of human liver cancer Bel-7404 cells. <i>Medicine (United States)</i> , 2020, 99, e20321.	0.4	5
3500	Treatment of solitary hepatocellular carcinoma up to 2 cm. <i>Medicine (United States)</i> , 2020, 99, e20321.	0.4	5
3501	Immune Checkpoint Inhibitors in Hepatocellular Cancer: Current Understanding on Mechanisms of Resistance and Biomarkers of Response to Treatment. <i>Gene Expression</i> , 2020, 20, 53-65.	0.5	65
3502	Diagnostic value of glypican-3, arginase-1 and hepatocyte paraffin antigen -1 in differentiating hepatocellular carcinoma from intrahepatic cholangiocarcinoma. <i>Translational Cancer Research</i> , 2020, 9, 128-136.	0.4	2
3503	Sorafenib Resistance in Hepatocellular Carcinoma: The Relevance of Genetic Heterogeneity. <i>Cancers</i> , 2020, 12, 1576.	1.7	90
3504	Validation study of perfusion parameter in hypervascular hepatocellular carcinoma and focal nodular hyperplasia using dynamic susceptibility magnetic resonance imaging with super-paramagnetic iron oxide: comparison with single level dynamic CT arteriography. <i>Quantitative Imaging in Medicine and Surgery</i> , 2020, 10, 1298-1306.	1.1	4
3505	New frontiers in liver resection for hepatocellular carcinoma. <i>JHEP Reports</i> , 2020, 2, 100134.	2.6	46
3506	Thrombocytosis is associated with worse survival in patients with hepatocellular carcinoma. <i>Liver International</i> , 2020, 40, 2522-2534.	1.9	20
3507	Talin-1; other than a potential marker for hepatocellular carcinoma diagnosis. <i>Arab Journal of Gastroenterology</i> , 2020, 21, 80-84.	0.4	6
3508	The Dual Role of the Liver in Nanomedicine as an Actor in the Elimination of Nanostructures or a Therapeutic Target. <i>Journal of Oncology</i> , 2020, 2020, 1-15.	0.6	33

#	ARTICLE	IF	CITATIONS
3509	The Changing Epidemiology of Hepatocellular Carcinoma Experience of a Single Center. <i>BioMed Research International</i> , 2020, 2020, 1-9.	0.9	15
3510	Global Trends in Incidence Rates of Primary Adult Liver Cancers: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2020, 10, 171.	1.3	139
3511	DSM-TACE of HCC: Evaluation of Tumor Response in Patients Ineligible for Other Systemic or Loco-Regional Therapies. <i>RoFo Fortschritte Auf Dem Gebiet Der Rontgenstrahlen Und Der Bildgebenden Verfahren</i> , 2020, 192, 862-869.	0.7	8
3512	Nomogram for Individualized Prediction of Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis on Conservative Treatment. <i>BioMed Research International</i> , 2020, 2020, 1-9.	0.9	1
3513	Transarterial chemoembolization with medium-sized doxorubicin-eluting Callisphere is safe and effective for patients with hepatocellular carcinoma. <i>Scientific Reports</i> , 2020, 10, 4434.	1.6	13
3514	Altered Microbiota Diversity and Bile Acid Signaling in Cirrhotic and Noncirrhotic NASH-HCC. <i>Clinical and Translational Gastroenterology</i> , 2020, 11, e00131.	1.3	68
3515	Sorafenib treatment has the potential to downstage advanced hepatocellular carcinoma before liver resection. <i>Personalized Medicine</i> , 2020, 17, 83-87.	0.8	15
3516	Dose-dependent regulation of mitochondrial function and cell death pathway by sorafenib in liver cancer cells. <i>Biochemical Pharmacology</i> , 2020, 176, 113902.	2.0	22
3517	Associated liver partition and portal vein ligation for staged hepatectomy: a review. <i>Translational Gastroenterology and Hepatology</i> , 2020, 5, 37-37.	1.5	22
3518	Long-Term Study of Hepatitis Delta Virus Infection at Secondary Care Centers: The Impact of Viremia on Liver-Related Outcomes. <i>Hepatology</i> , 2020, 72, 1177-1190.	3.6	65
3520	Risk Factors for Liver Function Deterioration after Transarterial Chemoembolization Refractoriness in Child-Pugh Class A Hepatocellular Carcinoma Patients. <i>Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, The</i> , 2020, 75, 147.	0.2	3
3521	Enhanced mLS18 Expression Correlates with Tumor Progression in Hepatocellular Carcinoma. <i>Annals of Surgical Oncology</i> , 2020, 27, 1546-1557.	0.7	12
3522	CyberKnife Stereotactic Body Radiation Therapy as an Effective Treatment for Hepatocellular Carcinoma Patients With Decompensated Cirrhosis. <i>Frontiers in Oncology</i> , 2020, 10, 100.	1.3	3
3523	Inflammatory Mechanisms of HCC Development. <i>Cancers</i> , 2020, 12, 641.	1.7	114
3524	Ablation for hepatocellular carcinoma: beyond the standard indications. <i>Medical Oncology</i> , 2020, 37, 23.	1.2	7
3525	Stereotactic body radiation therapy vs. radiofrequency ablation in Asian patients with hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2020, 73, 121-129.	1.8	116
3526	Real world clinical practice in treating advanced hepatocellular carcinoma: When East meets West. <i>PLoS ONE</i> , 2020, 15, e0230005.	1.1	8
3527	Prognostic Value of Albumin-to-Alkaline Phosphatase Ratio in Hepatocellular Carcinoma Patients Treated with Liver Transplantation. <i>Journal of Cancer</i> , 2020, 11, 2171-2180.	1.2	15

#	ARTICLE	IF	CITATIONS
3528	Transarterial Infusion of Epirubicin and Cisplatin Combined With Systemic Infusion of 5-Fluorouracil Versus Sorafenib for Hepatocellular Carcinoma With Refractoriness of Transarterial Chemoembolization Using Doxorubicin. <i>Cancer Control</i> , 2020, 27, 107327482093584.	0.7	6
3529	Comparison of radiofrequency ablation combined with sorafenib or sorafenib alone in patients with ECOG performance score 1: identifying optimal candidates. <i>Annals of Translational Medicine</i> , 2020, 8, 583-583.	0.7	8
3530	Melatonin and Mesenchymal Stem Cells as a Key for Functional Integrity for Liver Cancer Treatment. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4521.	1.8	15
3531	Transplantation of fetal liver tissue coated by ultra-purified alginate gel over liver improves hepatic function in the cirrhosis rat model. <i>Scientific Reports</i> , 2020, 10, 8231.	1.6	7
3532	ULBP1 Is Elevated in Human Hepatocellular Carcinoma and Predicts Outcome. <i>Frontiers in Oncology</i> , 2020, 10, 971.	1.3	10
3533	New metastasectomy criteria for peritoneal metastasis of hepatocellular carcinoma: A study of the Japanese Society of Hepato-Biliary-Pancreatic Surgery. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2020, 27, 673-681.	1.4	10
3534	<i>Fufang Banmao</i> Capsule, a Traditional Chinese Medicinal Formulation, Enhances the Survival of Patients with Hepatocellular Carcinoma and Vp3 Portal Vein Tumor Thrombosis Undergoing Supportive Treatment. <i>Journal of Alternative and Complementary Medicine</i> , 2020, 26, 956-965.	2.1	9
3535	Transarterial Chemoembolization Combined With Apatinib for Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis. <i>Frontiers in Oncology</i> , 2020, 10, 970.	1.3	33
3536	Antibody-Drug Conjugates and Targeted Treatment Strategies for Hepatocellular Carcinoma: A Drug-Delivery Perspective. <i>Molecules</i> , 2020, 25, 2861.	1.7	14
3537	Analysis of the clinical efficacy of liver resection combined with adjuvant microwave coagulation for patients with hepatocellular carcinoma. <i>Annals of Translational Medicine</i> , 2020, 8, 585-585.	0.7	3
3538	Systemic treatment of hepatocellular carcinoma: from sorafenib to combination therapies. <i>Hepatic Oncology</i> , 2020, 7, HEP20.	4.2	30
3539	Liver transplantation in hepatocellular carcinoma after tumour downstaging (XXL): a randomised, controlled, phase 2b/3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 947-956.	5.1	166
3540	Is it Rational to Perform Liver Resection for Patients with Intermediate and Advanced Stages of Hepatocellular Carcinoma?. <i>American Surgeon</i> , 2020, 86, 313-323.	0.4	5
3541	Response Assessment Following Image-Guided Therapy of Hepatocellular Carcinoma. <i>Journal of Clinical Interventional Radiology ISVIR</i> , 2020, 4, 088-097.	0.0	4
3542	Visceral Adipose Tissue Radiodensity Is Linked to Prognosis in Hepatocellular Carcinoma Patients Treated with Selective Internal Radiation Therapy. <i>Cancers</i> , 2020, 12, 356.	1.7	25
3543	Identification of an Upper Limit of Tumor Burden for Downstaging in Candidates with Hepatocellular Cancer Waiting for Liver Transplantation: A West-East Collaborative Effort. <i>Cancers</i> , 2020, 12, 452.	1.7	20
3544	Lipiodol as an Imaging Biomarker of Tumor Response After Conventional Transarterial Chemoembolization: Prospective Clinical Validation in Patients with Primary and Secondary Liver Cancer. <i>Translational Oncology</i> , 2020, 13, 100742.	1.7	20
3545	Efficacy of Cabozantinib and Nivolumab in Treating Hepatocellular Carcinoma with <i>RET</i> Amplification, High Tumor Mutational Burden, and PD-L1 Expression. <i>Oncologist</i> , 2020, 25, 470-474.	1.9	26

#	ARTICLE	IF	CITATIONS
3546	Applicability of scoring systems predicting outcome of transarterial chemoembolization for hepatocellular carcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 1033-1050.	1.2	14
3547	Hepatic Resection Is Associated With Improved Long-Term Survival Compared to Radio-Frequency Ablation in Patients With Multifocal Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2020, 10, 110.	1.3	8
3548	Treatment of Hepatocellular Carcinoma in the Precision Medicine Era: From Treatment Stage Migration to Therapeutic Hierarchy. <i>Hepatology</i> , 2020, 72, 2206-2218.	3.6	107
3549	Neutrophil-to-lymphocyte ratio is associated with survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib. <i>Liver International</i> , 2020, 40, 968-976.	1.9	51
3550	Validation of prognostic accuracy of MESH, HKLC, and BCLC classifications in a large German cohort of hepatocellular carcinoma patients. <i>United European Gastroenterology Journal</i> , 2020, 8, 444-452.	1.6	9
3551	A systematic review and meta-analysis of adjuvant transarterial chemoembolization after curative resection for patients with hepatocellular carcinoma. <i>Hpb</i> , 2020, 22, 795-808.	0.1	39
3552	Percutaneous cryoablation in early stage hepatocellular carcinoma: analysis of local tumor progression factors. <i>Diagnostic and Interventional Radiology</i> , 2020, 26, 111-117.	0.7	8
3553	Efficiency of whole-body 18F-FDG PET CT in detecting the cause of rising serum AFP level in post-therapeutic follow-up for HCC patients. <i>Japanese Journal of Radiology</i> , 2020, 38, 472-479.	1.0	12
3554	Yttrium-90 radioembolization for hepatocellular carcinoma: Outcome prediction with MRI derived fat-free muscle area. <i>European Journal of Radiology</i> , 2020, 125, 108889.	1.2	24
3555	Serum Fibroblast Growth Factor 19 and Total Bile Acid Concentrations Are Potential Biomarkers of Hepatocellular Carcinoma in Patients with Type 2 Diabetes Mellitus. <i>BioMed Research International</i> , 2020, 2020, 1-9.	0.9	7
3557	Defects in long-chain 3-hydroxy acyl-CoA dehydrogenase lead to hepatocellular carcinoma: A novel etiology of hepatocellular carcinoma. <i>International Journal of Cancer</i> , 2020, 147, 1461-1473.	2.3	11
3558	Transmembrane protein 106C promotes the development of hepatocellular carcinoma. <i>Journal of Cellular Biochemistry</i> , 2020, 121, 4484-4495.	1.2	8
3559	Liver stiffness measured by acoustic radiation force impulse elastography predicted prognoses of hepatocellular carcinoma after radiofrequency ablation. <i>Scientific Reports</i> , 2020, 10, 2006.	1.6	7
3560	The threshold of alpha-fetoprotein (AFP) for the diagnosis of hepatocellular carcinoma: A systematic review and meta-analysis. <i>PLoS ONE</i> , 2020, 15, e0228857.	1.1	120
3561	Hepatocellular carcinoma tumour burden score to stratify prognosis after resection. <i>British Journal of Surgery</i> , 2020, 107, 854-864.	0.1	83
3562	Contrast-Enhanced Ultrasound in the Short-Term Evaluation of Hepatocellular Carcinoma after Locoregional Treatment. <i>Digestive Diseases</i> , 2020, 38, 522-533.	0.8	7
3563	CONCISE REVIEW ON THE FREQUENCY, MAJOR RISK FACTORS AND SURVEILLANCE OF HEPATOCELLULAR CARCINOMA (HCC) IN β -THALASSEMIA: PAST, PRESENT AND FUTURE PERSPECTIVES. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2020, 12, e2020006.	0.5	18
3564	Exosome-transmitted circ_MMP2 promotes hepatocellular carcinoma metastasis by upregulating MMP2. <i>Molecular Oncology</i> , 2020, 14, 1365-1380.	2.1	87

#	ARTICLE	IF	CITATIONS
3565	Intratumoral heterogeneity and clonal evolution in liver cancer. <i>Nature Communications</i> , 2020, 11, 291.	5.8	230
3566	Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma. <i>The Cochrane Library</i> , 2020, 1, CD011313.	1.5	8
3567	Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B. <i>Journal of Hepatology</i> , 2020, 72, 1088-1096.	1.8	75
3568	Controlling Nutritional Status score does not predict patients' overall survival or hepatocellular carcinoma recurrence after deceased donor liver transplantation. <i>Clinical Transplantation</i> , 2020, 34, e13786.	0.8	7
3569	Trans-arterial chemoembolization + radiofrequency ablation versus surgical resection in hepatocellular carcinoma – A meta-analysis. <i>European Journal of Surgical Oncology</i> , 2020, 46, 763-771.	0.5	55
3570	mRECIST for HCC: Performance and novel refinements. <i>Journal of Hepatology</i> , 2020, 72, 288-306.	1.8	292
3571	Milestones in the pathogenesis and management of primary liver cancer. <i>Journal of Hepatology</i> , 2020, 72, 209-214.	1.8	39
3572	Predicting post-transarterial chemoembolization outcomes: A comparison of direct and total bilirubin serums levels. <i>Diagnostic and Interventional Imaging</i> , 2020, 101, 355-364.	1.8	7
3573	Knockdown of terminal differentiation induced ncRNA (TINCR) suppresses proliferation and invasion in hepatocellular carcinoma by targeting the miR-218/DEAD-box helicase 5 (DDX5) axis. <i>Journal of Cellular Physiology</i> , 2020, 235, 6990-7002.	2.0	14
3574	Moderate hyperthermic heating encountered during thermal ablation increases tumor cell activity. <i>International Journal of Hyperthermia</i> , 2020, 37, 119-129.	1.1	24
3575	Prognostic role of tumor mutation burden in hepatocellular carcinoma after radical hepatectomy. <i>Journal of Surgical Oncology</i> , 2020, 121, 1007-1014.	0.8	26
3576	A review of conventional and newer generation microwave ablation systems for hepatocellular carcinoma. <i>Journal of Medical Ultrasonics (2001)</i> , 2020, 47, 265-277.	0.6	19
3577	Safety and efficacy of stereotactic radiofrequency ablation for very large (>8cm) primary and metastatic liver tumors. <i>Scientific Reports</i> , 2020, 10, 1618.	1.6	34
3578	Contrast-enhanced ultrasound for the characterization of portal vein thrombosis vs tumor-in-vein in HCC patients: a systematic review and meta-analysis. <i>European Radiology</i> , 2020, 30, 2871-2880.	2.3	23
3579	Comparison of Hepatic Resection Combined with Intraoperative Radiofrequency Ablation, or Hepatic Resection Alone, for Hepatocellular Carcinoma Patients with Multifocal Tumors Meeting the University of California San Francisco (UCSF) Criteria: A Propensity Score-Matched Analysis. <i>Annals of Surgical Oncology</i> , 2020, 27, 2334-2345.	0.7	12
3580	Concordance Study in Hepatectomy Recommendations Between Watson for Oncology and Clinical Practice for Patients with Hepatocellular Carcinoma in China. <i>World Journal of Surgery</i> , 2020, 44, 1945-1953.	0.8	8
3581	Primary cultures of aspiration residual specimens predict outcomes of hepatocellular carcinoma patients receiving curative treatment. <i>Kaohsiung Journal of Medical Sciences</i> , 2020, 36, 750-756.	0.8	2
3582	Heterogeneities of Site-Specific N-Glycosylation in HCC Tumors With Low and High AFP Concentrations. <i>Frontiers in Oncology</i> , 2020, 10, 496.	1.3	34

#	ARTICLE	IF	CITATIONS
3583	A case of complete remission of advanced hepatocellular carcinoma with type III portal vein tumor thrombosis treated using transarterial chemoembolization with microspheres and radiation therapy. <i>Clinical Journal of Gastroenterology</i> , 2020, 13, 847-854.	0.4	0
3584	Natural History of Untreated HBeAg-Positive Chronic HBV Infection With Persistently Elevated HBV DNA but Normal Alanine Aminotransferase. <i>Clinical and Translational Gastroenterology</i> , 2020, 11, e00140.	1.3	13
3585	Impact of successful local ablative bridging therapy prior to liver transplantation on long-term survival in patients with hepatocellular carcinoma in cirrhosis. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 1819-1827.	1.2	12
3586	Endoscopic ultrasound-guided radiofrequency ablation of porcine liver. <i>Journal of Medical Ultrasonics (2001)</i> , 2020, 47, 435-443.	0.6	1
3587	Stereotactic Body Radiation Therapy vs. Transarterial Chemoembolization in Inoperable Barcelona Clinic Liver Cancer Stage a Hepatocellular Carcinoma: A Retrospective, Propensity-Matched Analysis. <i>Frontiers in Oncology</i> , 2020, 10, 347.	1.3	27
3588	Undefined/non-malignant hepatic nodules are associated with early occurrence of HCC in DAA-treated patients with HCV-related cirrhosis. <i>Journal of Hepatology</i> , 2020, 73, 593-602.	1.8	38
3589	Targeting Autophagy Augments Berberine-Mediated Cell Death in Human Hepatoma Cells Harboring Hepatitis C Virus RNA. <i>Cells</i> , 2020, 9, 908.	1.8	11
3590	Multicentre prospective study of drug-eluting bead chemoembolisation safety using tightly calibrated small microspheres in non-resectable hepatocellular carcinoma. <i>European Journal of Radiology</i> , 2020, 126, 108966.	1.2	20
3591	Downregulation of thioredoxin-1-dependent CD95 S-nitrosation by Sorafenib reduces liver cancer. <i>Redox Biology</i> , 2020, 34, 101528.	3.9	16
3592	Improved detection of hepatocellular carcinoma by dynamic computed tomography in cirrhotic patients with chronic hepatitis B: A multicenter study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 1795-1803.	1.4	3
3593	An optimized hepatocellular carcinoma prediction model for chronic hepatitis B with well-controlled viremia. <i>Liver International</i> , 2020, 40, 1736-1743.	1.9	23
3594	Microwave ablation versus sorafenib for intermediate-stage Hepatocellular carcinoma with transcatheter arterial chemoembolization refractoriness: a propensity score matching analysis. <i>International Journal of Hyperthermia</i> , 2020, 37, 384-391.	1.1	4
3595	Recurrence Patterns and Outcomes after Resection of Hepatocellular Carcinoma within and beyond the Barcelona Clinic Liver Cancer Criteria. <i>Annals of Surgical Oncology</i> , 2020, 27, 2321-2331.	0.7	76
3596	Prognosis after resection of single large hepatocellular carcinoma: Results from an Asian high-volume liver surgery center. <i>PLoS ONE</i> , 2020, 15, e0230897.	1.1	4
3597	Comparison of the diagnostic performance of imaging criteria for HCCs ≤ 3.0 cm on gadoxetate disodium-enhanced MRI. <i>Hepatology International</i> , 2020, 14, 534-543.	1.9	21
3598	Spleen volumetry and liver transient elastography: Predictors of persistent posthepatectomy decompensation in patients with hepatocellular carcinoma. <i>Surgery</i> , 2020, 168, 17-24.	1.0	8
3599	The combination of PIVKA-II and AFP improves the detection accuracy for HCC in HBV caucasian cirrhotics on long-term oral therapy. <i>Liver International</i> , 2020, 40, 1987-1996.	1.9	44
3600	Comparison of prognosis between surgical resection and transarterial chemoembolization for patients with solitary huge hepatocellular carcinoma. <i>Annals of Translational Medicine</i> , 2020, 8, 238-238.	0.7	17

#	ARTICLE	IF	CITATIONS
3601	Molecular Imaging of Extracellular Tumor pH to Reveal Effects of Locoregional Therapy on Liver Cancer Microenvironment. <i>Clinical Cancer Research</i> , 2020, 26, 428-438.	3.2	34
3602	Multidisciplinary Treatment of Advanced Hepatocellular Carcinoma. <i>Case Reports in Gastroenterology</i> , 2020, 14, 98-102.	0.3	1
3603	Embolotherapeutic Strategies for Hepatocellular Carcinoma: 2020 Update. <i>Cancers</i> , 2020, 12, 791.	1.7	54
3604	Down-regulation of Long Non-coding RNA LINC01554 in Hepatocellular Cancer and its Clinical Significance. <i>Journal of Cancer</i> , 2020, 11, 3369-3374.	1.2	16
3605	Plasma Lipidomic Fingerprinting to Distinguish among Hepatitis C-related Hepatocellular Carcinoma, Liver Cirrhosis, and Chronic Hepatitis C using MALDI-TOF Mass Spectrometry: a Pilot Study. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2020, 24, 43-49.	0.5	8
3606	The 8th Edition American Joint Committee on Cancer Staging for Hepato-pancreato-biliary Cancer: A Review and Update. <i>Archives of Pathology and Laboratory Medicine</i> , 2021, 145, 543-553.	1.2	43
3607	Preoperative predictors of liver decompensation after mini-invasive liver resection. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2021, 35, 718-727.	1.3	10
3608	Varices on computed tomography as predictor of survival after hepatic resection in patients with single hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 225-232.	1.4	2
3609	Morphophenotypic Classification of Hepatocellular Carcinoma: the Biliary/Stem Cell Subgroup and Worst Outcome—Implications on Patient Selection. <i>Journal of Gastrointestinal Surgery</i> , 2021, 25, 698-707.	0.9	1
3610	Liver Transplantation Following Yttrium-90 Radioembolization: 15-Year Experience in 207-Patient Cohort. <i>Hepatology</i> , 2021, 73, 998-1010.	3.6	62
3611	Is survival for hepatocellular carcinoma increasing? A population-based study on survival of hepatocellular carcinoma patients in the 1990s and 2000s. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2021, 45, 1014-33.	0.7	6
3612	Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference. <i>Hepatology</i> , 2021, 73, 158-191.	3.6	235
3613	Lower Serum Sodium Levels Are Associated with the Therapeutic Effect of Sorafenib on Hepatocellular Carcinoma. <i>Digestive Diseases and Sciences</i> , 2021, 66, 1720-1729.	1.1	4
3614	Serum Levels of Î±-Fetoprotein Increased More Than 10 Years Before Detection of Hepatocellular Carcinoma. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 162-170.e4.	2.4	24
3615	Hepatocellular carcinoma, novel therapies on the horizon. <i>Chinese Clinical Oncology</i> , 2021, 10, 12-12.	0.4	12
3616	Safety and feasibility of laparoscopic liver resection for hepatocellular carcinoma with clinically significant portal hypertension: a propensity score-matched study. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2021, 35, 3267-3278.	1.3	11
3617	Monofocal hepatocellular carcinoma: How much does size matter?. <i>Liver International</i> , 2021, 41, 396-407.	1.9	10
3618	Laparoscopic major hepatectomy for hepatocellular carcinoma in elderly patients: a multicentric propensity score-based analysis. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2021, 35, 3642-3652.	1.3	16

#	ARTICLE	IF	CITATIONS
3619	Improving the Efficacy of Liver Cancer Immunotherapy: The Power of Combined Preclinical and Clinical Studies. <i>Hepatology</i> , 2021, 73, 104-114.	3.6	54
3620	The PPRD score stratifies patients with hepatocellular carcinoma and portal vein tumor thrombus treated with sorafenib plus transarterial chemoembolization. <i>European Radiology</i> , 2021, 31, 232-243.	2.3	7
3621	Combining cellular immunotherapy was an optional choice for unresectable advanced HCC: A systematic review and meta-analysis. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2021, 45, 101440.	0.7	0
3622	The role of a "knowledge based dose" volume histogram predictive model in the optimisation of intensity-modulated proton plans for hepatocellular carcinoma patients. <i>Strahlentherapie Und Onkologie</i> , 2021, 197, 332-342.	1.0	8
3623	Eradication of hepatitis C virus preserve liver function and prolong survival in advanced hepatocellular carcinoma patients with limited life expectancy. <i>Kaohsiung Journal of Medical Sciences</i> , 2021, 37, 145-153.	0.8	8
3624	Reply to: "Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B". <i>Journal of Hepatology</i> , 2021, 74, 246-247.	1.8	1
3625	Pretreatment Neutrophil-to-Lymphocyte Ratio Predicts Survival and Liver Toxicity in Patients With Hepatocellular Carcinoma Treated With Stereotactic Ablative Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 474-484.	0.4	10
3626	The cost-effectiveness of TheraSphere in patients with hepatocellular carcinoma who are eligible for transarterial embolization. <i>European Journal of Surgical Oncology</i> , 2021, 47, 401-408.	0.5	15
3627	Microscopic portal vein invasion is a powerful predictor of prognosis in patients with hepatocellular carcinoma who have undergone liver resection. <i>Journal of Surgical Oncology</i> , 2021, 123, 222-235.	0.8	10
3628	Prediction of tumor recurrence by α -fetoprotein model after curative resection for hepatocellular carcinoma. <i>European Journal of Surgical Oncology</i> , 2021, 47, 660-666.	0.5	20
3629	Data-independent acquisition mass spectrometry (DIA-MS) for proteomic applications in oncology. <i>Molecular Omics</i> , 2021, 17, 29-42.	1.4	93
3630	Validation of risk prediction scores for hepatocellular carcinoma in patients with chronic hepatitis B treated with entecavir or tenofovir. <i>Journal of Viral Hepatitis</i> , 2021, 28, 95-104.	1.0	8
3631	Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores. <i>Journal of Hepatology</i> , 2021, 74, 775-782.	1.8	193
3632	Integrated Analysis of an lncRNA-Associated ceRNA Network Reveals Potential Biomarkers for Hepatocellular Carcinoma. <i>Journal of Computational Biology</i> , 2021, 28, 330-344.	0.8	5
3633	Negligible HCC risk during stringently defined untreated immune-tolerant phase of chronic hepatitis B. <i>European Journal of Internal Medicine</i> , 2021, 84, 68-73.	1.0	12
3634	Response prediction of hepatocellular carcinoma undergoing transcatheter arterial chemoembolization: unlocking the potential of CT texture analysis through nested decision tree models. <i>European Radiology</i> , 2021, 31, 4367-4376.	2.3	18
3635	Living Donor Liver Transplantation Versus Deceased Donor Liver Transplantation for Hepatocellular Carcinoma Within or Beyond the Milan Criteria: Comparable Long-Term Outcomes. <i>Transplantation Proceedings</i> , 2021, 53, 92-97.	0.3	6
3636	Circulating cell-free DNA species affect the risk of hepatocellular carcinoma in treated chronic hepatitis B patients. <i>Journal of Viral Hepatitis</i> , 2021, 28, 464-474.	1.0	4

#	ARTICLE	IF	CITATIONS
3637	Multicenter prospective study of stereotactic body radiotherapy for previously untreated solitary primary hepatocellular carcinoma: The STRSPH study. <i>Hepatology Research</i> , 2021, 51, 461-471.	1.8	40
3638	Dose-Response Relationship in Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma: A Pooled Analysis of an Asian Liver Radiation Therapy Group Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 464-473.	0.4	24
3639	A prediction model for overall survival after transarterial chemoembolization for hepatocellular carcinoma invading the hepatic vein or inferior vena cava. <i>European Radiology</i> , 2021, 31, 4232-4242.	2.3	13
3640	Reciprocal REG1 β -mTORC1 regulation promotes glycolytic metabolism in hepatocellular carcinoma. <i>Oncogene</i> , 2021, 40, 677-692.	2.6	8
3641	Six months as a cutoff time point to define early recurrence after liver resection of hepatocellular carcinoma based on post-recurrence survival. <i>Updates in Surgery</i> , 2021, 73, 399-409.	0.9	11
3642	Management consensus guideline for hepatocellular carcinoma: 2020 update on surveillance, diagnosis, and systemic treatment by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan. <i>Journal of the Formosan Medical Association</i> , 2021, 120, 1051-1060.	0.8	72
3643	Therapeutic Ultrasound Parameter Optimization for Drug Delivery Applied to a Murine Model of Hepatocellular Carcinoma. <i>Ultrasound in Medicine and Biology</i> , 2021, 47, 309-322.	0.7	10
3644	Predicting the risk of post-hepatectomy portal hypertension using a digital twin: A clinical proof of concept. <i>Journal of Hepatology</i> , 2021, 74, 661-669.	1.8	35
3645	Treatment strategies for early stage hepatocellular carcinoma: a systematic review and network meta-analysis of randomised clinical trials. <i>Hpb</i> , 2021, 23, 495-505.	0.1	9
3646	Hepatocellular carcinoma in patients with chronic renal disease: Challenges of interventional treatment. <i>Surgical Oncology</i> , 2021, 36, 42-50.	0.8	7
3647	Hypofractionated radiotherapy for hepatocellular carcinomas adjacent to the gastrointestinal tract. <i>Hepatology Research</i> , 2021, 51, 294-302.	1.8	7
3648	Repeated double cross-validation applied to the PCA-LDA classification of SERS spectra: a case study with serum samples from hepatocellular carcinoma patients. <i>Analytical and Bioanalytical Chemistry</i> , 2021, 413, 1303-1312.	1.9	28
3649	Transarterial chemoembolisation enhances programmed death-1 and programmed death-ligand 1 expression in hepatocellular carcinoma. <i>Histopathology</i> , 2021, 79, 36-46.	1.6	49
3650	High pretreatment static and dynamic alpha-fetoprotein values predict reduced overall survival in hepatocellular carcinoma. <i>United European Gastroenterology Journal</i> , 2021, 9, 388-397.	1.6	4
3651	Metabolic activity assessment by 18 F-fluorodeoxyglucose positron emission tomography in patients with hepatocellular carcinoma undergoing Yttrium-90 transarterial radioembolization. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 1679-1684.	1.4	1
3652	Effect of ramucirumab on ALBI grade in patients with advanced HCC: Results from REACH and REACH-2. <i>JHEP Reports</i> , 2021, 3, 100215.	2.6	31
3653	Comparison of PET imaging of activated fibroblasts and 18F-FDG for diagnosis of primary hepatic tumours: a prospective pilot study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 1593-1603.	3.3	87
3654	β -Glutamyltranspeptidase as a Prognostic Biomarker in Advanced Hepatocellular Carcinoma Treated with Transarterial Chemoembolization. <i>Journal of Vascular and Interventional Radiology</i> , 2021, 32, 419-428.e2.	0.2	7

#	ARTICLE	IF	CITATIONS
3655	Hepatocellular carcinoma and the Fontan circulation: Clinical presentation and outcomes. <i>International Journal of Cardiology</i> , 2021, 322, 142-148.	0.8	45
3656	Unique TP53 neoantigen and the immune microenvironment in long-term survivors of Hepatocellular carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 667-677.	2.0	34
3657	CT liver perfusion in patients with hepatocellular carcinoma: can we modify acquisition protocol to reduce patient exposure?. <i>European Radiology</i> , 2021, 31, 1410-1419.	2.3	5
3658	Clinical Application of Trans-Arterial Radioembolization in Hepatic Malignancies in Europe: First Results from the Prospective Multicentre Observational Study CIRSE Registry for SIR-Spheres Therapy (CIRT). <i>CardioVascular and Interventional Radiology</i> , 2021, 44, 21-35.	0.9	49
3659	Matrix stiffness-mediated effects on macrophages polarization and their LOXL2 expression. <i>FEBS Journal</i> , 2021, 288, 3465-3477.	2.2	40
3660	Living donor liver transplantation or hepatic resection combined with intraoperative radiofrequency ablation for Child-Pugh A hepatocellular carcinoma patient with Multifocal Tumours Meeting the University of California San Francisco (UCSF) criteria. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 607-618.	1.2	5
3661	Surgery for Recurrent Hepatocellular Carcinoma. <i>Annals of Surgery</i> , 2021, 273, 792-799.	2.1	66
3662	CLINICAL UTILITY OF LIVER AND TUMOR STIFFNESS MEASURED BY ULTRASOUND SHEAR WAVE ELASTOGRAPHY IN PATIENTS WITH HEPATOCELLULAR CARCINOMA TREATED BY THERMAL ABLATION.. , 2021, , 63-65.		0
3663	Segmentation of Liver Lesions Without Contrast Agents With Radiomics-Guided Densely UNet-Nested GAN. <i>IEEE Access</i> , 2021, 9, 2864-2878.	2.6	7
3664	Electromagnetic Navigation System-Guided Microwave Ablation of Hepatic Tumors: A Matched Cohort Study. <i>CardioVascular and Interventional Radiology</i> , 2021, 44, 500-506.	0.9	10
3665	Interventional Image-Guided HDR Brachytherapy as a Salvage Treatment: Exclusive or in Combination with Other Local Therapies. , 2021, , 201-217.		0
3666	Real-time virtual sonography-assisted radiofrequency ablation in liver tumors with conspicuous or inconspicuous images or peritumoral landmarks under ultrasonography. <i>Abdominal Radiology</i> , 2021, 46, 2814-2822.	1.0	2
3667	Therapeutic Guidelines for Patients with Liver Cancer from the Perspective of Radiation Oncologists. , 2021, , 155-168.		0
3668	Findings of Fat Containing Hepatocellular Carcinoma on Contrast-enhanced Ultrasound with Sonazoid: A Case Report. <i>Advanced Ultrasound in Diagnosis and Therapy</i> , 2021, 5, 98.	0.1	0
3669	Shear wave elastography and transient elastography in HCV patients after direct-acting antivirals. <i>Radiologia Medica</i> , 2021, 126, 894-899.	4.7	27
3670	Preoperative transarterial chemoembolization for laparoscopic liver resection in Child A cirrhotic patients with hepatocellular carcinoma. <i>Langenbeck's Archives of Surgery</i> , 2021, 406, 763-771.	0.8	6
3671	Association of aspirin and nonaspirin NSAIDs therapy with the incidence risk of hepatocellular carcinoma: a systematic review and meta-analysis on cohort studies. <i>European Journal of Cancer Prevention</i> , 2022, 31, 35-43.	0.6	9
3672	A new staging system for hepatocellular carcinoma associated with portal vein tumor thrombus. <i>Hepatobiliary Surgery and Nutrition</i> , 2021, 10, 0-0.	0.7	12

#	ARTICLE	IF	CITATIONS
3673	Liver Cancer (Current Therapies). , 2022, , 112-125.		1
3674	A narrative review of near-infrared fluorescence imaging in hepatectomy for hepatocellular carcinoma. <i>Annals of Translational Medicine</i> , 2021, 9, 171-171.	0.7	19
3675	The Role of Tumor Associated Macrophages in Hepatocellular Carcinoma. <i>Journal of Cancer</i> , 2021, 12, 1284-1294.	1.2	51
3676	Comparison of Prognostic Scores in Patients With Hepatocellular Carcinoma Treated With Sorafenib. <i>Clinical and Translational Gastroenterology</i> , 2021, 12, e00286.	1.3	15
3678	<i>In Vitro</i> Drug Loading, Releasing Profiles, and <i>In Vivo</i> Embolic Efficacy and Safety Evaluation of a Novel Drug-Eluting Microsphere (CalliSpheres). <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2023, 38, 512-520.	0.7	5
3679	Incomplete thermal ablation of tumors promotes increased tumorigenesis. <i>International Journal of Hyperthermia</i> , 2021, 38, 263-272.	1.1	16
3680	Expression and Role of Dickkopf-1 (Dkk1) in Tumors: From the Cells to the Patients. <i>Cancer Management and Research</i> , 2021, Volume 13, 659-675.	0.9	34
3681	Transcriptomic characterization reveals prognostic molecular signatures of sorafenib resistance in hepatocellular carcinoma. <i>Aging</i> , 2021, 13, 3969-3993.	1.4	7
3682	Is the Barcelona Clinic Liver Cancer guideline for treating intermediate to advanced staged hepatocellular carcinoma still appropriate?. <i>Annals of Translational Medicine</i> , 2021, 9, 1-1.	0.7	9
3683	A novel irinotecan-lipiodol nanoemulsion for intravascular administration: pharmacokinetics and biodistribution in the normal and tumor bearing rat liver. <i>Drug Delivery</i> , 2021, 28, 240-251.	2.5	3
3684	Whole-liver transcatheter arterial chemoinfusion and bland embolization with fine-powder cisplatin and trisacryl gelatin microspheres for treating unresectable multiple hepatocellular carcinoma. <i>Japanese Journal of Radiology</i> , 2021, 39, 494-502.	1.0	3
3685	Clinicopathological and prognostic value of preoperative lymphocyte to monocyte ratio for hepatocellular carcinoma following curative resection. <i>Medicine (United States)</i> , 2021, 100, e24153.	0.4	1
3686	Clinical Significance of Serum Antithrombin III Activity After Hepatectomy for Hepatocellular Carcinoma. <i>Yonago Acta Medica</i> , 2021, 64, 168-175.	0.3	0
3687	Transarterial Radioembolization of Hepatocellular Carcinoma, Liver-Dominant Hepatic Colorectal Cancer Metastases, and Cholangiocarcinoma Using Yttrium90 Microspheres: Eight-Year Single-Center Real-Life Experience. <i>Diagnostics</i> , 2021, 11, 122.	1.3	9
3688	Comparison between Milan and UCSF criteria for liver transplantation in patients with hepatocellular carcinoma: a systematic review and meta-analysis. <i>Translational Gastroenterology and Hepatology</i> , 2021, 6, 11-11.	1.5	20
3689	Phase 2 trial comparing sorafenib, pravastatin, their combination or supportive care in HCC with Child-Pugh B cirrhosis. <i>Hepatology International</i> , 2021, 15, 93-104.	1.9	28
3690	Hepatocellular Carcinoma in Pakistan: An Update. , 2021, , 387-396.		1
3691	Dynamic Contrast-Enhanced Ultrasound Radiomics for Hepatocellular Carcinoma Recurrence Prediction After Thermal Ablation. <i>Molecular Imaging and Biology</i> , 2021, 23, 572-585.	1.3	24

#	ARTICLE	IF	CITATIONS
3692	Ultrasound-guided percutaneous microwave ablation for hepatocellular carcinoma originating in the caudate lobe: A pilot clinical study. <i>Journal of Cancer Research and Therapeutics</i> , 2021, 17, 764.	0.3	5
3693	An Overview of Hepatocellular Carcinoma (HCC) in Lebanon: A Focus on Hepatitis B- and Thalassemia-Related HCC. , 2021, , 375-386.		0
3694	Computational intelligence identifies alkaline phosphatase (ALP), alpha-fetoprotein (AFP), and hemoglobin levels as most predictive survival factors for hepatocellular carcinoma. <i>Health Informatics Journal</i> , 2021, 27, 146045822098420.	1.1	9
3695	Comparative Analysis of Radiofrequency Ablation and Microwave Ablation for Critically Located Hepatocellular Carcinomas Smaller than 5 cm. <i>Journal of Clinical Interventional Radiology ISVIR</i> , 2021, 5, 22-28.	0.0	0
3696	Updates on the Diagnosis and Management of Hepatocellular Carcinoma. <i>Euroasian Journal of Hepato-gastroenterology</i> , 2021, 11, 32-40.	0.1	10
3697	Pathologic Basis and Classification of Biliary Epithelial Neoplasms. , 2021, , 69-133.		0
3698	A New Prognostic Model for Radiation-Based Hepatocellular Carcinoma Treatment. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
3699	Early recurrence after radiofrequency ablation for hepatocellular carcinoma: a multicenter retrospective study on definition, patterns and risk factors. <i>International Journal of Hyperthermia</i> , 2021, 38, 437-446.	1.1	11
3700	Identification and Characterization of Alcohol-related Hepatocellular Carcinoma Prognostic Subtypes based on an Integrative N6-methyladenosine methylation Model. <i>International Journal of Biological Sciences</i> , 2021, 17, 3554-3572.	2.6	12
3701	Spontaneous regression of lung metastases in hepatocellular carcinoma: A case report. <i>International Journal of Surgery Case Reports</i> , 2021, 78, 378-381.	0.2	0
3702	Usefulness of Cone-Beam CT-Based Liver Perfusion Mapping for Evaluating the Response of Hepatocellular Carcinoma to Conventional Transarterial Chemoembolization. <i>Journal of Clinical Medicine</i> , 2021, 10, 713.	1.0	4
3704	Clinical Benefit of Antiviral Agents for Hepatocellular Carcinoma Patients With Low Preoperative HBV-DNA Loads Undergoing Curative Resection: A Meta-Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 605648.	1.3	12
3705	Liver resection versus transarterial chemoembolization for huge hepatocellular carcinoma: a propensity score matched analysis. <i>Scientific Reports</i> , 2021, 11, 4493.	1.6	11
3706	Feasibility of laparoscopic liver lobectomy in dogs. <i>Veterinary Surgery</i> , 2021, 50, O89-O98.	0.5	2
3707	The role of dynamic and diffusion MR imaging in therapeutic response assessment after microwave ablation of hepatocellular carcinoma using LI-RADS v2018 treatment response algorithm. <i>Egyptian Journal of Radiology and Nuclear Medicine</i> , 2021, 52, .	0.3	2
3708	Combination treatment for advanced hepatocellular carcinoma with portal vein tumour thrombus: A case report. <i>Journal of International Medical Research</i> , 2021, 49, 030006052199440.	0.4	1
3709	Factors Enhancing Treatment of Hepatitis C Virus-Infected Italian People Who Use Drugs: The CLEO-GRECAS Experience. <i>American Journal of Gastroenterology</i> , 2021, 116, 1248-1255.	0.2	5
3710	Clinical utility of serum biomarkers for hepatocellular carcinoma. <i>Biomarkers in Medicine</i> , 2021, 15, 151-155.	0.6	3

#	ARTICLE	IF	CITATIONS
3711	PIWIL1 governs the crosstalk of cancer cell metabolism and immunosuppressive microenvironment in hepatocellular carcinoma. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 86.	7.1	25
3712	Hepatitis C positive Black patients develop hepatocellular carcinoma at earlier stages of liver disease and present with a more aggressive phenotype. <i>Cancer</i> , 2021, 127, 1395-1406.	2.0	16
3713	Prognostic Value of Preoperative Prognostic Nutritional Index and Body Mass Index Combination in Patients with Unresectable Hepatocellular Carcinoma After Transarterial Chemoembolization. <i>Cancer Management and Research</i> , 2021, Volume 13, 1637-1650.	0.9	6
3714	Pre- and Postoperative Models for Prediction of Recurrence in Non-B, Non-C Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 612588.	1.3	2
3715	Survival comparison between radiofrequency ablation and surgical resection for patients with small hepatocellular carcinoma. <i>Medicine (United States)</i> , 2021, 100, e24585.	0.4	8
3716	A comparison of factors associated with the temporal improvement in the overall survival of BCLC stage 0 hepatocellular carcinoma patients. <i>Digestive and Liver Disease</i> , 2021, 53, 210-215.	0.4	2
3717	Multi-institutional validation of novel models for predicting the prognosis of patients with huge hepatocellular carcinoma. <i>International Journal of Cancer</i> , 2021, 149, 127-138.	2.3	12
3718	From Liver Cirrhosis to Cancer: The Role of Micro-RNAs in Hepatocarcinogenesis. <i>International Journal of Molecular Sciences</i> , 2021, 22, 1492.	1.8	16
3719	Glisson pedicle ligation for unresectable hepatocellular carcinoma. <i>Medicine, Case Reports and Study Protocols</i> , 2021, 2, e0056.	0.0	0
3720	Gene expression profiles of liver cancer cell lines reveal two hepatocyte-like and fibroblast-like clusters. <i>PLoS ONE</i> , 2021, 16, e0245939.	1.1	9
3721	ASPP2 expression predicts the prognosis of patients with hepatocellular carcinoma after transcatheter arterial chemoembolization. <i>Experimental and Therapeutic Medicine</i> , 2021, 21, 397.	0.8	5
3722	High signal liver focal lesions on DWI: the differential diagnostic value of morphological characteristics and ADC value. <i>Chinese Journal of Academic Radiology</i> , 2021, 4, 48-55.	0.4	0
3723	Translational Perspective in Hepatocellular Carcinoma. , 0, , .		0
3724	Anti-programmed death-1 therapy in advanced hepatocellular carcinoma: A real-world experience. <i>Clinical Case Reports (discontinued)</i> , 2021, 9, 2162-2167.	0.2	2
3725	Survival Benefit of Hepatic Arterial Infusion Chemotherapy over Sorafenib in the Treatment of Locally Progressed Hepatocellular Carcinoma. <i>Cancers</i> , 2021, 13, 646.	1.7	19
3726	A preliminary study of hepatocellular carcinoma post proton beam therapy using MRI as an early prediction of treatment effectiveness. <i>PLoS ONE</i> , 2021, 16, e0249003.	1.1	2
3727	Imaging, Pathology, and Immune Correlates in the Woodchuck Hepatic Tumor Model. <i>Journal of Hepatocellular Carcinoma</i> , 2021, Volume 8, 71-83.	1.8	4
3728	Breath analysis for the detection of digestive tract malignancies: systematic review. <i>BJS Open</i> , 2021, 5, .	0.7	11

#	ARTICLE	IF	CITATIONS
3729	Liver resection in elderly patients with hepatocellular carcinoma: age does matter. Updates in Surgery, 2021, 73, 1371-1380.	0.9	5
3730	MULTIPARAMETRIC ULTRASOUND IN THE DIAGNOSIS OF LIVER TUMORS. Innovative Medicine of Kuban, 2021, , 72-78.	0.0	0
3731	Response Prediction in Immune Checkpoint Inhibitor Immunotherapy for Advanced Hepatocellular Carcinoma. Cancers, 2021, 13, 1607.	1.7	19
3732	Type III TGF- β 2 Receptor Down-Regulation Promoted Tumor Progression via Complement Component C5a Induction in Hepatocellular Carcinoma. Cancers, 2021, 13, 1503.	1.7	3
3733	Radiomics Model Based on Gadoteric Acid Disodium-Enhanced MR Imaging to Predict Hepatocellular Carcinoma Recurrence After Curative Ablation. Cancer Management and Research, 2021, Volume 13, 2785-2796.	0.9	11
3734	Comparison of the efficacy and safety of direct-acting antiviral therapy with or without hepatitis C-related hepatocellular carcinoma. Korean Journal of Internal Medicine, 2021, 36, 292-304.	0.7	1
3736	Factors predicting long-term outcomes of early-stage hepatocellular carcinoma after primary curative treatment: the role of surgical or nonsurgical methods. BMC Cancer, 2021, 21, 250.	1.1	10
3737	Development of human hepatocellular carcinoma in X-linked severe combined immunodeficient pigs: An orthotopic xenograft model. PLoS ONE, 2021, 16, e0248352.	1.1	5
3738	Recurrence of Hepatocellular Carcinoma After Liver Transplantation is Associated with Episodes of Acute Rejections. Journal of Hepatocellular Carcinoma, 2021, Volume 8, 133-143.	1.8	10
3739	Prediction of hepatocellular carcinoma risk in patients with chronic liver disease from dynamic modular networks. Journal of Translational Medicine, 2021, 19, 122.	1.8	1
3740	Feeding artery ablation before radiofrequency ablation for hepatocellular carcinoma may reduce critical recurrence. JGH Open, 2021, 5, 478-485.	0.7	4
3741	Comparison of the efficacy and safety of conventional transarterial chemoembolization with and without drug-eluting beads embolization for the treatment of unresectable large hepatocellular carcinoma. Hepatology Research, 2021, 51, 482-489.	1.8	6
3742	Immunotherapy for Hepatocellular Carcinoma: Current Limits and Prospects. Frontiers in Oncology, 2021, 11, 589680.	1.3	23
3743	Do combined assays of serum AFP, AFP-L3, DCP, GP73, and DKK-1 efficiently improve the clinical values of biomarkers in decision-making for hepatocellular carcinoma? A meta-analysis. Expert Review of Gastroenterology and Hepatology, 2021, 15, 1065-1076.	1.4	12
3744	Beyond First-Line Immune Checkpoint Inhibitor Therapy in Patients With Hepatocellular Carcinoma. Frontiers in Immunology, 2021, 12, 652007.	2.2	7
3745	The "Six-and-Twelve" Score for Recurrent HCC Patients Receiving TACE: Does it Still Work?. CardioVascular and Interventional Radiology, 2021, 44, 720-727.	0.9	4
3746	Adherence to the modified Barcelona Clinic Liver Cancer guidelines: Results from a high-volume liver surgery center in East Asias. PLoS ONE, 2021, 16, e0249194.	1.1	11
3747	Natural History of NAFLD. Journal of Clinical Medicine, 2021, 10, 1161.	1.0	23

#	ARTICLE	IF	CITATIONS
3748	Quantitative assessment of HCC wash-out on CT is a predictor of early complete response to TACE. <i>European Radiology</i> , 2021, 31, 6578-6588.	2.3	9
3749	A Machine Learning-Based Model to Predict Survival After Transarterial Chemoembolization for BCLC Stage B Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 608260.	1.3	6
3750	Palliative medicine referrals for hepatocellular carcinoma: a national survey of gastroenterologists. <i>BMJ Supportive and Palliative Care</i> , 2021, , bmjspcare-2020-002807.	0.8	2
3751	Predictive Factors for the Effectiveness of Repeated Lines of Transarterial Chemoembolization in the Treatment of Localized Hepatocellular Carcinoma. <i>Journal of Oncology Diagnostic Radiology and Radiotherapy</i> , 2021, 4, 42-52.	0.1	0
3752	High Rates of Liver Cirrhosis and Hepatocellular Carcinoma in Chronic Hepatitis B Patients with Metabolic and Cardiovascular Comorbidities. <i>Microorganisms</i> , 2021, 9, 968.	1.6	5
3753	Selecting an Optimal Staging System for Intermediate-Stage Hepatocellular Carcinoma: Comparison of 9 Currently Used Prognostic Models. <i>Journal of Hepatocellular Carcinoma</i> , 2021, Volume 8, 253-261.	1.8	2
3754	Therapies for hepatocellular carcinoma: overview, clinical indications, and comparative outcome evaluation—part one: curative intention. <i>Abdominal Radiology</i> , 2021, 46, 3528-3539.	1.0	6
3755	Combination of Sorafenib and Transarterial Chemoembolization in Selected Patients with Advanced-Stage Hepatocellular Carcinoma: A Retrospective Cohort Study at Three German Liver Centers. <i>Cancers</i> , 2021, 13, 2121.	1.7	14
3756	Conversion to Resectability Using Transarterial Chemoembolization Combined With Hepatic Arterial Infusion Chemotherapy for Initially Unresectable Hepatocellular Carcinoma. <i>Annals of Surgery Open</i> , 2021, 2, e057.	0.7	18
3757	Differentiation between hepatocellular carcinoma and intrahepatic cholangiocarcinoma using contrast-enhanced ultrasound: A systematic review and meta-analysis. <i>Clinical Hemorheology and Microcirculation</i> , 2021, 79, 293-309.	0.9	14
3758	Overview of Prognostic Systems for Hepatocellular Carcinoma and ITA.LI.CA External Validation of MESH and CNLC Classifications. <i>Cancers</i> , 2021, 13, 1673.	1.7	21
3759	Hypermethylation of secreted frizzled related protein 2 gene promoter serves as a noninvasive biomarker for HBV-associated hepatocellular carcinoma. <i>Life Sciences</i> , 2021, 270, 119061.	2.0	4
3760	Optimal stereotactic body radiotherapy dosage for hepatocellular carcinoma: a multicenter study. <i>Radiation Oncology</i> , 2021, 16, 79.	1.2	13
3761	Optimizing the management of intermediate-stage hepatocellular carcinoma: Current trends and prospects. <i>Clinical and Molecular Hepatology</i> , 2021, 27, 236-245.	4.5	38
3762	Cerium Oxide Nanoparticles: A New Therapeutic Tool in Liver Diseases. <i>Antioxidants</i> , 2021, 10, 660.	2.2	41
3763	Abdominal ultrasound and alpha-foetoprotein for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease. <i>The Cochrane Library</i> , 2021, 2021, CD013346.	1.5	24
3764	The rs599839 A>G Variant Disentangles Cardiovascular Risk and Hepatocellular Carcinoma in NAFLD Patients. <i>Cancers</i> , 2021, 13, 1783.	1.7	16
3765	Characteristics and prognosis of patients with large well-differentiated hepatocellular carcinoma who have undergone resection. <i>American Journal of Surgery</i> , 2022, 223, 339-345.	0.9	1

#	ARTICLE	IF	CITATIONS
3766	Differential Mutation Detection Capability Through Capture-Based Targeted Sequencing in Plasma Samples in Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 596789.	1.3	8
3767	Therapies for hepatocellular carcinoma: overview, clinical indications, and comparative outcome evaluation. Part two: noncurative intention. <i>Abdominal Radiology</i> , 2021, 46, 3540-3548.	1.0	3
3768	Manual versus automated image fusion of real-time ultrasonography and MR/CT images for radiofrequency ablation of hepatic tumors: results of a randomized prospective trial (NCT02705118). <i>Ultrasonography</i> , 2021, 40, 237-247.	1.0	1
3769	An Increase in the Levels of Middle Surface Antigen Characterizes Patients Developing HBV-Driven Liver Cancer Despite Prolonged Virological Suppression. <i>Microorganisms</i> , 2021, 9, 752.	1.6	10
3770	Human nuclear receptors (NRs) genes have prognostic significance in hepatocellular carcinoma patients. <i>World Journal of Surgical Oncology</i> , 2021, 19, 137.	0.8	11
3771	Current status of ctDNA in precision oncology for hepatocellular carcinoma. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 140.	3.5	15
3772	Carbon-ion radiotherapy subsequent to balloon-occluded retrograde transvenous obliteration for hepatocellular carcinoma with hepatic encephalopathy: a multidisciplinary approach. <i>Clinical Journal of Gastroenterology</i> , 2021, 14, 852-857.	0.4	1
3773	A Systematic Review and Narrative Synthesis of Health Economic Evaluations of Hepatocellular Carcinoma Screening Strategies. <i>Value in Health</i> , 2021, 24, 733-743.	0.1	6
3774	Radiologic Response Combined with Dermatologic Toxicities is the Most Robust Predictor of Survival Benefits in Patients with Inoperable Hepatocellular Carcinoma After Transarterial Chemoembolization Plus Sorafenib Therapy. <i>CardioVascular and Interventional Radiology</i> , 2021, 44, 1394-1402.	0.9	0
3775	Alpha-fetoprotein: A molecular bootstrap for hepatocellular carcinoma. <i>International Journal of Molecular and Immuno Oncology</i> , 0, 5, 92-95.	0.0	4
3776	Effectiveness and safety of focused ultrasound ablation surgery compared with radiofrequency ablation in primary hepatocellular carcinoma treatment: a meta-analysis. <i>Translational Cancer Research</i> , 2021, 10, 2080-2090.	0.4	1
3777	The efficacy of radiofrequency ablation versus cryoablation in the treatment of single hepatocellular carcinoma: A population-based study. <i>Cancer Medicine</i> , 2021, 10, 3715-3725.	1.3	7
3778	Surgical resection significantly promotes the overall survival of patients with hepatocellular carcinoma: a propensity score matching analysis. <i>BMC Gastroenterology</i> , 2021, 21, 220.	0.8	10
3779	Inpatient Specialty-Level Palliative Care Is Delivered Late in the Course of Hepatocellular Carcinoma and Associated With Lower Hazard of Hospital Readmission. <i>Journal of Pain and Symptom Management</i> , 2021, 61, 940-947.e3.	0.6	10
3780	Cost-Effectiveness of Lenvatinib in the Treatment of Patients With Unresectable Hepatocellular Carcinomas in Japan: An Analysis Using Data From Japanese Patients in the REFLECT Trial. <i>Value in Health Regional Issues</i> , 2021, 24, 82-89.	0.5	6
3781	Surgical strategies for hepatocellular carcinoma located in the left lateral lobe: A propensity score-matched and prognostic nomogram study. <i>Cancer Medicine</i> , 2021, 10, 3274-3287.	1.3	2
3782	Repeat hepatectomy versus radiofrequency ablation in management of recurrent hepatocellular carcinoma: an average treatment effect analysis. <i>Annals of Surgical Oncology</i> , 2021, 28, 7731-7740.	0.7	8
3783	Material decomposition using iodine quantification on spectral CT for characterising nodules in the cirrhotic liver: a retrospective study. <i>European Radiology Experimental</i> , 2021, 5, 22.	1.7	3

#	ARTICLE	IF	CITATIONS
3784	Glypican-3 and hepatocyte paraffin-1 combined with alpha-fetoprotein as a novel risk scoring model for predicting early recurrence of hepatocellular carcinoma after curative resection. <i>European Journal of Gastroenterology and Hepatology</i> , 2021, 33, e603-e609.	0.8	6
3785	Inspecting Management Strategies of Hepatocellular Carcinoma in a Tertiary Centre in Western Rajasthan. <i>Journal of Evolution of Medical and Dental Sciences</i> , 2021, 10, 1314-1318.	0.1	0
3786	Evaluation of two different transarterial chemoembolization protocols using Lipiodol and degradable starch microspheres in therapy of hepatocellular carcinoma: a prospective trial. <i>Hepatology International</i> , 2021, 15, 685-694.	1.9	6
3787	THE BENEFITS VS POTENTIAL SIDE EFFECTS OF POSTCHEMOEMBOLIZATION FOR HEPATOCELLULAR CARCINOMA. <i>Medico Oncology</i> , 2020, 1, 17-27.	0.3	0
3788	Successful management of the hepatocellular carcinoma with inferior vena cava tumor thrombus. <i>Medicine (United States)</i> , 2021, 100, e26081.	0.4	0
3789	Estimating the attributable fraction of cirrhosis and hepatocellular carcinoma due to hepatitis B and C. <i>Journal of Viral Hepatitis</i> , 2021, 28, 1177-1189.	1.0	12
3790	Non-cirrhotic hepatocellular carcinoma in chronic viral hepatitis: Current insights and advancements. <i>World Journal of Gastroenterology</i> , 2021, 27, 3466-3482.	1.4	13
3791	Protein synthesis inhibitor omacetaxine is effective against hepatocellular carcinoma. <i>JCI Insight</i> , 2021, 6, .	2.3	10
3792	The Role of Protease-Activated Receptor 2 in Hepatocellular Carcinoma after Hepatectomy. <i>Medicina (Lithuania)</i> , 2021, 57, 574.	0.8	1
3793	Significance of liver resection for intermediate stage hepatocellular carcinoma according to subclassification. <i>BMC Cancer</i> , 2021, 21, 668.	1.1	6
3794	Hepatic Steatosis Has No Effect in Diagnosis Accuracy of <i>LI-RADS</i> v2018 Categorization of Hepatocellular Carcinoma in <i>MR</i> Imaging. <i>Journal of Magnetic Resonance Imaging</i> , 2021, , .	1.9	1
3795	Role of chromosome 1q copy number variation in hepatocellular carcinoma. <i>World Journal of Hepatology</i> , 2021, 13, 662-672.	0.8	2
3796	The Short-Term Efficacy of Novel No-Touch Combined Directional Perfusion Radiofrequency Ablation in the Treatment of Small Hepatocellular Carcinoma with Cirrhosis. <i>Journal of Investigative Surgery</i> , 2022, 35, 880-887.	0.6	7
3797	Quantitative Ultrasound Elastography Methods in Focal Liver Lesions Including Hepatocellular Carcinoma. <i>Ultrasound Quarterly</i> , 2021, 37, 90-96.	0.3	1
3798	The short-term safety and efficacy of TANDEM microspheres of various sizes and doxorubicin loading concentrations for hepatocellular carcinoma treatment. <i>Scientific Reports</i> , 2021, 11, 12277.	1.6	5
3799	Working relationship between primary and specialist care in analysing elevated liver values—a survey from the point of view of gastroenterologists. <i>Wiener Medizinische Wochenschrift</i> , 2021, 171, 301-309.	0.5	2
3800	The Risk Assessment and Clinical Research of Bile Duct Injury After Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma. <i>Cancer Management and Research</i> , 2021, Volume 13, 5039-5052.	0.9	5
3801	HCC You Cannot See. <i>Digestive Diseases and Sciences</i> , 2021, 66, 2185-2189.	1.1	0

#	ARTICLE	IF	CITATIONS
3802	IL28B, TLR7 SNPs, and cytomegalovirus infection are risk factors for advanced liver disease in chronic hepatitis C patients. <i>Expert Review of Anti-Infective Therapy</i> , 2022, 20, 121-129.	2.0	1
3803	Effectiveness of Transarterial Chemoembolization-First Treatment for Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis. <i>Journal of Hepatocellular Carcinoma</i> , 2021, Volume 8, 587-598.	1.8	1
3804	Trends in high-risk rates and screening rates for the population-based cancer screening program on esophageal, stomach and liver cancer in China, 2010-2016. <i>Journal of the National Cancer Center</i> , 2021, 1, 101-107.	3.0	12
3805	Analysis of Medical Use and Treatment Costs of Hepatocellular Carcinoma Patients Using National Patient Sample Data. <i>Korean Journal of Clinical Pharmacy</i> , 2021, 31, 153-159.	0.0	0
3806	The Role of Non-Gaussian Models of Diffusion Weighted MRI in Hepatocellular Carcinoma: A Systematic Review. <i>Journal of Clinical Medicine</i> , 2021, 10, 2641.	1.0	9
3807	A genetic variant in toll-like receptor 5 is linked to chemokine levels and hepatocellular carcinoma in steatohepatitis. <i>Liver International</i> , 2021, 41, 2139-2148.	1.9	6
3808	MRI-Derived Sarcopenia Associated with Increased Mortality Following Yttrium-90 Radioembolization of Hepatocellular Carcinoma. <i>CardioVascular and Interventional Radiology</i> , 2021, 44, 1561-1569.	0.9	11
3809	Surgical treatment of hepatocellular carcinoma. <i>BioScience Trends</i> , 2021, 15, 138-141.	1.1	63
3810	Atezolizumab and bevacizumab-induced encephalitis in advanced hepatocellular carcinoma. <i>Medicine (United States)</i> , 2021, 100, e26377.	0.4	10
3811	Prognostic value of the ALBI grade among patients with single hepatocellular carcinoma without macrovascular invasion. <i>Medicine (United States)</i> , 2021, 100, e26265.	0.4	10
3812	Highly sensitive <i>Lensâculinaris</i> agglutinin-reactive fraction of Î±fetoprotein is a predictive marker for hepatocarcinogenesis in long-term observation of patients with chronic liver disease. <i>Molecular and Clinical Oncology</i> , 2021, 15, 174.	0.4	2
3813	Illustration of missing data handling technique generated from hepatitis C induced hepatocellular carcinoma cohort study. <i>Journal of King Saud University - Science</i> , 2021, 33, 101403.	1.6	3
3814	High trough levels of everolimus combined to sorafenib improve patients survival after hepatocellular carcinoma recurrence in liver transplant recipients. <i>Transplant International</i> , 2021, 34, 1293-1305.	0.8	5
3815	Inclusive Quantification Assay of Serum Desâ³âCarboxyprothrombin Proteoforms for Hepatocellular Carcinoma Surveillance by Targeted Mass Spectrometry. <i>Hepatology Communications</i> , 2021, 5, 1767-1783.	2.0	4
3816	Screening, clinical features and prognostic analysis of liver cirrhosis-related hepatocellular carcinoma. <i>Scandinavian Journal of Gastroenterology</i> , 2021, 56, 948-954.	0.6	1
3817	Inter-center agreement of mRECIST in transplanted patients for hepatocellular carcinoma. <i>European Radiology</i> , 2021, 31, 8903-8912.	2.3	3
3818	Predictive performance of newer Asian hepatocellular carcinoma risk scores in treated Caucasians with chronic hepatitis B. <i>JHEP Reports</i> , 2021, 3, 100290.	2.6	5
3819	Use of M2BPGi in HCC patients with TACE. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 2917-2924.	1.4	4

#	ARTICLE	IF	CITATIONS
3820	The Multidisciplinary Management of Hepatocellular Carcinoma. <i>Clinical Liver Disease</i> , 2021, 17, 405-408.	1.0	10
3821	Multiparametric Analyses of Hepatocellular Carcinoma Somatic Mouse Models and Their Associated Tumor Microenvironment. <i>Current Protocols</i> , 2021, 1, e147.	1.3	5
3822	The effect of chronic viral hepatitis on prognostic value of inflammatory biomarkers in hepatocellular carcinoma. <i>Cancer Medicine</i> , 2021, 10, 5395-5404.	1.3	0
3823	Advances in immunotherapeutic targets for childhood cancers: A focus on glypican-2 and B7-H3. , 2021, 223, 107892.		11
3824	Circulating MicroRNA-21 and MicroRNA-122 as Prognostic Biomarkers in Hepatocellular Carcinoma Patients Treated with Transarterial Chemoembolization. <i>Biomedicines</i> , 2021, 9, 890.	1.4	6
3825	MELD-Sarcopenia is Better than ALBI and MELD Score in Patients with Hepatocellular Carcinoma Awaiting Liver Transplantation. <i>Asian Pacific Journal of Cancer Prevention</i> , 2021, 22, 2005-2009.	0.5	9
3826	Hepatocellular carcinoma in patients with renal dysfunction: Pathophysiology, prognosis, and treatment challenges. <i>World Journal of Gastroenterology</i> , 2021, 27, 4104-4142.	1.4	15
3827	International study on the outcome of locoregional therapy for liver transplant in hepatocellular carcinoma beyond Milan criteria. <i>JHEP Reports</i> , 2021, 3, 100331.	2.6	10
3828	Anti-programmed cell death ligand 1-based immunotherapy in recurrent hepatocellular carcinoma with inferior vena cava tumor thrombus and metastasis: Three case reports. <i>World Journal of Clinical Cases</i> , 2021, 9, 5988-5998.	0.3	2
3829	Early Versus Late Hepatocellular Carcinoma Recurrence After Transplantation: Predictive Factors, Patterns, and Long-term Outcome. <i>Transplantation</i> , 2021, 105, 1778-1790.	0.5	15
3830	Assessment of the cut-off value of quantitative liverâ€“portal vein contrast ratio in the hepatobiliary phase of liver MRI. <i>Clinical Radiology</i> , 2021, 76, 551.e17-551.e24.	0.5	1
3831	Nonalcoholic Fatty Liver Disease-Related Hepatocellular Carcinoma: Clinical Patterns, Outcomes, and Prognostic Factors for Overall Survivalâ€“A Retrospective Analysis of a Slovak Cohort. <i>Journal of Clinical Medicine</i> , 2021, 10, 3186.	1.0	2
3832	Ras related GTP binding D promotes aerobic glycolysis of hepatocellular carcinoma. <i>Annals of Hepatology</i> , 2021, 23, 100307.	0.6	9
3833	Low serum magnesium concentration is associated with the presence of viable hepatocellular carcinoma tissue in cirrhotic patients. <i>Scientific Reports</i> , 2021, 11, 15184.	1.6	2
3834	Effects of Home Care on patients with hepatocellular carcinoma treated with sorafenib. <i>JGH Open</i> , 2021, 5, 864-870.	0.7	1
3835	Identification of New Biomarker for Prediction of Hepatocellular Carcinoma Development in Early-Stage Cirrhosis Patients. <i>Journal of Oncology</i> , 2021, 2021, 1-18.	0.6	3
3836	Colonization with multidrug-resistant organisms impairs survival in patients with hepatocellular carcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, , 1.	1.2	6
3837	Bariatric Surgery and Liver Disease: General Considerations and Role of the Gutâ€“Liver Axis. <i>Nutrients</i> , 2021, 13, 2649.	1.7	24

#	ARTICLE	IF	CITATIONS
3838	miRNA and long non-coding RNA transcriptional expression in hepatocellular carcinoma cell line-secreted extracellular vesicles. <i>Clinical and Experimental Medicine</i> , 2022, 22, 245-255.	1.9	9
3839	Bisegmentectomy 7‐8 for Small-for-Size Remanant Liver for Cirrhotic Patients Under Right Hemi-hepatectomy With Hepatocellular Carcinoma: A Case-Matched Comparative Study. <i>Frontiers in Surgery</i> , 2021, 8, 675666.	0.6	1
3840	The Role of Immunotherapy in a Tolerogenic Environment: Current and Future Perspectives for Hepatocellular Carcinoma. <i>Cells</i> , 2021, 10, 1909.	1.8	6
3841	Advances of Targeted Therapy for Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 719896.	1.3	23
3842	Efficacy and Safety of Transarterial Chemoembolization in Elderly Patients of Advanced Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Retrospective Study. <i>Frontiers in Oncology</i> , 2021, 11, 646410.	1.3	6
3843	External validation of hepatocellular carcinoma risk scores in patients with chronic hepatitis B virus infection in China. <i>Journal of Viral Hepatitis</i> , 2021, 28, 1373-1380.	1.0	5
3844	Radiofrequency ablation of hepatocellular carcinoma: Prognostic factors and recent advances. <i>World Chinese Journal of Digestology</i> , 2021, 29, 677-683.	0.0	0
3845	Immunotherapy against programmed death-1/programmed death ligand 1 in hepatocellular carcinoma: Importance of molecular variations, cellular heterogeneity, and cancer stem cells. <i>World Journal of Stem Cells</i> , 2021, 13, 795-824.	1.3	7
3846	Combination of natural killer cell-based immunotherapy and irreversible electroporation for the treatment of hepatocellular carcinoma. <i>Annals of Translational Medicine</i> , 2021, 9, 1089-1089.	0.7	5
3847	Impact of modified albumin‐bilirubin grade on survival in patients with HCC who received lenvatinib. <i>Scientific Reports</i> , 2021, 11, 14474.	1.6	13
3848	Liver Inflammation and Hepatobiliary Cancers. <i>Trends in Cancer</i> , 2021, 7, 606-623.	3.8	46
3849	Radiofrequency ablation versus stereotactic body radiotherapy for hepatocellular carcinoma: a meta-analysis. <i>Future Oncology</i> , 2021, 17, 4027-4040.	1.1	5
3850	Validation of an alpha-fetoprotein model to predict recurrence after liver resection for hepatocellular carcinoma. <i>Updates in Surgery</i> , 2021, , 1.	0.9	1
3851	Metastatic hepatocellular carcinoma cured by exclusive systemic antiangiogenic therapy: Two cases along with tumor molecular profiles. <i>Digestive and Liver Disease</i> , 2021, 53, 1059-1061.	0.4	0
3852	Circ_0027089 regulates NACC1 by targeting miR-136-5p to aggravate the development of hepatitis B virus-related hepatocellular carcinoma. <i>Anti-Cancer Drugs</i> , 2022, 33, e336-e348.	0.7	8
3853	Decreased Incidence of Hepatocellular Carcinoma after Directly Acting Antiviral Therapy in Patients with Hepatitis C‐Related Advanced Fibrosis and Cirrhosis. <i>Journal of Hepatocellular Carcinoma</i> , 2021, Volume 8, 925-935.	1.8	4
3854	Chemoembolization for Single Large Hepatocellular Carcinoma with Preserved Liver Function: Analysis of Factors Predicting Clinical Outcomes in a 302 Patient Cohort. <i>Life</i> , 2021, 11, 840.	1.1	8
3855	Effect of Transarterial Chemoembolization on ALBI Grade in Intermediate-Stage Hepatocellular Carcinoma: Criteria for Unsuitable Cases Selection. <i>Cancers</i> , 2021, 13, 4325.	1.7	8

#	ARTICLE	IF	CITATIONS
3856	Development of an AI system for accurately diagnose hepatocellular carcinoma from computed tomography imaging data. <i>British Journal of Cancer</i> , 2021, 125, 1111-1121.	2.9	24
3857	Systems analysis identifies endothelin 1 axis blockade for enhancing the anti-tumor effect of multikinase inhibitor. <i>Cancer Gene Therapy</i> , 2021, , .	2.2	4
3858	Upregulated LINC01667 Expression Is Correlated With Poor Prognosis in Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 650173.	1.3	4
3859	Comparison of prognostic models in advanced hepatocellular carcinoma patients undergoing Sorafenib: A multicenter study.. <i>Digestive and Liver Disease</i> , 2021, 53, 1011-1019.	0.4	7
3860	Pickering gel emulsion of lipiodol stabilized by hairy nanogels for intra-artery embolization antitumor therapy. <i>Chemical Engineering Journal</i> , 2021, 418, 129534.	6.6	23
3861	Downstaging and resection of hepatocellular carcinoma in patients with extrahepatic metastases after stereotactic therapy. <i>Hepatobiliary Surgery and Nutrition</i> , 2021, 10, 434-442.	0.7	28
3862	Long-term assessment of recurrence of hepatocellular carcinoma in patients with chronic hepatitis C after viral cure by direct-acting antivirals. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2022, 37, 190-199.	1.4	3
3863	Predictive Models for HCC Prognosis, Recurrence Risk, and Immune Infiltration Based on Two Exosomal Genes: MYL6B and THOC2. <i>Journal of Inflammation Research</i> , 2021, Volume 14, 4089-4109.	1.6	14
3864	Combination of Sorafenib, Camrelizumab, Transcatheter Arterial Chemoembolization, and Stereotactic Body Radiation Therapy as a Novel Downstaging Strategy in Advanced Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Case Series Study. <i>Frontiers in Oncology</i> , 2021, 11, 650394.	1.3	16
3865	Expression Status and Prognostic Significance of Gamma-Glutamyl Transpeptidase Family Genes in Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 731144.	1.3	8
3866	Safety of sitagliptin in treatment of hepatocellular carcinoma in chronic liver disease patients. <i>Liver Cancer International</i> , 0, , .	0.2	1
3867	Significance of hepatocyte atypia in liver fine needle aspiration. <i>Diagnostic Cytopathology</i> , 2021, , .	0.5	2
3868	The 10-year Survival Analysis of Radiofrequency Ablation for Solitary Hepatocellular Carcinoma 5 cm or Smaller: Primary versus Recurrent HCC. <i>Radiology</i> , 2021, 300, 458-469.	3.6	38
3869	Long noncoding RNAs as biomarkers for the diagnosis of hepatocellular carcinoma: A meta-analysis. <i>Pathology Research and Practice</i> , 2021, 224, 153546.	1.0	4
3870	Efficacy of apatinib in patients with sorafenib-transarterial chemoembolization refractory hepatocellular carcinoma: a retrospective study. <i>Hepatology International</i> , 2021, 15, 1268-1277.	1.9	7
3871	The value of intra-operative ultrasonography on safety margin and outcome during liver resection and radio-frequency ablation in the management of hepatocellular carcinoma patients. <i>Egyptian Journal of Radiology and Nuclear Medicine</i> , 2021, 52, .	0.3	0
3872	Iodized oil computed tomography versus ultrasound-guided radiofrequency ablation for early hepatocellular carcinoma. <i>Hepatology International</i> , 2021, 15, 1247-1257.	1.9	6
3873	Impact of alcohol abstinence on survival after hepatic resection for hepatocellular carcinoma in patients with alcohol-related liver disease. <i>Annals of Medicine and Surgery</i> , 2021, 68, 102644.	0.5	4

#	ARTICLE	IF	CITATIONS
3874	Genetic Heterogeneity, Therapeutic Hurdle Confronting Sorafenib and Immune Checkpoint Inhibitors in Hepatocellular Carcinoma. <i>Cancers</i> , 2021, 13, 4343.	1.7	8
3875	The therapeutic value and molecular mechanisms of lncRNA FENDRR in human cancer. <i>Current Pharmaceutical Design</i> , 2021, 27, 4100-4106.	0.9	5
3876	Preoperative predictors of early recurrence after resection for hepatocellular carcinoma. <i>American Journal of Surgery</i> , 2022, 223, 945-950.	0.9	7
3877	A new model based on gamma-glutamyl transpeptidase to platelet ratio (GPR) predicts prognostic outcome after curative resection of solitary hepatocellular carcinoma. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2021, 45, 101509.	0.7	9
3878	Real-time respiratory motion compensated roadmaps for hepatic arterial interventions. <i>Medical Physics</i> , 2021, 48, 5661-5673.	1.6	4
3879	RNA sequencing analysis reveals the competing endogenous RNAs interplay in resected hepatocellular carcinoma patients who received interferon-alpha therapy. <i>Cancer Cell International</i> , 2021, 21, 464.	1.8	5
3880	Comparison of liver cancer incidence and survival by subtypes across seven high-income countries. <i>International Journal of Cancer</i> , 2021, 149, 2020-2031.	2.3	30
3881	Comparison of treatments for hepatocellular carcinoma patients with portal vein thrombosis: a systematic review and network meta-analysis. <i>Annals of Translational Medicine</i> , 2021, 9, 1450-1450.	0.7	4
3882	Development and validation of prognostic nomograms for single large and huge hepatocellular carcinoma after curative resection. <i>European Journal of Cancer</i> , 2021, 155, 85-96.	1.3	19
3883	Changes in treatment pattern and costs in advanced hepatocellular carcinoma (HCC). <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2022, 22, 147-154.	0.7	0
3884	Treatment for Hepatocellular Carcinoma in South Asia. <i>Journal of Clinical and Experimental Hepatology</i> , 2021, 11, 641-645.	0.4	0
3885	Regorafenib Efficacy After Sorafenib in Patients With Recurrent Hepatocellular Carcinoma After Liver Transplantation: A Retrospective Study. <i>Liver Transplantation</i> , 2021, 27, 1767-1778.	1.3	19
3886	Safety and efficacy of percutaneous radiofrequency ablation for hepatocellular carcinoma: a textbook outcome analysis. <i>Hpb</i> , 2022, 24, 664-671.	0.1	2
3887	Serial circulating tumor DNA to predict early recurrence in patients with hepatocellular carcinoma: a prospective study. <i>Molecular Oncology</i> , 2022, 16, 549-561.	2.1	21
3888	Prognostic significance of viable tumor size measurement in hepatocellular carcinomas after preoperative locoregional treatment. <i>Journal of Pathology and Translational Medicine</i> , 2021, 55, 338-348.	0.4	3
3889	Association Between Adjuvant Sorafenib and the Prognosis of Patients With Hepatocellular Carcinoma at a High Risk of Recurrence After Radical Resection. <i>Frontiers in Oncology</i> , 2021, 11, 633033.	1.3	5
3890	Highly differential count of circulating and tumor infiltrating immune cells in patients with non-HCV/non-HBV hepatocellular carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 1103-1113.	2.0	7
3891	Inflow vascular occlusion technique versus hemihepatic vascular maneuver in hepatectomy: A systematic review and meta-analysis. <i>Asian Journal of Surgery</i> , 2021, 44, 1600-1601.	0.2	0

#	ARTICLE	IF	CITATIONS
3892	Long Noncoding RNA NTT Context-Dependently Regulates MYB by Interacting With Activated Complex in Hepatocellular Carcinoma Cells. <i>Frontiers in Oncology</i> , 2021, 11, 592045.	1.3	2
3893	Alteration of prognostic efficacy of albuminâ€bilirubin grade and Childâ€Pugh score according to liver fibrosis in hepatocellular carcinoma patients with Childâ€Pugh A following hepatectomy. <i>Annals of Gastroenterological Surgery</i> , 2022, 6, 127-134.	1.2	6
3894	Early evaluation of treatment response to transarterial chemoembolization in patients with advanced hepatocellular carcinoma: The role of dynamic three-dimensional contrast-enhanced ultrasound. <i>Clinical Hemorheology and Microcirculation</i> , 2021, 78, 365-377.	0.9	4
3895	Comparative efficacy and safety for second-line treatment with ramucirumab, regorafenib, and cabozantinib in patients with advanced hepatocellular carcinoma progressed on sorafenib treatment. <i>Medicine (United States)</i> , 2021, 100, e27013.	0.4	4
3896	Nomogram to Predict the Survival of Chinese Patients with Alcohol-Related Liver Disease. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2021, 2021, 1-8.	0.8	4
3897	Factors affecting longâ€term changes of liver stiffness in directâ€acting antiâ€hepatitis C virus therapy: A multicentre prospective study. <i>Journal of Viral Hepatitis</i> , 2022, 29, 26-34.	1.0	10
3898	The safety and efficacy of transarterial chemoembolisation with bleomycin for hepatocellular carcinoma unresponsive to doxorubicin: a prospective single-centre study. <i>Clinical Radiology</i> , 2021, 76, 864.e7-864.e12.	0.5	4
3899	Longâ€term effects of entecavir and tenofovir treatment on the fibrotic burden in patients with chronic hepatitis B. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2022, 37, 200-207.	1.4	5
3900	Prognostic Value of Serum Osteoprotegerin Level in Patients With Hepatocellular Carcinoma Following Surgical Resection. <i>Frontiers in Oncology</i> , 2021, 11, 731989.	1.3	4
3901	The Role of Cytokines in the Different Stages of Hepatocellular Carcinoma. <i>Cancers</i> , 2021, 13, 4876.	1.7	27
3902	Insufficient Radiofrequency Ablation Promotes Hepatocellular Carcinoma Metastasis Through N6â€Methyladenosine mRNA Methylationâ€Dependent Mechanism. <i>Hepatology</i> , 2021, 74, 1339-1356.	3.6	62
3903	Histotripsy for the Treatment of Cholangiocarcinoma Liver Tumors: <i>In Vivo</i> Feasibility and <i>Ex Vivo</i> Dosimetry Study. <i>IEEE Transactions on Ultrasonics, Ferroelectrics, and Frequency Control</i> , 2021, 68, 2953-2964.	1.7	17
3904	Portal vein thrombosis in patients with chronic liver diseases: From conventional to quantitative imaging. <i>European Journal of Radiology</i> , 2021, 142, 109859.	1.2	4
3905	Image-Guided Liver Stereotactic Body Radiotherapy Using VMAT and Real-Time Adaptive Tumor Gating: Evaluation of the Efficacy and Toxicity for Hepatocellular Carcinoma. <i>Cancers</i> , 2021, 13, 4853.	1.7	6
3906	Gene expression network related to DNA methylation and miRNA regulation during the process of aflatoxin B1â€induced malignant transformation of L02 cells. <i>Journal of Applied Toxicology</i> , 2022, 42, 475-489.	1.4	4
3907	The clinical application of PIVKAâ€II in hepatocellular carcinoma and chronic liver diseases: A multiâ€center study in China. <i>Journal of Clinical Laboratory Analysis</i> , 2021, 35, e24013.	0.9	11
3908	Risk factors for major complications after liver resection: A large liver resection study from Morocco and audit of a non-Eastern/non-Western experience. <i>Arab Journal of Gastroenterology</i> , 2021, 22, 229-235.	0.4	0
3909	Comparative Analysis of Lenvatinib and Hepatic Arterial Infusion Chemotherapy in Unresectable Hepatocellular Carcinoma: A Multi-Center, Propensity Score Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 4045.	1.0	11

#	ARTICLE	IF	CITATIONS
3910	A Systemic Inflammation Response Index (SIRI)-Based Nomogram for Predicting the Recurrence of Early Stage Hepatocellular Carcinoma After Radiofrequency Ablation. <i>CardioVascular and Interventional Radiology</i> , 2022, 45, 43-53.	0.9	11
3911	The Progress in the Treatment of Hepatocellular Carcinoma With Portal Vein Tumor Thrombus. <i>Frontiers in Oncology</i> , 2021, 11, 635731.	1.3	26
3912	Comprehensive analysis of prognostic immune-related genes in the tumor microenvironment of hepatocellular carcinoma (HCC). <i>Medicine (United States)</i> , 2021, 100, e27332.	0.4	1
3913	Asociación Mexicana de Hepatología A.C. Clinical guideline on hepatitis B. <i>Revista De Gastroenterología De México (English Edition)</i> , 2021, 86, 403-432.	0.1	0
3914	Association between HBs Ag quantification and the risk of hepatocellular carcinoma in patients treated with tenofovir disoproxil fumarate or entecavir. <i>Medicine (United States)</i> , 2021, 100, e27417.	0.4	0
3915	Hepatic Hilar Nerve Block for Hepatic Interventions: Anatomy, Technique, and Initial Clinical Experience in Thermal Ablation of Liver Tumors. <i>Radiology</i> , 2021, 301, 223-228.	3.6	4
3917	External validation of the Toronto hepatocellular carcinoma risk index in a Swedish population. <i>JHEP Reports</i> , 2021, 3, 100343.	2.6	2
3918	Diagnostic test accuracies of F-18 FDG PET/CT for prediction of microvascular invasion of hepatocellular carcinoma: A meta-analysis. <i>Clinical Imaging</i> , 2021, 79, 251-258.	0.8	6
3919	Preoperative combi-elastography for the prediction of early recurrence after curative resection of hepatocellular carcinoma. <i>Clinical Imaging</i> , 2021, 79, 173-178.	0.8	1
3920	Treatment of Chronic Hepatitis B Virus with Oral Anti-Viral Therapy. <i>Clinics in Liver Disease</i> , 2021, 25, 725-740.	1.0	5
3921	Advanced electrochemical nanobiosensor for ultraefficient Annexin A2 biomarker detection: A rapid, label free and minimal invasive approach towards early diagnosis of liver cancer. <i>Materials Letters</i> , 2021, 305, 130856.	1.3	5
3923	Targeting c-Met and AXL Crosstalk for the Treatment of Hepatocellular Carcinoma. , 2021, , 333-364.		0
3924	<i>Cistanche tubulosa</i> Phenylethanoid Glycosides Induce Apoptosis of Hepatocellular Carcinoma Cells by Mitochondria-Dependent and MAPK Pathways and Enhance Antitumor Effect through Combination with Cisplatin. <i>Integrative Cancer Therapies</i> , 2021, 20, 153473542110130.	0.8	10
3925	Development and validation of a novel nomogram predicting 10-year actual survival after curative hepatectomy for hepatocellular carcinoma. <i>Journal of the Royal College of Surgeons of Edinburgh</i> , 2021, 19, 329-337.	0.8	8
3927	Local Efficacy and Safety of Transarterial Chemoembolization for Hepatocellular Carcinoma: Epirubicin-Loaded DC Beads vs. Epirubicin-Lipiodol Emulsion with Gelatin Sponge (cTACE). <i>Interventional Radiology</i> , 2021, 6, 14-20.	0.2	0
3928	Preoperative Versus Postoperative Transarterial Chemoembolization on Prognosis of Large Hepatocellular Carcinoma. <i>Journal of Cancer</i> , 2021, 12, 6231-6241.	1.2	2
3929	Regional liver function analysis with gadoxetic acid-enhanced MRI and virtual hepatectomy: prediction of postoperative short-term outcomes for HCC. <i>European Radiology</i> , 2021, 31, 4720-4730.	2.3	15
3930	Assessment of Incidence of and Surveillance Burden for Hepatocellular Carcinoma Among Patients With Hepatitis C in the Era of Direct-Acting Antiviral Agents. <i>JAMA Network Open</i> , 2020, 3, e2021173.	2.8	15

#	ARTICLE	IF	CITATIONS
3931	Changing Epidemiology of Hepatocellular Carcinoma and Role of Surveillance. <i>Molecular and Translational Medicine</i> , 2019, , 53-67.	0.4	5
3932	Liver Transplantation for HCC: The Milan Criteria. , 2016, , 1-19.		1
3933	Hepatocellular Carcinoma and Patient Assessment. <i>Advances in Predictive, Preventive and Personalised Medicine</i> , 2015, , 21-32.	0.6	1
3935	Ultrasound of Hepatocellular Carcinoma: The Important Contribution of Contrast Enhancement. , 2016, , 367-390.		2
3936	Hepatocellular Carcinoma: Surgical Management and Evolving Therapies. <i>Cancer Treatment and Research</i> , 2016, 168, 165-183.	0.2	2
3937	Role of Tumor Microenvironment in Hepatocellular Carcinoma Resistance. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2017, , 45-64.	0.1	1
3938	Vaccine Approaches in Hepatocellular Carcinoma. , 2017, , 1-17.		1
3939	Surveillance for Hepatocellular Carcinoma. , 2019, , 13-21.		1
3940	HCC. , 2015, , 31-54.		1
3941	Diagnostik und Therapie des hepatozellulären Karzinoms. , 2015, , 95-104.		1
3942	Minimally invasive surgery versus radiofrequency ablation for single subcapsular hepatocellular carcinoma in compensated liver cirrhosis. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2020, 34, 5566-5573.	1.3	17
3943	Treatment of hepatocellular carcinoma with hepatic vein tumor thrombosis protruding into the inferior vena cava by conversion surgery following chemotherapy with regorafenib: a case report. <i>Clinical Journal of Gastroenterology</i> , 2020, 13, 428-433.	0.4	7
3944	Adjuncts to hepatic resection. , 2017, , 1684-1724.e3.		2
3945	Curative Irradiation Treatment of Hepatocellular Carcinoma: A Multicenter Phase 2 Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 107, 116-125.	0.4	63
3946	ACR Appropriateness Criteria for Chronic Liver Disease. <i>Journal of the American College of Radiology</i> , 2017, 14, S103-S117.	0.9	20
3947	Retrospective analysis of stereotactic body radiation therapy efficacy over radiofrequency ablation for hepatocellular carcinoma. <i>Radiotherapy and Oncology</i> , 2019, 131, 81-87.	0.3	70
3948	Expression patterns of programmed death ligand 1 correlate with different microenvironments and patient prognosis in hepatocellular carcinoma. <i>British Journal of Cancer</i> , 2018, 119, 80-88.	2.9	74
3949	Comparison of diagnostic accuracy of Midkine and AFP for detecting hepatocellular carcinoma: a systematic review and meta-analysis. <i>Bioscience Reports</i> , 2020, 40, .	1.1	23

#	ARTICLE	IF	CITATIONS
3950	Statin use and the prognosis of patients with hepatocellular carcinoma: a meta-analysis. <i>Bioscience Reports</i> , 2020, 40, .	1.1	13
3951	Revealing the clinical significance and prognostic value of small nucleolar RNA SNORD31 in hepatocellular carcinoma. <i>Bioscience Reports</i> , 2020, 40, .	1.1	4
3952	Synergistic Effect of Biejia-Ruangan on Fibrosis Regression in Patients With Chronic Hepatitis B Treated With Entecavir: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial. <i>Journal of Infectious Diseases</i> , 2022, 225, 1091-1099.	1.9	17
3953	Evaluation of Serum GDF15, AFP, and PIVKA-II as Diagnostic Markers for HBV-Associated Hepatocellular Carcinoma. <i>Laboratory Medicine</i> , 2021, 52, 381-389.	0.8	8
3954	Predicting the risk of postoperative liver failure and overall survival using liver and spleen stiffness measurements in patients with hepatocellular carcinoma. <i>Medicine (United States)</i> , 2017, 96, e7864.	0.4	17
3955	Platelet-lymphocyte ratio predicts survival in patients with hepatocellular carcinoma who receive lenvatinib: an inverse probability weighting analysis. <i>European Journal of Gastroenterology and Hepatology</i> , 2021, 32, 261-268.	0.8	9
3956	Oncological Resection for Liver Malignancies. <i>Annals of Surgery</i> , 2022, 275, 182-188.	2.1	10
3957	Liver Transplantation for Hepatocellular Carcinoma. Working Group Report from the ILTS Transplant Oncology Consensus Conference. <i>Transplantation</i> , 2020, 104, 1136-1142.	0.5	105
3960	Long-term follow-up of diabetic and non-diabetic patients with chronic hepatitis C successfully treated with direct-acting antiviral agents. <i>Liver International</i> , 2021, 41, 276-287.	1.9	15
3961	Tumour thrombus of the inferior vena cava extending into the right atrium in the setting of colon cancer. <i>BMJ Case Reports</i> , 2017, 2017, bcr2016218107.	0.2	4
3962	Hepatocellular Carcinoma Risk Steadily Persists over Time Despite Long-Term Antiviral Therapy for Hepatitis B: A Multicenter Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 832-837.	1.1	30
3963	Patient Comorbidities Drive High Mortality Rates Associated with Major Liver Resections Irrespective of Hospital Volume. <i>American Surgeon</i> , 2021, 87, 1163-1170.	0.4	3
3964	Follow-up after radiological intervention in oncology: ECIO-ESOI evidence and consensus-based recommendations for clinical practice. <i>Insights Into Imaging</i> , 2020, 11, 83.	1.6	34
3965	Albumin-Bilirubin Score for Predicting Post-Transplant Complications Following Adult-to-Adult Living Donor Liver Transplantation. <i>Annals of Transplantation</i> , 2018, 23, 639-646.	0.5	20
3966	Acoustic Radiation Force Impulse (ARFI) Elastography and Serological Markers in Assessment of Liver Fibrosis and Free Portal Pressure in Patients with Hepatitis B. <i>Medical Science Monitor</i> , 2017, 23, 3585-3592.	0.5	4
3967	Sperm-Associated Antigen 5 Expression Is Increased in Hepatocellular Carcinoma and Indicates Poor Prognosis. <i>Medical Science Monitor</i> , 2018, 24, 6021-6028.	0.5	12
3968	ADAR1 p110 Enhances Adhesion of Tumor Cells to Extracellular Matrix in Hepatocellular Carcinoma via Up-Regulating ITGA2 Expression. <i>Medical Science Monitor</i> , 2019, 25, 1469-1479.	0.5	22
3969	Hepatocellular Carcinoma in Diabetic Patients - a Single Center Experience. <i>Current Health Sciences Journal</i> , 2016, 42, 180-187.	0.2	1

#	ARTICLE	IF	CITATIONS
3970	Effect of double platinum agents, combination of miriplatintransarterial oily chemoembolization and cisplatinhepatic arterial infusion chemotherapy, in patients with hepatocellular carcinoma: Report of two cases. <i>World Journal of Clinical Cases</i> , 2017, 5, 238.	0.3	2
3971	Conversion therapy and suitable timing for subsequent salvage surgery for initially unresectable hepatocellular carcinoma: What is new?. <i>World Journal of Clinical Cases</i> , 2018, 6, 259-273.	0.3	12
3972	Safety and efficacy of transjugular intrahepatic portosystemic shunt combined with palliative treatment in patients with hepatocellular carcinoma. <i>World Journal of Clinical Cases</i> , 2019, 7, 1599-1610.	0.3	13
3973	The ITA.LI.CA Staging System: A Novel Staging System for Hepatocellular Carcinoma. <i>PLoS Medicine</i> , 2016, 13, e1002005.	3.9	6
3974	Development and Validation of a New Prognostic System for Patients with Hepatocellular Carcinoma. <i>PLoS Medicine</i> , 2016, 13, e1002006.	3.9	113
3975	Liver Fibrosis in Type I Gaucher Disease: Magnetic Resonance Imaging, Transient Elastography and Parameters of Iron Storage. <i>PLoS ONE</i> , 2013, 8, e57507.	1.1	45
3976	PNPLA3 I148M Polymorphism, Clinical Presentation, and Survival in Patients with Hepatocellular Carcinoma. <i>PLoS ONE</i> , 2013, 8, e75982.	1.1	42
3977	HIF-1 α and HIF-2 α : Siblings in Promoting Angiogenesis of Residual Hepatocellular Carcinoma after High-Intensity Focused Ultrasound Ablation. <i>PLoS ONE</i> , 2014, 9, e88913.	1.1	27
3978	Genetic Variants in the EPCAM Gene Is Associated with the Prognosis of Transarterial Chemoembolization Treated Hepatocellular Carcinoma with Portal Vein Tumor Thrombus. <i>PLoS ONE</i> , 2014, 9, e93416.	1.1	9
3979	Correlation of MicroRNA-16, MicroRNA-21 and MicroRNA-101 Expression with Cyclooxygenase-2 Expression and Angiogenic Factors in Cirrhotic and Noncirrhotic Human Hepatocellular Carcinoma. <i>PLoS ONE</i> , 2014, 9, e95826.	1.1	10
3980	Development of a Highly Sensitive Glycan Microarray for Quantifying AFP-L3 for Early Prediction of Hepatitis B Virus-Related Hepatocellular Carcinoma. <i>PLoS ONE</i> , 2014, 9, e99959.	1.1	22
3981	Quality Assessment of Clinical Practice Guidelines on the Treatment of Hepatocellular Carcinoma or Metastatic Liver Cancer. <i>PLoS ONE</i> , 2014, 9, e103939.	1.1	17
3982	Hepatic Resection Is Safe and Effective for Patients with Hepatocellular Carcinoma and Portal Hypertension. <i>PLoS ONE</i> , 2014, 9, e108755.	1.1	46
3983	Nuclear Expression of the Deubiquitinase CYLD Is Associated with Improved Survival in Human Hepatocellular Carcinoma. <i>PLoS ONE</i> , 2014, 9, e110591.	1.1	12
3984	Preclinical Trials for Prevention of Tumor Progression of Hepatocellular Carcinoma by LZ-8 Targeting c-Met Dependent and Independent Pathways. <i>PLoS ONE</i> , 2015, 10, e0114495.	1.1	22
3985	Plasma Protein Biomarkers of Hepatocellular Carcinoma in HCV-Infected Alcoholic Patients with Cirrhosis. <i>PLoS ONE</i> , 2015, 10, e0118527.	1.1	28
3986	Identifying Prognostic Features by Bottom-Up Approach and Correlating to Drug Repositioning. <i>PLoS ONE</i> , 2015, 10, e0118672.	1.1	12
3987	Use of Ethanol in the Trans-Arterial Lipiodol Embolization (TAELE) of Intermediated-Stage HCC: Is This Safer than Conventional Trans-Arterial Chemo-Embolization (c-TACE)? <i>PLoS ONE</i> , 2015, 10, e0129573.	1.1	8

#	ARTICLE	IF	CITATIONS
3988	Potential Role of Circulating microRNA-21 for Hepatocellular Carcinoma Diagnosis: A Meta-Analysis. PLoS ONE, 2015, 10, e0130677.	1.1	39
3989	Korean Version of a Model to Estimate Survival in Ambulatory Patients with Hepatocellular Carcinoma (K-MESIAH). PLoS ONE, 2015, 10, e0138374.	1.1	1
3990	Serum LncRNAs Profiles Serve as Novel Potential Biomarkers for the Diagnosis of HBV-Positive Hepatocellular Carcinoma. PLoS ONE, 2015, 10, e0144934.	1.1	45
3991	Diagnostic Performance of Alpha-Fetoprotein, Protein Induced by Vitamin K Absence, Osteopontin, Dickkopf-1 and Its Combinations for Hepatocellular Carcinoma. PLoS ONE, 2016, 11, e0151069.	1.1	68
3992	Radioembolization Is a Safe and Effective Treatment for Hepatocellular Carcinoma with Portal Vein Thrombosis: A Propensity Score Analysis. PLoS ONE, 2016, 11, e0154986.	1.1	48
3993	Solitary Large Hepatocellular Carcinoma: Staging and Treatment Strategy. PLoS ONE, 2016, 11, e0155588.	1.1	37
3994	Impact of MELD Allocation System on Waiting List and Early Post-Liver Transplant Mortality. PLoS ONE, 2016, 11, e0155822.	1.1	11
3995	Alpha-Fetoprotein Detection of Hepatocellular Carcinoma Leads to a Standardized Analysis of Dynamic AFP to Improve Screening Based Detection. PLoS ONE, 2016, 11, e0156801.	1.1	29
3996	Higher Ratio of Serum Alpha-Fetoprotein Could Predict Outcomes in Patients with Hepatitis B Virus-Associated Hepatocellular Carcinoma and Normal Alanine Aminotransferase. PLoS ONE, 2016, 11, e0157299.	1.1	15
3997	Analysis of Sorafenib Outcome: Focusing on the Clinical Course in Patients with Hepatocellular Carcinoma. PLoS ONE, 2016, 11, e0161303.	1.1	7
3998	Switching Monopolar Radiofrequency Ablation Using a Separable Cluster Electrode in Patients with Hepatocellular Carcinoma: A Prospective Study. PLoS ONE, 2016, 11, e0161980.	1.1	14
3999	Prognostic Significance of Concurrent Hypovascular and Hypervascular Nodules in Patients with Hepatocellular Carcinoma. PLoS ONE, 2016, 11, e0163119.	1.1	6
4000	Survival Analysis of Single Large (>5 cm) Hepatocellular Carcinoma Patients: BCLC A versus B. PLoS ONE, 2016, 11, e0165722.	1.1	33
4001	Optimizing Surveillance Performance of Alpha-Fetoprotein by Selection of Proper Target Population in Chronic Hepatitis B. PLoS ONE, 2016, 11, e0168189.	1.1	7
4002	Is Adjuvant Cellular Immunotherapy Essential after TACE-Predominant Minimally-Invasive Treatment for Hepatocellular Carcinoma? A Systematic Meta-Analysis of Studies Including 1774 Patients. PLoS ONE, 2016, 11, e0168798.	1.1	20
4003	Comparable Outcomes of Ultrasound versus Computed Tomography in the Guidance of Radiofrequency Ablation for Hepatocellular Carcinoma. PLoS ONE, 2017, 12, e0169655.	1.1	28
4004	No-touch radiofrequency ablation using multiple electrodes: An in vivo comparison study of switching monopolar versus switching bipolar modes in porcine livers. PLoS ONE, 2017, 12, e0176350.	1.1	20
4005	Survival and prognostic factors for patients with advanced hepatocellular carcinoma after stereotactic ablative radiotherapy. PLoS ONE, 2017, 12, e0177793.	1.1	21

#	ARTICLE	IF	CITATIONS
4006	Prognostic role of noninvasive liver reserve markers in patients with hepatocellular carcinoma undergoing transarterial chemoembolization. PLoS ONE, 2017, 12, e0180408.	1.1	31
4007	The impact of thyroid hormones on patients with hepatocellular carcinoma. PLoS ONE, 2017, 12, e0181878.	1.1	24
4008	Liver stiffness measurement predicts liver-related events in patients with chronic hepatitis C: A retrospective study. PLoS ONE, 2017, 12, e0184404.	1.1	10
4009	Mid-infrared spectroscopy of serum, a promising non-invasive method to assess prognosis in patients with ascites and cirrhosis. PLoS ONE, 2017, 12, e0185997.	1.1	17
4010	SOX9 is a proliferation and stem cell factor in hepatocellular carcinoma and possess widespread prognostic significance in different cancer types. PLoS ONE, 2017, 12, e0187814.	1.1	56
4011	Impact of tumor burden on prognostic prediction for patients with terminal stage hepatocellular carcinoma: A nomogram study. PLoS ONE, 2017, 12, e0188031.	1.1	14
4012	Transcatheter arterial chemoembolization after stopping sorafenib therapy for advanced hepatocellular carcinoma. PLoS ONE, 2017, 12, e0188999.	1.1	4
4013	Predicting outcomes for recurrent hepatocellular carcinoma within Milan criteria after complete radiofrequency ablation. PLoS ONE, 2020, 15, e0242113.	1.1	13
4014	Hepatocellular Carcinoma and Liver Transplantation: State of the Art. Journal of Clinical and Translational Hepatology, 2014, 2, 176-81.	0.7	35
4015	Hepatobiliary Tumors: Update on Diagnosis and Management. Journal of Clinical and Translational Hepatology, 2015, 3, 169-181.	0.7	39
4016	Chemotherapy for Hepatocellular Carcinoma: Current Evidence and Future Perspectives. Journal of Clinical and Translational Hepatology, 2017, XX, 1-14.	0.7	16
4017	Integration of Prealbumin into Child-Pugh Classification Improves Prognosis Predicting Accuracy in HCC Patients Considering Curative Surgery. Journal of Clinical and Translational Hepatology, 2018, 6, 1-8.	0.7	9
4018	Hepatocellular Carcinoma: State of the Art Imaging and Recent Advances. Journal of Clinical and Translational Hepatology, 2019, 7, 1-14.	0.7	28
4019	Rates and Predictors of Undergoing Different Hepatocellular Carcinoma Screening Tests in Patients With Cirrhosis. American Journal of Gastroenterology, 2021, 116, 411-415.	0.2	9
4020	Elevated a-Fetoprotein in the Absence of Carcinoma Caused by Relapse of Hepatitis C Viral Infection after Liver Transplantation. ACG Case Reports Journal, 2018, 5, e1031-4.	0.2	1
4021	Intra- and interobserver reliability of gray scale/dynamic range evaluation of ultrasonography using a standardized phantom. Ultrasonography, 2014, 33, 91-97.	1.0	8
4022	Local ablation therapy with contrast-enhanced ultrasonography for hepatocellular carcinoma: a practical review. Ultrasonography, 2015, 34, 235-245.	1.0	24
4023	Contrast-enhanced ultrasonography of the liver using SonoVue. Ultrasonography, 2018, 37, 25-35.	1.0	46

#	ARTICLE	IF	CITATIONS
4024	Failure of hepatocellular carcinoma surveillance: inadequate echogenic window and macronodular parenchyma as potential culprits. <i>Ultrasonography</i> , 2019, 38, 311-320.	1.0	17
4025	Contrast-enhanced ultrasound approach to the diagnosis of focal liver lesions: the importance of washout. <i>Ultrasonography</i> , 2019, 38, 289-301.	1.0	36
4026	Contrast-enhanced ultrasound imaging features and clinical characteristics of combined hepatocellular cholangiocarcinoma: comparison with hepatocellular carcinoma and cholangiocarcinoma. <i>Ultrasonography</i> , 2020, 39, 356-366.	1.0	20
4027	Predictors of In-Hospital Mortality in patients with hepatocellular carcinoma and Acute Variceal bleeding. <i>Electronic Physician</i> , 2015, 7, 1336-43.	0.2	7
4028	Number of Nodules but not Size of Hepatocellular Carcinoma Can Predict Refractoriness to Transarterial Chemoembolization and Poor Prognosis. <i>Journal of Clinical Medicine Research</i> , 2018, 10, 765-771.	0.6	16
4029	Grade III hand-foot skin reaction induced by sorafenib. <i>Anais Brasileiros De Dermatologia</i> , 2017, 92, 590-591.	0.5	1
4030	Liver transplantation in an adult patient with hepatocellular carcinoma following liver cirrhosis as a complication of the Fontan procedure -A case report-. <i>Anesthesia and Pain Medicine</i> , 2020, 15, 466-471.	0.5	2
4032	Integrative analysis of DNA methylation and gene expression reveals distinct hepatocellular carcinoma subtypes with therapeutic implications. <i>Aging</i> , 2020, 12, 4970-4995.	1.4	11
4033	The association between KLF4 as a tumor suppressor and the prognosis of hepatocellular carcinoma after curative resection. <i>Aging</i> , 2020, 12, 15566-15580.	1.4	6
4034	Serum microRNA profiles as prognostic biomarkers for HBV-positive hepatocellular carcinoma. <i>Oncotarget</i> , 2016, 7, 45637-45648.	0.8	22
4035	Prediction of early hepatocellular carcinoma recurrence using germinal center kinase-like kinase. <i>Oncotarget</i> , 2016, 7, 49765-49776.	0.8	9
4036	Androgen receptor mitigates postoperative disease progression of hepatocellular carcinoma by suppressing CD90+ populations and cell migration and by promoting anoikis in circulating tumor cells. <i>Oncotarget</i> , 2016, 7, 46448-46465.	0.8	22
4037	Occult HBV infection in HCC and cirrhotic tissue of HBsAg-negative patients: a virological and clinical study. <i>Oncotarget</i> , 2016, 7, 62706-62714.	0.8	46
4038	Retrospective analysis of transarterial chemoembolization and sorafenib in Chinese patients with unresectable and recurrent hepatocellular carcinoma. <i>Oncotarget</i> , 2016, 7, 83806-83816.	0.8	24
4039	HVPG signature: A prognostic and predictive tool in hepatocellular carcinoma. <i>Oncotarget</i> , 2016, 7, 62789-62796.	0.8	13
4040	Sirolimus and metformin synergistically inhibit hepatocellular carcinoma cell proliferation and improve long-term survival in patients with HCC related to hepatitis B virus induced cirrhosis after liver transplantation. <i>Oncotarget</i> , 2016, 7, 62647-62656.	0.8	20
4041	Tumor and circulating biomarkers in patients with second-line hepatocellular carcinoma from the randomized phase II study with tivantinib. <i>Oncotarget</i> , 2016, 7, 72622-72633.	0.8	60
4042	Trans-arterial radioembolization in intermediate-advanced hepatocellular carcinoma: systematic review and meta-analyses. <i>Oncotarget</i> , 2016, 7, 72343-72355.	0.8	57

#	ARTICLE	IF	CITATIONS
4043	Simple and robust diagnosis of early, small and AFP-negative primary hepatic carcinomas: an integrative approach of serum fluorescence and conventional blood tests. <i>Oncotarget</i> , 2016, 7, 64053-64070.	0.8	8
4044	Effect of marital status on the survival of patients with hepatocellular carcinoma treated with surgical resection: an analysis of 13,408 patients in the surveillance, epidemiology, and end results (SEER) database. <i>Oncotarget</i> , 2016, 7, 79442-79452.	0.8	24
4045	Transarterial chemoembolization for early stage hepatocellular carcinoma decrease local tumor control and overall survival compared to radiofrequency ablation. <i>Oncotarget</i> , 2017, 8, 32190-32200.	0.8	15
4046	Factors associated with ethnical disparity in overall survival for patients with hepatocellular carcinoma. <i>Oncotarget</i> , 2017, 8, 15193-15204.	0.8	25
4047	The lack of the organic cation transporter OCT1 at the plasma membrane of tumor cells precludes a positive response to sorafenib in patients with hepatocellular carcinoma. <i>Oncotarget</i> , 2017, 8, 15846-15857.	0.8	40
4048	Integration of the cancer-related inflammatory response as a stratifying biomarker of survival in hepatocellular carcinoma treated with sorafenib. <i>Oncotarget</i> , 2017, 8, 36161-36170.	0.8	44
4049	Tumor stage and primary treatment of hepatocellular carcinoma at a large tertiary hospital in China: A real-world study. <i>Oncotarget</i> , 2017, 8, 18296-18302.	0.8	54
4050	Outcomes of microwave ablation for hepatocellular carcinoma adjacent to large vessels: a propensity score analysis. <i>Oncotarget</i> , 2017, 8, 28758-28768.	0.8	27
4051	Adjuvant celecoxib and lanreotide following transarterial chemoembolisation for unresectable hepatocellular carcinoma: a randomized pilot study. <i>Oncotarget</i> , 2017, 8, 48303-48312.	0.8	17
4052	Interferon alpha antagonizes the anti-hepatoma activity of the oncolytic virus M1 by stimulating anti-viral immunity. <i>Oncotarget</i> , 2017, 8, 24694-24705.	0.8	14
4053	Lowered expression of microRNA-125a-5p in human hepatocellular carcinoma and up-regulation of its oncogenic targets sirtuin-7, matrix metalloproteinase-11, and c-Raf. <i>Oncotarget</i> , 2017, 8, 25289-25299.	0.8	33
4054	PLCE1 polymorphisms and expression combined with serum AFP level predicts survival of HBV-related hepatocellular carcinoma patients after hepatectomy. <i>Oncotarget</i> , 2017, 8, 29202-29219.	0.8	9
4055	Diagnostic performance of gait speed, G8 and G8 modified indices to screen for vulnerability in older cancer patients: the prospective PF-EC cohort study. <i>Oncotarget</i> , 2017, 8, 50393-50402.	0.8	21
4056	Soluble Axl is an accurate biomarker of cirrhosis and hepatocellular carcinoma development: results from a large scale multicenter analysis. <i>Oncotarget</i> , 2017, 8, 46234-46248.	0.8	49
4057	Prognostic nomogram for hepatocellular carcinoma in adolescent and young adult patients after hepatectomy. <i>Oncotarget</i> , 2017, 8, 106393-106404.	0.8	13
4058	Therapeutic vaccine to cure large mouse hepatocellular carcinomas. <i>Oncotarget</i> , 2017, 8, 52061-52071.	0.8	13
4059	Impact of tumor size and cirrhotic background for differentiating HCC and ICC with CEUS: does it matter for patients undergoing hepatectomy?. <i>Oncotarget</i> , 2017, 8, 83698-83711.	0.8	7
4060	Clinical outcomes and prognostic factors of stereotactic body radiation therapy for intrahepatic cholangiocarcinoma. <i>Oncotarget</i> , 2017, 8, 93541-93550.	0.8	27

#	ARTICLE	IF	CITATIONS
4061	Combination treatment of ergosterol followed by amphotericin B induces necrotic cell death in human hepatocellular carcinoma cells. <i>Oncotarget</i> , 2017, 8, 72727-72738.	0.8	10
4062	The stromal morphological changes for differential diagnosis of uninodular high-grade dysplastic nodule and well-differentiated small hepatocellular carcinoma. <i>Oncotarget</i> , 2017, 8, 87329-87339.	0.8	9
4063	Can Kushen injection combined with TACE improve therapeutic efficacy and safety in patients with advanced HCC? a systematic review and network meta-analysis. <i>Oncotarget</i> , 2017, 8, 107258-107272.	0.8	18
4064	Circulating tumor cells as liquid biomarker for high HCC recurrence risk after curative liver resection. <i>Oncotarget</i> , 2017, 8, 89978-89987.	0.8	58
4065	Efficacy of sorafenib in patients with hepatocellular carcinoma after resection: a meta-analysis. <i>Oncotarget</i> , 2017, 8, 109723-109731.	0.8	10
4066	Neutrophil-to-lymphocyte ratio predicts survival in European patients with hepatocellular carcinoma administered sorafenib. <i>Oncotarget</i> , 2017, 8, 103077-103086.	0.8	41
4067	Combination of dual serum fluorescence, AFP and hepatic function tests is valuable to identify HCC in AFP-elevated liver diseases. <i>Oncotarget</i> , 2017, 8, 97758-97768.	0.8	12
4068	Increased expression of stemness markers and altered tumor stroma in hepatocellular carcinoma under TACE-induced hypoxia: A biopsy and resection matched study. <i>Oncotarget</i> , 2017, 8, 99359-99371.	0.8	20
4069	Preoperative prediction of hepatocellular carcinoma with portal vein tumor thrombus based on conventional data. <i>Oncotarget</i> , 2017, 8, 104227-104237.	0.8	1
4070	Development of a nomogram for screening of hepatitis B virus-associated hepatocellular carcinoma. <i>Oncotarget</i> , 2017, 8, 106499-106510.	0.8	5
4071	High CYP2E1 activity correlates with hepatofibrogenesis induced by nitrosamines. <i>Oncotarget</i> , 2017, 8, 112199-112210.	0.8	22
4072	Mechanism of action and efficacy of LY2109761, a TGF- β 2 receptor inhibitor, targeting tumor microenvironment in liver cancer after TACE. <i>Oncotarget</i> , 2018, 9, 1130-1142.	0.8	16
4073	MEIS-1 level in unresectable hepatocellular carcinoma can predict the post-treatment outcomes of radiofrequency ablation. <i>Oncotarget</i> , 2018, 9, 15252-15265.	0.8	12
4074	Copper/MYC/CTR1 interplay: a dangerous relationship in hepatocellular carcinoma. <i>Oncotarget</i> , 2018, 9, 9325-9343.	0.8	30
4075	Laser ablation is superior to TACE in large-sized hepatocellular carcinoma: a pilot case-control study. <i>Oncotarget</i> , 2018, 9, 17483-17490.	0.8	12
4076	Patients with high serum substance P levels previously to liver transplantation for hepatocellular carcinoma have higher risk of one-year liver transplantation mortality. <i>Oncotarget</i> , 2018, 9, 21552-21559.	0.8	3
4077	Comparison of platelet-albumin-bilirubin (PALBI), albumin-bilirubin (ALBI), and child-pugh (CP) score for predicting of survival in advanced hcc patients receiving radiotherapy (RT). <i>Oncotarget</i> , 2018, 9, 28818-28829.	0.8	29
4078	Tourniquet-ALPPS is a promising treatment for very large hepatocellular carcinoma and intrahepatic cholangiocarcinoma. <i>Oncotarget</i> , 2018, 9, 28267-28280.	0.8	18

#	ARTICLE	IF	CITATIONS
4079	The over-expression of survivin enhances the chemotherapeutic efficacy of YM155 in human hepatocellular carcinoma. <i>Oncotarget</i> , 2015, 6, 5990-6000.	0.8	23
4080	SLC15A2 genomic variation is associated with the extraordinary response of sorafenib treatment: whole-genome analysis in patients with hepatocellular carcinoma. <i>Oncotarget</i> , 2015, 6, 16449-16460.	0.8	31
4081	Hepatic resection versus transarterial chemoembolization for the initial treatment of hepatocellular carcinoma: A systematic review and meta-analysis. <i>Oncotarget</i> , 2015, 6, 18715-18733.	0.8	58
4082	Tauroursodeoxycholic acid dampens oncogenic apoptosis induced by endoplasmic reticulum stress during hepatocarcinogen exposure. <i>Oncotarget</i> , 2015, 6, 28011-28025.	0.8	36
4083	Ack1 overexpression promotes metastasis and indicates poor prognosis of hepatocellular carcinoma. <i>Oncotarget</i> , 2015, 6, 40622-40641.	0.8	37
4084	Tolerability and efficacy of gamma knife radiosurgery on hepatocellular carcinoma with portal vein tumor thrombosis. <i>Oncotarget</i> , 2016, 7, 3614-3622.	0.8	12
4085	Decreased expression of PBLD correlates with poor prognosis and functions as a tumor suppressor in human hepatocellular carcinoma. <i>Oncotarget</i> , 2016, 7, 524-537.	0.8	16
4086	Alpha-fetoprotein still is a valuable diagnostic and prognosis predicting biomarker in hepatitis B virus infection-related hepatocellular carcinoma. <i>Oncotarget</i> , 2016, 7, 3702-3708.	0.8	49
4087	An individualized prognostic signature and multi-omics distinction for early stage hepatocellular carcinoma patients with surgical resection. <i>Oncotarget</i> , 2016, 7, 24097-24110.	0.8	37
4088	A novel scoring system predicts adjuvant chemolipiodolization benefit for hepatocellular carcinoma patients after hepatectomy. <i>Oncotarget</i> , 2016, 7, 25493-25506.	0.8	7
4089	Interaction of KLF6 and Sp1 regulates basigin-2 expression mediated proliferation, invasion and metastasis in hepatocellular carcinoma. <i>Oncotarget</i> , 2016, 7, 27975-27987.	0.8	21
4090	Next-generation proteasome inhibitor oprozomib synergizes with modulators of the unfolded protein response to suppress hepatocellular carcinoma. <i>Oncotarget</i> , 2016, 7, 34988-35000.	0.8	22
4091	Soluble Markers of Immune Activation Differentially Normalize and Selectively Associate with Improvement in AST, ALT, Albumin, and Transient Elastography During IFN-Free HCV Therapy. <i>Pathogens and Immunity</i> , 2018, 3, 149.	1.4	35
4092	Review of therapies for intermediate and advanced stage hepatocellular carcinoma, not suitable for curative therapies: a rapidly changing landscape. <i>Hepatoma Research</i> , 2019, 2019, .	0.6	2
4093	Current role of microwave ablation in the treatment of small hepatocellular carcinomas. <i>Annals of Gastroenterology</i> , 2016, 29, 460-465.	0.4	39
4094	Novel implications in the treatment of hepatocellular carcinoma. <i>Annals of Gastroenterology</i> , 2016, 30, 23-32.	0.4	24
4095	Hepatopulmonary syndrome is associated with the presence of hepatocellular carcinoma in patients with decompensated cirrhosis. <i>Annals of Gastroenterology</i> , 2016, 30, 225-231.	0.4	6
4096	Endoscopic ultrasound-guided ablation of pancreatic cystic neoplasms: ready for prime time?. <i>Annals of Gastroenterology</i> , 2018, 32, 39-45.	0.4	6

#	ARTICLE	IF	CITATIONS
4097	Cholecystectomy is associated with higher risk of recurrence after microwave ablation of hepatocellular carcinoma: a propensity score matching analysis. <i>Cancer Biology and Medicine</i> , 2020, 17, 478-491.	1.4	13
4098	Immune checkpoint inhibitor in liver cancer—unique regional differences. <i>Annals of Translational Medicine</i> , 2020, 8, 1336-1336.	0.7	4
4099	Does microvascular invasion in Barcelona Clinic Liver Cancer stage A multinodular hepatocellular carcinoma indicate early-stage behavior?. <i>Annals of Translational Medicine</i> , 2019, 7, 428-428.	0.7	15
4100	The role of microRNA in the resistance to treatment of hepatocellular carcinoma. <i>Annals of Translational Medicine</i> , 2019, 7, 577-577.	0.7	38
4101	Liver transplantation for hepatocellular carcinoma from living-donor vs. deceased donor. <i>Hepatobiliary Surgery and Nutrition</i> , 2016, 5, 422-428.	0.7	14
4102	A scientometric analysis on hepatocellular carcinoma magnetic resonance imaging research from 2008 to 2017. <i>Quantitative Imaging in Medicine and Surgery</i> , 2019, 9, 465-476.	1.1	26
4103	The albumin-bilirubin score stratifies the outcomes of Child-Pugh class A patients after resection of hepatocellular carcinoma. <i>Translational Cancer Research</i> , 2019, 8, S233-S244.	0.4	3
4104	Comparison of liver function and safety in hepatocellular cancer patients treated with DEB-TACE and cTACE: a multi-center, retrospective cohort study. <i>Translational Cancer Research</i> , 2019, 8, 1950-1964.	0.4	6
4105	PHARMACOLOGICAL THERAPY OF HEPATOCELLULAR CANCER PRACTICAL ISSUES AND SOLUTIONS. <i>Meditinskiy Sovet</i> , 2017, , 11-23.	0.1	2
4106	Deciphering the Novel Target Genes Involved in the Epigenetics of Hepatocellular Carcinoma Using Graph Theory Approach. <i>Current Genomics</i> , 2020, 20, 545-555.	0.7	3
4107	Study of Serum Soluble Programmed Death Ligand 1 as a Prognostic Factor in Hepatocellular Carcinoma in Egyptian Patients. <i>Current Cancer Drug Targets</i> , 2019, 19, 896-905.	0.8	34
4108	Pinocembrin-Enriched Fractions of <i>Elytranthe parasitica</i> (L.) Danser Modulates Apoptotic and MAPK Cellular Signaling in HepG2 Cells. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2019, 18, 1563-1572.	0.9	7
4109	Serum Vascular Endothelial Growth Factor in Patients with Hepatocellular Carcinoma and its Validity as a Tumor Biomarker. <i>Open Biomarkers Journal</i> , 2019, 9, 84-94.	0.1	1
4110	Sorafenib Combined with Radio-frequency Ablation Compared with Sorafenib Alone in Treatment of Hepatocellular Carcinoma Invading Portal Vein: A Western Randomized Controlled Trial. <i>Anticancer Research</i> , 2016, 36, 6179-6184.	0.5	35
4111	Parenchymal Liver Blood Volume and Dynamic Volume Perfusion CT Measurements of Hepatocellular Carcinoma in Patients Undergoing Transarterial Chemoembolization. , 2017, 37, 5681-5685.		7
4112	Efficacy and Safety of Drug Eluting Bead TACE with Microspheres $\leq 150 \mu\text{m}$ for the Treatment of Hepatocellular Carcinoma. <i>Anticancer Research</i> , 2018, 38, 1025-1032.	0.5	8
4113	Diagnostic Accuracy of PIVKA-II, Alpha-Fetoprotein and a Combination of both in Diagnosis of Hepatocellular Carcinoma in Patients Affected by Chronic HCV Infection. <i>In Vivo</i> , 2017, 31, 695-700.	0.6	15
4114	Clinical Application of Radioembolization in Hepatic Malignancies: Protocol for a Prospective Multicenter Observational Study. <i>JMIR Research Protocols</i> , 2020, 9, e16296.	0.5	8

#	ARTICLE	IF	CITATIONS
4115	VESPRO: An Individual Patient Data Prospective Meta-Analysis of Selective Internal Radiation Therapy Versus Sorafenib for Advanced, Locally Advanced, or Recurrent Hepatocellular Carcinoma of the SARA and SIRveNIB Trials. <i>JMIR Research Protocols</i> , 2017, 6, e17.	0.5	11
4116	Hepatocellular Carcinoma: a Comprehensive Review of Biomarkers, Clinical Aspects, and Therapy. <i>Asian Pacific Journal of Cancer Prevention</i> , 2017, 18, 863-872.	0.5	62
4117	Validation of The Hong Kong Liver Cancer Staging System in Patients with Hepatocellular Carcinoma after Curative Intent Treatment. <i>Asian Pacific Journal of Cancer Prevention</i> , 2017, 18, 1697-1701.	0.5	4
4118	SCCA-IgM in hepatocellular carcinoma patients treated with transarterial chemoembolization: gender-related differences. <i>Biomarkers in Medicine</i> , 2020, 14, 855-867.	0.6	4
4119	Biomarkers development for early detection of cancer: Reducing the burden of cancer in the ageing society. <i>The EuroBiotech Journal</i> , 2018, 2, 30-34.	0.5	1
4120	Relationship between portal HTN and cirrhosis as a cause for diabetes. <i>Journal of Translational Internal Medicine</i> , 2019, 7, 79-83.	1.0	5
4121	Risk factors of unfavorable prognosis of chronic hepatitis C. <i>Terapevticheskii Arkhiv</i> , 2019, 91, 59-66.	0.2	7
4122	Association of MicroRNA 196a and 499 Polymorphisms with Development of Cirrhosis and Hepatocellular Carcinoma Post-HCV Infection in Egyptian Patients. <i>Asian Pacific Journal of Cancer Prevention</i> , 2019, 20, 3479-3485.	0.5	3
4123	Baseline Sarcopenia is Associated with Lack of Response to Therapy, Liver Decompensation and High Mortality in Hepatocellular Carcinoma Patients. <i>Asian Pacific Journal of Cancer Prevention</i> , 2020, 21, 3285-3290.	0.5	19
4124	Long-Term Efficacy and Safety of Partial Splenic Embolization in Hepatocellular Carcinoma Patients with Thrombocytopenia Who Underwent Transarterial Chemoembolization. <i>Journal of Korean Medical Science</i> , 2019, 34, e208.	1.1	6
4125	2018 Korean Liver Cancer Association National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma. <i>Korean Journal of Radiology</i> , 2019, 20, 1042.	1.5	189
4126	Efficacy and safety of hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma as first-line therapy. <i>Clinical and Molecular Hepatology</i> , 2013, 19, 288.	4.5	15
4127	A synchronous hepatocellular carcinoma and renal cell carcinoma treated with radio-frequency ablation. <i>Clinical and Molecular Hepatology</i> , 2014, 20, 306.	4.5	5
4128	Alteration of laboratory findings after radiofrequency ablation of hepatocellular carcinoma: relationship to severity of the underlying liver disease and the ablation volume. <i>Clinical and Molecular Hepatology</i> , 2015, 21, 71.	4.5	3
4129	New perspectives on the management of hepatocellular carcinoma with portal vein thrombosis. <i>Clinical and Molecular Hepatology</i> , 2015, 21, 115.	4.5	41
4130	Benign nodules mimicking hepatocellular carcinoma on gadoxetic acid-enhanced liver MRI. <i>Clinical and Molecular Hepatology</i> , 2015, 21, 187.	4.5	11
4131	Long-term outcomes of patients with advanced hepatocellular carcinoma who achieved complete remission after sorafenib therapy. <i>Clinical and Molecular Hepatology</i> , 2015, 21, 287.	4.5	30
4132	Transarterial chemoembolization versus resection for intermediate-stage (BCLC B) hepatocellular carcinoma. <i>Clinical and Molecular Hepatology</i> , 2016, 22, 250-258.	4.5	42

#	ARTICLE	IF	CITATIONS
4133	Liver imaging reporting and data system (LI-RADS) version 2014: understanding and application of the diagnostic algorithm. <i>Clinical and Molecular Hepatology</i> , 2016, 22, 296-307.	4.5	49
4134	A lexicon for hepatocellular carcinoma surveillance ultrasonography: benign versus malignant lesions. <i>Clinical and Molecular Hepatology</i> , 2017, 23, 57-65.	4.5	2
4135	Clinical significance and predictive factors of early massive recurrence after radiofrequency ablation in patients with a single small hepatocellular carcinoma. <i>Clinical and Molecular Hepatology</i> , 2016, 22, 477-486.	4.5	23
4136	The role of scheduled second TACE in early-stage hepatocellular carcinoma with complete response to initial TACE. <i>Clinical and Molecular Hepatology</i> , 2017, 23, 42-50.	4.5	13
4137	Risk score model for the development of hepatocellular carcinoma in treatment-naïve patients receiving oral antiviral treatment for chronic hepatitis B. <i>Clinical and Molecular Hepatology</i> , 2017, 23, 170-178.	4.5	49
4138	Clinical features and outcomes of patients with hepatocellular carcinoma complicated with bile duct invasion. <i>Clinical and Molecular Hepatology</i> , 2017, 23, 160-169.	4.5	33
4139	Does obesity increase the risk of hepatocellular carcinoma in chronic hepatitis B patients?. <i>Clinical and Molecular Hepatology</i> , 2016, 22, 336-338.	4.5	1
4140	Microbiota, a key player in alcoholic liver disease. <i>Clinical and Molecular Hepatology</i> , 2018, 24, 100-107.	4.5	70
4141	Direct-acting antivirals-based therapy decreases hepatic fibrosis serum biomarker microfibrillar-associated protein 4 in hepatitis C patients. <i>Clinical and Molecular Hepatology</i> , 2019, 25, 42-51.	4.5	12
4142	Risk assessment of hepatocellular carcinoma development for indeterminate hepatic nodules in patients with chronic hepatitis B. <i>Clinical and Molecular Hepatology</i> , 2019, 25, 390-399.	4.5	20
4143	Biomarker microfibrillar-associated glycoprotein 4 for non-invasive diagnosis and therapeutic evaluation of hepatic fibrosis in patients with hepatitis C. <i>Clinical and Molecular Hepatology</i> , 2019, 25, 37-39.	4.5	2
4144	Underlying liver disease and advanced stage liver cancer are associated with elevated neutrophil-lymphocyte ratio. <i>Clinical and Molecular Hepatology</i> , 2019, 25, 305-316.	4.5	22
4145	KASL clinical practice guidelines for liver cirrhosis: Varices, hepatic encephalopathy, and related complications. <i>Clinical and Molecular Hepatology</i> , 2020, 26, 83-127.	4.5	67
4146	Sensitivity of ultrasound in detecting hepatocellular carcinoma in obese patients compared to explant pathology as the gold standard. <i>Clinical and Molecular Hepatology</i> , 2020, 26, 54-59.	4.5	52
4147	Hepatocellular carcinoma surveillance in the 21st century: Saving lives or causing harm?. <i>Clinical and Molecular Hepatology</i> , 2019, 25, 264-269.	4.5	50
4148	Performance of Comprehensive Complication Index and Clavien-Dindo Complication Scoring System in Liver Surgery for Hepatocellular Carcinoma. <i>Cancers</i> , 2020, 12, 3868.	1.7	15
4149	Trans-arterial chemo-embolization is safe and effective for very elderly patients with hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2013, 19, 2521.	1.4	49
4150	Treatment of hepatitis C in compensated cirrhotic patients is equally effective before and after liver transplantation. <i>World Journal of Gastroenterology</i> , 2013, 19, 3255.	1.4	6

#	ARTICLE	IF	CITATIONS
4151	Systematic review of surgical resection <i>vs</i> radiofrequency ablation for hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2013, 19, 4106.	1.4	77
4152	Multimodal treatment of hepatocellular carcinoma on cirrhosis: An update. <i>World Journal of Gastroenterology</i> , 2013, 19, 7316.	1.4	36
4153	Bridging and downstaging treatments for hepatocellular carcinoma in patients on the waiting list for liver transplantation. <i>World Journal of Gastroenterology</i> , 2013, 19, 7515.	1.4	102
4154	Hepatocellular carcinoma in chronic hepatitis B patients under antiviral therapy. <i>World Journal of Gastroenterology</i> , 2013, 19, 8822.	1.4	37
4155	Management of small hepatocellular carcinoma in cirrhosis: Focus on portal hypertension. <i>World Journal of Gastroenterology</i> , 2013, 19, 1193.	1.4	34
4156	Individualized hepatocellular carcinoma risk: The challenges for designing successful chemoprevention strategies. <i>World Journal of Gastroenterology</i> , 2013, 19, 1359.	1.4	18
4157	Non-invasive prediction of forthcoming cirrhosis-related complications. <i>World Journal of Gastroenterology</i> , 2014, 20, 2613.	1.4	13
4158	Chemotherapy for advanced hepatocellular carcinoma in the sorafenib age. <i>World Journal of Gastroenterology</i> , 2014, 20, 4151.	1.4	27
4159	Living-donor or deceased-donor liver transplantation for hepatic carcinoma: A case-matched comparison. <i>World Journal of Gastroenterology</i> , 2014, 20, 4393.	1.4	15
4160	Neo-adjuvant therapy for hepatocellular carcinoma before liver transplantation: Where do we stand?. <i>World Journal of Gastroenterology</i> , 2014, 20, 5308.	1.4	25
4161	Hepatocellular carcinoma treated by conventional transarterial chemoembolization in field-practice: Serum sodium predicts survival. <i>World Journal of Gastroenterology</i> , 2014, 20, 8158.	1.4	17
4162	Predictors of survival in patients with established cirrhosis and hepatocellular carcinoma treated with sorafenib. <i>World Journal of Gastroenterology</i> , 2014, 20, 786.	1.4	24
4163	Bortezomib effect on E2F and cyclin family members in human hepatocellular carcinoma cell lines. <i>World Journal of Gastroenterology</i> , 2014, 20, 795.	1.4	30
4164	Current management of hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2014, 20, 10223.	1.4	61
4165	Contrast-enhanced ultrasound: Improving the preoperative staging of hepatocellular carcinoma and guiding individual treatment. <i>World Journal of Gastroenterology</i> , 2014, 20, 12628.	1.4	13
4166	Hepatocellular carcinoma in nonalcoholic fatty liver: Role of environmental and genetic factors. <i>World Journal of Gastroenterology</i> , 2014, 20, 12945.	1.4	117
4167	Recent advances in the surgical treatment of hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2014, 20, 14381.	1.4	81
4168	Current surgical treatment strategies for hepatocellular carcinoma in North America. <i>World Journal of Gastroenterology</i> , 2014, 20, 15007.	1.4	19

#	ARTICLE	IF	CITATIONS
4169	Feasibility and safety of sorafenib treatment in hepatocellular carcinoma patients with spontaneous rupture. <i>World Journal of Gastroenterology</i> , 2014, 20, 16275.	1.4	10
4170	Hepatitis B and human immunodeficiency virus co-infection. <i>World Journal of Gastroenterology</i> , 2014, 20, 17360.	1.4	37
4171	Transjugular intrahepatic portosystemic shunt with covered stents for hepatocellular carcinoma with portal vein tumor thrombosis. <i>World Journal of Gastroenterology</i> , 2014, 20, 1602.	1.4	17
4172	Clinical outcome of medium-sized hepatocellular carcinoma treated with microwave ablation. <i>World Journal of Gastroenterology</i> , 2015, 21, 2997.	1.4	46
4173	Diagnostic value of PIVKA-II and alpha-fetoprotein in hepatitis B virus-associated hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2015, 21, 3928.	1.4	58
4174	MET inhibitors for treatment of advanced hepatocellular carcinoma: A review. <i>World Journal of Gastroenterology</i> , 2015, 21, 5445.	1.4	53
4175	Use of magnetic resonance elastography for assessing liver functional reserve: A clinical study. <i>World Journal of Gastroenterology</i> , 2015, 21, 7522.	1.4	9
4176	Grey zone in the Barcelona Clinic Liver Cancer Classification for hepatocellular carcinoma: Surgeons' perspective. <i>World Journal of Gastroenterology</i> , 2015, 21, 8256.	1.4	14
4177	Efficiency and safety of radiofrequency-assisted hepatectomy for hepatocellular carcinoma with cirrhosis: A single-center retrospective cohort study. <i>World Journal of Gastroenterology</i> , 2015, 21, 10159-10165.	1.4	9
4178	Sub-classification of intermediate-stage (Barcelona Clinic Liver Cancer stage-B) hepatocellular carcinomas. <i>World Journal of Gastroenterology</i> , 2015, 21, 10604.	1.4	18
4179	Synchronous splenectomy and hepatectomy for patients with hepatocellular carcinoma and hypersplenism: A case-control study. <i>World Journal of Gastroenterology</i> , 2015, 21, 2358.	1.4	26
4180	Outcome of transarterial chemoembolization-based multi-modal treatment in patients with unresectable hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2015, 21, 2395.	1.4	24
4181	Advances in computed tomography and magnetic resonance imaging of hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2016, 22, 205.	1.4	28
4182	Molecular imaging and therapy targeting copper metabolism in hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2016, 22, 221.	1.4	42
4183	Chemoprevention of obesity-related liver carcinogenesis by using pharmaceutical and nutraceutical agents. <i>World Journal of Gastroenterology</i> , 2016, 22, 394.	1.4	12
4184	Treatment of hepatocellular carcinoma with portal venous tumor thrombosis: A comprehensive review. <i>World Journal of Gastroenterology</i> , 2016, 22, 407.	1.4	61
4185	Dual-input two-compartment pharmacokinetic model of dynamic contrast-enhanced magnetic resonance imaging in hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2016, 22, 3652.	1.4	20
4186	Supportive therapies for prevention of hepatocellular carcinoma recurrence and preservation of liver function. <i>World Journal of Gastroenterology</i> , 2016, 22, 7252.	1.4	15

#	ARTICLE	IF	CITATIONS
4187	Hepatocellular carcinoma screening and surveillance in 2293 chronic hepatitis B patients in an endemic area. <i>World Journal of Gastroenterology</i> , 2016, 22, 7806.	1.4	13
4188	Development of a prognostic scoring system for resectable hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2016, 22, 8194.	1.4	7
4189	Significance of hepatitis virus infection in the oncogenic initiation of hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2016, 22, 1497.	1.4	47
4190	Practice guidelines for the pathological diagnosis of primary liver cancer: 2015 update. <i>World Journal of Gastroenterology</i> , 2016, 22, 9279.	1.4	261
4191	Incidence of hepatocellular carcinoma in outpatients with cirrhosis in Brazil: A 10-year retrospective cohort study. <i>World Journal of Gastroenterology</i> , 2016, 22, 10219.	1.4	18
4192	Combined locoregional treatment of patients with hepatocellular carcinoma: State of the art. <i>World Journal of Gastroenterology</i> , 2016, 22, 1935.	1.4	54
4193	Laparoscopic and robot-assisted laparoscopic digestive surgery: Present and future directions. <i>World Journal of Gastroenterology</i> , 2016, 22, 1975.	1.4	43
4194	Ombitasvir, paritaprevir, ritonavir, dasabuvir and ribavirin in cirrhosis after complete destruction of hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2016, 22, 2630.	1.4	6
4195	Ultrasound elastographic techniques in focal liver lesions. <i>World Journal of Gastroenterology</i> , 2016, 22, 2647.	1.4	21
4196	Barcelona clinic liver cancer nomogram and others staging/scoring systems in a French hepatocellular carcinoma cohort. <i>World Journal of Gastroenterology</i> , 2017, 23, 2545.	1.4	21
4197	Patients with non-viral liver disease have a greater tumor burden and less curative treatment options when diagnosed with hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2017, 23, 2763.	1.4	6
4198	Liver transplantation for intermediate hepatocellular carcinoma: An adaptive approach. <i>World Journal of Gastroenterology</i> , 2017, 23, 3195.	1.4	1
4199	Radiological response and inflammation scores predict tumour recurrence in patients treated with transarterial chemoembolization before liver transplantation. <i>World Journal of Gastroenterology</i> , 2017, 23, 3690.	1.4	29
4200	Emergence of immunotherapy as a novel way to treat hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2018, 24, 1839-1858.	1.4	30
4201	Considerations for bariatric surgery in patients with cirrhosis. <i>World Journal of Gastroenterology</i> , 2018, 24, 3112-3119.	1.4	46
4202	Management of sub-centimeter recurrent hepatocellular carcinoma after curative treatment: Current status and future. <i>World Journal of Gastroenterology</i> , 2018, 24, 5215-5222.	1.4	22
4203	Incidence of hepatocellular carcinoma in patients with chronic liver disease due to hepatitis B or C and coinfecting with the human immunodeficiency virus: A retrospective cohort study. <i>World Journal of Gastroenterology</i> , 2018, 24, 613-622.	1.4	24
4204	Emerging role of ¹⁸ F-fluorodeoxyglucose positron emission tomography for guiding management of hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2019, 25, 1289-1306.	1.4	34

#	ARTICLE	IF	CITATIONS
4205	Immunotherapy with dendritic cells and cytokine-induced killer cells for hepatocellular carcinoma: A meta-analysis. <i>World Journal of Gastroenterology</i> , 2019, 25, 3649-3663.	1.4	36
4206	Locoregional treatments for hepatocellular carcinoma: Current evidence and future directions. <i>World Journal of Gastroenterology</i> , 2019, 25, 4614-4628.	1.4	77
4207	Role of liver biopsy in hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2019, 25, 6041-6052.	1.4	92
4208	Effect of adipose-derived mesenchymal stem cells on hepatocellular carcinoma: <i>in vitro</i> inhibition of carcinogenesis. <i>World Journal of Gastroenterology</i> , 2019, 25, 567-583.	1.4	28
4209	Prognostic value of serum microRNA-122 in hepatocellular carcinoma is dependent on coexisting clinical and laboratory factors. <i>World Journal of Gastroenterology</i> , 2020, 26, 86-96.	1.4	8
4210	Can contrast enhanced ultrasound differentiate intrahepatic cholangiocarcinoma from hepatocellular carcinoma?. <i>World Journal of Gastroenterology</i> , 2020, 26, 3938-3951.	1.4	20
4211	Simultaneous transcatheter arterial chemoembolization and portal vein embolization for patients with large hepatocellular carcinoma before major hepatectomy. <i>World Journal of Gastroenterology</i> , 2020, 26, 4489-4500.	1.4	10
4212	Features of extrahepatic metastasis after radiofrequency ablation for hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2020, 26, 4833-4845.	1.4	13
4213	Indications of external radiotherapy for hepatocellular carcinoma from updated clinical guidelines: Diverse global viewpoints. <i>World Journal of Gastroenterology</i> , 2020, 26, 393-403.	1.4	29
4214	Modified Child-Pugh grade <i>vs</i> albumin-bilirubin grade for predicting prognosis of hepatocellular carcinoma patients after hepatectomy. <i>World Journal of Gastroenterology</i> , 2020, 26, 749-758.	1.4	12
4215	Transcatheter arterial chemoembolization and radiation therapy for treatment-naïve patients with locally advanced hepatocellular carcinoma. <i>Radiation Oncology Journal</i> , 2014, 32, 14.	0.7	28
4216	Treatment outcome of hepatic re-irradiation in patients with hepatocellular carcinoma. <i>Radiation Oncology Journal</i> , 2015, 33, 276.	0.7	13
4217	Liver Protective Effects of Renin-Angiotensin System Inhibition Have No Survival Benefits in Hepatocellular Carcinoma Induced By Repetitive Administration of Diethylnitrosamine in Mice. <i>Open Access Macedonian Journal of Medical Sciences</i> , 2018, 6, 955-960.	0.1	24
4218	Safety Profile and Efficacy of Chemoembolization with Doxorubicin - Loaded Polyethylene Glycol Microspheres in Patients with Hepatocellular Carcinoma. <i>Open Access Macedonian Journal of Medical Sciences</i> , 2019, 7, 742-746.	0.1	4
4219	Sustained virological response by direct-acting antivirals reduces the recurrence risk of hepatitis C-related hepatocellular carcinoma after curative treatment. <i>Molecular and Clinical Oncology</i> , 2020, 12, 111-116.	0.4	16
4220	Short term treatment results of local ablation with water-cooled microwave antenna for liver cancer: Comparison with radiofrequency ablation. <i>Molecular and Clinical Oncology</i> , 2020, 12, 230-236.	0.4	12
4221	Nicotinamide induces liver regeneration and improves liver function by activating SIRT1. <i>Molecular Medicine Reports</i> , 2019, 19, 555-562.	1.1	16
4222	Fuzheng Qingjie granules potentiate the anticancer effect of cyclophosphamide by regulating cellular immune function and inducing apoptosis in Hepatoma 22 tumor-bearing mice. <i>Oncology Letters</i> , 2017, 13, 3261-3268.	0.8	8

#	ARTICLE	IF	CITATIONS
4223	Identification of predictive factors in hepatocellular carcinoma outcome: A longitudinal study. <i>Oncology Letters</i> , 2020, 20, 765-773.	0.8	6
4224	High expression of TOP2A in hepatocellular carcinoma is associated with disease progression and poor prognosis. <i>Oncology Letters</i> , 2020, 20, 1-1.	0.8	23
4225	Anticancer effects of <i>PoncirusÂfructus</i> on hepatocellular carcinoma through regulation of apoptosis, migration, and invasion. <i>Oncology Reports</i> , 2020, 44, 2537-2546.	1.2	11
4226	Laparoscopic resection for hepatocellular carcinoma: eastern and western experiences. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2014, 26, 234-6.	0.7	6
4227	Transcatheter embolization therapy in liver cancer: an update of clinical evidences. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2015, 27, 96-121.	0.7	67
4228	Theranostics and contrast-agents for medical imaging: a pharmaceutical company viewpoint. <i>Quantitative Imaging in Medicine and Surgery</i> , 2013, 3, 292-7.	1.1	39
4229	High-intensity focused ultrasound (HIFU) for the treatment of hepatocellular carcinoma: is it time to abandon standard ablative percutaneous treatments?. <i>Hepatobiliary Surgery and Nutrition</i> , 2013, 2, 184-7.	0.7	8
4230	PNPLA3 genetic variation in alcoholic steatosis and liver disease progression. <i>Hepatobiliary Surgery and Nutrition</i> , 2015, 4, 152-60.	0.7	8
4231	Prediction of postoperative liver failure in patients diagnosed with hepatocellular carcinoma using (99m)Tc-GSA SPECT/CT. <i>Hepatobiliary Surgery and Nutrition</i> , 2015, 4, 203-5.	0.7	2
4232	Wading through the noise of "multi-omics" to identify prognostic biomarkers in hepatocellular carcinoma. <i>Hepatobiliary Surgery and Nutrition</i> , 2015, 4, 293-4.	0.7	3
4233	Doxorubicin-loaded drug-eluting beads versus conventional transarterial chemoembolization for nonresectable hepatocellular carcinoma. <i>Saudi Journal of Gastroenterology</i> , 2015, 21, 175.	0.5	40
4234	Pigment epithelium-derived factor and matrix metalloproteinase-9 in liver cirrhosis. <i>Saudi Journal of Gastroenterology</i> , 2016, 22, 375.	0.5	5
4235	The Global Nonalcoholic Fatty Liver Disease Epidemic: What a Radiologist Needs to Know. <i>Journal of Clinical Imaging Science</i> , 2015, 5, 32.	0.4	21
4236	Characterization of patients with hepatocellular carcinoma on the way for early detection: one center experience. <i>The Egyptian Journal of Internal Medicine</i> , 2018, 30, 231-238.	0.3	7
4237	EUS-guided radiofrequency ablation: an option for the extrapancreatic region. <i>Endoscopic Ultrasound</i> , 2018, 7, 282.	0.6	6
4238	Systematic review of endoscopy ultrasound-guided thermal ablation treatment for pancreatic cancer. <i>Endoscopic Ultrasound</i> , 2020, 9, 83.	0.6	46
4239	Genotyping & diagnostic methods for hepatitis C virus: A need of low-resource countries. <i>Indian Journal of Medical Research</i> , 2018, 147, 445.	0.4	24
4240	Cytochrome P450 family members are associated with fast-growing hepatocellular carcinoma and patient survival: An integrated analysis of gene expression profiles. <i>Saudi Journal of Gastroenterology</i> , 2019, 25, 167.	0.5	14

#	ARTICLE	IF	CITATIONS
4241	Real-Life Experience of Sorafenib Treatment for Hepatocellular Carcinoma in Korea: From GIDEON Data. <i>Cancer Research and Treatment</i> , 2016, 48, 1243-1252.	1.3	20
4242	Sub-classification of Advanced-Stage Hepatocellular Carcinoma: A Cohort Study Including 612 Patients Treated with Sorafenib. <i>Cancer Research and Treatment</i> , 2018, 50, 366-373.	1.3	15
4243	Hepatic Resection Provides Survival Benefit for Selected Intermediate-Stage (BCLC-B) Hepatocellular Carcinoma Patients. <i>Cancer Research and Treatment</i> , 2019, 51, 65-72.	1.3	22
4244	Surveillance Rate and its Impact on Survival of Hepatocellular Carcinoma Patients in South Korea: A Cohort Study. <i>Cancer Research and Treatment</i> , 2019, 51, 1357-1369.	1.3	7
4245	Novel Prognostic Nomograms Based on Inflammation-Related Markers for Patients with Hepatocellular Carcinoma Underwent Hepatectomy. <i>Cancer Research and Treatment</i> , 2019, 51, 1464-1478.	1.3	33
4246	Treatment Outcome after Fractionated Conformal Radiotherapy for Hepatocellular Carcinoma in Patients with Child-Pugh Classification B in Korea (KROG 16-05). <i>Cancer Research and Treatment</i> , 2019, 51, 1589-1599.	1.3	18
4247	Comparison of outcome between liver resection, radiofrequency ablation, and transarterial therapy for multiple small hepatocellular carcinoma within the Milan criteria. <i>Annals of Surgical Treatment and Research</i> , 2020, 99, 238.	0.4	20
4248	The Diagnostic Challenges, Possible Etiologies and Lack of Researches of Hepatocellular Carcinoma in Somalia. <i>Open Journal of Gastroenterology</i> , 2017, 07, 115-123.	0.1	4
4249	Advances and challenges in laparoscopic surgery in the management of hepatocellular carcinoma. <i>World Journal of Gastrointestinal Surgery</i> , 2017, 9, 233-245.	0.8	30
4250	Simultaneous transarterial chemoembolization and radiofrequency ablation for large hepatocellular carcinoma. <i>World Journal of Gastrointestinal Oncology</i> , 2020, 12, 92-100.	0.8	10
4251	Utility of endoscopic ultrasound and endoscopy in diagnosis and management of hepatocellular carcinoma and its complications: What does endoscopic ultrasonography offer above and beyond conventional cross-sectional imaging?. <i>World Journal of Gastrointestinal Endoscopy</i> , 2018, 10, 56-68.	0.4	11
4252	Endoscopy-guided ablation of pancreatic lesions: Technical possibilities and clinical outlook. <i>World Journal of Gastrointestinal Endoscopy</i> , 2017, 9, 41.	0.4	44
4253	Ultrasonogram of hepatocellular carcinoma is associated with outcome after radiofrequency ablation. <i>World Journal of Hepatology</i> , 2012, 4, 374.	0.8	3
4254	Fatty liver disease, an emerging etiology of hepatocellular carcinoma in Argentina. <i>World Journal of Hepatology</i> , 2018, 10, 41-50.	0.8	34
4255	Metabolomics: From liver chiromancy to personalized precision medicine in advanced chronic liver disease. <i>World Journal of Hepatology</i> , 2018, 10, 371-378.	0.8	11
4256	MR with Gd-EOB-DTPA in assessment of liver nodules in cirrhotic patients. <i>World Journal of Hepatology</i> , 2018, 10, 462-473.	0.8	23
4257	Balloon-occluded transcatheter arterial chemoembolization for hepatocellular carcinoma. <i>World Journal of Hepatology</i> , 2018, 10, 485-495.	0.8	31
4258	Cirrhotic patients and older people. <i>World Journal of Hepatology</i> , 2019, 11, 678-688.	0.8	22

#	ARTICLE	IF	CITATIONS
4259	Hepatocellular carcinoma staging systems: Hong Kong liver cancer <i>vs</i> Barcelona clinic liver cancer in a Western population. World Journal of Hepatology, 2019, 11, 689-700.	0.8	8
4260	Imaging response predictors following drug eluting beads chemoembolization in the neoadjuvant liver transplant treatment of hepatocellular carcinoma. World Journal of Hepatology, 2020, 12, 21-33.	0.8	8
4261	Comparison between hepatocellular carcinoma prognostic scores: A 10-year single-center experience and brief review of the current literature. World Journal of Hepatology, 2020, 12, 1239-1257.	0.8	10
4262	Management of hepatocellular carcinoma: Enlightening the gray zones. World Journal of Hepatology, 2013, 5, 302.	0.8	38
4263	Coadministration of telaprevir and transcatheter arterial chemoembolization in hepatitis C virus-associated hepatocellular carcinoma. World Journal of Hepatology, 2013, 5, 332.	0.8	2
4264	Management of "every early" hepatocellular carcinoma on cirrhotic patients. World Journal of Hepatology, 2014, 6, 766.	0.8	17
4265	Problem of hepatocellular carcinoma in West Africa. World Journal of Hepatology, 2014, 6, 783.	0.8	52
4266	Multidisciplinary perspective of hepatocellular carcinoma: A Pacific Northwest experience. World Journal of Hepatology, 2015, 7, 1460.	0.8	16
4267	Management of hepatocellular carcinoma in the elderly. World Journal of Hepatology, 2015, 7, 1521.	0.8	31
4268	Nucleos(t)ide analogs in the prevention of hepatitis B virus related hepatocellular carcinoma. World Journal of Hepatology, 2015, 7, 1742.	0.8	19
4269	Usefulness of contrast enhanced ultrasound in monitoring therapeutic response after hepatocellular carcinoma treatment. World Journal of Hepatology, 2015, 7, 1866.	0.8	24
4270	Cartilage oligomeric matrix protein: A novel non-invasive marker for assessing cirrhosis and risk of hepatocellular carcinoma. World Journal of Hepatology, 2015, 7, 1875.	0.8	26
4271	Selection tool alpha-fetoprotein for patients waiting for liver transplantation: How to easily manage a fractal algorithm. World Journal of Hepatology, 2015, 7, 1899.	0.8	11
4272	Current management of patients with hepatocellular carcinoma. World Journal of Hepatology, 2015, 7, 1913.	0.8	40
4273	Biological features and biomarkers in hepatocellular carcinoma. World Journal of Hepatology, 2015, 7, 2020.	0.8	12
4274	Optimal surveillance program for hepatocellular carcinoma - getting ready, but not yet. World Journal of Hepatology, 2015, 7, 2133.	0.8	5
4275	Surgical management of hepatocellular carcinoma. World Journal of Hepatology, 2014, 7, 245.	0.8	70
4276	Evaluation of antiangiogenic efficacy in advanced hepatocellular carcinoma: Biomarkers and functional imaging. World Journal of Hepatology, 2015, 7, 2245.	0.8	8

#	ARTICLE	IF	CITATIONS
4277	Hepatocellular carcinoma: From clinical practice to evidence-based treatment protocols. <i>World Journal of Hepatology</i> , 2015, 7, 2274.	0.8	46
4278	Clinical applications of squamous cell carcinoma antigen-immunoglobulins M to monitor chronic hepatitis C. <i>World Journal of Hepatology</i> , 2015, 7, 2913.	0.8	4
4279	Diagnosis and treatment of hepatocellular carcinoma: An update. <i>World Journal of Hepatology</i> , 2015, 7, 362.	0.8	103
4280	Treatment of hepatocellular carcinoma: Steps forward but still a long way to go. <i>World Journal of Hepatology</i> , 2015, 7, 566.	0.8	42
4281	Strategies to improve outcome of patients with hepatocellular carcinoma receiving a liver transplantation. <i>World Journal of Hepatology</i> , 2015, 7, 649.	0.8	29
4282	Recent advances in multidisciplinary management of hepatocellular carcinoma. <i>World Journal of Hepatology</i> , 2015, 7, 673.	0.8	77
4283	Radioembolization with Yttrium-90 microspheres in hepatocellular carcinoma: Role and perspectives. <i>World Journal of Hepatology</i> , 2015, 7, 738.	0.8	48
4284	Hepatocellular carcinoma: Surgeon's view on latest findings and future perspectives. <i>World Journal of Hepatology</i> , 2015, 7, 1168.	0.8	43
4285	Selection of patients with hepatocellular carcinoma for liver transplantation: Past and future. <i>World Journal of Hepatology</i> , 2016, 8, 58.	0.8	20
4286	Transarterial radioembolization vs chemoembolization for hepatocarcinoma patients: A systematic review and meta-analysis. <i>World Journal of Hepatology</i> , 2016, 8, 770.	0.8	55
4287	Polymorphisms of folate metabolism genes in patients with cirrhosis and hepatocellular carcinoma. <i>World Journal of Hepatology</i> , 2016, 8, 1234.	0.8	18
4288	Importance of surgical margin in the outcomes of hepatocholangiocarcinoma. <i>World Journal of Hepatology</i> , 2017, 9, 635.	0.8	12
4289	Reverse time-dependent effect of alphafetoprotein and disease control on survival of patients with Barcelona Clinic Liver Cancer stage C hepatocellular carcinoma. <i>World Journal of Hepatology</i> , 2017, 9, 1322-1331.	0.8	2
4290	Sequential tumor-directed and lobar radioembolization before major hepatectomy for hepatocellular carcinoma. <i>World Journal of Hepatology</i> , 2017, 9, 1372-1377.	0.8	6
4291	Annexin A2 as a biomarker for hepatocellular carcinoma in Egyptian patients. <i>World Journal of Hepatology</i> , 2017, 9, 469.	0.8	23
4292	Immunobiology of hepatocarcinogenesis: Ways to go or almost there?. <i>World Journal of Gastrointestinal Pathophysiology</i> , 2016, 7, 242.	0.5	12
4293	Current status of transarterial radioembolization. <i>World Journal of Radiology</i> , 2016, 8, 449.	0.5	43
4294	Transarterial chemoembolization using 40 μ m drug eluting beads for hepatocellular carcinoma. <i>World Journal of Radiology</i> , 2017, 9, 245.	0.5	25

#	ARTICLE	IF	CITATIONS
4295	Current Concepts in Hepatocellular Carcinoma and Liver Transplantation: A Review and 2014 Update. <i>Euroasian Journal of Hepato-gastroenterology</i> , 2015, 5, 19-25.	0.1	4
4296	Role of Radiofrequency Ablation in Patients with Hepatocellular Carcinoma Who Undergo Prior Transarterial Chemoembolization: Long-Term Outcomes and Predictive Factors. <i>Gut and Liver</i> , 2014, 8, 543-551.	1.4	15
4297	Disease Progression in Chronic Hepatitis B Patients under Long-Term Antiviral Therapy. <i>Gut and Liver</i> , 2015, 9, 395-404.	1.4	11
4298	Management of Hepatocellular Carcinoma: Current Status and Future Directions. <i>Gut and Liver</i> , 2015, 9, 437.	1.4	49
4299	Treatment Response and Long-Term Outcome of Peginterferon α and Ribavirin Therapy in Korean Patients with Chronic Hepatitis C. <i>Gut and Liver</i> , 2016, 10, 808-817.	1.4	4
4300	Survival Estimates after Stopping Sorafenib in Patients with Hepatocellular Carcinoma: NEXT Score Development and Validation. <i>Gut and Liver</i> , 2017, 11, 693-701.	1.4	5
4301	von Willebrand Factor Antigen Predicts Outcomes in Patients after Liver Resection of Hepatocellular Carcinoma. <i>Gut and Liver</i> , 2020, 14, 218-224.	1.4	9
4302	Subclassification and Detection of New Markers for the Discrimination of Primary Liver Tumors by Gene Expression Analysis Using Oligonucleotide Arrays. <i>Gut and Liver</i> , 2018, 12, 306-315.	1.4	5
4303	Assessment of the Surveillance Interval at 1 Year after Curative Treatment in Hepatocellular Carcinoma: Risk Stratification. <i>Gut and Liver</i> , 2018, 12, 571-582.	1.4	6
4304	The Impact of National Surveillance for Liver Cancer: Results from Real-World Setting in Korea. <i>Gut and Liver</i> , 2020, 14, 108-116.	1.4	16
4305	2018 Korean Liver Cancer Association's National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma. <i>Gut and Liver</i> , 2019, 13, 227-299.	1.4	255
4306	Proposal of a New Risk Score for Patients Treated with Transarterial Chemoembolization due to Recurrent Hepatocellular Carcinoma after Curative Resection: A Multicenter Study. <i>Gut and Liver</i> , 2020, 14, 477-485.	1.4	1
4307	How high is the inter-observer reproducibility in the LIRADS reporting system?. <i>Polish Journal of Radiology</i> , 2019, 84, 464-469.	0.5	7
4308	Clinicopathologic characteristics and outcomes of hepatocellular carcinoma associated with chronic hepatitis B versus hepatitis C infection. <i>Annals of Saudi Medicine</i> , 2018, 38, 358-365.	0.5	5
4309	Evolving role of Sorafenib in the management of hepatocellular carcinoma. <i>World Journal of Clinical Oncology</i> , 2017, 8, 203.	0.9	32
4310	Point-of-Care Tests for Hepatitis B Are Associated with A Higher Linkage to Care and Lower Cost Compared to Venepuncture Sampling During Outreach Screenings in an Asian Migrant Population. <i>Annals of Global Health</i> , 2020, 86, 81.	0.8	12
4311	New biomarkers for clinical management of hepatitis C virus infected patients. <i>World Journal of Clinical Infectious Diseases</i> , 2015, 5, 59.	0.5	1
4312	Liver transplantation and aging. <i>World Journal of Transplantation</i> , 2020, 10, 256-266.	0.6	9

#	ARTICLE	IF	CITATIONS
4313	Long-term survival of patients with hepatocellular carcinoma with inferior vena cava tumor thrombus treated with sorafenib combined with transarterial chemoembolization: report of two cases and literature review. Chinese Journal of Cancer, 2014, 33, 259-266.	4.9	8
4314	Performance of Protein Induced by Vitamin K Absence or Antagonist-II (PIVKA-II) for Hepatocellular Carcinoma Screening in Chinese Population. Hepatitis Monthly, 2015, 15, e28806.	0.1	24
4315	Intrahepatic Toll-Like Receptor 3 in Chronic HBV Infection Subjects: Asymptomatic Carriers, Active Chronic Hepatitis, Cirrhosis, and Hepatocellular Carcinoma. Hepatitis Monthly, 2016, 16, e34432.	0.1	5
4316	The Risk of Hepatocellular Carcinoma After Directly Acting Antivirals for Hepatitis C Virus Treatment in Liver Transplanted Patients: Is It Real?. Hepatitis Monthly, 2016, 16, e41933.	0.1	11
4317	Outcomes of Transarterial Chemoembolization With or Without Additional Radiofrequency Ablation in Hepatocellular Carcinoma of 2 to 5 cm in Diameter. Iranian Journal of Radiology, 2016, 14, .	0.1	2
4318	Comparative Analysis of Nonalcoholic Steatohepatitis Versus Viral Hepatitis and Alcohol-Related Liver Disease-Related Hepatocellular Carcinoma. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 322-329.	2.3	38
4319	Socioeconomic disparities in access to a hepatocellular carcinoma screening program in Brazil. Clinics, 2016, 71, 361-364.	0.6	7
4320	Long Non-coding RNAs are Differentially Expressed in Hepatocellular Carcinoma Cell Lines with Differing Metastatic Potential. Asian Pacific Journal of Cancer Prevention, 2015, 15, 10513-10524.	0.5	30
4321	Prognostic Value of Serum AFP, AFP-L3, and GP73 in Monitoring Short-term Treatment Response and Recurrence of Hepatocellular Carcinoma after Radiofrequency Ablation. Asian Pacific Journal of Cancer Prevention, 2014, 15, 1539-1544.	0.5	37
4322	Systematic Review of Single Large and/or Multinodular Hepatocellular Carcinoma: Surgical Resection Improves Survival. Asian Pacific Journal of Cancer Prevention, 2015, 16, 5541-5547.	0.5	21
4323	Hepatic Re-resection Versus Transarterial Chemoembolization for the Treatment of Recurrent Hepatocellular Carcinoma after Initial Resection: a Systematic Review and Meta-analysis. Asian Pacific Journal of Cancer Prevention, 2015, 16, 5573-5578.	0.5	17
4324	Real Life Treatment of Hepatocellular Carcinoma: Impact of Deviation from Guidelines for Recommended Therapy. Asian Pacific Journal of Cancer Prevention, 2015, 16, 6929-6934.	0.5	4
4325	¹³¹ I-Labeled-Metuximab Plus Transarterial Chemoembolization in Combination Therapy for Unresectable Hepatocellular Carcinoma: Results from a Multicenter Phase IV Clinical Study. Asian Pacific Journal of Cancer Prevention, 2015, 16, 7441-7447.	0.5	10
4326	Hepatic Resection after Initial Transarterial Chemoembolization Versus Transarterial Chemoembolization Alone for the Treatment of Hepatocellular Carcinoma: A Meta-analysis of Observational Studies. Asian Pacific Journal of Cancer Prevention, 2015, 16, 7871-7874.	0.5	6
4327	The Incidence and Mortality of Liver Cancer and its Relationship with Development in Asia. Asian Pacific Journal of Cancer Prevention, 2016, 17, 2041-2047.	0.5	27
4328	Hepatocellular Carcinoma in a Tertiary Referral Hospital in Indonesia: Lack of Improvement of One-Year Survival Rates between 1998-1999 and 2013-2014. Asian Pacific Journal of Cancer Prevention, 2016, 17, 2165-2170.	0.5	16
4329	Toward a clinical real time tissue ablation technology: combining electroporation and electrolysis (E2). PeerJ, 2020, 8, e7985.	0.9	5
4330	The Toronto Postliver Transplantation Hepatocellular Carcinoma Recurrence Calculator: A Machine Learning Approach. Liver Transplantation, 2022, 28, 593-602.	1.3	28

#	ARTICLE	IF	CITATIONS
4331	Multicentre external validation of the GES score for predicting HCC risk in Japanese HCV patients who achieved SVR following DAAs. <i>Liver Cancer International</i> , 0, , .	0.2	1
4332	Prognostic value of lung shunt fraction in hepatocellular carcinoma and unresectable liver dominant metastatic colorectal cancer undergoing transarterial radioembolisation. <i>Nuclear Medicine Communications</i> , 2021, Publish Ahead of Print, 24-31.	0.5	1
4333	Role of Serum Vitamin D, Interleukin 13, and microRNA-135a in Hepatocellular Carcinoma and Treatment Failure in Egyptian HCV-Infected Patients Receiving Direct Antiviral Agents. <i>Viruses</i> , 2021, 13, 2008.	1.5	3
4334	Development of Models to Predict Postoperative Complications for Hepatitis B Virus-Related Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 717826.	1.3	4
4335	Gene expression signature as a surrogate marker of microvascular invasion on routine hepatocellular carcinoma biopsies. <i>Journal of Hepatology</i> , 2022, 76, 343-352.	1.8	30
4336	Clinical outcomes of patients with two small hepatocellular carcinomas. <i>World Journal of Hepatology</i> , 2021, 13, 1439-1449.	0.8	0
4337	Preoperative ALBI grade predicts the outcomes in non-B non-C HCC patients undergoing primary curative resection. <i>BMC Gastroenterology</i> , 2021, 21, 386.	0.8	6
4338	Therapeutic efficacy of lenvatinib in nonviral unresectable hepatocellular carcinoma. <i>JGH Open</i> , 2021, 5, 1275-1283.	0.7	12
4339	Computed tomography for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease. <i>The Cochrane Library</i> , 2021, 2021, CD013362.	1.5	12
4340	Minimally Invasive Surgery for Hepatocellular Carcinoma; Latest Advances. , 0, , .		0
4341	Serum Fibrosis Tests Guide Prognosis in Metabolic Dysfunction-Associated Fatty Liver Disease Patients Referred From Primary Care. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2041-2049.e5.	2.4	6
4342	Effect of Severity of Liver Cirrhosis on Surgical Outcomes of Hepatocellular Carcinoma After Liver Resection and Microwave Coagulation. <i>Frontiers in Oncology</i> , 2021, 11, 745615.	1.3	2
4343	Maximum Plasma Concentration of Lenvatinib Is Useful for Predicting Thrombocytopenia in Patients Treated for Hepatocellular Carcinoma. <i>World Journal of Oncology</i> , 2021, 12, 165-172.	0.6	2
4344	Current Approach to Planning Angiography and MAA Administration. <i>Seminars in Interventional Radiology</i> , 2021, 38, 397-404.	0.3	0
4345	Performance of models to predict hepatocellular carcinoma risk among UK patients with cirrhosis and cured HCV infection. <i>JHEP Reports</i> , 2021, 3, 100384.	2.6	10
4346	Association between Time to Local Tumor Control and Treatment Outcomes Following Repeated Loco-Regional Treatment Session in Patients with Hepatocellular Carcinoma: A Retrospective, Single-Center Study. <i>Life</i> , 2021, 11, 1062.	1.1	0
4347	A Case of Pathological Complete Response after Combination Chemotherapy by Sorafenib and Cisplatin Hepatic Arterial Infusion for an Advanced Hepatocellular Carcinoma. <i>Japanese Journal of Gastroenterological Surgery</i> , 2013, 46, 915-923.	0.0	0
4348	Two cases with long-term survival following hepatocellular carcinoma with tumor thrombus invasion of the inferior vena cava, after multidisciplinary therapy including surgery. <i>Acta Hepatologica Japonica</i> , 2013, 54, 628-634.	0.0	0

#	ARTICLE	IF	CITATIONS
4349	The Korean National Liver Cancer Surveillance Program: Experience of a Single Healthcare Center in 2011. Korean Journal of Medicine, 2013, 84, 672.	0.1	4
4350	Transvaskuläre Therapie des hepatozellulären Karzinoms. , 2013, , 299-322.		1
4351	National Cancer Screening Program for Hepatocellular Carcinoma. Korean Journal of Medicine, 2013, 84, 670.	0.1	0
4352	The Conservative and Interventional Treatment of the Complications of Liver Cirrhosis. Deutsches Ärztblatt International, 2013, 110, 126-32, I.	0.6	12
4356	Hepatic Tumors. , 2014, , 423-442.		0
4358	Revisiting the role of pathological analysis in transarterial chemoembolization-treated hepatocellular carcinoma after transplantation. World Journal of Gastroenterology, 2014, 20, 13538.	1.4	4
4359	Relationship between proton pump inhibitor therapy and spontaneous bacterial peritonitis in cirrhotic patients with ascites. Acta Hepatologica Japonica, 2014, 55, 530-536.	0.0	0
4361	Current Diagnosis and Treatment Options for HCC. , 2014, , 7-13.		0
4362	Time to Progression of AFP (TPA) as a Predictor of Survival in Hepatocellular Carcinoma Treated with Sorafenib (SOR). Journal of Cancer Therapy, 2014, 05, 1332-1343.	0.1	1
4363	r-GT, A Promising Marker for HCC Development after SVR in Hepatitis C Patients?. Gastroenterology & Hepatology (Bartlesville, Okla), 2014, , .	0.0	0
4364	Percutaneous Microwave Ablation for Liver Tumors Adjacent to Large Vessels. , 2015, , 79-87.		3
4366	Hepatocarcinoma fibrolamelar un tumor de adultos jÃ³venes poco frecuente. Reporte de un caso. Revista Colombiana De Gastroenterologia, 2014, 29, 433-438.	0.1	0
4370	Surgical Treatment for Hepatocellular Carcinoma. Advances in Predictive, Preventive and Personalised Medicine, 2015, , 61-68.	0.6	0
4372	Evaluation of Response in Malignant Tumors Treated with Targeted Agents. Current Clinical Pathology, 2015, , 43-55.	0.0	0
4373	Indications for Liver Transplantation. , 2015, , 97-125.		1
4376	Systemic Chemotherapy in Orthotopic Liver Transplantation. , 2015, , 1-16.		0
4378	Hepatocellular cancer and venous thromboembolism. , 2015, , 109-120.		0
4379	The radiologic assessment of progressive disease for patients with hepatocellular carcinoma after transarterial chemoembolization should be stratified. Journal of Cancer Prevention & Current Research, 2018, 9, .	0.1	0

#	ARTICLE	IF	CITATIONS
4380	HCC RADIOLOGINÄ–S DIAGNOSTIKOS KITIMAS LIETUVOS SVEIKATOS MOKSLÄ² UNIVERSITETO KAUNO KLINIKOSE 2003â€“2014 METAIS. Medicinos Teorija Ir Praktika, 2015, 21, 553-558.	0.0	0
4382	Trans-arterial Chemo-Embolization in Treating Elderly Patients with Hepatocellular Carcinoma. Asian Pacific Journal of Cancer Prevention, 2015, 16, 7201-7204.	0.5	0
4383	Liver Transplantation for HCC: The Milan Criteria. , 2016, , 1-20.		0
4385	Experience with targeted therapy for liver cancer in the Republic of Sakha (Yakutia). Onkologiya Zhurnal Imeni P A Gertsena, 2016, 5, 77.	0.0	0
4386	Better Management of Adverse Events Favors Sorafenib Treatment of HCC Patients and Impact on Survival. Journal of Cancer Therapy, 2016, 07, 275-284.	0.1	1
4388	Radionuclide Therapy of Tumors of the Liver and Biliary Tract. , 2016, , 1-24.		0
4389	Systemic Chemotherapy in Orthotopic Liver Transplantation. , 2016, , 1-16.		0
4390	Thermal Ablative Treatments for Hepatocellular Carcinoma. , 2016, , 453-466.		1
4391	Which Is the Better Predictor of Hepatic Reserve Prior to Liver Resection: MELD or the Child-Pugh Score?. Difficult Decisions in Surgery: an Evidence-based Approach, 2016, , 189-199.	0.0	0
4392	What Is the Best Way to Screen Cirrhotic Patients for Hepatocellular Carcinoma in the United States?. Difficult Decisions in Surgery: an Evidence-based Approach, 2016, , 93-111.	0.0	0
4393	Liver Transplantation for Hepatocellular Carcinoma. , 2016, , 477-488.		0
4394	Resection of Hepatocellular Carcinoma. , 2016, , 467-475.		0
4395	Serum Alpha-Fetoprotein as a Biomarker in Liver Transplantation. Exposure and Health, 2016, , 1-34.	2.8	2
4396	Role of Neoadjuvant and Adjuvant Treatment in HCC Recurrence After Liver Transplantation. , 2016, , 187-203.		0
4399	Current HCC Staging Systems: Their Uses and Limitations. , 2016, , 425-442.		4
4400	Diagnosis and Management of Hepatocellular Carcinoma. In Clinical Practice, 2017, , 285-306.	0.1	0
4401	Added Value of Contrast-Enhanced Ultrasonography as a Planning Modality for Radiofrequency Ablation of Hepatocellular Carcinoma: Comparison with Gray-Scale Ultrasonography. Iranian Journal of Radiology, 2016, Inpress, .	0.1	0
4402	Hepatocellular carcinoma in patients without advanced fibrosis after eradication of HCV with antiviral treatment. Revista Espanola De Enfermedades Digestivas, 2017, 109, 734-735.	0.1	0

#	ARTICLE	IF	CITATIONS
4403	Benign and Malignant Tumors of the Liver. , 2017, , 1-20.		0
4404	Study of Pleural Effusion after Radiofrequency Ablation for Primary Hepatocellular Carcinoma. World Journal of Cancer Research, 2017, 07, 6-10.	0.1	0
4405	Serum Alpha-Fetoprotein as a Biomarker in Liver Transplantation. Biomarkers in Disease, 2017, , 837-870.	0.0	1
4406	The Liver. , 2017, , 95-125.		0
4407	Voeding bij galblaas- en leveraandoeningen. , 2017, , 57-100.		0
4408	Gastroenterologie. , 2017, , 185-264.		0
4409	Tumoren van lever, galwegen en pancreas. , 2017, , 343-360.		0
4410	H�patopathies chroniques. , 2017, , 29-62.		0
4411	Sorafenib and Clinical Patterns of Resistance in Hepatocellular Carcinoma. Resistance To Targeted Anti-cancer Therapeutics, 2017, , 117-131.	0.1	0
4412	Cytokine-Induced Killer Cells for the Adjuvant Treatment of Patients with HCC. , 2017, , 69-84.		0
4413	Radionuclide Therapy of Tumors of the Liver and Biliary Tract. , 2017, , 1337-1360.		0
4414	Squamous Cell Carcinoma Antigen-Immunoglobulin M (SCCA-IgM) as Biomarker in Liver Disease: Biological Aspects and Clinical Applications. Biomarkers in Disease, 2017, , 559-580.	0.0	0
4415	Radiological Assessment of Response to Palliative Treatments in Hepatocellular Carcinoma. Resistance To Targeted Anti-cancer Therapeutics, 2017, , 105-116.	0.1	0
4416	Biomarkers for Hepatocellular Carcinoma in East Asia. Biomarkers in Disease, 2017, , 901-925.	0.0	0
4418	Cost-Effectiveness of Surveillance for Hepatocellular Carcinoma: A Systematic Review. The Journal of Health Technology Assessment, 2017, 5, 49-58.	0.2	0
4420	Efficacy of anti-VEGF agents in the treatment of elderly hepatocellular carcinoma: a systematic review. Oncotarget, 2017, 8, 93179-93185.	0.8	2
4421	Role of Serum Glypican-3 in the Diagnosis of Hepatocellular Carcinoma in the Upper Egypt. Open Journal of Gastroenterology, 2018, 08, 415-423.	0.1	0
4426	Midterm Outcomes and Prognostic Factors of Patients Treated Using Microballoon-Occluded Transarterial Chemoembolization with Miriplatin: A Retrospective Study of 37 Cases. Interventional Radiology, 2018, 3, 97-109.	0.2	0

#	ARTICLE	IF	CITATIONS
4427	Guidelines on Radioisotope Treatment of Liver Cancer and Liver Metastases with Intra-arterial Radioactive Compounds. , 2018, , 199-203.		0
4428	Hepatocellular Carcinoma: Known and Emerging Risk Factors. Journal of Cancer Therapy, 2018, 09, 417-437.	0.1	0
4429	Maligne Lebertumoren. Evidenzbasierte Chirurgie, 2018, , 107-131.	0.0	0
4431	Transarterial chemoembolization as a substitute to radiofrequency ablation for treating Barcelona Clinic Liver Cancer stage 0/A hepatocellular carcinoma. Oncotarget, 2018, 9, 21560-21568.	0.8	6
4433	Đ;Đ°Ñ€Đ,Đ½Ñ–Đ½Đ³ Ñ– Ñ€Đ°Đ½Đ½Ñ•ĐÑ–Đ°Đ³Đ½Đ¾ÑÑ,Đ,Đ°Đ° Đ³ĐµĐ;Đ°Ñ,Đ¾Ñ†ĐµĐ»ÑŽĐ»ÑÑ€Đ½Đ¾Ñ†– Đ°Đ°Ñ€Ñ†Đ,Đ½		
4434	TRANSARTERIAL CHEMOEMBOLIZATION(TACE) EFFICACY IN PATIENTS WITH HEPATOCELLULAR CARCINOMA(HCC): CAN SIGNIFICANT PROGNOSTIC FACTORS BE REVEALED?. Voprosy Onkologii, 2018, 64, 793-798.	0.1	0
4435	Management of hepatocellular carcinoma: a study on 240 patients in a single referral center. Scripta Scientifica Medica, 2018, 50, 19.	0.1	0
4436	The possibility of applying magnetic resonance imaging with hepatospecific contrast agent.. Klinicheskaia Meditsina, 2018, 96, 213-221.	0.2	1
4437	Lamp2 inhibits epithelial-mesenchymal transition by suppressing Snail expression in HCC. Oncotarget, 2018, 9, 30240-30252.	0.8	3
4438	Radiofrequency thermal destruction in current treatment of liver malignancies. Literature review. Annals of HPB Surgery, 2018, 23, 11-25.	0.1	0
4439	Improved liver function after high dose intravenous vitamin C and Helxior SC injections in a patient with hepatocellular carcinoma progressed after chemotherapy and radiation. Journal of Cancer Prevention & Current Research, 2018, 9, .	0.1	1
4440	Outcome and predictors of transarterial chemo embolization in decompensate cirrhotic hepatocellular carcinoma patients. Gastroenterology & Hepatology (Bartlesville, Okla), 2018, 9, .	0.0	0
4441	Transarterial Embolization Therapies in Hepatocellular Carcinoma: Principles of Management. , 2019, , 123-138.		1
4442	The Role of Liver Resection for the Treatment of Hepatocellular Carcinoma. , 2019, , 83-97.		0
4443	Oncotherapies for HCC. , 2019, , 153-165.		0
4444	Role of Interventional Radiology in Management of Gastrointestinal Cancers and Neuroendocrine Tumors. , 2019, , 551-572.		0
4445	Radionuclide Therapy for Tumors of the Liver and Biliary Tract. , 2019, , 859-879.		0
4446	Characteristics and Prognosis of Patients with Hepatocellular Carcinoma at Campus Teaching Hospital of Lome. Open Journal of Gastroenterology, 2019, 09, 203-210.	0.1	0

#	ARTICLE	IF	CITATIONS
4447	Efficacy of Intensity-Modulated Radiotherapy for Recurrent or Residual PHC after Transcatheter Arterial Chemoembolization. <i>World Journal of Cancer Research</i> , 2019, 09, 105-109.	0.1	0
4448	Molecular Markers and Recurrence of Hepatocellular Carcinoma after Liver Transplantation. <i>Advances in Clinical Medicine</i> , 2019, 09, 310-318.	0.0	0
4449	Differences in CEUS and CE-MRI Appearance of HCC: A Case Report. <i>Advanced Ultrasound in Diagnosis and Therapy</i> , 2019, 3, 197.	0.1	1
4450	Intraoperative radiofrequency ablation and distilled water peritoneal lavage for spontaneously ruptured hepatocellular carcinoma. <i>Annals of Surgical Treatment and Research</i> , 2019, 97, 291.	0.4	0
4452	Characteristics and survival of hepatocellular carcinoma in non-cirrhotic liver.. <i>Revista Espanola De Enfermedades Digestivas</i> , 2019, 111, 760-766.	0.1	3
4453	Discrepancy between the Actual Clinical Status of Patients with Hepatocellular Carcinoma and Expectations from Hepatocellular Carcinoma Surveillance: a Single-Center Study. <i>Journal of Liver Cancer</i> , 2019, 19, 30-37.	0.3	2
4455	Surgical management of hepatocellular carcinoma—Western versus Eastern attitude. <i>Translational Cancer Research</i> , 2019, 8, S245-S260.	0.4	0
4456	Direct antiviral agents for HCV infection and hepatocellular carcinoma: facts and FADs. <i>Translational Cancer Research</i> , 2019, 8, S223-S232.	0.4	2
4457	The combination of transcatheter arterial chemoembolisation (TACE) and thermal ablation versus TACE alone for hepatocellular carcinoma. <i>The Cochrane Library</i> , 0, , .	1.5	1
4458	Assessing the characteristics and feasibility of preventing early mortality in patients with hepatocellular carcinoma. <i>Turkish Journal of Gastroenterology</i> , 2019, 30, 541-548.	0.4	3
4459	Prognostic value of interleukin-10 and tumor necrosis factor- γ polymorphisms in patients with hepatocellular carcinoma treated with transarterial chemoembolization. <i>The Egyptian Journal of Internal Medicine</i> , 2019, 31, 254-260.	0.3	0
4460	A scoring model combining serum alpha-fetoprotein and tumor size and number predicts prognosis in hepatitis B virus-related hepatocellular carcinoma patients after curative hepatectomy. <i>Translational Cancer Research</i> , 2019, 8, 1438-1448.	0.4	0
4461	A Proposal for Modification of the Barcelona Clinic Liver Cancer Staging System Considering the Prognostic Implication of Performance Status. <i>Gut and Liver</i> , 2019, 13, 557-568.	1.4	6
4463	Advances in understanding of mechanism of anti-hepatocellular carcinoma effects of curcumin. <i>World Chinese Journal of Digestology</i> , 2019, 27, 1043-1049.	0.0	0
4464	Rizikov's factory a surveillance hepatocellular carcinoma. <i>Vnitřní Lekarství</i> , 2019, 65, 583-587.	0.1	0
4465	Novel compound cedrelone inhibits hepatocellular carcinoma progression via PBLD and Ras/Rap1. <i>Experimental and Therapeutic Medicine</i> , 2019, 18, 4209-4220.	0.8	3
4466	An Efficient Semiautomatic Active Contour Model of Liver Tumor Segmentation from CT Images. <i>Asset Analytics</i> , 2020, , 75-85.	0.4	1
4467	Second-line treatment of hepatocellular carcinoma: from theory to practical issues. <i>Meditinskiy Sovet</i> , 2019, , 30-36.	0.1	2

#	ARTICLE	IF	CITATIONS
4468	Efficacy evaluation of the CEUS-LI-RADS-v2017 system in differential diagnosis of liver tumors. <i>Medical Visualization</i> , 2019, , 57-67.	0.1	0
4469	FIB-4 Is a Potential Tool for Hepatocellular Carcinoma Risk Stratification in Ethnically Diverse Chronic Hepatitis B Patients When Using Specific Cutoff Values. <i>Hepatitis Monthly</i> , 2019, In Press, .	0.1	0
4470	Assessment of the follow-up interval changes of the less than 2â€‰cm arterial phase enhancing hepatic nodules in correlation with Liver Imaging Reporting and Data System (LI-RADS) classification version 18 using contrast-enhanced multidetector computed tomography. <i>Egyptian Journal of Radiology and Nuclear Medicine</i> , 2019, 50, .	0.3	1
4473	The role of MDCT and MRI in the diagnosis of focal liver diseases. <i>Annals of HPB Surgery</i> , 2019, 24, 91-110.	0.1	5
4474	Systemic Therapy of Advanced Liver Cancer. , 2020, , 661-666.		0
4475	Diagnostic and Therapeutic Challenges in Hepatocellular Carcinoma. <i>ARS Medica Tomitana</i> , 2020, 26, 76-79.	0.0	0
4476	Differences in Survival Between First-Line Radiofrequency Ablation versus Surgery for Early-Stage Hepatocellular Carcinoma: A Population Study Using the Surveillance, Epidemiology, and End Results Database. <i>Medical Science Monitor</i> , 2020, 26, e921782.	0.5	2
4477	Challenges of hepatocellular cancer diagnosing in computed tomography. Lecture and demonstration of observations. <i>Annals of HPB Surgery</i> , 2020, 25, 39-48.	0.1	0
4478	Complex treatment of hepatocellular carcinoma at early (BCLC-A) and intermediate (BCLC-B) stages. <i>Annals of HPB Surgery</i> , 2020, 25, 55-66.	0.1	2
4479	Systemic therapy of hepatocellular carcinoma: reality and prospects. <i>Annals of HPB Surgery</i> , 2020, 25, 27-38.	0.1	2
4480	Individualized surveillance of chronic hepatitis B patients according to hepatocellular carcinoma risk based on PAGE-B scores. <i>European Journal of Gastroenterology and Hepatology</i> , 2021, 33, 1564-1572.	0.8	2
4481	Safety and effectiveness of new embolization microspheres SCBRM for intermediate-stage hepatocellular carcinoma: A feasibility study. <i>Bosnian Journal of Basic Medical Sciences</i> , 2021, 21, 339-345.	0.6	1
4482	Accurate ultrasonography-based portal pressure assessment in patients with hepatocellular carcinoma. <i>World Journal of Gastrointestinal Oncology</i> , 2020, 12, 931-941.	0.8	0
4483	Hepatocellular Carcinoma in the Adolescent With Classical Familial Adenomatous Polyposis: Clinical Case. <i>Voprosy Sovremennoi Pediatrii - Current Pediatrics</i> , 2020, 19, 291-297.	0.1	0
4484	Association of IL-10 and TNF-Î± polymorphisms with risk and aggressiveness of hepatocellular carcinoma in patients with HCV-related cirrhosis. <i>Egyptian Liver Journal</i> , 2020, 10, .	0.3	2
4485	Development of a novel prognostic nomogram for the early recurrence of liver cancer after curative hepatectomy. <i>Annals of Translational Medicine</i> , 2021, 9, 1541-1541.	0.7	6
4486	Artificial neural network for prediction of acute kidney injury after liver transplantation for cirrhosis and hepatocellular carcinoma. <i>Artificial Intelligence in Cancer</i> , 2021, 2, 51-59.	1.1	0
4487	EUS-Guided Crio-thermal Ablation of Pancreatic Neoplasia. , 2020, , 1-21.		0

#	ARTICLE	IF	CITATIONS
4488	Prognostic Factors for Patients With a Large Number of Hepatocellular Carcinoma Nodules. <i>Journal of Clinical Medicine Research</i> , 2020, 12, 26-35.	0.6	1
4489	Serum Biomarkers Study and the Establishment of Diagnostic Models for Hepatitids B-Related HCC. <i>Journal of Analytical Oncology</i> , 0, 9, 72-81.	0.1	0
4490	Long non-coding RNA TTN-AS1 aggravates carcinogenesis through Wnt/ β^2 -catenin signaling pathway by sponging miR-1271 in hepatocellular carcinoma. <i>Minerva Medica</i> , 2020, 111, 617-619.	0.3	4
4491	Combined regional and spatio-temporal approach improves hepatic tumors classification in Multiphase CT. , 2020, , .		0
4492	Juvenile Hepatocellular Carcinoma in a Healthy Liver. <i>Internal Medicine</i> , 2022, 61, 1531-1536.	0.3	4
4493	Identification of Susceptibility Genes in Hepatic Cancer Using Whole Exome Sequencing and Risk Prediction Model Construction. <i>Romanian Journal of Laboratory Medicine</i> , 2020, 28, 67-74.	0.1	0
4494	A Novel Deep Learning Approach for Liver MRI Classification and HCC Detection. <i>Lecture Notes in Computer Science</i> , 2020, , 635-645.	1.0	2
4495	Association of metabolic traits with occurrence of nonalcoholic fatty liver disease-related hepatocellular carcinoma: A systematic review and meta-analysis of longitudinal cohort studies. <i>Saudi Journal of Gastroenterology</i> , 2022, 28, 92.	0.5	9
4496	Thrombophilia in hepatocellular carcinoma. <i>Egyptian Liver Journal</i> , 2019, 9, .	0.3	0
4497	Indian Council of Medical Research consensus document on hepatocellular carcinoma. <i>Indian Journal of Medical Research</i> , 2020, 152, 468.	0.4	9
4498	Treatment Strategy for Post-Hepatectomy Recurrent Hepatocellular Carcinoma: A Single Center Experience with 556 Consecutive Cases in China. <i>Journal of Cancer Therapy</i> , 2020, 11, 389-400.	0.1	0
4499	NAFLD, Hepatocellular Carcinoma, and Extrahepatic Cancers. , 2020, , 199-209.		0
4500	Intrahepatic cholangiocarcinoma with fudroaiant course. <i>PONS - Medicinski Casopis</i> , 2020, 17, 27-32.	0.0	0
4501	Benign and Malignant Tumors of the Liver. , 2020, , 855-874.		0
4502	Lebertransplantation. <i>Pathologie</i> , 2020, , 437-497.	0.0	0
4503	Fusion imaging with contrast-enhanced ultrasonography for evaluating the early therapeutic efficacy of radiofrequency ablation for small hypervascular hepatocellular carcinomas with iso-echoic or unclear margins on conventional ultrasonography. <i>Choonpa Igaku</i> , 2020, 47, 81-91.	0.0	0
4504	Safety and efficacy analysis of microwave ablation in small hepatocellular carcinomas sized below 3 cm. <i>Polish Journal of Radiology</i> , 2020, 85, 202-208.	0.5	0
4505	PET in Gastrointestinal, Pancreatic, and Liver Cancers. , 2020, , 597-625.		0

#	ARTICLE	IF	CITATIONS
4506	EUS-Guided Anti-tumor Therapy: Ablation of Solid Neoplasms. , 2020, , 147-177.		0
4508	Outcomes associated with the intention of loco-regional therapy prior to living donor liver transplantation for hepatocellular carcinoma. World Journal of Gastrointestinal Surgery, 2020, 12, 17-27.	0.8	4
4509	Special Indications: Cirrhosis, Inflammatory Bowel Disease, and Organ Transplantation. , 2020, , 19-35.		0
4510	Percutaneous Radiofrequency Ablation for Liver Tumors: Technical Tips. Interventional Radiology, 2020, 5, 50-57.	0.2	0
4511	Tumoren van lever, galwegen en pancreas. , 2020, , 345-365.		0
4513	Long non-coding RNA GACAT3 promotes liver cancer progression by regulating the proliferation, apoptosis and migration of tumor cells. Experimental and Therapeutic Medicine, 2020, 19, 3377-3383.	0.8	3
4514	Expression of yhwaz and gene regulation network in hepatocellular carcinoma. Oncology Letters, 2020, 19, 3971-3981.	0.8	0
4515	Potential therapies for residual hepatoblastoma following incomplete ablation treatment in a nude mouse subcutaneous xenograft model based on lncRNA and mRNA expression profiles. Oncology Reports, 2020, 43, 1915-1927.	1.2	2
4516	Is the use of microwave ablation more effective and/or safe than radiofrequency ablation in the treatment of hepatocellular carcinoma?. Revista Da Associação Médica Brasileira, 2020, 66, 392-399.	0.3	1
4517	External Beam Radiation Therapy for Primary Liver Cancers: An ASTRO Clinical Practice Guideline. Practical Radiation Oncology, 2022, 12, 28-51.	1.1	92
4518	Proposal and Validation of a Novel Scoring System for Hepatocellular Carcinomas Beyond Curability Borders. Hepatology Communications, 2022, 6, 633-645.	2.0	4
4519	Intestinal Intervention Strategy Targeting Myeloid Cells to Improve Hepatic Immunity during Hepatocarcinoma Development. Biomedicines, 2021, 9, 1633.	1.4	5
4520	Histotripsy for the Treatment of Cholangiocarcinoma in a Patient-Derived Xenograft Mouse Model. Ultrasound in Medicine and Biology, 2022, 48, 293-303.	0.7	3
4521	Prothrombin induced by vitamin K absence or antagonist and alpha foetoprotein to predict development of hepatocellular carcinoma in Caucasian patients with hepatitis C-related cirrhosis treated with direct-acting antiviral agents. Alimentary Pharmacology and Therapeutics, 2022, 55, 350-359.	1.9	11
4522	Locoregional Treatments for Bridging and Downstaging HCC to Liver Transplantation. Cancers, 2021, 13, 5558.	1.7	16
4523	EUS-Guided Crio-thermal Ablation of Pancreatic Neoplasia. , 2022, , 1873-1893.		0
4524	Interventional Radiological Management of Hepatocellular Carcinoma. Indian Journal of Medical and Paediatric Oncology, 2020, 41, 484-487.	0.1	0
4525	Transarterial chemoembolization with hepatic arterial infusion chemotherapy plus S-1 for hepatocellular carcinoma. World Journal of Gastroenterology, 2020, 26, 3975-3988.	1.4	6

#	ARTICLE	IF	CITATIONS
4526	Transarterial chemoembolization with hepatic arterial infusion chemotherapy plus S-1 for hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2020, 26, 3971-3984.	1.4	0
4527	Hepatocyte ploidy and pathological mutations in hepatocellular carcinoma: impact on oncogenesis and therapeutics. <i>Global Health & Medicine</i> , 2020, 2, 273-281.	0.6	4
4528	Transarterial Chemoembolisation and Combined Therapy. <i>Medical Radiology</i> , 2021, , 283-317.	0.0	0
4529	Application of Gemstone CT Spectroscopy in the Evaluation of Abnormal Enhancement of Lesion Margin After Radiofrequency Ablation of Hepatocellular Carcinoma. <i>Iranian Journal of Radiology</i> , 2020, 17, .	0.1	0
4530	PREVALENCE OF HEPATITIS C VIRUS GENOTYPES REPORTED FROM A TERTIARY CARE CENTRE OF KERALA.. , 2020, , 101-103.		0
4532	Comparison between Computer Tomography and Magnetic Resonance Imaging in the Diagnosis of Small Hepatocellular Carcinoma. <i>Asian Pacific Journal of Cancer Prevention</i> , 2016, 17, 4805-4811.	0.5	3
4534	Fine needle aspiration biopsy of malignant mass lesions in the liver: a revisit of diagnostic profiles and challenges. <i>Journal of Gastrointestinal Oncology</i> , 2013, 4, 5-7.	0.6	3
4535	Unresectable hepatocellular carcinoma treated with transarterial chemoembolization: clinical data from a single teaching hospital. <i>International Journal of Clinical and Experimental Medicine</i> , 2013, 6, 367-71.	1.3	2
4536	Hepatocellular carcinoma in a young dog. <i>Canadian Veterinary Journal</i> , 2013, 54, 845-8.	0.0	3
4537	Surveillance for hepatocellular carcinoma after autologous stem cell transplantation in cirrhosis. <i>Middle East Journal of Digestive Diseases</i> , 2012, 4, 145-9.	0.2	7
4538	Current management of hepatocellular carcinoma. <i>Gastroenterology and Hepatology</i> , 2014, 10, 153-61.	0.2	73
4539	Extending survival with the use of targeted therapy in the treatment of hepatocellular carcinoma. <i>Gastroenterology and Hepatology</i> , 2013, 9, 1-24.	0.2	5
4540	Can TIE-2 expressing monocytes represent a novel marker for hepatocellular carcinoma?. <i>Hepatobiliary Surgery and Nutrition</i> , 2014, 3, 175-8.	0.7	2
4541	Challenges in combining antiangiogenic therapy with transarterial chemoembolization for hepatocellular carcinoma. <i>Gastrointestinal Cancer Research: GCR</i> , 2014, 7, 98-102.	0.8	4
4542	Considerations regarding current diagnosis and prognosis of hepatocellular carcinoma. <i>Journal of Medicine and Life</i> , 2015, 8, 120-8.	0.4	17
4543	Level of hepatitis B surface antigen might serve as a new marker to predict hepatocellular carcinoma recurrence following curative resection in patients with low viral load. <i>American Journal of Cancer Research</i> , 2015, 5, 756-71.	1.4	9
4545	The role of (18)F-FDG positron emission tomography in the follow-up of liver tumors treated with (90)Yttrium radioembolization. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 5, 220-32.	1.0	4
4547	Association between PNPLA3 rs738409 polymorphisms and risk of hepatocellular carcinoma and its development in patients with cirrhosis: a meta-analysis. <i>International Journal of Clinical and Experimental Medicine</i> , 2015, 8, 6638-49.	1.3	4

#	ARTICLE	IF	CITATIONS
4548	Subcutaneous metastasis—the first sign of hepatocellular carcinoma in chronic virus C hepatitis patient—Case report. <i>Journal of Medicine and Life</i> , 2015, 8, 361-4.	0.4	1
4549	Novel imaging biomarkers of response to transcatheter arterial chemoembolization in hepatocellular carcinoma patients. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2015, 27, 611-26.	0.7	0
4550	Surveillance and Diagnosis of Hepatocellular Carcinoma. <i>Gastroenterology and Hepatology</i> , 2015, 11, 38-46.	0.2	11
4551	Aspirin in combination with TACE in treatment of unresectable HCC: a matched-pairs analysis. <i>American Journal of Cancer Research</i> , 2016, 6, 2109-2116.	1.4	19
4552	The Negative Effect of Preoperative Transcatheter Arterial Chemoembolization on Long-Term Outcomes for Resectable Hepatocellular Carcinoma: A Propensity Score Matching Analysis. <i>Yonago Acta Medica</i> , 2016, 59, 270-278.	0.3	3
4554	Identification of miR-101-3p targets and functional features based on bioinformatics, meta-analysis and experimental verification in hepatocellular carcinoma. <i>American Journal of Translational Research (discontinued)</i> , 2017, 9, 2088-2105.	0.0	19
4555	The Chinese medicine, Jianpi Huayu Decoction, inhibits the epithelial mesenchymal transition via the regulation of the Smad3/Smad7 cascade. <i>American Journal of Translational Research (discontinued)</i> , 2017, 9, 2694-2711.	0.0	10
4556	Measuring levels of osteopontin as potential biomarker for hepatocellular carcinoma in Syrian patients. <i>Gastroenterology and Hepatology From Bed To Bench</i> , 2017, 10, 97-101.	0.6	8
4557	Advances and Future Directions in the Treatment of Hepatocellular Carcinoma. <i>Gastroenterology and Hepatology</i> , 2017, 13, 398-410.	0.2	10
4558	Current Status of Sorafenib Use for Treatment of Hepatocellular Carcinoma. <i>Gastroenterology and Hepatology</i> , 2017, 13, 623-625.	0.2	2
4559	Thymoquinone restores liver fibrosis and improves oxidative stress status in a lipopolysaccharide-induced inflammation model in rats. <i>Avicenna Journal of Phytomedicine</i> , 2017, 7, 502-510.	0.1	10
4560	Combined magnetic resonance imaging and optical surgical navigation system guidance of percutaneous liver cryoablation in a porcine model. <i>American Journal of Translational Research (discontinued)</i> , 2018, 10, 1531-1538.	0.0	1
4561	Inverse Association between Glucose 6 Phosphate Dehydrogenase Deficiency and Hepatocellular Carcinoma. <i>Asian Pacific Journal of Cancer Prevention</i> , 2018, 19, 1069-1073.	0.5	3
4562	Role of gadoxetic acid-enhanced 3T MRI combined with diffusion in small HCC diagnosis - case presentation. <i>Current Health Sciences Journal</i> , 2015, 41, 62-66.	0.2	0
4563	Update on HCC Management and Review of the New EASL Guidelines. <i>Gastroenterology and Hepatology</i> , 2018, 14, 384-386.	0.2	7
4564	Thalidomide Combined with Transcatheter Arterial Chemoembolization (TACE) for Intermediate or Advanced Hepatocellular Carcinoma: A Systematic Review and GRADE Approach. <i>Asian Pacific Journal of Cancer Prevention</i> , 2018, 19, 2043-2055.	0.5	3
4565	In Vivo Experimental Study of an Endoscopic Ultrasound Multifunctional Radiofrequency Ablation Probe. <i>Current Health Sciences Journal</i> , 2016, 42, 359-364.	0.2	0
4566	Clinical, Epidemiological and Histopathological Aspects in Patients with Hepatocellular Carcinoma Undergoing Liver Transplantation. <i>Asian Pacific Journal of Cancer Prevention</i> , 2018, 19, 2795-2802.	0.5	5

#	ARTICLE	IF	CITATIONS
4569	Paris saponin H suppresses human hepatocellular carcinoma (HCC) by inactivation of Wnt/ β 2-catenin pathway and. International Journal of Clinical and Experimental Pathology, 2019, 12, 2875-2886.	0.5	5
4570	Low expression of trafficking protein particle complex 4 predicts poor prognosis in hepatocellular carcinoma. International Journal of Clinical and Experimental Pathology, 2018, 11, 2691-2698.	0.5	0
4571	Overexpression of Sox3 is associated with promoted tumor progression and poor prognosis in hepatocellular carcinoma. International Journal of Clinical and Experimental Pathology, 2017, 10, 7873-7881.	0.5	2
4572	Ursodeoxycholic acid induces autophagy via LC3B to suppress hepatocellular carcinoma in vivo and in vitro. International Journal of Clinical and Experimental Pathology, 2017, 10, 11805-11813.	0.5	1
4573	Neoadjuvant therapy and immunotherapy strategies for hepatocellular carcinoma. American Journal of Cancer Research, 2020, 10, 1658-1667.	1.4	8
4574	Lenvatinib in elderly hepatocellular carcinoma patients, a new therapeutic option in first line. Annals of Translational Medicine, 2020, 8, 1335.	0.7	0
4575	A Simple Method to Avoid Bile Duct Injury during Percutaneous Radiofrequency Ablation Therapy for Hepatocellular Carcinoma. Case Reports in Oncology, 2020, 13, 1337-1342.	0.3	0
4576	Combination of NK-based immunotherapy and sorafenib against hepatocellular carcinoma. American Journal of Cancer Research, 2021, 11, 337-349.	1.4	0
4577	BRCA1-associated protein 1 serves as a tumor suppressor in hepatocellular carcinoma by deubiquitinating and stabilizing PTEN. American Journal of Cancer Research, 2021, 11, 2044-2061.	1.4	0
4578	Targeting the eicosanoid pathway in hepatocellular carcinoma. American Journal of Cancer Research, 2021, 11, 2456-2476.	1.4	1
4579	Predictive Outcomes Using Child-Turcotte-Pugh and Albumin-Bilirubin Scores in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization. Journal of Gastrointestinal Cancer, 2022, 53, 1006-1013.	0.6	4
4580	Long Term Survival Analysis in a Cohort of 125 Patients with Hepatocellular Carcinoma Treated with Transarterial Chemoembolization Using Small Drug Eluting Beads. CardioVascular and Interventional Radiology, 2022, 45, 54-61.	0.9	0
4581	Concurrent Cholecystectomy Is Associated with a Lower Risk of Recurrence after Curative Resection in Early-Stage Hepatocellular Carcinoma: A 10 Year Observational Single-Center Study. Journal of Personalized Medicine, 2021, 11, 1261.	1.1	2
4582	A baseline model including quantitative anti-HBc to predict response of peginterferon in HBeAg-positive chronic hepatitis B patients. Antiviral Therapy, 2021, 26, 126-133.	0.6	2
4583	How to interpret viral markers in the management of chronic hepatitis B infection. Clinical Microbiology and Infection, 2022, 28, 355-361.	2.8	1
4584	Novel biomarkers assist in detection of liver fibrosis in HCV patients. Egyptian Liver Journal, 2021, 11, .	0.3	6
4585	Risk Prediction Model Based on Magnetic Resonance Elastography-Assessed Liver Stiffness for Predicting Posthepatectomy Liver Failure in Patients with Hepatocellular Carcinoma. Gut and Liver, 2022, 16, 277-289.	1.4	5
4586	Role of Biobanks for Cancer Research and Precision Medicine in Hepatocellular Carcinoma. Journal of Gastrointestinal Cancer, 2021, 52, 1232-1247.	0.6	2

#	ARTICLE	IF	CITATIONS
4587	Evaluating the Effectiveness of Yttrium-90 Glass Microspheres in the Treatment of Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma, and Metastatic Colorectal Cancer in Practice: Protocol for the Prospective PROACTIF Phase IV Registry Study in France. <i>CardioVascular and Interventional Radiology</i> , 2022, 45, 1-11.	0.9	3
4588	Impact of prognostic nutritional index on the recurrence of hepatocellular carcinoma after a curative resection. <i>Annals of Hepato-biliary-pancreatic Surgery</i> , 2021, 25, 456-461.	0.1	1
4589	Liver cancer risk after HCV cure in patients with advanced liver disease without non-characterized nodules. <i>Journal of Hepatology</i> , 2022, 76, 874-882.	1.8	17
4590	Hepatocellular carcinoma: Understanding molecular mechanisms for defining potential clinical modalities. <i>World Journal of Hepatology</i> , 2021, 13, 1568-1583.	0.8	6
4591	Progression of Prothrombin Induced by Vitamin K Absence-II in Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 726213.	1.3	18
4592	The position of transarterial chemoembolization with drug-eluting beads and yttrium-90 transarterial radioembolization in patients with hepatocellular carcinoma: Consensus statements from a Delphi-method expert panel in Turkey. , 2021, 27, 732-739.		0
4593	Radiomics in hepatocellular carcinoma: A state-of-the-art review. <i>World Journal of Gastrointestinal Oncology</i> , 2021, 13, 1599-1615.	0.8	17
4594	The characteristics of patients with macrovascular invasion in hepatocellular carcinoma: when East meets West. <i>Langenbeck's Archives of Surgery</i> , 2021, , 1.	0.8	1
4595	Surgery versus radiofrequency ablation in patients with Child- Pugh class-A/single small (≤3 cm) hepatocellular carcinoma. <i>Clinical and Molecular Hepatology</i> , 2022, 28, 207-218.	4.5	22
4596	Prognostic Value of International Normalized Ratio-to-Albumin Ratio and Ferritin Level in Chronic Liver Patients with Hepatocellular Carcinoma. <i>Journal of Gastrointestinal Cancer</i> , 2021, , 1.	0.6	2
4597	TM6SF2/PNPLA3/MBOAT7 Loss-of-Function Genetic Variants Impact on NAFLD Development and Progression Both in Patients and in In Vitro Models. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2022, 13, 759-788.	2.3	44
4598	Multimarker Panels for Detection of Early Stage Hepatocellular Carcinoma: A Prospective, Multicenter, Case-Control Study. <i>Hepatology Communications</i> , 2022, 6, 679-691.	2.0	28
4599	Extended latissimus dorsi flap with propeller ascending design for reconstruction of a complex lateral lumbar defect: A case report and review of the literature. <i>Microsurgery</i> , 2021, , .	0.6	0
4600	Role of Tumor Biomarkers in the Surveillance of Hepatocellular Carcinoma. <i>Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, The</i> , 2021, 78, 284-288.	0.2	1
4601	Comparison between subtraction and dynamic MRI in assessing treatment response following radiofrequency ablation in patients with hepatocellular carcinoma. <i>Egyptian Journal of Radiology and Nuclear Medicine</i> , 2021, 52, .	0.3	1
4602	The circular RNA circSLC7A11 functions as a mir-330-3p sponge to accelerate hepatocellular carcinoma progression by regulating cyclin-dependent kinase 1 expression. <i>Cancer Cell International</i> , 2021, 21, 636.	1.8	5
4603	ABO Blood Group Differentials on Survival in Hepatocellular Carcinoma Patients Treated with Chemoembolization. <i>Asian Pacific Journal of Cancer Prevention</i> , 2021, 22, 3685-3692.	0.5	1
4604	Non-alcoholic steatohepatitis and risk of hepatocellular carcinoma. <i>Chinese Medical Journal</i> , 2021, 134, 2911-2921.	0.9	21

#	ARTICLE	IF	CITATIONS
4605	Inflammatory Scores: Comparison and Utility in HCC Patients Undergoing Transarterial Chemoembolization in a North American Cohort. <i>Journal of Hepatocellular Carcinoma</i> , 2021, Volume 8, 1513-1524.	1.8	5
4606	Incomplete radiofrequency ablation induced chemoresistance by up-regulating heat shock protein 70 in hepatocellular carcinoma. <i>Experimental Cell Research</i> , 2021, 409, 112910.	1.2	13
4607	Limitations and Possibilities of Transarterial Chemotherapeutic Treatment of Hepatocellular Carcinoma. <i>International Journal of Molecular Sciences</i> , 2021, 22, 13051.	1.8	14
4608	The clinical effects of ultrasound-guided microwave ablation in the treatment of primary hepatic carcinoma. <i>Medicine (United States)</i> , 2021, 100, e28045.	0.4	1
4609	Two is better than one: combinatorial receptor targeting enhances hepatocellular carcinoma (HCC) therapeutic response. <i>Hepatobiliary Surgery and Nutrition</i> , 2021, 11, 0-0.	0.7	0
4610	Goal-Directed Fluid Therapy During Hepatectomy a Systematic Review and Meta-Analysis. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
4611	A meta-analysis comparing hepatic arterial infusion chemotherapy and sorafenib for advanced hepatocellular carcinoma. <i>Translational Cancer Research</i> , 2022, 11, 99-112.	0.4	2
4612	The Face of Hepatocellular Carcinoma (HCC) is Changing: Analysis of the temporal trends in aetiology and clinical patterns of HCC in South Australia. <i>Internal Medicine Journal</i> , 0, , .	0.5	2
4613	Tumor Size, Not Small Vessel Invasion, Predicts Survival in Patients With Hepatocellular Carcinoma. <i>American Journal of Clinical Pathology</i> , 2022, 158, 70-80.	0.4	5
4614	Nanotheranostics: A powerful next-generation solution to tackle hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2022, 28, 176-187.	1.4	16
4615	Lenvatinib in elderly hepatocellular carcinoma patients, a new therapeutic option in first line. <i>Annals of Translational Medicine</i> , 2020, 8, 1335-1335.	0.7	0
4616	A Simple Method to Avoid Bile Duct Injury during Percutaneous Radiofrequency Ablation Therapy for Hepatocellular Carcinoma. <i>Case Reports in Oncology</i> , 2021, 13, 1337-1342.	0.3	2
4617	Robust End-to-End Focal Liver Lesion Detection Using Unregistered Multiphase Computed Tomography Images. <i>IEEE Transactions on Emerging Topics in Computational Intelligence</i> , 2023, 7, 319-329.	3.4	5
4618	Transcatheter chemoembolization plus percutaneous radiofrequency ablation versus laparoscopic radiofrequency ablation: improved outcome for inoperable hepatocellular carcinoma. <i>International Journal of Hyperthermia</i> , 2021, 38, 1685-1694.	1.1	2
4619	Preoperative predictors of non-transplantable recurrence after resection for early-stage hepatocellular carcinoma: application in an East Asian cohort. <i>Updates in Surgery</i> , 2022, , 1.	0.9	0
4620	Predictors of changes in preoperative tumor stage between dynamic computed tomography and gadoxetate disodium-enhanced magnetic resonance imaging for hepatocellular carcinoma. <i>Journal of the Formosan Medical Association</i> , 2022, 121, 1550-1559.	0.8	6
4621	Outcomes of patients presenting with elevated tumor marker levels but negative gadoxetic acid-enhanced liver MRI after a complete response to hepatocellular carcinoma treatment. <i>PLoS ONE</i> , 2022, 17, e0262750.	1.1	1
4622	Role of Pretransplant Treatments for Patients with Hepatocellular Carcinoma Waiting for Liver Transplantation. <i>Cancers</i> , 2022, 14, 396.	1.7	4

#	ARTICLE	IF	CITATIONS
4623	Outcomes of Liver Resection for Metabolic Dysfunction-Associated Fatty Liver Disease or Chronic Hepatitis B-Related HCC. <i>Frontiers in Oncology</i> , 2021, 11, 783339.	1.3	4
4624	Prognosis of Single Early-Stage Hepatocellular Carcinoma (HCC) with CEUS Inconclusive Imaging (LI-RADS LR-3 and LR-4) Is No Better than Typical HCC (LR-5). <i>Cancers</i> , 2022, 14, 336.	1.7	5
4625	Predictive performance and clinical utility of HCC risk scores in chronic hepatitis C: a comparative study. <i>Hepatology International</i> , 2022, 16, 159-170.	1.9	5
4626	The combination of transcatheter arterial chemoembolisation (TACE) and thermal ablation versus TACE alone for hepatocellular carcinoma. <i>The Cochrane Library</i> , 2022, 2022, CD013345.	1.5	8
4627	Clinical effects and safety of different transarterial chemoembolization methods for bridging and palliative treatments in hepatocellular carcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 3163-3174.	1.2	3
4628	Overexpression of PD-L1 is an Independent Predictor for Recurrence in HCC Patients Who Receive Sorafenib Treatment After Surgical Resection. <i>Frontiers in Oncology</i> , 2021, 11, 783335.	1.3	5
4629	Combinatorial Cetuximab targeted polymeric nanocomplexes reduce PRC1 level and abrogate growth of metastatic hepatocellular carcinoma in vivo with efficient radionuclide uptake. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2022, , 102529.	1.7	1
4630	The ratio of serum desâ€šgammaâ€šcarboxy prothrombin to tumor volume as a new biomarker for early recurrence of resected hepatocellular carcinoma. <i>Hepatology Research</i> , 2022, 52, 381-389.	1.8	2
4631	Predictors of post-recurrence survival in hepatocellular carcinoma patients following liver transplantation: Systematic review and meta-analysis. <i>Transplantation Reviews</i> , 2022, 36, 100676.	1.2	7
4632	Accuracy of Non-Contrast MRI for the Detection of Hepatocellular Carcinoma: A systematic review and meta-analysis. <i>Pakistan Journal of Medical Sciences</i> , 2022, 38, 743-750.	0.3	0
4633	Cardiopulmonary assessment of patients with unresectable hepatocellular carcinoma treated by transarterial chemoembolization. <i>Journal of Liver Transplantation</i> , 2022, 5, 100063.	0.2	1
4634	Knowledge Mapping of Immunotherapy for Hepatocellular Carcinoma: A Bibliometric Study. <i>Frontiers in Immunology</i> , 2022, 13, 815575.	2.2	63
4635	Percutaneous transhepatic treatment for biliary stricture after duct-to-duct biliary anastomosis in living donor liver transplantation: a 9-year single-center experience. <i>European Radiology</i> , 2022, 32, 2414.	2.3	1
4636	Biomarkers for Locally Advanced Hepatocellular Carcinoma Patients Treated with Liver-Directed Combined Radiotherapy. <i>Liver Cancer</i> , 2022, 11, 247-255.	4.2	1
4637	Diagnosis and staging of HCV associated fibrosis, cirrhosis and hepatocellular carcinoma with target identification for miR-650, 552-3p, 676-3p, 512-5p and 147b. <i>Cancer Biomarkers</i> , 2022, , 1-18.	0.8	4
4638	A hepatocellularis carcinoma komplex kezelÃ©se.. <i>Orvosi Hetilap</i> , 2022, 162, 2-31.	0.1	1
4639	Development of a prognostic gene signature for hepatocellular carcinoma. <i>Cancer Treatment and Research Communications</i> , 2022, 31, 100511.	0.7	3
4640	Potential therapeutic strategies to combat HCC. <i>Current Molecular Pharmacology</i> , 2022, 15, .	0.7	1

#	ARTICLE	IF	CITATIONS
4641	Efficacy of Adjuvant Transarterial Chemoembolization after Radical Hepatectomy in Solitary Hepatocellular Carcinoma Patients: A Retrospective Study. <i>Journal of Investigative Surgery</i> , 2022, 35, 1208-1216.	0.6	3
4642	Utility of Cell-Free DNA Detection in Transplant Oncology. <i>Cancers</i> , 2022, 14, 743.	1.7	10
4643	Local recurrence following complete radiologic response in patients treated with transarterial chemoembolization for hepatocellular carcinoma. <i>Diagnostic and Interventional Imaging</i> , 2022, 103, 143-149.	1.8	14
4644	SLAMF6/Ly108 promotes the development of hepatocellular carcinoma via facilitating macrophage M2 polarization. <i>Oncology Letters</i> , 2022, 23, 83.	0.8	9
4645	Machine Learning-Based Personalized Prediction of Hepatocellular Carcinoma Recurrence After Radiofrequency Ablation. , 2022, 1, 29-37.		5
4646	Efficacy of Local-Regional Treatment Plus Sorafenib in Intermediate-stage Hepatocellular Carcinoma Patients Refractory to Transarterial Chemoembolization. <i>Advances in Digestive Medicine</i> , 0, , .	0.1	0
4647	Contrast-enhanced magnetic resonance imaging perfusion can predict microvascular invasion in patients with hepatocellular carcinoma (between 1 and 5cm). <i>Abdominal Radiology</i> , 2022, 47, 3264-3275.	1.0	4
4648	Nonalcoholic non-virus-related hepatocellular carcinoma arising from nonsteatotic liver. <i>Medicine (United States)</i> , 2022, 101, e28746.	0.4	3
4649	Effects of Moderate Alcohol Consumption in Non-Alcoholic Fatty Liver Disease. <i>Journal of Clinical Medicine</i> , 2022, 11, 890.	1.0	7
4650	Tenofovir vs. entecavir on prognosis of hepatitis B virus-related hepatocellular carcinoma after curative resection. <i>Journal of Gastroenterology</i> , 2022, 57, 185-198.	2.3	16
4651	Duration and cost-effectiveness of hepatocellular carcinoma surveillance in hepatitis C patients after viral eradication. <i>Journal of Hepatology</i> , 2022, 77, 55-62.	1.8	19
4652	Prognostic Impact of Surgical Margin in Hepatectomy on Patients With Hepatocellular Carcinoma: A Meta-Analysis of Observational Studies. <i>Frontiers in Surgery</i> , 2022, 9, 810479.	0.6	3
4653	Prevalence and clinical significance of clinically evident portal hypertension in patients with hepatocellular carcinoma undergoing transarterial chemoembolization. <i>United European Gastroenterology Journal</i> , 2022, 10, 41-53.	1.6	12
4654	HCC risk stratification after cure of hepatitis C in patients with compensated advanced chronic liver disease. <i>Journal of Hepatology</i> , 2022, 76, 812-821.	1.8	59
4655	Tailoring Chemoimmunostimulant Bioscaffolds for Inhibiting Tumor Growth and Metastasis after Incomplete Microwave Ablation. <i>ACS Nano</i> , 2021, 15, 20414-20429.	7.3	18
4656	Similar 5-year HCC occurrence in Tenofovir- and Entecavir-treated HBV chronic infection in the French AFEF/ANRS CO22 Hepather cohort. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 616-629.	1.9	15
4657	VueBox® for quantitative analysis of contrast-enhanced ultrasound in liver tumors1. <i>Clinical Hemorheology and Microcirculation</i> , 2022, 80, 473-486.	0.9	11
4658	The Role of Immune Checkpoint Blockade in the Hepatocellular Carcinoma: A Review of Clinical Trials. <i>Frontiers in Oncology</i> , 2021, 11, 801379.	1.3	21

#	ARTICLE	IF	CITATIONS
4659	Emerging roles of long non-coding RNAs in cancer. <i>Journal of Biosciences</i> , 2019, 44, .	0.5	15
4660	Investigating the Association between COMMD3 Expression and the Prognosis of Hepatocellular Carcinoma. <i>Journal of Cancer</i> , 2022, 13, 1871-1881.	1.2	5
4663	Changes in immune profile affect disease progression in hepatocellular carcinoma. <i>International Journal of Immunopathology and Pharmacology</i> , 2022, 36, 039463202210784.	1.0	3
4664	The survival strength of younger patients in BCLC stage 0-B of hepatocellular carcinoma: basing on competing risk model. <i>BMC Cancer</i> , 2022, 22, 185.	1.1	0
4665	Radioembolization of Hepatocellular Carcinoma with 90Y Glass Microspheres: No Advantage of Voxel Dosimetry with Respect to Mean Dose in Doseâ€“Response Analysis with Two Radiological Methods. <i>Cancers</i> , 2022, 14, 959.	1.7	11
4666	Clinical features and diagnostic and therapeutic strategies of hepatic dysplastic nodules. <i>World Chinese Journal of Digestology</i> , 2022, 30, 169-181.	0.0	0
4667	Prognostic utility of systemic inflammatory markers and chronic hepatitis C virus infection status in hepatocellular carcinoma patients treated with local ablation. <i>BMC Cancer</i> , 2022, 22, 221.	1.1	4
4668	The clinical management of hepatocellular carcinoma worldwide: A concise review and comparison of current guidelines: 2022 update. <i>BioScience Trends</i> , 2022, 16, 20-30.	1.1	53
4669	TIPS improves outcomes in patients with HCC and symptomatic portal hypertension: a multi-institution experience. <i>Cancer Imaging</i> , 2022, 22, 13.	1.2	5
4670	Assessment of serum Talin-1 in liver cirrhosis and hepatocellular carcinoma. <i>Egyptian Liver Journal</i> , 2022, 12, .	0.3	0
4671	Dynamic Change of Albumin-Bilirubin Score Is Good Predictive Parameter for Prognosis in Chronic Hepatitis C-hepatocellular Carcinoma Patients Receiving Transarterial Chemoembolization. <i>Diagnostics</i> , 2022, 12, 665.	1.3	4
4672	IL-6 Promoter Hypomethylation Acts As a Diagnostic Biomarker in Hepatitis B Virus-Associated Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2022, 12, 746643.	1.3	4
4673	Breaking the Child-Pugh Dogma in Hepatocellular Carcinoma. <i>Journal of Clinical Oncology</i> , 2022, 40, 2078-2082.	0.8	11
4674	Characteristics and Clinical Significance of T-Cell Receptor Repertoire in Hepatocellular Carcinoma. <i>Frontiers in Immunology</i> , 2022, 13, 847263.	2.2	1
4675	Segmental Distribution of Hepatocellular Carcinoma in Cirrhotic Livers. <i>Diagnostics</i> , 2022, 12, 834.	1.3	6
4676	Aspartate aminotransferase-to-platelet ratio index for predicting late recurrence of hepatocellular carcinoma after radiofrequency ablation. <i>International Journal of Hyperthermia</i> , 2022, 39, 437-445.	1.1	4
4677	Safety and Efficacy of Sorafenib and Lenvatinib in Patients Who Underwent Surgery or Whole-Brain Radiotherapy for Brain Metastasis of Hepatocellular Carcinoma. <i>Journal of Clinical Medicine</i> , 2022, 11, 1536.	1.0	0
4678	Real-life data on the impact of successful downstaging in patients with hepatocellular carcinoma: A Dutch Multicenter Study. <i>European Journal of Internal Medicine</i> , 2022, 97, 56-61.	1.0	1

#	ARTICLE	IF	CITATIONS
4679	Yttrium-90 radioembolization for unresectable hepatocellular carcinoma: predictive modeling strategies to anticipate tumor response and improve patient selection. <i>European Radiology</i> , 2022, 32, 4687-4698.	2.3	8
4680	A Comparative Analysis of Efficacy of Apatinib Combined with Transarterial Chemoembolization and Transarterial Chemoembolization Alone in the Treatment of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus. <i>Journal of Oncology</i> , 2022, 2022, 1-10.	0.6	2
4681	Consensus subtypes of hepatocellular carcinoma associated with clinical outcomes and genomic phenotypes. <i>Hepatology</i> , 2022, 76, 1634-1648.	3.6	10
4682	Tumour site is a risk factor for hepatocellular carcinoma after hepatectomy: a 1:2 propensity score matching analysis. <i>BMC Surgery</i> , 2022, 22, 104.	0.6	1
4683	An emerging role of radiation-induced exosomes in hepatocellular carcinoma progression and radioresistance (Review). <i>International Journal of Oncology</i> , 2022, 60, .	1.4	7
4684	Lipid based nanoparticles as a novel treatment modality for hepatocellular carcinoma: a comprehensive review on targeting and recent advances. <i>Journal of Nanobiotechnology</i> , 2022, 20, 109.	4.2	42
4685	Serum Folate deficiency in HCV related Hepatocellular Carcinoma. <i>Scientific Reports</i> , 2022, 12, 5025.	1.6	3
4686	Prognostic value of protein biomarkers in liver transplantation: A systematic review. <i>Proteomics - Clinical Applications</i> , 2022, 16, e2100038.	0.8	0
4687	Safety and efficacy of cabozantinib for patients with advanced hepatocellular carcinoma who advanced to Child-Pugh B liver function at study week 8: a retrospective analysis of the CELESTIAL randomised controlled trial. <i>BMC Cancer</i> , 2022, 22, 377.	1.1	10
4688	Clinical and Molecular Basis of Hepatocellular Carcinoma after Hepatitis C Virus Eradication. <i>Pathogens</i> , 2022, 11, 430.	1.2	4
4689	Is hepatocellular carcinoma complicated with portal vein tumor thrombosis potentially curable by radiotherapy in the form of stereotactic body radiation therapy?. <i>International Journal of Radiation Biology</i> , 2022, 98, 1495-1509.	1.0	1
4690	Assessment of HCC response to Yttrium-90 radioembolization with gadoxetate disodium MRI: correlation with histopathology. <i>European Radiology</i> , 2022, 32, 6493-6503.	2.3	5
4691	Total Lesion Glycolysis on 18F-FDG PET/CT Is a Better Prognostic Factor Than Tumor Dose on 90Y PET/CT in Patients With Hepatocellular Carcinoma Treated With 90Y Transarterial Radioembolization. <i>Clinical Nuclear Medicine</i> , 2022, 47, e437-e443.	0.7	2
4692	Fully automated AI-based splenic segmentation for predicting survival and estimating the risk of hepatic decompensation in TACE patients with HCC. <i>European Radiology</i> , 2022, 32, 6302-6313.	2.3	13
4693	Rare ATG7 genetic variants predispose patients to severe fatty liver disease. <i>Journal of Hepatology</i> , 2022, 77, 596-606.	1.8	38
4694	Long-term outcomes of hepatectomy or radiofrequency ablation associated with splenectomy for treatment of hepatocellular carcinoma and esophagogastric variceal bleeding. <i>Asian Journal of Surgery</i> , 2022, 45, 1607-1607.	0.2	0
4695	The impact of MAFLD on the prognosis of HCC patients with radical resectionCRediT authorship contribution statement. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2022, , .	0.6	4
4696	The value of liver stiffness measured by two-dimensional shear wave elastography for predicting symptomatic posthepatectomy liver failure in patients with hepatocellular carcinoma. <i>European Journal of Radiology</i> , 2022, 150, 110248.	1.2	1

#	ARTICLE	IF	CITATIONS
4697	Analysis of the medication rules of traditional Chinese medicines (TCMs) in treating liver cancer and potential TCMs exploration. <i>Pharmacological Research Modern Chinese Medicine</i> , 2022, 3, 100086.	0.5	5
4698	Prognostic Factors of Liver Transplantation for HCC: Comparative Literature Review. <i>Journal of Gastrointestinal Cancer</i> , 2021, 52, 1223-1231.	0.6	3
4699	Conversion to resection post radioembolization in patients with HCC: recommendations from a multidisciplinary working group. <i>Hpb</i> , 2022, 24, 1007-1018.	0.1	8
4700	CCNB2, CDC20, AURKA, TOP2A, MELK, NCAPG, KIF20A, UBE2C, PRC1, and ASPM May Be Potential Therapeutic Targets for Hepatocellular Carcinoma Using Integrated Bioinformatic Analysis. <i>International Journal of General Medicine</i> , 2021, Volume 14, 10185-10194.	0.8	11
4701	Má»™t sá»‘ Á‘á°c Á‘iá»fm dá»ch tá»..., lĂđm sĂng vĂ cá°n lĂđm sĂng cá»Sa bá»†nh nhĂđn ung thĂ° biá»fu mĂ‘ tá°; bĂo gan tá°;i Bá» Chi Nghien Cuu Y Hoc, 2021, 147, 92-100.	0.6	2
4702	Laparoscopic versus open hepatectomy for hepatocellular carcinoma with cirrhosis: a single-center propensity score matching analysis. <i>Annals of Translational Medicine</i> , 2021, 9, 1733-1733.	0.7	1
4703	Genetic Variability in Patients with HCV-Related Hepatocellular Carcinoma. <i>Infection and Drug Resistance</i> , 2021, Volume 14, 5199-5208.	1.1	4
4704	Prediction of late recurrence after radiofrequency ablation of HBV-related hepatocellular carcinoma with the age-male-albumin-bilirubin-platelets (aMAP) risk score: a multicenter study. <i>Journal of Gastrointestinal Oncology</i> , 2021, 12, 2930-2942.	0.6	6
4705	Circulating Tumor Cells in Hepatocellular Carcinoma: A Comprehensive Review and Critical Appraisal. <i>International Journal of Molecular Sciences</i> , 2021, 22, 13073.	1.8	10
4706	Evaluation of anti-cancer effect of zerumbone and cisplatin on <i>N</i>-nitrosodiethylamine induced hepatic cancer in freshwater fish (<i>Danio rerio</i>). <i>Natural Product Research</i> , 2021, , 1-5.	1.0	0
4707	Evaluation of response in patients with hepatocellular carcinoma treated with intratumoral dendritic cell vaccination using intravoxel incoherent motion (IVIM) MRI and histogram analysis. <i>Acta Radiologica</i> , 2023, 64, 32-41.	0.5	2
4708	Validation of Pre-/Post-TACE-Predict Models among Patients with Hepatocellular Carcinoma Receiving Transarterial Chemoembolization. <i>Cancers</i> , 2022, 14, 67.	1.7	4
4709	Low incidence of COVID-19 in a prospective cohort of patients with liver cirrhosis and hepatocellular carcinoma treated at a tertiary medical center during the 2020 pandemic. <i>PLoS ONE</i> , 2021, 16, e0258450.	1.1	1
4710	Copper Isotope Evidence of Oxidative Stressâ€‘Induced Hepatic Breakdown and the Transition to Hepatocellular Carcinoma. , 2022, 1, 480-486.		5
4711	OUP accepted manuscript. <i>Gastroenterology Report</i> , 2022, 10, goac016.	0.6	2
4712	Data mining of key genes expression in hepatocellular carcinoma: novel potential biomarkers of diagnosis prognosis or progression. <i>Clinical and Experimental Metastasis</i> , 2022, 39, 589-602.	1.7	4
4713	Phase I/II Multicenter Trial of a Novel Therapeutic Cancer Vaccine, HepaVac-101, for Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , 2022, 28, 2555-2566.	3.2	31
4714	CircSEC24A (hsa_circ_0003528) interference suppresses epithelial-mesenchymal transition of hepatocellular carcinoma cells via miR-421/MMP3 axis. <i>Bioengineered</i> , 2022, 13, 9050-9063.	1.4	6

#	ARTICLE	IF	CITATIONS
4715	A Retrospective, Single-Centre Study on the Learning Curve for Liver Tumor Open Resection in Patients with Hepatocellular Cancers and Intrahepatic Cholangiocarcinomas. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 4872.	1.2	0
4716	Minimally invasive surgery versus percutaneous radiofrequency ablation for early-stage hepatocellular carcinoma: Results from a high-volume liver surgery center in East Asia. <i>Surgical Oncology</i> , 2022, 42, 101769.	0.8	8
4717	Immune Checkpoint Inhibitors as Therapy to Down-Stage Hepatocellular Carcinoma Prior to Liver Transplantation. <i>Cancers</i> , 2022, 14, 2056.	1.7	24
4718	Bioluminescent RAPPID Sensors for the Single-Step Detection of Soluble Axl and Multiplex Analysis of Cell Surface Cancer Biomarkers. <i>Analytical Chemistry</i> , 2022, 94, 6548-6556.	3.2	6
4719	Radiomics analysis of ultrasound to predict recurrence of hepatocellular carcinoma after microwave ablation. <i>International Journal of Hyperthermia</i> , 2022, 39, 595-604.	1.1	7
4720	Rim Enhancement after Technically Successful Transarterial Chemoembolization in Hepatocellular Carcinoma: A Potential Mimic of Incomplete Embolization or Reactive Hyperemia?. <i>Tomography</i> , 2022, 8, 1148-1158.	0.8	1
4721	Major postoperative complications are associated with early recurrence of hepatocellular carcinoma following hepatectomy. <i>Langenbeck's Archives of Surgery</i> , 2022, 407, 2373-2380.	0.8	2
4722	Optimization of the BCLC Staging System for Locoregional Therapy for Hepatocellular Carcinoma by Using Quantitative Tumor Burden Imaging Biomarkers at MRI. <i>Radiology</i> , 2022, 304, 228-237.	3.6	17
4742	Impact of metabolic indices of 18F-fluorodeoxyglucose positron emission tomography/computed tomography on post transplantation recurrence of hepatocellular carcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 1401-1410.	1.2	1
4743	Review article: immunisation against hepatitis B virus infection and the prevention of hepatocellular carcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 1166-1182.	1.9	6
4744	Analysis of the Heterogeneity of the Tumor Microenvironment and the Prognosis and Immunotherapy Response of Different Immune Subtypes in Hepatocellular Carcinoma. <i>Journal of Oncology</i> , 2022, 2022, 1-21.	0.6	0
4745	Detection of exosomal miR-18a and miR-222 levels in Egyptian patients with hepatic cirrhosis and hepatocellular carcinoma. <i>International Journal of Immunopathology and Pharmacology</i> , 2022, 36, 039463202210978.	1.0	5
4748	Hepatocellular carcinoma in non-alcoholic fatty liver disease (NAFLD) - pathological evidence for a predominance of steatohepatic inflammatory non-proliferative subtype. <i>Histology and Histopathology</i> , 2020, 35, 729-740.	0.5	2
4751	Effects of Stereotactic Body Radiation Therapy Plus PD-1 Inhibitors for Patients With Transarterial Chemoembolization Refractory. <i>Frontiers in Oncology</i> , 2022, 12, 839605.	1.3	8
4755	Clinical application of advances and innovation in radiation treatment of hepatocellular carcinoma.. <i>Journal of Clinical and Translational Research</i> , 2021, 7, 811-833.	0.3	1
4756	Digestive cancer screening across Europe. <i>United European Gastroenterology Journal</i> , 2022, 10, 435-437.	1.6	8
4757	Application and progress of the detection technologies in hepatocellular carcinoma. <i>Genes and Diseases</i> , 2023, 10, 1857-1869.	1.5	6
4758	MRI-Based Radiomic Features Help Identify Lesions and Predict Histopathological Grade of Hepatocellular Carcinoma. <i>Diagnostics</i> , 2022, 12, 1085.	1.3	11

#	ARTICLE	IF	CITATIONS
4759	Does Metabolic Syndrome Effect the Perioperative Course and Costs of Patients With Hepatocellular Carcinoma Undergoing Robotic Hepatectomy? A Propensity Score-Matched Analysis. <i>American Surgeon</i> , 2022, 88, 2108-2114.	0.4	2
4760	MRI features of treated hepatocellular carcinoma following locoregional therapy: a pictorial review. <i>Abdominal Radiology</i> , 2022, 47, 2299-2313.	1.0	4
4761	Nonsynonymous C1653T Mutation of Hepatitis B Virus X Gene Enhances Malignancy of Hepatocellular Carcinoma Cells. <i>Journal of Hepatocellular Carcinoma</i> , 2022, Volume 9, 367-377.	1.8	2
4762	Effect of Body Composition on Outcomes in Patients with Hepatocellular Carcinoma Undergoing Radiotherapy: A Retrospective Study. <i>Nutrition and Cancer</i> , 2022, 74, 3302-3311.	0.9	3
4763	Evaluation of elevated liver values in primary care - a series of studies on the status quo of care in Germany with special reference to alcoholic liver disease. , 2022, 23, 104.		0
4764	Screening, Surveillance, and Management of Hepatocellular Carcinoma During the COVID-19 Pandemic: a Narrative Review. <i>Journal of Gastrointestinal Cancer</i> , 2023, 54, 408-419.	0.6	12
4765	Safety and efficacy of drug-eluting microspheres chemoembolization under cone beam computed tomography control in patients with early and intermediate stage hepatocellular carcinoma. <i>Radiology and Oncology</i> , 2022, 56, 311-318.	0.6	0
4766	Molecular pathogenesis and systemic therapies for hepatocellular carcinoma. <i>Nature Cancer</i> , 2022, 3, 386-401.	5.7	126
4767	EGFR inhibition reverses resistance to lenvatinib in hepatocellular carcinoma cells. <i>Scientific Reports</i> , 2022, 12, 8007.	1.6	14
4769	Hepatic arterial infusion chemotherapy versus transarterial chemoembolization for patients with unresectable hepatocellular carcinoma: a systematic review and meta-analysis. <i>Acta Clinica Belgica</i> , 2023, 78, 171-179.	0.5	3
4770	Stereotactic body radiotherapy plus transcatheter arterial chemoembolization for inoperable hepatocellular carcinoma patients with portal vein tumour thrombus: A meta-analysis. <i>PLoS ONE</i> , 2022, 17, e0268779.	1.1	6
4771	Radiofrequency ablation combined with transcatheter arterial chemoembolization therapy versus surgical resection for Barcelona-Clinic Liver Cancer (BCLC) A hepatocellular carcinoma: a meta-analysis.. <i>Journal of Interventional Medicine</i> , 2018, 1, 49-57.	0.2	2
4772	Impact of Extended Use of Ablation Techniques in Cirrhotic Patients with Hepatocellular Carcinoma: A Cost-Effectiveness Analysis. <i>Cancers</i> , 2022, 14, 2634.	1.7	0
4773	HEPATOSELLÜLER KARSİNOMA TANILI HASTALARDA ETİYOLOJİ VE DEMOGRAFİK ZELLİKLER. <i>Bozok Tıp Dergisi</i> , 0, , .	0.0	0
4774	Anti-Cancer Effects of YAP Inhibitor (CA3) in Combination with Sorafenib against Hepatocellular Carcinoma (HCC) in Patient-Derived Multicellular Tumor Spheroid Models (MCTS). <i>Cancers</i> , 2022, 14, 2733.	1.7	7
4775	Prognostic Significance of Preoperative Integrated Liver Inflammatory Score in Patients with Hepatocellular Carcinoma. <i>Medical Science Monitor</i> , 0, 28, .	0.5	2
4776	New Staging Model for Radiation-based Hepatocellular Carcinoma Treatment: A National Multicenter Study. <i>Journal of Clinical and Translational Hepatology</i> , 2022, 000, 000-000.	0.7	0
4777	Eliminating METTL1-mediated accumulation of PMN-MDSCs prevents hepatocellular carcinoma recurrence after radiofrequency ablation. <i>Hepatology</i> , 2023, 77, 1122-1138.	3.6	39

#	ARTICLE	IF	CITATIONS
4778	Comprehensive Analyses of MELK-Associated ceRNA Networks Reveal a Potential Biomarker for Predicting Poor Prognosis and Immunotherapy Efficacy in Hepatocellular Carcinoma. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, .	1.8	1
4779	Practical utility of liver segmentation methods in clinical surgeries and interventions. <i>BMC Medical Imaging</i> , 2022, 22, .	1.4	14
4780	Diagnostic performance of clusterin in hepatocellular carcinoma: A meta-analysis. <i>International Journal of Biological Markers</i> , 2022, 37, 404-411.	0.7	3
4781	Durable complete response is achieved by balloon-occluded transcatheter arterial chemoembolization for hepatocellular carcinoma. <i>Hepatology Communications</i> , 2022, 6, 2594-2604.	2.0	3
4782	Radioembolization in patients with hepatocellular carcinoma: a series of 53 cases. <i>Radiologia</i> , 2023, 65, 12-21.	0.3	0
4784	Identification of prognostic immune cells and potential immune-related markers in hepatocellular carcinoma. <i>Translational Cancer Research</i> , 2021, .	0.4	1
4785	Circulating Tumor Cells as an Indicator of Treatment Options for Hepatocellular Carcinoma Less Than or Equal to 3 cm in Size: A Multi-Center, Retrospective Study. <i>Frontiers in Surgery</i> , 2022, 9, .	0.6	0
4786	Cross Analysis of Genomic-Pathologic Features on Multiple Primary Hepatocellular Carcinoma. <i>Frontiers in Genetics</i> , 2022, 13, .	1.1	1
4787	Preoperative and postoperative nomograms for predicting early recurrence of hepatocellular carcinoma without macrovascular invasion after curative resection. <i>BMC Surgery</i> , 2022, 22, .	0.6	3
4788	“NH GIÁ•GIAI “Oá”N UNG THÆ” BIÁ»,U MÃ” Tá¼ BĂEO GAN THEO PHÃ,N LOá”I BARCELONA VĂE Má»T Sá»Yá¼U Tá»LIĂŠN QUAN NGUYĂŠN NHĂ,N UNG THÆ” GAN Tá”I Bá»†NH VIÁ»†N Bá”CH MAI. <i>Y Hoc Viet Nam</i> , 2022, 514, .	0.0	0
4789	Validation and prognostic value of EZ-ALBI score in patients with intermediate-stage hepatocellular carcinoma treated with trans-arterial chemoembolization. <i>BMC Gastroenterology</i> , 2022, 22, .	0.8	9
4790	Using quantitative immunohistochemistry in patients at high risk for hepatocellular cancer. <i>Genes and Cancer</i> , 2022, 13, 9-20.	0.6	3
4791	Integrated Multi-Omics Data Analysis Reveals Associations Between Glycosylation and Stemness in Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2022, 12, .	1.3	5
4792	Laparoscopic versus open liver resection for resectable HCC with BCLC stage B: a propensity score-matched analysis. <i>Updates in Surgery</i> , 2022, 74, 1291-1297.	0.9	5
4793	Recent Advances and Perspectives on the Health Benefits of Urolithin B, A Bioactive Natural Product Derived From Ellagitannins. <i>Frontiers in Pharmacology</i> , 2022, 13, .	1.6	16
4794	The comparison between albumin-bilirubin grade and Child-Pugh grade for assessing the prognosis of hepatocellular carcinoma after thermal ablation: a propensity score-matched analysis. <i>Translational Cancer Research</i> , 2022, 11, 2523-2535.	0.4	3
4795	Long-term outcomes of living-donor liver transplantation, hepatic resection, and local therapy for hepatocellular carcinoma with three <3 cm nodules in a single institute. <i>JGH Open</i> , 2022, .	0.7	0
4796	Exploring the potential targets of Sanshimaof formula for hepatocellular carcinoma treatment by a method of network pharmacology combined with molecular biology. <i>Journal of Ethnopharmacology</i> , 2022, , 115531.	2.0	3

#	ARTICLE	IF	CITATIONS
4797	Intraarterial Therapies for the Management of Hepatocellular Carcinoma. <i>Cancers</i> , 2022, 14, 3351.	1.7	10
4798	Liver resection for single large hepatocellular carcinoma: a prognostic factors study. <i>Annals of Hepatology</i> , 2022, 27, 100739.	0.6	4
4800	The C-Reactive Protein to Albumin Ratio Is an Independent Prognostic Factor in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization: A Large Cohort Study. <i>CardioVascular and Interventional Radiology</i> , 0, , .	0.9	2
4801	Contrast-enhanced ultrasound Liver Imaging Reporting and Data System: Lights and shadows in hepatocellular carcinoma and cholangiocellular carcinoma diagnosis. <i>World Journal of Gastroenterology</i> , 2022, 28, 3488-3502.	1.4	8
4802	Tumor suppressor LHPP suppresses cell proliferation and epithelial-mesenchymal transition in hepatocellular carcinoma cell lines. <i>Journal of Physiology and Biochemistry</i> , 2022, 78, 807-817.	1.3	5
4803	Discriminatory Changes in Circulating Metabolites as a Predictor of Hepatocellular Cancer in Patients with Metabolic (Dysfunction) Associated Fatty Liver Disease. <i>Liver Cancer</i> , 2023, 12, 19-31.	4.2	5
4804	A Practical Nomogram and Risk Stratification System Predicting the Cancer-Specific Survival for Patients With Advanced Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	4
4805	Treatment of hepatocellular carcinoma in sub-Saharan Africa: challenges and solutions. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 1049-1060.	3.7	3
4806	MicroRNAs at the Crossroad between Immunoediting and Oncogenic Drivers in Hepatocellular Carcinoma. <i>Biomolecules</i> , 2022, 12, 930.	1.8	2
4807	Sulfatase-2 from Cancer Associated Fibroblasts: An Environmental Target for Hepatocellular Carcinoma?. <i>Liver Cancer</i> , 2022, 11, 540-557.	4.2	6
4808	Noninvasively Assessed Portal Hypertension Grade Predicts Post-Hepatectomy Liver Failure in Patients With HepatocellCarcinoma: A Multicenter Study. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
4809	A novel lncRNA RP11-386G11.10 reprograms lipid metabolism to promote hepatocellular carcinoma progression. <i>Molecular Metabolism</i> , 2022, 63, 101540.	3.0	19
4810	Baseline Splenic Volume Outweighs Immuno-Modulated Size Changes with Regard to Survival Outcome in Patients with Hepatocellular Carcinoma under Immunotherapy. <i>Cancers</i> , 2022, 14, 3574.	1.7	4
4811	Metformin Enhances the Anti-Cancer Efficacy of Sorafenib via Suppressing MAPK/ERK/Stat3 Axis in Hepatocellular Carcinoma. <i>International Journal of Molecular Sciences</i> , 2022, 23, 8083.	1.8	13
4812	Benefits of step-by-step debulking microwave ablation for huge unresectable hepatocellular carcinoma patients after transcatheter arterial chemoembolization refractoriness. <i>International Journal of Hyperthermia</i> , 2022, 39, 935-945.	1.1	0
4813	A Combination of Sorafenib, an Immune Checkpoint Inhibitor, TACE and Stereotactic Body Radiation Therapy versus Sorafenib and TACE in Advanced Hepatocellular Carcinoma Accompanied by Portal Vein Tumor Thrombus. <i>Cancers</i> , 2022, 14, 3619.	1.7	6
4814	Trends in radiotherapy administration in the management of hepatocellular carcinoma: Analysis of a Korean tertiary hospital registry of hepatocellular carcinoma patients diagnosed between 2005 and 2017. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
4815	Treatment Benefits and Side Effects of Transarterial Chemoembolization with Drug-Eluting Bead Microspheres (DEB-TACE) in Hepatocellular Carcinoma Patients with Conventional TACE Resistance: A Retrospective Study. <i>Iranian Journal of Radiology</i> , 2022, 19, .	0.1	1

#	ARTICLE	IF	CITATIONS
4816	Polymorphism AGT2 (rs4762) is involved in the development of dermatologic events: Proof-of-concept in hepatocellular carcinoma patients treated with sorafenib. <i>World Journal of Hepatology</i> , 2022, 14, 1438-1458.	0.8	1
4818	Utility of PET Scans in the Diagnosis and Management of Gastrointestinal Tumors. <i>Digestive Diseases and Sciences</i> , 2022, 67, 4633-4653.	1.1	4
4819	Prognosis and Risk Factors of Recurrence in HBV-Related Small Hepatocellular Carcinoma After Stereotactic Body Radiation Therapy. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
4820	Liver Abscess Formation After Laparoscopic Radiofrequency Ablation of Metastatic Colon Cancer. <i>Cureus</i> , 2022, , .	0.2	0
4821	Extending Surgical Resection for Hepatocellular Carcinoma Beyond Barcelona Clinic for Liver Cancer (BCLC) Stage A: A Novel Application of the Modified BCLC Staging System. <i>Journal of Hepatocellular Carcinoma</i> , 0, Volume 9, 839-851.	1.8	7
4822	Hepatocellular Carcinoma in Mongolia Delineates Unique Molecular Traits and a Mutational Signature Associated with Environmental Agents. <i>Clinical Cancer Research</i> , 2022, 28, 4509-4520.	3.2	3
4823	Transarterial Chemoembolization in Hepatocellular Carcinoma: A Binational Japanese-German Study. <i>Journal of Hepatocellular Carcinoma</i> , 0, Volume 9, 695-705.	1.8	0
4824	Long-Term Outcomes Associated with NAFLD, ASCVD, and All-Cause Mortality of Patients with Metabolic Syndrome. <i>Journal of Clinical Medicine</i> , 2022, 11, 4627.	1.0	2
4825	Initial therapeutic results of atezolizumab plus bevacizumab for unresectable advanced hepatocellular carcinoma and the importance of hepatic functional reserve. <i>Cancer Medicine</i> , 2023, 12, 2646-2657.	1.3	9
4826	Not a neuroendocrine tumor: A case of hepatocellular carcinoma in ectopic liver tissue in the pancreas. <i>Annals of Hepato-biliary-pancreatic Surgery</i> , 2023, 27, 102-106.	0.1	1
4827	Causal discoveries for high dimensional mixed data. <i>Statistics in Medicine</i> , 0, , .	0.8	1
4828	Comprehensive evaluation of microRNA as a biomarker for the diagnosis of hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2022, 28, 3917-3933.	1.4	6
4829	Radiofrequency ablation is an inferior option to liver resection for solitary hepatocellular carcinoma \leq 5 cm without cirrhosis: A population-based study with stratification by tumor size. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2023, 22, 605-614.	0.6	4
4830	Prognostic Nutritional Index and Neutrophil/Lymphocyte Ratio Can Serve as Independent Predictors of the Prognosis of Hepatocellular Carcinoma Patients Receiving Targeted Therapy. <i>Journal of Oncology</i> , 2022, 2022, 1-9.	0.6	4
4831	Roles and regulation of histone acetylation in hepatocellular carcinoma. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	8
4832	Methodology to derive preference for health screening programmes using discrete choice experiments: a scoping review. <i>BMC Health Services Research</i> , 2022, 22, .	0.9	4
4833	Benefits of tailored hepatocellular carcinoma screening in patients with cirrhosis on cancer-specific and overall mortality: A modeling approach. <i>Hepatology Communications</i> , 2022, 6, 2964-2974.	2.0	1
4834	Injectable magnetic montmorillonite colloidal gel for the postoperative treatment of hepatocellular carcinoma. <i>Journal of Nanobiotechnology</i> , 2022, 20, .	4.2	5

#	ARTICLE	IF	CITATIONS
4835	Integration of OV6 expression and CD68+ tumor-associated macrophages with clinical features better predicts the prognosis of patients with hepatocellular carcinoma. <i>Translational Oncology</i> , 2022, 25, 101509.	1.7	5
4836	Radiofrequency-thermal effect of cisplatin-crosslinked nanogels for triple therapies of ablation-chemo-embolization. <i>Chemical Engineering Journal</i> , 2022, 450, 138421.	6.6	3
4837	Development and validation of a deep learning model for survival prognosis of transcatheter arterial chemoembolization in patients with intermediate-stage hepatocellular carcinoma. <i>European Journal of Radiology</i> , 2022, 156, 110527.	1.2	9
4838	Stereotactic body radiation therapy and radiofrequency ablation in patients with hepatocellular carcinoma: not a rival but a partner for the cure. <i>Hepatobiliary Surgery and Nutrition</i> , 2022, 11, 770-772.	0.7	1
4839	Radionuclide Therapy of Tumors of the Liver and Biliary Tract. , 2022, , 1515-1545.		0
4840	Volumetric Analysis of Hepatocellular Carcinoma After Transarterial Chemoembolization and its Impact on Overall Survival. <i>In Vivo</i> , 2022, 36, 2332-2341.	0.6	1
4841	Obesity and cancers of the liver, gallbladder, and pancreas. , 2023, , 155-177.		1
4842	A Pathophysiological Approach To Current Biomarkers. , 2022, , 238-275.		0
4843	No increased risk of hepatocellular carcinoma after eradication of hepatitis C virus by direct-acting antivirals, compared with interferon-based therapy. <i>Global Health & Medicine</i> , 2022, 4, 216-224.	0.6	1
4844	Preoperative prognostic value of alfa-fetoprotein density in patients with hepatocellular carcinoma undergoing radiofrequency ablation. <i>International Journal of Hyperthermia</i> , 2022, 39, 1143-1151.	1.1	1
4845	Successful conversion therapy for unresectable hepatocellular carcinoma is getting closer: A systematic review and meta-analysis. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	4
4846	Hepatectomy is Beneficial in Select Patients with Multiple Hepatocellular Carcinomas. <i>Annals of Surgical Oncology</i> , 2022, 29, 8436-8445.	0.7	7
4847	The Current Role of Stereotactic Body Radiation Therapy (SBRT) in Hepatocellular Carcinoma (HCC). <i>Cancers</i> , 2022, 14, 4383.	1.7	15
4848	Pitavastatin-loaded bilosomes for oral treatment of hepatocellular carcinoma: a repurposing approach. <i>Drug Delivery</i> , 2022, 29, 2925-2944.	2.5	10
4850	Stereotactic body radiotherapy versus radiofrequency ablation as initial treatment of small hepatocellular carcinoma. <i>European Journal of Gastroenterology and Hepatology</i> , 2022, 34, 1187-1194.	0.8	2
4851	Is Hepatocellular Carcinoma in Fatty Liver Different to Non-Fatty Liver?. <i>Nutrients</i> , 2022, 14, 3875.	1.7	3
4852	ASAP Score versus GALAD Score for detection of hepatitis C-related hepatocellular carcinoma: A multicenter case-control analysis. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
4853	Ultrasonics prediction for cytokeratin 19 expression in hepatocellular carcinoma: A multicenter study. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3

#	ARTICLE	IF	CITATIONS
4854	Evaluation of the efficacy of transcatheter arterial embolization combined with apatinib on rabbit VX2 liver tumors by intravoxel incoherent motion diffusion-weighted MR imaging. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
4855	Isoginkgetin, a potential CDK6 inhibitor, suppresses <i>SLC2A1/GLUT1</i> enhancer activity to induce AMPK-ULK1-mediated cytotoxic autophagy in hepatocellular carcinoma. <i>Autophagy</i> , 2023, 19, 1221-1238.	4.3	13
4856	Simultaneous splenectomy improving the outcomes of patients with hepatocellular carcinoma, cirrhosis and portal hypertension treated with hepatectomy. , 2022, 1, 90-100.		0
4857	The Application of Liquid Biopsy Techniques in High-Risk Population for Hepatocellular Carcinoma. <i>Cancer Management and Research</i> , 0, Volume 14, 2735-2748.	0.9	1
4858	Sequential treatment after transcatheter arterial chemoembolization for patients with single large hepatocellular carcinoma. <i>Advances in Digestive Medicine</i> , 2022, 9, 141-143.	0.1	0
4859	PD-L1-Mediated Immunosuppression in Hepatocellular Carcinoma: Relationship with Macrophages Infiltration and Inflammatory Response Activity. <i>Biomolecules</i> , 2022, 12, 1226.	1.8	4
4860	No association of postoperative opioid usage with long-term surgery outcomes in patients with liver cancer: a population-based retrospective cohort study. <i>Pain</i> , 2022, Publish Ahead of Print, .	2.0	1
4861	Multimodal imaging of nano-assembled microspheres loaded with doxorubicin and Cisplatin for liver tumor therapy. <i>Frontiers in Bioengineering and Biotechnology</i> , 0, 10, .	2.0	2
4862	The impact of polymorphism in <i>PNPLA3</i> and <i>TM6SF2</i> genes on the susceptibility and survival of hepatitis C-related hepatocellular carcinoma. <i>Egyptian Liver Journal</i> , 2022, 12, .	0.3	0
4863	Surgical Resection Is Superior to TACE in the Treatment of HCC in a Well Selected Cohort of BCLC-B Elderly Patients—A Retrospective Observational Study. <i>Cancers</i> , 2022, 14, 4422.	1.7	4
4864	Antiplatelet agents aspirin and dipyridamole, and the risk of different carcinoma in patients with type 2 diabetes mellitus: A Taiwan retrospective cohort study. <i>Medicine (United States)</i> , 2022, 101, e30468.	0.4	2
4867	The Value of CT Perfusion Parameters and Apparent Diffusion Coefficient Value of Magnetic Resonance Diffusion Weighted Imaging in Diagnosis of Hepatocellular Carcinoma. <i>Computational and Mathematical Methods in Medicine</i> , 2022, 2022, 1-7.	0.7	1
4868	Transcriptome sequencing of hepatocellular carcinoma uncovers multiple types of dysregulated ncRNAs. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
4869	Phase 2 Evaluation of Neoadjuvant Intensity-Modulated Radiotherapy in Centrally Located Hepatocellular Carcinoma. <i>JAMA Surgery</i> , 2022, 157, 1089.	2.2	12
4870	Comprehensive Review of Hepatocellular Carcinoma in India: Current Challenges and Future Directions. <i>JCO Global Oncology</i> , 2022, , .	0.8	4
4871	Clinical factors associated with early disease progression after radioembolization for hepatocellular carcinoma and feasibility of post-progression systemic therapy. <i>Liver Cancer International</i> , 0, , .	0.2	0
4872	Estimation of post-therapeutic liver reserve capacity using ^{99m} Tc-GSA scintigraphy prior to carbon-ion radiotherapy for liver tumors. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2023, 50, 581-592.	3.3	2
4873	Promoting Surgical Resection through Future Liver Remnant Hypertrophy. <i>Radiographics</i> , 0, , .	1.4	4

#	ARTICLE	IF	CITATIONS
4874	Percutaneous and Laparoscopic-Assisted Ablation of Hepatocellular Carcinoma. Updates in Surgery Series, 2023, , 63-70.	0.0	0
4875	Stereotactic body radiation therapy versus radiofrequency ablation in hepatocellular carcinoma: an up-date meta-analysis. Abdominal Radiology, 0, , .	1.0	0
4876	A history of variceal bleeding is associated with further bleeding under atezolizumab and bevacizumab in patients with HCC. Liver International, 2022, 42, 2843-2854.	1.9	8
4877	Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy (ALPPS). Updates in Surgery Series, 2023, , 139-146.	0.0	0
4878	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma. Clinical and Molecular Hepatology, 2022, 28, 583-705.	4.5	102
4879	Prognostic significance of combined α -fetoprotein and CA19-9 for hepatocellular carcinoma after hepatectomy. World Journal of Surgical Oncology, 2022, 20, .	0.8	4
4880	A Conceptual Classification of Resectability for Hepatocellular Carcinoma. World Journal of Surgery, 2023, 47, 740-748.	0.8	10
4882	Clinical prognosis of intraoperative blood salvage autotransfusion in liver transplantation for hepatocellular carcinoma: A systematic review and meta-analysis. Frontiers in Oncology, 0, 12, .	1.3	3
4883	Prevention of variceal rebleeding in cirrhotic patients with advanced hepatocellular carcinoma receiving molecularly targeted therapy: a randomized pilot study of transjugular intrahepatic portosystemic shunt versus endoscopic plus β -blocker. Hepatology International, 2022, 16, 1379-1389.	1.9	3
4884	Ultrasound-based artificial intelligence in gastroenterology and hepatology. World Journal of Gastroenterology, 0, 28, 5530-5546.	1.4	7
4886	Treatment patterns for hepatocellular carcinoma in patients with Child-Pugh class B and their impact on survival: A Korean nationwide registry study. Liver International, 2022, 42, 2830-2842.	1.9	6
4887	Silencing of KNTC1 inhibits hepatocellular carcinoma cells progression via suppressing PI3K/Akt pathway. Cellular Signalling, 2023, 101, 110498.	1.7	7
4888	Diagnosis and Management of Hepatocellular Carcinoma. In Clinical Practice, 2022, , 327-354.	0.1	0
4889	Fontan-Associated Liver Disease (FALD). In Clinical Practice, 2022, , 307-325.	0.1	0
4890	Open Radiofrequency Ablation Combined with Splenectomy and Pericardial Devascularization vs. Liver Transplantation for Hepatocellular Carcinoma Patients with Portal Hypertension and Hypersplenism: A Case-Matched Comparative Study. Journal of Investigative Surgery, 2023, 36, 1-7.	0.6	0
4891	Biological impact and therapeutic perspective of targeting PI3K/Akt signaling in hepatocellular carcinoma: Promises and Challenges. Pharmacological Research, 2023, 187, 106553.	3.1	34
4892	Neo-Adjuvant Use of Sorafenib for Hepatocellular Carcinoma Awaiting Liver Transplantation. Transplant International, 0, 35, .	0.8	2
4893	Impact of WTAP in small HCC and paired adjacent non-neoplastic liver tissue on recurrence: A cohort study with external extension analysis. Frontiers in Cell and Developmental Biology, 0, 10, .	1.8	2

#	ARTICLE	IF	CITATIONS
4894	Persisting dental foci increase the risk for bacterial infections before and after liver transplant (99/120). <i>Clinical Transplantation</i> , 0, , .	0.8	1
4895	Actual over 3-year survival after stereotactic body radiation therapy in patients with unresectable intrahepatic cholangiocarcinoma. <i>Clinical and Translational Oncology</i> , 0, , .	1.2	0
4896	Factors impacting survival after transarterial radioembolization in patients with hepatocellular carcinoma: Results from the prospective CIRT study. <i>JHEP Reports</i> , 2023, 5, 100633.	2.6	8
4897	Tumor Necrosis Is an Indicator of Poor Prognosis Among Hepatoma Patients Undergoing Resection. <i>Journal of Surgical Research</i> , 2023, 283, 1091-1099.	0.8	4
4898	Comprehensive analysis of an autophagy-related prognostic model for predicting survival based on TCGA and ICGC database in hepatocellular carcinoma patients. <i>Journal of Gastrointestinal Oncology</i> , 2022, .	0.6	0
4899	2022 KLCA-NCC Korea Practice Guidelines for the Management of Hepatocellular Carcinoma. <i>Korean Journal of Radiology</i> , 2022, 23, 1126.	1.5	44
4900	A descriptive analysis of the characteristics, treatment response and prognosis of hepatic dominant solid tumors undergoing selective internal radiation therapy (SIRT). <i>Journal of Gastrointestinal Oncology</i> , 2022, .	0.6	0
4901	Kronik Hepatit B Hastalarında Hematolojik Parametrelerin Karaciğer İnflamasyonu ve Fibrozu ile İlişkisi. <i>Mustafa Kemal Üniversitesi Tıp Dergisi</i> , 0, , .	0.1	0
4902	Risk factors and management strategies of liver cancer. , 2022, , .		0
4903	Factors associated with nonadherence to surveillance for hepatocellular carcinoma among patients with hepatic C virus cirrhosis, 2000–2015. <i>Medicine (United States)</i> , 2022, 101, e31907.	0.4	1
4904	Regional Differences in Admissions and Treatment Outcomes for Hepatocellular Carcinoma Patients in Thailand. <i>Asian Pacific Journal of Cancer Prevention</i> , 2022, 23, 3701-3715.	0.5	0
4905	The Role of Immediate Post-Procedural Cone-Beam Computed Tomography (CBCT) in Predicting the Early Radiologic Response of Hepatocellular Carcinoma (HCC) Nodules to Drug-Eluting Bead Transarterial Chemoembolization (DEB-TACE). <i>Journal of Clinical Medicine</i> , 2022, 11, 7089.	1.0	3
4906	ACR Appropriateness Criteria® Management of Liver Cancer: 2022 Update. <i>Journal of the American College of Radiology</i> , 2022, 19, S390-S408.	0.9	1
4907	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma. <i>Journal of Liver Cancer</i> , 2023, 23, 1-120.	0.3	24
4908	Construction of a prediction model for chronic HBV-associated hepatocellular carcinoma based on ultrasound radiomics. <i>Journal of Radiation Research and Applied Sciences</i> , 2022, 15, 100487.	0.7	1
4909	Hepatic Resection vs Particle Therapy as an Initial Treatment for Single Hepatocellular Carcinoma: Bi-institutional Propensity Score-Matched Analysis. <i>Journal of the American College of Surgeons</i> , 2023, 236, 972-981.	0.2	1
4910	Quantitative Dual-Energy CT Image Guidance for Thermochemical Ablation: In Vivo Results in the Rabbit VX2 Model. <i>Journal of Vascular and Interventional Radiology</i> , 2023, 34, 782-789.	0.2	1
4911	Impact of treatment-duration-ratio of traditional Chinese medicine on survival period of primary liver cancer – A real-world study. <i>Heliyon</i> , 2022, 8, e12358.	1.4	1

#	ARTICLE	IF	CITATIONS
4912	Comparison of surgical resection and transcatheter arterial chemoembolization for large hepatocellular carcinoma: a systematic review and meta-analysis. <i>Annals of Hepatology</i> , 2023, 28, 100890.	0.6	1
4913	Surgical approach to microwave and radiofrequency liver ablation for hepatocellular carcinoma and colorectal liver metastases less than 5Åcm: a systematic review and meta-analysis. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2023, 37, 3340-3353.	1.3	6
4914	Diagnostic Value of Non-invasive Liver Function Tests in Liver Fibrosis and Changes in These Parameters Post-metabolic Surgery. <i>Obesity Surgery</i> , 0, , .	1.1	0
4915	Repeat hepatectomy versus microwave ablation for solitary and small (â‰¥3Åcm) recurrent hepatocellular carcinoma with early or late recurrence: A propensity score matched study. <i>European Journal of Surgical Oncology</i> , 2023, 49, 1001-1008.	0.5	7
4916	Applicability of multidimensional convolutional neural networks on automated detection of diverse focal liver lesions in multiphase CT images. <i>Medical Physics</i> , 2023, 50, 2872-2883.	1.6	1
4917	Efficacy and safety of radiotherapy combined with atezolizumab plus bevacizumab in treating hepatocellular carcinoma with portal vein tumour thrombus: a study protocol. <i>BMJ Open</i> , 2022, 12, e064688.	0.8	3
4918	A six lipid metabolism related gene signature for predicting the prognosis of hepatocellular carcinoma. <i>Scientific Reports</i> , 2022, 12, .	1.6	9
4919	Results of Application of Saturable Microspheres of Domestic Production in Locoregional Endovascular Treatment of Inoperable Patients with Malignant Liver Tumors. <i>Journal of Oncology Diagnostic Radiology and Radiotherapy</i> , 2022, 5, 96-106.	0.1	0
4920	Clinical efficacy of CT-guided 125I brachytherapy in patients with local residual or recurrent hepatocellular carcinoma after thermal ablation. <i>Insights Into Imaging</i> , 2022, 13, .	1.6	1
4921	Yttrium-90 Radioembolization: Current Indications and Outcomes. <i>Journal of Gastrointestinal Surgery</i> , 2023, 27, 604-614.	0.9	4
4922	Construction and validation of a novel signature based on epithelial-mesenchymal transitionâ€related genes to predict prognosis and immunotherapy response in hepatocellular carcinoma by comprehensive analysis of the tumor microenvironment. <i>Functional and Integrative Genomics</i> , 2023, 23, .	1.4	9
4923	Prediction of left lobe hypertrophy after right lobe radioembolization of the liver using a clinical data model with external validation. <i>Scientific Reports</i> , 2022, 12, .	1.6	0
4925	Study of ultrasound-guided percutaneous microwave ablation combined with portal vein embolization for rapid future liver remnant increase of planned hepatectomy. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
4926	PVRIG Expression Is an Independent Prognostic Factor and a New Potential Target for Immunotherapy in Hepatocellular Carcinoma. <i>Cancers</i> , 2023, 15, 447.	1.7	2
4927	Potential Molecular Targeted Therapy for Unresectable Hepatocellular Carcinoma. <i>Current Oncology</i> , 2023, 30, 1363-1380.	0.9	1
4928	Comparison of Ablation Performance between Octopus Multipurpose Electrode and Conventional Octopus Electrode. <i>Korean Journal of Radiology</i> , 2023, 24, 86.	1.5	1
4929	Patients with Chronic Liver Disease under Surveillance for Hepatocellular Carcinoma Have a Favorable Long-Term Outcome for Pancreatic Cancer Due to Early Diagnosis and High Resection Rate. <i>Cancers</i> , 2023, 15, 561.	1.7	0
4930	Clinical prognosis of surgical resection versus transarterial chemoembolization for single large hepatocellular carcinoma (â‰¥5Åcm): A propensity score matching analysis. <i>Kaohsiung Journal of Medical Sciences</i> , 0, , .	0.8	1

#	ARTICLE	IF	CITATIONS
4931	Growing need of adjuvant therapy and expanded access for liver transplant in hepatocellular carcinoma. <i>Annals of Translational Medicine</i> , 2023, .	0.7	0
4932	Impact of apparent diffusion coefficient on prognosis of early hepatocellular carcinoma: a case control study. <i>BMC Surgery</i> , 2023, 23, .	0.6	0
4933	Portal hypertension and variceal bleeding in patients with liver cancer: Evidence gaps for prevention and management. <i>Hepatology</i> , 2024, 79, 213-223.	3.6	3
4934	Transradial versus transfemoral approach for TACE: a retrospective study. <i>BMC Gastroenterology</i> , 2023, 23, .	0.8	2
4935	Short- and Long-Term Outcomes of Indocyanine Green Fluorescence Navigation-Versus Conventional-Laparoscopic Hepatectomy for Hepatocellular Carcinoma: A Propensity Score-Matched, Retrospective, Cohort Study. <i>Annals of Surgical Oncology</i> , 2023, 30, 1991-2002.	0.7	8
4936	Evaluation of Focal Hepatic Lesion and associated changes in Gallbladder and Kidneys using Spiral Computed Tomography. , 0, , 151-155.		0
4937	Bacterial metabolite butyrate in modulating sorafenib-targeted microRNAs to curtail its resistance in hepatocellular carcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 0, , .	1.2	1
4938	Hepatocellular Carcinoma: Current Therapeutic Algorithm for Localized and Advanced Disease. <i>Journal of Oncology</i> , 2022, 2022, 1-14.	0.6	4
4939	Low Frequency of Cancer-Predisposition Gene Mutations in Liver Transplant Candidates with Hepatocellular Carcinoma. <i>Cancers</i> , 2023, 15, 201.	1.7	2
4940	Risk factors for loss to follow-up after the start of direct-acting antiviral treatment for hepatitis C virus infection. <i>JGH Open</i> , 2023, 7, 98-104.	0.7	0
4941	Mechanisms of drug resistance in HCC. <i>Hepatology</i> , 2024, 79, 926-940.	3.6	23
4942	Glycoproteins and Cancer Biomarkers. , 2023, , 195-227.		0
4943	Perspectives in Biochemical Staging of Hepatocellular Carcinoma Over the Current Microscopical Methodology. , 2023, , 1-21.		0
4944	Safety, Efficacy and Distribution of Doxorubicin Loaded Radiopaque Beads in Chemoembolization in Intermediate Stage Hepatocellular Carcinoma (HCC) with Correlation with Local Response. <i>CardioVascular and Interventional Radiology</i> , 2023, 46, 337-349.	0.9	1
4945	Increasing liver stiffness is associated with higher incidence of hepatocellular carcinoma in hepatitis C infection and non-alcoholic fatty liver disease—A population-based study. <i>PLoS ONE</i> , 2023, 18, e0280647.	1.1	3
4946	Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Taiwan perspective. <i>Clinical and Molecular Hepatology</i> , 2023, 29, 230-241.	4.5	8
4947	Exosomal miRNA in early-stage hepatocellular carcinoma. <i>World Journal of Clinical Cases</i> , 0, 11, 528-533.	0.3	1
4948	Expression and function of myelin expression factor 2 in hepatocellular carcinoma. <i>BMC Gastroenterology</i> , 2023, 23, .	0.8	2

#	ARTICLE	IF	CITATIONS
4949	Adjuvant ICIs Plus Targeted Therapies Reduce HCC Recurrence after Hepatectomy in Patients with High Risk of Recurrence. <i>Current Oncology</i> , 2023, 30, 1708-1719.	0.9	2
4950	Adding MRI as a Surveillance Test for Hepatocellular Carcinoma in Patients with Liver Cirrhosis Can Improve Prognosis. <i>Biomedicines</i> , 2023, 11, 382.	1.4	0
4951	Transarterial chemoembolization plus immune checkpoint inhibitor as postoperative adjuvant therapy for hepatocellular carcinoma with portal vein tumor thrombus: A multicenter cohort study. <i>European Journal of Surgical Oncology</i> , 2023, 49, 1226-1233.	0.5	4
4952	A novel method for predicting hepatocellular carcinoma response to chemoembolization using an intraprocedural CT hepatic arteriography-based enhancement mapping: a proof-of-concept analysis. <i>European Radiology Experimental</i> , 2023, 7, .	1.7	0
4953	Cisplatin or Doxorubicin Reduces Cell Viability via the PTPIVA3-JAK2-STAT3 Cascade in Hepatocellular Carcinoma. <i>Journal of Hepatocellular Carcinoma</i> , 0, Volume 10, 123-138.	1.8	0
4954	Etiologic fractions in patients of hepatocellular carcinoma in India with and without a background of cirrhosis: a multi-centric study. <i>Hepatology International</i> , 2023, 17, 745-752.	1.9	5
4955	Current Concepts of Precancerous Lesions of Hepatocellular Carcinoma: Recent Progress in Diagnosis. <i>Diagnostics</i> , 2023, 13, 1211.	1.3	1
4956	Survival Benefit of Experience of Liver Resection for Advanced Recurrent Hepatocellular Carcinoma Treated with Sorafenib: A Propensity Score Matching Analysis. <i>Current Oncology</i> , 2023, 30, 3206-3216.	0.9	0
4957	Metabolic dysfunction outperforms ultrasonographic steatosis to stratify <scp>hepatocellular carcinoma</scp> risk in patients with advanced hepatitis C cured with <scp>direct-acting antivirals</scp>. <i>Liver International</i> , 2023, 43, 1593-1603.	1.9	2
4958	Liver transplantation and hepatocellular carcinoma: is TIPS deleterious? A multicentric retrospective study of the ARCHET research group with propensity score matching. <i>Langenbeck's Archives of Surgery</i> , 2023, 408, .	0.8	0
4959	Interactions between driver genes shape the signaling pathway landscape and direct hepatocellular carcinoma therapy. <i>Cancer Science</i> , 2023, 114, 2386-2399.	1.7	3
4960	Favorable Prognostic Factors for Survival Outcomes of Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis After Hepatectomy. <i>Annals of Surgical Oncology</i> , 2023, 30, 4279-4289.	0.7	2
4962	Improved diagnosis of histological capsule in hepatocellular carcinoma by using nonenhancing capsule appearance in addition to enhancing capsule appearance in gadoteric acid-enhanced MRI. <i>Scientific Reports</i> , 2023, 13, .	1.6	0
4964	Gynura procumbens methanolic extracts suppresses proliferation of hepatocellular carcinoma: In vitro assay. <i>AIP Conference Proceedings</i> , 2023, , .	0.3	0
4965	High producer variant of lipoprotein lipase may protect from hepatocellular carcinoma in alcohol-associated cirrhosis. <i>JHEP Reports</i> , 2023, 5, 100684.	2.6	3
4966	Clinical value of combined preoperativeâ€“postoperative neutrophil-to-lymphocyte ratio in predicting hepatocellular carcinoma prognosis after radiofrequency ablation. <i>British Journal of Radiology</i> , 2023, 96, .	1.0	1
4967	Repeat hepatic resection combined with intraoperative radiofrequency ablation versus repeat hepatic resection alone for recurrent and multiple hepatocellular carcinoma patients meeting the Barcelona Clinic Liver Cancer stage A: A propensity scoreâ€“matched analysis. <i>Cancer Medicine</i> , 0, , .	1.3	1
4968	Comparative Transcriptional Signature Analysis of Peripheral Blood Mononuclear Cells in Early Stage of Hepatitis B-related Hepatocellular Carcinoma. <i>Hepatitis Monthly</i> , 2023, 22, .	0.1	1

#	ARTICLE	IF	CITATIONS
4969	Breath Biopsy [®] to Identify Exhaled Volatile Organic Compounds Biomarkers for Liver Cirrhosis Detection. <i>Journal of Clinical and Translational Hepatology</i> , 2023, 000, 000-000.	0.7	4
4970	Recurrence of hepatocellular carcinoma in noncirrhotic patients with nonalcoholic fatty liver disease versus hepatitis B infection. <i>European Journal of Gastroenterology and Hepatology</i> , 2023, 35, 431-439.	0.8	0
4971	LV5plex: Immune-histological phenotypes staged by self-studying for a liver cancer multiplex staining set. <i>Frontiers in Cell and Developmental Biology</i> , 0, 11, .	1.8	0
4973	Immune checkpoint inhibition: a future guided by radiology. <i>British Journal of Radiology</i> , 0, , .	1.0	1
4974	Ozonated Water Inhibits Hepatocellular Carcinoma Invasion and Metastasis by Regulating the HMGB1/NF- κ B/STAT3 Signaling Pathway. <i>Journal of Hepatocellular Carcinoma</i> , 0, Volume 10, 203-215.	1.8	0
4975	Diagnostic accuracy of ultrasound and alpha-fetoprotein measurement for hepatocellular carcinoma surveillance: a retrospective comparative study. <i>Egyptian Journal of Radiology and Nuclear Medicine</i> , 2023, 54, .	0.3	4
4976	Microscopic vascular invasion may not be associated with survival of patients undergoing resection for solitary hepatoma of \geq 2 cm. <i>PLoS ONE</i> , 2023, 18, e0281154.	1.1	0
4977	Non-alcoholic fatty liver disease-related hepatocellular carcinoma. <i>Journal of Liver Cancer</i> , 2023, 23, 127-142.	0.3	5
4978	Comparisons of Hepatobiliary Phase Imaging Using Combinations of Parallel Imaging and Variable Degrees of Compressed Sensing With Use of Parallel Imaging Alone. <i>Journal of Computer Assisted Tomography</i> , 0, Publish Ahead of Print, .	0.5	0
4979	Comprehensive analysis of cuproptosis-related prognostic gene signature and tumor immune microenvironment in HCC. <i>Frontiers in Genetics</i> , 0, 14, .	1.1	3
4980	Prognostic and survival impact of BCL9 and RPS6KB1 copy number variation detected from circulating free DNA in hepatocellular carcinoma. <i>Expert Review of Molecular Diagnostics</i> , 2023, 23, 267-278.	1.5	2
4981	Updating the Clinical Application of Blood Biomarkers and Their Algorithms in the Diagnosis and Surveillance of Hepatocellular Carcinoma: A Critical Review. <i>International Journal of Molecular Sciences</i> , 2023, 24, 4286.	1.8	11
4982	Adherence to LI-RADS and EASL high-risk population criteria: A systematic review. <i>Hepatology</i> , 2023, 77, 1958-1967.	3.6	1
4983	Diagnostic Performance of Extrahepatic Protein Induced by Vitamin K Absence in the Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. <i>Diagnostics</i> , 2023, 13, 816.	1.3	3
4984	Computed Tomography-Defined Sarcopenia in Outcomes of Patients with Unresectable Hepatocellular Carcinoma Undergoing Radioembolization: Assessment with Total Abdominal, Psoas, and Paraspinal Muscles. <i>Liver Cancer</i> , 2023, 12, 550-564.	4.2	1
4985	Machine learning-based model for predicting the esophagogastric variceal bleeding risk in liver cirrhosis patients. <i>Diagnostic Pathology</i> , 2023, 18, .	0.9	3
4986	Recommendation of mHAP and ABCR scoring systems for the decision-making of the first and subsequent TACE session in HCC patients. <i>European Journal of Gastroenterology and Hepatology</i> , 2023, 35, 461-470.	0.8	0
4987	Hepatocellular Carcinoma Recognition from Ultrasound Images Using Combinations of Conventional and Deep Learning Techniques. <i>Sensors</i> , 2023, 23, 2520.	2.1	8

#	ARTICLE	IF	CITATIONS
4988	Asia-Pacific multicentre randomized trial of laparoscopic versus open major hepatectomy for hepatocellular carcinoma (AP-LAPO trial). <i>BJS Open</i> , 2023, 7, .	0.7	2
4989	Prospective Comparison of Hepatocellular Carcinoma Behavior and Survival of Patients who Did or Did not Receive HCV Direct-Acting Antivirals. <i>Asian Pacific Journal of Cancer Prevention</i> , 2023, 24, 597-605.	0.5	0
4990	Rapid Dissemination followed by Spontaneous Regression of Metastatic Hepatocellular Carcinoma after Liver Radiofrequency Thermal Ablation: A Case Report with Correlative Immune Assay. <i>Case Reports in Oncology</i> , 0, , 135-142.	0.3	0
4991	Imaging Recommendations for Diagnosis, Staging, and Management of Hepatic and Biliary Tract Cancer. <i>Indian Journal of Medical and Paediatric Oncology</i> , 0, , .	0.1	0
4992	Use of doxorubicin-eluting bead transarterial chemoembolization for unresectable hepatocellular carcinoma with portal vein invasion: a prospective study. <i>Journal of Liver Cancer</i> , 2023, 23, 166-176.	0.3	0
4993	Hepatocellular carcinoma presentation and prognosis among Nigerian adults with and without HIV. <i>PLoS ONE</i> , 2023, 18, e0282539.	1.1	1
4994	Overall survival and toxicity of hepatocellular carcinoma Barcelona Clinic Liver Cancer B patients receiving Y90 radioembolization: analysis of the radiation-emitting SIR-spheres in non-resectable liver tumor (RESiN) registry. <i>Journal of Gastrointestinal Oncology</i> , 2023, .	0.6	0
4996	Perspectives on the Underlying Etiology of HCC and Its Effects on Treatment Outcomes. <i>Journal of Hepatocellular Carcinoma</i> , 0, Volume 10, 413-428.	1.8	10
4997	Adjuvant transarterial chemoembolization timing after radical resection is an independent prognostic factor for patients with hepatocellular carcinoma. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	0
4998	Comparison of Child-Pugh, MELD, MELD-Na, and ALBI Scores in Predicting In-Hospital Mortality in Patients with HCC. <i>International Journal of Clinical Medicine</i> , 2023, 14, 148-162.	0.1	0
5000	Predictive Factors for Adverse Event Outcomes After Transarterial Radioembolization with Yttrium-90 Resin Microspheres in Europe: Results from the Prospective Observational CIRT Study. <i>CardioVascular and Interventional Radiology</i> , 2023, 46, 852-867.	0.9	7
5002	Deregulated bile acids may drive hepatocellular carcinoma metastasis by inducing an immunosuppressive microenvironment. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
5003	Adoptive Cell Therapy in Hepatocellular Carcinoma: A Review of Clinical Trials. <i>Cancers</i> , 2023, 15, 1808.	1.7	6
5004	A preoperative model for predicting early recurrence in patients undergoing resection for single hepatocellular carcinoma. <i>European Journal of Surgical Oncology</i> , 2023, 49, 1444-1449.	0.5	4
5005	Effects of hypersplenism on the outcome of hepatectomy in hepatocellular carcinoma with hepatitis B virus related portal hypertension. <i>Frontiers in Surgery</i> , 0, 10, .	0.6	0
5006	Alcoholic Liver Disease-Related Hepatocellular Carcinoma: Characteristics and Comparison to General Slovak Hepatocellular Cancer Population. <i>Current Oncology</i> , 2023, 30, 3557-3570.	0.9	1
5007	Non-invasive imaging in the diagnosis of combined hepatocellular carcinoma and cholangiocarcinoma. <i>Abdominal Radiology</i> , 0, , .	1.0	0
5008	Update on PET Radiopharmaceuticals for Imaging Hepatocellular Carcinoma. <i>Cancers</i> , 2023, 15, 1975.	1.7	4

#	ARTICLE	IF	CITATIONS
5009	Patient Selection and Outcomes of Laparoscopic Microwave Ablation of Hepatocellular Carcinoma. <i>Cancers</i> , 2023, 15, 1965.	1.7	1
5010	Chromosome 11q13 amplification correlates with poor response and prognosis to PD-1 blockade in unresectable hepatocellular carcinoma. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	0
5011	The Role of Ablative Techniques in the Management of Hepatocellular Carcinoma: Indications and Outcomes. <i>Biomedicines</i> , 2023, 11, 1062.	1.4	2
5012	Prognostic value of systemic immune-inflammation index/ albumin for transcatheter arterial chemoembolization treatment. <i>Heliyon</i> , 2023, 9, e15156.	1.4	1
5013	Hepatocellular Carcinoma: It Is Time to Focus on Prognosis. <i>Radiology</i> , 2023, 307, .	3.6	2
5014	Lipidomic study and diagnosis of hepatocellular carcinoma tumor with rapid evaporative ionization mass spectrometry. <i>Electrophoresis</i> , 0, , .	1.3	0
5015	Prognostic Analysis of Single Large Hepatocellular Carcinoma Following Radical Resection: A Single-Center Study. <i>Journal of Hepatocellular Carcinoma</i> , 0, Volume 10, 573-586.	1.8	1
5016	Early changes in immunoglobulin G levels during immune checkpoint inhibitor treatment are associated with survival in hepatocellular carcinoma patients. <i>PLoS ONE</i> , 2023, 18, e0282680.	1.1	1
5017	Slice-Fusion: Reducing False Positives in Liver Tumor Detection for Mask R-CNN. <i>IEEE/ACM Transactions on Computational Biology and Bioinformatics</i> , 2023, , 1-11.	1.9	0
5018	Correlation between immune-related adverse events and long-term outcomes in pembrolizumab-treated patients with unresectable hepatocellular carcinoma: A retrospective study. <i>World Journal of Gastrointestinal Oncology</i> , 0, 15, 689-699.	0.8	1
5021	Safety and dose escalation of the targeted oncolytic adenovirus OBP-301 for refractory advanced liver cancer: Phase I clinical trial. <i>Molecular Therapy</i> , 2023, 31, 2077-2088.	3.7	4
5022	Diagnostic and Prognostic Nomograms for Hepatocellular Carcinoma Based on PIVKA-II and Serum Biomarkers. <i>Diagnostics</i> , 2023, 13, 1442.	1.3	2
5023	Hepatocellular carcinoma surveillance based on the Australian Consensus Guidelines: a health economic modelling study. <i>BMC Health Services Research</i> , 2023, 23, .	0.9	0
5024	The roadmap to the adoption of computational intelligence in cancer diagnosis: The clinical-radiological perspective. , 2023, , 3-11.		0
5025	A Retrospective Analysis of Conversion Therapy with Lenvatinib, Sintilimab, and Arterially-Directed Therapy in Patients with Initially Unresectable Hepatocellular Carcinoma. <i>Journal of Hepatocellular Carcinoma</i> , 0, Volume 10, 673-686.	1.8	4
5029	Lenvatinib in the treatment of unresectable hepatocellular carcinoma: a systematic review of economic evaluations. <i>European Journal of Clinical Pharmacology</i> , 2023, 79, 885-895.	0.8	2
5052	Biomarkers for Hepatocellular Carcinoma in East Asia. <i>Biomarkers in Disease</i> , 2015, , 1-25.	0.0	0
5065	Thermoresponsive hydrogel for transcatheter arterial chemoembolization of hepatocellular carcinoma. <i>Chemical Communications</i> , 2023, 59, 9352-9355.	2.2	0

#	ARTICLE	IF	CITATIONS
5073	Consensus report from the 10th global forum for liver magnetic resonance imaging: multidisciplinary team discussion. <i>European Radiology</i> , 2023, 33, 9167-9181.	2.3	1
5100	Hepatic arterial infusion chemotherapy combined with sorafenib versus sorafenib alone for advanced hepatocellular carcinoma: a systematic review and meta-analysis. <i>Clinical Journal of Gastroenterology</i> , 0, , .	0.4	1
5104	Role of phospholipase A2 in squamous cell carcinoma and breast cancer. , 2023, , 315-335.		0
5106	Pulmonary Hypertension in Adults with Congenital Heart Disease. , 2023, , 1-50.		0
5120	Combined Therapy (TACE and Percutaneous Treatment). , 2023, , 95-105.		0
5153	Editorial: Prognostic factors in hepatocellular carcinoma. <i>Frontiers in Medicine</i> , 0, 10, .	1.2	0
5174	Biomarker in Hepatocellular Carcinoma. <i>Indian Journal of Surgical Oncology</i> , 0, , .	0.3	0
5190	Targeted Analysis of Glycerophospholipids and Mono-, Di-, or Tri-Acylglycerides in Liver Cancer. <i>Methods in Molecular Biology</i> , 2024, , 189-198.	0.4	0